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private-sector organizations in their efforts to improve the quality of health care in the United 
States. These reviews provide comprehensive, science-based information on common, costly 
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systematic reviews can help clarify whether assertions about the value of the intervention are 
based on strong evidence from clinical studies. For more information about AHRQ EPC 
systematic reviews, see www.effectivehealthcare.ahrq.gov/reference/purpose.cfm.  
AHRQ expects that these systematic reviews will be helpful to health plans, providers, 
purchasers, government programs, and the health care system as a whole. Transparency and 
stakeholder input are essential to the Effective Health Care Program. Please visit the Web site 
(www.effectivehealthcare.ahrq.gov) to see draft research questions and reports or to join an 
email list to learn about new program products and opportunities for input.  
We welcome comments on this systematic review. They may be sent by mail to the Task 
Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, 
Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.  
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Pharmacologic Therapies for the Management of 
Crohn’s Disease: Comparative Effectiveness 
Structured Abstract 
 
Objectives. The purpose of this review was to compare the efficacy and safety of biologics, 
immunomodulators, corticosteroids, and aminosalicylates in the treatment of Crohn’s disease.  
 
Data sources. We searched MEDLINE® (1966 through June 2011), Embase® (1974 through 
June 2011), and the Cochrane Central Register of Controlled Trials (Issue 2, 2011).  
 
Review methods. Two reviewers independently reviewed titles, abstracts, and articles, and 
included English-language articles that reported on induction or maintenance of remission in 
placebo-controlled or head-to-head randomized controlled trials. We also included observational 
studies with a comparison group if they reported on the safety of treatment. Two reviewers 
extracted study information using standardized forms and independently assessed study quality. 
Efficacy was measured by induction and maintenance of remission. Remission was defined using 
the Crohn’s Disease Activity Index, mucosal healing, the absence of Crohn’s disease 
hospitalizations or surgeries, reduction of steroids, fistula healing, and patient-reported 
outcomes. A difference of 10 percentage points in the outcome between treatment groups was 
considered clinically meaningful. The safety outcomes of interest were mortality, occurrence of 
lymphomas and other cancers, infections, infusion- and injection-site reactions, and bone 
fractures for adults and children. Growth was an additional safety concern for children. 
 
Results. We included 136 studies involving 148,733 patients. Twenty-three percent of trials 
directly compared different treatment strategies. The majority of trials excluded patients with 
mild disease and those with a history of surgical resection. The majority of trials allowed patients 
to take other Crohn’s disease treatments during the trial. For adults, infliximab and 6-methyl-
prednisolone were consistently favored over placebo across the induction and maintenance 
outcomes. Natalizumab and azathioprine were favored over placebo across the maintenance 
outcomes. Other comparisons either did not have more than one outcome reported or had 
inconsistent results. The quality of the safety evidence was poor due to poor reporting of the 
methods in trials and poor confounding control in observational studies, and no strong signals of 
harm were identified. For children, the strength of evidence was low or insufficient to support 
the efficacy of any medication to induce or maintain remission. No pediatric study reported on 
serious adverse events such as mortality, lymphoma, or other cancers.  
 
Conclusions. Measuring the efficacy of medications using multiple outcomes, infliximab and 6-
methyl-prednisolone induce and maintain remission in adults with Crohn’s disease. Natalizumab 
and azathioprine maintain remission. Comparing Crohn’s disease medications directly using 
pragmatic clinical trials will help to understand the effectiveness of medications in clinical 
practice using outcomes other than the Crohn’s Disease Activity Index. 
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Executive Summary 
Description of Crohn’s Disease 
Crohn’s disease is a type of inflammatory bowel disease. Other types of inflammatory bowel 
disease include ulcerative colitis and indeterminate colitis. The medical community characterizes 
Crohn’s disease as chronic full-thickness inflammation that can occur anywhere in the 
gastrointestinal tract but that most often affects the small bowel and colon. Typical symptoms of 
Crohn’s disease include abdominal pain, chronic diarrhea, and gastrointestinal bleeding. Crohn’s 
disease affects between 400,000 and 600,000 North Americans.1 Ten percent of Crohn’s disease 
patients are children aged 17 years or younger.2 
The activity of Crohn’s disease fluctuates over time, frequently leading to complications that 
require surgical intervention. One study estimated that during the first 7 years after diagnosis, 20 
percent of Crohn’s disease patients will have active disease at least once each year, 67 percent 
will fluctuate between years of active disease and years in remission, and 13 percent will have no 
relapses after the initial disease episode.3  
The clinical management of Crohn’s disease is complicated. Clinical practice guidelines for 
Crohn’s disease recommend that clinicians take into account the disease location, severity, 
complications, and extraintestinal manifestations when choosing a treatment strategy. However, 
no universal treatment strategy exists for patients.4 The lack of consensus about the best 
treatment strategy can result in confusion and frustration for both the clinicians who treat 
Crohn’s disease patients and the patients themselves. 
Interventions To Treat Crohn’s Disease 
Medical therapy in Crohn’s disease targets intestinal inflammation with the intent of altering 
the natural history of the disease. Clinicians have prescribed corticosteroids and aminosalicylates 
such as sulfasalazine since the mid-1900s to treat Crohn’s disease. Clinicians have prescribed 
immunomodulators (e.g., 6-mercaptopurine, azathioprine, and methotrexate) for the treatment of 
Crohn’s disease since the 1970s, although they did not routinely prescribe these medications 
until the 1990s.5 The biologics are a class comprised of four agents: three inhibit tumor necrosis 
factor-alpha (TNF-alpha) and one inhibits the cellular adhesion molecule alpha-4-integrin. The 
U.S. Food and Drug Administration (FDA) approved the first biologic TNF-alpha inhibitor, 
infliximab, for the treatment of Crohn’s disease in adults in 1998. The FDA-approved TNF-alpha 
inhibitor biologics also include adalimumab and certolizumab pegol.4 Natalizumab is another 
FDA-approved biologic for adults with Crohn’s disease, which works by inhibiting the cellular 
adhesion molecule alpha 4-integrin (Table A).6 Biologic treatments differ from other medication 
classes because they are synthesized using biologic, rather than chemical, processes.  
When patients have active disease, clinicians prescribe medications to induce remission. 
After the patient is in remission (no longer has active disease), clinicians prescribe medications 
to maintain the remission. If a patient is in a state of remission and symptoms increase to an 
active state, clinicians refer to the symptom increase as a relapse. Clinicians recommend surgery 
to induce remission when Crohn’s disease or its complications are resistant to medical therapy. 
Surgery is not a cure for disease, as recurrence is common. 
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Table A. Medications used for the treatment of Crohn’s disease 
Class Generic Name 
U.S. Trade 
Name Route Half-Life Mechanism of Action 
FDA 
Approved 
for CD in 
Adults 
FDA 
Approved 
for CD in 
Children 
Biologic Adalimumab Humira Subcutaneous 10-18 days TNF-alpha inhibitor Yes No 
Biologic Certolizumab pegol Cimzia Subcutaneous ~14 days TNF-alpha inhibitor Yes No 
Biologic Infliximab Remicade Intravenous 7.7-9.5 days TNF-alpha inhibitor Yes Yes 
Biologic Natalizumab Tysabri Intravenous 7-15 days Prevents attachment of 
inflammatory immune 
cells to intestinal cell 
layers 
Yes No 
Immunomodulator Azathioprine Azasan, Imuran Oral, intravenous 5 hours Purine synthesis inhibitor No No 
Immunomodulator 6-Mercaptopurine Purinethol Oral 1-2 hours Purine synthesis inhibitor No No 
Immunomodulator Methotrexate Methotrexate Intravenous, oral 3-15 hours Dihydrofolate reductase 
inhibitor 
No No 
Corticosteroid Prednisone, 
prednisolone,  
6-methyl-
prednisolone, 
hydrocortisone, 
budesonide 
Cortef, Entocort Oral, topical, 
intravenous 
8-54 hours Binds glucocorticoid 
receptors in cytoplasm, 
where it upregulates anti-
inflammatory genes 
No* No 
Aminosalicylate Mesalamine Asacol, Canasa, 
Pentasa, Lialda, 
Rowasa 
Oral, rectal 2-15 hours Unknown No No 
Aminosalicylate Sulfasalazine Azulfidine Oral 5-10 hours Unknown No No 
CD = Crohn’s disease; FDA = U.S. Food and Drug Administration; TNF = tumor necrosis factor 
*Budesonide is FDA approved for mild to moderate Crohn’s disease. 
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Current Uncertainties and Controversies in the Treatment of 
Crohn’s Disease  
A 2009 report from the Institute of Medicine stated that a priority for comparative 
effectiveness research is the comparison of algorithms for treating Crohn’s disease that introduce 
biologics at different time points in the disease course.7 Some experts believe that patients have 
better long-term outcomes taking immunomodulators and biologics early (“top-down therapy”), 
as opposed to taking them after prolonged steroid use (“step-up therapy”). Experts have 
cautioned, however, that the long-term safety of these treatments, particularly when used in 
combination, remains unknown.8,9 The disease treatment pyramid shown in Figure A 
summarizes the two treatment strategies from the onset of disease.10  
The treatment guidelines point to controversial areas in need of future research. These areas 
include treatments to achieve long-term remission, the benefits and harms of step-up versus top-
down treatment strategies, and how to optimize the use of biologic agents, given that many 
patients’ disease can be managed without the use of biologics.4 
 
Figure A. Treatment pyramid for patients with Crohn’s disease 
 
Purpose of This Report  
The purpose of this review is to give clinicians involved in the care of patients with Crohn’s 
disease a comprehensive comparison of the effectiveness and safety of biologics, 
immunomodulators, corticosteroids, and aminosalicylates in the treatment of Crohn’s disease. 
The specific Key Questions (KQs) of interest are listed below.  
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KQ1. What is the comparative effectiveness of therapies, alone or in 
combination, used to induce remission in adults and children with active 
Crohn’s disease?  
Remission is a decrease in or absence of Crohn’s disease symptoms. We define remission 
using the following markers: the Crohn’s Disease Activity Index (CDAI), mucosal healing, the 
absence of Crohn’s disease hospitalizations or surgeries, reduction of steroids, fistula healing, 
and patient-reported outcomes. We looked for data on remission rates at the following time 
points after randomization: 2–4 weeks, 2–16 weeks, and last reported time point (Table B).  
 
KQ2. What is the comparative effectiveness of therapies, alone or in 
combination, used to maintain remission in adults and children with inactive 
Crohn’s disease?  
We looked for data on the maintenance of remission from inactive disease or response to a 
medication in a previous induction trial at the following time points after randomization: 48–54 
weeks and last reported time point. 
 
KQ3. What is the comparative safety of therapies, alone or in combination, 
used in adults and children with Crohn’s disease in terms of minimizing 
short- and long-term adverse effects?  
The safety outcomes of interest were mortality, occurrence of lymphomas and/or other 
cancers, infections, infusion- and injection-site reactions, bone fractures, and growth in children. 
We looked for data on these outcomes at the last reported time point. Short-term adverse effects 
are events that occur within 1 year of initiating a medication. Long-term adverse effects occur at 
least 1 year after initiating a medication. 
 
KQ4. What is the comparative effectiveness of agents used to prevent 
postoperative recurrence in Crohn’s disease as pertains to patient-reported 
outcomes?  
The patient-reported outcomes of interest were standard quality-of-life indexes and specialty 
indexes (Inflammatory Bowel Disease Questionnaire [IBDQ], Short Inflammatory Bowel 
Disease Questionnaire), and days of work or school missed. We looked for data on patient-
reported outcomes at the following time points after randomization: 48–54 weeks and last 
reported time point. 
Figure B graphically depicts the KQs. 
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Figure B. Analytic framework for assessing the comparative effectiveness and safety of pharmacologic therapies for Crohn’s disease 
   
KQ = Key Question 
Note: KQ1: comparative effectiveness in inducing remission; KQ2: comparative effectiveness in maintaining remission; KQ3: comparative safety; KQ4: comparative effectiveness 
of treatments for postsurgical patient-reported outcomes. 
aFor KQ4, the only examined endpoint is patient-reported outcomes. 
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Table B. Outcomes considered for each Key Question concerning the comparative 
effectiveness and safety of medications for the treatment of Crohn’s disease 
Key 
Question Outcomes Time Points 
KQ1 • Disease activity measures (remission as measured by the 
CDAI, PCDAI, HBI, or other disease activity measurements) 
• Mucosal healing (presence of ulcers, CDEIS) 
• Hospitalizations 
• Surgeries 
• Reduction of steroids 
• Fistula response (complete or partial fistula closure or other 
measure of perianal disease) 
• Patient-reported outcomes (health-related quality of life, 
IBDQ, days of work or school missed) 
• 2 to 4 weeks after 
randomization 
• 12 to 16 weeks after 
randomization  
• Last reported time 
point 
KQ2 • Disease activity measures (relapse, CDAI, PCDAI, HBI, or 
other disease activity measurements) 
• Mucosal healing (presence of ulcers, CDEIS) 
• Hospitalizations 
• Surgeries 
• Reduction of steroids 
• Fistula response (fistula recurrence or other measure of 
perianal disease) 
• Patient-reported outcomes (health-related quality of life, 
IBDQ, days of work or school missed) 
• 48 to 54 weeks after 
randomization  
• Last reported time 
point 
KQ3 • Mortality 
• Lymphomas 
• Cervical cancer 
• Other cancers 
• Tuberculosis 
• Serious infections 
• Other infections 
• Infusion- and injection-site reactions 
• Bone fractures 
• Height and weight as indicators of growth (for pediatric 
studies only) 
• Last reported time 
point 
KQ4 • Patient-reported outcomes (health-related quality of life, 
IBDQ, days of work or school missed) 
• 48 to 54 weeks after 
randomization  
• Last reported time 
point 
CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; HBI = Harvey-
Bradshaw Index; IBDQ = Inflammatory Bowel Disease Questionnaire; KQ = Key Question; PCDAI = Pediatric 
Crohn’s Disease Activity Index. 
Note: KQ1: comparative effectiveness in inducing remission; KQ2: comparative effectiveness in maintaining 
remission; KQ3: comparative safety; KQ4: comparative effectiveness of treatments for postsurgical patient-reported 
outcomes. 
Total scores for the CDAI range from 0 to 600, with higher scores indicating more severe disease activity. Total scores 
for the PCDAI range from 0 to 100, with higher scores indicating more severe disease activity. Total scores for the HBI 
range from 0 to 19, with higher scores indicating more severe disease activity. Total scores for the CDEIS range from 0 
to 44, with higher scores indicating more severe disease activity. Total scores for the IBDQ range from 32 to 224, with 
higher scores indicating better quality of life. 
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Methods 
Topic Development 
The topic for this report was nominated in a public process. At the beginning of the project, 
we recruited a panel of Key Informants and Technical Experts to give input on the selection and 
refinement of the questions to be examined. In March 2010, we posted preliminary questions on 
the Effective Health Care Program Web site for public comment. With the Key Informants, 
Technical Experts, representatives of the Agency for Healthcare Research and Quality, and 
public comments, we finalized the KQs listed above. 
Search Strategy 
We searched the following databases for primary studies for the dates shown in parentheses: 
MEDLINE® (1966 through June 2011), Embase® (1974 through June 2011), and the Cochrane 
Central Register of Controlled Trials (Issue 2, 2011). We also reviewed the reference lists of 
each included article and relevant review articles. To assess the risk of two serious and rare 
complications that may be associated with the treatment for Crohn’s disease, hepatosplenic T-
cell lymphoma and progressive multifocal leukoencephalopathy, we supplemented our primary 
search strategy by also searching for cases reported to the FDA’s Adverse Event Reporting 
System. To identify additional studies, we reviewed the Scientific Information Packets provided 
by the pharmaceutical manufacturers. 
Study Selection 
Two reviewers independently reviewed titles and abstracts. We excluded titles and abstracts 
when both reviewers agreed on exclusion. We resolved differences regarding article inclusion 
through consensus adjudication. A third reviewer audited a random sample of abstract and article 
reviews to ensure consistency in the reviewing process. We included relevant English-language 
studies evaluating nonpregnant patients with Crohn’s disease.  
For KQ1 and KQ2, on induction and maintenance of remission, we included only 
randomized controlled trials (RCTs). Both placebo-controlled and head-to-head trials were 
eligible. We did not include RCTs that examined only the same medication administered at 
different dosages. We did not include nonrandomized trials. We chose the outcomes of interest 
for KQ1 and KQ2 to represent important clinical and patient-reported outcomes.  
For KQ3, on safety, we included RCTs and observational studies. We chose specific safety 
outcomes on the basis of the severity of the outcome, impact on quality of life, and potential for 
safety to differ by medication class. We selected clinical outcomes a priori for inclusion in the 
review. All RCTs that reported on safety-related outcomes were eligible. Observational studies 
were eligible if they reported: (1) clear comparison groups specified in the study aims or 
methods; (2) clear denominators (patients on groups of medications); and (3) clear numerators 
(patients who experienced the safety event of interest according to group of medication). We also 
included studies that reported an effect estimate or p-value for a safety outcome by medication 
use if they met the first criterion (clear comparison groups).  
For KQ4, on postoperative outcomes, we focused on the comparative effectiveness of 
medications only in terms of patient-reported outcomes. We chose this approach because a 
rigorously conducted systematic review11 recently assessed the other clinical outcomes 
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associated with the use of medications to maintain remission after intestinal resection in patients 
with Crohn’s disease. 
Data Abstraction 
For all articles, reviewers extracted information on general study characteristics, study 
participants, study eligibility criteria, interventions, outcome measures and their method of 
ascertainment, and the results of each outcome (including measures of variability). We abstracted 
information on subgroup analyses to understand how disease characteristics could modify the 
relationship between medications and remission, including baseline C-reactive protein or 
elevated inflammatory markers, medication history, concomitant use of medications during the 
trial, disease duration, disease location, and prior surgery related to Crohn’s disease. 
Quality Assessment 
We used study quality assessment to help us understand differences in results between 
studies. For RCTs, we based the dual independent review of article quality on the Cochrane 
Collaboration’s Risk of Bias Tool.12 For nonrandomized observational studies, we selected items 
from the Downs and Black quality checklist.13 We supplemented both quality assessment tools 
with items from the “Methods Guide for Effectiveness and Comparative Effectiveness 
Reviews.”14 The overall study quality was assessed as— 
• Good (low risk of bias). These studies had the least bias, and the results were considered 
valid. These studies adhered to the commonly held concepts of high quality, including the 
following: a clear description of the population, setting, interventions, and comparison 
groups; appropriate measurement of outcomes; appropriate statistical and analytic 
methods and reporting; no reporting errors; a low dropout rate; and clear reporting of 
dropouts. 
• Fair. These studies were susceptible to some bias, but not enough to invalidate the 
results. They did not meet all the criteria required for a rating of good quality because 
they had some deficiencies, but no flaw was likely to cause major bias. The study may 
have been missing information, making it difficult to assess limitations and potential 
problems.  
• Poor (high risk of bias). These studies had significant flaws that might have invalidated 
the results. They had serious errors in design, analysis, or reporting; large amounts of 
missing information; or discrepancies in reporting.14  
Applicability 
We assessed the applicability of the bodies of evidence for each KQ in terms of the degree to 
which the study population, interventions, comparisons, outcomes, timing, and settings 
(PICOTS) were typical of the treatment of individuals with Crohn’s disease. 
Data Synthesis and Meta-Analysis 
We synthesized the evidence for children separately from adults for all KQs. For each KQ, 
we created a set of detailed evidence tables containing the information we abstracted from 
eligible studies. We conducted meta-analyses when there were sufficient data (at least three 
studies) and when studies were sufficiently homogeneous with regard to study characteristics 
(PICOTS). For studies amenable to pooling for meta-analyses, we calculated pooled relative 
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risks using a DerSimonian and Laird random-effects model.15 We looked for statistical 
heterogeneity between the studies in meta-analyses using: (1) a chi-squared test with a 
significance level of alpha less than or equal to 0.10 and (2) an I-squared statistic with a value of 
50 percent or more, indicating substantial heterogeneity.16 We did not report the pooled result if 
we found substantial heterogeneity. 
We conducted sensitivity analyses by omitting one study at a time to assess the influence of 
any single study on the pooled estimate. For all meta-analyses, we conducted formal tests for 
publication bias using Begg’s17 and Egger’s tests;18 including an evaluation of the asymmetry of 
funnel plots for each comparison of interest. We conducted all meta-analyses using Intercooled 
STATA 9.2 (College Station, TX).  
When we were unable to pool studies for an outcome, we calculated and displayed absolute 
risk differences with 95-percent confidence intervals for the individual studies. For KQ1 and 
KQ2, we considered a difference to be clinically meaningful when there was an absolute 
difference of 10 percentage points in the outcome between the groups compared, even when the 
difference was not statistically significant at a p-value less than 0.05. For the IBDQ (the most 
commonly used patient-reported outcome), we considered a meaningful difference to be a 
between-group absolute difference of 17 points or greater in the change from baseline.19  
In terms of adverse effects, when a study did not report an effect estimate, we calculated a 
Peto odds ratio if the combined number of events in each group was greater than 5.20,21 We also 
calculated incidence rate ratios for person-time data when the authors did not report an effect 
estimate or when the reported effect estimate appeared to contradict the reported events per 
person-time. We did not specify a standard for a clinically meaningful difference in adverse 
events, because an absolute rate was rare for most of the adverse events. After performing the 
main analyses on adverse events, we carried out a sensitivity analysis with studies that evaluated 
patients with inflammatory bowel disease but did not report results separately for patients with 
Crohn’s disease. 
Grading the Strength of Evidence 
At the completion of our review, we graded the strength of the evidence addressing the KQs 
by using the evidence-grading scheme recommended by the “Methods Guide for Effectiveness 
and Comparative Effectiveness Reviews.”22 We based the strength-of-evidence grade on four 
domains: risk of bias, consistency, directness, and precision.  
We classified the strength of evidence pertaining to KQs 1 through 4 into four grades:  
• “High” grade, indicating high confidence that the evidence reflects the true effect and 
further research is very unlikely to change our confidence in the estimate of the effect  
• “Moderate” grade, indicating moderate confidence that the evidence reflects the true 
effect and further research may change our confidence in the estimate of the effect and 
may change the estimate  
• “Low” grade, indicating low confidence that the evidence reflects the true effect and 
further research is likely to change our confidence in the estimate of the effect and is 
likely to change the estimate  
• “Insufficient” grade: evidence is unavailable; no studies observed 
If the evidence grade or direction of the effect differed at two time points of interest, we 
reported the evidence grade separately for each time point.  
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Results 
Search Results 
We identified 136 studies involving 148,733 patients that met our inclusion criteria for one or 
more of the KQs. Combining KQ1 and KQ2 yielded 64 studies (94 publications) with 11,377 
patients. For KQ3, we found 47 RCTs involving 9,884 Crohn’s disease patients and 46 
observational studies involving 121,649 Crohn’s disease patients. We included an additional 15 
studies with 14,934 patients with inflammatory bowel disease as a sensitivity analysis. For KQ4, 
we found one RCT with 78 patients with Crohn’s disease. Five pediatric RCTs examined a total 
of 298 children, and five observational studies involving 397 children with Crohn’s disease 
reported data for KQs 1-3 but not KQ4.  
We reported the results of our systematic review first according to KQ and separated adult 
from pediatric results. When a study compared multiple medication classes, our report of the 
study begins with the first medication in our ordered list of medication classes, which we 
organized according to the top-down approach in the treatment pyramid (Figure A). The 
medication classes are: biologics (natalizumab, TNF-alpha inhibitor), immunomodulators 
(thiopurines, methotrexate), corticosteroids, and aminosalicylates.  
Key Questions 1 and 2. Induction and Maintenance of Remission 
Study Characteristics 
The duration of the 64 RCTs ranged from 2 weeks to 4 years. Most RCTs were multicenter 
(76 percent) and located in Europe and North America, with fewer than 10 multicenter or single-
center RCTs in Africa, Australia, Israel, or Asia.  
Most patients with active disease (whom we considered in KQ1 on induction of remission) 
were identified using the CDAI (lower limit, 150 to 220; upper limit, 350 to 600; 43 studies). 
Most patients with inactive disease (whom we considered in KQ2 on maintenance of remission) 
were also identified using the CDAI (upper limit, 120 to 220; 23 studies). One study used the 
Harvey-Bradshaw Index. Twenty-two studies did not report a scoring system to identify disease 
activity.  
Most studies allowed patients to use other medications during the RCT. Many specified that 
patients had to be on a stable dose at the time of randomization. These trials considered it a 
failure of treatment if patients made major dose changes during the trial.  
Population Characteristics 
A small percentage of RCTs reported on race. Of those studies, 84 to 100 percent of the 
patients were White. The largest non-White racial group in any individual study was 10 percent 
African American,23 8 percent Asian,24 and 7 percent unspecified other race.25 The mean or 
median disease duration ranged from 7 months to 14 years. The mean and median age at the time 
of randomization ranged from 26 to 47 years. The minimum age reported in any one study was 
14 years,26 and the maximum age was 78 years.27  
Remission Results 
Despite the large number of studies, we were able to perform very few meta-analyses 
because of the heterogeneity in the definition of the inclusion criteria and outcomes between 
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studies. Recently published studies tended to define remission using the CDAI, with scores 
below 150 indicating remission and scores of 150 or more indicating active disease. Older 
studies, including the study for which researchers developed the CDAI,28 tended to use disease 
activity measures with or without clinical outcomes, such as the need for surgery or laboratory 
measures, to indicate remission status. We found very few studies that used measures of 
remission other than the CDAI (e.g., mucosal healing, hospitalizations, surgeries, reduction of 
corticosteroid use, fistula response, or patient-reported outcomes).  
Key Question 1. Induction of Remission 
Of the 78 comparisons with evidence, 4 resulted in high strength of evidence and 20 resulted 
in moderate strength of evidence (Table C). Most patient-reported outcomes were measured by 
the IBDQ. Total scores for the IBDQ range from 32 to 224, with higher scores indicating better 
quality of life.29 
Key Question 2. Maintenance of Remission 
Of the 55 comparisons with evidence, none resulted in high strength of evidence and 11 
resulted in moderate strength of evidence (Table D). 
Subgroup Analyses 
Six trials reported a statistical interaction test on disease characteristics that might modify the 
relationship between medications and remission. No consistent relationship for a disease 
characteristic subgroup of interest was observed among the six comparisons.  
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Table C. Key findings and strength of evidence: comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure: 
Weeks 2–4 
Disease 
Activity 
Measure: 
Weeks 12–16 
Disease 
Activity 
Measure: After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Natalizumab 
vs. placebo 
 
12 weeks 
Favors 
natalizumab; 
moderate SOE 
Favors 
natalizumab;  
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 12: 
Favors neither; 
moderate SOE 
Natalizumab + 
infliximab vs. 
infliximab 
 
10 weeks 
Favors neither; 
low SOE 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 10: 
Favors neither; 
low SOE 
Adalimumab 
vs. placebo 
 
4 weeks 
>160 mg SC 
dose: 
Favors 
adalimumab; 
high SOE 
 
≤80 mg SC 
dose: 
Favors neither; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 4: 
Favors 
neither; low 
SOE 
Week 4: 
Favors neither; 
high SOE 
CP vs. placebo 
 
26 weeks 
Favors neither; 
low SOE 
Favors neither; 
low SOE 
Week 26: 
Favors CP; low 
SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors 
neither; low 
SOE 
Week 12 and 
Week 26: 
Favors neither; 
low SOE 
Infliximab vs. 
placebo 
 
12 weeks 
Favors 
infliximab; 
moderate SOE 
Favors 
infliximab; low 
SOE 
Insufficient Week 4: 
Favors 
infliximab;  
low SOE 
Insufficient Insufficient Week 6: 
Favors 
infliximab; 
high SOE 
Week 4: 
Favors 
infliximab; 
moderate SOE 
Infliximab vs. 
azathioprine 
 
26 weeks 
Insufficient Favors 
infliximab; 
moderate SOE 
Week 26: 
Favors 
infliximab; 
moderate SOE 
Week 26: 
Favors 
infliximab; 
low SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors neither; 
moderate SOE 
Infliximab + 
azathioprine 
vs. infliximab 
 
26 weeks 
Insufficient Favors 
infliximab + 
azathioprine; 
moderate SOE 
Week 26: 
Favors 
infliximab + 
azathioprine; 
moderate SOE 
Week 26: 
Favors 
infliximab + 
azathioprine; 
low SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors neither; 
moderate SOE 
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Table C. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2–4 
Disease 
Activity 
Measure 
Weeks 12–16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Infliximab + 
azathioprine 
vs. 
azathioprine 
 
26 weeks 
Insufficient Favors 
infliximab + 
azathioprine; 
moderate SOE 
Week 26: 
Favors 
infliximab + 
azathioprine; 
moderate SOE 
Week 26; 
Favors 
infliximab + 
azathioprine; 
low SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors neither; 
moderate SOE 
Infliximab + 
azathioprine 
vs. steroids 
 
104 weeks 
Insufficient Insufficient  Week 104: 
Favors neither;  
low SOE 
Week 104: 
Favors 
infliximab + 
azathioprine; 
low SOE 
Insufficient Insufficient Insufficient Week 10: 
Favors 
infliximab + 
azathioprine; 
low SOE 
Infliximab + 
methotrexate 
vs. infliximab 
 
48 weeks 
Favors 
infliximab + 
methotrexate; 
low SOE 
Favors 
infliximab + 
methotrexate; 
low SOE 
Week 48: 
Favors 
infliximab + 
methotrexate; 
low SOE 
Insufficient Insufficient Week 48: 
Favors 
infliximab + 
methotrexat
e; low SOE 
Insufficient Week 4 and 
Week 8: 
Favors 
infliximab + 
methotrexate; 
low SOE 
Thiopurines vs. 
placebo 
 
104 weeks 
Favors neither; 
low SOE 
Insufficient Weeks 17-38: 
Favors neither; 
low SOE 
 
Week 104: 
Favors 6-MP; 
low SOE 
Insufficient Insufficient Week 16: 
Favors 
neither; low 
SOE 
Week 17: 
Favors 
neither; low 
SOE 
 
Week 104: 
Favors 6-
MP; low 
SOE 
Week 16: 
Favors neither; 
low SOE‡ 
Thiopurines vs. 
oral 
methotrexate 
 
38 weeks  
Favors neither; 
low SOE 
Favors neither; 
low SOE 
Week 38: 
Favors neither;  
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines vs. 
steroids 
 
17 weeks 
Favors steroids; 
low SOE 
Favors steroids; 
low SOE 
Week 17:  
Favors steroids; 
low SOE 
Insufficient Insufficient Insufficient Week 17: 
Favors 
steroids; 
low SOE 
Insufficient 
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Table C. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2–4 
Disease 
Activity 
Measure 
Weeks 12–16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Thiopurines vs. 
ASA 
 
30 weeks 
Favors ASA; 
low SOE 
Favors neither; 
low SOE 
Week 17:  
Favors neither; 
low SOE 
 
Week 30: 
Favors 6-MP; 
low SOE 
Insufficient Insufficient Insufficient Week 17: 
Favors 
neither; low 
SOE 
Insufficient 
Thiopurines 
(IV, then oral) 
vs. thiopurines 
(oral) 
16 weeks 
 Insufficient Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines + 
steroids vs. 
steroids 
 
28 weeks 
Insufficient Favors 
thiopurines + 
steroids; low 
SOE 
Week 28:  
Favors 
thiopurines + 
steroids; low 
SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines + 
steroids vs. 
methotrexate 
(IV, then oral) 
+ steroids 
 
26 weeks 
Insufficient Favors neither; 
low SOE 
Week 26:  
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors 
methotrexat
e + 
steroids; 
low SOE 
Insufficient 
Methotrexate 
(oral) vs. 
placebo 
 
38 weeks 
Favors neither; 
low SOE 
Favors neither; 
low SOE 
Week 38:  
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Methotrexate 
(oral) vs. ASA 
 
30 weeks 
Insufficient Insufficient Week 30: 
Favors 
methotrexate; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table C. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2–4 
Disease 
Activity 
Measure 
Weeks 12–16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Methotrexate 
(IM) + 
prednisone vs. 
prednisone 
 
16 weeks 
Insufficient Favors 
methotrexate; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 16: 
Favors neither; 
moderate SOE 
Budesonide 
vs. placebo 
 
16 weeks 
≥9 mg daily: 
Favors 
budesonide; 
moderate SOE 
 
<9 mg daily: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 8: 
No difference; 
low SOE 
6-methyl-
prednisolone 
or prednisone 
vs. placebo 
 
104 weeks 
6-methyl-
prednisolone:  
Favors 6-
methyl-
prednisolone; 
low SOE 
 
Prednisone 
Favors neither; 
low SOE 
Favors steroids; 
low SOE 
Week 104: 
Favors steroids; 
low SOE 
Insufficient Insufficient Insufficient Week 17: 
Favors 
steroids; 
low SOE 
Insufficient 
Budesonide 
vs. other 
steroids 
 
10 weeks 
Favors neither; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 8: 
Favors neither; 
moderate SOE 
Steroids vs. 
ASA 
 
104 weeks 
Favors steroids; 
low SOE 
Favors steroids; 
low SOE 
Week 104: 
Favors steroids; 
low SOE 
Insufficient Insufficient Insufficient Week 17: 
Favors 
neither; low 
SOE 
Week 2: 
Favors steroids; 
high SOE§ 
 
Week 12: 
Favors neither; 
moderate SOE§ 
 
ES-15 
Table C. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2–4 
Disease 
Activity 
Measure 
Weeks 12–16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
6-methyl-
prednisolone + 
sulfasalazine 
vs. placebo 
 
104 weeks 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
low SOE 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
low SOE 
Week 104: 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. steroids 
 
104 weeks 
Favors neither; 
low SOE 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. 
sulfasalazine 
 
104 weeks 
Favors steroids 
+ sulfasalazine; 
low SOE 
Favors steroids 
+ sulfasalazine; 
low SOE 
Week 104: 
Favors steroids 
+ sulfasalazine; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Mesalamine 
vs. placebo 
 
17 weeks 
Favors neither; 
low SOE 
≥3.2 g daily: 
Favors 
mesalamine; 
low SOE 
 
<3.2 g daily: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient  Insufficient 
Sulfasalazine 
vs. placebo 
 
104 weeks 
Favors neither; 
low SOE 
Favors 
sulfasalazine; 
low SOE 
Week 104: 
Favors 
sulfasalazine; 
low SOE 
Insufficient Insufficient Insufficient Week 17: 
Favors 
sulfasalazine; 
low SOE 
Insufficient 
6-MP = 6-mercaptopurine; ASA = aminosalicylates; CP = certolizumab pegol; IM = intramuscular; IV = intravenous; SC = subcutaneous; SOE = strength of evidence; steroids = 
corticosteroids 
Note: The strength of the evidence was defined as follows: high = high confidence that the evidence reflects the true effect; moderate = moderate confidence that the evidence 
reflects the true effect; low = low confidence that the evidence reflects the true effect; insufficient = evidence is unavailable. 
*All other potential comparisons of therapies and outcomes were graded as insufficient because there were no eligible trials. The evidence for the last reported measure is provided 
for disease activity after 16 weeks, mucosal healing, hospitalizations and surgeries, reduction of steroids, fistula respons, and patient-reported outcomes. 
†Patient-reported outcomes were measured by the Inflammatory Bowel Disease Questionnaire except where indicated by a footnote. 
‡Outcome based on “feeling better” in 2 trials. 
§Used McMaster University Quality of Life scale. 
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Table D. Key findings and strength of evidence: comparing pharmacologic therapies for the management of Crohn’s disease to maintain 
remission* 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure: 
Weeks 48–54 
Disease 
Activity 
Measure: 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Natalizumab 
vs. placebo 
 
48 weeks 
Favors 
natalizumab; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Week 48: 
Favors 
natalizumab; 
moderate 
SOE 
Insufficient Week 48: 
Favors 
natalizumab; 
moderate SOE 
Adalimumab 
vs. placebo 
 
52 weeks 
Favors 
adalimumab; 
low SOE 
Insufficient Insufficient Week 52: 
Favors adalimumab 
for all-cause 
hospitalizations; 
favors neither for 
CD-related 
hospitalizations; 
moderate SOE 
Week 52: 
Favors neither; 
moderate SOE 
Week 52: 
Favors 
adalimumab; 
low SOE 
Insufficient Week 52: 
Favors neither; 
low SOE 
CP vs. placebo 
 
18 weeks 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 18: 
Favors neither; 
low SOE 
Infliximab vs. 
placebo 
 
52 weeks 
Favors neither 
among all 
randomized; 
favors infliximab 
among 
responders; low 
SOE 
Insufficient Week 52: 
Favors 
infliximab; 
low SOE 
Week 52: 
Favors infliximab; 
moderate SOE 
Week 52: 
Favors neither 
among 
patients with 
fistulizing 
disease; 
moderate SOE 
Week 52: 
Favors 
infliximab; 
low SOE 
Week 40: 
Favors 
infliximab; 
low SOE 
Week 52: 
Favors infliximab; 
low SOE 
Infliximab + 
azathioprine 
vs. infliximab 
 
104 weeks 
Insufficient Week 104: 
Favors neither; 
low SOE 
Week 104: 
Favors 
neither; low 
SOE 
Insufficient Insufficient Insufficient Insufficient Week 104: 
Favors neither; 
low SOE 
Infliximab + 
azathioprine 
vs. infliximab + 
hydrocortisone 
 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table D. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to maintain 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 48-54 
Disease 
Activity 
Measure 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Azathioprine 
vs. placebo 
 
104 weeks 
≥1.7 mg/kg/day: 
Favors 
azathioprine; 
low SOE 
<1 mg/kg/day: 
Favors neither; 
low SOE 
Week 104: 
Favors 
azathioprine at 
≥1.7 mg/kg/day; 
low SOE 
Favors neither 
at <1 
mg/kg/day; low 
SOE 
Insufficient Insufficient Insufficient Week 26: 
Favors 
azathioprine; 
low SOE 
Insufficient Insufficient 
Azathioprine 
vs. budesonide 
 
52 weeks 
Favors 
azathioprine; 
low SOE 
Insufficient Week 52: 
Favors 
azathioprin
e; 
moderate 
SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Azathioprine 
vs. prednisone 
 
104 weeks 
Favors 
azathioprine; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Azathioprine 
vs. 
sulfasalazine 
 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Methotrexate 
(IM) vs. 
placebo 
 
40 weeks 
Week 40: 
Favors 
methotrexate; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Budesonide 
vs. placebo 
 
52 weeks 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 52: 
Favors neither; 
low SOE 
Prednisone vs. 
placebo 
 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table D. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to maintain 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 48-54 
Disease 
Activity 
Measure 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
6-methyl-
prednisolone 
vs. placebo 
 
104 weeks 
Favors 6-
methyl-
prednisolone; 
low SOE 
Week 104: 
Favors 6-
methyl-
prednisolone; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Budesonide 
vs. 
mesalamine 
 
52 weeks 
Favors 
budesonide; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 52: 
Favors 
budesonide; 
moderate SOE 
Steroids (6-
methyl-
prednisolone 
or prednisone) 
vs. 
sulfasalazine 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
6-methyl-
prednisolone + 
sulfasalazine 
vs. placebo 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. steroids 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. 
sulfasalazine 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Mesalamine 
(controlled 
release) vs. 
placebo 
52 weeks 
Favors 
mesalamine; 
low SOE 
Week 104: 
Favors neither; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 48: 
Favors neither; 
low SOE 
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Table D. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to maintain 
remission* (continued) 
Comparison 
 
Maximum trial 
duration 
Disease 
activity 
measure 
Weeks 48-54 
Disease 
activity 
measure 
After 54 weeks 
Mucosal 
healing Hospitalizations Surgeries 
Reduction 
of steroids 
Fistula 
response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Mesalamine 
(pH release) 
vs. placebo 
 
208 weeks 
Favors 
mesalamine; 
low SOE 
Week 104:  
Favors placebo; 
low SOE 
Week 208:  
Favors 
mesalamine; 
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Olsalazine vs. 
placebo 
 
52 weeks 
Favors neither; 
moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Sulfasalazine 
vs. placebo 
 
104 weeks 
Favors neither; 
low SOE 
Week 104: 
Favors neither;  
low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
CD = Crohn’s disease; CP = certolizumab pegol; IM = intramuscular; SOE = strength of evidence; steroids = corticosteroids 
Note: The strength of the evidence was defined as follows: high = high confidence that the evidence reflects the true effect; moderate = moderate confidence that the evidence 
reflects the true effect; low = low confidence that the evidence reflects the true effect; insufficient = evidence is unavailable.  
*All other comparisons and outcomes were graded as insufficient because there were no eligible trials. 
†Patient-reported outcomes were measured by the Inflammatory Bowel Disease Questionnaire except where indicated by a footnote. Total scores for the Inflammatory Bowel 
Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.29 
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Key Question 3. Safety 
Study Characteristics of RCTs 
Of 64 RCTs, 45 (70 percent) reported a safety outcome of interest according to treatment 
group. The only information on safety assessment for nearly all RCTs was that researchers 
ascertained unspecified safety outcomes at study visits. These RCTs made no mention of the 
ascertainment method (questionnaire, patient-initiated report) or blinding.  
Study Characteristics of Observational Studies 
Seven prospective cohort (n=26,973), 26 retrospective cohort (n=53,856), 11 case-control 
(n=40,040), 1 cross-sectional (n=207),30 and 1 observational study of unclear study design 
(n=573)31 reported safety outcomes. All of the prospective and case-control studies stated a 
specific safety outcome of interest. All of the retrospective studies aimed to assess safety, but 
about half of them did not specify the exact safety outcomes of interest. No observational study 
mentioned active ascertainment or blinded assessment of safety outcomes.  
Most observational studies occurred at single study centers. Most single-center or multicenter 
studies took place in the United States, Europe, Canada, or Australia, with one study in Africa 
and no studies in Asia. 
Population Characteristics of Observational Studies 
The age distribution was very inclusive, with some studies including patients of all ages 
(from children up to 90 years). Twenty-eight studies reported results for inflammatory bowel 
disease patients without separately reporting results for Crohn’s disease patients. 
In contrast to the RCTs, most of the observational studies reporting safety included all 
activity levels and severities of Crohn’s disease. Most of the observational studies had no 
restrictions on previous medication use. Sixteen studies included only patients who had used 
infliximab. These 16 studies compared the safety of infliximab alone or in combination with 
other medications. Two retrospective studies required azathioprine use because researchers 
designed the studies to compare the effectiveness of azathioprine with or without concomitant 
aminosalicylate.32,33  
Safety Results 
We did not perform meta-analyses because very few safety outcomes had more than three 
studies that contributed to any monotherapy or combination therapy comparison. Also, when 
more than three studies were available, the inclusion criteria and study duration were too 
heterogeneous. We summarized the safety results in Table E. 
There was no obvious trend that any medication was more or less safe across the safety 
outcomes of interest. The ability to examine such trends was limited, as the strength of evidence 
(SOE) for nearly every comparison was insufficient or low. A few findings indicated effects with 
some confidence according to the SOE grading, although each finding was based on a single 
RCT. Two safety comparisons were graded as high SOE: one comparison favored oral 
azathioprine with placebo infusion over intravenous infliximab, and a second comparison 
favored placebo over intravenous azathioprine. Two safety comparisons were graded as 
moderate SOE: one comparison favored a combination of prednisone and sulfasalazine over 
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prednisone alone for infections, and a second comparison did not favor either budesonide or 
prednisolone for the development of bone fractures. 
Subgroup Analyses  
No study reported a statistical interaction test for a subgroup of interest for the safety 
outcomes. 
 
Table E. Summary of the comparative safety of pharmacologic therapies for the management of 
Crohn’s disease 
Outcome (Incidence) 
Strength of 
Evidence Conclusion 
Mortality (<1% in most 
observed comparisons) 
Low The only comparison for which mortality differed between groups was 
treatment with corticosteroids compared with treatment without 
corticosteroids. The RRs in observational studies ranged from 1.0 to 2.5 
favoring no corticosteroids, with followup ranging from 6 weeks to 7 
years. 
Mortality (<1% in most 
observed comparisons) 
Low In comparisons not involving corticosteroids, mortality did not differ 
among groups that received natalizumab, TNF-alpha inhibitors, 
immunomodulators, aminosalicylates, or combinations of these drugs. 
The RRs in observational studies compared with no treatment or 
another treatment ranged from 0.8 to 1.0 for TNF-alpha inhibitors, 0.7 to 
1.3 for immunomodulators, and 0.7 for aminosalicylates, with followup 
ranging from 4 weeks to 12 years. 
HSTCL (insufficient 
data to estimate 
incidence) 
Insufficient We identified 37 unique cases of HSTCL associated with treatment of 
Crohn’s disease from research reports, case series, and the AERS. Of 
these cases, 95% used a thiopurine and 76% used at least 1 biologic, 
but we could not establish a causal relationship because of limitations in 
the available information. 
Lymphoma (<1% in 
most observed 
comparisons) 
Low The risk of lymphoma did not differ among groups that received 
natalizumab, TNF-alpha inhibitors, immunomodulators, corticosteroids, 
aminosalicylates, or combinations of these drugs. The observational 
RRs compared with no treatment or another treatment were 0.6 to 1.7 
for TNF-alpha inhibitors, 0.3 to 5.3 for immunomodulators, 1.0 for 
corticosteroids, and 1.0 for aminosalicylates, with followup ranging from 
4 weeks to 12 years. 
Lymphoma (<1% in 
most observed 
comparisons) 
Insufficient RCTs of immunomodulators, corticosteroids, or aminosalicylates did not 
report lymphoma as an outcome. 
Cervical cancer 
(insufficient data to 
estimate incidence) 
Low The risk of cervical cancer did not differ among groups that received 
TNF-alpha inhibitors, immunomodulators, corticosteroids, 
aminosalicylates, or combinations of these drugs, with followup ranging 
from 26 weeks to 3 years. 
Cervical cancer 
(insufficient data to 
estimate incidence) 
Insufficient None of the studies of natalizumab reported on cervical cancer. 
All cancers (insufficient 
data to estimate 
incidence) 
Low The risk of nonmelanoma skin cancer was higher with TNF-alpha 
inhibitors alone or with immunomodulators used recently (within 90 
days) or persistently (within 90 days and greater than 365 days) than 
with no TNF-alpha inhibitors or no immunomodulators. The ORs in 
observational studies ranged from 2.1 to 6.8. 
All cancers (insufficient 
data to estimate 
incidence) 
Low The risk of nonmelanoma skin cancer was higher with thiopurines used 
recently (within 90 days) or persistently (within 90 days and greater than 
365 days) than with no thiopurines. The ORs in observational studies 
ranged from 3.8 to 4.3. 
All cancers (insufficient 
data to estimate 
incidence) 
Low The risk of adenocarcinoma of the small bowel was higher with 6-
mercaptopurine than with no 6-mercaptopurine. The OR in an 
observational study was 10.8; the study did not report length of 
followup. 
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Table E. Summary of the comparative safety of pharmacologic therapies for the management of 
crohn’s disease (continued) 
Outcome (Incidence) 
Strength of 
Evidence Conclusion 
All cancers (insufficient 
data to estimate 
incidence) 
Low The risk of other cancers did not differ between treatment groups. The 
RRs compared with no treatment or another treatment from 
observational studies ranged from 0 to 10.8, with followup ranging from 
4 weeks to 12 years. 
Infections (<5% in most 
trials for serious 
infections; <5 out of 
every 100 person-years 
for opportunistic 
infections; 5 to 20% in 
most trials) 
Low The risk of infection did not differ among groups that received 
natalizumab, TNF-alpha inhibitors, immunomodulators, or 
aminosalicylates. The RRs, HRs, or ORs from RCTs and observational 
studies, compared with no treatment or another treatment, were 0.3 to 
1.3 for natalizumab, 0.3 to 11.1 for TNF-alpha inhibitors, 0.3 to 5.4 for 
immunomodulators, 0.4 to 3.4 for corticosteroids, and 0.9 to 1.8 for 
aminosalicylates, with followup ranging from 4 weeks to 9 years. 
Infections (<5% in most 
trials for serious 
infections; <5 out of 
every 100 person-years 
for opportunistic 
infections; 5 to 20% in 
most trials) 
Moderate The risk of infection was lower with prednisone and sulfasalazine than 
with prednisone alone. The RR from one RCT was 0.3, with 8 weeks of 
followup. 
Tuberculosis 
(insufficient data to 
estimate incidence) 
Low The risk of developing tuberculosis did not differ between treatment 
groups in 5 RCTs comparing TNF-alpha inhibitors with placebo, 1 RCT 
comparing a combination of infliximab and immunomodulators with 
infliximab, and 1 RCT comparing a combination of infliximab and 
immunomodulators with immunomodulators. The followup ranged from 
4 to 52 weeks. 
Infusion-site reactions 
(0 to 40% in most trials 
of biologics) 
Low The rate of infusion reactions did not differ between treatment groups in 
most comparisons. The RRs, HRs, or ORs from RCTs and 
observational studies were: natalizumab vs. placebo, RR ranged from 
0.8 to 1.5; certolizumab pegol vs. placebo, RR ranged from 0.2 to 1.7; 
combinations with infliximab vs. infliximab alone, RR ranged from 0.3 to 
1.5; infliximab combined with thiopurine vs. infliximab combined with 
methotrexate, RR ranged from 0.8 to 1.4. 
Infusion-site reactions 
(0 to 40% in most trials 
of biologics) 
Low The rate of infusion reactions was higher with infliximab and 
adalimumab than with placebo. The RRs from RCTs ranged from 1.1 to 
3.2. 
Infusion-site reactions 
(0 to 40% in most trials 
of biologics) 
High The rate of infusion reactions was higher with infliximab than with 
azathioprine. The RR from one RCT was 3.0, with 1 year of followup. 
Bone fractures 
(insufficient data to 
estimate incidence) 
Moderate The risk of bone fracture did not differ between treatment groups that 
received budesonide or prednisolone. The RR from one RCT with 2 
years of followup was 1.0. 
Bone fractures 
(insufficient data to 
estimate incidence) 
Low The risk of bone fracture did not differ between corticosteroid users and 
corticosteroid nonusers. The RR from observational studies ranged 
from 0 to 2.5, with 2 years of followup. 
AERS = Adverse Event Reporting System; HR = hazard ratio; HSTCL = hepatosplenic T-cell lymphoma; OR = odds ratio; 
RCT = randomized controlled trial; RR = relative risk; TNF = tumor necrosis factor 
Key Question 4. Patient-Reported Outcomes After Surgery 
We identified only one study that met the inclusion criteria for KQ4. This RCT compared 
azathioprine with mesalamine and reported on the IBDQ among patients who had undergone 
ileocolonic anastomosis within 6 to 24 months prior to randomization. The strength of the 
evidence was high for no difference in the effect on the IBDQ between azathioprine and 
mesalamine.  
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Key Questions 1–4 for Pediatrics 
Study Characteristics 
Five studies were RCTs,34-38 two were prospective cohort studies,39,40 and three were 
retrospective cohort studies.41-43 Studies were conducted in various countries, and five studies 
were multicentered. The length of followup ranged from 8 weeks to 18 months for RCTs and up 
to 3.6 years in an observational study.  
Population Characteristics 
The mean age of patients ranged from 12 to 14 years. In the RCTs, 55 to 69 percent of 
patients were male, more than 90 percent of patients were White, and mean disease duration 
ranged from 7 to 36 months. Individual studies restricted their patients in terms of disease 
location, disease duration, and/or medications allowed prior to and during the study.  
Pediatric Results 
Few studies examined the efficacy and safety of Crohn’s disease treatments in the pediatric 
population (younger than 18 years old). Four RCTs compared the efficacy of therapies, alone or 
in combination, in inducing or maintaining remission in children with Crohn’s disease. Eight 
studies reported the comparative safety of therapies, alone or in combination, in children with 
Crohn’s disease. Of these eight studies, most used height or weight change as their primary 
outcomes of interest. No study reported patient-reported outcomes after surgical resection.  
The SOE was graded as insufficient or low for all but two comparisons in the pediatric 
population. The SOE was graded as moderate for no difference in the effectiveness of 
budesonide versus prednisolone in inducing remission. The SOE was also graded as moderate 
that patients treated with prednisolone had fewer infections than patients treated with 
budesonide. 
Discussion 
Key Findings 
We found that a number of medications were effective in inducing and maintaining remission 
in Crohn’s disease, but no single medication or class of medications stood out as being most 
effective while also providing the highest quality of life and the best safety profile. Consistency 
of effect was based on a medication comparison having the same direction of effect for both 
disease activity (across evaluable time points) and at least one other outcome. 
For KQ1, on induction of remission, infliximab was found to have the greatest consistency 
across the outcomes of disease activity, mucosal healing, fistula healing, and IBDQ when 
compared with placebo (based on two trials). It was also the only comparison that included a 
high SOE for a given outcome (fistula healing).  
Other consistent comparisons that included at least one outcome with a moderate SOE 
included the following: infliximab was favored over azathioprine for disease activity and 
mucosal healing (based on one trial); the combination of infliximab and azathioprine was 
favored over azathioprine alone for disease activity and mucosal healing (based on two trials); 
and the combination of infliximab and azathioprine was favored over infliximab alone for 
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disease activity and mucosal healing (based on one trial). In all three of these comparisons, 
IBDQ was not different between treatment arms. 
Several placebo-controlled trials were also found to be consistent across outcomes. However, 
all the individual outcomes were rated as low SOE. The following interventions were favored 
over placebo: prednisone/6-methyl-prednisolone for disease activity and fistula healing (based on 
two trials); sulfasalazine for disease activity and fistula healing (based on two trials); and 
thiopurine for disease activity and fistula healing (based on one trial). Thiopurines and placebo 
did not differ in corticosteroid reduction and IBDQ. 
For head-to-head trails, the following comparisons were consistent across outcomes, with all 
individual outcomes rated as low SOE: combination of infliximab and methotrexate favored over 
infliximab alone for disease activity, steroid reduction, and IBDQ (based on one trial); and 
corticosteroids favored over thiopurines for disease activity and fistula healing (based on one 
trial). 
For KQ2, on maintenance of remission, infliximab was found to have the greatest 
consistency across outcomes when compared with placebo for disease activity, mucosal healing, 
hospitalization, surgery, corticosteroid reduction, fistula healing, and IBDQ (based on three 
trials). Adalimumab was also favored over placebo for the outcomes of disease activity, 
hospitalization, surgery, and corticosteroid reduction (based on two trials); however, adalimumab 
was not favored over placebo for IBDQ.   
Other consistent comparisons with at least one outcome rated as moderate SOE included: 
natalizumab favored over placebo for disease activity, steroid reduction, and IBDQ (based on 
one trial); azathioprine over budesonide for disease activity and mucosal healing (based on one 
trial); and budesonide over aminosalicylates for disease activity and IBDQ (based on one trial). 
Thiopurines were consistently favored over placebo for disease activity and corticosteroid 
reduction (based on four trials); however, all the outcomes were rated as low SOE. 
For KQ3, on safety, the SOE for nearly every comparison was graded as insufficient or low 
for safety-related outcomes. 
Applicability of Remission Results for Adults 
Older populations and non-Whites were underrepresented. Additionally, the relevance of the 
study findings beyond the clinical trial setting may be limited due to the lack of routine reporting 
on outcomes other than the CDAI, which is not used in clinical practice. The applicability to 
newly diagnosed patients and comparisons of step-up versus top-down treatment were limited 
because almost all of the trials included patients with at least 10 years of Crohn’s disease prior to 
randomization and no trial compared patients receiving their first treatment after diagnosis. 
Finally, very few trials had endpoints beyond a 1-year duration.  
Applicability of Safety Results for Adults 
Because they had fewer inclusion and exclusion criteria than RCTs, the observational studies 
likely apply to Crohn’s disease patients of all disease activity and severity levels. Very few 
observational studies required disease activity or prior medication use for study entry. Despite 
the differences in inclusion and exclusion criteria between the RCTs and observational studies, 
we did not see meaningful differences in safety signals between the RCTs and observational 
studies. The studies that included all inflammatory bowel disease patients had safety findings 
similar to those of studies that included only Crohn’s disease patients or that reported results for 
both Crohn’s disease and all inflammatory bowel disease patients. 
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Pediatric Applicability 
The applicability of the pediatric studies was limited because of the small number of studies, 
with few participants per study. Also, very few medications were compared. The longest RCT 
had only 18 months of followup, and the longest prospective study had less than 4 years of 
followup.  
Limitations 
The identified body of evidence had several limitations that restricted the ability to draw 
conclusions about the effectiveness of medications to treat Crohn’s disease. Head-to-head studies 
were limited, especially with regard to maintenance of remission. Although much attention has 
been given to top-down therapy (starting TNF-alpha inhibitors and/or thiopurines early in the 
disease course), few studies have compared this strategy with more traditional step-up therapy 
(escalating therapy after treatment with aminosalicylates or corticosteroids fails) in an RCT 
setting. Additionally, data were lacking on measures of remission other than the CDAI, such as 
patient-reported outcomes, mucosal healing, steroid reduction, fistula healing, hospitalization, 
and surgical rates. Comparisons for safety outcomes almost always had low or insufficient SOE 
due to lack of details on their assessment in RCTs and poor control for confounding in 
nonrandomized studies. The scope of studies in pediatric patients was very limited, as there are 
no double-blind RCTs among this population. None of the studies directly addressed safety 
concerns relevant to children, who may have longer lifetime exposures to these medications. 
Safety concerns of particular interest are the risk of hepatosplenic T-cell lymphoma, which 
affects boys and young men more than other demographic groups.  
Findings in Relation to What Is Known 
The major difference in findings between this review and previous reviews4,44-57 pertains to 
infliximab. Other reviews found that all TNF-alpha inhibitors are efficacious at inducing and 
maintaining remission. When the clinically meaningful threshold for a difference in treatment 
effects is considered for consistency of efficacy across the different outcomes of interest, 
infliximab is the only TNF-alpha inhibitor that is consistently favored over placebo at multiple 
time points and for multiple outcomes. Consistency was not found for adalimumab or 
certolizumab pegol because of inconsistency of efficacy between outcomes and absence of 
outcome information other than the CDAI. 
Research Gaps 
Multiple gaps in the literature on medical therapy for Crohn’s disease were isolated:  
• Studies underrepresented non-White patients, pediatric patients, and newly diagnosed 
populations. 
• Few studies made direct comparisons of medications. 
• Trials were not powered to compare safety, and observational studies did not account 
for confounders when comparing adverse events. 
• Few studies evaluated outcomes other than the CDAI, such as mucosal healing, rates 
of hospitalization and surgery, fistula healing, and patient-reported outcomes. 
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• Maintenance therapy outcomes in RCTs have rarely extended beyond 1 year, while 
observational studies have been insufficiently long to capture adverse events that may 
not manifest for years.  
Conclusions 
Infliximab was the only medication that was found to be consistently effective compared 
with placebo across a number of outcomes for both induction and maintenance of remission. 
There was little consistency across outcomes for head-to-head trials. For most medication 
comparisons, data were lacking on outcomes other than disease activity indexes. In children, the 
evidence was insufficient to permit assessment of the consistency of medication efficacy across 
outcomes. The quality of the safety evidence was poor due to poor reporting of the methods in 
trials and poor confounding control in observational studies. No strong or previously unidentified 
signals of harm were identified. Comparing Crohn’s disease medications directly using 
pragmatic clinical trials will help to understand the effectiveness of medications in clinical 
practice using outcomes other than the Crohn’s Disease Activity Index. 
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Introduction 
Background 
Description of Disease 
Crohn’s disease is a type of inflammatory bowel disease. Other types of inflammatory bowel 
disease include ulcerative colitis and indeterminate colitis. Current medical science defines 
Crohn’s disease as chronic full thickness inflammation that can occur anywhere in the 
gastrointestinal tract, but most often affects the small bowel and colon. Typical symptoms of 
Crohn’s disease include abdominal pain, chronic diarrhea, and gastrointestinal bleeding. Crohn’s 
disease affects between 400,000 and 600,000 North Americans.1 Ten percent of Crohn’s disease 
patients are children under the age of 17.2 
Crohn’s disease is an inappropriate immune response to intestinal microbes that is genetic in 
origin.3 Key symptoms include focal ulcerations or acute and chronic inflammation, detected 
through endoscopy and biopsy, respectively. 
The activity of Crohn’s disease fluctuates over time. One study estimated that during the first 
7 years after diagnosis, 20 percent of Crohn’s disease patients will have active disease at least 
once each year, 67 percent will fluctuate between years of active disease and years in remission, 
and 13 percent will have no relapses after the initial disease episode.4  
Crohn’s disease frequently leads to complications that require surgical intervention. One of 
the most common complications of Crohn’s disease is fibrotic narrowing of the intestines 
(stricture), which can lead to obstruction, collections of pus in the abdomen or around the rectum 
(abscess), and spontaneous rupture of the bowel contents through the skin or other organs 
(fistula). In a study based on a cohort from Olmsted County, Minn., half of all patients had 
experienced at least one intestinal complication within 10 years of diagnosis.5 Two studies based 
on the same cohort reported that half of patients required at least one surgical resection within 10 
years of diagnosis.5 
Interventions To Treat Crohn’s Disease 
Dr. Burrill Crohn’s initial description of this disease suggested that it could be cured with 
wide surgical resection. Research has since proven this to be false.6 The current accepted 
treatment is to administer medications designed to stop the intestinal inflammation and prevent 
further complications. Physicians refer to patients who no longer have inflammation as being in 
remission. To maintain remission, patients must continue to use these drugs. However, in spite of 
the success of this form of treatment, some patients relapse with renewed disease activity and an 
increase of symptoms. We show these disease states in Figure 1. 
There are four major classes of medications physicians have used to induce and maintain 
remission: biologics, immunomodulators, corticosteroids, and aminosalicylates. The 
aminosalicylate, sulfasalazine, and corticosteroids emerged in the mid-1900s. 
Immunomodulators (such as 6-mercaptopurine, azathioprine, and methotrexate) came out in the 
1970s, although the use of these medications was not routine until the 1990s.7 The Food and 
Drug Administration (FDA) approved the first biologic tumor necrosis factor-alpha (TNF-alpha) 
inhibitor, infliximab, for Crohn’s disease in 1998. Additional FDA-approved biologics include 
the TNF-alpha inhibitors adalimumab and certolizumab pegol, and the cellular adhesion 
molecule alpha-4 integrin inhibitor natalizumab.8  
1 
Table 1 summarizes the Crohn’s disease medications (biologics, immunomodulators, 
corticosteroids, and aminosalicylates) their mechanisms of action, and FDA approval status. 
Table 2 summarizes the black box warnings for safety for these medications. 
 
Figure 1. Crohn’s disease activity changes over time 
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Table 1. List of medications used for treatment of Crohn’s disease 
Class Generic Name 
United States 
Trade Name Route Half-Life Mechanism of Action 
FDA 
Approved 
for CD in 
Adults 
FDA 
Approved 
for CD in 
Children 
Biologic Adalimumab Humira Subcutaneous 10-18 days TNF-alpha inhibitor Yes No 
Biologic Certolizumab pegol Cimzia Subcutaneous ~14 days TNF-alpha inhibitor Yes No 
Biologic Infliximab Remicade Intravenous 7.7-9.5 days TNF-alpha inhibitor Yes Yes 
Biologic Natalizumab Tysabri Intravenous 7-15 days Prevents attachment of 
inflammatory immune 
cells to intestinal cell 
layers 
Yes No 
Immunomodulator Azathioprine Azasan; Imuran Oral, intravenous 5- hours Purine synthesis inhibitor No No 
Immunomodulator 6-mercaptopurine Purinethol Oral 1-2 hours Purine synthesis inhibitor No No 
Immunomodulator Methotrexate Methotrexate  Intravenous, oral 3-15 hours Dihydrofolate reductase 
inhibitor 
No No 
Corticosteroid Prednisone, 
prednisolone,  
6-methylpredisolone, 
hydrocortisone, 
budesonide 
Cortef, Entocort Oral, topical, 
intravenous 
8-54 hours Binds glucocorticoid 
receptors in cytoplasm, 
where it upregulates anti-
inflammatory genes 
No* No 
Aminosalicylate Mesalamine Asacol, Canasa, 
Pentasa, Lialda, 
Rowasa 
Oral, rectal 2-15 hours Unknown No No 
Aminosalicylate Sulfasalazine Azulfidine Oral 5-10 hours Unknown No No 
CD = Crohn’s disease; FDA = Food and Drug Administration; TNF = tumor necrosis factor; U.S. = United States 
*Budesonide is approved by the Food and Drug Administration for mild to moderate Crohn’s disease. 
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Table 2. Black box warnings listed on the prescribing information sheets of medications to treat Crohn’s disease 
Class Generic Name Boxed Warning 
Biologic Adalimumab • Malignancies (lymphoma and other malignancies, some fatal) 
• Hepatosplenic T-cell lymphoma 
• Serious infections (hospitalization, death, tuberculosis, bacterial sepsis, invasive fungal infections, 
opportunistic infections) 
Biologic Certolizumab pegol • Malignancies (lymphoma and other malignancies, some fatal) 
• Serious infections (hospitalization, death, tuberculosis, bacterial sepsis, invasive fungal infections, 
opportunistic infections) 
Biologic Infliximab • Malignancies (lymphoma and other malignancies, some fatal) 
• Hepatosplenic T-cell lymphoma 
• Serious infections (hospitalization, death, tuberculosis, bacterial sepsis, invasive fungal infections, 
opportunistic infections) 
Biologic Natalizumab • Progressive multifocal leukoencephalopathy 
Immunomodulator Azathioprine • Malignancies (post-transplant lymphoma and hepatosplenic T-cell lymphoma) 
Immunomodulator Methotrexate • Fetal death and/or congenital anomalies 
• Reduced elimination in patients with impaired renal function, ascites, or pleural effusions 
• Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and gastrointestinal 
toxicity 
• Hepatotoxicity, fibrosis, and cirrhosis 
• Lung disease 
• Diarrhea and ulcerative stomatitis 
• Malignant lymphomas 
• Tumor lysis syndrome 
• Severe, occasionally fatal, skin reactions 
• Potentially fatal opportunistic infections 
• Soft tissue necrosis and osteonecrosis 
Immunomodulator 6-mercaptopurine No black box warnings 
Corticosteroid Prednisone, 
prednisolone,  
6-methylpredisolone, 
hydrocortisone, 
budesonide 
No black box warnings 
Aminosalicylate Sulfasalazine No black box warnings 
Aminosalicylate Mesalamine No black box warnings 
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Current Controversies in the Treatment of Crohn’s Disease  
One of the Institute of Medicine’s priorities for comparative effectiveness research is to 
compare algorithms for Crohn’s disease treatment that introduce biologics at different time 
points in the disease course.9 Another treatment that warrants study is the use of biologics in 
combination with immunomodulators. Some research has suggested that improved long-term 
outcomes result from using immunomodulators and biologics early (“top-down therapy”), as 
opposed to using them after a patient has undergone prolonged steroid therapy (“step-up 
therapy”) (Figure 2).10 Science needs to weigh the benefits of this early treatment approach 
against the risks of increased immunosuppression, including lymphoma,11 and the expense and 
harms of over-treating patients who will not receive an intestinal resection (40 percent) and 
patients who will not have aggressive, disabling disease (70 percent).1 The major challenge and 
focus of current research is to arrest the natural progression of disease while minimizing adverse 
events and interventions, such as surgeries.12 
 
Figure 2. Treatment pyramid for patients with Crohn’s disease 
 
Treatment Guidelines and Meta-Analyses on the Management of 
Crohn’s Disease 
When evidence-based research is sparse, treatment guidelines for the management of Crohn’s 
disease often combine evidence-based medicine with expert panel review. In the United States, 
the American College of Gastroenterology, the American Gastroenterological Association, and 
the American Society of Colon and Rectal Surgeons publish management guidelines for Crohn’s 
disease.8 13-18 The treatment guidelines point to controversial areas in need of future research 
including: treatments to achieve long-term remission; the benefits and harms of step-up versus 
top-down treatment strategies; and optimizing the use of biologic agents, given that other 
treatments are effective at managing disease for large number of patients. This report addresses 
these aims. 
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Previous Systematic Reviews 
Meta-analyses have compared individual medications with placebo but few have compared 
medications to each other. There are 43 high-quality meta-analyses for Crohn’s disease that have 
compared biologics, immunomodulators, corticosteroids, and aminosalicylates with placebo. 
Eighteen of these are from the Cochrane Collaboration.  
A recent high-quality meta-analysis of randomized control trials published through February 
2009 examined the efficacy of treatments after surgical resection, but did not report on the 
quality of life effects.19 Few meta-analyses reported quality of life, although quality of life 
remains a high priority topic for patients.  
The central question for patients and their caretakers is the comparison of medications to 
each other at relevant time points in the natural progression of disease. This report focuses on 
these questions and includes the comparison of combinations of medications.  
Scope of the Evidence Report and Key Questions 
As displayed in Figure 3, the purpose of this review is to give clinicians a comprehensive 
comparison of the effectiveness and safety of biologics, immunomodulators, corticosteroids, and 
aminosalicylates in the treatment of Crohn’s disease. The specific Key Questions (KQs) of 
interest are:  
KQ1: What is the comparative effectiveness of therapies alone or in 
combination used to induce remission in adults and children with active 
Crohn’s disease? 
KQ2: What is the comparative effectiveness of therapies alone or in 
combination used to maintain remission in adults and children with inactive 
Crohn’s disease? 
KQ3: What is the comparative safety of therapies alone or in combination 
used in adults and children with Crohn’s disease in terms of minimizing 
short- and long-term adverse effects? 
KQ4: What is the comparative effectiveness of agents used to prevent 
post-operative recurrence in Crohn’s disease as pertains to patient-
reported outcomes? 
 
For each KQ, we aimed to evaluate specific outcomes as listed in Table 3. Table 4 lists the 
disease activity indexes and disease-specific quality of life instruments the studies commonly 
used. 
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Figure 3. Analytic framework for assessing the comparative effectiveness and safety of pharmacologic therapies for Crohn’s disease 
 
KQ = Key Question 
Note: KQ1: comparative effectiveness in inducing remission; KQ2: comparative effectiveness in maintaining remission; KQ3: comparative safety; KQ4: comparative effectiveness 
of treatments for post-surgical patient-reported outcomes 
*For KQ4, the only examined endpoint is patient-reported outcomes. 
7 
Table 3. List of outcomes considered for each Key Question on the comparative effectiveness and 
safety of medications for treatment of Crohn’s disease 
Key Question Outcomes 
KQ1 • Disease activity measures (remission, CDAI, PCDAI, HBI, or other disease activity 
measurements) 
• Mucosal healing (presence of ulcers, CDEIS) 
• Hospitalizations 
• Surgeries 
• Reduction of steroids 
• Fistula response (complete or partial fistula closure or other measure of perianal disease) 
• Patient-reported outcomes (health-related quality of life, IBDQ, days of work or school missed) 
KQ2 • Disease activity measures (relapse, CDAI, PCDAI, HBI, or other disease activity 
measurements) 
• Mucosal healing (presence of ulcers, CDEIS) 
• Hospitalizations 
• Surgeries 
• Reduction of steroids 
• Fistula response (fistula recurrence or other measure of perianal disease) 
• Patient-reported outcomes (health-related quality of life, IBDQ, days of work or school missed) 
KQ3 • Mortality 
• Lymphomas 
• Cervical cancer 
• Other cancers 
• Tuberculosis 
• Serious infections 
• Other infections 
• Infusion- and injection-site reactions 
• Bone fractures 
• Height and weight (for pediatric studies only) 
KQ4 • Patient-reported outcomes (health-related quality of life, IBDQ, days of work or school missed) 
CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; HBI = Harvey-Bradshaw 
Index; IBDQ = Inflammatory Bowel Disease Questionnaire; KQ = Key Question; PCDAI = Pediatric Crohn’s Disease Activity 
Index 
Note: KQ1: comparative effectiveness in inducing remission; KQ2: comparative effectiveness in maintaining remission; KQ3: 
comparative safety; KQ4: comparative effectiveness of treatments for post-surgical patient-reported outcomes 
 
Table 4. List of disease activity indexes and disease-specific quality of life instruments 
Measure or Instrument Range of Total Scores Higher Scores Indicate 
Crohn’s Disease Activity Index 0 to 600 More severe disease activity 
Pediatric Crohn’s Disease Activity Index 0 to 100 More severe disease activity 
Harvey-Bradshaw Index 0 to 19 More severe disease activity 
Crohn’s Disease Endoscopic Index of Severity 0 to 44 More severe disease activity 
Inflammatory Bowel Disease Questionnaire 32 to 224 Better quality of life 
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Methods 
A patient with Crohn’s disease nominated this topic because she was frustrated by the lack of 
consensus among physicians about her treatment options after surgical resection. Her experience 
reflects the general lack of consensus about pharmacologic therapies for the management of 
Crohn’s disease. Our Evidence-based Practice Center established a team and a work plan to 
develop this evidence report. The project involved recruiting Key Informants and technical 
experts, formulating and refining the Key Questions (KQs), performing a comprehensive 
literature search, summarizing the state of the literature, constructing evidence tables, 
synthesizing the evidence, and submitting the report for peer review and public comment. 
Topic Development 
At the beginning of the project, we recruited a panel of Key Informants to give input on the 
selection and refinement of the KQs. The Key Informants included a patient with Crohn’s 
disease, clinician-investigators having experience in research on treatment of Crohn’s disease, 
and a pharmaceutical company representative. Our draft KQs appeared on the Agency for 
Healthcare Research and Quality (AHRQ) Web site for public comment in March 2010. 
Assessing input from Key Informants, representatives of AHRQ, and public comments, we 
developed the KQs that we listed in the Scope and Key Questions section of the Introduction. 
The final KQs focus on the comparative effectiveness and safety of individual and combined 
therapies for Crohn’s disease (including biologics, immunomodulators, corticosteroids, and 
aminosalicylates) in terms of: (1) induction of remission, (2) maintenance of remission, (3) 
adverse effects, and (4) patient-reported outcomes after surgical resection.  
We drafted a protocol to address our KQs. We then recruited a panel of technical experts, 
which included the Key Informants, an epidemiologist, and a pediatric gastroenterologist. With 
input from the Technical Expert Panel and representatives from AHRQ, we finalized the 
protocol. 
Search Strategy 
We searched the following databases for primary studies for the dates shown in parentheses: 
MEDLINE® (1966 through June 2011), Embase® (1974 through June 2011), and the Cochrane 
Central Register of Controlled Trials (Issue 2, 2011). We developed a search strategy for 
MEDLINE, accessed via PubMed, based on an analysis of the medical subject heading (MeSH) 
terms and text words of key articles identified a priori (Appendix A).  
To identify additional studies, we reviewed the following material from the Evidence-based 
Practice Center’s Program’s Scientific Resource Center: 
• Medical and/or statistical reviews of adalimumab, certolizumab pegol, infliximab, 
natalizumab, hydrocortisone, prednisone, prednisolone, and mesalamine from the Food 
and Drug Administration (FDA) Web site, 
• Health Canada Product Monographs for adalimumab, certolizumab pegol, infliximab, 
natalizumab, azathioprine, 6-mercaptopurine, methotrexate, hydrocortisone, and 6-
methylprednisolone, 
• Public registries of clinical trials, including the Clinical Study Results Web site 
(www.clinicalstudyresults.org) and ClinicalTrials.gov (www.clinicaltrials.gov). 
 
We also reviewed the reference lists of each included article and relevant review articles.  
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To assess the risk of two serious rare complications of treatment for Crohn’s disease, 
hepatosplenic T-cell lymphoma and primary multifocal leukoencephalopathy, we supplemented 
the primary search strategy by also searching for cases reported to the FDA’s Adverse Event 
Reporting System. 
We downloaded the results of the searches and imported into ProCite® version 5 (ISI 
ResearchSoft, Carlsbad, Calif.). We scanned for exact article duplicates, author/title duplicates, 
and title duplicates using the duplication check feature in ProCite®. From ProCite, we uploaded 
the articles to DistillerSR (Evidence Partners, Ottawa, Ontario, Canada), a Web-based software 
package developed for systematic review data management. We used this database to track the 
search results at the levels of title review, abstract review, article inclusion/exclusion, and data 
abstraction.  
Study Selection 
Two independent reviewers conducted title scans. To eliminate the title at this level, both 
reviewers had to agree that it was ineligible (Appendix B, Title Review Form). If they disagreed, 
we promoted the article to the next level. We designed the title review to capture as many studies 
as possible that potentially reported on the efficacy or safety of therapies for the management of 
Crohn’s disease.  
Two investigators reviewed abstracts independently, and we excluded articles if both 
investigators agreed that the article met one or more of the exclusion criteria (see inclusion and 
exclusion criteria listed in Table 5 and the Abstract Review Form in Appendix B). We resolved 
differences between investigators regarding abstract inclusion or exclusion through consensus 
adjudication. 
When reviewers promoted articles on the basis of abstract review, additional independent 
investigators determined if they should be included for data abstraction (Appendix B, Article 
Review Form). We resolved differences regarding article inclusion through consensus 
adjudication. A third reviewer audited a random sample of abstract and article reviews to ensure 
consistency in the reviewing process. 
To evaluate induction and maintenance of remission (KQ1 and KQ2), we included only 
randomized controlled trials (RCTs). Both placebo-controlled and head-to-head trials were 
eligible. We did not include trials that only examined the same medication administered at 
different time points or at different dosages. We chose clinically important and patient-centered 
outcomes of interest for KQ1 and KQ2. 
To evaluate the safety of treatment (KQ3), we included RCTs and observational studies. We 
chose specific safety outcomes based on the severity of the outcome, impact on quality of life, 
and potential for safety to differ by medication class. We selected clinical outcomes a priori for 
inclusion. All RCTs that reported on safety were eligible. Observational studies were eligible if 
they reported a relevant comparison group with clear numerators and denominators for each 
group or an effect estimate or p-value for a safety outcome by medication use. Because of the 
rarity and severity of hepatosplenic T-cell lymphoma and progressive multifocal 
leukoencephalopathy, we included all study types (including case reports) for these outcomes. 
A rigorously conducted systematic review19 had recently assessed the efficacy and safety of 
medications to maintain remission of Crohn’s disease after intestinal resection. Instead of 
duplicating that work, we limited the focus of KQ4 to the comparative effects of medications on 
patient-reported outcomes as reported in RCTs and observational studies. The previous review 
did not include these outcomes.  
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Table 5. Inclusion and exclusion criteria for identifying eligible studies 
Category Inclusion Criteria Exclusion Criteria 
Population 
and 
condition 
• Included studies of human subjects of all ages 
with Crohn’s disease 
• Sensitivity analysis for KQ3 included patients with 
any inflammatory bowel disease 
• Excluded studies if they included only 
pregnant women 
Interventions • Included studies evaluating a Crohn’s disease 
medication of interest (see Table 1) or 
combination of medications of interest compared 
with each other or with placebo 
 
Comparisons  • Included studies that had a comparison group, 
where the comparison was either a medication or 
combination of medications of interest or placebo 
• Excluded studies that compared a 
medication of interest to a medication 
not of interest (such as antibiotics or 
fish oil supplements)  
• Excluded studies that only evaluated 
the same medication given at 
different times or at different doses 
Outcomes • Included the following outcomes for KQ1 and KQ2: 
Crohn’s Disease Activity Index (CDAI), mucosal 
healing, hospitalizations, surgery, corticosteroid 
reduction, fistula response, and patient-reported 
outcomes representing quality of life  
• Included the following harms of medications for 
KQ3: mortality, lymphomas, cervical cancer, other 
cancers, tuberculosis, serious infections, other 
infections, infusion and injection-site reactions, 
bone fractures, and, in children, height and weight 
as indicators of growth 
• Included the following patient-reported outcomes 
for KQ4: generic and disease-specific quality of life 
indices (e.g., IBDQ), and days of work or school 
missed 
• Excluded studies that did not apply to 
the KQs 
Type of 
study 
• Included studies with any sample size from any 
year that met all other criteria 
• Included only RCTS for KQ1 and KQ2 
• Included all study designs with a comparison 
group, for KQ3 and KQ4, including: RCTs, 
prospective and retrospective cohorts, crossover 
studies, case-control studies and cross-sectional 
studies 
• Included all study types (including case reports) 
for hepatosplenic T-cell lymphoma and 
progressive multifocal leukoencephalopathy 
because these outcomes are very rare and 
frequently fatal 
• Excluded articles not written in 
English, articles with no original data 
(reviews, editorials, comments, 
letters), and abstract-only 
publications 
IBDQ = Inflammatory Bowel Disease Questionnaire; KQ = Key Question; RCT = randomized controlled trial 
Data Abstraction 
We used a systematic approach for extracting data to minimize the risk of bias in this 
process. We created and pilot tested standardized forms for data extraction. By creating 
standardized forms for data extraction, we sought to maximize consistency in identifying all 
pertinent data available for synthesis.  
For all articles, reviewers extracted information on general study characteristics (e.g., study 
design, study period, and followup), study participants (e.g., age, sex, race/ethnicity, duration of 
Crohn’s disease, smoking status, disease severity, and disease location), eligibility criteria, 
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interventions (e.g., route of administration and dosing), outcome measures and the method of 
ascertainment, and the results of each outcome (including measures of variability).  
For KQ1, KQ2, and KQ4, we abstracted data on the following time points: (1) first time 
point after randomization or study start; (2) 12 to 16 weeks after randomization or study start; (3) 
48 to 54 weeks after randomization or study start; and (4) last prespecified time point. For KQ3, 
we abstracted data for the last reported time point only. 
We abstracted information on subgroup analyses to understand how disease characteristics 
could modify the relationship between medications and remission. We considered the following 
characteristics for subgroup analyses a priori because these characteristics are most clinically 
relevant: elevated baseline markers of inflammation (including C-reactive protein rates), baseline 
mucosal lesions, medications used at randomization (baseline), prior medication exposure, 
disease duration, disease location, and prior Crohn’s disease-related surgery. We only reported 
on studies that performed and reported a statistical test for interaction. 
Study investigators double reviewed each article for data abstraction. We abstracted all 
information into the DistillerSR database (Evidence Partners, Ottawa, Canada). The second 
reviewer confirmed the first reviewer’s data abstraction within DistillerSR for completeness and 
accuracy. We formed reviewer pairs to include personnel with both clinical and methodological 
expertise. Reviewers abstracted relevant data from figures when they were not available in text 
or table format. Reviewers entered comments into the system whenever applicable. We used the 
DistillerSR database to maintain the data, as well as to generate Excel files, which we used to 
create detailed evidence tables and summary tables. 
Quality Assessment 
We used study quality assessment to help us understand differences in results between 
studies. We used different quality assessment tools for RCTs and observational studies. For 
RCTs, we based the dual independent review of article quality on the Cochrane Collaboration’s 
Risk of Bias Tool20 and supplemented with items from the Evidence-based Practice Center 
Program’s “Methods Guide for Effectiveness and Comparative Effectiveness Reviews.”21 The 
quality assessment for RCTs included items on: (1) adequate allocation sequence generation, (2) 
adequate allocation concealment, (3) blinding, (4) incomplete outcome data, (5) other potential 
threats to validity, (6) pharmaceutical support, (7) company involvement in the design, conduct, 
or reporting of the study, (8) loss to followup, and (9) an overall rating of the quality assessment. 
We assessed the overall study quality in the following manner: 
• Good (low risk of bias). These studies had the least bias, and we considered the results 
valid. These studies adhered to the commonly held concepts of high quality, including the 
following: a clear description of the population, setting, interventions, and comparison 
groups; appropriate measurement of outcomes; appropriate statistical and analytic 
methods and reporting; no reporting errors; a low dropout rate; and clear reporting of 
dropouts. 
• Fair. These studies were susceptible to some bias, but not enough to invalidate the 
results. They did not meet all the criteria required for a rating of good quality because 
they had some deficiencies, but no flaw was likely to cause major bias. The study may 
have been missing information, making it difficult to assess limitations and potential 
problems.  
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• Poor (high risk of bias). These studies had significant flaws that might have invalidated 
the results. They had serious errors in design, analysis, or reporting; large amounts of 
missing information; or discrepancies in reporting.21  
 
For observational studies, we selected quality concepts from the Downs and Black quality 
checklist22 and added items from the “Methods Guide for Effectiveness and Comparative 
Effectiveness Reviews.”21 We assessed observational studies based on the following criteria: (1) 
clear description of main outcome to be measured, (2) clear description of patient characteristics, 
(3) clear description of interventions of interest, (4) clear description of the distributions of 
principal confounders, (5) recruitment of the different intervention groups from the same 
population, (6) handling of loss to followup, (7) adequate adjustment for confounding, (8) 
pharmaceutical support, (9) company involvement in the design, conduct, or reporting of the 
study, and (10) overall study quality. We assessed the overall study quality as “good” if the 
responses for items 1 to 7 were all “yes”; “fair” if most of the responses to items 1 to 4 were 
“yes” and all of the responses to items 5 to 7 were “yes”; and “poor” if none of the responses to 
items 1 to 4 were “yes” or any of the responses to items 5 to 7 were “no” or “unable to 
determine.” 
Reviewers resolved differences in study quality through consensus adjudication. We reported 
only the adjudicated quality scores.  
Applicability 
Throughout the report, we discuss the applicability of the bodies of evidence in terms of the 
degree to which the study population (e.g., age, race, disease severity), interventions (e.g., 
dosing, frequency, duration), comparisons, outcomes, timings, and settings are typical of the 
treatment of individuals with Crohn’s disease.  
Data Analysis and Synthesis 
For each KQ, we created a set of detailed evidence tables containing all information 
abstracted from eligible studies. We conducted meta-analyses when there were sufficient data (at 
least three trials) and when studies were sufficiently homogenous with respect to the population 
characteristics, intervention, comparison, outcome, timing, and setting. When possible for KQ1 
(induction of remission), we decided to conduct meta-analyses at the following clinically 
relevant time points:  
• 2 to 4 weeks (using the earliest available time point) 
• 12 to 16 weeks (using earliest available time point) 
• Last reported time point 
 
For KQ2 (maintenance of remission), we conducted meta-analyses at these time points: 
• 48 to 54 weeks  
• Last reported time point 
 
For KQ3 (adverse effects), the meta-analyses used the last reported time point available from 
at least three studies.  
For studies amenable to pooling with meta-analyses, we calculated pooled relative risks 
using a DerSimonian and Laird random effects model.23 We identified heterogeneity among the 
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trials in all the meta-analyses using: (1) a chi-squared test with a significance level of alpha less 
than or equal to 0.10, and (2) an I-squared statistic with a value greater than 50 percent indicating 
substantial heterogeneity.24 We did not report the pooled result if we found substantial 
heterogeneity. We conducted sensitivity analyses by omitting one study at a time to assess the 
influence of any single study on the pooled estimate. For all meta-analyses, we conducted formal 
tests for publication bias using Begg’s25 and Eggers tests,26 including an evaluation of the 
asymmetry of funnel plots for each comparison of interest. We conducted all meta-analyses 
using STATA (Intercooled, version 9.2, StataCorp, College Station, Texas).  
When we were unable to pool trials for an outcome, we calculated and displayed risk ratios 
with 95 percent confidence intervals for the individual studies. For KQ1 and KQ2, we considered 
a difference to be clinically meaningful when there was an absolute difference of 10 percentage 
points in the outcome between the groups compared, even when the difference was not 
statistically significant (p-value less than 0.05). Similarly, we did not report statistically 
significant relationships unless there was a clinically meaningful difference. For the Crohn’s 
Disease Endoscopic Index of Severity, we defined a clinically meaningful difference as an 
absolute difference in change from baseline of greater than 5 points.27 For the Inflammatory 
Bowel Disease Questionnaire (the most commonly employed outcome for patient-reported 
outcomes), we used an absolute difference in change from baseline of 17 points or greater.28 We 
considered a clinically significant reduction in corticosteroids to be a between-group difference 
of 10 mg in the average daily dose. Since there is no reference standard, we chose a 10 mg 
difference because it represents at least a 25 percent reduction in a typical steroid dose and 
patients are often tapered in 5 mg increments. In terms of adverse effects, when a study did not 
report an effect estimate, we calculated a Peto odds ratio if the combined number of events in 
each arm was greater than 5.29,30 We also calculated incidence rate ratios for person-time data 
when the authors did not report an effect estimate, or when the reported effect estimate appeared 
to contradict the reported events per person-time. We did not specify a standard for a clinically 
meaningful difference in the adverse events because the absolute rate was rare for most of the 
adverse events. 
Grading the Strength of Evidence 
At the completion of our review, we graded the best available evidence addressing KQ1 
through KQ4 by modifying the evidence grading scheme recommended by the “Methods Guide 
for Effectiveness and Comparative Effectiveness Reviews.”31 We applied evidence grades to the 
bodies of evidence for each outcome of each intervention comparison by population (e.g., adult 
or pediatric). If necessary, we created separate evidence grades by time point.  
We assessed the potential for bias by ranking study designs with RCTs higher than 
observational studies. We also evaluated the consistency, directness, and precision of the effects. 
We rated the body of evidence as “consistent” if most of the studies showed the same direction 
of effect. We rated the consistency of a single study as “unknown,” without downgrading the 
strength of evidence. We rated the body of evidence as “direct” if most studies directly measured 
the outcome of interest. We based our evaluation of precision on the clinically meaningful 
difference.   
We classified the strength of evidence pertaining to KQ1 through KQ4 into four grades:  
• “high” grade (indicating high confidence that the evidence reflects the true effect and 
further research is very unlikely to change our confidence in the estimate of the effect)  
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• “moderate” grade (indicating moderate confidence that the evidence reflects the true 
effect and further research may change our confidence in the estimate of the effect and 
may change the estimate)  
• “low” grade (indicating low confidence that the evidence reflects the true effect and 
further research is likely to change our confidence in the estimate of the effect and is 
likely to change the estimate) 
• “insufficient” grade (evidence is unavailable; no studies observed) 
 
We gave a high grade for strength of evidence to comparisons that included RCTs and a 
moderate grade to studies that did not include RCTs. For each domain (risk of bias, consistency, 
directness, precision, and other limitations) that was not optimal (moderate/high risk of bias, 
inconsistent, indirect, imprecise, or other limitations), we downgraded strength of evidence one 
level. 
Peer Review and Public Commentary 
We invited experts in adult and pediatric gastroenterology and individuals representing 
stakeholder and user communities to provide external peer review of this comparative 
effectiveness review. AHRQ and an associate editor also provided comments. AHRQ posted the 
draft report on its Web site for 4 weeks to elicit public comment. We addressed all reviewer 
comments, revising the text as appropriate, and documented everything in a “disposition of 
comments report” that will be made available 3 months after AHRQ posts the final comparative 
effectiveness review on the AHRQ Web site. 
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Results 
Search Results 
From our searches, we retrieved 17,745 articles after removing duplicates (Figure 4). After 
title and abstract review, we decided 1,138 articles were potentially relevant to review, and we 
retrieved the full articles. We included a total of 136 studies in this review (see Appendix C for 
list of articles excluded at the full text level). 
We reported the results of our systematic review according to Key Question, and separated 
adults from children. For the efficacy results, we organized the results for each Key Question by 
medication class--natalizumab, TNF-alpha inhibitor, thiopurines, methotrexate, corticosteroids, 
or aminosalicylates. When a study compared multiple medication classes, we began with the first 
medication in our list of medication classes, which we organized according to the top-down 
approach in the treatment pyramid (Figure 2). 
Within each medication class, we reported the study design, population characteristics, key 
points, strength of evidence (SOE) grading, and the outcomes results. We created key points for 
each comparison that had at least moderate SOE or a clinically meaningful difference. In the key 
points we presented the conclusion, the pooled relative risk or the range of risk differences, the 
placebo rates, and the SOE. We also presented the relative risk and risk differences in the SOE 
tables. We arranged the outcomes results by comparison. We presented the monotherapy 
placebo-controlled trials first, followed by monotherapy head-to-head comparisons, combination 
therapy placebo-controlled trials, combination therapy versus monotherapy comparisons, and 
combination therapy head-to-head comparisons. We reported the results of those meta-analyses 
for which we were able to combine clinically homogenous studies. When we were unable to pool 
the results, we presented the data in tables. 
We organized the safety results by outcome then by medication class. We reported the 
subgroup analyses at the end of each Key Question. Detailed evidence tables are found in 
Appendix D. 
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Figure 4. Summary of the literature search (number of articles) 
 
CENTRAL = Central Register of Controlled Trials; KQ = Key Question; OS = observational study; RCT = randomized 
controlled trial 
*The total may exceed number in corresponding box, as articles could be excluded for more than one reason at this level. 
Key Question 1: Effectiveness of Therapies To Induce 
Remission in Adults  
In order for trials to qualify for KQ1, patients had to have active disease at the time of 
randomization so that we could identify the effect of treatments to induce remission. In the 
Methods we describe induction of remission as occurring within 16 weeks of treatment for active 
disease. From a clinical perspective, later time points are better measures of maintenance of 
remission after induction. Regardless, the trials that reported on outcomes after 16 weeks are 
included in this section rather than in KQ2 because we distinguished KQ1 from KQ2 based on 
the disease activity at randomization. 
Table 6 summarizes the evidence grades and specific conclusions for each comparison. 
Details of the evidence grades are included in the Results and in Appendix D, Table 1. 
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Table 6. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2-4 
Disease 
Activity 
Measure 
Weeks 12-16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Natalizumab 
vs. placebo 
 
12 weeks 
Favors 
natalizumab; 
Moderate SOE 
Favors 
natalizumab;  
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 12 
Favors neither; 
Moderate SOE 
Natalizumab + 
infliximab vs. 
infliximab 
 
10 weeks 
Favors neither; 
Low SOE 
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 10 
Favors neither; 
Low SOE 
Adalimumab 
vs. placebo 
 
4 weeks 
>160 mg sc 
dose 
Favors 
adalimumab; 
High SOE 
 
≤80 mg sc dose 
Favors neither; 
Moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 4 
Favors 
neither; 
Low SOE 
Week 4 
Favors neither; 
High SOE 
CP vs. placebo 
 
26 weeks 
Favors neither; 
Low SOE 
Favors neither; 
Low SOE 
Week 26 
Favors CP; Low 
SOE 
Insufficient Insufficient Insufficient Week 26 
Favors 
neither; 
Low SOE 
Week 12 and 
Week 26 
Favors neither; 
Low SOE 
Infliximab vs. 
placebo 
 
12 weeks 
Favors 
infliximab; 
Moderate SOE 
Favors 
infliximab; Low 
SOE 
Insufficient Week 4 
Favors 
infliximab;  
Low SOE 
Insufficient Insufficient Week 6 
Favors 
infliximab; 
High SOE 
Week 4 
Favors 
infliximab; 
Moderate SOE 
Infliximab vs. 
azathioprine 
 
26 weeks 
Insufficient Favors 
infliximab; 
Moderate SOE 
Week 26 
Favors 
infliximab; 
Moderate SOE 
Week 26 
Favors 
infliximab; 
Low SOE 
Insufficient Insufficient Insufficient Week 26 
Favors neither; 
Moderate SOE 
Infliximab + 
azathioprine 
vs. infliximab 
 
26 weeks 
Insufficient Favors 
infliximab + 
azathioprine; 
Moderate SOE 
Week 26 
Favors 
infliximab + 
azathioprine; 
Moderate SOE 
Week 26 
Favors 
infliximab + 
azathioprine; 
Low SOE 
Insufficient Insufficient Insufficient Week 26 
Favors neither; 
Moderate SOE 
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Table 6. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2-4 
Disease 
Activity 
Measure 
Weeks 12-16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Infliximab + 
azathioprine 
vs. 
azathioprine 
 
26 weeks 
Insufficient Favors 
infliximab + 
azathioprine; 
Moderate SOE 
Week 26 
Favors 
infliximab + 
azathioprine; 
Moderate SOE 
Week 26 
Favors 
infliximab + 
azathioprine; 
Low SOE 
Insufficient Insufficient Insufficient Week 26 
Favors neither; 
Moderate SOE 
Infliximab + 
azathioprine 
vs. steroids 
 
104 weeks 
Insufficient Insufficient  Week 104 
Favors neither;  
Low SOE 
Week 104 
Favors 
infliximab + 
azathioprine; 
Low SOE 
Insufficient Insufficient Insufficient Week 10 
Favors 
infliximab + 
azathioprine; 
Low SOE 
Infliximab + 
methotrexate 
vs. infliximab 
 
48 weeks 
Favors 
infliximab + 
methotrexate; 
Low SOE 
Favors 
infliximab + 
methotrexate; 
Low SOE 
Week 48 
Favors 
infliximab + 
methotrexate; 
Low SOE 
Insufficient Insufficient Week 48 
Favors 
infliximab + 
methotrexat
e; Low 
SOE 
Insufficient Week 4 and 
Week 8 
Favors 
infliximab + 
methotrexate; 
Low SOE 
Thiopurines vs. 
placebo 
 
104 weeks 
Favors neither; 
Low SOE 
Insufficient Week 17-38 
Favors neither; 
Low SOE 
 
Week 104 
Favors 6-MP; 
Low SOE 
Insufficient Insufficient Week 16 
Favors 
neither; 
Low SOE 
Week 17 
Favors 
neither; 
Low SOE 
 
Week 104 
Favors 6-
MP; Low 
SOE 
Week 16 
Favors neither; 
Low SOE‡ 
Thiopurines vs. 
oral 
methotrexate 
 
38 weeks  
Favors neither; 
Low SOE 
Favors neither; 
Low SOE 
Week 38 
Favors neither;  
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines vs. 
steroids 
 
17 weeks 
Favors steroids; 
Low SOE 
Favors steroids; 
Low SOE 
Week 17  
Favors steroids; 
Low SOE 
Insufficient Insufficient Insufficient Week 17 
Favors 
steroids; 
Low SOE 
Insufficient 
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Table 6. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2-4 
Disease 
Activity 
Measure 
Weeks 12-16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Thiopurines vs. 
ASA 
 
30 weeks 
Favors ASA; 
Low SOE 
Favors neither; 
Low SOE 
Week 17  
Favors neither; 
Low SOE 
 
Week 30 
Favors 6-MP; 
Low SOE 
Insufficient Insufficient Insufficient Week 17 
Favors 
neither; 
Low SOE 
Insufficient 
Thiopurines (IV 
+ oral) vs. 
thiopurines 
(oral) 
 
16 weeks 
 Insufficient Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines + 
steroids vs. 
steroids 
 
28 weeks 
Insufficient Favors 
thiopurines + 
steroids; Low 
SOE 
Week 28  
Favors 
thiopurines + 
steroids; Low 
SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Thiopurines + 
steroids vs. 
methotrexate 
(IV, oral) + 
steroids 
 
26 weeks 
Insufficient Favors neither; 
Low SOE 
Week 26  
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Week 26 
Favors 
methotrexat
e + 
steroids; 
Low SOE 
Insufficient 
Methotrexate 
(oral) vs. 
placebo 
 
38 weeks 
Favors neither; 
Low SOE 
Favors neither; 
Low SOE 
Week 38  
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Methotrexate 
(oral) vs. ASA 
 
30 weeks 
Insufficient Insufficient Week 30 
Favors 
methotrexate; 
Moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table 6. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2-4 
Disease 
Activity 
Measure 
Weeks 12-16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Methotrexate 
(IM) + 
prednisone vs. 
prednisone 
 
16 weeks 
Insufficient Favors 
methotrexate; 
Moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 16 
Favors neither; 
Moderate SOE 
Budesonide 
vs. placebo 
 
16 weeks 
≥9 mg daily 
Favors 
budesonide; 
Moderate SOE 
 
<9 mg daily 
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 8 
No difference; 
Low 
6-methyl-
prednisolone 
or prednisone 
vs. placebo 
 
104 weeks 
6-methyl-
prednisolone  
Favors 6-
methylprednisol
one; Low SOE 
 
Prednisone 
Favors neither; 
Low SOE 
Favors steroids; 
Low SOE 
Week 104 
Favors steroids; 
Low SOE 
Insufficient Insufficient Insufficient Week 17 
Favors 
steroids; 
Low SOE 
Insufficient 
Budesonide 
vs. other 
steroids 
 
10 weeks 
Favors neither; 
Moderate SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 8 
Favors neither; 
Moderate SOE 
Steroids vs. 
ASA 
 
104 weeks 
Favors steroids; 
Low SOE 
Favors steroids; 
Low SOE 
Week 104 
Favors steroids; 
Low SOE 
Insufficient Insufficient Insufficient Week 17 
Favors 
neither; 
Low SOE 
Week 2 
Favors steroids; 
High SOE§ 
 
Week 12 
Favors neither; 
Moderate SOE§ 
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Table 6. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 2-4 
Disease 
Activity 
Measure 
Weeks 12-16 
Disease 
Activity 
Measure After 
16 Weeks  
Mucosal 
Healing 
Hospitalizations 
and Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
6-methyl-
prednisolone + 
sulfasalazine 
vs. placebo 
 
104 weeks 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
Low SOE 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
Low SOE 
Week 104 
Favors 6-
methyl-
prednisolone + 
sulfasalazine; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. steroids 
 
104 weeks 
Favors neither; 
Low SOE 
Favors neither; 
Low SOE 
Week 104 
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. 
sulfasalazine 
 
104 weeks 
Favors steroids 
+ sulfasalazine; 
Low SOE 
Favors steroids 
+ sulfasalazine; 
Low SOE 
Week 104 
Favors steroids 
+ sulfasalazine; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Mesalamine 
vs. placebo 
 
17 weeks 
Favors neither; 
Low SOE 
≥3.2 g daily 
Favors 
mesalamine; 
Low SOE 
 
<3.2 g daily 
Favors neither; 
Low SOE 
Insufficient Insufficient Insufficient Insufficient Insufficient  Insufficient 
Sulfasalazine 
vs. placebo 
 
104 weeks 
Favors neither; 
Low SOE 
Favors 
sulfasalazine; 
Low SOE 
Week 104 
Favors 
sulfasalazine; 
Low SOE 
Insufficient Insufficient Insufficient Week 17 
Favors 
sulfasalazine; 
Low SOE 
Insufficient 
6-MP = 6-mercaptopurine; ASA = aminosalicylates; CP = certolizumab pegol; g = grams; IM = intramuscular; IV = intravenous; mg = milligrams; SC = subcutaneous; SOE = 
strength of evidence; Steroid = corticosteroids; vs = versus 
The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence reflects 
the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
*All other potential comparisons of therapies and outcomes were graded as insufficient because there were no eligible trials. The evidence for the last reported measure is provided 
for disease activity after 16 weeks, mucosal healing, hospitalizations and surgeries, reduction of steroids, fistula response and patient-reported outcomes. 
†Patient-reported outcomes were measured by the Inflammatory Bowel Disease Questionnaire except where indicated by a footnote. 
‡Outcome based upon “feeling better” in 2 trials 
§Used McMaster University Quality of Life scale 
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Natalizumab 
Four trials randomized 1,523 participants to compare the efficacy of natalizumab with 
placebo to induce remission among patients with active Crohn’s disease at randomization. Three 
trials32-34 evaluated natalizumab versus placebo, while one trial35 evaluated the combination of 
natalizumab and infliximab versus infliximab and placebo. 
Study Design 
The trials defined active disease as a CDAI greater than 150 or 220 (Appendix D, Evidence 
Table 2).32-35 All trials used randomized double-blind designs. The treatment group received 300 
mg natalizumab administered intravenously three times at baseline, 4 and 8 weeks in three 
trials,32,33,35 whereas one trial34 evaluated a single 3 mg/kg baseline dose of intravenous 
natalizumab. One trial took place at multiple centers in the United States,35 another occurred in 
two centers in the United Kingdom,34 and the others were multinational.32,33 All trials except 
one34 reported the starting year of enrollment, with the first year of enrollment ranging from 
2001 to 2004.32,33,35 The outcome definition was consistent in all trials; CDAI less than 150 was 
the definition of remission. Inclusion criteria were generally consistent including the exclusion of 
patients with abscesses and obstructive symptoms consistent with strictures in three trials.32,33,35 
Medication exclusions included previous treatment with a TNF-alpha inhibitor within three 
months32,33 and treatment with methotrexate, cyclosporine, or tacrolimus within 3 to 4 months of 
enrollment.34 Elevated C-reactive protein ([CRP] > 2.7 mg/L) was an inclusion criteria in one 
trial32 based on subgroup analysis findings from a previous trial.33 All trials permitted patients to 
use aminosalicylates, antibiotics, corticosteroids, and thiopurines during the trial if they had been 
on a stable dose of the medication prior to baseline. 
Population Characteristics 
The populations tended to be similar across trials with the exception of sex, disease location, 
and concomitant medication use (Appendix D, Evidence Table 3). The proportion of male 
participants in each trial group ranged from 3 to 63 percent. Three trials reported on race32,34,35 
with white patients comprising between 85 and 95 percent of participants. Two trials32,33 reported 
smoking status, with smokers comprising 19 and 24 percent of participants. Mean age at 
enrollment was between 34 and 39 years. The mean duration of disease was between 8.5 and 
12.5 years. All trials32-35 reported disease location including ileal location (ranging between 15 
and 40 percent), ileocolonic location (ranging between 28 and 56 percent), and colonic location 
(ranging between 22 and 30 percent). One trial34 also reported that 30 percent of patients had 
perianal disease at baseline. All trials reported baseline CDAI, with mean CDAI ranging from 
244 to 330 points. Concurrent medication use during the trial was as follows: aminosalicylates 
use ranged between 37 and 75 percent,32-35 antibiotic use ranged from 5 to 19 percent,32,33,35 
corticosteroids use ranged between 27 and 75 percent, methotrexate use ranged from 3 to 4 
percent,33,35 and thiopurine use ranged between 17 and 33 percent.33-35 Two trials32,33 reported 
prior use of TNF-alpha inhibitors in 38 and 50 percent of participants. In the trial of combination 
therapy, all patients were unresponsive to infliximab as part of the inclusion criteria.35 
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Key Points 
Table 7 summarizes the strength of evidence for the trials evaluating natalizumab in terms of 
remission induction. We found at least moderate strength of evidence or a clinically meaningful 
difference for the following comparisons and outcomes: 
• Natalizumab was more effective than placebo in inducing a remission at weeks 2 to 4 
(pooled relative risk [RR], 1.5; 95% confidence interval [CI], 1.1 to 2.0; placebo rate, 8 to 
16 percent). (Strength of evidence [SOE]: Moderate) 
• Natalizumab was more effective than placebo in inducing a remission at week 12 
(absolute risk difference [RD], 9 to 13 percent; placebo rate, 0 to 31 percent). (SOE: 
Low) 
• Natalizumab (300 mg intravenous every 4 weeks) and placebo did not differ in improving 
patient-reported outcomes at week 12 (absolute between-group difference in change in 
mean Inflammatory Bowel Disease Questionnaire [IBDQ] from baseline, 12 points; 
placebo change in IBDQ, 15 points). (SOE: Moderate) 
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Table 7. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating natalizumab to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome 
Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of Bias Consistency Directness Precision 
Natalizumab vs. 
placebo – wks 2-
4  
Disease 
activity 
measures 
3 (1444)32-34 Medium Consistent Direct Precise Favors natalizumab 
Pooled RR, 1.5; 95% CI 1.1 to 
2.0; placebo rate, 8% to 16% 
 
SOE: Moderate 
Natalizumab vs. 
placebo–wk 12 
Disease 
activity 
measures 
3 (1444)32-34 Medium Consistent Direct Imprecise Favors natalizumab 
RD range, 9% to 13%; placebo 
rate, 0% to 31% 
 
SOE: Low 
Natalizumab vs. 
placebo–wk 12 
Patient-
reported 
outcomes 
2 (539)32 34 Medium Consistent Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 12 pts; 
placebo change in IBDQ, 15 pts 
 
SOE: Moderate 
Natalizumab + 
infliximab vs. 
infliximab–wks 2 
and 10 
Disease 
activity 
measures 
1 (79)35 Low Unknown 
(single trial) 
Indirect 
 
Combination no 
longer used in 
clinical practice 
Imprecise Favors neither 
RD across time points, 7% to 
8%; infliximab rate, 7% to 30% 
 
SOE: Low 
Natalizumab + 
infliximab vs. 
infliximab–wk 10 
Patient-
reported 
outcomes 
1 (79)35  Low Unknown 
(single trial) 
Indirect 
 
Combination no 
longer used in 
clinical practice 
Imprecise Favors neither  
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 2 pts; 
infliximab change in IBDQ, 17 pts 
 
SOE: Low 
CI = confidence interval; IBDQ = Inflammatory Bowel Disease Questionnaire; pts = points; RD = absolute risk difference; RR = relative risk; SOE = strength of evidence; vs. = 
versus; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
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Monotherapy Versus Placebo 
Three trials randomized 1,444 participants and compared the efficacy of natalizumab with 
placebo to induce remission among patients with active Crohn’s disease at randomization.32-34  
Natalizumab Versus Placebo 
Disease Activity Measures 
Table 8 summarizes the efficacy of each treatment in inducing remission for the 2- to 4-week 
and 12- to 16-week time periods of interest (see also Appendix D, Table 4). 
When we pooled the week 2 to 4 data, natalizumab was more likely to induce remission 
compared with placebo (pooled RR, 1.5; 95% CI, 1.1 to 2.0) (Figure 5). The RDs ranged from 4 
percent to 31 percent. The small trial was the only trial to meet our clinically meaningful 
threshold when examined alone.34 The largest trial was the only trial to be statistically 
significant, but did not meet the clinically meaningful threshold when examined alone.32 There 
was no statistical heterogeneity across the three trials (I-squared, 0) and no trial significantly 
influenced results. At week 12, natalizumab was more likely to induce remission than placebo 
according to our clinically meaningful threshold in two of the three trials,32,34 and one of these 
trials reported a statistically significant result.32 A meta-analysis was not performed for week 12 
because the dose was 3 mg/kg delivered at baseline only in one trial,34 compared with 300 mg 
delivered 3 times in 8 weeks in the other two trials.32,33 
Patient-Reported Outcomes 
Two of the trials32,34 reported the IBDQ score for 539 participants. In one trial of 509 
participants, mean IBDQ rose from 124 to 151 points in the natalizumab group and from 123 to 
138 points in the placebo group at week 12 (P < 0.001); which did not meet our clinically 
meaningful threshold of a 17-point difference between groups.32 The other trial reported a 19-
point change from baseline to week 4 in the natalizumab group, but did not report the 
corresponding difference in the placebo patients other than to say that the placebo group did not 
have a statistically significant change over time.34  
Combination Therapy Versus Monotherapy 
Natalizumab and Infliximab Versus Infliximab Alone 
Disease Activity Measures 
One trial of 79 participants compared a combination of natalizumab and infliximab with 
infliximab and placebo among patients who had an elevated CDAI (greater than 150) despite 
initial infliximab.35 There was not a clinically meaningful added benefit of the combination of 
intravenous natalizumab with infliximab compared with infliximab alone to induce remission at 
2 or 10 weeks. Table 8 summarizes the efficacy of each treatment in inducing remission for the 
time periods of interest (see also Appendix D, Table 4). 
Patient-Reported Outcomes 
At 10 weeks, the mean IBDQ rose from 138 to 157 points in the group receiving a 
combination of infliximab and natalizumab, and from 133 to 150 points in the group receiving 
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infliximab and placebo.35 The 2-point difference between groups did not meet the clinically 
meaningful threshold. 
 
Table 8. Randomized controlled trials comparing the efficacy of natalizumab with placebo or 
another treatment to induce remission among patients with active Crohn’s disease at 
randomization 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (Dose), n 
Remission Rate 
(%) (CDAI<150) 
Gordon, 
200134 
2 Natalizumab (3 mg/kg IV 
once), 18 
Placebo, 12 39% vs. 8% 
12  Natalizumab (3 mg/kg IV 
once), 18 
Placebo, 12 11% vs. 0% 
Sandborn, 
200533 
2 Natalizumab (300 mg IV 
every 4 wks until wk 8), 724 
Placebo, 181 14% vs. 10% 
12 Natalizumab (300 mg IV 
every 4 wks until wk 8), 724 
Placebo, 181 40% vs. 31% 
Targan, 
200732 
4 Natalizumab (300 mg IV 
every 4 wks until wk 8), 259 
Placebo, 250 24% vs. 16%* 
12 Natalizumab (300 mg IV 
every 4 wks until wk 8), 259 
Placebo, 250 38% vs. 25%* 
Sands, 200735 2 Natalizumab (300 mg IV at 
wks 0, 4, 8) + infliximab (5 
mg/kg IV at wk -2 and 6), 52 
Infliximab (5 mg/kg IV at 
wk -2 and 6), 27 
15% vs. 7% 
10 Natalizumab (300 mg IV at 
wks 0, 4, 8) + infliximab (5 
mg/kg IV at wk -2 and 6), 52 
Infliximab (5 mg/kg IV at 
wk -2 and 6), 27 
37% vs. 30% 
CDAI = Crohn’s Disease Activity Index; IV = intravenous; mg = milligrams; mg/kg = milligrams per kilogram; vs. = versus; 
wk = week 
*Trial reported P < 0.01.  
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Figure 5. Pooled relative risk of inducing remission as measured by a Crohn’s Disease Activity Index less than 150 at weeks 2 to 4 
comparing natalizumab with placebo 
 
CI = confidence interval; NAT = natalizumab; RR = relative risk 
Note: Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, with larger boxes contributing more to the pooled estimate. The width of the 
horizontal lines represents the 95% confidence intervals for each trial. The diamond at the bottom of the graph indicates the 95% confidence interval for the random-effects pooled 
estimate. 
Test for heterogeneity: Q=1.36 with 2 degrees of freedom (p=0.51) 
I-squared statistic = 0% 
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TNF-Alpha Inhibitors 
Twelve trials evaluated the effectiveness of a TNF-alpha inhibitor as monotherapy or in 
combination with another drug to induce remission. Seven trials compared TNF-alpha inhibitor 
monotherapy with placebo: two evaluated adalimumab,37,38 four evaluated certolizumab pegol,39-
42 and two evaluated infliximab.43,44 One trial compared infliximab with azathioprine.45 Four 
trials compared TNF-alpha inhibitor combination therapy with another therapy: two trials45,46 
compared a combination of infliximab and a thiopurine with thiopurine alone, while one trial45 
compared a combination of infliximab and azathioprine with infliximab alone. Schroder et al. 
studied the combination of infliximab and methotrexate versus infliximab alone.47 Another trial 
compared the combination of infliximab and azathioprine with corticosteroids.48 One trial 
compared a TNF-alpha inhibitor as an early treatment prior to using a thiopurine with TNF-alpha 
inhibitor treatment after the use of a thiopurine and corticosteroids, which is often called a top-
down versus step-up approach.48 
Study Design 
All 12 trials were RCTs, although two did not blind investigators or patients (Appendix D, 
Evidence Table 2).47,48 The design characteristics and inclusion criteria were not homogeneous, 
with the exception of the trial locations. Ten trials were multinational, one was a multicenter 
European trial46 and one took place at a single center in Europe.47 Enrollment started between 
1995 and 2008. The median time under trial per participant was 12 weeks (range, 4 weeks to 104 
weeks). All trials included adults, although one trial enrolled patients as young as 1648 rather 
than 18 years of age. Disease activity inclusion criteria included a minimum CDAI of 150 to 220 
and no greater than 450,37-43,45,46,48 steroid dependency,46,47 thiopurine resistance or intolerance,47 
or at least one active abdominal or perianal fistula.44 Other common disease activity related 
exclusions included abscess,39,40,42,44-46 symptomatic strictures,37-46,48 and previous surgery within 
6 months.37,38,42,45 Remission was defined as a CDAI less than 150, with three trials using an 
even more stringent definition of remission including a CDAI less than 150 combined with the 
absence of corticosteroids.45,46,48 
Medication inclusion criteria were common. One trial aimed to enroll recently diagnosed 
patients by restricting the population to people with a disease duration of 4 years or less who had 
not been treated with corticosteroids, thiopurines, or biologics.48 Another trial allowed prior 
corticosteroid use but excluded patients with prior thiopurine or biologic use.45 Six trials allowed 
prior corticosteroid and thiopurine use but excluded previous users of biologics.37,42-44,46,47 Lack 
of response or dependency on corticosteroids was required in two trials46,47 while failure to 
respond to thiopurines was required in at least some of the patients in these trials.46,47 Previous 
response followed by loss of response or intolerance to infliximab was required in one trial.38 
Patients who had an adverse reaction or no response to TNF-alpha inhibitor were excluded in 
two trials.39,40 All trials that did not restrict patients based on the following medications 
permitted patients to use aminosalicylates, antibiotics, corticosteroids, and thiopurines during the 
trial if they had been on a stable dose of the medication prior to baseline. 
Population Characteristics 
The trials randomized 2,932 patients (Appendix D, Evidence Table 3). The participants of 
trials were demographically similar except for the disease duration at randomization, disease 
location, and use of other medications during the trial. By trial group, males comprised 041 to 
29 
6335 percent of the participants. Only two trials45,48 commented on race; the percentage of whites 
ranged from 84 to 99 percent. Smoking was reported in five trials37-39,45,48 and ranged from 31 to 
43 percent. Mean age at enrollment ranged from 29 to 40 years. Mean or median duration of 
disease ranged between 2 weeks and 13.6 years. In terms of disease location, ileal only location 
ranged between 7 and 68 percent, ileocolonic location between 5 and 68 percent, and colonic 
location between 9 and 36 percent. All but one trial40 reported baseline CDAI. Mean CDAI 
ranged from 251 to 330 points. Among trials that did not exclude or require prior use of the 
medications or randomize patients to the medication, concomitant medication use included the 
following ranges, as recorded at baseline in at least one group of a trial: aminosalicylate use 
between 041 and 7534 percent, antibiotic use between 532 and 1944 percent, budesonide or 
corticosteroid use between 1145 and 8847 percent, and methotrexate or thiopurine between 041 and 
5638 percent. 
Key Points 
Table 9 summarizes the strength of evidence for the trials evaluating TNF-alpha inhibitors to 
induce remission. We found at least moderate strength of evidence or a clinically meaningful 
difference for the following areas: 
• TNF-alpha inhibitors (infliximab, adalimumab, and certolizumab pegol) were more 
effective than placebo in inducing a remission at week 2 (pooled RR, 1.8; 95% CI, 1.4 to 
2.4; placebo rate, 4 to 16 percent). (SOE: Moderate) 
• One dose of adalimumab (at 160 mg) was more effective than placebo in inducing a 
remission at week 2 (absolute RD, 10 to 15 percent; placebo rate, 6 to 14 percent). (SOE: 
High) 
• One dose of adalimumab (at 80 mg or less) did not differ from placebo in inducing a 
remission at week 2 (absolute RD, 0 to 6 percent; placebo rate, 14 percent). (SOE: High) 
• Adalimumab and placebo did not differ in improving patient-reported outcomes at week 
4 (absolute between-group difference in change in mean IBDQ from baseline, 2 to 15 
points; placebo change in IBDQ, 15 points). (SOE: High) 
• Certolizumab pegol was more effective than placebo in inducing a remission at week 26 
(absolute RD, 11 percent; placebo rate, 18 percent). (SOE: Low) 
• One dose of infliximab was more effective than placebo in inducing a remission at week 
2 (absolute RD, 16 to 34 percent; placebo rate, 4 percent). (SOE: Moderate) 
• One dose of infliximab was more effective than placebo in inducing a remission at week 
12 (absolute RD, 10 to 22 percent; placebo rate, 8 percent). (SOE: Low) 
• Infliximab was more effective than placebo in achieving mucosal healing at week 4 
(absolute between-group difference in the change from baseline in Crohn’s Disease 
Endoscopic Index of Severity [CDEIS] score, 7.7; placebo difference, 0.9). (SOE: Low) 
• Infliximab was more effective than placebo in healing fistulas at week 6 in patients with 
actively draining fistulas (absolute RD in fistula closure, 25 to 42 percent; placebo rate, 
13 percent). (SOE: High) 
• Infliximab was more effective than placebo in improving patient-reported outcomes at 
week 4 (absolute between-group difference in change in mean IBDQ from baseline, 31 
points; placebo change in IBDQ, 5 points). (SOE: Moderate) 
• Infliximab (5 mg/kg induction and maintenance) was more effective than azathioprine 
(2.5 mg/kg/day) in inducing a steroid-free remission at weeks 10 and 26 (absolute RD 
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across time points, 13 to 14 percent; azathioprine rate, 24 to 30 percent). (SOE: 
Moderate) 
• Infliximab (5 mg/kg induction and maintenance) was more effective than azathioprine 
(2.5 mg/kg daily) in achieving mucosal healing at week 26 (absolute RD in percentage of 
patients who achieved absence of mucosal ulcers, 13 percent; azathioprine rate, 17 
percent). (SOE: Low) 
• Infliximab (5 mg/kg induction and maintenance) and azathioprine (2.5 mg/kg/day) did 
not differ in improving patient-reported outcomes at 26 weeks (absolute between-group 
difference in change in mean IBDQ from baseline, 9 points; azathioprine change in 
IBDQ, 31 points). (SOE: Moderate) 
• A combination of infliximab (5 mg/kg induction and maintenance) and azathioprine (2.5 
mg/kg/day) was more effective than infliximab (5 mg/kg induction and maintenance) 
alone in inducing a steroid-free remission at weeks 10 and 26 (absolute RD across time 
points, 10 to 13 percent; infliximab alone rate, 37 to 44 percent). (SOE: Moderate) 
• A combination of infliximab (5 mg/kg induction and maintenance) and azathioprine (2.5 
mg/kg daily) was more effective than infliximab (5 mg/kg induction and maintenance) 
and placebo in achieving mucosal healing at week 26 (absolute RD in percentage of 
patients who achieved absence of mucosal ulcers, 14 percent; infliximab and placebo 
rate, 30 percent). (SOE: Low) 
• The combination of infliximab (5 mg/kg induction and maintenance) and azathioprine 
(2.5 mg/kg/day) and the combination of infliximab (5 mg/kg induction and maintenance) 
and placebo did not differ in improving patient-reported outcomes at 26 weeks (absolute 
between-group difference in change in mean IBDQ from baseline, 5 points; infliximab 
change in IBDQ, 40 points). (SOE: Moderate) 
• A combination of infliximab (5 mg/kg induction and maintenance) and a thiopurine 
(azathioprine or 6-mercaptopurine) was more effective than a thiopurine alone in 
inducing a steroid-free remission at weeks 10 to 12 and weeks 24 to 26 (absolute RD 
across time points, 12 to 30 percent; azathioprine rate, 24 to 44 percent). (SOE: 
Moderate) 
• A combination of infliximab (5 mg/kg induction and maintenance) and azathioprine (2.5 
mg/kg daily) was more effective than azathioprine (2.5 mg/kg daily) and placebo in 
achieving mucosal healing at week 26 (absolute RD in percentage of patients who 
achieved absence of mucosal ulcers, 27 percent; azathioprine and placebo rate, 17 
percent). (SOE: Low) 
• The combination of infliximab (5 mg/kg induction and maintenance) and azathioprine 
(2.5 mg/kg/day) and the combination of azathioprine (2.5 mg/kg/day) and placebo did not 
differ in improving patient-reported outcomes at 26 weeks (absolute between-group 
difference in change in mean IBDQ from baseline, 14 points; azathioprine change in 
IBDQ, 31 points). (SOE: Moderate) 
• A combination of infliximab (5 mg/kg induction only) and azathioprine (2-2.5 
mg/kg/day) was more effective than corticosteroids alone in achieving mucosal healing at 
week 104 (absolute RD in percentage of patients with no ulcers, 43 percent; 
corticosteroid rate, 30 percent). (SOE: Low) 
• A combination of infliximab (5 mg/kg induction only) and azathioprine (2-2.5 
mg/kg/day) was more effective than corticosteroids alone in improving patient-reported 
31 
outcomes at week 10 (absolute between-group difference in change in mean IBDQ from 
baseline, 22 points; corticosteroid change in IBDQ, 37 points). (SOE: Low) 
• A combination of infliximab (5 mg/kg at weeks 0 and 2) and methotrexate (intravenous 
weekly to week 5, then oral) was more effective than infliximab (5 mg/kg at weeks 0 and 
2) alone in inducing a remission at weeks 2, 12, and 48 (absolute RD across time points, 
17 to 39 percent; infliximab rate, 25 to 50 percent). (SOE: Low) 
• A combination of infliximab (5 mg/kg at weeks 0 and 2) and methotrexate (intravenous 
weekly to week 5, then oral) was more effective than infliximab (5 mg/kg at weeks 0 and 
2) alone in being able to discontinue steroids (reduction in prednisolone dose from 
baseline, 17 mg vs. 6 mg). (SOE: Low) 
• A combination of infliximab (5 mg/kg at weeks 0 and 2) and methotrexate (intravenous 
weekly to week 5, then oral) was more effective than infliximab (5 mg/kg at weeks 0 and 
2) alone in improving patient-reported outcomes at 4 and 8 weeks (absolute between-
group difference in change in mean IBDQ from baseline, 22 points; infliximab alone 
change in IBDQ, 28 points). (SOE: Low) 
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Table 9. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating TNF-alpha inhibitors to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome 
Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of 
Bias Consistency Directness Precision 
TNF vs. 
placebo–wk 2 
Disease 
activity 
measures 
7 (2208)37-43 Medium Consistent Direct Precise Favors TNF 
Pooled RR, 1.8; 95% CI, 1.4 to 2.4; 
placebo rate, 4 to 16% 
 
SOE: Moderate 
Adalimumab vs. 
placebo (160 mg 
x 1) –wk 2 
Disease 
activity 
measures 
2 (475)37 38 Low Consistent Direct Precise Favors adalimumab 
RD, 10% to 15%; placebo rate, 6% 
to 14% 
 
SOE: High 
Adalimumab vs. 
placebo (≤ 80 mg 
x 1) –wk 2 
Disease 
activity 
measures 
2 (223)37 Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, 0% to 6%; placebo rate, 14% 
 
SOE: Moderate 
Adalimumab vs. 
placebo–wk 4 
Fistula 
response 
1 (32)37 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -17% to 58%; placebo rate, 
17% 
 
SOE: Low 
Adalimumab vs. 
placebo–wk 4 
Patient-
reported 
outcomes 
2 (624)37 38 Low Consistent Direct Precise Favors neither 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 2 to 15 pts; placebo 
change in IBDQ, 15 pts 
 
SOE: High 
Certolizumab 
pegol vs. 
placebo–wk 2, 
12-16 
Disease 
activity 
measures 
4 (1478)39-42 Medium Inconsistent Indirect 
 
IV formulation not 
presently 
approved41 
Imprecise Favors neither  
RD, -19% to 31%; placebo rate, 8% 
to 32% 
 
SOE: Low 
Certolizumab 
pegol vs. 
placebo–wk 26 
Disease 
activity 
measures 
1 (331)39 High Unknown 
(single trial) 
Direct Precise Favors certolizumab pegol 
RD, 11%; placebo rate, 18% 
 
SOE: Low 
Certolizumab 
pegol vs. 
placebo–wk 26 
Fistula 
response 
1 (107)39  High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -1%; placebo rate, 31% 
 
SOE: Low 
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Table 9. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating TNF-alpha inhibitors to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome 
Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of 
Bias Consistency Directness Precision 
Certolizumab 
pegol vs. 
placebo–wks 12, 
26 
Patient-
reported 
outcomes 
2 (954)39 40 High Consistent Indirect 
 
Single dose for 
induction not 
presently used in 
practice40 
Precise Favors neither 
Absolute between-group difference 
in change in mean IBDQ from 
baseline across time points, 5 to 11 
pts; placebo change in IBDQ, 18 to 
21 pts 
 
SOE: Low 
Infliximab vs. 
placebo–wk 2 
Disease 
activity 
measures 
1 (106)43 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD, 16% to 34%; placebo rate, 4% 
 
SOE: Moderate 
Infliximab vs. 
placebo–wk 12 
Disease 
activity 
measures 
1 (106)43 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Imprecise Favors infliximab 
RD, 10% to 22%; placebo rate, 8% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 4 
Mucosal 
healing 
1 (30)49 High Unknown 
(single trial) 
Direct Precise Favors infliximab 
Absolute between-group difference 
in the change from baseline in 
CDEIS, 7.7; placebo difference, 0.9 
 
SOE: Low 
Infliximab vs. 
placebo–wk 6 
Fistula 
response 
1 (94)44 Low Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD, 25% to 42%; placebo rate, 
13% 
 
SOE: High 
Infliximab vs. 
placebo–wk 4 
Patient-
reported 
outcomes 
1 (83)43 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 31 pts; placebo change in 
IBDQ, 5 pts 
 
SOE: Moderate 
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Table 9. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating TNF-alpha inhibitors to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome 
Number of trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of 
Bias Consistency Directness Precision 
Infliximab vs. 
azathioprine–wks 
10, 26 
Disease 
activity 
measures 
1 (339)45 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD across time points, 13% to 
14%; azathioprine rate, 24% to 
30% 
 
SOE: Moderate 
Infliximab vs. 
azathioprine–wk 
26 
Mucosal 
healing 
1 (202)45  High Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD in percentage of patients who 
achieved absence of mucosal 
ulcers, 13%; azathioprine rate, 17% 
 
SOE: Low  
Infliximab vs. 
azathioprine–wk 
26 
Patient-
reported 
outcomes 
1 (339)45  Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 9 pts; azathioprine 
change in IBDQ, 31 pts 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
infliximab–wks 
10, 26 
Disease 
activity 
measures 
1 (338)45 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD across time points, 10% to 
13%; infliximab alone rate, 37% to 
44% 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
infliximab–wk 26 
Mucosal 
healing 
1 (200)45  High Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD in percentage of patients who 
achieved absence of mucosal 
ulcers, 14%; infliximab rate, 30% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
infliximab–wk 26 
Patient-
reported 
outcomes 
1 (338)45 Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 5 pts; infliximab change in 
IBDQ, 40 pts 
 
SOE: Moderate 
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Table 9. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating TNF-alpha inhibitors to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome 
Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of 
Bias Consistency Directness Precision 
Infliximab + 
azathioprine vs. 
azathioprine–wks 
10-12, 24-26 
Disease 
activity 
measures 
2 (393)45 46 Medium Consistent Direct Precise Favors infliximab + azathioprine 
RD across time points, 12% to 
30%; azathioprine rate, 24% to 
44% 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
azathioprine–wk 
26 
Mucosal 
healing 
1 (216)45 High Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD in percentage of patients who 
achieved absence of mucosal 
ulcers, 27%; azathioprine rate, 17% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
azathioprine–wk 
26 
Patient-
reported 
outcomes 
1 (508)45 Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 14 pts; azathioprine 
change in IBDQ, 31 pts 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
steroids–wk 104 
Disease 
activity 
measures 
1 (129)48 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Imprecise Favors neither 
RD, 6%; corticosteroid rate, 49% 
 
SOE: Low 
Infliximab+ 
azathioprine vs. 
steroids–wk 104 
Mucosal 
healing 
1 (49)48  High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Precise Favors infliximab + azathioprine 
RD in percentage of patients with 
no ulcers, 43%; steroid rate, 30% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
steroids–wk 10 
Patient-
reported 
outcomes 
1 (129)48 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Precise Favors infliximab + azathioprine 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 22 pts; steroids change in 
IBDQ, 37 pts 
 
SOE: Low 
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Table 9. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating TNF-alpha inhibitors to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome 
Number of 
Rrials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of 
Bias Consistency Directness Precision 
Infliximab + 
methotrexate vs. 
infliximab–wks 2, 
12, 48 
Disease 
activity 
measures 
1 (19)47 High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
RD across time points, 17% to 
39%; infliximab rate, 25% to 50% 
 
SOE: Low 
Infliximab + 
methotrexate vs. 
infliximab–wk 48 
Reduction of 
steroids 
1 (13)47 High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
Reduction in prednisolone dose 
from baseline, 17 mg vs. 6 mg  
 
SOE: Low 
Infliximab + 
methotrexate vs. 
infliximab–wk 4 
and 8 
Patient-
reported 
outcomes 
1 (19)47  High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
Absolute between-group difference 
in change in mean IBDQ from 
baseline, 22 pts; infliximab change 
in IBDQ, 28 pts 
 
SOE: Low 
CDEIS = Crohn’s Disease Endoscopic Index of Severity; CI = confidence interval; IBDQ = Inflammatory Bowel Disease Questionnaire; IV = intravenous; pts = points; RD = 
absolute risk difference; RR = relative risk; SOE = strength of evidence; TNF = tumor necrosis factor-alpha inhibitor; TPMT = thiopurine methyltransferase; vs. = versus; wk = 
week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire (IBDQ) range from 32 to 224, with higher scores indicating better quality of life.36 Scores for the Crohn’s Disease 
Endoscopic Index of Severity (CDEIS) range from 0 to 44, with higher scores indicating more severe disease. 
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Monotherapy Versus Placebo 
TNF-Alpha Inhibitor Versus Placebo 
Disease Activity Measures 
Seven RCTs compared a TNF-alpha inhibitor versus placebo and reported the percent of 
participants who achieved a CDAI less than 150 as the indicator of remission.37-43 Combining the 
week 2 results for infliximab, adalimumab, and certolizumab pegol in a meta-analysis, TNF-
alpha inhibitor was favored over placebo (RR, 1.8; 95% CI, 1.4 to 2.4; P < 0.001) (Table 10 and 
Figure 6). The RD ranged from 0 to 34 percent. No one trial significantly influenced results and 
there was not substantial statistical heterogeneity (I-squared, 19 percent). Previous use or 
response to a TNF-alpha inhibitor may explain the wide range of observed RD and this 
possibility was examined in separate meta-analyses. Among the four trials that allowed prior 
TNF-alpha inhibitor use, the RR was 2.1 (95% CI, 1.5 to 3.0) (Appendix E). An elevated RR of 
1.5 (95% CI, 1.1 to 2.2; P=0.03) was observed in the three trials that excluded patients who 
previously received TNF-alpha inhibitor, and the finding was statistically significant (Appendix 
E).37,42,43 The trial38 that included only patients with a previous response to infliximab, found that 
21 percent of adalimumab patients were in remission at week 2 compared with 6 percent of 
controls (RR, 3.6; 95% CI, 1.8 to 6.9) (Figure 6).  
The adalimumab trials did not report results beyond week 4. For the 12 to 16 week analysis, 
only certolizumab pegol and infliximab had available data (Table 11). The initial remission was 
not sustained at 12 weeks in these trials. Placebo met the threshold for having a clinically 
meaningful difference compared with certolizumab pegol in one trial,41 although the trial did not 
report that the difference was statistically significant. Infliximab met the standard for a clinically 
meaningful difference compared with placebo, but that finding was also not reported as 
statistically significant.43 One reason for the lack of sustained remission from that observed at 2 
weeks may be that infliximab and certolizumab pegol were given only at baseline in three of the 
four trials. However, the single trial that gave doses of certolizumab pegol beyond baseline did 
not find a clinically meaningful difference between certolizumab pegol and placebo at week 12 
(RD, 6 percent), but certolizumab pegol had a 11 percent higher remission rate at week 26 (Table 
12).39  
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Table 10. Randomized controlled trials comparing the efficacy of TNF-alpha inhibitor therapy with 
placebo or another treatment to induce remission at week 2 among patients with active Crohn’s 
disease at randomization 
Author, Year Main Intervention (Dose), n 
Comparison (Dose), 
n 
Remission Rate 
(%) (CDAI<150) 
Hanauer, 
200637 
Adalimumab (40 mg sc at week 0), 74 Placebo, 74 14% vs. 14%  
Adalimumab (80 mg sc at week 0), 75 Placebo, 74 20% vs. 14%  
Adalimumab (160 mg sc at week 0), 76 Placebo, 74 24% vs. 14%  
Sandborn, 
200738 
Adalimumab (160 mg sc at week 0), 159  Placebo, 166 21% vs. 6%* 
Winter, 200441 Certolizumab pegol (5 mg/kg IV once), 25 Placebo, 25 35% vs. 16%  
Certolizumab pegol (10 mg/kg IV once), 17 Placebo, 25 47% vs. 16%* 
Certolizumab pegol (20 mg/kg IV once), 23 Placebo, 25 20% vs. 16%  
Schreiber, 
200540 
Certolizumab pegol (100 mg sc at week 0), 74 Placebo, 73 18% vs. 8%  
Certolizumab pegol (200 mg sc at week 0), 72 Placebo, 73 10% vs. 8%  
Certolizumab pegol (400 mg sc at week 0), 72 Placebo, 73 18% vs. 8%  
Sandborn, 
200739 
Certolizumab pegol (400 mg sc at week 0), 
331 
Placebo, 328 13% vs. 8%  
Sandborn, 
201142 
Certolizumab pegol (400 mg sc at week 0), 
223 
Placebo, 215 23% vs. 16%* 
Targan, 199743 Infliximab (5 mg/kg IV once), 26 Placebo, 24 38% vs. 4%  
Infliximab (10 mg/kg IV once), 23 Placebo, 24 20% vs. 4%  
Infliximab (20 mg/kg IV once), 28 Placebo, 24 20% vs. 4%  
Schroder, 
200647 
Infliximab (5 mg/kg IV at week 0) + 
methotrexate (20 mg IV weekly for weeks 0-1), 
11 
Infliximab (5 mg/kg IV 
week 0), 8 
64% vs. 25%  
CDAI = Crohn’s Disease Activity Index; IV = intravenous infusion; mg = milligrams; mg/kg = milligrams per kilogram; sc = 
subcutaneous injections; vs. = versus 
*Trial reported P < 0.05 
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Figure 6. Pooled relative risk of inducing remission* at week 2 comparing a TNF-alpha inhibitor with placebo 
 
ADA = adalimumab; CI = confidence interval; CP = certolizumab pegol; IFX = infliximab; RR = relative risk; TNF-a = tumor necrosis factor-alpha inhibitor  
*In all trials, remission was defined as a Crohn’s Disease Activity Index less than 150. 
Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, with larger boxes contributing more to the pooled estimate. The width of the horizontal 
lines represents the 95% confidence intervals for each trial. The diamond at the bottom of the graph indicates the 95% confidence interval for the random-effects pooled estimate. 
Test for heterogeneity: Q=7.41 with 6 degrees of freedom (p=0.29) 
I-squared statistic = 19% 
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Table 11. Randomized controlled trials comparing the efficacy of TNF-alpha inhibitor therapy with 
placebo or another treatment to induce remission at weeks 12 to 16 (or closest time point) among 
patients with active Crohn’s disease at randomization 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (Dose), n 
Remission Rate 
(%) (CDAI<150) 
Winter, 200441 12 Certolizumab pegol (5 mg/kg IV 
once), 25 
Placebo, 25 32% vs. 32%  
Certolizumab pegol (10 mg/kg IV 
once), 17 
Placebo, 25 24% vs. 32%  
Certolizumab pegol (20 mg/kg IV 
once), 23 
Placebo, 25 13% vs. 32%  
Schreiber, 
200540 
12 Certolizumab pegol (100 mg sc 
once), 74 
Placebo, 73 27% vs. 23%  
Certolizumab pegol (200 mg sc 
once), 72 
Placebo, 73 19% vs. 23% 
Certolizumab pegol (400 mg sc 
once), 72 
Placebo, 73 26% vs. 23%  
Sandborn, 
200739 
16 Certolizumab pegol (400 mg sc at 
0, 2, 4 weeks, then every 4 
weeks), 331 
Placebo, 328 26% vs. 20%  
Targan, 199743 12 Infliximab (5 mg/kg IV once), 27 Placebo, 24 30% vs. 8%  
Infliximab (10 mg/kg IV once), 27 Placebo, 24 18% vs. 8%  
Infliximab (20 mg/kg IV once), 28 Placebo, 24 25% vs. 8%  
Colombel, 
201045 
10 Infliximab (5 mg/kg IV at 0, 2, and 
6 weeks, then every 8 weeks), 169 
Azathioprine (2.5 mg/kg 
orally daily), 170 
37% vs. 24%*† 
Colombel, 
201045 
10 Infliximab (5 mg/kg IV at 0, 2, and 
6 weeks, then every 8 weeks) + 
azathioprine (2.5 mg/kg orally 
daily),169 
Azathioprine (2.5 mg/kg 
orally daily), 170 
47% vs. 24%*† 
Lemann, 
200646  
12 Infliximab (5 mg/kg IV at 0, 2, and 
6 weeks) + azathioprine (2-3 
mg/kg/day orally) or 6-
mercaptopurine (1-1.5 mg/kg/day 
orally), 25 
Azathioprine (2-3 
mg/kg/day orally) or 6-
mercaptopurine (1-1.5 
mg/kg/day orally), 29 
64% vs. 34%*† 
D’Haens, 
200848 
14 Infliximab (5 mg/kg IV at 0, 2, 6 
weeks) + azathioprine (2–2.5 
mg/kg orally daily), 65 
Methylprednisolone (32 
mg orally daily with 
taper), or budesonide (9 
mg orally daily with 
taper), 64 
65% vs. 32%*† 
Colombel, 
201045 
10 Infliximab (5 mg/kg IV at 0, 2, and 
6 weeks, then every 8 weeks) + 
azathioprine (2.5 mg/kg orally 
daily), 169 
Infliximab (5 mg/kg IV at 
0, 2, and 6 weeks), 169 
47% vs. 37%* 
Schroder, 
200647 
12 Infliximab (5 mg/kg IV at 0 and 2 
weeks) + methotrexate (20 mg IV 
weekly for weeks 0-5; then 20 mg 
orally weekly), 11 
Infliximab (5 mg/kg 
once), 8 
82% vs. 50%  
CDAI = Crohn’s Disease Activity Index; IV = intravenous infusion; mg = milligrams; mg/kg = milligrams per kilogram; NR = 
not reported; pt = point; sc = subcutaneous injections; vs. = versus 
*Steroid-free remission 
†Trial reported P < 0.05 
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Table 12. Randomized controlled trials comparing the efficacy of TNF-alpha inhibitor therapy with 
placebo or another treatment to induce remission (last reported time point) among patients with 
active Crohn’s disease at randomization 
Author, Year 
Followup 
(weeks) Main Intervention (Dose), n Comparison (Dose), n 
Remission Rate 
(%) (CDAI<150) 
Sandborn, 
200739 
26 Certolizumab pegol (400 mg sc at 0, 
2, 4 wks, then every 4 wks), 331 
Placebo, 328 29% vs. 18%* 
Colombel, 
201045 
26 Infliximab (5 mg/kg IV at 0, 2, 6 wks, 
then every 8 wks), 169 
Azathioprine (2.5 mg/kg 
orally daily), 170 
44% vs. 30%*† 
Colombel, 
201045 
26 Infliximab (5 mg/kg IV at 0, 2, 6 wks, 
then every 8 wks) + azathioprine 
(2.5 mg/kg orally daily),169 
Azathioprine (2.5 mg/kg 
orally daily), 170 
57% vs. 30%*† 
Lemann, 
200646 
24 Infliximab (5 mg/kg IV at 0, 2, 6 wks) 
+ azathioprine (2-3 mg/kg/day orally) 
or 6-mercaptopurine (1-1.5 
mg/kg/day orally), 24 
Azathioprine (2-3 
mg/kg/day orally) or 6-
mercaptopurine (1-1.5 
mg/kg/day orally), 27 
50% vs. 26%† 
D’Haens, 
200848 
104 Infliximab (5 mg/kg IV at 0, 2, 6 wks) 
+ azathioprine (2–2.5 mg/kg orally 
daily), 65 
Methylprednisolone (32 
mg orally daily with 
taper), or budesonide (9 
mg orally daily with 
taper), 64 
55% vs. 49%  
Colombel, 
201045 
26 Infliximab (5mg/kg IV at 0, 2, 6 wks, 
then every 8 wks) + azathioprine 
(2.5 mg/kg orally daily), 169 
Infliximab (5 mg/kg IV at 
0, 2, 6 wks, then every 8 
wks), 169 
57% vs. 44%*† 
Schroder, 
200647 
48 Infliximab (5 mg/kg IV at 0, 2 wks) + 
methotrexate (20 mg IV weekly for 
weeks 0-5; then 20 mg orally 
weekly), 11 
Infliximab (5 mg/kg IV 
once), 8 
45% vs. 25%  
CDAI = Crohn’s Disease Activity Index; IV = intravenous infusion; mg = milligrams; mg/kg = milligrams per kilogram; NR = 
not reported; pt = point; sc = subcutaneous injections; vs. = versus; wk = week 
*Trial reported P < 0.05 
†Steroid-free remission  
Mucosal Healing 
The infliximab trial43 reported on mucosal healing for a subset of 30 participants.49 The 4-
week Crohn’s Disease Endoscopic Index of Severity (CDEIS), which is measured on a scale of 0 
to 44 with higher scores indicating more severe disease, decreased in all doses of infliximab 
compared with baseline indicating less severe disease (mean change of 7.7 compared with 13.0 
at baseline; within group P < 0.001). The mean change in CDEIS for placebo was 0.9 compared 
with an 8.4 score at baseline (within group P=NS). Infliximab was favored over placebo 
according to the clinically meaningful threshold of a 5-point difference between groups. The trial 
did not report the statistical significance of the change from baseline in infliximab compared 
with placebo.  
Fistula Response 
Two trials reported on subsets of participants with draining fistulas at baseline37,39 and one 
trial required a draining fistula at baseline for inclusion with fistula healing the primary goal of 
the trial.44 The trials considered three different comparisons: adalimumab at three different doses 
versus placebo at 4 weeks (N=32),37 certolizumab pegol (400 mg subcutaneous every 4 weeks) 
versus placebo at 26 weeks (N=107),39 and infliximab (5 mg/kg or 10 mg/kg) versus placebo 
administered at 0, 2, and 6 weeks (N=94).44  
We did not find a class effect of TNF-alpha inhibitor on fistula response. Three of 26 
adalimumab patients had closure of all draining fistula at two consecutive visits at week 4 
compared with one of six placebo patients.37 Similarly, no difference was seen in complete 
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fistula closure for certolizumab pegol versus placebo at week 26 (30 versus 31 percent).39 
However, infliximab decreased the number of draining fistulas over two consecutive visits 
according to the clinically meaningful and statistically significant thresholds for each dose of 
infliximab: with 55 percent of those receiving 5 mg/kg, 38 percent of 10 mg/kg having no 
draining fistulas compared with a 13 percent fistula closure rate by 18 weeks in placebo 
(P=0.001 and P=0.04 compared with placebo).44 The infliximab trial also reported the Perianal 
Disease Activity Index (PDAI), which is measured on a scale of 0 to 20 with higher scores 
indicating more severe disease. Although changes in the PDAI from baseline were not compared 
between infliximab and placebo, there was a 4- to 5-point decrease in PDAI score at 18 weeks in 
the infliximab groups compared with a 2-point decrease in placebo.44  
Patient-Reported Outcomes 
Six trials with 1,675 total participants reported the IBDQ.37-40,42,43 We did not see a class 
effect of TNF-alpha inhibitor on the IBDQ. Adalimumab and certolizumab pegol did not lead to 
increases in the IBDQ that met our clinically meaningful criterion of a 17-point between group 
change in the score from baseline. Two trials compared adalimumab with placebo and did not 
meet the clinically meaningful threshold compared with placebo at week 4.37,38 Three trials 
compared certolizumab pegol with placebo; certolizumab pegol did not meet the clinically 
meaningful threshold compared with placebo at week 6, 12, or 26.39,40,42 Infliximab was both 
clinically and statistically superior to placebo at week 4.43 Mean IBDQ rose from 118 to 154 in 
the infliximab groups and from 128 to 133 in the placebo group (P=0.001). The week 12 results 
were not reported for all randomized patients in the infliximab trial. 
Monotherapy Versus Monotherapy 
Infliximab Versus Azathioprine 
Disease Activity Measures 
One trial, of 338 patients with relatively short median disease duration of 2 years who had 
not received thiopurines or TNF-alpha inhibitors,45 found infliximab to be clinically and 
statistically superior to azathioprine for the induction of steroid-free remission at weeks 10 and 
26 (Tables 10 and 11). The finding at 26 weeks is particularly meaningful because a response to 
azathioprine is not expected until at least 12 weeks based on its pharmacokinetics.50 The 
exclusion of homozygous mutant and heterozygous thiopurine methyltransferase phenotypes is 
also unlikely to explain the difference between infliximab and azathioprine at 26 weeks. Notably, 
patients were followed out to 52 weeks, but starting at week 30 patients were given the choice of 
continuing with the assigned therapy; this extension period did not meet our inclusion criteria.  
Mucosal Healing 
At baseline, 63 percent of patients (n=214) had mucosal lesions.45 At 26 weeks, 30 percent 
(28 out of 93) of the infliximab group had no mucosal ulcers compared with 17 percent (18 out 
of 109) of the azathioprine group (P=0.02). This finding is clinically meaningful and statistically 
significant. The patients who did not have ulcerations were excluded as well as the 12 patients 
with an unclear video or no colonoscopy at 26 weeks. 
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Patient-Reported Outcomes 
The change in IBDQ score from baseline was not different for infliximab and azathioprine at 
2, 10, or 26 weeks according to our between-group difference threshold of a 17-point change 
from baseline between groups (Appendix D, Evidence Table 4).  
Combination Therapy Versus Monotherapy 
Infliximab and Azathioprine Versus Infliximab Alone 
Disease Activity Measures 
One trial of 338 patients45 found a combination of infliximab and azathioprine was clinically 
superior to infliximab and placebo at weeks 10 and 26, although the results were only 
statistically significant at week 26. This is consistent with azathioprine generally taking 12 weeks 
to have an effect based on its pharmacokinetics (Tables 10 and 11). 
Mucosal Healing 
In the above trial,45 210 patients for this comparison had mucosal lesions. The trial evaluated 
these patients again after the primary endpoint. Rates of mucosal healing (no ulcers) at 26 weeks 
were 47 out of 107 (44 percent) for the combination of infliximab and azathioprine and 28 out of 
93 (30 percent) for infliximab and placebo (P=0.06). Ten patients did not have a colonoscopy at 
week 26 or the quality of the video was insufficient for inclusion. 
Patient-Reported Outcomes 
The absolute difference in mean IBDQ change from baseline at week 26 was not clinically 
significant.45 
Infliximab and Thiopurine Versus Thiopurine Alone 
Disease Activity Measures 
Two trials randomized 393 patients to a combination of infliximab and a thiopurine or 
thiopurine alone (with a placebo for infliximab).45,46 In the smaller study46 patients were divided 
into two strata – thiopurine naïve patients and those that had previously failed thiopurines. The 
thiopurine naïve stratum included a mix of patients with CDAI less than and greater than 150, 
while all patients in the thiopurine failure stratum had a CDAI greater than 150. By contrast, the 
larger study45 excluded any prior thiopurine use. The larger trial of 339 patients45 found the 
combination of infliximab and azathioprine clinically and statistically superior to azathioprine 
for the induction of steroid-free remission at weeks 10 and 26 (Tables 10 and 11). Among the 
thiopurine failure stratum of the smaller trial,46 the combination of infliximab and a thiopurine 
(azathioprine or 6-mercaptopurine) was clinically and statistically significant compared with a 
thiopurine alone at 12 weeks, but was clinically meaningful but not statistically significant at 24 
weeks. Among all randomized patients in this trial, the findings were clinically meaningful and 
statistically significant at both time points.46 
Mucosal Healing 
Both trials reported on mucosal healing. In the larger trial,45 226 patients (67 percent) for this 
comparison had mucosal lesions at baseline. At 26 weeks, 47 out of 107 (44 percent) 
combination of infliximab and azathioprine patients had no ulcers compared with 18 out of 109 
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(17 percent) for azathioprine patients (P < 0.001). Of the 20 patients in the other trial46 who 
underwent colonoscopy at baseline and at 24 weeks, the number of patients with no ulcers at 
week 24 was neither clinically nor statistically significantly different between the two groups (27 
versus 33 percent).  
Patient-Reported Outcomes 
The absolute difference in mean IBDQ change from baseline was not clinically significant at 
week 2, 10, or 26.45 
Infliximab and Thiopurine Versus Corticosteroids in a Top-Down Versus 
Step-Up Trial 
Disease Activity Measures 
One trial48 sought to compare top-down therapy with step-up therapy. At entry, patients were 
newly diagnosed, and were naïve to corticosteroids, thiopurines, and TNF-alpha inhibitor 
therapy. The trial randomized patients to receive either the combination of infliximab (given at 0, 
2, and 6 weeks) and azathioprine (top-down therapy), or a taper with corticosteroids (step-up 
therapy). The top-down group received corticosteroids if they did not respond to infliximab and 
azathioprine. The step-up group received azathioprine if they relapsed after a second course of 
corticosteroids, and infliximab if they continued to have active disease after receiving 
azathioprine. Thus, there was significant overlap between groups in terms of which therapies 
could be received. In this non-blinded trial, the primary outcome was steroid-free remission. The 
patients who started on infliximab and azathioprine at baseline were more likely to be in steroid-
free remission at 14 weeks compared with the step-up group according to our clinically 
meaningful and statistically significant thresholds (Table 11). However, at the final measurement 
at week 104, there was no clinically or statistically significant difference between the groups 
(Table 12). At week 104, less than 20 percent of either group was still receiving corticosteroids 
or infliximab, but patients did continue to use azathioprine with 90 percent of the top-down 
group receiving azathioprine compared with 71 percent of the step-up group. 
Mucosal Healing 
In the above trial,48 49 out of 129 patients underwent colonoscopy at the end of the followup 
period. At 104 weeks, 73 percent of the top-down group had no ulcers compared with 30 percent 
of the step-up group (P=0.003). However, the percent of patients with ulcers at baseline was not 
reported. 
Patient-Reported Outcomes 
After 10 weeks of treatment, patients receiving top-down therapy had clinically and 
statistically greater increases in the mean IBDQ change from baseline than patients receiving 
step-up therapy (mean between-group difference in change from baseline IBDQ, 21.8 points; 
95% CI, 8.4 to 34.9 points; P=0.0014).48 This trial did not report any long-term results for 
IBDQ, although IBDQ was assessed throughout the 104-week trial. 
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Infliximab and Methotrexate Versus Infliximab Alone 
Disease Activity Measures 
One small unblinded trial47 compared the effectiveness of a combination of infliximab and 
methotrexate with infliximab monotherapy at inducing remission at 2 and 12 weeks and 
maintaining remission at 48 weeks. Across time points, the trial showed a clinically but not 
statistically significant difference in remission rates (Tables 9, 10, and 11). 
Reduction of Steroids 
In the above trial,47 mean prednisolone dose decreased from 17 mg to 0 mg in the 
combination infliximab and methotrexate group compared to a decrease from 21 mg to 15 mg in 
the infliximab alone group at week 48. This was clinically (using a definition of a delta in steroid 
reduction of 10 mg or more of prednisone) and statistically significant (P=0.02). 
Patient-Reported Outcomes 
At 48 weeks, the mean IBDQ score rose from 113 to 163 points in the infliximab and 
methotrexate group and from 107 to 135 points in the infliximab alone group, meeting our 
threshold for clinical significance.47 The trial did not provide a P-value to assess statistical 
significance. 
Thiopurines 
Twelve RCTs evaluated the effectiveness of thiopurines (azathioprine or 6-mercaptopurine) 
as monotherapy or in combination with other therapies to induce remission.51-62 
Study Design 
Ten of the 12 RCTs were double blind (Appendix D, Evidence Table 2). One trial stated that 
the investigators were blinded, but the patients were aware of the medication.58 Another did not 
mention blinding.52 The trials were heterogeneous in all aspects of design including the 
locations, years of recruitment, duration, minimum age of enrollment, definition of active 
disease, doses and administration of the trial medications, and definition of remission outcomes.  
Two trials were multinational,51,59 three took place at multiple centers in Israel57 or the 
United States,56,60 and six at single centers in Germany,54 Italy,58 South Africa,53 Spain,52 the 
United Kingdom,61 and the United States.62 Enrollment started between 197156 and 200451 
although trials published in 1971 and 1974 did not report the enrollment year.61,62 All but one 
trial51 was completed prior to the approval of TNF-alpha inhibitors. The average time under trial 
per participant was longer than the natalizumab and TNF-alpha inhibitor trials with a median of 
26 weeks (range, 12 weeks to 106 weeks). The minimum eligibility age was 18 years in four 
trials,51,54,58,59 17 years in one trial,57 15 years in four trials,52,53,56,60 and not reported in two 
trials.61,62 
Common disease activity inclusion criteria included a minimum CDAI of 150 to 220 and no 
greater than 450,51-54,56,58,59 Harvey-Bradshaw Index (HBI) of 7 or greater,57 and steroid 
dependency.51,58,59 One trial required gastroenterologist-assessed active disease that had not 
previously responded to sulfasalazine or corticosteroids.60 Two trials published during the 1970s 
required active disease based on weight loss, fistula, diarrhea, inflammation on sigmoidoscopy, 
failure to respond to other medications and need for surgery.61,62 Common disease activity 
related exclusions included abscess,54,57-59 symptomatic strictures,51,53,57-59 and previous surgery 
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within 3 months.51 Remission was defined as a CDAI less than 150 in seven trials,51-54,56,58,59 
with three trials using an even more stringent definition of remission including a CDAI less than 
150 combined with the absence of corticosteroids.51,58,59 Another trial required an HBI less than 
3 and no use of corticosteroids.57 One trial did not use the CDAI but the gastroenterologist 
assessed symptoms, steroid dose, and fistula healing to assign patients to “improvement” or 
not.60 Two trials published during the 1970s reported patient assessments of symptoms,61 62 with 
one also reporting reduction of steroids.62 
In contrast with the TNF-alpha inhibitor trials, medication inclusion criteria were rare. Most 
trials allowed patients with previous use of the medications under trial.51,53,54,56-59 One trial 
specifically excluded patients with prior use of thiopurines or methotrexate.52 Six trials required 
that patients had not used medications within the previous 3 to 6 months.51,53,54,57-59 Two trials 
specifically mentioned that patients with previous use of a biologic agent in a trial or practice 
settling were eligible as long as they had not used the medication 3 to 6 months prior.51 59 In 
contrast with the TNF-alpha inhibitor trials that allowed patients to use other medications as long 
as the patient was receiving a stable dose, most of the thiopurine trials specifically mentioned 
that they did not allow patients to use medications other than those under trial.51-53,56,58,59 
Population Characteristics 
The 12 trials randomized a total of 786 patients with Crohn’s disease (Appendix D, Evidence 
Table 3). One trial52 included patients with Crohn’s disease and ulcerative colitis, but we only 
included information from those with Crohn’s disease.  
The population characteristics had wide variability across the trials. The proportion of male 
participants in a treatment group ranged from 2153 to 7561 percent, among the  
trials that reported patient sex. One trial reported on race56 with white patients comprising 
between 90 and 94 percent of participants across the four trial groups. Smoking status was 
reported in five trials51-53,57,59 and ranged between 2457 and 86 percent.52 Average age at 
enrollment ranged between 2754 to 3857 years (mean) and 3253 to 4051 years (median). Duration 
of disease ranged between 3.356 to 8.4 years57 (mean) and 0.651 to 7.159 years (median).  
Disease location and disease activity were also heterogeneous across trials. Disease location 
was variable across trials: ileal location ranged between 554 and 8351 percent, ileocolonic location 
between 2557 and 6754 percent, colonic location between 762 and 7351 percent, and perianal 
lesions ranged between 1452 and 2552 percent. Baseline CDAI was reported for all seven trials 
using this measure, with mean CDAI ranging from 19152 and 29054 and median CDAI ranging 
from 24459 and 30153 points. In the trial that used HBI,57 mean HBI scores ranged from 7.8 to 9 
across the three trial groups. 
Key Points 
Table 13 summarizes the strength of evidence for the trials evaluating thiopurines in terms of 
induction of remission. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following areas: 
• 6-mercaptopurine (1.5 mg/kg/day) was more effective than placebo in inducing a 
remission at week 104 (absolute RD, 33 percent; placebo rate, 14 percent). (SOE: Low) 
• 6-mercaptopurine (1.5 mg/kg/day) was more effective than placebo in healing fistulas 
between 54-104 weeks in patients with actively draining fistulas (absolute RD in fistula 
closure, 25 percent; placebo rate, 6 percent). (SOE: Low) 
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• Azathioprine (2.5 mg/kg/day) was less effective than prednisone in inducing a remission 
at week 17 (absolute RD, -24 percent; prednisone rate, 77 percent). (SOE: Low) 
• Azathioprine (2.5 mg/kg/day) was less effective than prednisone in healing fistulas at 
week 17 (absolute RD, -17 percent; prednisone rate, 30 percent). (SOE: Low) 
• Azathioprine (2.5 mg/kg/day) was less effective than sulfasalazine (1 g /15 kg) in 
inducing a remission at week 2 (absolute RD, -14 percent; sulfasalazine rate, 20 percent). 
(SOE: Low). 
• 6-mercaptopurine (1.5 mg/kg/day) was more effective than aminosalicylates (3 g/day) in 
inducing a remission at week 30 (absolute RD, 80 percent; aminosalicylate rate, 14 
percent). (SOE: Low) 
• A combination of azathioprine (2.5 mg/kg/day) and corticosteroids was more effective 
than corticosteroids alone in inducing a remission at weeks 12 and 28 (absolute RD 
across time points, 10 percent; corticosteroid rate, 28 to 63 percent). (SOE: Low) 
• A combination of azathioprine (2 mg/kg/day) and corticosteroids was less effective than a 
combination of methotrexate (25 mg intravenous/week) and corticosteroids in healing 
fistulas at 26 weeks in patients with actively draining fistulas (absolute RD in fistula 
closure, -42 percent; methotrexate and corticosteroids rate, 67 percent). (SOE: Low) 
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Table 13. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating thiopurines to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence Risk of bias Consistency Directness Precision 
Thiopurine vs. 
placebo–wks 3-4, 
17-38 
Disease 
activity 
measures 
2 (158)56 57 High Inconsistent Indirect 
 
 
Imprecise Favors neither 
RD across time points, -5% to 13%; 
placebo rate, 5% to 48% 
 
SOE: Low 
Thiopurine vs. 
placebo–wk 104 
Disease 
activity 
measures 
1 (33)60 High Unknown 
(single trial) 
Indirect Imprecise Favors 6-MP 
RD, 33%; placebo rate, 14% 
 
SOE: Low 
Thiopurines vs. 
placebo–wk 16 
Reduction of 
steroids 
1 (26)62  Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
Reduction in steroid dose from 
baseline, 7 mg vs. 12 mg  
 
SOE: Low 
Thiopurine vs. 
placebo–wk 17  
Fistula 
response 
1 (17)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD in perianal fistula closure, 2%; 
placebo rate, 11% 
 
SOE: Low 
Thiopurine vs. 
placebo– 
wk 104 
Fistula 
response 
1 (46)60  High Unknown 
(single trial) 
Direct Imprecise Favors 6-MP 
RD in perianal fistula closure, 25%; 
placebo rate, 6% 
 
SOE: Low 
Thiopurines vs. 
placebo–wk 8 
and 16 
Patient-
reported 
outcomes 
3 (116)57 61 62  Medium Inconsistent Direct Imprecise Favors neither 
Multiple measures; see text 
 
SOE: Low 
Thiopurines vs. 
methotrexate 
(oral)–wks 4, 12, 
30-38 
Disease 
activity 
measures 
2 (89)52 57 Medium Inconsistent Indirect Imprecise Favors neither 
RD across time points, -1% to 21%; 
placebo rate, 9% to 80% 
 
SOE: Low 
Azathioprine vs. 
prednisone–wks 
2, 13, 17 
Disease 
activity 
measures 
1 (144)56 High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD across time points, -24 to -12%; 
prednisone rate, 27-77% 
 
SOE: Low 
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Table 13. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating thiopurines to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence Risk of Bias Consistency Directness Precision 
Azathioprine vs. 
prednisone–wk 
17 
Fistula 
response 
1 (18)55 High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD, -17%; prednisone rate, 30% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–wk 
2 
Disease 
activity 
measures 
1 (133)56 High Unknown 
(single trial) 
Direct Precise Favors sulfasalazine 
RD, -14%; sulfasalazine rate, 20% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–
wks 13, 17 
Disease 
activity 
measures 
1 (133)56 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, 0% to 6%; 
sulfasalazine rate, 32% to 53% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–wk 
17 
Fistula 
response 
1 (17)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -9%; sulfasalazine rate, 22% 
 
SOE: Low 
6-MP vs. ASA–
wks 12, 30 
Disease 
activity 
measures 
1 (23)52 High Unknown 
(single trial) 
Direct Precise Favors 6-MP 
RD across time points, 67% to 80%; 
ASA rate, 14% 
 
SOE: Low 
Azathioprine (IV 
and oral) vs. 
thiopurine (oral)–
wk 8, 16 
Disease 
activity 
measures 
1 (96)59 Medium Unknown 
(single trial) 
Indirect 
 
IV AZA is not 
presently used 
as a treatment 
Imprecise Favors neither 
RD across time points, 1% to 4%; 
oral azathioprine alone rate, 24% to 
27% 
 
SOE: Low 
Azathioprine + 
steroid vs. 
steroid–wks 12, 
28 
Disease 
activity 
measures 
3 (186)51 53 54 Medium Inconsistent Direct Imprecise Favors azathioprine + steroid 
RD across time points, 10%; steroid 
rate, 28% to 63% 
 
SOE: Low 
Azathioprine + 
prednisone vs. 
methotrexate (IV 
followed by oral) 
+ prednisone–wk 
13, 26 
Disease 
activity 
measures 
1 (54)58 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, -11% to 7%; 
methotrexate + prednisone rate, 
44% to 56% 
 
SOE: Low 
50 
Table 13. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating thiopurines to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence Risk of Bias Consistency Directness Precision 
Azathioprine + 
prednisone vs. 
methotrexate (IV 
followed by oral) 
+ prednisone–wk 
26 
Fistula 
response 
1 (10)58  High Unknown 
(single trial) 
Direct Imprecise Favors methotrexate + prednisone 
RD in fistula closure, -42%; 
methotrexate + prednisone rate, 
67% 
 
SOE: Low 
6-MP = 6-mercaptopurine; ASA = aminosalicylates; IV = intravenous; mg = milligrams; RD = risk difference; SOE = strength of evidence; steroid = corticosteroids; vs. = versus; 
wk = weeks 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
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Monotherapy Versus Placebo 
Thiopurines Versus Placebo 
Disease Activity Measures 
Three trials, comprising 227 participants, compared thiopurines with placebo in inducing 
remission in those with active disease (Table 14; Appendix D, Table 4).56,57,60 Two trials had 
neither clinically nor statistically significant difference in remission rates between thiopurines 
and placebo groups at 17 and 38 weeks, the first time disease activity was reported.57,60 The trial 
that used physician assessment of disease activity did find a difference between groups.60 This 
trial employed a crossover design and we included the information reported for those patients 
that did not cross over (N=33). 6-mercaptopurine was clinically and statistically favored over 
placebo at 104 weeks according to the physician assessment. Because the CDAI had not been 
developed as part of the initial design steps of another trial,56 this measure was not used for 
inclusion or for outcome assessment. Because patients had to have no symptoms, fistula closure, 
or not use corticosteroids, the physician assessment could be considered a more difficult outcome 
to achieve than the CDAI less than 150 threshold which allows symptoms and does not assess 
corticosteroid use or fistula activity. 
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Table 14. Randomized controlled trials comparing the effectiveness of thiopurines with placebo or another treatment to induce 
remission among patients with active Crohn’s disease at randomization 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (Dose), n Remission Definition 
Remission 
Rate (%) 
Summers, 
197956 
3 Azathioprine (2.5 mg/kg/day), 59 Placebo, 77 CDAI<150 6 vs. 10% 
13 Azathioprine (2.5 mg/kg/day), 59 Placebo, 77 CDAI<150 38 vs. 25% 
17 Azathioprine (2.5 mg/kg/day), 59 Placebo, 77 CDAI<150 53 vs. 48% 
Present, 
198060 
104 6-mercaptopurine (1.5mg/kg/day), 19 Placebo, 14 “Excellent improvement”† 47 vs. 14%‡ 
Oren, 199757 4 6-mercaptopurine (50 mg/day), 32 Placebo, 26 HBI 3 and steroid-free 8 vs. 5% 
12 6-mercaptopurine (50 mg/day), 32 Placebo, 26 HBI 3 and steroid-free 30 vs. 27% 
38 6-mercaptopurine (50 mg/day), 32 Placebo, 26 HBI 3 and steroid-free 41 vs. 46% 
Oren, 199757 4 6-mercaptopurine (50 mg/day), 32 Methotrexate (12.5 mg/wk oral), 26 HBI 3 and steroid-free 8 vs. 9% 
12 6-mercaptopurine (50 mg/day), 32 Methotrexate (12.5 mg/wk oral), 26 HBI 3 and steroid-free 30 vs. 30% 
38 6-mercaptopurine (50 mg/day), 32 Methotrexate (12.5 mg/wk oral), 26 HBI 3 and steroid-free 41 vs. 38% 
Mate-
Jimenez, 
200052 
12 6-mercaptopurine (1.5 mg/kg/day), 16 Methotrexate (15 mg/wk oral), 15 CDAI<150, steroid-free, 
normal serum orosomucoid 
concentrations 
81 vs. 60% 
30 6-mercaptopurine (1.5 mg/kg/day), 16 Methotrexate (15 mg/wk oral), 15 CDAI<150, steroid-free, 
normal serum orosomucoid 
concentrations 
94 vs. 80% 
Summers, 
197956 
2 Azathioprine (2.5 mg/kg/day), 59  Prednisone (0.25-0.75 mg/kg/day), 85 CDAI<150 6 vs. 27% 
13 Azathioprine (2.5 mg/kg/day), 59  Prednisone (0.25-0.75 mg/kg/day), 85 CDAI<150 38 vs. 50% 
17 Azathioprine (2.5 mg/kg/day), 59  Prednisone (0.25-0.75 mg/kg/day), 85 CDAI<150 53 vs. 77% 
Summers, 
197956 
2 Azathioprine (2.5 mg/kg/day), 59 Sulfasalazine (1 g/15 kg/day), 74 CDAI<150 6 vs. 20% 
13 Azathioprine (2.5 mg/kg/day), 59 Sulfasalazine (1 g/15 kg/day), 74 CDAI<150 38 vs. 32% 
17 Azathioprine (2.5 mg/kg/day), 59 Sulfasalazine (1 g/15 kg/day), 74 CDAI<150 53 vs. 53% 
Mate-
Jimenez, 
200052 
12 6-mercaptopurine (1.5 mg/kg/day), 16 Aminosalicylates (3 g/day), 7 CDAI<150, steroid-free, 
normal serum orosomucoid 
concentrations 
81 vs. 14% 
30 6-mercaptopurine (1.5 mg/kg/day), 16 Aminosalicylates (3 g/day), 7 CDAI<150, steroid-free, 
normal serum orosomucoid 
concentrations 
94 vs. 14%‡ 
Sandborn, 
199959 
8 Azathioprine (IV 40 mg/kg loading dose 
then oral 2 mg/kg/day), 51 
Azathioprine (oral 2 mg/kg/day), 45 CDAI<150 and steroid-free 25 vs. 24% 
16 Azathioprine (IV 40 mg/kg loading dose 
then oral 2 mg/kg/day), 51 
Azathioprine (oral 2 mg/kg/day), 45 CDAI<150 and steroid-free 31 vs. 27% 
Ewe, 199354 16 Azathioprine (2.5 mg/kg/day) + 
prednisolone (60 mg/day then taper), 21 
Prednisolone (60 mg/day then taper), 
21 
CDAI<150 and 60-pt drop 
in CDAI 
76 vs. 38%‡ 
Candy, 199553 12 Azathioprine (2.5 mg/kg/day) + 
prednisolone (1 mg/kg/day then taper), 33 
Prednisolone (1 mg/kg/day then 
taper), 30 
CDAI<150 and steroid-free 73 vs. 63% 
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Table 14. Randomized controlled trials comparing the effectiveness of thiopurines with placebo or another treatment to induce 
remission among patients with active Crohn’s disease at randomization (continued) 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (dose), n Remission Definition 
Remission 
Rate (%) 
Reinisch, 
200851 
28 Azathioprine (2.5 mg/kg/day) + 
prednisone (1 mg/kg/day or ≥ 40 mg/day 
then taper after response), 50 
Prednisone (1 mg/kg/day or ≥ 40 
mg/day then taper after response), 28 
Treatment success§ 38 vs. 28% 
Ardizzone, 
200358 
13 Azathioprine (2 mg/kg/day) + prednisone 
(40 mg/day), 27 
Methotrexate (25 mg/wk)║ + 
prednisone (40 mg/day), 27 
CDAI≤150 and steroid-free 33 vs. 44% 
26 Azathioprine (2 mg/kg/day) + prednisone 
(40 mg/day), 27 
Methotrexate (25 mg/wk)║ + 
prednisone (40 mg/day), 27 
CDAI≤150 and steroid-free 63 vs. 56% 
CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; IV = intravenous, kg = kilogram; mg = milligram; pt = point; wk = week 
†“Excellent improvement” – disappearance of symptoms, complete closure of fistula, total withdrawal from steroids 
‡Trial reported P < 0.05 
§Treatment success was defined as absence of treatment failure, which encompassed patients: who prematurely discontinued the trial drug due to unsatisfactory therapeutic effect; 
who failed to achieve steroid-free remission (i.e., CDAI ≥150) by the end of month 3; who used steroids after the end of month 3; who used any prohibited efficacy-related 
treatment; and with a relapse (i.e., any CDAI ≥150 points and a minimum increase in CDAI ≥70 compared with the score at beginning of remission) recorded after end of month 3. 
║Methotrexate was given intravenously for 12 weeks then orally. 
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Reduction of Steroids 
One trial with 26 participants showed reduction in the average daily dose of corticosteroid 
use in azathioprine (from 13.3 mg to 6.3 mg) and placebo (from 19.8 mg to 7.8 mg) during 4 
months of followup prior to crossover (Appendix D, Evidence Table 4).62 Although the trial did 
not calculate statistical significance, the percent reduction in steroids between groups is not 
clinically significant (defined as delta reduction between groups as 10 mg of prednisone or 
more), especially in light of the much higher initial dose in the placebo group.  
Fistula Response 
Among a subset of 17 patients with draining perianal fistulas at the time of randomization,56 
fistula response at 17 weeks was no different between azathioprine at 2.5 mg/kg daily with 
placebo (13 vs. 11 percent).55 However, 6-mercaptopurine resulted in greater fistula closer by 
104 weeks, although statistical significance was not assessed.60 Nine out of 29 (31 percent) 
fistulas in the 6-mercaptopurine group compared with one of 17 (6 percent) in the placebo group 
healed completely. However, some of the placebo patients eventually took 6-mercaptopurine and 
some 6-mercaptopurine patients discontinued use as part of the crossover design. 
Patient-Reported Outcomes 
Three trials with 116 participants compared azathioprine with placebo and included patient-
reported outcomes.57 61 62 Azathioprine did not improve patient reported outcomes in any trial. 
One trial,57 using the Treatment Goal Score for Wellbeing where everyone starts out with a score 
of 0 at week 0 and is graded as having better (+3 maximum score) or worse (-3 minimum score) 
based on general well-being, Crohn’s disease-related symptoms, steroids, and extraintestinal 
manifestations, reported a statistically significant difference after 16 weeks on the well-being and 
abdominal pain components but did not find a statistically significant difference on the overall 
score at any time point through 36 weeks.57 A crossover trial showed no improvement in patient-
reported quality of life (“feeling better”) with azathioprine compared with placebo; in both 
groups, six patients reported symptomatic improvement after crossover at 16 weeks, while five 
reported no change.62 In one trial61 after 8 weeks, no patients reported subjective improvement in 
their symptoms with azathioprine or placebo. More patients reported that their symptoms were 
worse with azathioprine versus placebo and fewer patients reported that their symptoms were 
unchanged with azathioprine versus placebo. The lack of response at 8 weeks with azathioprine 
is not unexpected because azathioprine may take up to 16 weeks to become clinically effective 
based on its pharmacokinetics.50 Pharmacokinetics cannot explain the lack of difference between 
azathioprine and placebo at 16 weeks.  
Monotherapy Versus Monotherapy 
Thiopurine Versus Methotrexate 
Disease Activity Measures 
Two trials including 89 participants compared thiopurine with methotrexate therapy (Table 
14).52,57 One trial of 58 participants57 compared 6-mercaptopurine and placebo with oral 
methotrexate and placebo in steroid-dependent patients with active Crohn’s disease defined by 
an HBI of 7 or greater. At 4, 12, and 38 weeks, there was no statistically significant difference in 
remission rates between the two groups. In a trial with unclear allocation concealment52 of 31 
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steroid-dependent patients, the group randomized to 6-mercaptopurine 1.5 mg/kg/day had higher 
remission rates than those randomized to oral methotrexate 15 mg/week at 30 weeks (94 versus 
80 percent), although the trial did not report on statistical significance (Table 14). 
Thiopurines Versus Corticosteroids 
Disease Activity Measures 
A trial of 144 participants compared azathioprine with prednisone (Table 14).56 At 2, 12, and 
17 weeks, patients on azathioprine had a clinically meaningful lower rate of remission than 
patients on prednisone (week 17: 53 versus 77 percent), although the trial did not report 
statistical significance beyond showing that the standard errors did not overlap at any time point.  
Fistula Response 
Among a subset of 18 patients with draining perianal fistulas at the time of randomization,56 
fistula response at 17 weeks was lower in patients receiving azathioprine at 2.5 mg/kg daily 
versus patients receiving prednisone (13 vs. 30 percent).55  
Thiopurine Versus Aminosalicylates 
Disease Activity Measures 
Two trials including 156 participants compared thiopurine with aminosalicylate therapy 
(Table 14).52 56 One larger trial, comprising 133 participants, compared azathioprine with 
sulfasalazine therapy in inducing remission in those with active disease (CDAI greater than 
150).56 There was no clinically or statistically significant difference in remission rates between 
the groups at 13 or 17 weeks, although at week 2 sulfasalazine had a higher remission rate (16 
percent versus 2 percent) and the standard errors did not overlap. In the other trial of 23 steroid-
dependent participants,52 the group receiving 6-mercaptopurine 1.5 mg/kg/day had clinically 
higher remission rates than the group receiving aminosalicylate 3 g/day at 12 and 30 weeks 
(statistically significant at 30 weeks). 
Fistula Response 
Among a subset of 17 patients with draining perianal fistulas at the time of randomization,56 
there was no difference in fistula response at 17 weeks between those receiving azathioprine at 
2.5 mg/kg daily versus those receiving sulfasalazine (13 vs. 22 percent).55  
Combination Therapy Versus Monotherapy 
Intravenous and Oral Thiopurines Versus Oral Thiopurines Alone 
Disease Activity Measures 
One trial of 96 steroid-dependent participants with active Crohn’s disease assessed whether a 
loading dose of intravenous azathioprine combined with an oral regimen of daily azathioprine 
would yield higher remission rates compared with an oral regimen alone (Table 14).59 The trial 
standardized prednisone therapy in all participants to 20 mg per day during a 2-week period prior 
to randomization. There were no clinically or statistically significant differences in steroid-free 
remission rates between the two groups at 8 or 16 weeks.  
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Thiopurines and Corticosteroids Versus Corticosteroids Alone 
Disease Activity Measures 
Three trials51,53,54 comprising 186 participants compared azathioprine and prednisolone taper 
with prednisolone taper and placebo to induce remission (Table 14). One trial,54 which tapered 
prednisolone but continued it at a maintenance dose of 10 mg daily throughout the 16-week trial, 
found that the addition of azathioprine was favored to prednisolone alone according to the 
clinically meaningful and statistically significant thresholds. The other trials51,53 which evaluated 
steroid-free remission, found that more patients on azathioprine had lower CDAI scores and were 
free of steroids at 12 and 28 weeks that met the clinically meaningful threshold, although the 
results were not statistically significant.  
Combination Therapy Versus Combination Therapy 
Thiopurines and Corticosteroids Versus Methotrexate and Corticosteroids 
Disease Activity Measures 
One trial blinded investigators but not patients and compared a combination of azathioprine 
and prednisone with a combination of methotrexate (intravenous route for 12 weeks followed by 
oral route) and prednisone in 54 patients (Table 14).58 At 12 weeks, more methotrexate patients 
were in steroid-free remission, but at 26 weeks more azathioprine patients were in steroid-free 
remission, according to the clinically meaningful threshold. There were no statistically 
significant differences in remission rates between the two groups at 12 or 26 weeks.  
Fistula Response 
In the above trial,58 10 patients had active perianal fistulizing disease.58 At week 26, one out 
of four patients in the azathioprine group and four out of six patients in the methotrexate group 
had fistula closure, but this finding was not statistically significant. 
Methotrexate 
Two trials evaluated the effectiveness of methotrexate as monotherapy to induce 
remission.52,57 Both of these trials also included comparisons with azathioprine and are described 
above. An additional trial63 compared methotrexate in combination with prednisone with placebo 
with prednisone. Two trials52,57 used oral methotrexate between 12.5 mg and 15 mg weekly, 
while one trial63 used intramuscular methotrexate at 25 mg a week. 
Study Design 
One of the three RCTs did not mention blinding (Appendix D, Evidence Table 2).52 Two 
trials used the CDAI for inclusion and to define the outcome, while one used the HBI.57 One trial 
took place in North America,63 one took place in Europe,52 and the last took place in Israel.57 
Two of the trials were multicenter in design.57 63 All trials reported the starting year of 
enrollment, ranging between 1992 and 1994. The median trial duration was 39 weeks (ranging 
between 16 and 106 weeks). All trials included only steroid-dependent patients, except one57 
which required prior steroid use for at least 4 of the prior 12 months. In one trial,63 patients who 
had a baseline prednisone dose under 20 mg daily raised their prednisone up to 20 mg daily for 2 
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weeks following randomization. One trial included adults ages 17 or older,57 one included those 
15 and older,52 and one did not specify an age range.63  
Population Characteristics 
Three trials randomized a total of 215 Crohn’s disease patients (Appendix D, Evidence Table 
3). The proportion of male participants in each trial group ranged from 46 to 60 percent. No trials 
reported on race. Smoking status was reported in all trials, ranging between 24 and 86 percent 
across all trial groups. All but one trial reported mean age at enrollment,52 ranging between 33 
and 39 years. All trials reported mean duration of disease, ranging between 4 and 8 years. All 
trials reported disease location: ileal location ranged between 17 and 50 percent, ileocolonic 
location between 25 and 86 percent, colonic location between 14 and 40 percent, and perianal 
location between 14 and 20 percent. Two trials reported baseline CDAI52,63 with mean CDAI 
ranging from 181 and 215 points. In the trial that used HBI,57 mean baseline HBI scores was 7.8 
and 9 in the relevant trial groups.  
Key Points 
Table 15 summarizes the strength of evidence for the trials evaluating methotrexate in terms 
of induction of remission. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following comparisons: 
• Oral methotrexate (15 mg a week) was more effective than aminosalicylates in inducing a 
remission at weeks 12, 30 (absolute RD across time points, 46 to 66 percent; 
aminosalicylates rate, 14 percent). (SOE: Moderate) 
• Intramuscular methotrexate (25 mg per week) with prednisone was more effective than 
prednisone plus placebo in inducing a steroid-free remission at week 16 (absolute RD, 20 
percent; prednisone plus placebo rate, 19 percent). (SOE: Moderate) 
• Intramuscular methotrexate (25 mg per week) with prednisone did not differ from 
prednisone plus placebo in improving patient-reported outcomes at 16 weeks (absolute 
between-group difference in change in mean IBDQ from baseline, 15 points; prednisone 
plus placebo change in IBDQ, -8 points). (SOE: Moderate) 
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Table 15. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating methotrexate to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of Bias Consistency Directness Precision 
Methotrexate 
(oral) vs. 
placebo–wks 4, 
12, 38 
Disease 
activity 
measures 
1 (52)57 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, -8% to 
3%; placebo rate, 5% to 46% 
 
SOE: Low 
Methotrexate 
(oral) vs. ASA–
wks 12, 30 
Disease 
activity 
measures 
1 (22)52 Medium Unknown 
(single trial) 
Direct Precise Favors methotrexate 
RD, 46% to 66%; ASA rate, 
14% 
 
SOE: Moderate 
Methotrexate 
(IM) + 
prednisone vs. 
placebo + 
prednisone–wk 
16 
Disease 
activity 
measures 
1 (141)63 Medium 
 
Unknown 
(single trial) 
Direct Precise Favors methotrexate + 
prednisone 
RD, 20%; prednisone only 
rate, 19% 
 
SOE: Moderate 
Methotrexate 
(IM) + 
prednisone vs. 
placebo + 
prednisone–wk 
16 
Patient-
reported 
outcomes 
1 (141)63  Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 15; 
prednisone only change in 
IBDQ, -8 
 
SOE: Moderate 
ASA = aminosalicylates; IBDQ = Inflammatory Bowel Disease Questionnaire; IM = intramuscular; RD = risk difference; SOE = strength of evidence; vs. = versus; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 Treatment Score for Wellbeing starts at 0 and 
improvement and worsening are graded from +3 to -3.60  
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Monotherapy Versus Placebo 
Methotrexate Versus Placebo 
Disease Activity Measures 
One trial included 52 steroid-dependent patients who had used at least 4 months of 
corticosteroids in the year prior to randomization.57 There was no clinically meaningful or 
statistically significant difference in remission rates between 12.5 mg of oral methotrexate 
weekly compared with placebo (Table 16; see also Appendix D, Evidence Table 4).  
Monotherapy Versus Monotherapy 
Methotrexate Versus Aminosalicylates 
Disease Activity Measures 
One trial52 of only 22 total patients compared methotrexate with aminosalicylates in steroid-
dependent patients. A substantially higher proportion of Crohn’s disease patients receiving oral 
methotrexate 15 mg per week achieved steroid-free remission (defined as CDAI < 150 and 
normal serum orosomucoid concentrations) than patients receiving 3 g per day of 
aminosalicylates therapy (80 vs.14 percent; P < 0.01). However, given the small sample size, and 
the fact that this was a subgroup analysis, the results should be interpreted with caution. 
Combination Therapy Versus Monotherapy 
Methotrexate and Corticosteroids Versus Corticosteroids Alone 
Disease Activity Measures 
We analyzed one RCT involving 141 patients.63 Table 16 summarizes the effects of 
methotrexate therapy in terms of inducing remission. 
A trial of 141 patients found 25 mg intramuscular methotrexate weekly and prednisone taper 
was superior to placebo plus prednisone taper in inducing steroid-free remission at 16 weeks 
(Table 16; see also Appendix D, Evidence Table 4).63 
Patient-Reported Outcomes 
At 16 weeks, there was no clinically meaningful difference in the IBDQ between the 
methotrexate and placebo groups.63  
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Table 16. Randomized controlled trials comparing the efficacy of methotrexate with placebo or 
another treatment to induce remission among patients with active Crohn’s disease at 
randomization 
Author, 
Year 
Followup 
(Weeks) 
Main Intervention 
(Dose), n 
Comparison 
(Dose), n 
Remission 
Definition 
Remission 
Rate, % 
Oren, 
199757 
4 Methotrexate (12.5 mg 
oral/week), 26 
Placebo, 26 HBI of 3 and steroid-
free at any time 
during trial 
8% vs. 5% 
12 Methotrexate (12.5 mg 
oral/week), 26 
Placebo, 26 HBI of 3 and steroid-
free at any time 
during trial 
20% vs. 22% 
38 Methotrexate (12.5 mg 
oral/week), 26 
Placebo, 26 HBI of 3 and steroid-
free at any time 
during trial 
38% vs. 46% 
Mate-
Jimenez, 
2000†52 
30 Methotrexate (15 mg 
oral/week), 15 
Aminosalicylates 
(3 g/day), 7 
CDAI<150 and 
steroid-free and 
normal serum 
orosomucoid 
concentrations 
80% vs. 14%* 
Feagan, 
199563 
16 Methotrexate (25 mg 
IM/week) + prednisone, 
94 
Placebo + 
prednisone, 47 
CDAI<150 and 
steroid-free 
39% vs. 19%* 
CDAI = Crohn’s Disease Activity Index; g = grams; HBI = Harvey-Bradshaw Index; IM = intramuscular; mg = milligrams; NS = 
not significant; vs. = versus 
*Trial reported P < 0.05 
†Trial also randomized ulcerative colitis patients, but only Crohn’s disease results included. 
Corticosteroids 
Thirteen RCTs compared corticosteroids therapy (alone or in combination with other 
medications) with placebo or other therapies to induce remission. One trial64 included 
participants with both active (CDAI > 150) and inactive (CDAI < 150) disease at randomization 
and we included results for those with active disease only in this section. Three trials56,65,66 
evaluated corticosteroids (budesonide, prednisone) versus placebo. Three trials67-69 evaluated 
budesonide versus prednisone or prednisolone. Six trials56,70-74 evaluated corticosteroids 
(budesonide, prednisone, 6-methylprednisolone) versus aminosalicylates. One trial75 evaluated a 
combination of prednisone and sulfasalazine versus prednisone alone. One trial also randomized 
patients to thiopurine and the results of thiopurine compared with corticosteroids are reported in 
the thiopurine section of the report.56 
Study Design 
The 13 RCTs were double blind (Appendix D, Evidence Table 2).56 64-75 The trials were 
heterogeneous in all aspects of design including the locations, years of recruitment, and doses 
and administration of the trial medications. 
The trials took place at multiple centers in the United States,56,65,75 Canada,66,73 
Europe,64,69,71,72 and Israel.67 Three trials were multinational.68,70,74 Enrollment started between 
1971 and 2004. All but one trial was completed prior to the approval of TNF-alpha inhibitors.74 
Trial duration ranged from 664 to 17 weeks.56 The minimum eligibility age was 18 years in ten 
trials, 15 years in one trial,56 and two did not report the minimum eligibility age.72,75 
Common disease activity inclusion criteria included a minimum CDAI of 150 or 200 with no 
upper limit or the use of a range of minimum (150 to 200) and maximum criteria (350 to 450). 
Common disease activity related exclusions included abscess,64,68-70,74 fistula, obstructive 
symptoms or strictures,67-71,74 and previous extensive surgery (more than 50 to 100 cm of 
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resection).66,68-71,73,74 Six of the seven trials of budesonide included patients with disease in the 
ileum or ascending colon only where budesonide is released.65-70 Remission was defined as a 
CDAI less than 150 in all trials.  
Most trials prohibited patients from taking therapies that were not assigned as part of the 
trial. No trial specifically excluded patients with prior use of any medication, although exclusion 
of patients taking immunomodulators within 3 months of randomization,65,67-74 aminosalicylates 
within 1 day to 30 days prior to randomization,66-70,72-74 and corticosteroids within 1 week to 3 
months of randomization65-72,74 were common. The trial conducted after the approval of 
biologics74 excluded patients who had used a TNF-alpha inhibitor within 6 months of 
randomization. 
Population Characteristics 
The trial that included patients with active and inactive disease did not report the population 
characteristics separately and is excluded from the description of population characteristics.64 
The other 12 trials randomized a total of 2,089 patients (Appendix D, Evidence Table 3). The 
proportion of male participants in each trial group ranged from 23 to 66 percent. Three trials 
reported on race56,74,75 with Caucasian patients comprising between 86 and 99 percent of all 
participants across the five trial groups. Four trials66,67,71,74 reported smoking status, ranging 
between 25 and 58 percent. All trials reported age at enrollment, ranging between 26 to 41 years 
(mean) and 30 to 38 years (median). All trials except two75,76 reported duration of disease, 
ranging between 2.4 to 11.9 years (mean) and 4.6 to 9.2 years (median). All but four 
trials65,68,69,74 reported disease location: ileal location ranged between 23 and 100 percent, 
ileocolonic location between 12 and 66 percent, and colonic location between 0 and 94 percent. 
All trials reported baseline CDAI, with mean CDAI ranging from 236 and 305 points and median 
CDAI ranging between 220 and 293 points. Prior medication use was as follows: 
aminosalicylates use ranged from 31 to 81 percent of participants in five trials,56,67,70,71,75 
antibiotic use ranged from 28 to 35 percent across two groups of one trial,67 and corticosteroids 
use ranged from 25 to 52 percent across five trials.56,66,67,73,75 
Key Points 
Table 17 summarizes the strength of evidence for the trials evaluating corticosteroids in 
terms of remission induction. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following comparisons: 
• Budesonide (at least 9 mg daily) was more effective than placebo in inducing a remission 
at week 2 (absolute RD, 17 to 27 percent; placebo rate, 11 to 13 percent). (SOE: 
Moderate) 
• Budesonide was more effective than placebo in inducing a remission at week 8 (absolute 
RD, 13 to 31 percent; placebo rate, 20 to 33 percent). (SOE: Moderate) 
• 6-methylprednisolone was more effective than placebo in inducing a remission at week 3 
(absolute RD, 14 percent; placebo rate, 79 percent). (SOE: Low) 
• Corticosteroids (including prednisone, 6-methylprednisolone) were more effective than 
placebo in inducing a remission at weeks 16-17, and 104 (absolute RD across time points, 
25 to 47 percent; placebo rate, 8 to 42 percent). (SOE: Low) 
• Prednisone was more effective than placebo in healing fistulas at 17 weeks in patients 
with actively draining fistulas (absolute RD in fistula closure, 19 percent; placebo rate, 11 
percent). (SOE: Low) 
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• Budesonide (9 mg a day) and corticosteroids (prednisone, prednisolone at 40 mg/day) did 
not differ in inducing a remission at weeks 2 and 8 (pooled RR at week 8, 0.9; 95% CI, 
0.8 to 1.0; corticosteroid rate, 55 to 65 percent). (SOE: Moderate) 
• Budesonide (9 mg daily) and prednisone (taper starting with 40 mg daily) did not differ 
in improving patient-reported outcomes at 8 weeks (absolute between-group difference in 
change in mean IBDQ from baseline, -8 points; prednisone change in IBDQ, 34 points). 
(SOE: Moderate) 
• Corticosteroids (budesonide, prednisone, 6-methylprednisolone) were more effective than 
aminosalicylates in inducing a remission at weeks 2 to 3, 12 to 17, 54, and 104 (absolute 
RD across time points, -18 to 30 percent; aminosalicylates rate, 6 to 87 percent). (SOE: 
Low) 
• Prednisone (taper starting at 40 mg daily) was more effective than aminosalicylates 
(Salofalk® 1 g, 3 times daily) in improving patient-reported outcomes at 2 weeks 
(absolute between-group difference in improvement in Quality of Life Index from 
baseline, 16 percent; Salofalk® improvement in Quality of Life Index, 7 percent). (SOE: 
High) 
• Prednisone (taper starting at 40 mg daily) and aminosalicylates (Salofalk® 1 g, 3 times 
daily) did not differ in improving patient-reported outcomes at 12 weeks (absolute 
between-group difference in improvement in Quality of Life Index from baseline, 4 
percent; Salofalk® improvement in Quality of Life Index, 33 percent). (SOE: Moderate) 
• A combination of 6-methylprednisolone (48 mg/day) and sulfasalazine (3 g/day) was 
more effective than placebo in inducing a remission at weeks 3, 16, and 104 (absolute RD 
across time points, 19 to 47 percent; placebo rate, 8 to 79 percent). (SOE: Low) 
• A combination of corticosteroids (prednisone, 6-methylprednisolone) and sulfasalazine 
was more effective than sulfasalazine alone in inducing a remission at weeks 3, 16, and 
104 (absolute RD across time points, 11 to 26 percent; sulfasalazine rate, 22 to 87 
percent). (SOE: Low) 
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Table 17. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating corticosteroids to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome Number of trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of Bias Consistency Directness Precision 
Budesonide (≥ 9 
mg) vs. placebo–
wk 2 
Disease 
activity 
measures 
2 (391)65 66 Medium Consistent Direct Precise Favors budesonide 
RD, 17% to 27%; placebo rate, 11% to 
13% 
 
SOE: Moderate 
Budesonide (< 9 
mg) vs. placebo–
wk 2 
Disease 
activity 
measures 
1 (128)66 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -1%; placebo rate, 11%  
 
SOE: Low 
Budesonide vs. 
placebo–wk 8 
Disease 
activity 
measures 
2 (458)65 66 Medium Consistent Direct Precise Favors budesonide 
RD across time points, 13% to 31%; 
placebo rate, 20% to 33% 
 
SOE: Moderate 
Budesonide vs. 
placebo–wk 8 
Patient-
reported 
outcomes 
2 (458)65 66  High Consistent Direct Imprecise Favors neither 
Absolute between-group difference in 
change in IBDQ from baseline, 7 to 30; 
placebo change in IBDQ, 10 to 29 
 
SOE: Low 
Prednisone vs. 
placebo – wk 2 
Disease 
activity 
measures 
1 (162)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, 5%; placebo rate, 15% 
 
SOE: Low 
6-methyl-
prednisolone vs. 
placebo–wk 3 
Disease 
activity 
measures 
1 (105)64 High Unknown 
(single study) 
Direct Precise Favors 6-methylprednisolone 
RD, 14%; placebo rate, 79% 
 
SOE: Low 
Steroid (6-
methyl-
prednisolone, 
prednisone) vs. 
placebo–wks 16-
17, 104 
Disease 
activity 
measures 
2 (267)56 64 High Consistent Direct Precise Favors steroids 
RD across time points, 25% to 47%; 
placebo rate, 8% to 42% 
 
SOE: Low 
Prednisone vs. 
placebo–wk 17 
Fistula 
response 
1 (19)55  High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD in fistula closure, 19%; placebo rate, 
11%  
 
SOE: Low 
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Table 17. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating corticosteroids to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome Number of trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of Bias Consistency Directness Precision 
Budesonide vs. 
other steroid 
(prednisolone, 
prednisone)–wks 
2, 8 
Disease 
activity 
measures 
3 (557)67-69 Medium Consistent Direct Precise Favors neither 
Pooled RR at wk 8, 0.9; CI, 0.8 to 1.0; 
steroid rate, 55% to 65% 
 
SOE: Moderate 
Budesonide vs. 
prednisone–wk 8 
Patient-
reported 
outcomes 
1 (201)67  Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
Absolute between-group difference in 
change in mean IBDQ from baseline,  
-8; prednisone change in IBDQ, 34 
 
SOE: Moderate 
Steroid vs. ASA–
wks 2-3, 12-17, 
54-104 
Disease 
activity 
measures 
7 (919)56 64 70-74 Medium Inconsistent Direct Imprecise Favors steroids 
RD across time points, -18% to 30%; 
ASA rate, 6% to 87% 
 
SOE: Low 
Prednisone vs. 
sulfasalazine 
Fistula 
healing 
2 (19)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD in fistula closure, 9%; sulfasalazine 
rate, 22% 
 
SOE: Low 
Prednisone vs. 
ASA – wk 2 
Patient-
reported 
outcomes 
1 (50)73  Low Unknown 
(single trial) 
Direct Precise Favors prednisone 
Absolute between-group difference in 
Quality of Life Index from baseline, 16%; 
ASA improvement in Quality of Life 
Index, 7%  
 
SOE: High 
Prednisone vs. 
ASA – wk 12 
Patient-
reported 
outcomes 
1 (50)73  Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
Absolute between-group difference in 
Quality of Life Index from baseline, 4%; 
ASA improvement in Quality of Life 
Index, 33% 
 
SOE: Moderate 
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Table 17. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating corticosteroids to induce remission among patients with active Crohn’s disease at randomization (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
Risk of Bias Consistency Directness Precision 
Prednisolone + 
sulfasalazine vs. 
placebo–wks 
3,16, 104 
Disease 
activity 
measures 
1 (114)64 High Unknown 
(single trial) 
Direct Precise Favors prednisolone + sulfasalazine 
RD across time points, 19% to 47%; 
placebo rate, 8% to 79% 
 
SOE: Low 
Steroid + 
sulfasalazine vs. 
steroid–wks 3, 8-
16, 104 
Disease 
activity 
measures 
2 (192)64 75 Medium Consistent Direct Imprecise Favors neither 
RD across time points, 2% to 19%; 
steroid rate, 33% to 93% 
 
SOE: Low 
Steroid + 
sulfasalazine vs. 
sulfasalazine–
wks 3, 16, 104 
Disease 
activity 
measures 
1 (110)64 High Consistent Direct Precise Favors steroids + sulfasalazine 
RD across time points, 11% to 26%; 
sulfasalazine rate, 22% to 87% 
 
SOE: Low 
ASA = aminosalicylates; CI = 95% confidence interval; IBDQ = Inflammatory Bowel Disease Questionnaire; mg = milligrams; RD = absolute risk difference; RR = relative risk; 
SOE = strength of evidence; steroid = corticosteroids; vs. = versus; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire and the Quality of Life Index range from 32 to 224, with higher scores indicating better quality of life.36 
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Monotherapy Versus Placebo 
Corticosteroids Versus Placebo 
Table 18 summarizes the effects of corticosteroids to induce remission compared with 
placebo (see also Appendix D, Evidence Table 4). 
Disease Activity Measures 
Four trials, comprising 725 participants, compared corticosteroids with placebo to induce 
remission.56,64-66 
Budesonide 9 mg had higher remission rates at 2 and 8 weeks compared with placebo in two 
trials,65,66 but the finding was statistically significant in only one of the trials at 265 and 8 
weeks.66 Budesonide 15 mg was clinically favored at 2 and 8 weeks and was statistically 
significant at 8 weeks.66 Prednisone was clinically and statistically favored over placebo at 17 
weeks, but not 2 weeks.56 Methylprednisolone (48 mg/day with taper) was clinically favored 
over placebo at 3 and 104 weeks, but was statistically significant only at 104 weeks.64 A meta-
analysis of the four trials was not performed because the medications act in different portions of 
the intestines and the patient populations accordingly differed in location of disease. 
Fistula Response 
One trial reported in two publications compared prednisone with placebo.55,56 Nineteen 
patients had draining perianal disease at the time of randomization. Fistula response was higher 
in the prednisone group (30 vs.11 percent; study reported P > 0.05). 
Patient-Reported Outcomes 
Two trials with 458 participants compared budesonide with placebo.65,66 In the larger trial of 
258 participants,66 at 8 weeks mean IBDQ rose from a baseline value of 131 to 138 points in the 
3 mg/day group, 125 to 165 points in the 9 mg/day group, 130 to 155 points in the 15 mg/day 
group, and 130 to 140 points in the placebo group. Budesonide was only clinically and 
statistically significant compared with placebo at the 9 mg dosage.66 In a trial of 200 patients, 
there was no difference between groups.65 The change in IBDQ score from baseline (values not 
provided) was 36 points in the 9 mg/day group, 34 points in the 4.5 mg oral twice daily group, 
and 29 points in the placebo group at 8 weeks.65  
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Table 18. Randomized controlled trials comparing the efficacy of corticosteroids with placebo or another treatment to induce remission 
among patients with active Crohn’s disease at randomization 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (Dose), n 
Remission 
Definition 
Remission Rate 
(%) 
Greenberg, 
199466 
2 Budesonide (1.5 mg twice daily), 67 Placebo, 66 CDAI<150 10% vs. 11% 
2 Budesonide (4.5 mg twice daily), 61 Placebo, 66 CDAI<150 32% vs. 11% 
2 Budesonide (7.5 mg twice daily), 64 Placebo, 66 CDAI<150 28% vs. 11% 
8 Budesonide (1.5 mg twice daily), 67 Placebo, 66 CDAI<150 33% vs. 20% 
8 Budesonide (4.5 mg twice daily), 61 Placebo, 66 CDAI<150 51% vs. 20%* 
8 Budesonide (7.5 mg twice daily), 64 Placebo, 66 CDAI<150 43% vs. 20%* 
Tremaine, 
200265 
2 Budesonide (9 mg/day), 80 Placebo, 41 CDAI<150 31% vs. 13%* 
2 Budesonide (4.5 mg twice daily), 79 Placebo, 41 CDAI<150 40% vs. 13%* 
8 Budesonide (9 mg/day), 80 Placebo, 41 CDAI<150 48% vs. 33% 
8 Budesonide (4.5 mg twice daily), 79 Placebo, 41 CDAI<150 53% vs. 33% 
Summers, 
197956  
2 Prednisone (0.5-0.75 mg/kg), 85 Placebo, 77 CDAI<150† 20% vs. 15% 
17 Prednisone (0.5-0.75 mg/kg), 85 Placebo, 77 CDAI<150† 59% vs. 42%* 
Malchow, 
198464 
3 6-methylprednisolone (48 mg/day with 
taper), 47 
Placebo, 58 CDAI<150‡ 93% vs. 79%* 
16 6-methylprednisolone (48 mg/day with 
taper), 47 
Placebo, 58 CDAI<150‡ 83% vs. 36%* 
104 6-methylprednisolone (48 mg/day with 
taper), 47 
Placebo, 58 CDAI<150‡ 33% vs. 8%* 
Rutgeerts, 
199469 
2 Budesonide (9 mg/day), 86 Prednisolone (40 mg/day), 86 CDAI≤150 45% vs. 56% 
10 Budesonide (9 mg/day), 86 Prednisolone (40 mg/day), 86 CDAI≤150 53% vs. 66% 
Bar-Meir, 
199867 
8 Budesonide (9 mg/day), 100 Prednisone (40 mg/day), 101 CDAI<150 51% vs. 53% 
Campieri, 
199768 
2 Budesonide (4.5 mg twice daily), 58 Prednisolone (40 mg/day), 61 CDAI≤150 27% vs. 37% 
2 Budesonide (9 mg/day), 61 Prednisolone (40 mg/day), 61 CDAI≤150 48% vs. 37% 
8 Budesonide (4.5 mg twice daily), 58 Prednisolone (40 mg/day), 61 CDAI≤150 48% vs. 60% 
8 Budesonide (9 mg/day), 61 Prednisolone (40 mg/day), 61 CDAI≤150 60% vs. 60% 
Thomsen, 
199870 
8 Budesonide (9 mg/day), 93 Mesalamine (4 g/day), 89 CDAI<150 69% vs. 45%* 
16 Budesonide (9 mg/day), 93 Mesalamine (4 g/day), 89 CDAI<150  62% vs. 36%* 
Tromm 
201174 
8 Budesonide (9mg/day), 154 Mesalamine (4.5 g/day), 153 CDAI<150  69% vs. 62% 
Summers, 
197956  
3 Prednisone (0.5-0.75 mg/kg/day), 85 Sulfasalazine (1.5 mg/15 kg/day), 74 CDAI<150† 25% vs. 6% 
17 Prednisone (0.5-0.75 mg/kg/day), 85 Sulfasalazine (1.5 mg/15 kg/day), 74 CDAI<150† 59% vs. 29% 
Malchow, 
198464 
3 6-methylprednisolone (48 mg/day with 
taper), 47 
Sulfasalazine (3g/day), 54 CDAI<150‡ 93% vs. 87% 
16 6-methylprednisolone (48 mg/day with 
taper), 47 
Sulfasalazine (3g/day), 54 CDAI<150‡ 83% vs. 57% 
104 6-methylprednisolone (48 mg/day with 
taper), 47 
Sulfasalazine (3g/day), 54 CDAI<150‡ 33% vs. 22% 
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Table 18. Randomized controlled trials comparing the efficacy of corticosteroids with placebo or another treatment to induce remission 
among patients with active Crohn’s disease at randomization (continued) 
Author, year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison (Dose), n 
Remission 
Definition 
Remission Rate 
(%) 
Gross, 199572 8 6-methylprednisolone (48 mg/day), 16 Aminosalicylates (4.5 g/day), 15 CDAI<150, 60-pt 
decrease in 
CDAI 
56% vs. 40% 
Prantera, 
199971 
3 6-methylprednisolone (40 mg/day), 31 Aminosalicylate tablets (4 g/day), 35 CDAI<150 61% vs. 46% 
3 6-methylprednisolone (40 mg/day), 31 Aminosalicylate granules (4 g/day), 
28 
CDAI<150 61% vs. 61% 
12 6-methylprednisolone (40 mg/day), 31 Aminosalicylate tablets (4 g/day), 35 CDAI<150 61% vs. 60% 
12 6-methylprednisolone (40 mg/day), 31 Aminosalicylate granules (4 g/day), 
28 
CDAI<150 61% vs. 79% 
Martin, 199073 12 Prednisone (40 mg/day), 26 Mesalamine (750 mg/day), 19 CDAI < 150 46% vs. 47% 
Malchow, 
198464 
3 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Placebo, 58 CDAI<150‡ 98% vs. 79%* 
16 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Placebo, 58 CDAI<150‡ 83% vs. 36%* 
104 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Placebo, 58 CDAI<150‡ 35% vs. 8%* 
Singleton, 
197975  
8 Prednisone (0.25-0.75 mg/kg/day) + 
sulfasalazine (1 g/15 kg/day), 46 
Prednisone (0.25-0.75 mg/kg/day), 43 CDAI<150 76% vs. 57% 
Malchow, 
198464 
3 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
6-methylprednisolone (48 mg/day 
with taper), 47 
CDAI<150‡ 98% vs. 93% 
16 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
6-methylprednisolone (48 mg/day 
with taper), 47 
CDAI<150‡ 83% vs. 75% 
104 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
6-methylprednisolone (48 mg/day 
with taper), 47 
CDAI<150‡ 35% vs. 33% 
Malchow, 
198464 
3 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Sulfasalazine (3g/day), 54 CDAI<150‡ 98% vs. 87% 
16 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Sulfasalazine (3g/day), 54 CDAI<150‡ 83% vs. 57% 
104 6-methylprednisolone (48 mg/day with taper) 
+ sulfasalazine (3g/day), 56 
Sulfasalazine (3g/day), 54 CDAI<150‡ 35% vs. 22% 
CDAI = Crohn’s Disease Activity Index; g = grams; kg = kilograms; mg = milligrams; pt = point; vs. = versus 
*Study reported significance at the 0.05 alpha level. For Malchow 1984,64 significance level does not specify time point in the 104 week trial – thus all time points are marked as 
significant for a given comparison where appropriate 
†One component of a composite outcome 
‡One component of a composite outcome including CDAI criteria (decrease or less than 100 points increase during first treatment, no increase during second treatment, and score 
less than 150 or 60 point decrease after third treatment), no need to repeat induction therapy, absence of clinical criteria (death due to Crohn’s disease, fever for more than 2 weeks, 
need for Crohn’s disease surgery, development of new fistulas or abscesses, or disease worsening by endoscopy or radiography) and not withdrawn from the trial 
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Monotherapy Versus Monotherapy 
Budesonide Versus Other Corticosteroids 
Disease Activity Measures 
Three trials, including 553 participants, compared budesonide with prednisone or 
prednisolone in the ability to induce remission at 2, 8, and 10 weeks after randomization.67-69 The 
daily doses were consistent across the trials. The daily dose of budesonide was 9 mg and 40 mg 
for prednisolone or prednisone. A meta-analysis was performed (Figure 7). We found no 
clinically meaningful or statistically significant difference in pooled remission rates at 8 weeks 
(RR of inducing remission, 0.88; 95% CI, 0.76 to 1.02). There was no significant heterogeneity 
(I-squared, 0 percent). 
Patient-Reported Outcomes 
One trial with 201 participants compared prednisone and placebo with budesonide and 
placebo.67 At 8 weeks, mean IBDQ rose from 130 to 164 in the prednisone group and 136 to 162 
in the budesonide group, which did not meet the 17-point difference threshold for clinical 
significance. Additionally, there were no difference in the Short Form-36 (SF-36) mental score 
(increase from 42.2 to 60.9 points vs. 46.5 to 56.9 points, respectively) or physical score 
(increase from 40.8 to 62.3 points vs. 44.8 to 58.3 points, respectively). 
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Figure 7. Pooled relative risk of inducing remission* of Crohn’s disease at week 8 comparing budesonide with another corticosteroid 
 
BUD = budesonide; CI = confidence interval; PRED = prednisone; PREDL = prednisolone; RR = relative risk; Steroid = corticosteroid  
*In all trials, remission was defined as a Crohn’s Disease Activity Index less than 150. Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, 
with larger boxes contributing more to the pooled estimate. The width of the horizontal lines represents the 95% confidence intervals for each trial. The diamond at the bottom of 
the graph indicates the 95% confidence interval for the random-effects pooled estimate. 
Test for heterogeneity: Q=0.65 with 2 degrees of freedom (p=0.72) 
I-squared statistic = 0% 
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Corticosteroids Versus Aminosalicylates 
Disease Activity Measures 
Seven trials, including 874 participants, compared corticosteroids with aminosalicylates to 
induce remission.56,64,70-74 Meta-analysis was not performed because of the disease location 
differences in the budesonide trials70,74 compared with the other trials and differences in time 
periods of the study and definition of remission in the methylprednisolone and prednisone 
trials.56,64,71-73 
The budesonide trials had inconsistent findings.70,74 The 1998 trial found clinically 
meaningful and statistically significant results favoring budesonide 9 mg/day compared with 
mesalamine 4 mg/day at 8 and 16 weeks,70 but the 2011 budesonide trial found no difference 
using the same dose of budesonide and 0.5 mg/day more of mesalamine at 8 weeks.74  
The prednisone trials also had inconsistent results.56,73 Prednisone 0.5 to 0.75 mg/kg/day was 
clinically favored over sulfasalazine 1.5 mg/15 kg/day at 3 and 17 weeks, although statistical 
significance was not reported in the trial.56 Prednisone 40 mg/day for 2 weeks followed by a 
decrease in the dose for an additional 10 weeks was no different than mesalamine 750 mg/d at 12 
weeks at inducing remission.73 
The three 6-methylprednisolone trials also had inconsistent results.64,71,72 The remission 
outcomes and formulations and doses of aminosalicylates were different between the trials 
prohibiting meta-analysis. 6-methylprednisolone 48 mg/day was clinically, but not statistically, 
favored over aminosalicylates 4.5 g/day at 8 weeks.72 The other two 6-methylprednisolone trials 
had inconsistent results based on the time of measure and formulation of the aminosalicylate.64 71 
Fistula Response 
Among a subset of 19 patients with draining perianal fistulas at the time of randomization,56 
there was no difference in fistula response at 17 weeks between those receiving prednisone daily 
versus those receiving sulfasalazine (30 vs. 22 percent).55  
Patient-Reported Outcomes 
One trial with 50 participants compared prednisone with aminosalicylates using the 
McMaster University Quality of Life Index.73 At 2 weeks, improvement, not defined in the 
manuscript, in the Quality of Life Index was 23 percent in the prednisone group and 7 percent in 
the aminosalicylates group, which met our 10 percent between group difference threshold (P < 
0.005). At 12 weeks, the improvement was 37 and 33 percent, respectively, and was not 
clinically meaningful nor statistically significant (P > 0.05). 
Combination Therapy Versus Placebo 
Corticosteroids and Aminosalicylates Versus Placebo 
Disease Activity Measures 
In the trial64 that randomized patients with active and inactive disease, the active disease 
patients that received combination therapy with methylprednisolone (48 mg/day with taper) and 
sulfasalazine (3 g/day) had clinically and statistically significantly higher rates of remission than 
the placebo group at 3, 16, and 104 weeks after randomization.  
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Combination Therapy Versus Monotherapy 
Corticosteroids and Aminosalicylates Versus Corticosteroids Alone 
Disease Activity Measures 
Two trials64,75 including 192 participants compared a combination of corticosteroids and 
aminosalicylates versus corticosteroids alone.  
One trial found a clinically meaningful difference, but the other trial did not. A trial of 89 
participants75 compared a combination of prednisone and sulfasalazine with prednisone alone. 
The trial favored combination therapy over prednisone at week 8, but this finding was not 
statistically significant. The other trial,64 did not find a clinically meaningful difference between 
combination therapy with methylprednisolone (48 mg/day with taper) and sulfasalazine (3 g/day) 
and 6-methylprednisolone (48 mg/day with taper) alone.  
Corticosteroids and Aminosalicylates Versus Aminosalicylates Alone 
Disease Activity Measures 
One trial,64 including 110 participants, compared a combination of corticosteroids and 
aminosalicylates with aminosalicylates alone. Combination therapy with 6-methylprednisolone 
(48 mg/day with taper) and sulfasalazine (3 g/day) resulted in higher rates of remission at 3, 16, 
and 104 weeks than sulfasalazine (3 g/day) alone. Statistical tests were not reported in the 
publication for this medication comparison.  
Aminosalicylates 
Five trials evaluated the effectiveness of aminosalicylates as monotherapy to induce 
remission.56,64,77-79 Two trials evaluated sulfasalazine at doses between 1 g/15 kg and 6 g a day,56 
64 two trials evaluated mesalamine (Asacol) between 1 g to 4 g a day,77,79 and one trial evaluated 
mesalamine (Pentasa) at 1.5 g a day.78 Two of these trials included comparisons with 
corticosteroids56,64 and one included comparisons with immunomodulators.56 These trials are 
also reported in those sections of the report. 
Study Design 
The five RCTs were double blind (Appendix D, Evidence Table 2).56,64,77-79 One trial64 
included participants with both active (CDAI greater than 150) and inactive (CDAI less than 
150) disease at randomization; patients with active disease were analyzed as part of a subgroup 
analysis. The trials were conducted in the United States and Europe and had very few inclusions 
but used different definitions of remission. 
The trials took places at multiple centers in the United States,56,79 Canada,56 and Europe.64,78 
One trial occurred at a single center in the United States.77 One trial occurred in the United States 
and Canada.56 The trials occurred during the 1970s through 1990s with the most recent 
publication in 1994.77 Trial duration ranged from 664 to 17 weeks.56 77 The minimum eligibility 
age was 18 years in 3 trials and 15 years in two trials.56 78  
Four trials required a minimum CDAI of 150 and one trial required at least two bowel 
movements a day to indicate active disease.78 Maximum CDAI inclusion criteria included 400,79 
45056,77 and no upper limit.64 The trial that required at least two bowel movements per day 
excluded patients with more than five bowel movements per day or any patient with fever, 
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inability to work, or other symptoms indicative of severe disease.78 Disease activity related 
exclusions were rare. One study excluded patients with abscess,64 another excluded patients with 
an extensive resection.77 Disease location requirements included ileal disease,64 small bowel 
disease,78 and colonic disease.77  
Remission was defined as a CDAI less than 150 in one trial.64 Another trial used CDAI less 
than 150 as part of a composite outcome included clinical events.56 Two trials required CDAI 
less than 150 combined with a 5079 or 7077 point decrease in the CDAI. The trial that required 
bowel movements per day for inclusion defined remission based on a review of the clinical notes 
and endoscopic records.78 
Most trials prohibited patients from taking therapies that were not assigned as part of the 
trial. No trial specifically excluded patients with prior use of any medication, although exclusion 
of patients taking immunomodulators, aminosalicylates, or corticosteroids one week to 90 days 
before randomization occurred in three trials.77-79  
Population Characteristics 
The trial64 that included patients with active and inactive disease at randomization did not 
report the population characteristics separately by disease activity and is not included in the 
population characteristics summary. The four remaining trials randomized 710 participants 
(Appendix D, Evidence Table 3). The proportion of male participants in each trial group ranged 
from 27 to 67 percent. Only two trials56,77 commented on the percentage of Caucasians, which 
ranged from 90 to 100 percent among all groups. Only one trial reported on smoking 
(“smoker”),79 ranging between 29 and 50 percent across the four groups. Two trials reported 
mean age at enrollment with means of 30 and 37 years with the other two trials reporting median 
age at enrollment of 31 and 38 years. All trials reported duration of disease, ranging between 3.3 
and 9.9 years (mean) and 3.5 and 7 years (median). All but one trial77 reported on disease 
location: ileal-only location ranged between 23 and 100 percent, ileocolonic location between 44 
and 85 percent, and colonic location between 9 and 25 percent. All trials reported baseline 
CDAI, ranging between 205 and 277 (mean) and 153 and 177 (median). We derived the value of 
153 from the trial78 that included participants based on bowel movements per day. None of the 
trials reported concurrent medication use. Prior medication use was reported in two trials56,79: 
aminosalicylate use was 17 and 38 percent and prior corticosteroids use was 16 and 38 percent. 
Key Points 
Table 19 summarizes the strength of evidence for the trials evaluating aminosalicylates in 
terms of remission induction. We found at least moderate strength of evidence or a clinically 
meaningful difference in the following comparisons: 
• Aminosalicylates (mesalamine at least 3.2 g daily, or sulfasalazine) were more effective 
than placebo in inducing a remission at weeks 16-17 (absolute RD, 12 to 25 percent; 
placebo rate, 18 to 36 percent). (SOE: Low) 
• Sulfasalazine (3 g/day) was more effective than placebo in inducing a remission at week 
104 (absolute RD, 14 percent; placebo rate, 8 percent). (SOE: Low) 
• Sulfasalazine (1 g/15 kg) was more effective than placebo in healing fistulas at 17 weeks 
in patients with actively draining fistulas (absolute RD in fistula closure, 11 percent; 
placebo rate, 11 percent). (SOE: Low) 
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Table 19. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating aminosalicylates to induce remission among patients with active Crohn’s disease at randomization 
Comparison Outcome 
Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence Risk of Bias Consistency Directness Precision 
ASA vs. placebo-
wks 2-3 
Disease 
activity 
measures 
5 (330)56 64 78 Medium Inconsistent Direct Imprecise Favors neither 
RD, -8 to 9%; placebo rate, 
8 to 79% 
 
SOE: Low  
ASA 
(mesalamine ≥ 
3.2 g daily or 
sulfasalazine) vs. 
placebo-wks 16-
17 
Disease 
activity 
measures 
5 (456)56 64 77 79 Medium Consistent Direct Imprecise Favors ASA 
RD, 12 to 25%; placebo 
rate, 18 to 36% 
 
SOE: Low  
ASA 
(mesalamine < 
3.2 g daily) vs. 
placebo-wk 16 
Disease 
activity 
measures 
5 (302)78 79 Medium Consistent Direct Imprecise Favors neither 
RD, 2 to 6%; placebo rate, 
18 to 25% 
 
SOE: Low  
Sulfasalazine vs. 
placebo – wk 104 
Disease 
activity 
measures 
1 (112)64 High Unknown 
(single trial) 
Direct Precise Favors sulfasalazine 
RD, 14%; placebo rate, 8% 
 
SOE: Low 
Sulfasalazine vs. 
placebo-wk 17 
Fistula 
response 
1 (18)55 High Unknown 
(single trial) 
Direct Imprecise Favors sulfasalazine 
RD in fistula closure, 11%; 
placebo rate, 11% 
 
SOE: Low 
ASA = aminosalicylates; RD = risk difference; SOE = strength of evidence; vs. = versus; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
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Monotherapy Versus Placebo 
Aminosalicylates Versus Placebo 
Disease Activity Measures 
Five RCTs involving 678 patients met the inclusion criteria.56,64,77-79 Table 20 summarizes 
the effects of aminosalicylate therapy to induce remission (see also Appendix D, Evidence Table 
4). A meta-analysis was not performed due to variability in aminosalicylate preparation, doses, 
outcome definitions, and outcome time points. Four of five trials clinically favored 
aminosalicylates over placebo at one or more time points but only two trials reported statistical 
significance at the last reported time point.64,79  
Fistula Response 
One trial reported in two publications compared daily sulfasalazine with placebo.55,56 
Eighteen patients had draining perianal disease at the time of randomization. Fistula response 
was higher in the sulfasalazine group (22 vs. 11 percent) but was not statistically significant (P > 
0.05). 
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Table 20. Randomized controlled trials comparing the efficacy of aminosalicylates with placebo to induce remission among patients 
with active Crohn’s disease at randomization 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n 
Total Dose 
(g/day) Comparison, n Remission Definition 
Remission Rate 
(%) 
Summers, 
197956 
3 Sulfasalazine (1 g/15 kg/day), 74 1g/15 kg Placebo, 77 CDAI<150† 20% vs. 11% 
17 Sulfasalazine (1 g/15 kg/day), 74 1 g/15 kg Placebo, 77 CDAI<150† 42% vs. 30% 
Malchow, 
198464 
3 Sulfasalazine (3 g/day), 54 3 Placebo, 58 CDAI<150‡ 87% vs. 79%* 
16 Sulfasalazine (3 g/day), 54 3 Placebo, 58 CDAI<150‡ 57% vs. 36%* 
104 Sulfasalazine (3 g/day), 54 3 Placebo, 58 CDAI<150‡ 22% vs. 8%* 
Rasmussen, 
198778 
2 Mesalamine (1500 mg every 24 
hr), 30 
1.5 Placebo, 37 CDAI decrease by >33% 0% vs. 8% 
16 Mesalamine (1500 mg every 24 
hr), 30 
1.5 Placebo, 37 CDAI decrease by >33% 27% vs. 25% 
Singleton, 
199379 
16 Mesalamine (1 g every 24 hr), 80 1 Placebo, 80 CDAI≤150 and 50-pt decrease 23% vs. 18% 
16 Mesalamine (2 g every 24 hr), 75 2 Placebo, 80 CDAI≤150 and 50-pt decrease 24% vs. 18% 
16 Mesalamine (4 g every 24 hr), 75 4 Placebo, 80 CDAI≤150 and 50-pt decrease 43% vs. 18%* 
Tremaine, 
199477 
16 Mesalamine (800 mg every 6 hr), 
20 
3.2 Placebo, 18 CDAI<150 and 70-pt decrease 45% vs. 22% 
CDAI = Crohn’s Disease Activity Index; g = gram; HBI = Harvey-Bradshaw Index; hr = hour; kg = kilogram; mg = milligram; pt = point; vs. = versus  
*Study report significant difference at 0.05 alpha level. For Malchow 1984,64 significance level does not specify time point in the 104 week trial – thus all time points are marked 
as significant for a given comparison where appropriate 
†One component of a composite outcome. 
‡One component of a composite outcome including CDAI criteria (decrease or less than 100 points increase during first treatment, no increase during second treatment, and score 
less than 150 or 60-point decrease after third treatment), no need to repeat induction therapy, absence of clinical criteria (death due to Crohn’s disease, fever for more than 2 weeks, 
need for Crohn’s disease surgery, development of new fistulas or abscesses, or disease worsening by endoscopy or radiography) and not withdrawn from the trial 
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Comparative Effectiveness of Therapies To Induce Remission in 
Adult Subgroups 
We abstracted all subgroup analyses that reported on all levels of the effect-modifying 
variable (Appendix G). Only trials that performed a statistical test for interaction were included 
in this section.  
Key Points 
• We saw no consistent relationship for the interaction of a medication and disease 
characteristic on remission rates in adults with Crohn’s disease. 
Baseline CRP 
Three trials reported results by baseline CRP in categories of high versus low CRP.37 38 45 
Only one trial,38 which evaluated remission at 4 weeks for adalimumab versus placebo, reported 
a P-value for an interaction term. Remission rates for high-versus-low CRP (cutoff at 10 mg/L) 
did not differ between groups (P=0.67). 
Baseline Corticosteroid Use 
Three trials reported a subgroup analysis by baseline corticosteroid use.38 44 45 Only one 
trial,38 that evaluated remission at 4 weeks for adalimumab versus placebo, reported a P-value 
for an interaction term. Remission rates were higher for patients who were on corticosteroids at 
the time of randomization (P=0.01). 
Baseline Immunomodulator Use 
Four trials reported a subgroup analysis by baseline immunomodulator use.33,37-39 Two of the 
trials33,38 reported a P-value for an interaction term. One trial,38 evaluating 4 week remission for 
adalimumab versus placebo, found no effect of baseline immunomodulator use (P=0.88). 
Another trial, evaluating natalizumab versus placebo at 10 weeks, found higher response and 
remission rates for patients on baseline immunomodulators at randomization (P < 0.05). 
Prior TNF-Alpha Inhibitor Exposure 
Three trials reported a subgroup analysis by prior TNF-alpha inhibitor use.33,39,80 Only one 
trial,33 which evaluated natalizumab versus placebo at 10 weeks, reported a P-value for an 
interaction term. Response rates were higher for patients with prior TNF-alpha inhibitor 
exposure (P < 0.05). The trial saw no effect for remission (P > 0.05).  
The following subgroup analyses were reported in the trials, but did not meet the criteria for 
inclusion: baseline mucosal lesions, baseline aminosalicylates, baseline antibiotic use, prior 
immunomodulator exposure, prior aminosalicylates exposure, prior corticosteroids exposure, 
disease duration, disease location, and prior Crohn’s disease-related surgery. 
Quality Assessment 
Out of the 53 trials included in this report that addressed KQ1, 32 percent were rated as good 
quality, 45 percent as fair quality, and 23 percent as poor quality (Appendix D, Evidence Table 
5). All were RCTs with parallel group design by inclusion criteria for the systematic review. 
Among these 53 RCTs, 59 percent reported adequately generated allocation sequence. Sixty-two 
78 
percent adequately concealed allocation. Seventy-two percent reported being double blinded 
while 28 percent were not double blinded or did not report on blinding. Seventy percent of trials 
reported withdrawals and dropouts while 30 percent had incomplete outcome data. Fifty-one 
percent of these RCTs had some form of threat to the validity of results that they reported such as 
not clearly differentiating between patients with active and inactive disease or not performing a 
statistical test for interaction in subgroup analyses. Seventy percent received pharmaceutical 
support with 38 percent having pharmaceutical company employed co-authors. Twenty-three 
percent did not report on conflicts. 
Key Question 2: Effectiveness of Therapies To Maintain 
Remission in Adults  
Table 21 summarizes the evidence grades and specific conclusions for each comparison. 
Details of the evidence grades are included in the Results and in Appendix D, Table 6. 
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Table 21. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to 
maintain remission* 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 48-54 
Disease 
Activity 
Measure 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Natalizumab 
vs. placebo 
 
48 weeks 
Favors 
natalizumab; 
Moderate 
Insufficient Insufficient Insufficient Insufficient Week 48 
Favors 
natalizumab; 
Moderate 
Insufficient Week 48 
Favors 
natalizumab; 
Moderate 
Adalimumab 
vs. placebo 
 
52 weeks 
Favors 
adalimumab; 
Low 
Insufficient Insufficient Week 52 
Favors adalimumab 
for all-cause 
hospitalizations 
Favors neither for 
CD-related 
hospitalizations; 
Moderate 
Week 52 
Favors neither; 
Moderate 
Week 52 
Favors 
adalimumab; 
Low 
Insufficient Week 52 
Favors neither; 
Low 
CP vs. placebo 
 
18 weeks 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 18 
Favors neither; 
Low 
Infliximab vs. 
placebo 
 
52 weeks 
Favors neither 
among all 
randomized 
Favors 
infliximab 
among 
responders; 
Low 
Insufficient Week 52 
Favors 
infliximab; 
Low 
Week 52 
Favors infliximab; 
Moderate 
Week 52 
Favors neither 
among 
patients with 
fistulizing 
disease; 
Moderate 
Week 52 
Favors 
infliximab; 
Low 
Week 40 
Favors 
infliximab; 
Low 
Week 52 
Favors infliximab; 
Low 
Infliximab + 
azathioprine 
vs. infliximab 
 
104 weeks 
Insufficient Week 104 
Favors neither; 
Low 
Week 104 
Favors 
neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Week 104 
Favors neither; 
Low 
Infliximab + 
azathioprine 
vs. infliximab + 
hydrocortisone 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table 21. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to 
maintain remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 48-54 
Disease 
Activity 
Measure 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Azathioprine 
vs. placebo 
 
104 weeks 
Favors 
azathioprine 
(≥1.7 
mg/kg/day) 
Favors neither 
(<1 mg/kg/day); 
Low 
Week 104 
Favors 
azathioprine 
(≥1.7 
mg/kg/day) 
Favors neither 
(<1 mg/kg/day); 
Low 
Insufficient Insufficient Insufficient Week 26 
Favors 
azathioprine; 
Low 
Insufficient Insufficient 
Azathioprine 
vs. budesonide 
 
52 weeks 
Favors 
azathioprine; 
Low 
Insufficient Week 52 
Favors 
azathioprin
e; 
Moderate 
Insufficient Insufficient Insufficient Insufficient Insufficient 
Azathioprine 
vs. prednisone 
 
104 weeks 
Favors 
azathioprine; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Azathioprine 
vs. 
sulfasalazine 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Methotrexate 
(IM) vs. 
placebo 
 
40 weeks 
Week 40 
Favors 
methotrexate; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Budesonide 
vs. placebo 
 
52 weeks 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 52 
Favors neither; 
Low 
Prednisone vs. 
placebo 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
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Table 21. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to 
maintain remission* (continued) 
Comparison 
 
Maximum 
Trial Duration 
Disease 
Activity 
Measure 
Weeks 48-54 
Disease 
Activity 
Measure 
After 54 Weeks 
Mucosal 
Healing Hospitalizations Surgeries 
Reduction 
of Steroids 
Fistula 
Response 
Inflammatory 
Bowel Disease 
Questionnaire† 
6-methyl-
prednisolone 
vs. placebo 
 
104 weeks 
Favors 6-
methyl-
prednisolone; 
Low 
Week 104 
Favors 6-
methyl-
prednisolone; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Budesonide 
vs. 
mesalamine 
 
52 weeks 
Favors 
budesonide; 
Moderate 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Week 52 
Favors 
budesonide; 
Moderate 
Steroids 
(other) vs. 
sulfasalazine 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
6-methyl-
prednisolone + 
sulfasalazine 
vs. placebo 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. steroids 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Steroids + 
sulfasalazine 
vs. 
sulfasalazine 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Mesalamine 
(controlled-
release) vs. 
placebo 
 
52 weeks 
Favors 
mesalamine; 
Low 
Week 104 
Favors neither; 
Moderate 
Insufficient Insufficient Insufficient Insufficient Insufficient Week 48 
Favors neither; 
Low 
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Table 21. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to 
maintain remission* (continued) 
Comparison 
 
Maximum trial 
duration 
Disease 
activity 
measure 
Weeks 48-54 
Disease 
activity 
measure 
After 54 weeks 
Mucosal 
healing Hospitalizations Surgeries 
Reduction 
of steroids 
Fistula 
response 
Inflammatory 
Bowel Disease 
Questionnaire† 
Mesalamine 
(pH-release) 
vs. placebo 
 
208 weeks 
Favors 
mesalamine; 
Low 
Week 104  
Favors placebo; 
Low 
Week 208  
Favors 
mesalamine; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Olsalazine vs. 
placebo 
 
52 weeks 
Favors neither; 
Moderate 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Sulfasalazine 
vs. placebo 
 
104 weeks 
Favors neither; 
Low 
Week 104 
Favors neither;  
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
ASA = aminosalicylates; CP = certolizumab pegol; NA = not applicable; evidence grading was not conducted for this comparison and outcome; Steroids = corticosteroids; TNF = 
tumor necrosis factor-alpha inhibitor; vs. = versus 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable.  
*All other comparisons and outcomes were graded as insufficient because there were no eligible trials. 
†Patient reported outcomes were measured by the Inflammatory Bowel Disease Questionnaire except where indicated by a footnote. Scores for the Inflammatory Bowel Disease 
Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
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Natalizumab 
Trial Design and Population Characteristics 
One placebo-controlled RCT reported in two publications evaluated the efficacy of 
natalizumab to maintain remission subsequent to an induction trial reported in KQ1 (Appendix 
D, Evidence Tables 7 and 8).33,81 The maintenance trial randomized 339 patients who responded 
to natalizumab or placebo as defined by a 70-point decrease from baseline CDAI at weeks 10 
and 12, had an absolute CDAI less than 220 at week 12 and who did not require an 
intervention.33 The induction responders were randomized to the same dose used in the induction 
trial. The induction non-responders were randomized, but their results were not reported. 
Participants received an intravenous infusion every 4 weeks of natalizumab 300 mg (n=168) or 
placebo (n=171) for 44 weeks and were followed for 48 weeks. Concomitant medications 
allowed during the trial period included aminosalicylates, corticosteroids, immunomodulators, 
and antibiotics.  
The population characteristics are described in KQ1.81 There were no major differences 
between the induction and maintenance populations. However, the placebo and natalizumab 
groups differed in the maintenance trial. Placebo patients were more likely to be female, more 
likely to smoke, and had a 13-point higher mean CDAI at the beginning of the maintenance 
trial.33 
Key Points 
Table 22 summarizes the strength of evidence for the trial evaluating natalizumab in terms of 
maintenance of remission. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following areas: 
• Natalizumab (300 mg every 4 weeks) was more efficacious than placebo to maintain 
remission at week 48 among patients who achieved at least a response during a 
natalizumab induction trial (48-week absolute RD, 33 percent; placebo rate, 22 percent). 
(SOE: Moderate) 
• Natalizumab patients were less likely to require steroids than placebo among patients in a 
sustained remission at 48 weeks (absolute RD, 27 percent; placebo rate, 15 percent). 
(SOE: Moderate) 
• Natalizumab was favored over placebo as measured by a patient-reported outcome at 
week 48, although both natalizumab and placebo patients had lower scores at the end of 
the trial (absolute between-group difference in change in mean IBDQ from 
randomization, 19 points; placebo mean change in IBDQ, -23 points). (SOE: Moderate) 
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Table 22. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating natalizumab to maintain remission 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Natalizumab vs. 
placebo–wk 48 
Disease activity 
measures 
1 (339)33 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
RD, 33%; placebo rate, 22%  
 
SOE: Moderate 
Natalizumab vs. 
placebo–wk 48 
Reduction of 
steroids 
1 (143)33 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
RD, 27%; placebo rate, 15%  
 
SOE: Moderate 
Natalizumab vs. 
placebo–wk 48 
Patient-reported 
outcomes 
1 (217)81 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
Absolute between-group 
difference in change in mean 
IBDQ from randomization to 
induction trial, 19 pts; placebo 
change in mean IBDQ, -23 pts  
 
SOE: Moderate 
IBDQ = Inflammatory Bowel Disease Questionnaire; pts = points; pts = points; RD = absolute risk difference; SOE = strength of evidence; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
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Monotherapy Versus Placebo 
Natalizumab Versus Placebo 
Disease Activity Measures 
At week 48, 33 percent more natalizumab patients were in remission than placebo, which 
was clinically meaningful and statistically significant (Table 23).33 The persistence of remission 
from the time of randomization was also reported. Of the 250 patients who were in remission at 
the time of randomization, 39 percent in the natalizumab group and 15 percent in the placebo 
group (24 percent difference) remained in remission for all measures through 48 weeks (trial 
reported P < 0.001). We presented details of the results in Appendix D, Evidence Table 9. 
 
Table 23. Randomized controlled trials comparing the efficacy of natalizumab with placebo to 
maintain remission at week 48 in patients with Crohn’s disease who have at least achieved a 
response to a prior induction trial 
Author, Year 
Followup 
(Weeks) Main Intervention (Dose), n Comparison, n 
Remission Rate (CDAI<150, 
No Need for Rescue 
Therapy, and No Missing 
Data), % 
Sandborn, 
200533 
48 Natalizumab (300 mg IV every 
4 wks), 168 
Placebo, 171 55% vs. 22%* 
IV = intravenous; wks = weeks 
*Trial reported P < 0.05 
Reduction of Steroids 
Of the 143 patients in sustained remission at 48 weeks, 42 percent of the natalizumab group 
no longer required treatment with corticosteroids compared with 15 percent in the placebo group. 
This finding is clinically meaningful and statistically significant (P < 0.001).33 
Patient-Reported Outcomes 
Patient-reported outcomes were reported in a separate publication from the disease activity 
measures.81 Forty-eight weeks after the initiation of maintenance therapy, the mean change in 
IBDQ decreased in both groups, but the decrease was not as substantial for natalizumab and the 
difference met the clinically meaningful difference threshold. At 48 weeks, the mean total IBDQ 
score dropped from 184 to 180 in the natalizumab group and from 179 to 156 in the placebo 
group, the difference between groups was statistically significant when measured from the value 
at the beginning of the induction trial (P < 0.001), but was not reported from the beginning of the 
maintenance trial. There were no meaningful differences between any component of the SF-36 
between randomization for the maintenance trial and week 48.  
TNF-Alpha Inhibitors 
Eight trials evaluated a TNF-alpha inhibitor as monotherapy or in combination with another 
drug to maintain remission. Six of the trials compared TNF-alpha inhibitor monotherapy with 
placebo: two evaluated adalimumab,82,83 one evaluated certolizumab pegol,84 and three evaluated 
infliximab.85-87 The two combination therapy trials focused on the role of azathioprine with 
infliximab. One trial compared a combination of infliximab and azathioprine versus infliximab 
with hydrocortisone pretreatment.88 An azathioprine withdrawal trial89 examined a combination 
86 
of infliximab and azathioprine versus infliximab alone in patients that previously controlled their 
disease for at least 6 months using a combination of infliximab and azathioprine. 
Trial Design 
Eight RCTs reported in 16 publications met the inclusion criteria (Appendix D, Evidence 
Table 7).82-97 Trials reported in multiple publications included an adalimumab trial with four 
publications,82,90,95,96 an infliximab trial with four publications,86,91,93,94 and another infliximab 
trial with three publications.87,92,97 
Six of the eight RCTs were blinded.82-87 The two combination therapy trials were not blinded. 
In the hydrocortisone pre-treatment trial, the patients were aware which medications they were 
taking but the investigators were not.88 In the azathioprine withdrawal trial, all participants and 
study personnel were aware of the treatment assignment.89 All trials except the azathioprine 
withdrawal trial89 had run-in periods when all patients received the study drug prior to 
randomization. The duration of the run-in period ranged between 2 and 12 weeks. Subsequent to 
the run-in period, the trials randomized all patients or those that had a clinical response (CDAI 
drop of 70 to 100 points) or remission (CDAI<150). In five trials, an inclusion criteria at the start 
of the trial (before the run-in) was a CDAI of 220 to 450.82-86 All trials reported a CDAI outcome 
except one study that used fistula closure at 14 weeks as a measure of response.87 
All trials allowed patients to take medications to treat their Crohn’s disease as long as they 
were using them at stable doses during the trial. Most studies allowed for stable doses of 
prednisone (20-30mg or less), thiopurines or methotrexate, aminosalicylates, and antibiotics at 
entry. Two studies evaluating adalimumab and certolizumab pegol allowed for prior exposure to 
an TNF-alpha inhibitor more than 12 weeks from randomization82 84 as long as the patients 
responded to the drug and did not have an adverse reaction. Two trials83 88 did not permit prior 
TNF-alpha inhibitor use. In the azathioprine withdrawal trial, all participants had used infliximab 
and azathioprine for at least 6 months prior to randomization.89 Because infliximab was the first 
approved TNF-alpha inhibitor agent for Crohn’s disease, patients in the three infliximab trials85-
87 would not have received TNF-alpha inhibitors prior to the induction or run-in period. 
Not all patients had entered remission by using the study drug. In two trials,83 85 the run-in 
period occurred as part of induction trials that are described in KQ1.37 43 These two trials differ 
from the others because patients who experienced clinical remission85 or response83 using 
placebo were eligible for randomization. In three trials, all patients who received the induction 
doses during the run-in period were randomized, even if they did not experience clinical 
remission or response after the induction dose.82,86,87 The results for the responders are reported 
because these results are most representative of maintenance of remission consistent with our 
definition for this KQ. The results for all patients who were randomized, representing the 
intention to treat population, are also summarized when available.  
In four studies randomized patients were not required to complete the study using the 
assigned treatment.82,83,86,87 Patients who relapsed were permitted to withdraw from the trial and 
initiate active drug or increase the dose of the drug. Patients who withdrew were considered not 
in remission for the disease activity endpoints. For hospitalization and surgery, one study 
considered patients as hospitalized or as having had surgery among those who withdrew and 
initiated active drug or increased dose,90 while another allowed patients to switch to active drug 
or increase dose and were not considered treatment failures in the hospitalization and surgery 
analyses.94 For other outcomes including fistula response, reduction of steroids, and patient-
reported outcomes, it was unclear if patients who withdrew were considered treatment failures. 
87 
To account for the patients who were no longer followed under ideal RCT conditions (unaware 
of treatment assignment and disease activity unrelated to treatment), the risk of bias was 
considered Medium or High for these trials. Early withdrawal and downgrading of the risk of 
bias for outcomes other than disease activity occurred for adalimumab at 8 weeks82,95 and 
infliximab at 12 weeks.86,87,94  
Five out of eight trials took place in North America,82,83,85-87 while seven out of eight took 
place in Europe.82,83,85-89 All of the trials but one88 was multicenter in design. The starting year of 
enrollment ranged between 1995 and 2004. Following randomization, the maximum trial 
duration was 52 weeks (range, 18 to 104 weeks). All trials were limited to adult patients with 
Crohn’s disease, although one trial89 included patients 16 years and older.  
Population Characteristics 
The trials randomized 1,798 patients (Appendix D, Evidence Table 8). Males comprised 44 
percent of participants. Response to open-label induction was 64 percent for the largest 
adalimumab maintenance trial,82 64 percent for the only certolizumab pegol trial,84 and 59 
percent for the largest infliximab maintenance trial.86 Response to open-label drug in the 
infliximab fistula trial was 69 percent.87 The remission rate of those who enrolled from the 
primary adalimumab induction trial37 into a subsequent maintenance trial83 was 20 percent. Only 
one trial reported race,90 which was more than 90 percent Caucasians. Of trials that reported 
current smokers, rates ranged from 32 to 45 percent. Median duration of disease ranged from 5 to 
12 years. Mean age at enrollment ranged between 34 to 38 years old. Disease location 
distribution was as follows: ileal, 16 to 30 percent; ileocolonic, 46 to 62 percent; and colonic 17 
to 39 percent. Mean CDAI after the run-in period ranged from 152 to 170, reflecting that some 
patients attained a remission while others attained only a response. Drug use rates were as 
follows: concomitant aminosalicylates, 38 to 74 percent; corticosteroids, 21 to 56 percent; 
thiopurine, 11 to 42 percent, and methotrexate, 0 to 12 percent. 
Key Points 
Table 24 summarizes the strength of evidence for the trials evaluating a TNF-alpha inhibitor 
in terms of maintenance of remission. We found at least moderate strength of evidence or a 
clinically meaningful difference in the following comparisons: 
• Adalimumab was more efficacious than placebo in maintaining a remission at week 52 
among patients who had at least a response to open-label adalimumab (range in week 52 
absolute RD, 11 to 39 percent; placebo rate range, 12 percent to 44 percent). (SOE: Low) 
• Adalimumab was superior to placebo in decreasing Crohn’s disease-related 
hospitalization rates during a 52-week period in patients who have achieved at least a 
response to open-label drug (HR, 0.4; 95% CI, 0.2 to 0.7). (SOE: Moderate) 
• Adalimumab and placebo did not differ in decreasing surgical rates during a 52-week 
period in patients who had achieved at least a response to open-label drug (surgery rates, 
0.3 percent for adalimumab group and 4.1 percent for placebo group). (SOE: Moderate) 
• Adalimumab was superior to placebo in maintaining a steroid-free state at 52 weeks in 
patients who had achieved at least a response to open-label drug and were able to come 
off steroids (absolute RD in steroid-free state, 10 to 31 percent; placebo rate, 6 to 57 
percent). (SOE: Low) 
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• Certolizumab pegol (400 mg every 4 weeks) was more efficacious than placebo to 
maintain remission at week 18 among patients who had at least a response to open-label 
certolizumab pegol (absolute RD, 19 percent; placebo rate, 29 percent). (SOE: Low) 
• Infliximab was more efficacious than placebo to maintain remission at week 52 among 
patients who had at least a response to open-label infliximab (absolute RD, 6 to 25 
percent; placebo rate, 15 to 35 percent). (SOE: Low) 
• Infliximab was superior to placebo in achieving mucosal healing at week 52 in patients 
who have achieved at least a response to open-label drug (absolute RD, 26 to 43 percent; 
placebo rate, 7 to 18 percent). (SOE: Low) 
• Infliximab was superior to placebo in decreasing Crohn’s disease-related hospitalization 
rates during a 52-week period (including both responders and non-responders to 
induction) (9 to 23 per 100 patients in the infliximab group, 19 to 38 per 100 patients in 
the placebo group). (SOE: Moderate). 
• Infliximab was no different from placebo in decreasing Crohn’s disease-related surgeries 
during a 52-week period (including both responders and non-responders to induction) 
(3% in the infliximab group, 8% in the placebo group). (SOE: Moderate) 
• Infliximab was superior to placebo in decreasing surgical rates during a 40-week period 
in patients with active fistulizing disease who had achieved fistula response to open-label 
drug (number of surgeries and procedures per 100 patients, 65 surgeries/procedures for 
infliximab and 126 surgeries/procedures per 100 patients for placebo). (SOE: Moderate) 
• Infliximab was superior to placebo in reducing corticosteroid use at week 52 in patients 
who had achieved at least a response to open-label drug (discontinuation of steroids while 
in remission, OR, 4.2; 95% CI, 1.5 to 11.5). (SOE: Low) 
• Infliximab was superior to placebo in closing fistulas at week 40 in adults with Crohn’s 
disease who had achieved an initial fistula response to open-label drug (absolute RD, 17 
percent; placebo rate, 19 percent). (SOE: Low) 
• Infliximab was superior to placebo in improving patient-reported outcomes at weeks 28 
and 52 in patients who had achieved at least one response to open-label drug (absolute 
between-group difference in change in mean IBDQ from baseline [prior to open-label 
run-in], -5 to 23 points; placebo mean change in IBDQ, -31 to 9 points). (SOE: Low) 
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Table 24. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a TNF-alpha inhibitor to maintain remission 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Adalimumab 
vs. placebo–
wk 52 
Disease 
activity 
measures 
2 (554)82 83 95 High Consistent Direct Precise Favors adalimumab 
RD range, 11% to 39%; placebo rate 
range, 12% to 44% 
 
SOE: Low 
Adalimumab 
vs. placebo–
wk 52 
Hospitalization 1 (778)90 Medium Unknown 
(single study) 
Direct Precise Favors adalimumab for all-cause 
hospitalizations 
Favors neither for Crohn’s disease related 
hospitalizations 
RD range, -6% to -13%; placebo rate 
range, 16% to 25% 
 
SOE: Moderate 
Adalimumab 
vs. placebo–
wk 52 
Surgery 1 (778)90 Medium Unknown 
(single study) 
Direct Precise Favors neither 
RD, -3.4%; placebo rate, 3.8%  
 
SOE: Moderate 
Adalimumab 
vs. placebo–
wk 52 
Reduction of 
steroids 
2 (219)82 83  High Consistent Direct Precise Favors adalimumab 
RD, 10% to 31%; placebo rate, 6% to 57%  
 
SOE: Low 
Adalimumab 
vs. placebo–
wk 52 
Patient-
reported 
outcomes 
2 (554)95 96 High Consistent Direct Precise Favors neither 
Absolute between-group difference in 
change in mean IBDQ from randomization, 
14 to 22 pts; placebo mean change, -10 to 
-25 pts  
 
SOE: Low 
CP vs. 
placebo–wk 18 
Disease 
activity 
measures 
1 (428)84 Medium Unknown 
(single study) 
Indirect Precise Favors CP 
RD, 19%; placebo rate, 29% 
 
SOE: Low 
CP vs. 
placebo–wk 18 
Patient-
reported 
outcomes 
1 (424)84 Medium Unknown 
(single study) 
Indirect Precise Favors neither 
Difference in final adjusted mean IBDQ, 8 
pts; final placebo mean, 163 pts 
 
SOE: Low 
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Table 24. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a TNF-alpha inhibitor to maintain remission (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Infliximab vs. 
placebo–wk 52 
Disease 
activity 
measures 
1 (573)86 94 High Unknown 
(single study) 
Direct Imprecise Favors neither among all randomized 
Favors infliximab among responders to 
induction 
RD range, 6% to 25%; placebo rate, 15% 
to 35% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 52 
Mucosal 
healing 
1(58)91 94 High Unknown 
(single study) 
Direct Precise Favors infliximab 
RD, 26% to 43%; placebo rate, 7% to 18% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 
40, 52 
Hospitalization 2 (855)92 94  Medium Consistent Direct Precise Favors infliximab 
Crohn’s disease-related hospitalizations 
per 100 patients, 9 to 23 in infliximab 
group, 19 to 38 in placebo group  
 
SOE: Moderate 
Infliximab vs. 
placebo–wk 52 
Surgery 1 (573)94  Medium Unknown 
(single study) 
Direct Precise Favors neither 
Rate of Crohn’s disease-related surgery, 
3%; placebo rate, 8% 
 
SOE: Moderate 
Infliximab vs. 
placebo 
(patients with 
fistulas) –wk 
40 
Surgery 1 (195)92 Medium Unknown 
(single study) 
Direct Precise Favors infliximab 
Rate of Crohn’s disease-related surgery 
per 100 patients, 65; placebo rate per 100 
patients, 126 
 
SOE: Moderate 
Infliximab vs. 
placebo–wk 52 
Reduction of 
steroids 
1 (325)86  High Unknown 
(single study) 
Direct Precise Favors infliximab 
RD, 20%; placebo rate, 9% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 40 
Fistula 
response 
1 (282)87  Medium Unknown 
(single study) 
Indirect Precise Favors infliximab 
RD, 17%; placebo rate, 19%  
 
SOE: Low 
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Table 24. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a TNF-alpha inhibitor to maintain remission (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Infliximab vs. 
placebo–wks 
36-52 
Patient-
reported 
outcomes 
3 (603)85 87 93  High Inconsistent Direct Imprecise Favors infliximab 
Absolute between-group difference in 
change in median IBDQ -5 to 23 pts; 
placebo mean change, -31 to 9 pts  
 
SOE: Low 
Infliximab + 
azathioprine 
vs. infliximab–
wk 104 
Disease 
activity 
measures 
1 (80)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Absolute difference [with regard to need 
for infliximab stoppage or change in 
dosage interval], 5%; infliximab alone rate, 
55% 
 
SOE: Low 
Infliximab + 
azathioprine 
vs. infliximab–
wk 104 
Mucosal 
healing 
1 (49)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD for absence of ulcers, 3%; infliximab 
alone rate, 61% 
 
SOE: Low 
Infliximab + 
azathioprine 
vs. infliximab–
wk 104 
Patient-
reported 
outcomes 
1 (80)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Difference in overall median IBDQ, -2 pts; 
infliximab only median, 176 pts 
 
SOE: Low 
Infliximab + 
azathioprine 
vs. infliximab + 
hydrocortisone 
IV 
premedication
–wk 52, 104 
Disease 
activity 
measures 
1 (46)88 High Unknown -
(single study) 
Direct Imprecise Favors neither 
RD across time points, -5%; infliximab and 
hydrocortisone rate range, 77% to 84% 
 
SOE: Low  
CI = 95% confidence interval; CP = certolizumab pegol; HR = hazard ratio; IBDQ = Inflammatory Bowel Disease Questionnaire; NA = not applicable; OR = odds ratio; pts = 
points; RD = absolute risk difference; SOE = strength of evidence; TNF = tumor necrosis factor; wk = week 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
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Monotherapy Versus Placebo 
TNF-Alpha Inhibitors Versus Placebo 
Disease Activity Measures 
Six trials published in nine publications reported on disease activity.82-86,94,95,97 Table 25 
summarizes the effects of TNF-alpha inhibitor therapy versus placebo to maintain remission at 
week 52. Among all patients who were randomized and among those who responded to 
induction dosing, adalimumab was consistently favored over placebo according to the clinically 
meaningful difference and statistical significance. Infliximab was favored over placebo only 
among responders to induction dosing. 
Three trials (totaling 889 patients) compared infliximab or adalimumab with placebo at 52 
weeks.82,83,86,94,95 The efficacy differed between the analyses that included responders to 
induction and all randomized patients. Two of these trials reported results for all randomized 
patients and responders to induction dosing. In the analysis of all randomized patients for the 
adalimumab trial at 52 weeks, remission rates were 51, 49, and 38 percent for the 40 mg every 
other week, 40 mg weekly, and placebo groups, respectively (P < 0.05 for both groups vs. 
placebo).95 The responders to induction dosing also had clinically and statistically significant 
results at 52 weeks.82 In contrast, the infliximab trial did not have clinically or statistically 
significant results when all randomized patients were analyzed at 52 weeks (41 vs. 35 percent),94 
but did have clinically and statistically significant results in the responders to induction 
analysis.86 In the third trial83 that randomized patients who achieved remission in an induction 
trial,37 remission rates were clinically and statistically significantly higher in the adalimumab 
compared with the placebo group. A meta-analysis was not performed because two trials 
randomized all patients after induction dosing and one trial randomized those in remission after 
an induction trial. 
In two trials, the last reported time point was earlier than 48 weeks: 18 weeks for 
certolizumab pegol84 and 28 weeks for infliximab.85 Both trials found clinically meaningful 
differences compared with placebo, although only the certolizumab pegol results were 
statistically significant. An infliximab trial that included women with rectovaginal fistulas was 
not included because it reported changes in median CDAI scores rather than remission and the 
last reported time point was 40 weeks.97 
Mucosal Healing 
One infliximab trial94 included 58 patients with ulceration at baseline who received an 
additional colonoscopy at 52 weeks.91 In the analysis of all randomized patients (44 vs. 18 
percent; P=0.04)94 and the analysis of responders to induction (50 vs. 7 percent; P=0.007),91 the 
infliximab groups were more likely to have clinically meaningful and statistically significant 
complete mucosal healing (absence of ulcers) at 52 weeks compared with placebo. 
Hospitalization 
Three trials reported on hospitalizations.90,92,94 Adalimumab and infliximab were consistently 
favored over placebo at 52 weeks according to the clinically meaningful threshold and were 
statistically significant.  
One trial90 with 778 randomized participants compared adalimumab with placebo at 52 
weeks with regard to Crohn’s disease-related and all-cause hospitalizations. The results were 
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clinically meaningful for all-cause but not Crohn’s disease-related hospitalizations. Those who 
received the drug either every other week or weekly had a 14 and 12 percent risk of 12-month 
all-cause hospitalization respectively, compared with 25 percent for placebo (P < 0.01 for both 
comparisons with placebo based on a log-rank test). The 12-month risk of Crohn’s disease-
related hospitalizations was 10 and 7 percent, respectively, compared with 16 percent for placebo 
(P < 0.02 for both comparisons with placebo based on a log-rank test). The clinically meaningful 
results for all-cause but not Crohn’s disease-related hospitalizations was also found in analysis 
restricted to responders to induction therapy. 
Two infliximab trials reported on hospitalizations.92,94 One infliximab trial94 randomized 573 
participants and evaluated the rate of hospitalization. At 52 weeks, the rates of Crohn’s disease-
related hospitalization per 100 patients were 23, 24, and 38 in the 5 mg/kg infliximab, 10 mg/kg 
infliximab, and placebo groups, respectively (P < 0.05 for both comparisons). The finding was 
clinically meaningful and statistically significant for both doses of infliximab.  
The infliximab trial that included only patients with draining fistulas92 compared infliximab 
with placebo among the 282 randomized patients and the 195 patients to had a response to the 
induction dose. Among the 282 randomized patients, hospitalizations occurred in 9 percent of the 
infliximab and 19 percent of the placebo group by week 40. This difference was clinically 
meaningful and statistically significant for all randomized patients and among those who 
responded to the induction dose (P < 0.05).  
Surgery 
The same three trials that reported on hospitalizations also reported on surgeries.90,92,94 
Compared with placebo, there was no difference in the occurrence of surgery according to the 
clinically meaningful threshold when considering the rate equivalent of the 10 percent difference 
threshold to be a difference in 10 per 100 patients between groups. All three trials reported 
statistically significant findings. 
One trial compared adalimumab with placebo with regard to Crohn’s disease-related 
surgeries in 778 randomized patients.90 Surgeries for abscess drainage and seton placement were 
not counted as events.90 At 52 weeks, fewer Crohn’s disease-related surgeries occurred in the 
groups who received adalimumab every other week and weekly compared with placebo (0.4 and 
0.8 vs. 3.8 per 100 patients; P < 0.05 for all comparisons vs. placebo), but the differences were 
not clinically meaningful. Statistically significant but not clinically meaningful differences were 
also observed among those that responded to induction therapy. 
Another trial94 evaluated the rate of hospitalization in 573 patients randomized to infliximab 
or placebo. At 52 weeks, the number of patients requiring Crohn’s disease-related intra-
abdominal surgeries in the 5 and 10 mg scheduled infliximab groups combined was 11 of 385 
(3%), compared with 14 of 188 (8%) in the placebo group, which was not clinically meaningful 
but was statistically significant. Reported values are for both responders and non-responders to 
induction; values for responders only were not reported separately.  
One trial with 195 total responders (among 282 total randomized patients with fistulas) 
compared infliximab with placebo.92 Among patients who responded to open-label infliximab, 
infliximab maintenance had a significantly decreased rate of all surgeries and procedures (65 vs. 
126 surgeries per 100 patients; P < 0.05) as well as major surgeries (2 vs. 11 surgeries per 100 
patients; P < 0.05) at 40 weeks compared with those who received placebo. The findings were 
clinically meaningful for all surgeries but not major surgeries. Results for all randomized patients 
were similar. 
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Reduction of Steroids 
Three trials reported on reduction in steroids, including two adalimumab82 83 and one 
infliximab trials.86 All three found clinically meaningful differences favoring the TNF-alpha 
inhibitor over placebo. 
One trial82 randomized patients to placebo, 40 mg of adalimumab every other week, and 40 
mg of adalimumab weekly. Of the 198 responders who did not require steroids at randomization, 
the proportion of individuals who remained steroid-free at 52 weeks was 6, 29, and 23 percent, 
respectively. Adalimumab was clinically favored and statistically significant compared with 
placebo (P < 0.001 for both adalimumab groups compared with placebo). In a smaller trial,83 21 
of 55 patients were on systemic steroids or budesonide at randomization and had results available 
at 52 weeks. At 52 weeks, rates of steroid discontinuation for the placebo, 40 mg every other 
week and 40 mg every week groups were 57, 67, and 88 percent, respectively. The difference 
was clinically meaningful, but statistical significance was not provided. 
One trial with 335 participants compared infliximab (5 mg every 8 weeks or 10 mg every 8 
weeks) with placebo.86 At 52 weeks, three times as many patients in the infliximab groups 
combined had discontinued corticosteroids while in remission compared with placebo (29 vs. 9 
percent; OR, 4.2; 95% CI, 1.5 to 11.5). This finding was clinically meaningful and statistically 
significant. 
Fistula Response 
One trial87 with 282 participants compared infliximab with placebo for fistula healing. At 40 
weeks, infliximab was favored over placebo according to the clinically meaningful and 
statistically significant thresholds. All of the patients had a fistula for at least 3 months’ duration 
and received open-label induction with infliximab as part of the trial. The trial assessed response 
(50 percent reduction in the number of draining fistulas) 10 and 14 weeks after starting 
induction, and randomized 195 total responders to infliximab or placebo. Eight weeks after 
randomization, all patients who had lost response (both groups) could receive infliximab. At 
week 40 after randomization, the proportion of patients in the placebo group with complete 
fistula healing (complete absence of draining fistulas) was 19 percent, compared with 36 percent 
in the infliximab group (P=0.009). This finding was clinically meaningful and statistically 
significant. 
Patient-Reported Outcomes 
Six trials with 2,581 participants compared TNF-alpha inhibitors with placebo.82-85,87,93,95 
There was not a consistent finding that TNF-alpha inhibitors were favored over placebo 
according to the clinically meaningful difference. A meta-analysis was not performed because 
some studies reported the mean IBDQ values at baseline and followup while others reported the 
percent of patients who achieved a particular IBDQ threshold, two studies reported at less than 
48 weeks84,85 and one study included only fistulizing disease patients.87 
Two trials with 554 participants compared adalimumab with placebo.95,96 In both trials, there 
was no clinically meaningful difference between adalimumab and placebo at 52 weeks when all 
randomized patients were analyzed.95 Among patients who responded to induction,96 clinically 
meaningful results were observed for some patient-reported outcomes. 
One trial compared certolizumab pegol with placebo.84 At 18 weeks after randomization, 
patients on certolizumab pegol did not have clinically meaningful adjusted mean IBDQ scores 
than those on placebo (final IBDQ scores 171 versus 163, respectively). This trial did not report 
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baseline IBDQ scores by intervention group, so the change in IBDQ per group was not 
calculable.  
Three trials compared infliximab with placebo.85 87 93 In the largest trial, there was not a 
clinically meaningful difference in the IBDQ score at 52 weeks in the 5 mg/kg group, but there 
was a meaningful difference in the 10 mg/kg group, although neither was statistically 
significant.93 At 52 weeks, the proportion of patients in the 5 and 10 mg/kg infliximab groups 
with an IBDQ greater than 170 was 38 and 46 percent, compared with 35 percent in the placebo 
group (P > 0.05). One trial87 looked exclusively at fistulizing Crohn’s disease and did not find a 
clinically meaningful difference between 5 mg/kg infliximab and placebo at 40 weeks. Another 
infliximab trial85 had its final time point at 36 weeks and observed a decrease in both groups 
although the decrease was less in the infliximab group and met the clinically meaningful 
difference threshold (8-point median decrease from baseline in the 10 mg/kg infliximab group 
compared with a 31-point decrease in the placebo group), although statistical significance was 
not reported. A meta-analysis was not performed for the infliximab trials because only one trial 
reported at 52 weeks.93 
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Table 25. Randomized controlled trials comparing the efficacy of TNF-alpha inhibitor therapy with 
placebo or another treatment to maintain remission in patients with Crohn’s disease who had a 
response to the study medication prior to randomization 
Author, Year 
Time 
Point Main Intervention (Dose), n Comparison, n 
Remission Rate 
(CDAI<150 and 
Remained on 
Randomized 
Treatment or 
Did Not Require 
Rescue 
Therapy), % 
Colombel, 
200782 
52 wks Adalimumab (40 mg sc every 2 wks), 172 Placebo, 170 36% vs. 12%*  
52 wks Adalimumab (40 mg sc every wk), 157 Placebo, 170 41% vs. 12%*  
Sandborn, 
200783 
52 wks Adalimumab (40 mg sc every 2 wks), 19 Placebo, 18 79% vs. 44%* 
52 wks Adalimumab (40 mg sc every wk), 18 Placebo, 18 83% vs. 44%* 
Schreiber, 
200784 
18 wks Certolizumab pegol (400 mg sc every 4 
wks), 216 
Placebo, 212 48% vs. 29%* 
Hanauer, 
200286 
52 wks Infliximab (5 mg/kg IV every 8 wks), 113 Placebo, 110 30% vs. 15%* 
52 wks Infliximab (10 mg/kg IV every 8 wks), 112 Placebo, 110 40% vs. 15%*  
Rutgeerts, 
199985 
28 wks Infliximab (10 mg/kg IV every 8 wks), 37 Placebo, 36 64% vs. 35%  
Van Assche, 
200889 
104 wks Infliximab (5 mg/kg IV every 8 wks) + 
azathioprine (pre-trial dose), 40 
Infliximab (5 mg/kg 
IV every 8 wks), 40 
40% vs. 45% 
Mantzaris, 
200988 
52 wks Infliximab (5 mg/kg IV every 8 wks) + 
azathioprine (2-2.5 mg/kg/day), 21 
Infliximab (5 mg/kg 
IV every 8 wks) + 
hydrocortisone (250 
mg), 22 
79% vs. 84% 
104 wks Infliximab (5 mg/kg IV every 8 wks) + 
azathioprine (2-2.5 mg/kg/day), 21 
Infliximab (5 mg/kg 
IV every 8 wks) + 
hydrocortisone (250 
mg), 22 
72% vs. 77% 
CDAI = Crohn’s Disease Activity Index; IV = intravenous infusion; mg = milligrams; mg/kg = milligrams per kilogram; NR = 
not reported; sc = subcutaneous injections; vs. = versus; wk = week 
*Trial reported P < 0.05 
Combination Therapy Versus Monotherapy 
Infliximab and Azathioprine Versus Infliximab Alone 
Disease Activity Measures 
One trial89 with 80 participants examined Crohn’s patients who were in an extended 
remission (>6 months) on combination infliximab and azathioprine. The trial then randomized 
patients to continue or discontinue azathioprine and studied them for 104 weeks. Both the 
patients and study personnel where aware of the treatment assignment for the duration of the 
trial. Twenty-four out of 40 (60 percent) patients in the azathioprine continuation group and 22 
out of 40 (55 percent) patients in the discontinuation group required a change in the infliximab 
dosing interval or stoppage of infliximab, the outcome most closely related to disease activity. 
The difference between groups was not clinically meaningful. 
Mucosal Healing 
The above trial89 performed baseline and end of trial colonoscopy in 49 out of 80 randomized 
patients (all but one patient had colonic lesions at baseline). Sixteen out of 25 (64 percent) 
participants on a combination of infliximab and immunomodulators showed an absence of 
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ulcers, compared with 14 out of 23 (61 percent) participants on infliximab alone. There was no 
clinically meaningful difference in mucosal healing between groups. 
Patient-Reported Outcomes 
This trial89 reported that the median IBDQ from week 8 through week 104 did not differ 
between the two groups. Baseline IBDQ was not provided and the IBDQ at each measure was 
not reported so the change in IBDQ could not be calculated. 
Combination Therapy Versus Combination Therapy 
Infliximab and Azathioprine Versus Infliximab With Hydrocortisone 
Intravenous Premedication 
Disease Activity Measures 
In one trial of 46 participants88 rates of remission at 12 and 24 months were not clinically 
meaningfully different between the groups. At 12 months, 79 percent in the infliximab and 
azathioprine group and 84 percent in the infliximab with hydrocortisone premedication group 
were in remission. At 24 months, rates of remission were 72 and 77 percent, respectively. This 
trial had two major limitations. The trial blinded the investigators, but not the subjects. 
Additionally, the groups were not well balanced with respect to prior Crohn’s medication use. 
All of the patients in the infliximab and azathioprine group were azathioprine naïve, whereas 
only six out of 23 patients in the infliximab and corticosteroids group were azathioprine naïve. 
Thiopurines 
We identified six trials. Five trials56,98-101 compared azathioprine with placebo, two trials56,102 
compared azathioprine with corticosteroids, and one trial56 compared azathioprine with 
sulfasalazine. No trials used 6-mercaptopurine. One trial is also included in the corticosteroids 
and aminosalicylates sections.56 
Trial Design 
Per our inclusion criteria, all six trials were RCTs (Appendix D, Evidence Table 7). In all 
trials, patients were in remission at the time of randomization. All trials were multicenter with 
five trials98-102 conducted in Europe, and one in the U.S.56 The years of enrollment ranged from 
1971 to 2009. In one trial the azathioprine dose was 1 mg/kg/day,56 in two trials the dose was 2.0 
mg/kg/day,99,103 and in one trial the dose was 2.0 to 2.5 mg/kg/day.102 Prior to randomization, 
patients were in remission for one month,102 6 months,100 24 months,101 or 42 months.98 Two 
trials56,99 did not report duration of remission prior to randomization. In three trials,98,100,101 
patients had to have been in remission on azathioprine. Trial duration ranged between 6 and 18 
months. Relapse was defined by CDAI scores in four trials56,98,101,102 while two trials used an 
unnamed disease activity score.99,100 
One trial required steroid dependence for entry, but with a prednisone dose less than 30 
mg.102 One trial101 excluded patients receiving corticosteroids or aminosalicylates at the time of 
randomization. One trial98 excluded patients taking more than 10 mg of prednisone in addition to 
any immunosuppressant, aminosalicylates, or antibiotic. The remainder allowed prednisone or 
aminosalicylates at trial entry. Three trials excluded patients with previous surgery,98,101,102 while 
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the other trials allowed remission to be achieved with medication or surgery. One trial excluded 
patients with left-sided colonic disease.102 
Population Characteristics 
Half of the patients were males (Appendix D, Evidence Table 8). The mean ages ranged from 
28 to 40 years and the median ages ranged from 31 to 47 years. Race was reported in one trial 
(92 percent Caucasian).56 All trials reported mean duration of disease at randomization ranging 
from 2 to 11 years. Mean CDAI ranged from 39 to 132 across all reporting trial groups. Two 
trials reported smoking histories ranging from 42 to 92 percent.98,102 In trials that reported 
disease distribution, ileal involvement ranged from 3 to 60 percent, ileocolonic 11 to 67 percent, 
and colonic 7 to 63 percent. Concomitant steroid use ranged from 5 to 100 percent across trial 
groups, while concomitant aminosalicylates use was excluded in two trials,98,102 allowed in two 
trials,100,101 and use was not mentioned or unclear in two trials.99,100 
Key Points 
Table 26 summarizes the strength of evidence for the trials evaluating a thiopurine in terms 
of maintenance of remission. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following comparisons: 
• Azathioprine (1.7 to 2.1 mg/kg/day) was more efficacious than placebo to maintain 
remission at weeks 52, 78, and 104 (range in absolute RD, 13 to 39 percent; placebo rate, 
47 to 79 percent). (SOE: Low) 
• Azathioprine was superior to placebo in reducing steroid use at week 26 in adults with 
Crohn’s disease participating in a maintenance trial (absolute reduction in prednisone use 
from baseline, 9.4 mg; placebo reduction, 6.1 mg). (SOE: Low) 
• Azathioprine was more efficacious than budesonide to maintain remission at week 52 
(absolute RD, 15 percent; budesonide rate, 64 percent). (SOE: Low) 
• Azathioprine was more efficacious than prednisone to maintain remission at week 52 
(absolute RD, 12 percent; prednisone rate, 57 percent). (SOE: Low) 
• Azathioprine was superior to budesonide in achieving mucosal healing at week 52 in 
adults with Crohn’s disease participating in a maintenance trial (absolute RD for absence 
of ulcers, 55 percent; budesonide rate, 5 percent). (SOE: Moderate) 
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Table 26. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a thiopurine to maintain remission 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Azathioprine (1 
mg/kg/d) vs. 
placebo - wks 52, 
104 
Disease 
activity 
measures 
1 (155)56 Medium Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, -11 to 5%; placebo rate, 40 to 64% 
 
SOE: Low 
Azathioprine (1.7 to 
2.1 mg/kg/d) vs. 
placebo - wks 52, 
78, 104 
Disease 
activity 
measures 
3 (163)98 100 101 Medium Inconsistent Direct Imprecise Favors azathioprine 
RD, 13 to 39%; placebo rate, 47 to 79% 
 
SOE: Low 
Azathioprine vs. 
placebo - wk 26 
Reduction 
of steroids 
1 (20)104  Medium Unknown 
(single study) 
Indirect Precise Favors azathioprine 
Absolute reduction in prednisone use from 
baseline, 9.4 mg; placebo reduction, 6.1 mg  
 
SOE: Low 
Azathioprine vs. 
budesonide - wk 52 
Disease 
activity 
measures 
1 (77)102 Medium Unknown 
(single study) 
Direct Imprecise Favors azathioprine 
RD, 15%; budesonide rate, 64% 
 
SOE: Low 
Azathioprine vs. 
prednisone - wk 52 
Disease 
activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors azathioprine 
RD, 12%; prednisone rate, 57%  
 
SOE: Low 
Azathioprine vs. 
prednisone - wk 
104 
Disease 
activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Wk 104: RD, -3%; corticosteroid rate, 32% 
 
SOE: Low 
Azathioprine vs. 
budesonide - wk 52 
Mucosal 
healing 
1 (77)102  Medium Unknown 
(single study) 
Direct Precise Favors azathioprine 
RD for absence of ulcers, 55%; budesonide 
rate, 5% 
 
SOE: Moderate 
Azathioprine vs. 
sulfasalazine - wks 
52, 104 
Disease 
activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD range, -2% to 7%; sulfasalazine rate 
range, 31% to 62% 
 
SOE: Low 
mg = milligrams; RD = absolute risk difference; vs. = versus; wk = weeks 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
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Monotherapy Versus Placebo 
Azathioprine Versus Placebo 
Disease Activity Measures 
Five trials56,98-101 with 328 patients compared azathioprine with placebo (Table 27 and 
Appendix D, Evidence Table 9). Among the trials using 2 mg/kg/day of azathioprine, 
azathioprine was favored over placebo. The two trials that used less than 2 mg/kg/day did not 
find a clinically meaningful difference between azathioprine and placebo.56,98 
Three trials98,100,101 involving 163 patients assessed the efficacy of withdrawing azathioprine 
in patients who were in remission for at least 6 months using azathioprine (range 6 to 42 
months). Two of these trials included 80 participants and found azathioprine to be clinically and 
statistically superior to placebo at 52 weeks.100,101 One trial98 found that azathioprine was 
clinically, but not statistically favored compared with placebo at 78 weeks. The trial that did not 
find statistical significance included lower doses of azathioprine (1.7 mg/kg/day) and patients 
had been in remission for a longer duration of time prior to randomization (minimum of 42 
months) than the statistically significant trials. Meta-analysis was not performed because only 
two studies100,101 analyzed doses of 1.7 mg/kg/day or above at 52 weeks.  
One trial56 involving 155 patients included patients who had inactive disease within the year 
before randomization that had been induced medically, as part of an induction trial reported in 
the same publication, or surgically. No meaningful differences between azathioprine and placebo 
were found at 1 or 2 years. The trial used a low dose of azathioprine at 1 mg/kg/day. Post-
operative patients may behave differently from those who are medically induced into remission, 
but no subgroup analysis was reported to examine if disease activity differed by method of 
remission induction.  
One trial99 included steroid-dependent patients at randomization and involved steroid 
tapering as part of the design, but did not report results at 48 weeks or later. Disease activity 
results were clinically meaningful at 24 weeks but the trial did not report statistical significance. 
The trial included ten patients in total. 
Reduction in Steroids 
One trial with 20 participants compared azathioprine with placebo.104 Average baseline daily 
prednisone dose was 19 mg in the azathioprine group and 17 mg in placebo. The trial compared 
the numerical reduction (in grams) in dose of steroid between the groups at 26 weeks. Patients on 
azathioprine had a 15.5 mg mean reduction in steroids compared with 6.1 mg for patients given 
placebo (P < 0.05). Although there was a substantial decrease in prednisone dose in both groups, 
and especially azathioprine, it is not possible to assess the clinical meaning given our definitions. 
Monotherapy Versus Monotherapy 
Azathioprine Versus Corticosteroids 
Disease Activity Measures 
We included two trials56,102 with 192 patients (Table 27). In both trials, the remission rate at 1 
year was higher in the azathioprine group according to the clinically meaningful threshold but 
was not statistically significant.56,102 At 2 years there was no clinically meaningful difference.56  
101 
Mucosal Healing 
One trial with 77 participants compared azathioprine with budesonide at 52 weeks.102 The 
rate of complete mucosal healing (absence of ulcers) was 60 percent in the azathioprine group 
and 5 percent in the budesonide group, which was clinically meaningful and statistically 
significant (P < 0.0001). Comparisons using the CDEIS also favored azathioprine.  
Azathioprine Versus Sulfasalazine 
Disease Activity Measures 
One trial56 with 115 patients was included (Table 27). There was no meaningful difference 
between the azathioprine and sulfasalazine groups at 1 or 2 years.  
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Table 27. Randomized controlled trials comparing the efficacy of thiopurines with placebo or another treatment to maintain remission in 
patients with inactive Crohn’s disease 
Author, Year Time Point 
Main Intervention 
(Dose), n Comparison, n Relapse Definition 
Remission Rate, 
% 
Willoughby, 197199 24 wks Azathioprine (2 
mg/kg/d), 5 
Placebo, 5 Significant deterioration in clinical state requiring 
change in treatment 
80% vs. 40%  
O’Donoghue 
1978100 
1 yr Azathioprine (2 
mg/kg/d), 24 
Placebo, 27 Significant deterioration in clinical state requiring 
change in treatment 
95% vs. 59% 
Summers, 197956 1 yr Azathioprine (1 
mg/kg/d), 54 
Placebo, 101 CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
69% vs. 64% 
Summers, 197956 2 yr Azathioprine (1 
mg/kg/d), 54 
Placebo, 101 CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
29% vs. 40% 
Villien, 2004101 1 yr Azathioprine (median 
dose 2.1 mg/kg), 14 
Placebo, 15 CDAI rise of >75 and CDAI >150, or increased 
disease activity requiring new medication or surgical 
therapy 
86% vs. 47%* 
Lemann, 200598 18 mos Azathioprine (median 
dose 1.7 mg/kg), 40 
Placebo, 43 CDAI > 250, CDAI of 150-250 on 3 consecutive 
weeks with at least 75 points above baseline, or 
need for Crohn’s abdominal surgery 
92% vs. 79%  
Mantzanis, 2009102 1 yr Azathioprine (2.0-2.5 
mg/kg/d),38  
Budesonide (6-9 
mg/d), 39 
CDAI increase of > 100 points from baseline and > 
150 
79% vs. 64%  
Summers, 197956 1 yr Azathioprine (1 
mg/kg/d), 54 
Prednisone (1-4 
mg/kg), 61 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
69% vs. 57% 
Summers, 197956 2 yr Azathioprine (1 
mg/kg/d), 54 
Prednisone (1-4 
mg/kg), 61 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
29% vs. 32% 
Summers, 197956 1 yr Azathioprine (1 mg/kg 
d), 54 
Sulfasalazine (1-
2 g/15 kg), 58 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
69% vs. 62% 
Summers, 197956 2 yr Azathioprine (1 mg/kg 
d), 54 
Sulfasalazine (1-
2 g/15 kg), 58 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, 
development of a fistula, fever, or radiologic 
progression 
29% vs. 31% 
CDAI = Crohn’s Disease Activity Index; d = day; g = gram; kg = kilogram; mg = milligrams; mos = months; NA = not applicable; vs. = versus; wks = weeks; yr = year 
*Study reported P < 0.05 
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Methotrexate 
One trial105 randomized 76 patients to intramuscular methotrexate or placebo (Appendix D, 
Evidence Table 9). All patients had previously taken part in an induction trial reported in KQ1.63 
Trial Design 
The trial blinded both participants and study personnel and randomized adults with Crohn’s 
disease who were in a steroid-free remission (CDAI < 150) at entry (Appendix D, Evidence 
Table 7). Patients achieved remission through methotrexate at 25 mg intramuscular weekly for a 
period of 16 to 24 weeks. The trial randomized participants to receive weekly intramuscular 
injections of either 15 mg of methotrexate or placebo for a period of 40 weeks. The primary 
outcome measure was relapse, defined as an increase in the CDAI of at least 100 points or the 
initiation of steroids or thiopurines. Immunomodulators, corticosteroids, infliximab, 
aminosalicylates, antibiotics, tube feeding, and parental nutrition were not allowed. 
Population Characteristics 
A total of 76 patients participated (Appendix D, Evidence Table 8). Males ranged from 40 to 
61 percent across both groups. Mean age ranged from 32 to 38 years. Forty-two to 50 percent 
were smokers. Mean duration of disease ranged from 4 to 8 years. Mean CDAI ranged from 84 
to 94. Ranges of disease location were as follows: ileal disease 31 to 45 percent, ileocolonic 
disease 28 to 44 percent, and colonic disease 25 to 28 percent. Prior thiopurine use was less than 
5 percent in both groups. 
Key Points 
Table 28 summarizes the strength of evidence for the trial evaluating methotrexate in terms 
of remission maintenance. We found at least moderate strength of evidence or a clinically 
meaningful difference for the following comparison: 
• Intramuscular methotrexate (15 mg weekly) was more efficacious than placebo to 
maintain remission at week 40 (absolute RD, 26 percent; placebo rate, 39 percent). (SOE: 
Low) 
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Table 28. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating methotrexate to maintain remission 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Methotrexate 
(intramuscular) 
vs. placebo – wk 
40 
Disease activity 
measures 
1 (76)105 Medium Unknown 
(single study) 
Indirect Precise Favors methotrexate 
RD, 26%; placebo rate, 
39% 
 
SOE: Low 
RD = absolute risk difference; SOE = strength of evidence; vs. = versus; wk = weeks 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
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Monotherapy Versus Placebo 
Methotrexate Versus Placebo 
Disease Activity Measures 
One RCT105 evaluated the difference between methotrexate and placebo to maintain 
remission in patients with Crohn’s disease (Table 29). Sustained remission was not reported in 
the trial. Relapses were less common in the methotrexate than placebo group. The difference in 
relapse met the clinically meaningful and statistically significant thresholds at 40 weeks. 
 
Table 29. Remission rates reported in randomized controlled trials comparing the efficacy of 
methotrexate with placebo in patients with inactive Crohn’s disease 
Author, Year 
Followup 
(Weeks) 
Main Intervention 
(Dose), n 
Comparison, 
n 
Relapse 
Definition Remission Rate, % 
Feagan, 
2000105 
40 Methotrexate (15 
mg/wk IM), 36 
Placebo, 40 (≥100 increase in 
CDAI or use of a 
thiopurine or 
steroid 
65% vs. 39%* 
CDAI = Crohn’s Disease Activity Index; IM = intramuscular; mg/wk = milligrams per week; vs. = versus 
*Trial reported difference in relapse rates significant at 0.05 alpha level 
Corticosteroids 
Eleven trials evaluated the efficacy of corticosteroids to maintain remission in patients with 
inactive Crohn’s disease (Appendix D, Evidence Table 7). Nine trials compared corticosteroids 
with placebo.56,64,106-112 Two trials56,64 compared corticosteroids with aminosalicylates in addition 
to placebo, one trial compared budesonide directly with mesalamine,113 and one trial75 compared 
a combination of corticosteroids and aminosalicylates with aminosalicylates alone. Seven trials 
used budesonide 3 to 6 mg per day, two trials used prednisone 0.25 mg/kg per day alone and in 
combination with sulfasalazine,56,75 and two trials used 6-methylprednisolone 0.25 mg/kg per 
day to 8 mg per day alone112 or in combination with sulfasalazine.64  
Five trials also appear in KQ1. One trial64 reported relapse rates in the population with 
inactive disease at randomization with the active disease patients reported in KQ1. Four trials 
included patients who had previously participated in an induction trial.65,66,68,69 One trial is also 
included in the thiopurines and aminosalicylates sections.56 
Trial Design 
Nine of the 11 trials were described as double-blind. One study blinded investigators, but not 
patients,113 and blinding was not reported in one study.56 Of the 11 trials, four trials were 
conducted in the U.S. and North America, seven in Europe, one in Australia, one in Asia, and 
one in Africa (Appendix D, Evidence Table 7). One was a single center trial113 and the remaining 
ten took place at multiple sites. Seven trials reported enrollment dates; these trials took place 
between 1971 and 1996. Six trials had run-in periods from 4 to 12 weeks in duration; in these 
trials the participants were already in remission due to a separate prior trial comparing 
corticosteroids with placebo;75,106,108-111 in one trial75 the run-in period was part of the same trial 
comparing corticosteroids or corticosteroids and aminosalicylates. Five trials did not have a run-
in period,56,64,107,112,113 with one trial113 requiring all patients to taper their corticosteroids dose 
before beginning the trial. Median trial duration was 52 weeks (range from 13 to 104 weeks). 
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Nine trials included patients with CDAI less than or equal to 150 while one trial107 defined 
inactive disease as having a CDAI less than or equal to 200 and another64 included patients with 
both active (CDAI ≥ 150) and inactive (CDAI < 150) disease initially, and then analyzed them 
separately (the active disease results are reported in KQ1). Two trials106,109 required a minimum 
duration of remission beyond the induction period, from 8 to 10 weeks. Two trials required 
patients to be steroid-dependent.107,113 All trials reported a minimum age of inclusion of 18 years, 
with three exceptions,56,75,112 which did not report a minimum age. No trials required any other 
prior medication use aside from what is mentioned above. One trial113 excluded patients who had 
been maintained on mesalamine or azathioprine at the time of enrollment. Another trial106 
excluded patients who had received mesalamine at any time, or immunomodulator or 
corticosteroids at the time of the initial run-in trial.65 All trials used CDAI as the outcome 
measure. No trials used alternative activity indices. 
Population Characteristics 
The description of the population characteristics exclude one trial64 because it included both 
active and inactive disease in the baseline population. These ten trials randomized a total of 
1,028 patients across all trial groups (Appendix D, Evidence Table 8). The proportion of male 
participants in each trial group ranged from 22 to 67 percent. Only two trials56,107 reported on 
race, with Caucasian participants making up 91 to 98 percent across all trial groups. Only one 
trial113 reported smoking (with no definition given), which ranged between 82 and 86 percent 
across both trial groups. Six trials reported mean age at enrollment, which ranged between 32 
and 41 years. Seven trials reported mean duration of disease, which ranged between 3 to 9 years. 
Seven trials reported disease location: ileal location ranged between 33 and 89 percent, 
ileocolonic location between 11 and 49 percent, and colonic location between 0 and 33 percent. 
No trials reported perianal location. All but two trials reported mean baseline CDAI,75,112 ranging 
from 65 to 139. Only one trial reported concurrent medication use:107 aminosalicylates in 48 to 
49 percent of participants and thiopurine in 9 to 15 percent of participants across both trial 
groups. One trial reported prior thiopurine use113 in 41 to 43 percent of all participants across 
both trial groups. Of the six trials where patients were in an induction trial involving 
corticosteroids, corticosteroid frequency ranged from 80 to 100 percent across groups of five 
trials. In one trial75 corticosteroids use prior to entry ranged from 47 to 52 percent across groups.  
Key Points 
Table 30 summarizes the strength of evidence for the trials evaluating corticosteroids to 
maintain remission. We found at least moderate strength of evidence or a clinically meaningful 
difference for the following comparisons: 
• 6-methylprednisolone was more efficacious than placebo to maintain remission at weeks 
54 and 104 (absolute RD across time points, 11 to 12 percent; placebo rate, 32 to 48 
percent). (SOE: Low) 
• Budesonide (6 mg daily) was more efficacious than mesalamine (3 g daily) to maintain 
remission at week 52 (absolute RD, 27 percent; mesalamine rate, 18 percent). (SOE: 
Moderate) 
• Budesonide was favored over mesalamine as measured by the IBDQ quality of life 
outcome at 12 months, although both budesonide and mesalamine patients had lower 
quality of life at the end of the trial than at the beginning (absolute between-group 
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difference in change in mean IBDQ, 30 to 36 points; mesalamine mean change, -51 to  
-76 points). (SOE: Moderate) 
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Table 30. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a corticosteroid to maintain remission  
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Budesonide vs. 
placebo--wk 52 
Disease 
activity 
measures 
5 (557)106 108-111 Medium- Inconsistent Direct Imprecise Favors neither 
3mg pooled RR, 1.0; CI, 0.8 to 
1.2; placebo rate, 33% to 40% 
 
6mg pooled RR, 1.2; CI, 0.9 to 
1.5; placebo rate, 33% to 42% 
 
SOE: Low 
Budesonide vs. 
placebo--wks 13 
and 52 
Patient-
reported 
outcomes 
2 (122)107 111 Medium Consistent Direct Imprecise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 2 to 11 pts; 
placebo mean change, -4 to -31 
pts  
 
SOE: Low 
Prednisone vs. 
placebo--wks 54 
and 104 
Disease 
activity 
measures 
1 (162)56 High Unknown 
(single study) 
Direct Imprecise Neither favored 
RD across time points, 0% to 9%; 
placebo rate, 59% to 72% 
 
SOE: Low 
6-
methylprednisolone 
vs. placebo--wks 
54 and 104 
Disease 
activity 
measures 
1 (118)64 High Unknown 
(single study) 
Direct Imprecise Favors 6-methylprednisolone 
RD across time points, 11% to 
12%; placebo rate, 32% to 48% 
 
SOE: Low 
Budesonide vs. 
mesalamine--wk 52 
Disease 
activity 
measures 
1 (57)113 Medium Unknown 
(single study) 
Direct Precise Favors budesonide 
RD, 27%; mesalamine rate, 18% 
 
SOE: Moderate 
Budesonide vs. 
mesalamine--wk 52 
Patient-
reported 
outcomes 
1 (57)113 Medium Unknown 
(single study) 
Direct Precise Favors budesonide 
Absolute between-group 
difference in change in mean 
IBDQ, 30 to 36 pts; mesalamine 
mean change, -51 to -76 pts  
 
SOE: Moderate 
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Table 30. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating a corticosteroid to maintain remission (continued) 
Comparison Outcome Number of 
Trials 
(Participants) 
Domains Pertaining To Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Prednisone or 6-
methylprednisolone 
vs. sulfasalazine --
wks 54, 104 
Disease 
activity 
measures 
2 (248)56 64 High Consistent Direct Imprecise Favors neither 
RD across time points, 5% to 9%; 
ASA rate, 37% to 67% 
 
SOE: Low 
6-
methylprednisolone 
+ sulfasalazine vs. 
placebo--wks 54, 
104 
Disease 
activity 
measures 
1 (108)64 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD across time points, 2% to 5%; 
placebo rate, 32% to 48% 
 
SOE: Low 
Steroids + 
sulfasalazine vs. 
steroids--wks 26-
54, 104 
Disease 
activity 
measures 
2 (181)64 75 Medium Inconsistent Direct Imprecise Favors neither 
RD across time points, -9% to  
-6%; steroid rate, 22% to 60% 
 
SOE: Low 
6-
methylprednisolone 
+ sulfasalazine vs. 
sulfasalazine--wks 
54, 104 
Disease 
activity 
measures 
1(119)64 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, -3% to -2%; sulfasalazine 
rate, 37% to 55% 
 
SOE: Low 
ASA = aminosalicylates; CI = 95% confidence interval; IBDQ = Inflammatory Bowel Disease Questionnaire; NA = not applicable; pt = points; RD = absolute risk difference; RR 
= relative risk; SOE = strength of evidence; steroid = corticosteroids; vs. = versus; wk = weeks 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
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Monotherapy Versus Placebo 
Corticosteroids Versus Placebo 
Disease Activity Measures 
Nine trials, including 854 participants, compared corticosteroids with placebo (Table 31; 
Appendix D, Evidence Table 9).56,64,106-112 Six trials used budesonide 3 to 6 mg per day, two64,112 
used 6-methylprednisolone, and one56 used prednisone. In two trials107,112 the final time point 
was at 26 weeks or less. 
Two meta-analyses were conducted on five trials106 108-111 comparing budesonide 3 and 6 mg 
per day with placebo at 52 weeks (Figure 8). Four of the trials included participants from 
induction trials summarized in KQ1.106 108 110 111 There was no difference between budesonide 
and placebo to maintain remission at 52 weeks for the 3 mg dose (RR of remission, 1.0; 95% CI, 
0.8 to 1.2) nor the 6 mg dose (RR of remission, 1.2; 95% CI, 0.9 to 1.5). There was no significant 
heterogeneity among the trials for either dose (I-squared, 0). The excluded budesonide trial 
found that 33 percent more patients who switched to 6 mg budesonide were in remission 
compared with placebo at 13 weeks, which was clinically and statistically significant.107 
There was no meaningful difference in relapse rates in the prednisone trial at 54 or 104 
weeks.56  
More 6-methylprednisolone patients were in remission compared with placebo at 54 and 104 
weeks, although statistical significance was not reported.64 A 6-methylprednisolone trial that 
reported its last measure at 26 weeks also favored 6-methylprednisolone to placebo according to 
the clinically meaningful threshold, but did not report statistical significance.112  
Patient-Reported Outcomes 
Two trials with 122 participants compared budesonide with placebo and did not find 
clinically meaningful differences.107,111 In a trial111 of patients who had participated in an 8-week 
induction trial, the IBDQ decreased in all groups and there were not clinically meaningful nor 
statistically significant differences. At 12 months, IBDQ decreased from 185 to 156 in the 
budesonide 3 mg group, 184 to 161 in the budesonide 6 mg group, and 181 to 150 in the placebo 
group.114 Another trial107 examined steroid-dependent patients and measured the IBDQ at week 
13. The mean IBDQ score rose from 162 to 169 in the budesonide group and dropped from 158 
to 154 in the placebo group, which was not clinically meaningful but was statistically 
significant.107 
Monotherapy Versus Monotherapy 
Corticosteroids Versus Aminosalicylates 
Disease Activity Measures 
Three trials,56,64,113 involving 305 participants, included comparisons of corticosteroid 
therapy with aminosalicylates to maintain remission from 52 to 104 weeks (Table 31). An 
investigator- but not patient-blinded trial of 6 mg budesonide found a clinically and statistically 
significant difference compared with 3 g mesalamine at 52 weeks,113 but the 6-
methylprednisolone64 and prednisone56 trials did not find clinically meaningful differences 
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compared with sulfasalazine. No meta-analysis was performed because of the different 
formulations of corticosteroids and aminosalicylates used.  
Patient-Reported Outcomes 
In the budesonide trial, all patients reported worse quality of life at the end of the trial.113 At 
1 year, mean IBDQ score decreased from 188 to 148 in the budesonide group and 186 to 110 in 
the mesalamine group. Budesonide was clinically and statistically (P=0.0001) favored to 
mesalamine, although the budesonide patients also reported feeling significantly worse.  
Combination Therapy Versus Placebo 
Combination of Corticosteroids and Aminosalicylates Versus Placebo 
Disease Activity Measures 
In one trial64 of 108 participants (Table 31), there was no clinically meaningful difference in 
remission at 54 and 104 weeks between those on 6-methylprednisolone 8 mg per day and 
sulfasalazine 3 g per day combination therapy and those on placebo. 
Combination Therapy Versus Monotherapy 
Combination of Corticosteroids and Aminosalicylates Versus Corticosteroids 
Alone 
Disease Activity Measures 
Two trials,64,75 including 181 participants, compared a combination of corticosteroids and 
sulfasalazine with corticosteroids alone to maintain remission of Crohn’s disease (Table 31). 
Neither trial found a clinically meaningful difference. 
Combination of Corticosteroids and Aminosalicylates Versus 
Aminosalicylates Alone 
Disease Activity Measures 
In one trial64 of 119 participants (Table 31), there was no clinically meaningful difference in 
relapse rates at 54 or 104 weeks in those randomized to the combination of 6-methylprednisolone 
8 mg/day and sulfasalazine 3 g/day compared with those randomized to sulfasalazine 3 g/day 
alone. 
112 
Table 31. Remission rates reported in randomized controlled trials comparing the efficacy of corticosteroids with placebo or another 
treatment in patients with inactive Crohn’s disease 
Author, Year 
Followup 
(Weeks) 
Main Intervention (Daily 
Dose), n 
Comparison (Daily 
Dose), n Relapse Definition 
Remission 
Rate (%) 
Lofberg, 
1996110 
52 Budesonide (3 mg), 31 Placebo, 27 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline, or 
acute deterioration in status 
26 vs. 37% 
Lofberg, 
1996110 
52 Budesonide (6 mg), 32 Placebo, 27 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline, or 
acute deterioration in status 
41 vs. 37% 
Greenberg, 
1996111 
52 Budesonide (3 mg), 33 Placebo, 36 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline 30 vs. 33% 
Greenberg, 
1996111 
52 Budesonide (6 mg), 36 Placebo, 36 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline 39 vs. 33% 
Ferguson, 
1998108 
52 Budesonide (3 mg), 26 Placebo, 27 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline, or 
any deterioration requiring a different medication or surgery 
54 vs. 40% 
Ferguson, 
1998108 
52 Budesonide (6 mg), 22 Placebo, 27 CDAI > 150 and ≥ 60-pt increase in CDAI from baseline, or 
any deterioration requiring a different medication or surgery 
52 vs. 40% 
Gross, 
1998109 
52 Budesonide (3 mg), 84 Placebo, 95 CDAI > 150 on 2 consecutive weeks 33 vs. 35% 
Cortot, 
2001107 
13 Budesonide (6 mg), 59 Placebo, 58 CDAI > 200 and ≥ 60-pt increase in CDAI from baseline 68 vs. 
35%* 
Hanauer, 
2005106 
52 Budesonide (6 mg), 54 Placebo, 54 CDAI ≥ 150 and ≥ 60-pt increase in CDAI from baseline or 
clinical deterioration 
53 vs. 42% 
Summers, 
197956 
54 Prednisone (0.25 mg/kg), 
61 
Placebo, 101 CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, development of 
a fistula, fever, or radiologic progression 
72 vs. 72% 
Summers, 
197956 
104 Prednisone (0.25 mg/kg), 
61 
Placebo, 101 CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, development of 
a fistula, fever, or radiologic progression 
68 vs. 59% 
Malchow, 
198464 
54 6-Methylprednisolone  
(8 mg), 66 
Placebo, 52 CDAI > 150 or clinical deterioration 60 vs. 48% 
Malchow, 
198464 
104 6-Methylprednisolone  
(8 mg), 66 
Placebo, 52 CDAI > 150 or clinical deterioration 43 vs. 32% 
Brignola, 
1988112 
26 6-Methylprednisolone  
(0.25 mg/kg), 9 
Placebo, 9 CDAI > 150 and ≥ 100-pt increase in CDAI for 2 weeks 89 vs. 22% 
Mantzaris, 
2003113 
52 Budesonide (6 mg), 29 Mesalamine (3 g), 28 CDAI > 150 and ≥ 100-pt increase in CDAI 45 vs. 
18%* 
Summers, 
197956 
54 Prednisone (0.25 mg/kg), 
61 
Sulfasalazine  
(0.5 mg/kg), 58 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, development of 
a fistula, fever, or radiologic progression 
72 vs. 67% 
Summers, 
197956 
104 Prednisone (0.25 mg/kg), 
61 
Sulfasalazine  
(0.5 mg/kg), 58 
CDAI > 150 and ≥ 100-pt increase in CDAI for 2 
consecutive weeks, or a need for surgery, development of 
a fistula, fever, or radiologic progression 
68 vs. 59% 
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Table 31. Remission rates reported in randomized controlled trials comparing the efficacy of corticosteroids with placebo or another 
treatment in patients with inactive Crohn’s disease (continued) 
Author, Year 
Followup 
(Weeks) 
Main Intervention (Daily 
Dose), n 
Comparison (Daily 
Dose), n Relapse Definition 
Remission 
Rate (%) 
Malchow, 
198464 
54 6-Methylprednisolone  
(8 mg), 66 
Sulfasalazine (3 g), 
63 
CDAI > 150 or clinical deterioration 60 vs. 55% 
Malchow, 
198464 
104 6-Methylprednisolone  
(8 mg), 66 
Sulfasalazine (3 g), 
63 
CDAI > 150 or clinical deterioration 43 vs. 37% 
Malchow, 
198464 
54 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
Placebo, 52 CDAI > 150 or clinical deterioration 53 vs. 48% 
Malchow, 
198464 
104 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
Placebo, 52 CDAI > 150 or clinical deterioration 34 vs. 32% 
Singleton, 
197975 
26 Prednisone (0.25 mg/kg) + 
sulfasalazine (1 mg/15 kg), 
29 
Prednisone  
(0.25 mg/kg), 30 
CDAI > 150 and CDAI 100-point increase  16 vs. 22% 
Malchow, 
198464 
54 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
6-Methylprednisolone  
(8 mg), 66 
CDAI > 150 or clinical deterioration 53 vs. 60% 
Malchow, 
198464 
104 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
6-Methylprednisolone  
(8 mg), 66 
CDAI > 150 or clinical deterioration 34 vs. 43% 
Malchow, 
198464 
54 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
Sulfasalazine (3 g), 
63 
CDAI > 150 or clinical deterioration 53 vs. 55% 
Malchow, 
198464 
104 6-Methylprednisolone  
(8 mg) + sulfasalazine  
(3 g), 56 
Sulfasalazine (3 g), 
63 
CDAI > 150 or clinical deterioration 34 vs. 37% 
CDAI = Crohn’s Disease Activity Index; mg = milligrams; kg = kilograms; pt = points; vs. = versus 
*Trial reported significant at the 0.05 alpha level. 
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Figure 8. Pooled relative risk of a remission* of Crohn’s disease at week 52 comparing budesonide with placebo 
 
CI = confidence interval; mg = milligrams; RR = relative risk  
Note: Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, with larger boxes contributing more to the pooled estimate. The width of the 
horizontal lines represents the 95% confidence intervals for each trial. The diamond at the bottom of the graph indicates the 95% confidence interval for the random-effects pooled 
estimate.3 mg Test for heterogeneity: Q=1.83 with 3 degrees of freedom (p=0.61).6 mg Test for heterogeneity: Q=0.30 with 3 degrees of freedom (p=0.96).3 mg and 6 mg I-
squared statistic = 0%.*In all trials, relapse was defined as a Crohn’s Disease Activity Index more than 150 with at least a 60-point increase from baseline. Ferguson 1998, Lofberg 
1996, and Hanauer 2005 also defined relapse to include clinical deterioration. All patients who did not relapse were considered in remission for the analysis. 
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Aminosalicylates 
Fourteen trials compared aminosalicylates versus placebo to maintain remission (Appendix 
D, Evidence Table 7).56,64,115-126 One trial64 included both those with active (CDAI greater than 
150) and inactive disease (CDAI less than 150) at randomization, with the active disease group 
reported in KQ1. One trial is also included in the thiopurines and corticosteroids sections.56 
Trial Design 
Of the 14 trials, ten trials were conducted in Europe, four in North America and the U.S., two 
in Asia, and one in Africa (Appendix D, Evidence Table 7). All were multicenter trials except 
two,124,125 and one126 which said that patients were recruited from outpatient clinics but did not 
specify the study sites. Eleven trials used mesalamine; seven used pH-release mesalamine and 
four used controlled-release. The pH-release mesalamine begins release in the terminal ileum but 
is mainly released in the colon. The controlled-release mesalamine begins release in the proximal 
small bowel. Two trials used sulfasalazine and one used olsalazine. Mesalamine doses ranged 
from 1 to 4 grams daily. The starting year of enrollment was between 1971 and 2000. Three 
trials115,118,119 had run-in periods involving induction of remission with 6-methylprednisolone or 
prednisone for 4 to 8 weeks. Median trial duration was 52 weeks (range, 6 to 208 weeks).  
Twelve trials included only patients with a CDAI less than 150, one with a CDAI less than 
120,126 and one with a HBI less than 4.121 Five trials required a minimum duration of remission 
prior to the trial, ranging from 4 weeks to 24 months.116,121,122,124,126 No trials required patients to 
be steroid-dependent or resistant. Seven trials reported a minimum age of inclusion of 18 years, 
with two119,122 including those 15 years old and over, and the remaining trials not reporting a 
minimum age. Regarding medication use in the 1 to 3 months prior to the trials, four 
trials116,122,124,126 excluded patients who had used corticosteroids within this time frame, 
four116,118,120,122,excluded those on any other immunosuppressives, and one trial117 excluded those 
with recent thiopurine or cyclosporine use. 
Population Characteristics 
All of the following statistics exclude one trial64 due to its inclusion of both those with active 
and inactive disease in the baseline population (Appendix D, Evidence Table 8). Thirteen trials 
are summarized here. Another trial117 did not distinguish between those patients in medical 
remission and those in surgical remission when reporting population characteristics, so we 
included statistics on both groups in the totals below.  
The included trials randomized a total of 1,825 patients across all trial groups. The proportion 
of male participants in each trial group ranged from 39 to 70 percent. Only one trial56 reported on 
race, with Caucasian participants making up 94 to 98 percent across both trial groups. Three 
trials117,118,121 reported smoking (“smoker” or “present smoker”), which ranged between 18 and 
38 percent. Six trials reported mean age at enrollment, which ranged between 29 and 40 years. 
All seven trials reported mean duration of disease, which ranged between 3 and 7 years. The 
trials reported disease location as follows: ileal location ranged between 11 and 100 percent, 
ileocolonic location between 18 and 91 percent, and colonic location between 9 and 97 percent. 
One trial reported perianal location,122 which ranged from 11 to 14 percent. All but four trials 
reported baseline CDAI.115,121,122,126 Mean CDAI ranged from 48 to 89 points. One trial121 
reported mean HBI values, ranging from 2.2 to 2.3 across the two groups. No trials reported 
concurrent medication use. Prior corticosteroid use ranged from 13 to 94 percent across three 
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trials.119,124,125 In one trial,121 82 to 87 percent of patients were on an aminosalicylate at trial 
entry.  
Key Points 
Table 32 summarizes the strength of evidence for the trials evaluating aminosalicylates in 
terms of remission maintenance. Listed are the comparisons with at least moderate strength of 
evidence or a clinically meaningful difference. 
• Mesalamine (controlled-release) at 3 to 4 g daily was more efficacious than placebo to 
maintain remission at weeks 48 to 52 (absolute RD across time points, 7 to 11 percent; 
placebo rate, 22 to 58 percent). (SOE: Low) 
• Mesalamine (controlled-release) at 2 g daily was no more efficacious than placebo to 
maintain remission at week 104 (absolute RD, 6 percent, placebo rate, 58 percent). (SOE: 
Moderate). 
• Mesalamine (pH-release) at 2.4 g daily was more efficacious than placebo to maintain 
remission at week 208 (absolute RD, 18 percent; placebo rate, 29 percent). (SOE: Low ) 
• Olsalazine at 2 g daily was no more efficacious than placebo to maintain remission at 
week 52 (absolute RD, 2 percent, placebo rate, 74 percent). (SOE: Moderate). 
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Table 32. Numbers of trials and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for trials 
evaluating an aminosalicylate to maintain remission  
ASA = aminosalicylates; IBDQ = Inflammatory Bowel Disease Questionnaire; pt = points; RD = absolute risk difference; SOE = strength of evidence; vs. = versus; wk = weeks 
Note: The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable 
Scores for the Inflammatory Bowel Disease Questionnaire range from 32 to 224, with higher scores indicating better quality of life.36 
Comparison Outcome Number of  
Trials 
(Participants) 
Domains Pertaining to Strength of Evidence Magnitude of Effect 
 
Strength of Evidence 
   Risk of Bias Consistency Directness Precision  
Mesalamine 
(controlled-release) vs. 
placebo—wks 48, 52 
Disease 
activity 
measures 
2 (309)117 119 High Consistent Direct Imprecise Favors mesalamine (controlled-release) 
RD, 7 to 11%; placebo rate, 22 to 58% 
 
SOE: Low 
Mesalamine 
(controlled-release) vs. 
placebo—wk 104 
Disease 
activity 
measures 
1 (161)122 Low Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, 6%; placebo rate, 58% 
 
SOE: Moderate 
Mesalamine 
(controlled-release), 
vs. placebo--wk 48 
Patient-
reported 
outcomes 
1 (246)117  Medium Unknown 
(single study) 
Direct Imprecise Favors neither 
Absolute between-group difference in 
change in mean IBDQ, 1 pt; placebo 
mean change, -14 pts 
 
SOE: Low 
Mesalamine (pH-
release) vs. placebo—
wk 52 
Disease 
activity 
measures 
7 (756)115 118 
120 121 123 125 126 
Medium Inconsistent Direct Precise Favors mesalamine (pH-release) 
RR, 1.1; 95% CI, 1.0 to 1.3 
 
SOE: Low 
Mesalamine (pH-
release) vs. placebo—
wk 104 
Disease 
activity 
measures 
1 (117)118 High Unknown 
(single study) 
Direct Imprecise Favors placebo 
RD, -17%; placebo rate, 42% 
 
SOE: Low 
Mesalamine (pH-
release) vs. placebo—
wk 208 
Disease 
activity 
measures 
1 (59)121 Medium Unknown 
(single study) 
Direct Imprecise Favors mesalamine (pH-release) 
RD, 18%; placebo rate, 29% 
 
SOE: Low 
Olsalazine vs. 
placebo—wk 52 
Disease 
activity 
measures 
1 (328)116 Low Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, 2%; placebo rate, 74% 
 
SOE: Moderate 
Sulfasalazine vs. 
placebo—wks 54, 104 
Disease 
activity 
measures 
2 (274)56 64 High Inconsistent Direct Imprecise Favors neither 
RD, -5 to 7%; placebo rate, 32 to 72% 
SOE: Low 
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Monotherapy Versus Placebo 
Aminosalicylates Versus Placebo 
Disease Activity Measures 
Fourteen trials, including 1,789 participants, compared aminosalicylate compounds with 
placebo to maintain remission (Table 33; Appendix D, Evidence Table 9).56,64,115-126 One trial64 
included both patients with active and inactive Crohn’s disease at randomization with the active 
disease results reported in KQ1. There was a great deal of heterogeneity in the absolute relapse 
rates across the included trials with a range of 0 to 71 percent for the groups receiving 
aminosalicylates and 14 to 78 percent for placebo.  
Thirteen of 14 trials reported at 48 weeks or later (Figure 9). One controlled-release 
mesalamine trial reported the last measure at 16 weeks and found no clinically meaningful 
difference between mesalamine and placebo.124 Of the remaining 13 trials, there was variation in 
efficacy by the formulation of the aminosalicylate and, particularly, the brand of mesalamine. 
pH-release mesalamine was favored over placebo in seven trials115,118,120,121,123,125,126 at 52 
weeks (RR, 1.1; 95% CI, 1.0 to 1.3) (Figure 9). At 104 weeks, placebo was favored over pH-
release mesalamine, while at 208 weeks pH-release mesalamine was favored over placebo. 
Controlled-release mesalamine was favored over placebo in one117 of two trials at 48 to 52 
weeks,117,119 but there was no difference from placebo at 104 weeks.122 There was no clinically 
meaningful difference between sulfasalazine and placebo at 54 or 104 weeks,56,64 or olsalazine 
and placebo at 52 weeks.116  
Patient-Reported Outcome 
One 48-week trial with 246 patients compared controlled-release mesalamine (750 mg every 
6 hours) with placebo.117 At the last visit (early termination or trial completion), mean IBDQ 
dropped from 193 to 180 in the controlled-release mesalamine group, while it dropped from 193 
to 179 in the placebo group. The difference is not clinically meaningful. Patients who were 
randomized after a surgically induced remission were included in the results and no subgroup 
analysis was performed to examine the effect of the medication on medically induced remission.  
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Table 33. Remission rates reported in randomized controlled trials comparing the efficacy of aminosalicylates with placebo in patients 
with inactive Crohn’s disease 
Author, Year  
Followup 
(Weeks) Main Intervention (daily dose), n 
Comparison, 
n Relapse Definition 
Remission 
Rate (%) 
Summers, 
197956 
54 Sulfasalazine (0.5 g/15 kg), 58 Placebo, 101 CDAI > 150 and 100-pt rise in CDAI or clinical criteria 67 vs. 72% 
Summers, 
197956 
104 Sulfasalazine (0.5 g/15 kg), 58 Placebo, 101 CDAI > 150 and 100-pt rise in CDAI or clinical criteria 59 vs. 59% 
Malchow, 198464 54 Sulfasalazine (3 g), 63 Placebo, 52 CDAI > 150 or clinical deterioration 55 vs. 48% 
Malchow, 198464 104 Sulfasalazine (3 g), 63 Placebo, 52 CDAI > 150 or clinical deterioration 37 vs. 32% 
Wellmann, 
1988126 
52 Mesalamine (pH-release), 31 Placebo, 35 CDAI > 150 68 vs. 60% 
Prantera, 1992123 52 Mesalamine (pH-release) (2.4 g), 
64 
Placebo, 61 CDAI > 150 and 100-pt increase in CDAI 66 vs. 45%* 
Brignola, 1992124 16 Mesalamine (controlled-release) 
(2 g), 21 
Placebo, 22 CDAI > 150 for 2 weeks or 100-pt increase in CDAI 48 vs. 41% 
Gendre, 1993122 104 Mesalamine (controlled-release) 
(2 g), 80 
Placebo, 81 CDAI > 250 or CDAI between 150 and 250 with 50-pt 
increase for 2 weeks 
64 vs. 58% 
Arber, 1995121 52 Mesalamine (pH-release) (1 g), 28 Placebo, 31 HBI > 4 73 vs. 45% 
Bresci, 1995125 52 Mesalamine (pH-release) (2.4 g), 
32 
Placebo, 31 CDAI ≥ 150 or 100-pt increase in CDAI and LI ≥ 100 – 
cumulative† 
84 vs. 71% 
Bresci, 1995125 208 Mesalamine (pH-release) (2.4 g), 
32 
Placebo, 31 CDAI ≥ 150 or 100-pt increase in CDAI and LI ≥ 100 – 
cumulative† 
47 vs. 29% 
Thomson, 
1995120 
52 Mesalamine (pH-release) (3 g), 
102‡ 
Placebo, 105‡ CDAI > 150 and 60-pt increase in CDAI 73 vs. 68%‡ 
Thomson, 
1995120 
52 Mesalamine (pH-release) (3 g), 
36§ 
Placebo, 43§ CDAI > 150 and 60-pt increase in CDAI 60 vs. 74%§ 
Modigliani, 
1996119 
52 Mesalamine (controlled-release) 
(4 g), 65 
Placebo, 64 CDAI > 150 and 100-pt increase in CDAI or failure to 
discontinue steroids 
29 vs. 22% 
de Franchis, 
1997118 
52  Mesalamine (pH-release) (3 g), 58 Placebo, 59 CDAI > 150 and 60-pt increase in CDAI and increase 
in at least 2 of 3 acute phase reactants 
34 vs. 41% 
de Franchis, 
1997118 
104 Mesalamine (pH-release) (3 g), 58 Placebo, 59 CDAI > 150 and 60-pt increase in CDAI and increase 
in at least 2 of 3 acute phase reactants 
25 vs. 42% 
Sutherland, 
1997117 
48 Mesalamine (controlled-release) 
(3 g), 87 
Placebo, 93 CDAI > 150 and 60-pt increase in CDAI, or physician-
diagnosed disease flare, hospitalization for disease 
flare, or need for corticosteroids therapy 
69 vs. 58% 
Mahmud, 2001116 52 Olsalazine (2 g), 167 Placebo, 161 CDAI > 150 or 60-pt increase in CDAI 76 vs. 74% 
Prantera, 2005115 52 Mesalamine (pH-release) (4 g), 23 Placebo, 17 CDAI > 150 or withdrawal for other reasons 13 vs. 18% 
CDAI = Crohn’s Disease Activity Index; g = grams; HBI = Harvey-Bradshaw Index; ITT = intention-to-treat; LI = Laboratory Index; pt = points; vs. = versus 
*Trial reported significant at the 0.05 alpha level 
†LI - laboratory index (-26 + (1.3 X erythrocyte sedimentation rate) + (0.03 X white blood cell) + (5.5 X C-reactive protein) + (0.08 X alpha-1-antitrypsin) 
‡Results were reported separately for patients with Crohn’s colitis and Crohn’s ileitis. These are the results for patients with Crohn’s colitis. 
§Results were reported separately for patients with Crohn’s colitis and Crohn’s ileitis. These are the results for patients with Crohn’s ileitis.  
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Figure 9. Pooled relative risk of remission* of Crohn’s disease at weeks 48 to 54 comparing an aminosalicylate with placebo 
 
ASA = aminosalicylates; CI = confidence interval; diff = difference; g = grams; kg = kilograms; RR = relative risk  
Note: Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, with larger boxes contributing more to the pooled estimate. The width of the 
horizontal lines represents the 95% confidence intervals for each trial. The diamond at the bottom of the graph indicates the 95% confidence interval for the random-effects pooled 
estimateSulfasalazine test for heterogeneity: Q=1.03 with 1 degree of freedom (p=0.31); I-squared = 3%Mesalamine, pH-release test for heterogeneity: Q=10.06 with 7 degrees of 
freedom (p=0.19); I-squared = 30% 
Mesalamine, controlled-release test for heterogeneity: Q=0.13 with 1 degree of freedom (p=0.72); I-squared = 0% 
Olsalazine test for heterogeneity: Q=0 with 0 degrees of freedom; I-squared is not applicable. 
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Comparative Effectiveness of Therapies To Maintain Remission in 
Adult Subgroups 
Key Points 
• We saw no consistent relationship for the interaction of a medication and disease 
characteristic on remission rates in adults with Crohn’s disease. 
 
We planned to report results for trials that performed a statistical test for interaction. The 
following subgroup analyses were performed, but did not contain any trials that reported a P-
value for an interaction term: baseline CRP, baseline immunomodulator use, baseline antibiotic 
use, prior TNF-alpha inhibitor exposure, disease location, and prior Crohn’s disease-related 
surgery (Appendix G). 
Quality Assessment 
Among the 47 included RCTs, 66 percent adequately generated their allocation sequence and 
32 percent were unclear in how they generated their allocation sequence (Appendix D, Evidence 
Table 10). Seventy-two percent of these RCTs adequately concealed their allocation of 
participants into the different trial groups. Seventy percent of trials were double blind, while 30 
percent were not double blinded or did not report on blinding. Fifty-three percent of these trials 
reported withdrawals and dropouts, but the other 47 percent did not report on withdrawals or 
dropouts. Forty-three percent of these RCTs had some additional form of threat to the validity of 
results that they reported such as not clearly differentiating between patients with active and 
inactive disease or not performing a statistical test for interaction in subgroup analyses. Fifty-
seven percent and 33 percent of these RCTs received pharmaceutical support and company 
involvement in the design, conduct or reporting of the trial, respectively. The funding source was 
not reported in 23 percent of the trials. The overall quality ratings included 30 percent were rated 
as good quality, 43 percent as fair quality, and 27 percent as poor quality.  
Five TNF-alpha inhibitor trials were double blind trials at randomization, but allowed 
patients to increase the dose of the drug or switch from placebo to active drug if they were not 
responding to the randomized dose.83,87,88,94,95 When assessing the risk of bias, we downgraded 
these trials to at least medium risk of bias.  
Key Question 3: Safety of Therapies in Adults 
Forty-seven RCTs including 9,139 Crohn’s disease patients and 61 observational studies 
including 136,583 inflammatory bowel disease (IBD) patients reported data on one or more 
adverse effects of treatment. As noted for Key Questions 1 and 2, the main drug classes of 
interest were biologics, thiopurines, methotrexate, corticosteroids, and aminosalicylates. Because 
some observational studies combined thiopurines and methotrexate as immunomodulators, the 
additional classification of immunomodulators appears in this section. If more than three trials of 
similar design (e.g., induction trial, maintenance trial, prospective, retrospective, or case-control 
study) reported on a medication-outcome relationship, we considered a meta-analysis. 
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Key Points 
We summarized the key points below with the corresponding evidence grades. We provided 
additional details about the evidence grades in Table 34 and Appendix D, Evidence Table 11. 
Mortality 
• Mortality rates were less than 1 percent in most of the observed comparisons.  
• The only comparison for which mortality differed between groups was treatment with corticosteroids 
compared with treatment without corticosteroids. The relative risks (RRs) in observational studies 
ranged from 1.0 to 2.5, favoring no corticosteroids, with followup ranging from 6 weeks to 7 years. 
(SOE: Low) 
• In other comparisons, mortality did not differ between groups that received natalizumab, TNF-alpha 
inhibitors, immunomodulators, aminosalicylates, or combinations of these drugs. The RRs in 
observational studies compared with no treatment or another treatment ranged from 0.8 to 1.0 for 
TNF-alpha inhibitors, 0.7 to 1.3 for immunomodulators, and 0.7 for aminosalicylates, with followup 
ranging from 4 weeks to 12 years. (SOE: Low) 
Hepatosplenic T-Cell Lymphoma 
• We identified 37 unique cases of hepatosplenic T-cell lymphoma associated with treatment of 
Crohn’s disease from research reports, case series, and the Adverse Events Reporting System.  
• Ninety-five percent of the cases used a thiopurine, and 76 percent of the cases used at least one 
biologic, but we could not establish a causal relationship because of limitations in the available 
information.  
Lymphoma 
• Lymphoma occurred in less than 1 percent of patients in most observed comparisons.  
• The risk of lymphoma did not differ between groups that received natalizumab, TNF-alpha inhibitors, 
immunomodulators, corticosteroids, aminosalicylates, or combinations of these drugs. The 
observational RRs, compared with no treatment or another treatment, ranged from 0.6 to 1.7 for TNF-
alpha inhibitors, 0.3 to 5.3 for immunomodulators, 1.0 for corticosteroids, and 1.0 for 
aminosalicylates, with followup ranging from 4 weeks to 12 years. (SOE: Low) 
• RCTs of immunomodulators, corticosteroids, or aminosalicylates did not report lymphoma as an 
outcome. 
Cervical Cancer 
• The studies reported very few cervical cancer cases. 
• The risk of cervical cancer did not differ between groups that received TNF-alpha inhibitors, 
immunomodulators, corticosteroids, or aminosalicylates, or combinations of these drugs, with 
followup ranging from 26 weeks to 3 years. (SOE: Low)  
• Most of the RCTs, and all of the studies of natalizumab, did not include cervical cancer as an 
outcome. 
All Cancers 
• The risk of non-melanoma skin cancer was higher with TNF-alpha inhibitors alone or with 
immunomodulators used recently (within 90 days) or persistently (within 90 days and greater than 
365 days), than it was with no TNF-alpha inhibitors or no immunomodulators. The odds ratios (ORs) 
in observational studies ranged from 2.1 to 6.8. (SOE: Low) 
• The risk of non-melanoma skin cancer was higher with thiopurines used recently (within 90 days) or 
persistently (within 90 days and greater than 365 days), than it was with no thiopurines. The ORs in 
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observational studies ranged from 3.8 to 4.3. (SOE: Low) 
• The risk of adenocarcinoma of the small bowel was higher with 6-mercaptopurine than with no 6-
mercaptopurine. The odds ratio (OR) in an observational study was 10.8, with an unreported length of 
followup. (SOE: Low) 
• For all other comparisons, the risk of specific cancers or all cancers did not differ between treatment 
groups. The RRs, compared with no treatment or another treatment, from observational studies 
ranged from 0 to 10.8, with followup ranging from 4 weeks to 12 years. (SOE: Low) 
Infections 
• Trials frequently reported serious infections, and they occurred in less than 5 percent of patients in 
most trials.  
• Trials occasionally reported opportunistic infections, and they occurred less than 5 out of every 100 
person-years.  
• Trials frequently reported infections (including serious and opportunistic), with a maximum incidence 
of 83 percent of patients in one trial. Most trials reported far fewer infections (5 to 20 percent of 
patients). 
• The risk of infection did not differ between groups that received natalizumab, TNF-alpha inhibitors, 
immunomodulators, or aminosalicylates. The RRs, hazard ratios (HRs), or ORs from RCTs and 
observational studies, compared with no treatment or another treatment, were 0.3 to 1.3 for 
natalizumab, 0.3 to 11.1 for TNF-alpha inhibitors, 0.3 to 5.4 for immunomodulators, 0.4 to 3.4 for 
corticosteroids, and 0.9 to 1.8 for aminosalicylates, with followup ranging from 4 weeks to 9 years. 
(SOE: Low) 
• The risk of infection was lower with prednisone and sulfasalazine than with prednisone alone. The 
RR from one RCT was 0.3, with 8 weeks of followup. (SOE: Moderate) 
Tuberculosis 
• The studies reported only six cases of tuberculosis, most likely because many RCTs screened patients 
for tuberculosis or treated them before enrollment. 
• The risk of developing tuberculosis did not differ between treatment groups in five RCTs comparing 
TNF-alpha inhibitors with placebo, one RCT comparing a combination of infliximab and 
immunomodulators with infliximab, and one RCT comparing a combination of infliximab and 
immunomodulators with immunomodulators. The followup ranged from 4 to 52 weeks. (SOE: Low) 
Infusion- and Injection-Site Reactions 
• Trials of biologics frequently reported infusion and injection-site reactions, with infusion reactions 
occurring in 0 to 40 percent of patients. Most trials reported that fewer than 20 percent of patients 
experienced reactions. 
• The rate of infusion reactions did not differ between treatment groups in most comparisons. (SOE: 
Low) The RRs from RCTs and observational studies were as follows: for natalizumab versus placebo, 
RR ranged from 0.8 to 1.5; for certolizumab pegol versus placebo, RR ranged from 0.2 to 1.7; for 
combinations with infliximab versus infliximab alone, RR ranged from 0.3 to 1.5; and for infliximab 
combined with thiopurine versus infliximab combined with methotrexate, RR ranged from 0.8 to 1.4. 
• The rate of infusion reactions was higher with infliximab and adalimumab than with placebo. The 
RRs from RCTs ranged from 1.1 to 3.2. (SOE: Low) 
• The rate of infusion reactions was higher with infliximab than with azathioprine. The RR from one 
RCT was 3.0, with 1 year of followup. (SOE: High) 
• We did not find any trials that administered corticosteroids or aminosalicylates intravenously. 
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Bone Fractures 
• None of the studies of biologics, immunomodulators, or aminosalicylates reported on bone fractures. 
• The risk of bone fracture did not differ between treatment groups that received budesonide or 
prednisolone. The RR from one RCT with 2 years of followup was 1.0. (SOE: Moderate)  
• The risk of bone fracture did not differ between corticosteroid users and corticosteroid non-users. The 
RR from observational studies ranged from 0 to 2.5, with 2 years of followup. (SOE: Low)  
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Table 34. Key findings and strength of the available evidence comparing pharmacologic therapies for the management of Crohn’s 
disease in terms of safety-related outcomes 
Comparison Mortality Lymphoma 
Cervical 
Cancer All Cancers  Infections Tuberculosis 
Infusion- and  
Injection-Site 
Reactions 
Bone 
Fractures 
Natalizumab  
vs. placebo 
NF; Low 
SOE 
NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
 NF; Low SOE  
Natalizumab  
+ infliximab 
vs. infliximab 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
 NF; Low SOE  
TNF vs. no TNF   NF; Low SOE NF; Low 
SOE 
NF; Low 
SOE 
NF; Low SOE   
Infliximab  
vs. placebo 
NF; Low 
SOE 
NF; Low 
SOE 
    Placebo favored;  
Low SOE 
 
Adalimumab  
vs. placebo 
NF; Low 
SOE 
NF; Low 
SOE 
    Placebo favored;  
Low SOE 
 
CP vs. placebo NF; Low 
SOE 
NF; Low 
SOE 
    NF; Low SOE  
Infliximab  
vs. azathioprine 
NF; Low 
SOE 
  NF; Low 
SOE 
NF; Low 
SOE 
 Azathioprine favored;  
Low SOE 
 
TNF + IMM  
vs. no therapy 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
   
Infliximab + IMM  
vs. infliximab 
NF; Low 
SOE 
NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
NF; Low SOE NF; Low SOE  
Infliximab + IMM  
vs. IMM 
NF; Low 
SOE 
  NF; Low 
SOE 
NF; Low 
SOE 
NF; Low SOE NF; Low SOE  
Infliximab + IMM  
vs. steroids 
NF; Low 
SOE 
NF; Low 
SOE 
  NF; Low 
SOE 
   
Infliximab 
+ Thiopurine 
vs. infliximab  
+ methotrexate 
      NF; Low SOE  
TNF + IMM  
+ steroids  
vs. no therapy 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
   
Infliximab  
+ steroids  
vs. no therapy 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
   
Infliximab  
+ steroids  
vs. infliximab 
   NF; Low 
SOE 
  NF; Low SOE  
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Table 34. Key findings and strength of the available evidence comparing pharmacologic therapies for the management of Crohn’s 
disease in terms of safety-related outcomes (continued) 
Comparison Mortality Lymphoma 
Cervical 
Cancer All Cancers  Infections Tuberculosis 
Infusion- 
and 
injection-
Site 
Reactions 
Bone 
Fractures 
IMM vs. placebo NF; Low SOE NF; Low 
SOE 
NF; Low SOE NF; Low 
SOE 
NF; Low 
SOE 
 Placebo 
favored; High 
SOE 
 
Azathioprine vs. 
steroids 
NF; Low SOE   NF; Low 
SOE 
NF; Low 
SOE 
   
Azathioprine  
vs. sulfasalazine 
NF; Low SOE   NF; Low 
SOE 
NF; Low 
SOE 
   
Thiopurine + 
prednisone  
vs. placebo 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
   
Azathioprine  
+ prednisone  
vs. azathioprine 
NF; Low SOE        
IMM + steroids  
vs. steroids 
    NF; Low 
SOE 
   
Thiopurine + ASA  
vs. thiopurine 
 NF; Low 
SOE 
 NF; Low 
SOE 
NF; Low 
SOE 
   
Steroids vs. placebo Placebo 
favored; Low 
SOE 
NF; Low 
SOE 
NF; Low SOE NF; Low 
SOE 
NF; Low 
SOE 
  NF; Low SOE 
Budesonide  
vs. prednisone 
       NF;  
Moderate SOE 
Prednisone vs. ASA NF; Low SOE   NF; Low 
SOE 
NF; Low 
SOE 
   
Steroids + ASA vs. 
other  
NF; Low SOE    NF; Low 
SOE 
   
ASA vs. placebo NF; Low SOE NF; Low 
SOE 
NF; Low SOE NF; Low 
SOE 
NF; Low 
SOE 
   
ASA = aminosalicylates; CP = certolizumab pegol; IMM = immunomodulator; NF = neither favored; SOE = strength of evidence; steroids = corticosteroids; TNF = tumor necrosis 
factor-alpha inhibitor 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. Mod = Moderate confidence that the evidence reflects 
the true effect. Low = Low confidence that the evidence reflects the true effect. Insufficient = Evidence is unavailable. Blank cells indicate insufficient evidence. 
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Study Design and Population Characteristics 
Forty-seven RCTs and 61 observational studies reported on one or more safety-related 
outcomes. Tables 12 and 13 in Appendix D list the study designs and population characteristics 
of those studies.  
Forty-five of 87 RCTs (52 percent) that reported efficacy also reported a safety outcome of 
interest by treatment group. The 45 RCTs reporting safety included 9,139 Crohn’s disease 
patients. The majority of RCTs assessed safety at study visits but did not indicate how they 
ascertained safety (e.g., study-specific form or open-ended question) nor did they indicate if 
there were specific safety concerns of interest. We assumed all RCTs that actively assessed 
efficacy outcomes also actively assessed safety. Similarly, we assumed all RCTs that used 
blinded assessment for efficacy outcomes also used blinded assessment of safety. 
The observational studies included 12 prospective studies (n=29,075), 37 retrospective 
studies (n=66,177), 11 case-control studies (n=40,040), one cross-sectional study (n=207),127 and 
two observational studies of unclear study design (n=694).128 129 All of the case-control and 75 
percent of the prospective studies clearly stated a specific safety outcome of interest. Eight case-
control studies reported cancer outcomes, two reported on infections, and one reported on bone 
fractures. All of the retrospective studies aimed to assess safety, but only about half of the studies 
specified the exact safety outcomes of interest. No observational study mentioned active 
ascertainment or blinded assessment of safety outcomes. Three of the prospective studies relied 
upon the patients’ personal gastroenterologists to complete study-specific forms related to 
safety.130-132  
Multiple publications used data from several cohorts. These included 23 studies based on a 
general practice database, a single health center with care delivered at multiple sites, or a single 
IBD clinic.128,133-154 Most cohorts with multiple publications reported different outcomes in each 
publication. However, when relevant, we noted the duplication of outcomes in different studies 
from the same center.  
Some of the centers also served as sites for clinical trials. Unless the authors of the 
observational study reported that the patients’ outcomes were also reported in clinical trials, we 
did not note duplication of reporting in clinical trials and observational studies. 
Study Design of Observational Studies 
Thirty-two observational studies occurred at multiple centers. Twenty-eight observational 
studies occurred at single centers. Of the single-center studies, 13 occurred in the United States 
(U.S.), one in Canada, 12 in Europe, one in Australia, and one in Africa. Of the multi-center 
studies, eight occurred in the U.S., one occurred in the U.S. and Europe, and the remainder 
occurred in Canada, Australia, or a single country in Europe. No single or multi-center study 
included a site in Asia. Among 45 studies that reported year of enrollment, the starting year 
ranged from 1946 to 2009 (seven studies did not report year of enrollment). Median followup 
ranged from 16 weeks to 9 years (mean 34 weeks to 3.7 years). Eighteen studies did not report 
average followup. The majority of case-control studies used information from electronic records 
collected for routine care from multiple centers.  
Population Characteristics of Observational Studies 
Thirty-two studies reported results for IBD patients without reporting results for Crohn’s 
disease patients separately. Twenty-nine studies reported results separately for Crohn’s disease 
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patients or included these patients exclusively. The age distribution was very inclusive with some 
studies including patients of all ages (zero to 90 years).  
The majority of observational studies reporting safety included all activity levels and 
severities of Crohn’s disease. One study explicitly included patients by disease behavior and 
activity. One study included patients without abscess or stricture with either fistulizing disease or 
luminal refractory Crohn’s disease with a Crohn’s Disease Activity Index (CDAI) of 220 to 
400.128 A study on maintenance of remission required patients have 6 months of remission with 
azathioprine therapy to be eligible.146 Another prospective azathioprine study required patients to 
have well-controlled IBD to be eligible.155 
Most of the observational studies had no restrictions for previous medication use. Twenty 
studies included only patients who had used infliximab, five studies required adalimumab use, 
one study required certolizumab pegol use, and two studies required that patients had used a 
TNF-alpha inhibitor. These studies compared safety of the TNF-alpha inhibitors alone or in 
combination with other medications. Three retrospective studies required azathioprine use as 
they aimed to compare effectiveness of azathioprine with or without another medication.146,156,157 
Mortality 
Twenty-seven RCTs including 6,867 Crohn’s disease patients reported mortality by 
comparison group. No RCTs of methotrexate reported on mortality. Seven prospective, 13 
retrospective, and one observational study of unclear study design (including 41,877 Crohn’s 
disease patients in total) reported mortality as an outcome by comparison group128 (Appendix D, 
Evidence Table 14).  
Biologics 
Tables 35 and 36 summarize the RCTs and Figure 10 summarizes the observational studies 
evaluating biologics in terms of mortality. We provided additional details about these studies 
below. 
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Table 35. Summary of reported mortality results in randomized controlled trials comparing a biologic alone or in combination with 
placebo or another treatment in patients with Crohn’s disease 
Author, Year 
Followup 
(Weeks) Biologic Comparison 
# of Deaths 
in Biologic 
Group 
# of Patients 
in Biologic 
Group 
# of Deaths in 
Comparison 
Group 
# of Patients 
in 
Comparison 
Group 
Rutgeerts, 199985 36 Infliximab Placebo 0 37 1 36 
Hanauer, 200286 52 Infliximab Placebo 3 193 0 188 
Sandborn, 200533 48 Natalizumab Placebo 2 723 0 181 
Colombel, 201045 54 Infliximab + placebo Azathioprine + 
placebo 
0 163 1 161 
Van Assche, 
200889 
104 Infliximab + 
immunomodulators 
Infliximab 0 40 1 40 
Colombel, 201045 54 Infliximab + azathioprine Azathioprine + 
placebo 
0 179 1 161 
 
Table 36. Summary of randomized controlled trials that reported no deaths when comparing the effectiveness of a biologic alone or in 
combination with placebo or another treatment in patients with Crohn’s disease* 
Biologic Comparison 
# of Trials 
Reporting no 
Deaths 
Range of 
Followup 
(Weeks) 
# of Participants (Estimated 
Person-Years) in Biologic 
Group 
# of Participants (Estimated 
Person-Years) in 
Comparison Group 
Natalizumab Placebo 232 81 12 474 (109) 464 (107) 
Adalimumab Placebo 437 38 82 83 4-52 938 (584) 519 (297) 
Certolizumab pegol Placebo 439-41 84 12-26 833 (284) 638 (243) 
Infliximab Placebo 344 86 87 18-52 363 (310) 362 (309) 
Infliximab + 
azathioprine 
Infliximab + placebo 145 54 179 (186) 163 (169) 
Infliximab+ azathioprine Infliximab + 
hydrocortisone 
188 104 23 (46) 23 (46) 
Infliximab + thiopurine Thiopurine + placebo 146 52 57 (57) 56 (56) 
*Eight RCTs compared a biologic to another medication and did not report on mortality.33-35 42 43 47 48 80 
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Figure 10. Summary of Peto odds ratios of mortality among observational studies comparing a biologic alone or in combination with 
another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; ASA = aminosalicylates; BUDE = budesonide; CI = confidence interval; Comp = comparison; CP = certolizumab pegol; IFX = infliximab; IMM = 
immunomodulator; MTX = methotrexate; NR = not reported; OR = odds ratio; Pro = prospective cohort; Retro = retrospective cohort; STEROID = corticosteroids; THIO = 
thiopurine; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Inflammatory bowel disease population 
‡Adjusted OR, 0.8 (95% CI, 0.3 to 1.8) 
§Adjusted OR, 1.0 (95% CI, 0.5 to 1.9) 
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Adalimumab Versus Placebo 
Four RCTs compared adalimumab with placebo in 1,457 patients and reported 
mortality.37,38,83,95 The 4- or 52-week trials reported no deaths during the study periods. However, 
one person died during an induction period prior to randomization after receiving adalimumab.95 
Other Combinations With Adalimumab 
Four prospective studies (n=2,042) reported no deaths in patients taking adalimumab alone or 
in combination with aminosalicylates, corticosteroids, or immunomodulators.158-161 There were 
two deaths after the study period in one study.161 One death was from aminosalicylates toxicity 
(the study did not report any other concomitant medications). The study also did not report any 
concomitant medications for the other patient who died. 
Certolizumab Pegol Versus Placebo 
Four RCTs compared certolizumab pegol with placebo in 1,472 patients and reported 
mortality.39-41 84 Three studies were induction trials lasting 12- or 26-weeks.39-41 The trials did not 
report any deaths during the study periods. One 26-week trial reported one death after the study 
period in the certolizumab pegol group.39  
An 18-week trial of 428 responders from an 8-week induction phase compared certolizumab 
pegol with placebo among patients without obstruction, stricture, or abscess.84 One patient died 
of an accidental fentanyl overdose during the induction phase (1 percent), but the trial did not 
report any deaths during the randomization period.84  
Other Combinations With Certolizumab Pegol 
One prospective study (n=60) reported no deaths in patients taking certolizumab pegol with 
or without concomitant aminosalicylates, budesonide, other corticosteroids, or thiopurine.132 
Infliximab Versus Placebo 
Four RCTs including 1,022 patients compared infliximab with placebo and reported 
mortality.44,85-87 An 18-week induction trial of 94 fistulizing Crohn’s disease patients compared 
infliximab infusion with placebo.44 It reported no deaths during the study period.  
A 36-week maintenance trial85 compared retreatment with infliximab or placebo among 73 
responders to a single induction dose in a previous 12-week trial.43 The trial reported no deaths 
in the infliximab group, but reported one death in the placebo group. The deceased patient 
received infliximab during the induction period.85 The trial corresponding to the induction period 
did not report on mortality and did not report this death.43  
A 40-week maintenance trial of 282 responders and non-responders to a 14-week induction 
period with infliximab, compared infliximab with placebo.87 They reported no deaths during the 
study period, but did report two deaths after the completion of the study. (The deaths occurred in 
1 percent of the 306 given an induction dose prior to randomization.)  
In a 52-week maintenance trial, 573 responders and non-responders to a 2-week induction 
period of a single infliximab dose were given either infliximab or a placebo in 5 and 10 mg/kg 
doses administered intravenously every 8 weeks.86 They reported three deaths in the 5 mg/kg 
infliximab group (2 percent), but reported no deaths in the 10 mg/kg infliximab and placebo 
groups.86 
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Infliximab Versus No Infliximab 
One prospective study of 6,290 Crohn’s disease patients compared no infliximab use during 
the observation period with infliximab use within 12 weeks of enrollment, after 30 days of 
enrollment, or any other time during the observation period.131 The study followed mortality 
through June 30, 2004, instead of August 2004, because there was incomplete information on 
medication usage after June 30, 2004. There was no statistically significant increase in mortality 
comparing infliximab with no infliximab during the study period in the relative rate (incidence 
rate ratio [IRR], 1.2; 95% CI, 0.7 to 2.1), unadjusted OR (OR, 1.1; 95% CI, 0.6 to 1.9), or OR 
adjusted for demographic factors and ever having used prednisone, immunomodulators, or 
narcotic analgesics (1.0; 95% CI, 0.5 to 1.9). The OR analysis excluded two deaths because they 
occurred after June 30, 2004. The relative rate appears to have included these deaths.  
Infliximab Versus Immunomodulators 
One RCT including 324 patients compared infliximab with immunomodulators and reported 
mortality. A 50-week induction trial compared infliximab with azathioprine among patients who 
were naïve to TNF-alpha inhibitors, azathioprine, 6-mercaptopurine, and methotrexate.45 The 
trial collected safety information through week 54. There was one death among the 161 
azathioprine patients, and no deaths among the 163 infliximab patients. 
Combination of Infliximab and Immunomodulators Versus Infliximab 
Three RCTs and three observational studies including 1,296 patients compared a 
combination of infliximab and immunomodulators with infliximab alone, and reported 
mortality.45,46,89,128,162,163 Three RCTs including 535 patients compared a combination of 
infliximab and immunomodulators with infliximab alone. A 50-week induction trial compared 
infliximab and concomitant azathioprine with infliximab alone, among patients who were naïve 
to TNF-alpha inhibitors, azathioprine, 6-mercaptopurine, and methotrexate.45 The trial collected 
safety information through week 54. One patient died prior to randomization of the 817 patients 
assessed for eligibility (less than 1 percent). The trial did not report any deaths in the 179 
combination infliximab and azathioprine patients or 161 infliximab patients during the study 
period. An open-label 104-week RCT of 80 patients compared retreatment with infliximab with 
or without continuation of the current immunomodulators.89 One patient who discontinued 
immunomodulators died during the study period (1 percent). A 52-week induction trial, of 113 
steroid-dependent patients with luminal Crohn’s disease reported no deaths in the combination 
infliximab and thiopurines or infliximab alone treatment groups.46 
Two retrospective studies including 761 Crohn’s disease patients compared a combination of 
infliximab and immunomodulators with infliximab alone and reported mortality. A single-center 
retrospective study of 122 patients administered a mean of three infliximab infusions per patient 
and followed them for an average of 40 to 65 weeks.162 The trial did not record any deaths in the 
charts of the 58 patients treated with infliximab with concomitant azathioprine or 6-
mercaptopurine, nor did it record any deaths in the charts of the 23 patients treated with 
concomitant methotrexate. The trial recorded one death in the medical records of 36 patients who 
received infliximab without concomitant thiopurines or methotrexate (3 percent). Another single-
center study reported no deaths in either treatment group.163 
One study reported no deaths among 362 patients treated with infliximab without 
immunomodulators, and no deaths among 211 patients who received infliximab and an 
immunomodulator during the 12-week treatment period.128 Researchers describe the study as a 
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large series. It was likely retrospective in design because another study at the same center 
(reporting cancer outcomes) was retrospective.149 The study reporting cancer outcomes 
compared infliximab with no infliximab and reported that three patients treated with infliximab 
died from their cancer through September 2004. Because the 12-week study reporting on 
mortality did not report these deaths, they likely did not occur during the first 12 weeks of 
followup, or occurred after the end of followup of the mortality study.128 
Combination of Infliximab and Immunomodulators Versus 
Immunomodulators 
One 50-week trial including 340 patients naïve to TNF-alpha inhibitors, azathioprine, 6-
mercaptopurine, and methotrexate compared infliximab and concomitant azathioprine with 
azathioprine alone and reported on mortality.45 The trial reported no deaths in the 169 
combination infliximab and azathioprine patients. One of 170 azathioprine patients died during 
the study period (less than 1 percent). 
Combination of Infliximab and Immunomodulators Versus Corticosteroids  
One 2-year trial studied 46 corticosteroid-dependent patients with luminal Crohn’s disease 
who achieved remission during the 8-week induction period. The trial compared infliximab and 
concomitant azathioprine given daily with infliximab and hydrocortisone given at the time of the 
infusion.88 The trial reported no deaths during the study period. One retrospective study of 71 
patients reported no deaths in either the infliximab combined with corticosteroids group, or the 
infliximab combined with no previous use of corticosteroids group.163 
Other Combinations With Infliximab 
Three retrospective cohorts including 954 patients reported on the safety profile of infliximab 
use at their study centers.137 145 164 For all Crohn’s disease patients, the studies reported 
concomitant medications at the time of the first infliximab infusion given at the center. However, 
the studies only reported on concomitant medication use between infusion and the time of death 
for patients who died. They classified patients with unavailable information as infliximab 
without concomitant medication. Because of the potential misclassification, we did not include 
these studies in the tables or the strength of evidence grading, but we did report them here 
because they met our inclusion criteria. 
When studies categorized patients who had received infliximab but were not taking 
concomitant medications through the time of death as infliximab with no concomitant 
medications at infliximab initiation, they had the greatest mortality in two of three studies (11 
and 32 percent) compared with infliximab with corticosteroids (9 and 3 percent) or compared 
with infliximab with an immunomodulator with or without corticosteroids (less than 5 percent). 
The other study reported no deaths in the groups including infliximab without concomitant 
medication, 2 percent mortality when patients received infliximab combined with an 
immunomodulator, and 12 percent mortality when patients received infliximab combined with 
immunomodulators and corticosteroids.164 A previous study from one of the centers reported on 
the infliximab outcomes among the first 100 patients, and included one death from chronic 
pancreatitis 16 weeks after last infliximab infusion.138 Based on the age at death, this patient is 
likely the same patient who died of organ failure 8 weeks after the last infusion as reported in the 
first 500 infliximab patients.137 
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One of these studies also reported mortality among 30 of the 157 patients who used 
adalimumab after infliximab.145 The study did not observe any deaths among the 30 adalimumab 
patients, compared with seven deaths among 127 infliximab users who did not subsequently use 
adalimumab (6 percent). The Peto OR comparing infliximab followed by adalimumab, with 
infliximab not followed by adalimumab, in terms of risk of mortality, was 0.3 (95% CI, 0 to 
3.5).145 
Natalizumab Versus Placebo 
Three RCTs from two articles reported mortality for natalizumab versus placebo in 1,414 
patients.32 33 The two trials (reported in the same publication) included an initial induction trial of 
904 patients followed for 8 weeks, and a subsequent maintenance trial of 428 responders from 
that initial trial.33 One death occurred during the induction trial study period in the natalizumab 
group (less than 1 percent) and an additional death from progressive multifocal 
leukoencephalopathy occurred in the natalizumab group after the study ended during the open-
label extension (less than 1 percent).33 No deaths occurred in the placebo groups. A 12-week trial 
of 510 patients did not report any deaths in the induction or study periods.32  
Other Combinations With TNF-Alpha Inhibitors 
One retrospective study reported no deaths from infection in 489 patients who received 
adalimumab, certolizumab pegol, or infliximab alone or in combination with steroids or 
immunomodulators.165 A 104-week retrospective study reported that 10 percent of adalimumab 
or infliximab users died during the study period compared to 3 percent of patients who had never 
used a biologic. The corresponding Peto OR is 4.3 (95% CI, 0.9 to 27.6).150 
Immunomodulators 
We summarized the effects of immunomodulators on mortality in patients with Crohn’s 
disease in Table 37 (for RCTs) and Figure 11 (for observational studies). We provided additional 
details about the studies below.  
 
Table 37. Summary of reported mortality results in randomized controlled trials comparing an 
immunomodulator alone or in combination with placebo or another treatment in patients with 
Crohn’s disease 
Author, 
Year 
Follow-
up 
(Weeks) 
Immuno-
modulator Comparison 
# 
Deaths 
in IMM 
Group 
 # of 
Patients 
in IMM 
Group 
# of Deaths 
in 
Comparison 
Group 
# of Patients 
in 
Comparison 
Group 
O’Donoghue, 
1978100 
52 Azathioprine Placebo 1 24 0 27 
Lemann, 
200598 
48 Azathioprine Placebo 1 40 0 43 
Summers, 
197956 
104 Azathioprine Placebo 0 113 0 178 
Mantzaris, 
2009102 
52 Azathioprine Budesonide 0 112 0 83 
Summers, 
197956 
104 Azathioprine Prednisolone 0 113 0 146 
Summers, 
197956 
104 Azathioprine Sulfasalazine 0 113 0 132 
Reinisch, 
200851 
28 Azathioprine 
+ 
prednisone 
Prednisone 0 52 0 28 
IMM = immunomodulator 
135 
Figure 11. Summary of Peto odds ratios of mortality among observational studies comparing an immunomodulator alone or in 
combination with another treatment in patients with Crohn’s disease  
 
CI = confidence interval; Comp = comparison; IMM = immunomodulator; NR = not reported; OR = odds ratio; Pro = prospective cohort; Retro = retrospective cohort; THIO = 
thiopurine 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
† Inflammatory bowel disease population 
‡ Adjusted OR, 0.7 (95% CI, 0.4 to 1.3) 
§ Adjusted OR, 1.3 (95% CI, 0.9 to 1.9) 
║ Adjusted hazards ratio, 0.8 (95% CI, 0.4 to 1.9); the total number of mortality events for all treatment groups combined is 264 out of 5,537 patients. The studies did not report 
the number of events by treatment group. 
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Azathioprine Versus Placebo 
Three RCTs compared azathioprine with placebo in 425 patients and reported on mortality. 
One RCT reported no deaths due to Crohn’s disease in either group.56 Two RCTs compared 
continuation of azathioprine with placebo among 134 prevalent users of azathioprine. 
Researchers conducted one RCT at multiple centers and powered it as a non-inferiority trial to 
assess recurrent Crohn’s disease among those who had used azathioprine and been in remission 
for at least 42 months. This trial reported one death in the 40 azathioprine patients (3 percent) 
compared with zero deaths in the 43 placebo patients.98 One RCT required at least 6 months of 
azathioprine-induced remission before randomizing patients to azathioprine or placebo.100 One 
patient, who had been randomized to continue azathioprine after 10 years of azathioprine use, 
died during the study period. The trial did not report any deaths in the placebo group.  
Azathioprine Versus Aminosalicylates 
One 2-year RCT including 245 patients compared azathioprine with sulfasalazine. The trial 
reported no deaths due to Crohn’s disease during the study period.56 
Azathioprine Versus Corticosteroids 
Two RCTs reported on mortality when comparing azathioprine with prednisone in 336 
patients.56,102 One RCT compared 113 azathioprine patients and 146 prednisone patients over 2 
years. The RCTs reported no deaths due to Crohn’s disease during the study period.56 Another 
RCT compared 112 azathioprine with 83 budesonide patients, and reported no deaths during the 
study period.102  
Combination of Azathioprine and Prednisone Versus Prednisone 
One RCT including 81 patients compared three separate treatment regimens: 2.5 mg/kg per 
day azathioprine with concomitant 1 mg/kg per day of prednisone or at least 40 mg per day of 
prednisone (n=52), the same dose of prednisone and a placebo (n=29); and a medication not of 
interest for this report, everolimus (n=63).51 Researchers stopped the study early due to lack of 
efficacy with everolimus, and reported no deaths within 7 months of followup.  
Immunomodulators Versus No Immunomodulators 
One prospective study and two retrospective studies including a total of 11,829 Crohn’s 
disease patients reported on mortality. One prospective and one retrospective study reported on 
mortality comparing immunomodulators with no immunomodulators.131,151 The prospective 
study reported 1 percent mortality among 3,764 persons who had taken immunomodulators 
during the study period, compared with 1 percent mortality among 2,526 who had not taken 
immunomodulators during the study period.131 The OR was 0.7 (95% CI, 0.4 to 1.3) comparing 
immunomodulators with no immunomodulators, after adjusting for age; sex; race; disease 
location; duration of disease; severity; and having ever used infliximab, prednisone, and narcotic 
analgesics.131 The retrospective study compared current use of thiopurine with no use of 
thiopurine during the study period. The hazard ration (HR) was 0.8 (95% CI, 0.4 to 1.9) 
comparing current thiopurine use versus no use (no recorded use, or no use within 182 days of 
death), after adjusting for age, sex, comorbidity, and time from registration.134 In contrast, the 
third retrospective study reported an OR of 1.3 (95% CI, 0.9 to 1.0), comparing 
immunomodulators with no immunomodulators, after adjusting for age, sex, and smoking.151 
This retrospective studies did not adjust for use of other Crohn’s disease medications or disease 
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characteristics.  
Corticosteroids 
We summarized the effects of corticosteroids on mortality in patients with Crohn’s disease in 
Table 38 (for RCTs) and Figure 12 (for observational studies). 
 
Table 38. Summary of reported mortality results in randomized controlled trials comparing 
prednisone alone or in combination with placebo or another treatment in patients with Crohn’s 
disease 
Author, 
Year 
Followup 
(Weeks) Corticosteroid Comparison 
# of 
Deaths 
in 
Steroid 
Group 
# of 
Patients 
in 
Steroid 
Group 
# of Deaths 
in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Summers, 
197956 
104 Prednisone Placebo 0 146 0 178 
Malchow, 
198464 
104 Prednisone Placebo 3 113 0 110 
Summers, 
197956 
104 Prednisone Sulfasalazine 0 146 0 132 
Malchow, 
198464 
104 Prednisone Sulfasalazine 3 113 0 117 
Malchow, 
198464 
104 Prednisone + 
sulfasalazine 
Placebo 1 112 0 110 
Malchow, 
198464 
104 Prednisone + 
sulfasalazine 
Sulfasalazine 1 112 0 117 
Malchow, 
198464 
104 Prednisone + 
sulfasalazine 
Prednisone 1 112 3 113 
Steroid = corticosteroid. 
Note: One trial did not report on mortality.74 
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Figure 12. Summary of Peto odds ratios of mortality among observational studies comparing a corticosteroid alone or in combination 
with another treatment in patients with Crohn’s disease 
 
CI = confidence interval; Comp = comparison; NR = not reported; OR = odds ratio; PRED = prednisone; Pro = prospective cohort; Retro = retrospective cohort; STEROID = 
corticosteroid 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Adjusted OR, 2.1 (95% CI, 1.1 to 3.8) 
‡Adjusted OR, 1.0 (95% CI, 0.7 to 1.4) 
§Adjusted hazards ratio, 2.5 (95% CI, 1.9 to 3.3); the total number of mortality events for all treatment groups combined is 264 out of 5537 patients. The studies did not report the 
number of events by treatment group. 
║Inflammatory bowel disease population 
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Corticosteroids Versus Placebo 
Two RCTs including 547 patients compared corticosteroids with placebo and reported on 
mortality.56,64 A 2-year RCT compared prednisone with placebo and reported no deaths due to 
Crohn’s disease during the study period.56 An RCT that included a 6-week corticosteroid taper 
for patients with active disease and a 2-year maintenance phase for inactive disease reported 
three deaths in the prednisolone group during the 2-year period.64 An additional prednisolone 
patient died after the study period.  
Corticosteroids Versus No Corticosteroids 
Three observational studies including 15,070 Crohn’s disease patients compared 
corticosteroids with no corticosteroids and reported mortality.131,134,151 One prospective study of 
6,290 Crohn’s disease patients compared mortality rates among patients who used prednisone 
during the study period versus those who did not.131 After adjusting for demographics, disease 
characteristics, and use of other Crohn’s disease medications and narcotic analgesics, patients 
who used prednisone had a 2-fold increased odds of mortality compared with those who did not 
use prednisone during the study period (OR, 2.1; 95% CI, 1.1 to 3.8).  
A retrospective study that observed 3,241 Crohn’s disease patients for a median of 7 years 
reported no difference in mortality between those who used steroids during the study period and 
those who did not (age, sex, and smoking adjusted OR, 1.0; 95% CI, 0.7 to 1.4).151 A 
retrospective study that observed Crohn’s disease patients for a mean of 4 years compared those 
who used corticosteroids currently, recently, or never during the study period. The HR was 2.5 
(95% CI, 1.9 to 3.3) comparing current (within 91 days) corticosteroid use versus no use (no 
recorded use or use more than 182 days prior to death), after adjusting for age, sex, comorbidity, 
and time from registration.134 The adjusted HR comparing recent use (92 to 182 days prior to 
death) with no use (no recorded use or use more than 182 days prior to death) was 1.2 (95% CI, 
0.6 to 2.4).134 The retrospective studies did not adjust for use of other Crohn’s disease 
medications or disease characteristics. 
Corticosteroids Versus Aminosalicylates 
Two RCTs including 508 Crohn’s disease patients compared corticosteroids with 
sulfasalazine and reported on mortality.56,64 One RCT compared prednisone with sulfasalazine 
and reported no deaths due to Crohn’s disease during the study period.56 The other RCT reported 
three deaths in the prednisolone group during the study period and an additional death after the 
study period in both the prednisolone and sulfasalazine groups.64 
Combination of Corticosteroids and Aminosalicylates Versus Other 
Treatment 
One RCT of 452 Crohn’s disease patients compared a combination of prednisolone and 
sulfasalazine with placebo, prednisolone, or sulfasalazine and reported on mortality. During the 
study period, there were three deaths on prednisolone, one death on prednisolone and 
sulfasalazine, and no deaths on sulfasalazine or placebo. After the study period, the trial reported 
an additional death in each group except the placebo group.64 
Aminosalicylates 
We summarized the effects of aminosalicylates on mortality in Table 39. 
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Table 39. Summary of reported mortality results in randomized controlled trials and observational studies comparing an aminosalicylate 
alone or in combination with placebo or another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) 
Study 
Design ASA Comparison 
# of 
Deaths 
in ASA 
Group 
# of 
Patients 
in ASA 
Group 
# of Deaths 
in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
OR* (95% 
CI) 
Lennard-
Jones, 
1977166 
52 RCT Sulfasalazine Placebo 0 6 0 2 NA 
Summers, 
197956 
104 RCT Sulfasalazine Placebo 0 132 0 178 NA 
Malchow, 
198464 
104 RCT Sulfasalazine Placebo 0 117 0 110 NA 
Modigliani, 
1996119 
48 RCT Mesalamine Placebo 0 65 1 64 NA 
Hutfless, 
2007151 
364 Retrospective 
cohort 
ASA No ASA 175 2566 56 675 0.8 (0.6 to 
1.1) † 
ASA = aminosalicylates; CI = confidence interval; NA = not applicable; OR = odds ratio; RCT = randomized controlled trial 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Adjusted OR, 0.7 (95% CI, 0.5 to 1.1) 
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Aminosalicylates Versus Placebo 
Four RCTs including 674 patients compared aminosalicylates with placebo and reported on 
mortality.56,64,119,166 One RCT treated 150 patients with prednisolone for 3 to 7 weeks. Those 
patients who entered clinical remission were then randomized to receive either mesalamine or 
placebo until weaned from prednisolone. The trial included an additional year of followup.119 
One of 37 placebo patients died in the year after prednisolone discontinuation.  
Three RCTs compared sulfasalazine with placebo. The first included eight patients who had 
not undergone intestinal resection within the preceding 6 months.166 No patients died. The 
second reported no deaths due to Crohn’s disease during the study period.56 The third reported no 
deaths during the study period. However, one sulfasalazine patient died after the study period.64 
Aminosalicylates Versus No Aminosalicylates 
One retrospective study of 3,241 Crohn’s disease patients reported 1 percent fewer deaths in 
the aminosalicylates-treated group compared with those who did not fill a prescription for 
aminosalicylates during the study period (age, sex, and smoking adjusted OR, 0.7; 95% CI, 0.5 
to 1.1).151 
Studies Evaluating Patients With IBD 
Five studies reported on mortality in the treatment of IBD. The studies did not separate 
Crohn’s disease from ulcerative colitis or indeterminate colitis. In general, the results were 
consistent between the studies. We provided details about those studies in Appendix F.  
Studies Reporting Results for Crohn’s Disease and IBD 
One study (using administrative data) looked at the relationship between medications and 
mortality and did not find meaningful difference between Crohn’s disease and IBD.151 The 
mortality ORs (adjusting for age, sex, and smoking) were similar in Crohn’s disease and IBD for 
patients who used corticosteroid during the study period versus patients who did not (Crohn’s 
disease OR, 1.0; IBD OR, 0.9); the same was true for aminosalicylate versus no aminosalicylate 
(Crohn’s disease OR, 0.7; IBD OR, 0.8). The OR for mortality was greater than 1 for Crohn’s 
disease patients who used immunomodulators during the study period versus those who did not, 
(OR, 1.3; 95% CI, 0.9 to 1.9) and less than 1 for IBD patients who used immunomodulators 
versus those who did not (OR, 0.9; 95% CI, 0.7 to 1.2), although neither finding was statistically 
significant. The study did not adjust ORs for use of the other medications that the study 
examined.  
A collection of referral centers reported on mortality for patients with Crohn’s disease or 
ulcerative colitis.150 In both the Crohn’s disease and ulcerative colitis groups, there were more 
deaths in the patients treated with adalimumab or infliximab compared with those who never 
received a biologic.  
Progressive Multifocal Leukoencephalopathy  
We identified one case of Progressive Multifocal Leukoencephalopathy (PML) associated 
with treatment of Crohn’s disease.167 A 60-year-old man with a 28-year history of Crohn’s 
disease was experiencing confusion and disorientation on July 2003. The patient expired three 
months later from PML. Subsequent immunohistochemical analysis of the brain tissue 
demonstrated positive staining for polyomavirus John Cunningham genotype 2, confirming the 
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diagnosis of PML. The patient had received 5 doses of natalizumab over a 16-month interval. 
The last natalizumab dose was in May or June 2003, within 2 months of symptom presentation. 
The patient had also previously received infliximab starting in September 1998 (prior to 
European approval of infliximab in August 1999). The patient received the last infliximab 
infusion in September 2001, 20 months prior to the PML diagnosis. The patient had also used 
corticosteroids, antibiotics, and azathioprine (discontinued 8 months prior to suspected PML due 
to refractory anemia with low platelet counts and lymphopenia). The authors of the study linked 
the timing of the PML diagnosis to the use of natalizumab because John Cunningham virus 
appeared in serum samples (available from the IBD center’s serum bank from March 1999) only 
after this patient received natalizumab. A randomized trial reported on this case during the period 
when the patient first received natalizumab.33 And an observational study reported the safety of 
infliximab at the study center.153 A search of the Adverse Events Reporting System did not 
identify additional cases. 
Lymphoma 
Thirteen RCTs including 4,956 Crohn’s disease patients reported on lymphoma risk by 
comparison group (Appendix D, Evidence Table 14). Three prospective studies (n=20,219), 12 
retrospective studies (n=32,056), and one case-control study (n=15,471) reported lymphoma as 
an outcome. Lymphoproliferative disorders (including lymphoma) were a primary interest of 
outcome in one prospective study.130 No trials of immunomodulators, corticosteroids, or 
aminosalicylates reported on lymphoma risk. The total number of patients in the RCTs was 
71,554.  
Biologics 
We summarized the risk of lymphoma associated with use of biologics in Crohn’s disease in 
Table 40 (for RCTs) and Figure 13 (for observational studies). We also provided additional 
details regarding related studies. 
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Table 40. Summary of lymphoma risk in randomized controlled trials comparing a biologic alone 
or in combination with placebo or another treatment in patients with Crohn’s disease* 
Author, 
Year 
Followup 
(Weeks) Biologic Comparison 
# of 
Lymphoma 
Cases in 
Biologic 
Group 
# of 
Patients 
in 
Biologic 
Group 
# of 
Lymphoma 
Cases in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Rutgeerts, 
199985 
36 Infliximab Placebo 0 37 1 36 
Hanauer, 
200286 
52 Infliximab Placebo 0 385 1 188 
Schreiber, 
200540 
20 Certolizumab 
pegol 
Placebo 0 218 0 73 
Schreiber, 
200784 
18 Certolizumab 
pegol 
Placebo 0 216 0 212 
Sandborn, 
200739 
26 Certolizumab 
pegol 
Placebo 0 331 1 329 
Sandborn, 
200738 
4 Adalimumab Placebo 0 159 0 166 
Hanauer, 
200637 
4 Adalimumab Placebo 0 225 0 74 
Sandborn, 
200783 
52 Adalimumab Placebo 0 37 0 18 
Sandborn, 
200533 
48 Natalizumab Placebo 0 723 0 181 
Targan, 
200732 
8 Natalizumab Placebo 0 260 0 250 
Sands, 
200735 
20 Natalizumab 
+ infliximab 
Infliximab 0 52 0 27 
*Three RCTs compared a biologic with placebo or another medication and did not report on lymphomas.42 45 89 
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Figure 13. Summary of Peto odds ratios of lymphoma among observational studies comparing a biologic alone or in combination with 
another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; ASA = aminosalicylates; BIO = biologics; Bude = budesonide; CI = confidence interval; Comp = comparison; CP = certolizumab pegol; IFX = infliximab; 
IMM = immunomodulator; Main = main intervention; NR = not reported; OR = odds ratio; Retro = retrospective cohort; STEROID = corticosteroids; THIO = thiopurine; TNF = 
tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Inflammatory bowel disease population 
‡Incidence rate ratio, 1.7 events per person-year (95% CI, 0.2 to 6.3) 
§Incidence rate ratio, 0 events per person-year (95% CI, 0 to 6.5) 
║Incidence rate ratio, 1.5 events per person-year (95% CI, 0.04 to 8.7) 
¶ Incidence rate ratio, 0 events per person-year (95% CI, 0 to 30.0) 
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Adalimumab Versus Placebo 
Three RCTs including 679 patients compared adalimumab with placebo and reported no 
cases of lymphoma.37,38,83 
Other Combinations With Adalimumab 
One prospective (n=673)161 and one retrospective (n=118)140 study reported no cases of 
lymphoma in patients who used adalimumab alone or in combination with aminosalicylates, 
corticosteroids, or immunomodulators. 
Certolizumab Pegol Versus Placebo 
Three RCTs including 1,379 patients compared certolizumab pegol with placebo and 
reported on lymphoma risk.39,40,84 One trial reported one lymphoma case in a placebo group (less 
than 1 percent).39 The other two RCTs reported no cases of lymphoma.40 84 
Other Combinations With Certolizumab Pegol 
One prospective study (n=60) reported no deaths in patients who used certolizumab pegol 
alone or in combination with aminosalicylates, corticosteroids, or immunomodulators.132  
Infliximab Versus Placebo 
Two RCTs including 646 patients compared infliximab with placebo and reported on 
lymphoma risk.85,86 One study randomized infliximab responders and non-responders after a 
single infusion of infliximab or placebo.86 The other study85 compared retreatment with 
infliximab with placebo among responders to a single infusion from a previous RCT.43 The two 
trials reported no lymphoma cases in the infliximab groups (0 percent of 385 and 37 patients, 
respectively). However, in the placebo groups, one trial reported one lymphoma among 188 
patients (less than 1 percent),86 and the other study saw one lymphoma in 36 patients (4 
percent).85 The retreatment RCT reported that one lymphoma patient received infliximab in the 
induction period and later died from sepsis, although the induction study did report lymphoma or 
death.43 
Natalizumab Versus Placebo 
Three RCTs (published in two articles) included 1,414 patients and reported no cases of 
lymphoma in any natalizumab or control group during the study periods.32,33 One trial reported 
lymphoma after the study in a patient who had received natalizumab induction, placebo 
maintenance, and natalizumab during the open-label extension period.32 
Combination of Natalizumab and Infliximab Versus Infliximab 
One 20-week RCT including 79 infliximab non-responders randomized patients to additional 
treatments with natalizumab or placebo.35 The trial followed patients for up to 6 months. It 
reported no lymphoma cases. 
TNF-Alpha Inhibitor Versus No TNF-Alpha Inhibitor 
Two retrospective studies including 9,389 Crohn’s disease patients compared a TNF-alpha 
inhibitor with no TNF-alpha inhibitor and reported on lymphoma risk.149,153,168 
One study reported no lymphoma cases among 404 Crohn’s disease patients with a record of 
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infliximab in their charts, compared with one case of lymphoma among 404 Crohn’s disease 
patients who did not have a record of infliximab in their charts. The study matched both sets of 
patients with respect to age, sex, followup, immunomodulator use, Crohn’s disease location and 
duration, and study center.149 Because the non-Hodgkin’s lymphoma patient did not use 
infliximab, the patient did not meet the inclusion criteria for another infliximab study at the 
center.128  
A claims-based study of health plan members included 8,581 patients with one or more 
encounter with Crohn’s disease. The study reported two lymphoma cases in TNF-alpha inhibitor 
users (1 per 100 person-years) and 64 lymphoma cases in patients who received no TNF-alpha 
inhibitor, immunomodulator, or corticosteroid (less than one per 100 person-years).168 Although 
the authors did not report a rate ratio; the unadjusted rate ratio comparing TNF-alpha inhibitor 
use with no therapy (based on the provided information) was 1.7 (95% CI, 0.2 to 6.3).168 
Combination of TNF-Alpha Inhibitors, Immunomodulators, and 
Corticosteroids Versus No Therapy 
The same claims-based study reported no lymphoma cases among 31 person-years of 
exposure to combination therapy with TNF-alpha inhibitors, immunomodulators, and 
corticosteroids, compared with 64 cases among 15,673 person-years of no therapy.168 
Combination of TNF-Alpha Inhibitors and Immunomodulators Versus No 
Therapy 
The same claims-based study reported one lymphoma case among 162 person-years of 
exposure to combination therapy with TNF-alpha inhibitors and immunomodulators (with or 
without corticosteroids), compared with 64 cases among 15,673 person-years of no therapy (less 
than one per 100 person-years in both groups).168 The corresponding unadjusted rate ratio was 
1.5 (95% CI, 0 to 8.7). 
Combination of TNF-Alpha Inhibitor and Corticosteroids Versus No Therapy 
The same claims-based study reported no lymphoma cases among 142 person-years of 
exposure to combination therapy with TNF-alpha inhibitor and corticosteroids (with or without 
immunomodulators), compared with 64 cases among 15,673 person-years of no therapy.168 
Other Combinations With Infliximab 
Three retrospective cohorts including 954 patients described the safety profile of infliximab 
use at their study centers.137,145,164 As described in the mortality section, it is unclear if we have 
accurately classified patients by medication exposures. When these studies categorize patients 
who had received infliximab and immunomodulators at the time of lymphoma diagnosis as users 
of infliximab with immunomodulators at infliximab initiation, the three studies report four 
lymphomas. One of the studies reported four lymphomas among the 25 patients receiving 
infliximab in combination with immunomodulators and corticosteroids.164 The study reported no 
other lymphomas for the other treatment combinations (combination of infliximab, 
immunomodulators, and corticosteroids, combination of infliximab and corticosteroids, or 
infliximab alone). 
Immunomodulators 
Figure 14 summarizes the risk of lymphoma in observational studies evaluating 
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immunomodulators in patients with Crohn’s disease.  
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Figure 14. Summary of Peto odds ratios of lymphoma among observational studies comparing an immunomodulator alone or in 
combination with another treatment in patients with Crohn’s disease 
 
ASA = aminosalicylates; AZA = azathioprine; CaCo = case-control study; CI = confidence interval; Comp = comparison; IMM = immunomodulator; NR = not reported; OR = 
odds ratio; Pro = prospective cohort; Retro = retrospective cohort; STEROID = corticosteroids; THIO = thiopurine; TNF = tumor necrosis factor-alpha inhibitors 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Inflammatory bowel disease population 
‡Incidence rate ratio, 0.8 events per person-year (95% CI, 0.2 to 2.5) 
§Incidence rate ratio, 0 events per person-year (95% CI, 0 to 48.9) 
║Adjusted OR, 3.2 (95% CI, 1.0 to 10.2) 
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Immunomodulators Versus No Immunomodulators 
Two retrospective studies including 15,186 Crohn’s disease patients reported lymphoma risk 
from immunomodulator use.136,168 A claims-based study including 8,581 Crohn’s disease patients 
reported less than one lymphoma case per 100 person-years in both the no therapy group and the 
immunomodulator group (with or without corticosteroids or TNF-alpha inhibitors) (unadjusted 
relative rate, 0.8; 95% CI, 0.2 to 2.5).168 In one study comparing at least one prescription for a 
thiopurine with no thiopurine prescription, none of the 837 thiopurine users developed 
lymphoma, compared with seven of 5,768 non-users (less than 1 percent). The corresponding 
Peto OR was 0.3 (95% CI, 0 to 2.9).136 
Combination of Immunomodulators and Corticosteroids Versus No Therapy 
A claims-based study reported no lymphoma cases among patients receiving a combination 
of immunomodulators and corticosteroids (with or without TNF-alpha inhibitors), compared 
with less than one lymphoma per 100 person-years among patients receiving no therapy.168 
Combination of Azathioprine and Aminosalicylates Versus Azathioprine 
One retrospective study of 104 Crohn’s disease patients reported a case of Waldenstrom’s 
macroglobulinemia in the azathioprine and aminosalicylate group, compared with no lymphoma 
in the azathioprine-alone group.146 
Corticosteroids 
No trials that included corticosteroids reported on lymphoma. Table 41 summarizes the risk 
of lymphoma in observational studies evaluating corticosteroids in patients with Crohn’s disease. 
We also provided additional details regarding related studies. 
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Table 41. Summary of risk of lymphoma in observational studies comparing a corticosteroid alone or in combination with placebo or 
another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) 
Study 
Design Corticosteroid Comparison 
# of 
Lymphoma 
Cases in 
Steroid 
Group 
# of 
Patients 
in 
Steroid 
Group 
# of 
Lymphoma 
Cases in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
Relative 
Measure 
(95% CI) 
Adjusted 
Relative 
Measure 
(95% CI) 
Lewis, 
2001136* 
208 Retrospective 
cohort 
Steroid No steroid 4 4064 11 11100 OR, 1.0 (0.3 
to 3.1) 
NR 
Marehbian, 
2009168 
104 Retrospective 
cohort 
Steroid No TNF or 
IMM or 
steroid 
NR† NR NR‡ NR IRR, 0 (0 to 
2.5) 
HR, 1.0 
(0.4 to 
2.4) 
CI = confidence interval; HR = hazards ratio; IMM = immunomodulator; IRR = incidence rate ratio; NR = not reported; OR = odds ratio; Steroid = corticosteroid; TNF = tumor 
necrosis factor-alpha inhibitor 
*Inflammatory bowel disease population 
†There were 0 events during 379 person-years. 
‡There were 64 events during 15,673 person-years. 
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Corticosteroids Versus No Therapy 
A claims-based study, that included 8,581 Crohn’s disease patients, reported no lymphoma 
cases among the corticosteroid users (with or without immunomodulators or TNF-alpha 
inhibitors), compared with the no therapy group.168 The study reported a HR of 1.0 (95% CI, 0.4 
to 2.4) comparing use of corticosteroids alone with no therapy, after adjustment for age, gender, 
geographic region, health plan, and comorbidity. 
Studies Evaluating Patients with IBD 
Seven studies reported on lymphoma risk in IBD patients without separating Crohn’s disease 
from ulcerative colitis or indeterminate colitis patients. In general, the results were consistent 
between the studies. See Appendix F for more information about these studies.  
Studies Reporting Results for Crohn’s Disease and IBD 
One retrospective study reported similar results for IBD patients as Crohn’s disease patients, 
one lymphoma (less than 1 percent) among 1,465 thiopurine users compared with 14 lymphomas 
(less than 1 percent) among 15,531 non-users.136 The incidence density ratio comparing 
thiopurine to no thiopurine use was 0.8 for IBD, compared with the Peto OR of 0.3 for Crohn’s 
disease. Neither was statistically significant. The study excluded a lymphoma case with 
diagnosis codes for both Crohn’s disease and ulcerative colitis, according to the exclusion 
criteria. The patient had also received a liver transplant 4 months before the lymphoma 
diagnosis. 
Hepatosplenic T-Cell Lymphoma 
The medical community first identified hepatosplenic T-cell lymphoma (HSTCL) as a 
diagnosis distinct from other T-cell lymphomas in 1996.169 HSTCL is a very rare type of 
lymphoma that is generally fatal.169 To assess the risk of HSTCL associated with treatment for 
Crohn’s disease, we supplemented the primary search strategy by searching for case reports or 
case series published in the literature, or cases reported to the Food and Drug Administration’s 
(FDA) Adverse Event Reporting System (AERS). A search of the publicly available AERS data 
files through March 2011 yielded 132 patient identification numbers representing 48 unique 
FDA-ascribed case numbers. From the literature and AERS search results, we considered 37 
HSTCL cases unique based on age, sex, medications, country of origin, and length of survival. 
We considered two cases duplicative. We considered the remaining nine cases possibly unique. 
The case studies reported two of the 37 unique cases survived and none of the nine possibly 
unique cases survived (4 percent of 46 cases). 
Tables 42 and 43 summarize the demographic and medication characteristics of the unique 
and possibly unique cases of HSTCL in patients with Crohn’s disease. Of the 37 unique cases 
with Crohn’s disease-associated HSTCL, most were young (86 percent younger than 40 years of 
age) and male (86 percent). Most cases (70 percent) had reported exposure to both a TNF-alpha 
inhibitor and thiopurines. Almost all cases (95 percent) had reported exposure to thiopurines 
compared with 75 percent who had exposure to at least one TNF-alpha inhibitor. Two cases (4 
percent) reported exposure to a TNF-alpha inhibitor without thiopurines.  
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Table 42. Demographic and survival characteristics of patients with Crohn’s disease who 
developed hepatosplenic T-cell lymphoma 
Patient Characteristic Unique Cases (n=37) 
Possibly Unique Additional 
Cases (n=9)  
Age at HSTCL diagnosis (in years) N=36*  N=0  
Mean  30 -- 
Median  26 -- 
Range 12 to 79 -- 
Crohn’s disease duration (in years) N=16  N=0 
Mean 10 -- 
Median 6 -- 
Range 4 to 35 -- 
Sex, number of cases (%) N=36  N=6 
Female 5 (14%) 1 (17%) 
Survival, number of cases (%) N=37 N=9 
Died 24 (65%) 4 (44%) 
Survived  2 (5%) 0 (0%) 
Outcome unclear or not reported 11 (30%) 5 (56%) 
HSTCL = hepatosplenic T-cell lymphoma 
*Number with report of characteristic. Mean and percentages based on this denominator. 
 
Table 43. Medications used prior to diagnosis of hepatosplenic T-cell lymphoma in 37 unique 
patients with Crohn’s disease 
Medication 
Number of Cases 
With Exposure (%) 
Mean Cumulative 
Dose in Mg* 
(Range) 
Mean Duration of 
Drug Use in Years 
(Range) 
Mean Number of 
Injections or 
Infusions (Range) 
Biologics 28 (76%) -- -- -- 
Adalimumab 8 (22%) 920 (800-1040) 1.5 (120 days-2.6 
years) 
11.5 (10-13) 
Infliximab 27 (73%) 41 (10-120) mg/kg 1.8 (1 day-6 years) 9 (1-24) 
Natalizumab 1 (3%) NR NR 3 (n=1 ) 
Certolizumab pegol 0 NR NR NR 
Thiopurines 35 (95%) -- -- -- 
6-mercaptopurine 19 (51%) 55,290 (3900-
93530) 
4.5 (39 days-8 
years) 
NA 
Azathioprine 23 (62%) 151,288 (1450-
301,125) 
5.8 (39 days-13.5 
years) 
NA 
Aminosalicylates 15 (41%) -- -- -- 
Balsalazide 1 (3%) NR NR NA 
Mesalamine 13 (35%) NR 5 (n=1) NA 
Salazopyrine 2 (5%) NR 10 (n=1) NA 
Corticosteroids 21 (57%) -- -- -- 
Budesonide 2 (5%) NR NR NA 
Hydrocortisone 1 (3%) NR NR NA 
Prednisone 14 (38%) NR NR NA 
Prednisolone 4 (11%) NR 13 (n=1) NA 
Corticosteroid, 
unspecified 
6 (16%) NR 10 (n=1) NA 
Antibiotics† 7 (19%) NR NR NA 
Cyclosporine 1 (3%) NR NR NA 
kg = kilograms; mg = milligrams; NA = not applicable; NR = not reported 
*Reported as mg/kg for infliximab only 
†The antibiotics used include ciprofloxacin, doxycycline, metronidazole, nitrofurantoin, and piperacillin/tazobactam.  
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Cervical Cancer 
One trial (n=660) reported on cervical cancer risk associated with medications for treatment 
of Crohn’s disease. No trials of infliximab, adalimumab, natalizumab, immunomodulators, 
corticosteroids, or aminosalicylates reported on cervical cancer.  
Certolizumab Pegol Versus Placebo 
One RCT reported one carcinoma in situ of the cervix (grade 0) in a placebo patient (less 
than 1 percent of 197 females) and no cervical cancer in the 174 female certolizumab pegol 
patients during followup.39 
Studies Evaluating Patients With Inflammatory Bowel Disease 
Four observational studies reported on cervical cancer risk in IBD patients without separating 
Crohn’s disease from ulcerative colitis or indeterminate colitis patients. We provided a summary 
of these studies in Appendix F. 
Studies Reporting Results for Crohn’s Disease and Inflammatory 
Bowel Disease 
We did not identify any studies that reported on the comparative safety, in terms of cervical 
cancer, for patients with Crohn’s disease and IBD. 
Other Cancers 
Twenty-one RCTs including 7,149 Crohn’s disease patients reported on other cancers by 
comparison group (Appendix D, Evidence Table 14). No methotrexate trial reported on cancer. 
One prospective (n=19,486), 12 retrospective (n=15,015), and one observational study of unclear 
study design (n=573)128 reported cancer as an outcome by comparison group.  
Biologics 
We summarized the risk of other cancers associated with treatment of Crohn’s disease in 
Table 44 (for RCTs) and Figure 15 (for observational studies). We also provided additional 
details regarding related studies. 
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Table 44. Summary of the risk of other cancers in randomized controlled trials comparing a biologic alone or in combination with 
placebo or another treatment in patients with Crohn’s disease* 
Author, Year 
Followup 
(Weeks) Biologic Comparison 
# of Cancer 
Cases in 
Biologic 
Group 
# of 
Patients in 
Biologic 
Group 
# of Cancer 
Events in 
Comparison 
Group 
# of Patients in 
Comparison 
Group 
Sands, 200487 40 Infliximab Placebo 0 139 0 143 
Hanauer, 200286 52 Infliximab Placebo 4 385 2 188 
Sandborn, 201142  6 Certolizumab pegol Placebo 1 223 0 215 
Schreiber, 200784 18 Certolizumab pegol Placebo 0 216 0 212 
Sandborn, 200739 26 Certolizumab pegol Placebo 2 331 2 329 
Schreiber, 200540 12 Certolizumab pegol Placebo 0 219 0 73 
Sandborn, 200738 4 Adalimumab Placebo 0 159 0 166 
Sandborn, 200783 52 Adalimumab Placebo 0 37 1 18 
Colombel, 200782 52 Adalimumab Placebo 0 517 1 261 
Targan, 200732 12 Natalizumab Placebo 1 260 0 250 
Sandborn, 200533 48 Natalizumab Placebo 1 723 7 181 
Colombel, 201045 54 Infliximab Azathioprine 0 163 2 161 
Lemann, 200646 24 Infliximab + thiopurine Thiopurine 0 57 0 56 
Colombel, 201045 54 Infliximab + azathioprine Infliximab 0 179 0 163 
Colombel, 201045 54 Infliximab + azathioprine Azathioprine 0 179 2 161 
Van Assche, 
200889 
104 Infliximab + 
immunomodulator 
Infliximab 0 40 2 40 
Schroder, 200647 48 Infliximab + 
methotrexate 
Infliximab 0 11 0 8 
Sands, 200735 20 Natalizumab + infliximab Infliximab 0 52 0 27 
*Seven randomized controlled trials evaluating biologics did not report on any cancer outcomes.34,41,43,44,48,81,88 
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Figure 15. Summary of Peto odds ratios of cancer risk among observational studies comparing a biologic alone or in combination with 
another treatment in patients with Crohn’s disease 
 
BIO = biologics; CI = confidence interval; Comp = comparison; IFX = infliximab; IMM = immunomodulator; NR = not reported; OR = odds ratio; Pro = prospective cohort; Retro 
= retrospective cohort; STEROID = corticosteroids; THIO = thiopurine; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Incidence rate ratio, 0.1 events per person-year (95% CI, 0.01 to 0.2) 
‡Incidence rate ratio, 0.9 events per person-year (95% CI, 0.6 to 1.4) 
§Incidence rate ratio, 0.7 events per person-year (95% CI, 0.1 to 2.1) 
║Incidence rate ratio, 0.6 events per person-year (95% CI, 0.3 to 1.0) 
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Adalimumab Versus Placebo 
Three RCTs including 1,158 Crohn’s disease patients compared adalimumab with placebo 
and reported on cancer.37,38,82 A 4-week induction trial, including 325 patients randomized to 
adalimumab or placebo among patients who had lost response or were intolerant to infliximab, 
reported no cancers during the study period.38 A 52-week maintenance trial reported one cancer 
case in 261 placebo patients (less than 1 percent) and no cancer cases in 517 adalimumab 
patients.82 A 52-week maintenance trial of 276 responders to induction in a previous trial37 
reported one cancer in 18 placebo patients, compared with no cancers in the 37 adalimumab 
patients who remained on randomized treatment during the entire study period.83 
Other Combinations With Adalimumab  
Two prospective (n=717)159,161 and one retrospective (n=118)140 study reported no deaths in 
patients who used adalimumab alone or in combination with aminosalicylates, corticosteroids, or 
immunomodulators. 
Certolizumab Pegol Versus Placebo 
Four RCTs including 1,818 Crohn’s disease patients compared certolizumab pegol with 
placebo and reported on cancer.39,40,42,84 A 6-week induction trial reported one cancer (less than 1 
percent) in the certolizumab pegol patients and no cancers in placebo.42 A 12-week induction 
trial (followed an additional 8 weeks for safety) reported no cancers in the 292 included 
patients.40 A 26-week induction trial reported two cancers in placebo patients (1 percent of 329) 
and two cancers in certolizumab pegol patients (1 percent of 331) during the study period.39 An 
18-week maintenance trial reported no cancers during the study period.84 The trial reported one 
benign, malignant, or unspecified neoplasm (including cyst or polyp) during the 8-week 
induction phase which included 668 patients, but the trial did not provide specifics of the event.84 
Other Combinations With Certolizumab Pegol 
One prospective study (n=60) reported no deaths in patients who used certolizumab pegol 
alone or in combination with aminosalicylates, corticosteroids, or immunomodulators.132  
Infliximab Versus Placebo 
Two trials including 855 Crohn’s disease patients reported on cancer risk.86 87 A maintenance 
trial reported one case of cancer in the 10 mg/kg intravenous every 8 weeks infliximab group, 
three cases in the 5 mg/kg intravenous every 8 weeks infliximab group, and two cases in the 
placebo group over 52 weeks of followup.86 A maintenance trial of fistulizing Crohn’s disease 
reported no cancers during the 40-week trial period.87 Two cancers occurred after the trial ended. 
Both patients had received infliximab. 
Infliximab Versus No Infliximab 
One retrospective study including 808 Crohn’s disease patients reported on cancer, 
comparing infliximab use with no use.149 The study reported nine cancers among 404 infliximab 
users followed for 48 months, compared with seven cancers among 404 no infliximab users 
followed for 60 months (2 percent in both groups). The study matched the two groups by factors 
including age, sex, followup, immunomodulator use, Crohn’s disease site, Crohn’s disease 
duration, and study center.149 The OR was 1.3 (95% CI, 0.5 to 3.8) comparing infliximab users 
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with infliximab non-users accounting for the matching factors.149 Another study reporting results 
from the same infliximab patients,128 compared a combination of infliximab and 
immunomodulators with infliximab alone and reported one additional case of cancer among 
infliximab users. 
Infliximab Versus Immunomodulators 
One induction trial of 324 Crohn’s disease patients, naïve to TNF-alpha inhibitors and 
immunomodulators, compared infliximab with azathioprine and reported mortality.45 The trial 
did not report any cancers in the 163 infliximab patients, and reported two cancers in the 161 
azathioprine patients during the 50-week study period. 
Combination of Infliximab and Immunomodulators Versus Infliximab 
Three RCTs45,47,89 and two observational studies128,129 reporting on cancer risk (1,135 
Crohn’s disease patients total) compared a combination of infliximab and immunomodulators 
versus infliximab alone. The RCTs included 441 patients. One induction trial of 342 patients, 
naïve to TNF-alpha inhibitors and immunomodulators, reported no cancers during the 50-week 
study period in the combination infliximab and azathioprine, and infliximab alone groups.45 An 
open-label trial of 19 azathioprine intolerant or resistant patients compared a combination of 
infliximab and methotrexate with infliximab alone, and reported no malignancies during the 48-
week study period.47 An 104-week open-label RCT of 80 non-fistulizing Crohn’s disease 
patients, retreated with infliximab while continuing or discontinuing immunomodulators, 
reported two cancers in the infliximab group and no cancers in the combination infliximab and 
immunomodulators group.89 
In the observational studies, one retrospective study of 573 Crohn’s disease patients, 
followed for 12 weeks or 6 months, reported five cancers among 211 combination infliximab and 
immunomodulator patients and three cancers in 362 patients using infliximab without 
immunomodulators.128 The corresponding Peto OR was 2.9 (95% CI, 0.6 to 18.9). The other 
study reported no cancers.129 
Combination of Infliximab and Immunomodulators Versus 
Immunomodulators 
Two RCTs including 453 Crohn’s disease patients compared a combination of infliximab and 
immunomodulators with immunomodulators alone and reported on cancer.45 46 One induction 
trial of Crohn’s disease patients naïve to TNF-alpha inhibitors and immunomodulators reported 
no cancers in the 179 patients taking infliximab and azathioprine and two cancers in the 161 
patients taking azathioprine during the 50-week study period.45 A 52-week induction trial of 113 
steroid-dependent Crohn’s disease patients with luminal disease reported no cancers during the 
study period, comparing combination infliximab and thiopurines with thiopurines alone.46 
Other Combinations With Infliximab 
Four retrospective trials including 1,069 Crohn’s disease patients studied the safety profile of 
infliximab use at their centers.137,145,147,164 The trials met the inclusion criteria but may have 
misclassified the cancer cases’ concomitant medications. We described this in detail in the 
mortality section. The trials reported one cancer in patients receiving a triple combination of 
infliximab, immunomodulators, and corticosteroids, or a combination of infliximab and 
corticosteroids. One trial reported cancers in three of 51 patients (6 percent) taking infliximab 
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and an immunomodulator and one of 19 patients (5 percent) taking infliximab.145 One study 
reported one cancer among 30 patients who used adalimumab after infliximab, compared with 
four cancers among 127 who did not subsequently use adalimumab.145 The other three studies 
reported eight cancers in patients taking infliximab and an immunomodulator, one cancer in 
patients taking infliximab with corticosteroids, and five cancers in patients not receiving 
concomitant medications.137,147,164 
Natalizumab Versus Placebo 
Three RCTs including 1,414 Crohn’s disease patients reported on cancer risk comparing 
natalizumab with placebo (reported in two publications).32 33 A 12-week induction trial reported 
one basal cell carcinoma in the natalizumab group (1 out of 260) and no cancers in the 250 
placebo patients.32 A 12-week induction trial, followed by randomization of the responders to a 
48-week maintenance trial, reported no cancers during the induction trial.33 In the maintenance 
trial, one natalizumab patient (out of 214) and one placebo patient (out of 214) developed 
cancer.33  
Combination of Natalizumab With Infliximab Versus Infliximab 
One RCT including 79 Crohn’s disease patients compared a combination of natalizumab and 
infliximab with infliximab alone and reported on cancer. The 20-week trial reported that no 
cancers occurred.35 
TNF-Alpha Inhibitors Versus No Therapy 
A claims-based study, that included 8,581 Crohn’s disease patients, reported two solid tumor 
cancer cases among 92 person-years of exposure to TNF-alpha inhibitors (with or without 
immunomodulators or corticosteroids), compared with 2,115 cases among 15,673 person-years 
of no therapy.168 The study reported an adjusted HR of 1.0 (95% CI, 0.7 to 1.3) for TNF-alpha 
inhibitors (with or without immunomodulators or corticosteroids) compared with no therapy, and 
an adjusted HR of 1.0 (95% CI, 0.8 to 1.3) for TNF-alpha inhibitors compared with no therapy 
(HRs adjusted for age, gender, geographic region, health plan, and comorbidity). An unadjusted 
rate ratio of 0.2 (95% CI, 0 to 0.6) favored TNF-alpha inhibitors (with or without 
immunomodulators or corticosteroids) over no therapy using the cancer cases and person-time 
provided. 
TNF-Alpha Inhibitors Versus Never User of Biologic 
A collection of referral centers reported 3 percent of adalimumab or infliximab patients and 3 
percent of patients who never used biologics developed cancer over 104 weeks of followup.150 
Combination of TNF-Alpha Inhibitors, Immunomodulators, and 
Corticosteroids Versus No Therapy 
A claims-based study that included 8,581 Crohn’s disease patients reported three cancer 
cases among 31 person-years of exposure to TNF-alpha inhibitors with immunomodulators and 
corticosteroids, compared with 2,115 cases among 15,673 person-years of no therapy.168 The 
study reported an adjusted HR of 0.9 (95% CI, 0.3 to 2.4), comparing the 10 cancers per 100 
person-years in the combination TNF-alpha inhibitor, immunomodulators, and corticosteroids 
group with 13 cancers per 100 person-years in the no therapy group. These estimates are 
consistent with an unadjusted rate ratio of 0.7 (95% CI, 0.1 to 2.1). 
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Combination of TNF-Alpha Inhibitors and Immunomodulators Versus No 
Therapy 
The same claims-based study reported 20 cancer cases among 162 person-years of exposure 
to TNF-alpha inhibitor with immunomodulators (with or without corticosteroids), compared with 
2,115 cases among 15,673 person-years of no therapy.168 The study reported an adjusted HR of 
1.1 (95% CI, 0.7 to 1.8). The corresponding unadjusted rate ratio was 0.9 (95% CI, 0.6 to 1.4). 
Combination of TNF-Alpha Inhibitors and Corticosteroids Versus No 
Therapy 
The same claims-based study reported 11 cancer cases among 142 person-years of exposure 
to TNF-alpha inhibitors with corticosteroids (with or without immunomodulators), compared 
with 2,115 cases among 15,673 person-years of no therapy.168 The study reported an adjusted 
HR of 0.3 (95% CI, 0 to 2.3). The corresponding unadjusted rate ratio was 0.6 (95% CI, 0.3 to 
1.0). 
Immunomodulators 
We summarized the risk of other cancers associated with use of immunomodulators for 
Crohn’s disease in Table 45 (for RCTs) and Figure 16 (for observational studies). We also 
provided additional details regarding related studies. 
 
Table 45. Summary of the risk of other cancers in randomized controlled trials comparing an 
immunomodulator alone or in combination with placebo or another treatment in patients with 
Crohn’s disease* 
Author, 
Year 
Follow-
up 
(Weeks) IMM Comparison 
# of 
Cancer 
Cases in 
IMM 
Group 
# of 
Patients 
in IMM 
Group 
# of Cancer 
Cases in 
Comparison 
Group 
# of Patients 
in 
Comparison 
Group 
Summers, 
197956 
104 Azathioprine Placebo 0 113 0 178 
Summers, 
197956 
104 Azathioprine Prednisone 0 113 1 146 
Summers, 
197956 
104 Azathioprine Sulfasalazine 0 113 0 132 
IMM = immunomodulator 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
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Figure 16. Summary of Peto odds ratios of cancer among observational studies comparing an immunomodulator alone or in 
combination with another treatment in patients with Crohn’s disease 
 
ASA = aminosalicylates; AZA = azathioprine; CaCo = case-control study; CI = confidence interval; Comp = comparison; IMM = immunomodulator; NR = not reported; OR = 
odds ratio; Pro = prospective cohort; Retro = retrospective cohort; STEROID = corticosteroids; THIO = thiopurine; TNF = tumor necrosis factor-alpha inhibitors 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
† Adjusted OR, 2.1 (95% CI, 1.3 to 3.3) 
‡ Incidence rate ratio, 0.02 events per person-year (95% CI, 0.005 to 0.07) 
§ Incidence rate ratio, 0 events per person-year (95% CI, 0 to 1.4) 
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Azathioprine Versus Placebo 
One RCT including 291 Crohn’s disease patients compared azathioprine with placebo and 
reported on cancer risk.56 The trial did not report any cancers during the 2-year period. 
Azathioprine Versus Prednisone 
One 2-year RCT included 259 Crohn’s disease patients in an azathioprine versus prednisone 
comparison and reported no cancers in 113 azathioprine and one cancer in 146 prednisone 
patients.56 
Azathioprine Versus Sulfasalazine 
The same 2-year RCT included 245 patients in an azathioprine versus sulfasalazine 
comparison and reported no cancers in either group.56 
Combination Azathioprine and Aminosalicylates Versus Azathioprine 
A retrospective chart review in 104 Crohn’s disease patients compared a combination of 
azathioprine and aminosalicylates with azathioprine and reported on cancer risk.146 The review 
required that all patients have at least 6 months of azathioprine use, no side effects to 
azathioprine, and be in remission to be eligible. The reviews reported one Waldenstrom’s 
macroglobulinemia among 48 patients on a combination of azathioprine and aminosalicylates, 
compared with no cancers among 56 patients receiving azathioprine without aminosalicylates. 
The review also reported Waldenstrom’s macroglobulinemia in its lymphoma section. 
Immunomodulators Versus No Therapy 
A claims-based study that included 8,581 Crohn’s disease patients reported three cancer 
cases among 911 person-years of exposure to immunomodulators (with or without 
corticosteroids or TNF-alpha inhibitors), compared with 2,115 cases among 15,673 person-years 
of no therapy.168 The study reported an adjusted HR of 1.2 (95% CI, 1.0 to 1.4). The 
corresponding unadjusted rate ratio is 0 (95% CI, 0 to 0.1). The study also reported an adjusted 
HR of 1.2 (95% CI, 1.0 to 1.4) comparing immunomodulators (with no corticosteroids and no 
TNF-alpha inhibitor) with no therapy.168  
Combination of Immunomodulators and Corticosteroids Versus No Therapy 
The same claims-based study reported no cancer cases among 19 person-years of exposure to 
immunomodulators with corticosteroids (with or without TNF-alpha inhibitors), compared with 
2,115 cases among 15,673 person-years of no therapy.168 The study reported an adjusted HR of 
1.0 (95% CI, 0.7 to 1.4). The corresponding unadjusted rate ratio is not estimable because of the 
absence of events in the group receiving a combination of immunomodulators and 
corticosteroids. 
Corticosteroids 
Table 46 summarizes the risk of other cancers in RCTs and observational studies evaluating 
corticosteroids in patients with Crohn’s disease. 
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Table 46. Summary of the risk of other cancers in randomized controlled trials and observational studies comparing a corticosteroid 
alone or in combination with placebo or another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) 
Study 
Design Corticosteroid Comparison 
# of 
Cancer 
Cases 
in 
Steroid 
Group 
# of 
Patients 
in 
Steroid 
Group 
# of Cancer 
Cases in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
Relative 
Measure* 
(95% CI) 
Adjusted 
Relative 
Measure 
(95% CI) 
Summers, 
197956 
104 RCT Prednisone Placebo 1 146 0 178 (Excluded) NR 
Summers, 
197956 
104 RCT Prednisone Sulfasalazine 1 146 0 132 (Excluded) NR 
Marehbian, 
2009168 
104 Retrospective 
cohort 
Steroid No TNF or 
IMM or 
Steroid 
NR† NR NR‡ NR IRR, 0 (0 to 
0.7) 
HR, 1.1 
(0.9 to 1.3) 
CI = confidence interval; HR = hazards ratio; IMM = immunomodulator; IRR = incidence rate ratio; NR = not reported; RCT = randomized controlled trial; Steroid = 
corticosteroid; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate relative measures when there were fewer than five events total in the main intervention and comparison arms. 
†There were 0 events during 379 person-years. 
‡There were 2115 events during 15,673 person-years. 
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Prednisone Versus Placebo 
One 2-year RCT, that included 324 Crohn’s disease patients in a prednisone versus placebo 
comparison, reported one cancer in 146 patients on prednisone and no cancers in 178 patients 
taking placebo.56 
Prednisone Versus Sulfasalazine 
The same 2-year RCT that included 278 Crohn’s disease patients in a prednisone versus 
sulfasalzine comparison reported one cancer in 146 patients on prednisone and no cancers in 132 
patients taking sulfasalazine.56 
Corticosteroids Versus No Therapy 
A claims-based study, that included 8,581 Crohn’s disease patients, reported no cancer cases 
among 379 person-years of exposure to corticosteroids (with or without immunomodulators or 
TNF-alpha inhibitors), compared with 2,115 cases among 15,673 person-years of no therapy.168 
The study reported an adjusted HR of 1.1 (95% CI, 0.9 to 1.3). The corresponding unadjusted 
rate ratio is not estimable because of a lack of events in the corticosteroids group. The study also 
reported a HR comparing corticosteroids (with no immunomodulators and no TNF-alpha 
inhibitors) with no therapy (adjusted HR, 1.0; 95% CI, 0.8 to 1.3).168 
Aminosalicylates 
Table 47 summarizes the risk of other cancers in the one RCT reporting on cancer risk 
associated with use of aminosalicylates in patients with Crohn’s disease. 
 
Table 47. Summary of the risk of other cancers in a randomized controlled trial comparing an 
aminosalicylate with placebo in patients with Crohn’s disease 
# of 
Cancer # of # of Cancer # of Patients 
Cases Patients Cases in in 
Author, Followup in ASA in ASA Comparison Comparison 
Year (Weeks) ASA Comparison Group Group Group Group 
Summers, 
197956 
104 Sulfasalazine Placebo 0 132 0 178 
ASA = aminosalicylates 
Sulfasalazine Versus Placebo 
A 2-year RCT including 310 Crohn’s disease patients reported no cancers in the sulfasalazine 
and placebo groups.56 
Studies Evaluating Patients With IBD 
Seven studies reported other cancers in IBD patients without separating Crohn’s disease from 
ulcerative colitis or indeterminate colitis patients. We provided information about these studies 
in Appendix F.  
Studies Reporting Results for Crohn’s Disease and IBD 
The retrospective chart review that reported a Waldenstrom’s macroglobulinemia in a 
Crohn’s disease patient reported no additional cancers among the 82 ulcerative colitis patients 
who received azathioprine with or without aminosalicylates.146 
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Case-Control Studies Designed To Examine Specific Cancers 
Four case-control studies including 3,554 patients examined specific cancers. Two studies 
included only Crohn’s disease patients.143,170 Two studies conducted nested-case control studies 
using a claims databases.170,171 A study of small bowel cancer risk included only patients with 
small bowel Crohn’s disease.143 A study of colon cancer risk included only patients with colonic 
IBD.172 
Comparisons Including TNF-Alpha Inhibitor 
A claims database study of TNF-alpha inhibitors and immunomodulators included 1,935 
Crohn’s disease patients and followed them for a median of 484 days. The study reported on the 
relationship between the risk of non-melanoma skin cancer and either recent medication use (a 
pharmacy claim within 90 days of diagnosis) or persistence use (recent medication use plus a 
pharmacy claim greater than 365 days prior to diagnosis).170 The TNF-alpha inhibitors included 
infliximab and adalimumab. The immunomodulators included thiopurines, methotrexate, 
calcineurin inhibitor, and mycophenolate mofetil. Sixty-five percent of non-melanoma skin 
cancer cases and 86 percent of controls did not have a TNF-alpha inhibitor or immunomodulator 
claim within 90 days of the index date. Six percent of 387 cases and 1 percent of 1,548 controls 
were recent users of both TNF-alpha inhibitors and immunomodulators (Medicaid insurance 
adjusted OR compared with no use of TNF-alpha inhibitors or immunomodulators, 5.9; 95% CI, 
3.2 to 10.8). Five percent of 228 cases and 1 percent of 913 controls had persistent use of a TNF-
alpha inhibitor and immunomodulator (Medicaid insurance adjusted OR, 6.8; 95% CI, 2.7 to 
16.7). Comparing TNF-alpha inhibitor use with no TNF-alpha inhibitor and no 
immunomodulator use, 4 percent of 387 cases and 2 percent of 1,548 controls were recent users 
of a TNF-alpha inhibitor (Medicaid insurance adjusted OR, 2.5; 95% CI, 1.3 to 4.7) and 3 
percent of 228 cases and 1 percent of 913 controls were persistent users of a TNF-alpha inhibitor 
(Medicaid insurance adjusted OR, 3.2; 95% CI, 1.2 to 8.5). Comparing TNF-alpha inhibitor use 
versus no use, cases were more likely to be recent (immunomodulators and Medicaid insurance 
adjusted OR, 2.1; 95% CI, 1.3 to 3.3) and persistent (immunomodulators and Medicaid insurance 
adjusted OR, 2.2; 95% CI, 1.1 to 4.5) users of TNF-alpha inhibitor.  
Comparisons Including Immunomodulators 
Four case-control studies including 3,554 patients compared an immunomodulator with other 
medications.143,170-172 One of these was the claims database study that included 1,935 Crohn’s 
disease patients. This study evaluated the relationship between thiopurine use and non-melanoma 
skin cancer risk.170 Cases were more likely to be recent (OR adjusted for Medicaid insurance and 
use of other immunomodulators and TNF-alpha inhibitors, 3.8; 95% CI, 2.9 to 5.2) and persistent 
(OR adjusted for Medicaid insurance and other immunomodulators and TNF-alpha inhibitors, 
4.3; 95% CI, 2.8 to 6.4) users of thiopurines, compared with controls. This study also compared 
methotrexate with no methotrexate use. Cases were more likely to be recent (OR adjusted for 
Medicaid insurance and other immunomodulators and TNF-alpha inhibitors, 1.6; 95% CI, 0.6 to 
4.3) and persistent (OR adjusted for Medicaid insurance and other immunomodulators and TNF-
alpha inhibitors, 2.7; 95% CI, 0.6 to 11.6) users of methotrexate compared with controls, 
although these associations were not statistically significant. 
A case-control study of 35 Crohn’s disease patients compared seven small bowel 
adenocarcinoma cases with controls matched on age, sex, and small bowel Crohn’s disease.143 
The medical charts for two of seven (29 percent) cases showed at least 6 months of 6-
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mercaptopurine use, compared with one of 28 controls (4 percent; OR, 10.8; 95% CI, 1.1 to 
108.7). 
A case-control study of 48 patients with colonic IBD compared thiopurines use with non-
use.172 One of 18 colorectal cancer cases and four of 30 controls had thiopurine use in their paper 
or electronic medical record. The corresponding Peto OR is 0.4 (95% CI, 0 to 4.4). None of the 
patients in the study had a record of TNF-alpha inhibitor and methotrexate use. 
A case-control study using International Classification of Diseases, Ninth Revision, Clinical 
Modification claim codes, and outpatient pharmacy claims identified 364 colorectal cancer cases 
and 1,172 controls without a record of colorectal cancer or bowel surgery.171 In the 12 months 
prior to or on the date of the colorectal cancer diagnosis, 41 of 364 cases (11 percent) and 101 of 
1,172 controls (9 percent) had a pharmacy claim for immunomodulators. The study reported a 
crude OR of 1.4 (95% CI, 0.9 to 2.0), comparing immunomodulator use with no 
immunomodulator use.  
Comparisons Including Corticosteroids 
Three case-control studies including 1,619 patients compared corticosteroid with other 
medications.143,171,172 A case-control study of 35 Crohn’s disease patients compared prednisone 
with no prednisone.143 Five of seven cases (71 percent) had a record of prednisone use for at least 
6 months prior to small bowel adenocarcinoma diagnosis, compared with 17 of 28 controls (61 
percent). The corresponding Peto OR was 1.6 (95% CI, 0.2 to 19.6). The case-control study of 48 
IBD patients reported that 15 of 18 colorectal cancer cases (83 percent) and 25 of 30 controls (83 
percent) had a record of corticosteroids use.172 The corresponding Peto OR was 1.0 (95% CI, 0.2 
to 7.4). A claims-based study of colorectal cancer in IBD reported 28 percent of 364 colorectal 
cancer cases, and 21 percent of 1,172 controls had a pharmacy claim for corticosteroids in the 12 
months prior to or on the date of the colorectal cancer diagnosis.171 The study reported a crude 
OR of 1.4 (95% CI, 1.1 to 1.9). 
Comparisons Including Aminosalicylates 
Three case-control studies including 1,619 patients reported a comparison of outcomes 
related to aminosalicylate use.143,171,172 A case-control study of 35 Crohn’s disease patients 
reported four of seven cases (57 percent) had a record of sulfasalazine use for at least 6 months 
prior to small bowel adenocarcinoma diagnosis, compared with 19 of 28 controls (68 percent).143 
The corresponding Peto OR was 0.6 (95% CI, 0.1 to 5.3). A case-control study of 48 IBD 
patients reported 15 of 18 colorectal cancer cases (83 percent), and 29 of 30 controls (97 percent) 
had a record of mesalamine use.172 The corresponding Peto OR was 0.2 (95% CI, 0 to 2.4). 
A claims-based case-control study of colorectal cancer in IBD reported 43 percent of 364 
colorectal cancer cases, and 44 percent of 1,172 controls had a pharmacy claim for 
aminosalicylates in the 12 months prior to or on the date of the colorectal cancer diagnosis (crude 
OR, 1.0; 95% CI, 0.8 to 1.2).171 The comparison of aminosalicylates with colorectal cancer risk 
was the primary aim of the study. They also reported relationships with colorectal cancer risk for 
the different aminosalicylate formulations (mesalamine OR, 0.9; 95% CI, 0.7 to 1.2; 
sulfasalazine OR, 1.2; 95% CI, 0.8 to 1.7; and balsalazide OR, 1.3; 95% CI, 0.7 to 2.4). When 
they performed a test for trend to examine a relationship between number of aminosalicylate 
prescription claims in the 12 months prior to diagnosis and odds of colorectal cancer, they 
observed a p-value for trend of borderline statistical significance for any aminosalicylate 
(P=0.11) and mesalamine (P=0.08) but not sulfasalazine (P=0.27). They did not report a test of 
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trend p-value for balsalazide.  
Studies Reporting for Crohn’s Disease and IBD 
A claims-based study of non-melanoma skin cancer reported results for all IBD patients, and 
also reported results exclusively for Crohn’s disease patients.170 The results for thiopurine use 
versus no thiopurine use in IBD patients were similar in direction for the Crohn’s disease 
patients, (IBD OR, 3.1; 95% CI, 2.1 to 4.5; Crohn’s disease OR, 3.9; 95% CI, 2.9 to 5.2), when 
adjusted for other classes of medications and Medicaid insurance status. The authors stated that 
because infliximab was approved for ulcerative colitis after the study period ended in June 2005, 
they did not calculate TNF-alpha inhibitor and combination TNF-alpha inhibitor and 
immunomodulators versus no immunomodulators ORs for all IBD patients. They also stated that 
they did not report the methotrexate relationship, because methotrexate use is not indicated for 
the treatment of ulcerative colitis in the U.S.170 
Infections 
Immune suppression caused by medications to treat Crohn’s disease or the disease itself 
might increase the risk of infection. These infections can range from relatively mild to life 
threatening. Because serious infections, that may be life threatening or associated with 
hospitalization, have different implications for clinical care and patient quality of life, we have 
indicated when studies reported serious infections compared with any infection, regardless of 
severity. We have also indicated when the study considered an infection opportunistic. 
Sixty-one studies including 42,008 patients reported on infections (Appendix D, Evidence 
Table 14). Thirty-eight RCTs including 8,435 patients reported infections as an outcome by 
comparison of interest. Four prospective studies (n=7,253), 17 retrospective studies (n=23,782), 
and two case-control studies (n=2,538) reported infections by a comparison of interest. Infections 
were a primary outcome of interest in 17 studies.  
Natalizumab 
In Figures 17 and 18 we summarize the serious infections and any infections reported by 
RCTs evaluating natalizumab. In Table 48 we listed the RCTs evaluating natalizumab that 
reported no opportunistic infections. We also provided additional details regarding related 
studies. 
 
Table 48. Summary of the randomized controlled trials reporting no opportunistic infections when 
comparing the effectiveness of a biologic alone or in combination with placebo or another 
treatment in patients with Crohn’s disease 
Biologic Comparison 
# of Trials 
Reporting 
No Events 
Range of 
Followup 
(Weeks) 
# Participants in 
Biologic Group 
# Participants 
in Comparison 
Group 
Natalizumab Placebo 132 8 260 250 
Natalizumab + infliximab Infliximab 135 NR 52 27 
NR = not reported 
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Figure 17. Summary of Peto odds ratios of serious infections among randomized controlled trials comparing a biologic alone or in 
combination with placebo or another treatment in patients with Crohn’s disease 
 
CI = confidence interval; Comp = comparison; i = induction trial; IFX = infliximab; m = maintenance trial; Main = main intervention; NAT = natalizumab; OR = odds ratio 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
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Figure 18. Summary of Peto odds ratios of other infections among randomized controlled trials comparing a biologic alone or in 
combination with placebo or another treatment in patients with Crohn’s disease 
 
CI = confidence interval; Comp = comparison; i = induction trial; IFX = infliximab; m = maintenance trial; Main = main intervention; NAT = natalizumab; NR = not reported; OR 
= odds ratio 
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Natalizumab Versus Placebo 
Three natalizumab versus placebo RCTs including 1,414 Crohn’s disease patients reported 
on infections in two publications.32,33  
Serious Infections 
All three trials reported on serious infections.32,33 Serious infections were rare with 
natalizumab patients (less than 1 to 3 percent) and placebo patients (2 percent). 
Opportunistic Infections  
One RCT including 510 patients reported no opportunistic infections (including PML) during 
the study period.32 
Any Infection 
Three trials including 1,414 patients reported on any infection.32,33  
Infections (including serious) were more common in natalizumab patients (35 to 62 percent) than 
placebo patients (30 to 56 percent).  
Combination of Natalizumab and Infliximab Versus Infliximab 
One RCT including 79 Crohn’s disease patients reported on infections comparing a 
combination of natalizumab and infliximab with infliximab alone in initial non-responders to 
infliximab.35  
Serious Infections 
There were no trials that reported serious infections during the study period.35 
Opportunistic Infections 
There were no trials that reported opportunistic infections during the study period.35 
Any Infection 
One trial reported infections in 14 out of 52 patients taking natalizumab and infliximab (27 
percent) and eight out of 27 patients taking infliximab (30 percent ).35  
TNF-Alpha Inhibitors 
We did not conduct a meta-analysis of the RCTs comparing TNF-alpha inhibitors with 
placebo in terms of serious infections, because four out of the five trials had fewer than five 
events. Figures 19 and 20 summarize the RCTs and observational studies evaluating TNF-alpha 
inhibitors in terms of serious infections. Figure 21 summarizes the opportunistic infections 
reported in RCTs evaluating TNF-alpha inhibitors. Figure 22 and Table 49 summarize any 
infections reported in RCTs and observational studies evaluating TNF-alpha inhibitors. We also 
provided additional details regarding related studies. 
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Figure 19. Summary of Peto odds ratios of serious infections among randomized controlled trials comparing a TNF-alpha inhibitor alone 
or in combination with placebo or another treatment in patients with Crohn’s disease 
 
6-Methylpred = 6-methylprednisolone; ADA = adalimumab; AZA = azathioprine; BUDE = budesonide; CI = confidence interval; Comp = comparison; CP = certolizumab pegol; 
IFX = infliximab; MTX = methotrexate; OR = odds ratio; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†The number of events is for serious cases of perianal abscess or fistula. 
‡The number of events is for serious cases of pneumonia. 
§The number of events is for serious cases of hepatitis C. 
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Figure 20. Summary of Peto odds ratios of serious infections among observational studies comparing a TNF-alpha inhibitor alone or in 
combination with placebo or another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; ASA = aminosalicylates; BIO = biologics; CI = confidence interval; Comp = comparison; IFX = infliximab; IMM = immunomodulator; NR = not reported; 
OR = odds ratio; Pro = prospective cohort; Retro = retrospective cohort; STEROID = corticosteroids; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Adjusted relative risk, 2.2 (95% CI, 1.4 to 3.2) 
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Figure 21. Summary of Peto odds ratios of opportunistic infections among randomized controlled trials comparing a TNF-alpha inhibitor 
alone or in combination with placebo or another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; CI = confidence interval; Comp = comparison; CP = certolizumab pegol; OR = odds ratio; TNF = tumor necrosis factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
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Figure 22. Summary of Peto odds ratios of other infections among randomized controlled trials comparing a TNF-alpha inhibitor alone 
or in combination with placebo or another treatment in patients with Crohn’s disease 
 
6-methylpred = 6-methylprednisolone; ADA = adalimumab; AZA = azathioprine; BUDE = budesonide; CI = confidence interval; Comp = comparison; CP = certolizumab pegol; 
GI = gastrointestinal; IFX = infliximab; IMM = immunomodulator; MTX = methotrexate; NR = not reported; OR = odds ratio; TEI = treatment-emergent infections; THIO = 
thiopurine; TNF = tumor necrosis factor-alpha inhibitor; URI = upper respiratory infection; UTI = urinary tract infection 
*There were 18 events in the combination infliximab and thiopurine arm and 16 events in the thiopurine arm. 
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Table 49. Summary of other infections reported in observational studies comparing a TNF-alpha 
inhibitor alone or in combination with placebo or another treatment in patients with Crohn’s 
disease 
Author, 
Year 
Followup 
(Weeks) 
TNF-Alpha 
Inhibitor Comparison 
# of Other 
Infections 
in TNF 
Group 
# of 
Patients 
in TNF 
Group 
# of Other 
Infections 
in Comp 
Group 
# of 
Patients 
in Comp 
Group 
Seiderer, 
2004173 
NR Infliximab + 
thiopurine 
Infliximab + no 
thiopurine 
4 82 0 18 
Seiderer, 
2004173 
NR Infliximab + 
corticosteroids 
Infliximab + no 
corticosteroids 
0 42 3 58 
Comp = comparison; NR = not reported; TNF = tumor necrosis factor-alpha inhibitor 
Adalimumab Versus Placebo 
Four RCT’s appearing in five publications included 1,457 Crohn’s disease patients and 
compared infections with adalimumab or placebo.37,38,82,83,95  
Serious Infections 
Four RCTs including 1,457 patients reported on serious infection. Serious infections were 
rare in adalimumab patients (0 to 4 percent) and placebo patients (0 to 5 percent).37,38,82,83 
One of these trials allowed patients to switch medications after 12 weeks and reported on 
infections separately for patients who maintained randomized therapy and unblinded patients. A 
maintenance trial of those who achieved remission in a previous trial37 reported no infections in 
37 adalimumab patients and 18 placebo patients who stayed on their randomized treatment for 
the duration of the 52-week period.83 Nine of 221 patients (4 percent) who elected to switch to 
adalimumab from placebo, increase the adalimumab dose, or discontinue at week 4, experienced 
a serious infection. A 52-week maintenance trial reported 3 percent of adalimumab and placebo 
patients experienced serious infections during the study period.82 Another publication of the 
same trial reported serious infections in 4 percent of adalimumab patients and 5 percent of 
placebo patients.95 The corresponding Peto OR was 0.8 (95% CI, 0.3 to 1.9). During the 
adalimumab induction period prior to randomization, serious infections occurred in 1 percent of 
854 patients.82  
Opportunistic Infections 
Three RCTs including 1,402 patients reported on opportunistic infections.37,38,82 The two 
induction trials reported that no opportunistic infections occurred.37,38 A 52-week maintenance 
trial reported six (1 percent) opportunistic infections in the adalimumab patients compared with 
five (2 percent) opportunistic infections in the placebo group.82 The corresponding Peto OR was 
0.6 (95% CI, 0.2 to 2.1). 
Any Infection 
Three RCTs including 679 patients reported on any infections.37,38,83 Infections were 
common in adalimumab patients (16 to 57 percent) and placebo patients (16 to 83 percent). 
Other Combinations With Adalimumab 
A prospective study of 112 patients who used adalimumab combined with aminosalicylates, 
corticosteroids, or immunomodulators reported one serious infection in a patient who used 
concomitant immunomodulators.161 
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Certolizumab Pegol Versus Placebo 
Five RCTs including 1,910 Crohn’s disease patients compared certolizumab pegol with 
placebo and reported on infections.39-42,84 
Serious Infections 
Four RCTs including 1,472 patients reported on serious infections.39-41,84 Serious infections 
were rare (1 to 3 percent of certolizumab pegol patients and 0 to 1 percent of placebo patients). 
Two trials, that excluded patients with abscesses related to Crohn’s disease, reported 
gastrointestinal and perianal abscesses as serious infections.40,41 
Opportunistic Infections 
Two RCTs including 384 patients reported on opportunistic infections.40,41 One 12-week 
induction trial did not report any opportunistic infections.41 Another reported “no increase” in 
opportunistic infections but did not specify the infections considered.40 
Any Infection 
Five RCTs including 1,910 patients reported on any infections.39-42,84 Infections were 
common in certolizumab pegol patients (3 to 31 percent) and placebo patients (2 to 23 
percent).40-42 
An induction trial, followed by maintenance trial, reported on specific infections. Both trials 
reported on nasopharyngitis. The induction trial reported 13 percent of certolizumab pegol 
patients and 8 percent of placebo patients had nasopharyngitis (Peto OR, 1.7; 95% CI, 1.0 to 
2.8).39 The maintenance trial may have randomized some of these patients; it reported that 12 of 
216 certolizumab pegol patients (6 percent) and eight of 212 placebo patients (4 percent) had 
nasopharyngitis (Peto OR, 1.5; 95% CI, 0.6 to 3.7).84  
Infliximab Versus Placebo 
Five RCTs including 1,130 Crohn’s disease patients compared infliximab with placebo and 
reported on infections.43,44,85-87  
Serious Infections 
Three RCTS including 963 patients reported on serious infections.43,86,87 Serious infections 
were uncommon in the maintenance trials (3 to 4 percent of infliximab and 4 to 6 percent of 
placebo patients).86,87 A 12-week trial of a single infusion reported one case of salmonella colitis 
requiring hospitalization among 83 infliximab patients and one case of abdominal abscess 
requiring hospitalization among 25 placebo patients.43  
Opportunistic Infections 
No study reported on opportunistic infections. 
Any Infection 
Four RCTs including 1,022 patients reported on any infections.44,85-87 Infections requiring 
antimicrobial treatment (including serious in infections) were common in the maintenance trials 
(30 to 34 percent of infliximab patients and 27 to 37 percent of placebo patients).86,87 
The other trials reported specific infections in at least 10 percent of patients. An 18-week 
induction trial including a single infusion reported adverse events occurring in at least 10 percent 
of the population (63 infliximab patients and 31 placebo patients with fistulizing disease).44 
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Infectious adverse events included gastrointestinal abscess (seven infliximab patients versus one 
placebo patient; Peto OR, 2.7; 95% CI, 0.6 to 12.6), and upper respiratory infection (five 
infliximab patients vs. two placebo patients; Peto OR, 1.6; 95% CI, 0.5 to 8.2).44 A 36-week 
retreatment trial subsequent to another trial43 reported adverse events occurring in at least 10 
percent of any group including 37 infliximab patients and 36 placebo patients.85 Infectious 
adverse events included bronchitis (six infliximab patients vs. three placebo patients; Peto OR, 
2.1; 95% CI, 0.5 to 8.2); pharyngitis (seven infliximab patients vs. one placebo patient; Peto OR, 
5.1; 95% CI, 1.2 to 22.0); and upper respiratory infection, which may or may not have included 
bronchitis and pharyngitis (nine infliximab patients vs. six placebo patients; Peto OR, 1.6; 95% 
CI, 0.5 to 8.2).85 
Infliximab Versus Azathioprine 
One RCT including 324 Crohn’s disease patients compared infliximab with azathioprine and 
reported on infections.45  
Serious Infections 
The same RCT reported eight serious infections in 163 infliximab patients (5 percent) 
compared with nine serious infections in 161 azathioprine patients (6 percent).45 The 
corresponding Peto OR was 0.9 (95% CI, 0.3 to 2.3). 
Opportunistic Infections 
This trial did not report on opportunistic infections.45 
Any Infection 
This RCT reported a serious or non-serious infection in 46 percent of infliximab patients and 
45 percent of azathioprine patients. The corresponding Peto OR was 1.0 (95% CI, 0.7 to 1.6).45 
Combination of Infliximab and Corticosteroids Versus Infliximab 
One retrospective study of 71 patients reported no serious infections.163 The study did not 
report on opportunistic infections or other infections. 
Combination of Infliximab and Immunomodulators Versus Infliximab 
Three RCTs including 607 Crohn’s disease patients compared a combination of infliximab 
and immunomodulators with infliximab and reported on infections.45,47,89 Two observational 
studies including 128 Crohn’s disease patients compared a combination of infliximab and 
immunomodulators with infliximab and reported on infections.163,174 
Serious Infections 
Two RCTs including 527 patients reported on serious infections.45,47 The trials reported 
serious infections in less than 5 percent of patients in any study arm. 
Two observational studies including 128 Crohn’s disease patients reported on serious 
infections. A study of the early experience with infliximab at several centers reported one case of 
pneumocystis carinii pneumonia among 42 patients on infliximab and immunomodulator 
(thiopurines, methotrexate, or mycophenolate mofetil), and one episode of sepsis among 15 users 
of infliximab without an immunomodulator.174 The other study reported no serious infections in 
either the infliximab combined with immunomodulators group, or the infliximab group that 
never used immunomodulators.163 
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Opportunistic Infections 
None of the RCTs reported on opportunistic infections. 
Any Infection 
All three RCTs including 607 patients reported and included serious and non-serious 
infections.45,47,89 Infections were common in patients who used infliximab combined with an 
immunomodulator (30 to 55 percent) and infliximab alone (25 to 46 percent).  
Other Combinations With Infliximab 
Five retrospective studies including 1,267 Crohn’s disease patients met the inclusion criteria 
but the studies might have misclassified the concomitant medications (as described in the 
mortality section). Four studies evaluated the safety profile of infliximab use at their 
centers,137,145,164,175 and one study focused specifically on the role of concomitant 
immunomodulators on outcomes.147  
Serious Infections 
Four studies including 1,152 patients reported on serious infections in five manuscripts.137,138 
145,164,175 The four retrospective studies reported serious infections in patients who received (at 
baseline) either a triple combination of infliximab, immunomodulators, and corticosteroids; a 
combination of infliximab and immunomodulators; a combination of infliximab and 
corticosteroids; or infliximab alone. The studies reported serious infections in 0 to 7 percent of 
patients receiving the combination of infliximab, immunomodulator, and corticosteroid; 3 to 18 
percent of patients receiving infliximab and an immunomodulator; 0 to 9 percent of patients 
receiving infliximab and corticosteroids; and 0 to 16 percent of patients receiving only 
infliximab. A previous report on 500 patients from one center reported on outcomes for the first 
100 patients using infliximab.138 The report included six “significant” infections in five of the six 
patients using concomitant immunomodulators (with or without corticosteroids) and two of the 
six patients using concomitant corticosteroids (with or without immunomodulators).138 The study 
of 157 patients also reported on 30 patients who received adalimumab after infliximab.145 Of the 
30 adalimumab patients, two experienced sepsis-related complications. 
Opportunistic Infections 
Two studies including 657 patients reported on opportunistic infections.137,145 One study (157 
patients) reported no opportunistic infections.145 The other study (500 patients) considered three 
non-serious varicella-zoster infections “probably” opportunistic.137 The study treated two of 
these patients with a combination of infliximab, azathioprine, and corticosteroids and treated the 
other with a combination of infliximab and azathioprine. 
Any Infection 
Four studies including 970 patients reported on any infection in five 
manuscripts.137,138,145,147,175 The two retrospective studies included 157 and 500 Crohn’s disease 
patients and reported infections (respectively) in 16 and 3 percent of patients receiving the 
combination of infliximab, immunomodulator, and corticosteroid; 33 and 9 percent of patients 
receiving infliximab and an immunomodulator; 6 and 13 percent of patients receiving infliximab 
and corticosteroids; and 26 and 14 percent of patients receiving only infliximab.137,145 The 
reported infections included serious infections. A previous study on 500 patients from the center 
reported on the infliximab outcomes among the first 100 patients and did not report other 
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infections.138 The study of 157 patients also reported on 30 patients who received adalimumab 
after infliximab.145 Of the 30 adalimumab patients, seven patients (23 percent) had an infection. 
A retrospective study with a mean followup of 29 months reported one pneumonia in 127 
patients receiving infliximab and an immunomodulator, compared with no infections in 71 
patients receiving infliximab without concomitant immunomodulators (this came from a 
database that included most of the patients treated with infliximab at the center).175 A followup 
study, with a median followup of 9 years, reported two “atypical” infections in 53 patients 
receiving infliximab with no concomitant thiopurine use, compared with no infections among 
those with concomitant thiopurine use.147 The infections reported were necrotizing pneumonia 
and methicillin-resistant Staphylococcus aureus skin abscess. 
Combination of Infliximab and Immunomodulators Versus 
Immunomodulators 
Two RCTs including 340 Crohn’s disease patients compared the combination of infliximab 
and immunomodulators with immunomodulators alone and reported on infections.45 46 
Serious Infections  
The two studies reported serious infections in less than 5 percent of patients in any study 
arm.45 46 
Opportunistic Infections 
Neither of the RCTs reported on opportunistic infections. 
Any Infection 
Infections were common in all study arms (32 to 42 percent of infliximab combined with 
thiopurines patients and 29 to 45 percent of thiopurines patients).45,46  
Combination of Infliximab and Immunomodulators Versus Corticosteroids 
A 104-week open-label trial including 129 Crohn’s disease patients compared a combination 
of infliximab and immunomodulators with corticosteroids and reported on infections.48 
Serious Infections 
Six percent of the combination of infliximab and azathioprine or methotrexate patients had a 
serious infection, compared with 13 percent of patients on prednisone or budesonide.48 
Opportunistic Infections 
This RCT did not report on opportunistic infections. 
Any Infection 
The trial reported 77 infectious events in 65 patients on infliximab and azathioprine or 
methotrexate, compared with 80 infectious events in 64 patients on prednisone or budesonide.48 
TNF-Alpha Inhibitor Versus No TNF-Alpha Inhibitor 
One prospective study and two retrospective observational studies including 15,045 Crohn’s 
disease patients reported on infections comparing patients who had used a TNF-alpha inhibitor 
with those who had not used a TNF-alpha inhibitor or never used a biologic.131,150,168 
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Serious Infections 
Two observational studies including 6,464 patients reported on serious infections.131,150 An 
observational study (with 2 mean years of followup) reported serious infections (undefined) in 2 
percent of 3,179 infliximab users, compared with 1 percent of non-users during the study period. 
The study reported an OR of 1.0 (95% CI, 0.6 to 1.5) when comparing infliximab with no 
infliximab (excluding infliximab used in the 6-month period during which the infection 
occurred); this is after adjusting for age, sex, race, disease location, severity of Crohn’s disease, 
duration of followup and possibly other medication use. The relative rate comparing number of 
infections by person-years of exposure (unadjusted for potential confounders) was 2.2 (95% CI, 
1.4 to 3.2). A 104-week prospective study reported 10 serious infections requiring hospitalization 
among patients who used adalimumab or infliximab, and no serious infections among those who 
never used a biologic.150 
Opportunistic Infections 
A claims-based study that included 8,581 Crohn’s disease patients reported on opportunistic 
infections, candidiasis, and tuberculosis together.168 The study reported 11 of these infections in 
292 infliximab person-years, compared with 305 in 15,673 person-years with no associated 
Crohn’s disease pharmacy claims. The study reported a HR of 2.0 (95% CI, 1.1 to 3.7) 
comparing infliximab (with or without corticosteroids or immunomodulators) with no therapy, 
adjusted for age, gender, geographic region, health plan, and comorbidity. They also reported an 
adjusted HR of 2.1 (95% CI, 1.1 to 3.8), comparing infliximab alone (without corticosteroids or 
immunomodulators) with no therapy. 
Any Infection 
The study also reported four additional infections that the authors did not specifically identify 
as serious.168 For herpes simplex, herpes zoster, and encephalopathy, encephalitis, or meningitis; 
the unadjusted rate ratios and adjusted hazard ratios ranged from 0.9 to 1.7 without statistical 
significance. There was an increased risk of sepsis among infliximab users, compared with those 
without therapy. There were 48 sepsis events reported in 292 person-years of infliximab use, 
compared with 1,833 events among 15,673 person-years of no therapy (adjusted HR comparing 
infliximab [with or without corticosteroids and immunomodulators] with no therapy, 1.5; 95% 
CI, 1.1 to 2.0; HR for infliximab alone vs. no therapy, 1.5; 95% CI, 1.1 to 2.0).  
Combination of TNF-Alpha Inhibitors, Immunomodulators, and 
Corticosteroids Versus No Therapy 
The same claims-based study compared a triple combination of TNF-alpha inhibitors, 
immunomodulators, and corticosteroids with no therapy; the study reported on opportunistic and 
other specific infections.168 
Opportunistic Infections 
The study reported two opportunistic infections among 31 person-years of exposure to 
combination therapy with TNF-alpha inhibitors, immunomodulators, and corticosteroids, 
compared with 305 opportunistic infections among 15,673 person-years of no therapy.168 The 
study reported an adjusted HR of 3.6 (95% CI, 0.9 to 14.6), comparing triple combination 
therapy with no therapy. 
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Any Infection 
The study also reported four additional infections that the authors did not specifically identify 
as serious. The study compared 31 person-years of triple combination therapy of infliximab, 
immunomodulators, and corticosteroids with 15,673 person-years of no therapy over an average 
of 2 years per person. The study did not identify claims associated with herpes simplex in any of 
the triple therapy patients, compared with 134 in the no therapy patients.168 The study reported 
one herpes zoster infection in the triple therapy group, compared with 123 infections in the no 
therapy group (unadjusted rate ratio, 4.1; 95% CI, 0.1 to 23.3). The study reported nine claims 
for sepsis in the triple therapy group, compared with 1,833 claims in the no therapy group (study 
reported adjusted HR, 2.4; 95% CI, 1.2 to 4.7). The study reported four encephalopathy, 
encephalitis, or meningitis infections in the triple therapy group, compared with 499 infections in 
the no therapy group (unadjusted rate ratio, 4.1; 95% CI, 1.1 to 1.4). 
Combination of TNF-Alpha Inhibitors and Immunomodulators Versus No 
Therapy 
The same claims-based study compared a combination of TNF-alpha inhibitors and 
immunomodulators with no therapy and reported on opportunistic and specific other 
infections.168  
Opportunistic Infections  
The study reported 15 opportunistic infections among 162 person-years of exposure to 
combination therapy with TNF-alpha inhibitors and immunomodulators (with or without 
corticosteroids), compared with 305 opportunistic infections among 15,673 person-years of no 
therapy.168 The corresponding unadjusted rate ratio was 4.8 (95% CI, 2.6 to 8.0). 
Any Infection 
The study reported three herpes simplex infections among the patients receiving a TNF-alpha 
inhibitor and immunomodulator and 134 infections among patients receiving no therapy. The 
corresponding rate ratio was 2.2 (95% CI, 0.4 to 6.5). The study reported four herpes zoster 
infections among patients receiving a TNF-alpha inhibitor and immunomodulator, compared 
with 123 infections among patients receiving no therapy (unadjusted rate ratio, 3.1; 95% CI, 0.8 
to 8.3). The study reported sepsis claims in 23 patients receiving the combination therapy and 
1,833 patients receiving no therapy (adjusted HR, 1.9; 95% CI, 0.8 to 1.8). The study reported 
encephalopathy, encephalitis, or meningitis claims in 12 patients receiving the combination 
therapy and 499 patients receiving no therapy (unadjusted rate ratio, 2.3; 95% CI, 1.2 to 4.1).168 
Combination of TNF-Alpha Inhibitor and Corticosteroids Versus No Therapy 
The same claims-based study compared no therapy with a combination of TNF-alpha 
inhibitors and corticosteroids and reported on opportunistic and specific other infections.168  
Opportunistic Infections 
The study reported two opportunistic infections among 142 person-years of exposure to 
combination therapy with TNF-alpha inhibitors and corticosteroids (with or without 
immunomodulators), compared with 305 opportunistic infections among 15,673 person-years of 
no therapy.168 The corresponding unadjusted rate ratio was 0.7 (95% CI, 0.1 to 2.6). 
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Any Infection 
The study reported one herpes simplex infection in the group receiving a TNF-alpha inhibitor 
and corticosteroids, compared with 134 infections in the no therapy group (unadjusted rate ratio, 
0.8; 95% CI, 0 to 4.7). The study reported herpes zoster claims in three patients receiving the 
combination therapy and 123 patients receiving no therapy (unadjusted rate ratio, 2.7; 95% CI, 
0.5 to 8.1). The study reported sepsis claims in 27 patients receiving the combination therapy and 
1,833 patients receiving no therapy. The study reported an adjusted HR for sepsis of 2.8 (95% 
CI, 1.2 to 6.5) that differed in magnitude from the unadjusted rate ratio of 1.6 (95% CI, 1.1 to 
2.4). The study reported encephalopathy, encephalitis, or meningitis in six patients receiving the 
combination therapy and 499 patients receiving no therapy (unadjusted rate ratio 1.3; 95% CI, 
0.5 to 2.9). 
Other Combinations With TNF-Alpha Inhibitors 
A retrospective study reported no serious infections requiring hospitalization in the 44 people 
who used TNF-alpha inhibitors without concomitant corticosteroids and immunomodulators. 
Eight percent of patients on TNF-alpha inhibitors combined with corticosteroids, 2 percent of 
patients on TNF-alpha inhibitors combined with immunomodulators, and 2 percent of patients on 
TNF-alpha inhibitors combined with corticosteroids and immunomodulators had serious 
infections.165 
Immunomodulators 
Table 50 summarizes the risk of serious infections in observational studies evaluating 
immunomodulators in patients with Crohn’s disease. Figure 23 and Table 51 summarize the risk 
of any infection in RCTs and observational studies evaluating immunomodulators in patients 
with Crohn’s disease. We also provided additional details regarding related studies. 
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Table 50. Summary of the risk of serious infections in observational studies comparing an immunomodulator alone or in combination 
with placebo or another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) Design IMM Comparison 
# of 
Serious 
Infections 
in IMM 
Group 
# of 
Patients 
in IMM 
Group 
# of Serious 
Infections 
in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
OR (95% 
CI) 
Adjusted 
OR (95% 
CI) 
Lichtenstein, 
2006131 
99 Prospective 
cohort 
IMM No IMM 58 3478 48 2775 1.0 (0.7 to 
1.4) 
0.8 (0.5 to 
1.2) 
CI = confidence interval; IMM = immunomodulator; OR = odds ratio 
 
Table 51. Summary of the risk of other infections in observational studies comparing an immunomodulator alone or in combination with 
placebo or another treatment in patients with Crohn’s disease 
# of Other 
# of Other # of Infections in # of Patients in 
Author, Year 
Followup 
(Weeks) Immunomodulator Comparison 
Infections in 
IMM Group 
Patients in 
IMM Group 
Comparison 
Group 
Comparison 
Group 
Maher, 2009176 NR Azathioprine Never NR* 12 NR* 60 
azathioprine 
Shah, 2008156 NR Azathioprine + Azathioprine + 2 104 2 95 
mesalamine never 
mesalamine 
IMM = immunomodulator; NR = not reported 
*There were two events among 12 patients in the azathioprine group and seven events among 60 patients in the never azathioprine group. 
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Figure 23. Summary of Peto odds ratios of other infections among randomized controlled trials comparing an immunomodulator alone 
or in combination with placebo or another treatment in patients with Crohn’s disease 
AZA = azathioprine; BUDE = budesonide; CI = confidence interval; Comp = comparison; IMM = immunomodulator; IV = intravenous; LRI = lower respiratory infection; MTX = 
methotrexate; NR = not reported; OR = odds ratio; PRED = prednisone; PREDL = prednisolone; SUL = sulfasalazine; URI = upper respiratory infection 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
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Azathioprine Versus Corticosteroids 
Two RCTs including 454 Crohn’s disease patients compared azathioprine with 
corticosteroids and reported on infections.102,177 
Serious Infections 
One RCT including 259 patients reported on serious infections.177 The study termed serious 
infections a “disaster” if the patient required hospitalization or suffered a disability for at least 3 
months, or “serious” if the patient had to withdraw from the study or needed treatment. During 
induction, two of 59 patients on azathioprine (3 percent) and two of 85 patients on prednisone (2 
percent) experienced a serious infection.177 Seven percent of both groups had a serious infection 
during the maintenance period. 
Opportunistic Infections 
Neither of the RCTs reported on opportunistic infections. 
Any Infection 
Two RCTs including 454 patients reported on any infection. The study reported non-serious 
infections during induction in 8 percent of patients on azathioprine and 32 percent of patients on 
prednisone.177 During maintenance, the studies reported infections in 31 percent of patients on 
azathioprine and 13 percent of patients on prednisone. A 1.5-year maintenance trial comparing 
azathioprine with budesonide reported infections in 66 percent of azathioprine and 36 percent of 
budesonide patients.102 The majority of infections were upper respiratory or herpes infections.  
Azathioprine Versus Sulfasalazine 
One RCT including 245 Crohn’s disease patients compared azathioprine with sulfasalazine 
and reported on infections.177 
Serious Infections 
During the induction period, 3 percent of patients on azathioprine and 0 percent of patients 
on sulfasalazine had serious infections.177 During maintenance therapy, 7 percent of patients on 
azathioprine and no patients on sulfasalazine had a serious infection. 
Opportunistic Infections 
This RCT did not report on opportunistic infections. 
Any Infection 
The study reported non-serious infections during induction in 8 percent of patients on 
azathioprine and 14 percent of patients on sulfasalazine.177 During maintenance therapy, the 
study reported infections in 31 percent of patients on azathioprine and 54 percent of patients on 
sulfasalazine.  
Combination of Immunomodulators and Corticosteroids Versus 
Corticosteroids 
Three RCTs including 263 Crohn’s disease patients compared a combination of 
immunomodulators and corticosteroids with corticosteroids alone and reported on 
infections.51,54,63 
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Any Infections  
Three RCTs including 263 patients reported on any infections.51,54,63 A 4-month induction 
trial comparing a combination of azathioprine and prednisolone with prednisolone alone reported 
no infections in the 42 patients.54 A 7-month induction trial reported adverse events that occurred 
in at least 10 percent of the study population.51 The trial reported nasopharyngitis in seven of 52 
patients (13 percent) receiving azathioprine and prednisone and three of 28 patients (11 percent) 
receiving prednisone. A 16-week induction trial reported influenza in 11 percent of patients on 
methotrexate and prednisone compared with 13 percent of patients on prednisone.63 The trial 
reported pneumonia in one patient taking methotrexate and prednisone and no patients taking 
prednisone.63 None of the RCTs reported on serious or opportunistic infections. 
Immunomodulators Versus Placebo 
Three RCTs including 463 Crohn’s disease patients compared azathioprine with placebo and 
reported on infections.56 59 105 One study included an induction and maintenance phase comparing 
oral azathioprine with placebo.56 Some patients participated in induction and maintenance, 
whereas some patients in remission at enrollment only participated in the maintenance phase. We 
considered serious infections those where patients were hospitalized, suffered a disability of at 
least 3 months, had to withdraw from the study or needed treatment. Another study compared a 
single infusion of azathioprine or placebo followed by oral azathioprine in both groups.59 A 40-
week methotrexate trial included patients who were in steroid-free remission from a previous 
trial63 or who responded to methotrexate within 16 to 24 weeks.105 
Serious Infections  
Two studies including 367 patients reported on serious infections.105,177 One study reported 
serious infections in 3 percent of the azathioprine and 4 percent of placebo patients during 
induction, and 7 percent of azathioprine and 2 percent of placebo patients during maintenance.177 
The second study, a methotrexate trial, reported one infection-related severe adverse event in a 
placebo patient.105 
Opportunistic Infections 
No study reported on opportunistic infections for this comparison. 
Any Infection 
Three studies including 463 patients reported on any infection.59 105 177 One study reported 
infections in 8 percent of the azathioprine patients and 13 percent of the placebo patients during 
the 17-week induction phase, compared with 31 percent of azathioprine patients and 19 percent 
of placebo patients in the 104-week maintenance phase.177 A 16-week study that compared a 
single infusion of azathioprine with placebo to induce remission combined with oral azathioprine 
in both groups reported no pneumonia cases in the 51 azathioprine patients, compared with two 
pneumonia cases in the 45 placebo patients.59 The trial reported viral lower respiratory infections 
in six azathioprine patients (12 percent) compared with two placebo patients (4 percent). A 
methotrexate trial reported two flu-like illnesses in both the methotrexate group (5 percent) and 
the placebo group (5 percent).105 
Immunomodulators Versus No Immunomodulators 
One prospective study including 6,290 Crohn’s disease patients compared 
immunomodulators with no immunomodulators and reported on infections.131 
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Serious Infections 
Two percent of patients using immunomodulators and 2 percent of patients not using 
immunomodulators had a serious infection. The study reported an OR of 0.8 (95% CI, 0.5 to 
1.2), comparing immunomodulators with no immunomodulators, adjusted for age, sex, race, 
disease location, severity of Crohn’s disease, duration of followup, and possibly other 
medications. The authors did not include in the analysis the medication exposure during the 6-
month time period when the infection occurred. This prospective study did not report on 
opportunistic or any other infections. 
Immunomodulators Versus No Therapy 
A claims-based study that included 8,581 Crohn’s disease patients reported opportunistic 
infections, candidiasis, and tuberculosis together.168 The study reported 17 of these infections in 
911 person-years associated with claims for immunomodulator use, compared with 305 in 
15,673 person-years with no claims for medical treatment of Crohn’s disease. The study reported 
an HR of 1.1 (95% CI, 0.6 to 1.8), comparing immunomodulators (with or without infliximab or 
corticosteroids) with no therapy, adjusted for age, gender, geographic region, health plan, and 
comorbidity. The study also reported an adjusted HR of 1.1, comparing immunomodulators 
alone (without infliximab or corticosteroids) with no therapy (95% CI, 0.6 to 1.8). 
Any Infection 
The study also reported four additional infections that were not specifically identified by the 
authors as serious. There were 911 immunomodulator person-years compared with 15,673 no 
therapy person-years.168 The comparison between immunomodulators and no therapy did not 
produce any statistically significant associations for herpes simplex, herpes zoster, sepsis, 
encephalopathy, encephalitis, or meningitis. The HRs ranged from 0.6 to 1.0. 
Combination of Immunomodulators With Corticosteroids Versus No Therapy 
The same claims-based study reported opportunistic infections, candidiasis, and tuberculosis 
together.168 The study reported two of these infections in 19 person-years of followup on a 
combination of immunomodulator and corticosteroid, compared with 305 infections in 15,673 
person-years of followup without any claims for medical treatment of Crohn’s disease. The study 
reported a HR of 4.8 (95% CI, 2.7 to 8.3), comparing a combination of immunomodulators and 
corticosteroids (with or without infliximab) with no therapy, adjusted for age, gender, geographic 
region, health plan, and comorbidity. The corresponding unadjusted rate ratio was 5.4 (95% CI, 
0.7 to 19.7). 
Any Infection 
The study also reported four additional infections that were not specifically identified by the 
authors as serious. The study had 19 person-years of followup on patients receiving an 
immunomodulator and corticosteroid, compared with 15,673 person-years of followup on 
patients receiving no therapy.168 The reported infections included herpes simplex (zero in the 
combination group vs. 134 in the no therapy group), herpes zoster (zero in the combination 
group vs. 123 in the no therapy group), sepsis (six in the combination group vs. 1,833 in the no 
therapy group; the adjusted HR for sepsis, comparing a combination of immunomodulators and 
corticosteroids [with or without infliximab] with no therapy was 1.2; 95% CI, 0.8 to 1.8; the 
unadjusted rate ratio was 2.7; 95% CI, 1.0 to 5.9), and encephalopathy, encephalitis, or 
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meningitis (three in the combination group vs. 499 in the no therapy group; the unadjusted rate 
ratio for encephalopathy, encephalitis, or meningitis was 5.0; 95% CI, 1.0 to 14.6). 
Corticosteroids 
Table 52 summarizes the risk of serious infections in studies evaluating corticosteroids in 
patients with Crohn’s disease. Figure 24 and Table 53 summarize the risk of any infection in 
RCTs and observational studies evaluating corticosteroids in patients with Crohn’s disease. We 
also provided additional details regarding related studies. We did not identify any RCT or 
observational study that evaluated corticosteroids in patients with Crohn’s disease and reported 
on opportunistic infections. 
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Table 52. Summary of the risk of serious infections in observational studies comparing a corticosteroid alone or in combination with 
placebo or another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) Design Corticosteroid Comparison 
# of 
Serious 
Infections 
in Steroid 
Group 
# of 
Patients 
in 
Steroid 
Group 
# of Serious 
Infections 
in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
OR (95% 
CI) 
Adjusted 
OR (95% 
CI) 
Lichtenstein, 
2006131 
99 Prospective 
cohort 
Prednisone No prednisone 61 2142 45 4111 2.9 (1.9 to 
4.3) 
2.2 (1.5 to 
3.3) 
CI = confidence interval; OR = odds ratio; Steroid = corticosteroid 
 
Table 53. Summary of the risk of other infections in observational studies comparing a corticosteroid alone or in combination with 
placebo or another treatment in patients with Crohn’s disease 
Author, 
Year 
Followup 
(Weeks) Design Corticosteroid Comparison 
# of Other 
Infections 
in Steroid 
Group 
# of 
Patients 
in 
Steroid 
Group 
# of Other 
Infections 
in 
Comparison 
Group 
# of 
Patients in 
Comparison 
Group 
Unadjusted 
OR (95% 
CI) 
Goldstein, 
1967142 
NR Retrospective 
cohort 
Corticosteroid Never 
corticosteroid 
95 430 17 124 1.7 (1.0 to 
2.8) 
CI = confidence interval; NR = not reported; OR = odds ratio; steroid = corticosteroid 
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Figure 24. Summary of Peto odds ratios of other infections among randomized controlled trials comparing a corticosteroid alone or in 
combination with placebo or another treatment in patients with Crohn’s disease 
 
BUDE = budesonide; CI = confidence interval; Comp = comparison; NR = not reported; OR = odds ratio; PRED = prednisone; steroid = corticosteroid; UTI = urinary tract 
infections 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†The number of patients with urinary tract infections was reported to be higher in the budesonide twice daily group. 
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Corticosteroids Versus Placebo 
Two RCTs including 362 Crohn’s disease patients compared corticosteroids with placebo 
and reported on infections.65,177 They did not report on opportunistic infections. 
Serious Infections 
One RCT including 302 patients reported on serious infections.177 The study reported serious 
infections during the induction period in 2 percent of patients on prednisone and 4 percent of 
patients on placebo.177 During the maintenance trial, 7 percent of patients on prednisone and 2 
percent of patients on placebo had a serious infection.177  
Any Infection 
Two trials including 362 patients reported on any infection.65 177 The study reported non-
serious infections during the induction period in 32 percent of patients on prednisone and 13 
percent of patients on placebo.177 During the maintenance trial 13 percent of patients on 
prednisone and 19 percent of patients on placebo had a nonserious infection.177 A trial comparing 
budesonide with placebo reported common adverse events. The trial reported respiratory 
infections in 6 percent of patients on budesonide and 12 percent of patients on placebo (Peto OR, 
0.4; 95% CI, 0.1 to 1.6).65 The trial reported flu-like disorder in 6 percent of budesonide patients 
and 6 percent of placebo patients.  
Corticosteroids Versus No Corticosteroids 
One prospective study including 6,253 Crohn’s disease patients compared corticosteroids 
with no corticosteroids and reported on infections.131  
Serious Infections 
The trial reported serious infections in 3 percent of patients on prednisone taken at least 6 
months prior to the infection and 1 percent of patients not taking prednisone.131 The study 
reported a demographics and medication adjusted OR of 2.2 (95% CI, 1.5 to 3.3). The study did 
not report on opportunistic or other infections.  
Corticosteroids Versus No Therapy 
A claims-based study that included 8,581 Crohn’s disease patients reported opportunistic 
infections, candidiasis, and tuberculosis together.168 The study reported 25 of these infections in 
379 person-years of followup for corticosteroid use, compared with 305 infections in 15,673 
person-years of followup without therapy for Crohn’s disease. The study reported a HR of 3.2 
(95% CI, 2.1 to 4.8), comparing corticosteroids (with or without immunomodulators and 
infliximab) with no therapy, adjusted for age, gender, geographic region, health plan, and 
comorbidity. The HR for corticosteroids only, compared with no therapy, was also 3.2 (95% CI, 
2.1 to 4.8). 
Any Infection 
The study also reported on four additional infections that the authors did not specifically 
identify as serious. The study reported 379 person-years of followup for corticosteroid users and 
15,673 person-years of followup for the no therapy group.168 The reported infections included 
herpes simplex (three in the corticosteroid group vs. 134 in the no therapy group; the HR for 
corticosteroids only was 0.9; 95% CI, 0.2 to 2.8); herpes zoster (nine in the corticosteroid group 
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vs. 123 in the no therapy group; the HR for corticosteroids only was 3.1; 95% CI, 1.6 to 6.2); 
sepsis (72 in the corticosteroid group vs. 1,833 in the no therapy group; the adjusted HR 
comparing corticosteroids [with or without immunomodulators and infliximab] with no therapy 
was 1.6; 95% CI, 1.3 to 2.0; the HR for corticosteroids only was 1.6; 95% CI, 1.3 to 2.0); and 
encephalopathy, encephalitis, or meningitis (34 in the corticosteroid group vs. 499 in the no 
therapy group; the unadjusted rate ratio for corticosteroids only was 2.6; 95% CI, 1.8 to 3.7). 
Corticosteroids Versus Aminosalicylates 
Three RCTs including 525 Crohn’s disease patients compared corticosteroids with 
aminosalicylates and reported on infections.74,113,177 
Serious Infections 
One trial including 159 patients reported on serious infections. The study reported serious 
infections during the induction period in 2 percent of patients on prednisone and 0 percent of 
patients on sulfasalazine.177 During the maintenance trial, 7 percent of patients on prednisone and 
0 percent of patients on sulfasalazine had a serious infection.177  
Any Infection 
Three trials including 525 patients reported on any infection.74,113,177 One study reported non-
serious infections during the induction period in 32 percent of patients on prednisone and 14 
percent of patients on sulfasalazine.177 During the maintenance trial, 13 percent of patients on 
prednisone and 29 percent of patients on sulfasalazine had a non-serious infection.177 A RCT 
comparing 29 patients on budesonide with 28 patients on mesalamine reported 19 infections in 
budesonide patients and 16 infections in mesalamine patients.113 The infections reported included 
upper respiratory tract infections and urinary tract infections. A larger trial of budesonide 
compared with aminosalicylates reported 16 percent of budesonide and 13 percent of 
aminosalicylates patients had an infection.74 
Combination of Prednisone and Sulfasalazine Versus Sulfasalazine 
One RCT including 89 Crohn’s disease patients reported on infections.75  
Any Infection 
The 8-week induction trial reported 44 percent of patients on prednisone and 72 percent of 
patients on sulfasalazine had an infection75). It did not report serious infections and opportunistic 
infections. 
Aminosalicylates 
Figure 25 summarizes the risk of infection in the one RCT evaluating infections associated 
with use of aminosalicylates in patients with Crohn’s disease. 
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Figure 25. Summary of Peto odds ratios of other infections in a randomized controlled trial comparing an aminosalicylate alone or in 
combination with placebo or another treatment in patients with Crohn’s disease 
 
ASA = aminosalicylate; CI = confidence interval; Comp = comparison; Main = main intervention; OR = odds ratio; SUL = sulfasalazine 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
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Sulfasalazine Versus Placebo 
One RCT included 159 Crohn’s disease patients and reported on infections.177 
Serious Infections 
The trial reported serious infections in zero of 74 patients (0 percent) on sulfasalazine and 
three of 55 patients (5 percent) on placebo during the induction period.177 During maintenance 
therapy, the trial reported serious infections in zero of 61 patients (0 percent) on sulfasalazine 
and two of 101 patients (2 percent) on placebo. 
Any Infection 
The trial reported non-serious infections during the induction period in 14 percent of patients 
on sulfasalazine and 13 percent of patients on placebo.177 During the maintenance trial, 29 
percent of patients on sulfasalazine and 19 percent of patients on placebo had an infection. This 
RCT did not report on opportunistic infections. 
Studies Evaluating Patients With Crohn’s Disease and IBD  
One study reported results for Crohn’s disease and all IBD patients.150 In both groups, the 
study reported more infections in patients who used adalimumab or infliximab, compared with 
patients who had never used biologics.  
Studies Evaluating Patients With IBD  
Eight studies reported infections in IBD patients without separating Crohn’s disease from 
ulcerative colitis or indeterminate colitis patients. We provided details about these studies in 
Appendix F.  
Case-Control Studies Designed To Examine Specific Infections 
Two case-control studies including 2,538 IBD patients examined specific infections. One 
study reported on opportunistic infections139 and the other on herpes zoster.135 Researchers 
nested the case-control studies within a large primary care database covering multiple centers135 
and a single-center.139 Both studies may have patients that contributed to other studies using 
these data sources.133,134,136-138  
Combinations Including Infliximab 
The single-center case-control study included 300 IBD patients and reported on specific 
infections associated with combination therapy including infliximab.139 
Infliximab Versus No IBD Medication 
The single-center case-control study cross-referenced the system’s diagnostic index for 
inpatient and outpatient IBD patients with a viral, fungal, or bacterial opportunistic infection.139 
The study required microbiologic, pathologic, or physician consensus to confirm infection. The 
study analyzed and matched each of the first 100 consecutive infection cases diagnosed between 
1998 and 2003 with two controls (patients who did not have an opportunistic infection). The 
study matched patients by type of IBD, sex, geographic region, and duration of visits for IBD at 
the center. Three of 100 opportunistic infection cases (3 percent) had used infliximab alone while 
being treated at the center, compared with two of 200 controls (1 percent). Compared with no use 
of mesalamine, corticosteroids, immunomodulators, and infliximab, the age and matching factor 
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adjusted OR was 11.1 (95% CI, 0.8 to 148). The study did not provide the percent of cases and 
controls that did not use an IBD medication. One patients developed Epstein-Barr virus 
lymphoma, but the study did not provide the medication history. The authors also reported that 
no patient died as a result of their opportunistic infection. 
Combination of Infliximab, Thiopurines, and Corticosteroids Versus No IBD 
Medication 
The single-center case-control study reported five of 100 opportunistic infection cases (5 
percent), compared with zero of 200 matched controls (0 percent), used a triple combination of 
infliximab, thiopurines, and corticosteroids.139 
Combination of Infliximab and Thiopurines Versus No IBD Medication 
The single-center case-control study reported one of 100 opportunistic infection cases (1 
percent), compared with five of 200 matched controls (2 percent), used a combination of 
infliximab and thiopurines.139 Compared with no IBD medication use, the age and matching 
factor adjusted OR was 1.6 (95% CI, 0.1 to 19).  
Combinations Including Immunomodulators 
Two case-control studies including 2,538 IBD patients reported on specific infections 
associated with combination therapy including immunomodulators.135,139 
Thiopurines Versus No IBD Medication 
The single-center case-control study reported that 20 of 100 opportunistic infection cases (20 
percent), compared with 31 of 200 matched controls (15 percent), used thiopurines alone. 
Compared with no IBD medication, the age and matching factor adjusted OR was 3.4 (95% CI, 
1.5 to 7.5).139  
A case-control study of herpes zoster infections looked at IBD patients within a multi-center 
general practice database.135 The study matched controls to cases on sex, year of birth, and 
duration of followup (prior to the case’s herpes zoster diagnosis date). The study matched up to 
four controls that did not have herpes zoster during the followup to each case. Herpes zoster 
cases had 4 times higher odds of having a prescription for thiopurines alone, versus no IBD 
medication, in the 30 days prior to the index date, compared with controls (OR, 4.1; 95% CI, 1.9 
to 8.7). When the study adjusted corticosteroids and mesalamine in the model (instead of 
excluding them), the OR was 3.1 (95% CI, 1.7 to 5.6). When the study considered thiopurine use 
31 to 90 days before herpes zoster index date, the odds of infection with thiopurine use were no 
longer higher (OR, 0.6; 95% CI, 0.2 to 1.8). 
Combination of Thiopurines and Corticosteroids Versus No IBD Medication 
The single-center case-control study reported that 16 of 100 opportunistic infection cases (16 
percent), compared with six of 200 matched controls (3 percent), used a combination of 
infliximab and thiopurines.139 Compared with no IBD medication use, the age and matching 
factor adjusted OR was 17.5 (95% CI, 4.5 to 68). The multi-center case-control study reported 
herpes zoster cases had 3 times higher odds of having a prescription for thiopurines alone, versus 
no IBD medication, in the 30 days prior to the index date, compared with controls (OR, 3.0; 95% 
CI, 1.2 to 7.3).135 
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Combinations Including Corticosteroids 
Two case-control studies including 2,538 IBD patients reported on specific infections 
associated with combination therapy including corticosteroids.135,139 
Corticosteroids Versus No IBD Medication 
The single-center case-control study reported that 16 of 100 opportunistic infection cases (15 
percent), compared with 27 of 200 matched controls (14 percent), used corticosteroids alone, 
compared with no IBD medication (the age and matching factor adjusted OR was 2.2, 95% CI, 
1.0 to 4.9).139 The multiple center case-control study reported herpes zoster cases had 60 percent 
higher odds of having a prescription for thiopurines alone, versus no IBD medication, in the 30 
days prior to the index date, compared with controls (OR, 1.6; 95% CI, 1.1 to 2.4).135 
Combinations Including Aminosalicylates 
One multiple center case-control study including 2,238 IBD patients reported on specific 
infections associated with combination therapy including aminosalicylates.135 
Mesalamine Versus No Mesalamine 
The case-control study reported that herpes zoster patients did not have an increased odds of 
having a prescription for mesalamine, compared with controls, in the 30 days prior to the index 
date (OR, 0.9; 95% CI, 0.7 to 1.2).135 
Tuberculosis 
Tuberculosis is of special concern in Crohn’s disease because the treatments suppress the 
immune system. The U.S. Food and Drug Administration has mandated a warning on 
adalimumab, infliximab, and certolizumab pegol regarding the risk of tuberculosis.178-180 Nine 
RCTs (n=3,295), two prospective studies (n=733), and five observational studies (n=2,655) 
reported on the risk of tuberculosis in patients receiving treatment for Crohn’s disease (Appendix 
D, Evidence Table 14). Four of the RCTs excluded patients with a prior history of tuberculosis or 
initiating treatment prior to randomization. None of the RCTs described active assessment of 
tuberculosis specifically.  
No RCTs of natalizumab, immunomodulators, corticosteroids, or aminosalicylates reported 
tuberculosis as an outcome. One study randomized patients to sulfasalazine, prednisone, or 
azathioprine, and included isoniazid as part of the treatment regimen in patients randomized to 
prednisone because of the known increased risk of tuberculosis associated with prednisone.56  
Table 54 summarizes the reported rates of tuberculosis in studies of the treatment of Crohn’s 
disease. We also provided additional details regarding related studies. 
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Table 54. Summary of reported rates of tuberculosis in randomized controlled trials* comparing 
the safety of therapies for the management of Crohn’s disease 
Author, 
Year 
Design, 
Duration 
 
N With CD 
 
New Users 
Only (Y/N) 
Comparison, 
Dose 
Specific 
Aim 
(Y/N) 
Ascertainment 
of Tuberculosis 
During Study 
 
Tuberculosis 
Testing Before 
Enrollment 
Concomitant 
Medications 
Tuberculosis 
Results 
Hanauer, 
200286 
RCT, 52 wk 
 
573  
 
N 
Infliximab 
vs. 
placebo 
N Not specified 
 
N 
ASA 
Steroids 
IMM 
Antibiotics 
1/385 (<1%) 
vs. 
0/188 (0%) 
Colombel, 
201045 
RCT, 52 wk 
 
503  
 
Y 
Infliximab vs. 
azathioprine 
vs.  
infliximab + 
azathioprine  
N Not specified 
 
Y 
ASA 
Steroids 
Antibiotics NR 
0/161 (0%) 
vs. 
0/163 (0%) 
vs. 
1/179 (1%) 
Colombel, 
200995 
RCT, 52 wk 
 
778  
 
N 
Adalimumab 
vs.  
placebo 
N Not specified 
 
Y 
ASA 
Steroids 
IMM 
Antibiotics NR 
2/517 (<1%) 
vs. 
0/261 (0%) 
Sandborn, 
200783 
RCT, 52 wk 
 
55  
 
N 
Adalimumab 
vs.  
placebo 
 
N Not specified 
 
Y 
ASA 
Steroids 
IMM 
Antibiotics 
0/37 (0%) 
vs. 
0/18 (0%) 
Sandborn, 
200738 
RCT, 4 wk 
 
325  
 
N 
Adalimumab 
vs.  
placebo 
 
N Not specified 
 
Y 
 0/159 
vs. 
0/166 
Hanauer, 
200637 
RCT, 4 wk 
 
299  
 
Y 
Adalimumab 
vs. 
placebo 
 
N Not specified 
 
Y 
ASA 
Steroids 
IMM 
Antibiotics 
0/225 (0%) 
vs. 
0/74(0%) 
 
Schreiber, 
200784 
RCT, 18 wk 
 
668  
 
N 
Certolizumab 
pegol 
vs. 
placebo 
N Not specified 
 
Y 
ASA 
Steroids 
IMM 
Antibiotics 
1/216 (<1%) 
vs. 
0/212 (0%) 
 
Schreiber, 
200540 
RCT, 12 wk 
 
292  
 
N 
Certolizumab 
pegol 
vs. 
placebo 
N Not specified 
 
Y 
 0/219 
vs. 
0/73 
Winter, 
200141 
RCT, 12 wk 
 
92  
 
N 
Certolizumab 
pegol 
vs. 
placebo 
N Not specified 
 
Y 
 0/68 
vs. 
0/24 
ASA = aminosalicylates; CD = Crohn’s disease; IBD = inflammatory bowel disease; IMM = immunomodulators; N = no; NR = 
not reported; RCT = randomized controlled trial; Steroids = corticosteroids; vs. = versus; wk = weeks; Y = yes 
*Four observational studies reported on tuberculosis. Two cases among 743 infliximab users compared with no cases among 666 
never users of biologic.153 No cases among 757 patients treated with combinations of medications with infliximab or infliximab 
alone.137,145,173 
197 
Adalimumab Versus Placebo 
Four RCTs37,38,82,83 including 1,447 patients compared adalimumab with placebo. One of 
those studies82 reported two cases of tuberculosis, one patient receiving adalimumab 40 mg 
weekly and one patient receiving adalimumab 40 mg every other week, compared with no cases 
of tuberculosis in the placebo group. The other three studies reported no incident cases of 
tuberculosis. One study excluded patients with untreated tuberculosis within 3 months.38 
Certolizumab Pegol Versus Placebo 
Three RCTs including 812 Crohn’s disease patients compared certolizumab pegol with 
placebo and reported on tuberculosis.40,41,84 A maintenance trial after induction response reported 
one tuberculosis case in the certolizumab pegol group (less than 1 percent of 216 patients) during 
26 weeks of followup despite having excluded purified protein derivative positive patients from 
the study.84 The trials reported no other tuberculosis cases.40,41 
Infliximab Versus Placebo 
One RCT86 including 573 patients evaluated infliximab compared with placebo. The trial 
detected one incident case of tuberculosis in an infliximab patient. 
Other Combinations With TNF-Alpha Inhibitors 
An induction trial45 including 503 Crohn’s disease patients compared infliximab, 
azathioprine, and the combination of infliximab and azathioprine. The trial reported one incident 
case of tuberculosis in the group receiving infliximab and azathioprine. 
Two prospective studies (n=733) and five retrospective studies (n=2,655) reported on 
tuberculosis.132,137,145,153,161,165,173 Six studies compared combinations of medications with a TNF-
alpha inhibitor and reported no tuberculosis cases.132,137,145,161,165,173 One retrospective study 
reported two tuberculosis cases among 743 infliximab users, compared with no cases among 666 
non-users.153 
Infusion- and Injection-Site Reactions 
Infusion and injection-site reactions can include a wide range of symptoms (from local 
irritation or pain to anaphylaxis) that occur during or shortly after an infusion. This definition is 
generally consistent (when reported) in the studies we included. Other types of reactions can 
occur a few days to a few weeks after medication administration, including hypersensitivity-type 
reactions, delayed infusion reactions, and serum sickness. We did not address these longer-term 
reactions in this review. In some cases, the study authors did not define the symptoms and timing 
of the infusion or injection-site reactions; we included these studies in this review.  
Twenty-two RCTs including 6,809 patients reported infusion reactions as an outcome by 
comparison group, one of which addressed infusion reactions as a primary outcome of interest 
(Appendix D, Evidence Table 14).88 Four prospective studies, with 1,067 patients, and 10 
retrospective studies, with 2,972 patients, reported on infusion reactions. Three observational 
studies mentioned active ascertainment as a means of identifying infusion reactions.138,161,181 All 
retrospective studies relied on chart reviews to identify infusion reactions. Many of the 
prospective and retrospective studies specifically stated or implied that patients were pre-treated 
with medications at the infusion center to prevent infusion reactions. Most RCTs did not report 
pre-treating patients with medications to prevent infusion reactions.  
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Natalizumab 
Figure 26 summarizes the data on infusion- and injection-site reactions in RCTs evaluating 
natalizumab in patients with Crohn’s disease. We also provided additional details regarding 
related studies. 
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Figure 26. Summary of Peto odds ratios of infusion- and injection-site reactions among randomized controlled trials comparing 
natalizumab to placebo in patients with Crohn’s disease 
 
CI = confidence interval; comp = comparison; NAT = natalizumab; OR = odds ratio 
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Natalizumab Versus Placebo 
Three RCTs including 1,414 Crohn’s disease patients reported infusion reactions within 2 
hours of the start of infusion in patients receiving natalizumab, compared with placebo. These 
appeared in two publications.32,33 During the induction trials, the trials reported infusion 
reactions in 9 to 11 percent of natalizumab and 7 to 8 percent of placebo patients.32,33 
Researchers re-randomized 228 responders from one of these trials for a 48-week maintenance 
trial.33 They reported any adverse event occurring during or within 2 hours of infusion in 7 
percent of natalizumab users and 8 percent of placebo users.  
Combination of Natalizumab and Infliximab Versus Infliximab 
One 20-week RCT including 79 non-responders to infliximab randomized patients to 
continued infliximab alone or natalizumab and infliximab. Three of 52 patients taking 
natalizumab and infliximab had a non-serious hypersensitivity reaction during or within 120 
minutes of infusion, compared with zero of 27 patients taking only infliximab.35 
TNF-Alpha Inhibitors 
For studies that we combined in Key Questions 1 and 2 we tried to conduct meta-analyses 
separately for induction and maintenance RCTs comparing TNF-alpha inhibitors with placebo in 
terms of infusion- and injection-site reactions. However, we were unable to do so because of 
statistical heterogeneity (I-squared, 82 percent for induction trials and 87 percent for 
maintenance trials). Figures 27 and 28 summarize the data on infusion- and injection-site 
reactions in RCTs and observational studies evaluating TNF-alpha inhibitors in patients with 
Crohn’s disease. We also provided additional details regarding related studies. 
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Figure 27. Summary of Peto odds ratios of infusion- and injection-site reactions among randomized controlled trials comparing a TNF-
alpha inhibitor alone or in combination with another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; AZA = azathioprine; CI = confidence interval; comp = comparison; CP = certolizumab pegol; IFX = infliximab; OR = odds ratio; THIO = thiopurine; TNF = 
tumor necrosis factor-alpha inhibitor  
* We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
† Infusion and injection site reactions were defined as any adverse event occurring within 1 hour of infusion/injection. 
‡ Infusion and injection site reactions were not defined in the study. 
§ Infusion and injection site reactions were defined as any adverse event that occurred at the infusion/injection site and was temporarily related to the infusion/injection. 
║ Infusion and injection site reactions were defined as any adverse event occurring within 2 hours of infusion/injection. 
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Figure 28. Summary of Peto odds ratios of infusion- and injection-site reactions among observational studies comparing a TNF-alpha 
inhibitor alone or in combination with another treatment in patients with Crohn’s disease 
 
ADA = adalimumab; ASA = aminosalicylate; CI = confidence interval; comp = comparison; CP = certolizumab pegol; IFX = infliximab; IMM = immunomodulator; MTX = 
methotrexate; NR = not reported; OR = odds ratio; Pro = prospective study; Retro = retrospective study; Steroid = corticosteroids; THIO = thiopurine; TNF = tumor necrosis 
factor-alpha inhibitor 
*We did not calculate odds ratios when there were fewer than five events total in the main intervention and comparison arms. 
†Adjusted odds ratio, 0.7 (95% CI, 0.4 to 1.1). 
‡Adjusted odds ratio, 0.3 (95% CI, 0.2 to 0.9). 
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Adalimumab Versus Placebo 
Four RCTs including 1,457 Crohn’s disease patients compared adalimumab with placebo and 
reported injection reactions. In two induction trials, injection-site reactions were more common 
in adalimumab (11 to 29 percent) and placebo (10 to 16 percent) patients.37,38 
A 52-week maintenance trial of 55 patients who achieved remission during induction, 
reported injection-site reactions in one of 37 patients on adalimumab and two of 18 patients on 
placebo.83 Those who the trial did not randomize for the maintenance study received adalimumab 
without blinding. Twenty-six of 221 (12 percent) patients who entered open-label adalimumab 
therapy, or were not randomized, had an injection-site reaction.83 The publications that studied 
maintenance and induction reported different numbers of patients randomized in the induction 
trial (n=299 and n=276). 
A 52-week maintenance trial of responders from a 4-week induction period reported 
injection-site reactions in 26 percent of patients on adalimumab and 14 percent of patients on 
placebo who re-initiated adalimumab after week 12 (blinding maintained).95 Another publication 
of this trial reported injection-site reactions during the randomized followup in 5 percent of 
patients on adalimumab and less than 1 percent of the patients on placebo.82 The publications did 
not define injection-site reactions. 
Other Combinations With Adalimumab 
A prospective cohort of 673 patients, treated with adalimumab with or without concomitant 
aminosalicylates, corticosteroids, or immunomodulators, reported no injection-site reactions at 
18 weeks.161 
Certolizumab Pegol Versus Placebo 
Five RCTs including 1,910 Crohn’s disease patients compared certolizumab pegol with 
placebo and reported infusion or injection-site reactions.39-41,84 The duration of the four induction 
trials ranged from 6 to 26 weeks. Reactions occurred in 0 to 11 percent of certolizumab pegol 
and 0 to 14 percent of placebo patients.39-42 The Peto OR ranged from 0.2 to 6.4.39,40,42 
A maintenance trial of 428 patients who responded to certolizumab pegol induction39 
reported any local reaction to infusion in six out of 216 patients on certolizumab pegol (3 
percent) and 31 out of 212 patients on placebo (15 percent ), during the 18-week followup.84 The 
corresponding Peto OR was the same as the induction OR (0.2; 95% CI, 0.1 to 0.4). 
Infliximab Versus Placebo 
Four RCTs including 1,022 patients compared infliximab with placebo and reported infusion 
reactions.44,85-87 Infusion reactions, defined as an adverse event during or within 2 hours of 
infusion, occurred in 6 percent of infliximab and 0 percent of placebo patients, during an 
induction trial.44  
A 36-week trial85 compared retreatment with infliximab or placebo among 73 responders to a 
single induction dose in a previous 12-week trial.43 The trial reported an acute infusion reaction 
with dyspnea in one of 36 infliximab patients. The trial did not report infusion reactions in 36 
patients on placebo, although it is unclear if infusion reactions were a possible safety outcome 
for placebo patients. The trial corresponding to the induction period reported infusion reactions 
only for those who received two doses of infliximab and only during the second infusion (two of 
29 patients).43  
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A 40-week maintenance trial, of 282 responders and non-responders to a 14-week induction 
period with infliximab for fistulizing Crohn’s disease, compared infliximab with placebo.87 They 
reported infusion reactions during or within 1 hour of infusion in 9 percent of patients on 
infliximab and 3 percent of patients on placebo, during the randomized period. During induction 
(among patients randomized for maintenance therapy), 7 percent of patients on infliximab and 8 
percent of patients on placebo had an infusion reaction (the trial did not randomize nine of 306 
given induction because of adverse events; the trial did not report the adverse events). At 22 
weeks, placebo patients were eligible to crossover to 5 mg/kg intravenous every 8 weeks 
infliximab treatment; and patients receiving 5 mg/kg of infliximab were eligible to have the dose 
increased to 10 mg/kg (the trial maintained blinding after crossover). During crossover, 9 percent 
of those who had a dose increase to 10 mg/kg experienced an infusion reaction, compared with 
23 percent of patients who crossed over to infliximab from placebo.  
A 52-week maintenance trial, of 573 responders and non-responders to a 2-week induction 
period of a single infliximab dose, compared infliximab with placebo and reported adverse 
events during or within 1 hour of infusion.86 The trial reported infusion reactions in 21 percent of 
infliximab patients and 9 percent of placebo patients, during the maintenance period (the trial did 
not report reactions during the initial infusion).  
Infliximab Versus Azathioprine 
One RCT including 324 Crohn’s disease patients compared infliximab with azathioprine and 
reported on infusion reactions.45 Seventeen percent of patients taking infliximab and 6 percent of 
patients taking azathioprine experienced an adverse event during or within 1 hour of infusion.  
Other Combinations With Infliximab 
Four retrospective studies including 1,152 Crohn’s disease patients met the inclusion criteria, 
but the studies may have misclassified the concomitant medications (as described previously in 
the mortality section). The studies evaluated the safety profile of infliximab use at their 
centers.137,145,164,175 A retrospective study reported infusion reactions that resulted in medication 
discontinuation in 5 percent of 127 patients taking infliximab and an immunomodulator, 
compared with 13 percent of 71 patients receiving infliximab without concomitant 
immunomodulators, as recorded in a database that included most of the patients treated with 
infliximab at the center.175 The other studies reported infusion reactions in 2 to 5 percent of 
patients receiving a triple combination of infliximab, immunomodulators, and corticosteroids, 4 
to 20 percent of patients receiving the combination of infliximab and immunomodulator, 0 to 7 
percent of patients receiving the combination of infliximab and corticosteroid, and 5 to 21 
percent of patients receiving only infliximab.137,145,164 In a previous report from one of these 
centers, 19 infusion reactions occurred in the first 100 patients given infliximab.138 However, we 
noted a discrepancy between the two reports from this center. One article reported concomitant 
medications in 18 of 19 infusion reactions among the first 100 patients,138 but the other article 
reported concomitant medications in only 17 of 19 infusion reactions among the first 500 
patients.137 
Combination of Infliximab and Immunomodulators Versus Infliximab  
Three RCTs including 468 Crohn’s disease patients and three retrospective studies 
(n=1,025), compared a combination of infliximab and immunomodulators with infliximab and 
reported infusion reactions.45,88,89 A 50-week induction trial compared an infliximab-azathioprine 
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combination with infliximab among patients who were naïve to TNF-alpha inhibitors, 
azathioprine, 6-mercaptopurine, and methotrexate.45 They reported adverse events during or 
within 1 hour of infusion in 5 percent of 179 patients taking infliximab and azathioprine and 17 
percent of 163 patients taking infliximab.45  
A 104-week induction trial, of blinded physicians and unblinded steroid-dependent luminal 
Crohn’s disease patients, reported severe infusion reactions in zero of 23 patients taking 
infliximab and azathioprine and one of 23 patients taking infliximab and hydrocortisone.88 The 
group taking infliximab and azathioprine included only azathioprine-naïve patients whereas the 
infliximab group included both azathioprine-naïve patients as well as those who had previously 
taken azathioprine for less than a month (but stopped because of intolerance or severe adverse 
events). The infliximab group received a pre-infusion dose of hydrocortisone whereas the 
infliximab and azathioprine group did not. 
A 104-week open-label retreatment trial of non-fistulizing Crohn’s disease patients reported 
three unspecified infusion reactions in the 40 patients taking infliximab and an 
immunomodulator (it is possible that these reactions occurred in the same person), and two 
infusion reactions in the 40 patients taking infliximab.89  
One prospective and three retrospective observational studies including 1,025 patients 
reported on infusion reactions.148,154,162,182 The prospective study154 included patients receiving 
infliximab without concomitant immunomodulators. The study occurred in 2000 and 2001, 
before the authors reported that concomitant immunomodulators appeared to be associated with a 
decreased risk of infusion reactions and changed their practice pattern.183 During 2002 and 2003, 
a study treated patients with infliximab and concomitant azathioprine, 6-mercaptopurine, or 
methotrexate.154 The study gave luminal disease patients a single induction infusion, and 
fistulizing disease patients a three-dose induction regimen (at 0, 2, and 6 weeks). If clinicians felt 
the patients lost response or had an acute flare, they treated patients with infliximab and 
considered them at risk of infusion reaction. Infusion reactions in retreated patients occurred in 
16 percent of 115 patients taking infliximab and an immunomodulator, compared with 40 
percent of 59 patients taking infliximab without an immunomodulator. The Peto OR was similar 
for both the combination of infliximab and a thiopurine (OR, 0.3; 95% CI, 0.2 to 0.7) and the 
combination of infliximab and methotrexate (OR, 0.3; 95% CI, 0.1 to 0.6), compared with 
infliximab. 
The retrospective studies reported infusion reactions in 11 to 18 percent of infliximab 
combined with immunomodulators, compared to 22 to 25 percent in patients not receiving a 
concomitant immunomodulators.148,162,182,184 The Peto OR favored infliximab combined with 
immunomodulators to decrease infusion reactions in all studies. We did not perform a meta-
analysis because of the different time periods of followup, definitions of infusion reaction, and 
immunomodulators allowed. 
Combination of Infliximab and Immunomodulators Versus 
Immunomodulators 
Two RCTs45,46 including 452 Crohn’s disease patients reported infusion reactions in users of 
infliximab and an immunomodulator, compared with users of an immunomodulator alone.  
A 52-week induction trial in steroid-dependent, luminal Crohn’s disease patients reported a 
severe infusion reaction in one of 57 patients taking infliximab and a thiopurine, and zero of 56 
patients taking a thiopurine alone.46 A 50-week induction trial compared infliximab and 
azathioprine with azathioprine alone among patients who were naïve to TNF-alpha inhibitors, 
206 
azathioprine, 6-mercaptopurine, and methotrexate.45 The trial reported adverse events during or 
within 1 hour of infusion in 5 percent of patients taking infliximab and azathioprine, and 6 
percent of patients taking azathioprine.45  
Combination of Infliximab and Thiopurines Versus Combination of 
Infliximab and Methotrexate 
Two observational studies including 291 Crohn’s disease patients compared a combination of 
infliximab and azathioprine with a combination of infliximab and methotrexate and reported 
infusion reactions.154,162 A prospective study of retreated patients reported infusion reactions by 
type of concomitant immunomodulators. Infusion reactions occurred in 18 percent of patients 
taking infliximab and azathioprine, compared with 14 percent of patients taking infliximab and 
methotrexate.154 A retrospective study of 1 year mean followup reported infusion reactions in 14 
percent of patients taking infliximab and a thiopurine, and 13 percent of patients taking 
infliximab and methotrexate.162  
Immunomodulators 
Azathioprine Versus Placebo 
One RCT including 96 patients evaluated infusion reactions (not defined) following a single 
infusion of azathioprine 40 mg/kg, compared with placebo.59 The trial reported infusion reactions 
in 11 of 51 patients receiving azathioprine (22 percent) and one of 45 patients receiving placebo 
(2 percent). The corresponding Peto OR was 5.8 (95% CI, 1.7 to 19.2). 
Studies Evaluating Patients With IBD  
Four studies reported infusion- and injection-site reactions in IBD patients without separating 
Crohn’s disease patients from ulcerative colitis or indeterminate colitis patients. We provided 
details about these studies in Appendix F.  
Bone Fractures 
We did not identify any studies comparing biologics, immunomodulators, or 
aminosalicylates in terms of the risk of bone fracture. Three studies including 1,032 patients with 
at least one corticosteroids group reported bone fractures (Table 55; Appendix D, Evidence 
Table 14).127,185,186 Two of these studies excluded patients who had used medications for 
preventing fractures or osteoporosis,187 such as bisphosphonates; hormone replacement therapy; 
and certain doses of calcium, fluoride or Vitamin D supplements, within 6 or 24 months of the 
study.127,185 One of the studies that made these exclusions recruited patients with osteoporosis.127 
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Table 55. Summary of the risk of bone fracture in studies comparing the safety of therapies for the management of Crohn’s disease 
Author, Year 
Design, 
Duration 
 
N CD/IBD 
 
New Users 
Only / Specific 
Aim (Y/N) 
Comparison, Dose 
 
Source for Non-RCTs 
Assessment of Bone 
Fracture 
Surveillance 
 
Blinded 
Assessments 
(Y/N) 
Concomitant 
Medications 
Bone Fracture 
Results 
Schoon, 
2005185 
RCT, 2y 
 
271 CD 
 
N / Y 
Budesonide, 9 mg qd vs. 
prednisolone, 40 mg qd 
Vertebrae with a height 
reduction of >20% as 
measured by X-ray and 
traumatic fractures  
Active 
 
Y 
ASA, IMM, vitamin 
D and calcium 
supplementation  
2/137 (2%) 
vs. 
3/134 (2%) 
Siffledeen, 
2007127 
Cross-sectional 
 
207 CD 
 
N / Y 
Steroid use vs. no steroid 
use in past year 
 
Questionnaire 
Vertebrae with a height 
reduction of >20% and a loss 
of surface area >10% in the 
presence of a biconcave, 
crush, or wedge deformity as 
measured by DXA scan 
Active 
 
Y 
NR 25/105 (24%) 
vs. 
17/102 (17%) 
Bernstein, 
2003186 
Case-control 
 
116 CD 
 
N / Y 
Steroid use in two years 
prior to fracture vs. no 
steroid use in two years 
prior to fracture 
 
Electronic pharmacy 
record 
ICD-9 codes 805, 807.0, 
807.1, 813 and 820 
representing fractures at the 
hip, spine, ribs or wrist 
NA NR 7/13 (54%) 
vs. 
23/103 (22%) 
Goldstein, 
1967142 
Retrospective 
cohort, NR 
 
554 IBD 
N / N 
Steroid non-user vs. 
steroid user 
 
Chart review 
Pathologic fractures 
recorded in patient chart 
Passive 
 
NR 
NR* 0/124 (0%) 
vs. 
6/430 (1%) 
ASA = aminosalicylates; CD = Crohn’s disease; DXA = dual energy x-ray absorptiometry; IBD = inflammatory bowel disease; ICD-9 = International Classification of Diseases, 
Ninth Revision; IMM = immunomodulators; mg = milligrams; N = no; NA = not applicable, secondary database analysis; NR = not reported; qd = once daily; RCT = randomized 
controlled trial; vs. = versus; y = year; Y = yes 
* Concomitant medication use other than aminosalicylates was deemed unlikely because the last point of data collection was 1965. 
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Budesonide Versus Prednisolone 
One 2-year RCT (n=271) specifically compared the risk of vertebral fractures between 
budesonide and prednisolone in ileal or ileocolonic uncomplicated Crohn’s disease.185 The study 
found a similar percentage of vertebral or traumatic fractures in both study groups (2 percent). 
The authors also reported that 14 percent of patients had non-symptomatic vertebral fractures at 
baseline.  
Corticosteroids Versus No Corticosteroids 
A cross-sectional study of 207 Crohn’s disease patients compared questionnaire-reported use 
of corticosteroids in the year prior to a dual-energy X-ray absorptiometry (DXA) scan with no 
reported use of corticosteroids in the prior year.127 Seventeen percent of 102 non-users had a 
vertebral fracture, compared with 24 percent of 105 corticosteroid users. The study reported a 
Pearson correlation coefficient P-value of 0.27 for this comparison. A case-control study of 
Crohn’s disease patients reported seven out of 13 cases of hip, spine, rib, or wrist fracture had 
used corticosteroid within 2 years of injury (54 percent), compared with 23 corticosteroid users 
among 103 controls (22 percent).186 
Studies Evaluating Patients With IBD  
One retrospective cohort reported on bone fractures in the treatment of IBD without 
separating Crohn’s disease from ulcerative colitis or indeterminate colitis (see Appendix F). 
Studies Reporting Results for Crohn’s Disease and IBD 
A case-control study reported similar rates of bone fracture for all IBD patients (30 percent 
of 40 cases of bone fracture were corticosteroid users, compared with 22 percent of 276 controls; 
the unadjusted OR was 1.8; 95% CI, 0.6 to 3.7).186 
Study Quality 
We rated many of the studies containing data relevant to Key Question 3 as low quality for 
assessing the question of patient safety because they did not report on the specific safety 
outcomes that we sought to assess in this review. In many cases, the studies did not report their 
primary exposure-outcome relationship sufficiently and did not account for confounding and 
selection bias in the safety analyses. Another common reason we rated studies as poor quality 
was the inability to adjust for confounders because of the small number of events, even if all 
other reporting and bias adjustment categories were sufficient. 
Of the prospective and retrospective observational studies, we rated all as poor quality except 
eight. We rated seven studies good quality and one study fair quality. Of the nine included case-
control studies, we rated four good quality and five poor quality (see Appendix D, Tables 15 and 
16).  
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Key Question 4: Effectiveness of Therapies Used To Prevent 
Post-Operative Recurrence as Pertains to Patient-Reported 
Outcomes 
Studies Included 
We included two studies with 120 participants, in KQ4--an RCT and a prospective cohort 
study (Appendix D, Evidence Tables 17-20).188,189 These studies considered comparisons with 
azathioprine and mesalamine; no evidence is available for this KQ with regard to other agents. 
Study Design and Population Characteristics  
Randomized Controlled Trial 
The RCT was a 1-year, double-blind, double-dummy, randomized trial which took place in 
21 gastroenterology centers in Austria, the Czech Republic, Germany, and Israel.188 The study 
participants were 78 adults with Crohn’s disease who had undergone resection with ileocolonic 
anastomosis in the preceding 6 to 24 months without subsequent clinical recurrence. The 
participants had a CDAI score less than 200, but with moderate or severe endoscopic recurrence. 
The study drugs were azathioprine 2.0-2.5 mg/kg/day (N=41) or mesalamine 4 g/day (N=37) 
over 1 year.  
The mean age in the groups was 35.5 years for azathioprine and 36.0 for mesalamine. Fifty-
nine percent of the azathioprine group and 54 percent of the mesalamine group were male. 
Proportions of continuous, recurrent, and unknown course were similar in the two groups. Mean 
baseline IBDQ in the two groups was 191 and 175 for azathioprine and mesalamine, 
respectively.  
Observational Study 
The observational study189 was a prospective cohort study with 42 participants, which 
investigated the influence of azathioprine on postoperative recurrence in a subgroup of Crohn’s 
disease patients considered to have aggressive disease. In a nested case-control study, controls 
were patients selected to treatment but intolerable to azathioprine or 6-mercaptopurine; the study 
compared their postoperative course with that of patients receiving and tolerating the drugs 
postoperatively.  
Twenty-eight participants received azathioprine, compared with 14 controls. The participants 
receiving azathioprine had a median age of 34.5 years (range, 17 to 71 years); the controls had a 
median age of 38.0 years (range, 19 to 64 years). Of patients receiving azathioprine, three (10 
percent) were smokers, compared with none of the controls. The duration of disease among 
participants receiving azathioprine was a median of 13 years (range, 0 to 34 years); among 
controls it was a median of 12.5 years (range, 0 to 36 years). Fourteen (50 percent) of the 
azathioprine recipients and six (43 percent) of the controls had perianal disease. Median 
followup among azathioprine recipients and controls was 85.1 months (range, 23 to 139 months) 
and 78.7 months (range, 25.4 to 140 months), respectively. 
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Study Results 
Randomized Controlled Trial 
The RCT used the IBDQ as its patient-reported outcome.188 The change in mean IBDQ score 
from baseline (azathioprine, 191; mesalamine, 175) to last on-treatment visit (azathioprine, 200; 
mesalamine, 180) was similar in both treatment arms (change in the azathioprine group, 9; 
standard deviation, 17.7, change in the mesalamine group, 5; standard deviation, 27.4; P=0.4565, 
two-sided Wilcoxon test). 
Observational Study 
The prospective cohort used as its patient-reported outcome the patients’ assessment of 
general health according to a visual analogue scale (VAS) integrated over time.189 The VAS used 
runs from 0 to 100, where 0 is the worst possible score and 100 corresponds to perfect health. 
The authors stated that “repeated observations on the VAS …were integrated over time as a way 
of describing the patients’ condition during the study period.”189 The study did not offer any 
more details. 
The study did not find any difference between the groups in perceived health over time, as 
evaluated on the VAS. In the azathioprine group, the mean VAS integrated over time was 65.4 
(range, 0 to 99.4); in the control group it was 55.5 (range, 14.6 to 98.6). The study rated this 
difference as not statistically significant, although it did not provide any measures of variation. 
Study Quality and Limitations 
Randomized Controlled Trial 
The risk of bias for the RCT188 is low. However, one should give consideration to the fact 
that the study was industry-funded and that industry investigators were among the co-authors. 
The study did not provide any information on what role industry played in design or analysis. 
Consistency is unclear, given that this is a single study. With regard to directness, this study is 
direct. The study is precise. In summary, the quality of this study is high. 
Observational Study 
The risk of bias for this study is moderate to high,189 given its small sample size and 
uncontrolled nature; in addition, it is unclear whether the study blinded participants to their 
treatment assignment, and whether the study authors (in “integrating” the VAS over time [about 
which no detail was given]), were blinded to the participants’ treatment group. Consistency is 
unclear given that this is a single study. With regard to directness, this study is direct. We could 
not determine the precision given the lack of information. In summary, the quality of this study is 
low. Limitations of this study include the lack of information on variation and statistical 
procedures used in integrating the VAS, and that the study selected a measure of patient outcome 
not used in other studies (e.g., the SF-36 or IBDQ). 
Pediatric Results 
Few studies compared the efficacy or safety of Crohn’s disease treatments in the pediatric 
population (younger than 18 years old).  
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Five randomized controlled trials (RCTs) compared the efficacy of therapies, alone or in 
combination, to induce or maintain remission in children with Crohn’s disease. No other RCTs 
that included participants less than 18 years of age reported results separately for the pediatric 
population. 
Nine studies reported the comparative safety of therapies alone or in combination in children 
with Crohn’s disease. Of these nine studies, the majority studied height or weight change as their 
primary outcomes of interest. Five additional studies included both children and adults, but did 
not report results separately for the pediatric population.  
Key Question 1: Effectiveness of Therapies To Induce Remission in 
Children 
Key Points 
Disease Activity Scales 
• The combination therapy 6-mercaptopurine and prednisone was more effective than 
prednisone alone in reducing remission after 1 month of treatment in children with 
Crohn’s disease (relative risk [RR], 1.18; 95% confidence interval [CI], 0.95 to 1.47). 
(strength of evidence [SOE]: Low) 
• Budesonide and prednisolone did not differ in inducing remission at week eight in 
children with Crohn’s disease (RR, 0.77; 95% CI, 0.49 to 1.22). (SOE: Moderate) 
• Combination therapy with prednisone and mesalamine and combination therapy with 
budesonide and mesalamine did not differ in inducing remission at week 12 in children 
with Crohn’s disease (RR, 0.95; 95% CI 0.47 to 1.92). (SOE: Low) 
• We did not find any studies addressing the comparative effectiveness of other therapies 
alone or in combination to induce remission in children with Crohn’s disease. (SOE: 
Insufficient) 
Reduction of Steroids 
• The drug 6-mercaptopurine was more effective than placebo in reducing the need for 
corticosteroids in children with Crohn’s disease (observed-to-expected ratio of days on 
prednisone, 0.73 for the 6-mercaptopurine group, and 1.34 for the placebo group; P < 
0.001). (SOE: Low) 
• We found insufficient evidence to determine the comparative effectiveness of other 
therapies alone or in combination to reduce the need for corticosteroids in children with 
Crohn’s disease. We did not find any studies evaluating the effects of biologics, 
azathioprine, methotrexate, corticosteroids, or aminosalicylates on the reduction of 
steroids in children. 
Mucosal Healing, Hospitalization, Surgery, Fistula Response, and Patient-
Reported Outcomes 
• We found insufficient evidence to determine the comparative effectiveness of therapies 
alone, or in combination, with respect to mucosal healing, hospitalization, surgery, fistula 
response, and patient-reported outcomes, in children with Crohn’s disease. No studies 
evaluating those outcomes in children met our inclusion criteria. 
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Table 56 summarizes the evidence grades and specific conclusions for each comparison. 
Details of the evidence grades are in Appendix D, Table 21. 
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Table 56. Key findings and strength of evidence comparing pharmacologic therapies for the management of Crohn’s disease to induce 
remission in children 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in 
the estimate of the effect. Mod = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may 
change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. Insufficient = Evidence is unavailable. 
We graded all other comparisons and outcomes as insufficient since there were no eligible studies. 
 
Comparison Disease Activity 
Scale 
Mucosal 
Healing 
Hospitalizations Surgeries Reduction of 
Steroids 
Fistula 
Response 
Patient-Reported 
Outcomes 
6-Mercaptopurine 
and prednisone 
vs. prednisone 
alone 
Favors 6-
mercaptopurine 
and prednisone; 
Low 
Insufficient Insufficient Favors 6-
mercaptopurine; 
Low 
Insufficient Insufficient Insufficient 
Prednisone and 
mesalamine vs. 
budesonide and 
mesalamine 
Neither drug 
combination 
favored; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Budesonide vs. 
prednisolone 
Neither drug 
favored; 
Mod 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
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Study Design and Population Characteristics 
Three RCTs compared the effectiveness of therapies alone or in combination to induce 
remission in children with Crohn’s disease (Appendix D, Evidence Tables 22 and 23).190-192 
None of these RCTs were crossover studies and none had a run-in period. All three RCTs were 
multi-centered studies (one in the United States, one in Europe, and one in Israel). The total 
length of followup was 8 weeks, 12 weeks, and 18 months. 
All three RCTs included pediatric patients exclusively, totaling 136 children. All three 
studies reported the mean age of the children was 13.3 years (range: 13.0 to 13.9 years). One 
study (48 children) reported the mean disease duration was 0.7 years.190 Eighty-six of the 136 
children were male (63 percent, range: 60 to 69 percent). One study reported race, listing 51 of 
55 children (93 percent) as white.192  
Age, disease location, disease severity, and baseline disease activity were comparable in the 
RCTs. Two of the three studies reported disease location.190,192 Twenty-five of 103 children (24 
percent, range: 9 to 42 percent) had ileal disease, 65 of 103 children (63 percent, range: 50 to 75 
percent) had ileocolonic disease, 12 of 103 children (12 percent, range: 6 to 16 percent) had 
colonic disease, and zero of 103 children had perianal disease. All three studies reported disease 
severity.190-192 The mean baseline Pediatric Crohn’s Disease Activity Index (PCDAI) score was 
consistent with moderate-to-severe disease in all three studies (range, 29.1 to 45.7]).193 One 
study (48 children) reported the Crohn’s Disease Activity Index (CDAI) and Harvey-Bradshaw 
index (HBI).190 The mean CDAI score was 255 and mean baseline HBI score was 7.5. None of 
these studies reported on smoking status, age at diagnosis, disease behavior, baseline 
Inflammatory Bowel Disease Questionnaire (IBDQ) score, or C-reactive protein (CRP) level.  
Other inclusion criteria were similar for the three studies. Individual studies further restricted 
their patients on disease location, disease duration, and medications allowed prior to and during 
the study. One study, comparing budesonide with prednisolone,190 included children with disease 
of the ileum or ascending colon exclusively. One study, comparing a combination of prednisone 
and mesalamine with a combination of budesonide and mesalamine,191 only included children 
with a disease duration of at least 2 months; while another study, comparing a combination of 6-
mercaptopurine and prednisone with prednisone alone, included children with a disease duration 
of less than 8 weeks.192 Two studies191,192 did not allow children any additional treatment during 
the study. The third study190 allowed children to continue taking additional aminosalicylates or 
antibiotics as long as they received a constant dose for the 30 days prior to randomization of 
budesonide or prednisolone.  
Disease Activity Measures 
All three RCTs used disease activity scales to measure remission (Appendix D, Evidence 
Table 24).190-192 The disease activity scales were the PCDAI, CDAI, and HBI. We summarized 
the absolute disease activity scores in Table 57. None of these studies provided a measure of 
variability, thereby limiting our ability to comment of the effectiveness of these therapies on 
affecting these indexes. 
Combination of 6-Mercaptopurine and Prednisone Versus Prednisone Alone 
One RCT randomized 55 children to a combination of 1.5 mg/kg per day of 6-
mercaptopurine and prednisone or prednisone alone with a scheduled taper, and evaluated 
inactive disease (defined as total HBI score less than 3).192 After 1 month of treatment, 93 
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percent of 27 children in the combination group and 79 percent of 28 children in the prednisone 
alone group had inactive disease.  
Budesonide Versus Prednisolone 
One RCT assessed remission (defined as CDAI less than or equal to 150) in 18 children with 
active Crohn’s disease (CDAI greater than 150). The study randomized the children to 9 mg per 
day of budesonide taper or 1 mg/kg per day of prednisolone taper.190 The study saw remission at 
8 weeks in 12 of 22 children (55 percent) in the budesonide treatment group, and 17 of 24 
children (71 percent) in the prednisolone treatment group. The remission rate difference between 
the two groups was 16 percent (95% CI, 13 to 45 percent, P=0.25).  
Combination of Budesonide and Mesalamine Versus Combination of 
Prednisone and Mesalamine 
One RCT examined remission within 12 weeks (defined as PCDAI of less than or equal to 
10) in 33 pediatric patients with mild-to-moderate Crohn’s disease (PCDAI 12.5 to 40).191 The 
percent of children in remission did not differ between the two treatment groups at 4, 8, or 12 
weeks. At 12 weeks, nine of 19 children (47 percent) receiving 9 mg per day budesonide taper 
with mesalamine, and seven of 14 children (50 percent) receiving 40 mg per day prednisone 
taper with mesalamine, were in remission. 
 
Table 57. Summary of absolute disease activity scores in studies comparing the effectiveness of 
medications in inducing remission in children with Crohn’s disease 
Author, 
Year  
Length of 
Followup 
Main Intervention 
(Dose), N 
Comparison (Dose), 
N 
Baseline 
Activity Score 
Final Activity 
Score 
Markowitz, 
2000192 
1 mo 6-Mercaptopurine (1.5 
mg/kg daily) + 
prednisone taper, 27 
Placebo + prednisone 
taper, 28 
7.7 vs. 7.4 
(mean HBI) 
NR 
Escher, 
2004190 
8 wks  Budesonide (9 mg 
daily x 8 wks, then 6 
mg daily x 4 wks), 22 
Prednisolone (1 mg/kg 
daily x 4 wks, then 
tapering for 8 wks), 24 
39 vs. 45 
(mean PCDAI) 
149 vs. 97 
(mean CDAI) 
Levine, 
2003191 
12 wks Budesonide (3 mg q 8 
hours x 8 wks, then 
tapered wks 9-10, 
discontinued after 10 
wks) + mesalamine, 
(3-4 g daily wks 11-
12), 19 
Prednisone (40 mg 
daily x 2 wks, then 
tapered wks 3-10, 
discontinued after 10 
wks) + mesalamine (3-
4 g daily wks 11-12), 
14 
29.3 vs. 28.9 
(mean PCDAI) 
-9.3 vs. -13.4 
(change in 
PCDAI) 
CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; mg = milligram; mg/kg = milligrams per kilogram;  
mo = month; NR = not reported; PCDAI = Pediatric Crohn’s Disease Activity Index; wks = weeks 
Mucosal Healing 
We did not find any studies conducted among children with active Crohn’s disease that 
evaluated mucosal healing.  
Hospitalizations 
We did not find any studies conducted among children with active Crohn’s disease that 
evaluated hospitalization rates. 
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Surgeries 
No study of children with Crohn’s disease reported surgeries as an outcome of interest. One 
study of children with Crohn’s disease did comment that four children who withdrew from the 
study (one patient from the 6-mercaptopurine and prednisone group and three children from the 
placebo and prednisone group) required surgery after withdrawal.192  
Reduction of Steroids 
6-Mercaptopurine Versus Placebo 
One RCT of pediatric patients with Crohn’s disease192 looked at the reduction of 
corticosteroids as an outcome of interest among children. The study randomized the children to a 
combination of 6-mercaptopurine and prednisone or prednisone alone (Appendix D, Evidence 
Table 24). The study increased, decreased, or did not change prednisone dosage based on the 
patient’s change in partial HBI score. Children in the 1.5 mg/kg per day 6-mercaptopurine group 
required fewer days of prednisone treatment than the children in the placebo group, with an 
observed-to-expected ratio of days on prednisone of 0.73 for the 6-mercaptopurine group, and 
1.34 for the placebo group (P < 0.001). Both groups required comparable time to initially wean 
off prednisone, with the children in the 6-mercaptopurine group requiring a median of 121 days 
(95% CI, 117 to 143 days), and the children in the placebo group requiring a median of 131 days 
(95% CI, 120 to 178 days, P > 0.05).  
Fistula Response 
None of the studies looked at fistula response as an outcome of interest among children with 
active Crohn’s disease. 
Patient-Reported Outcomes 
We did not find any studies evaluating patient-reported outcomes as an outcome of interest 
among children with active Crohn’s disease. 
Study Quality 
Of the studies on treatment of children with Crohn’s disease, two studies190 192 had good 
quality and one study191 had poor quality (Appendix D, Evidence Table 25). The two good-
quality studies had an adequate allocation sequence and concealment, adequate blinding, and 
complete outcome data. The other study was unclear about the allocation sequence and 
concealment, blinding technique, and completeness of outcome data. Only one of the studies 
reported pharmaceutical support and company involvement in the design, conduct, or reporting 
of the trial.190 
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Key Question 2: Effectiveness of Therapies To Maintain Remission 
in Children 
Key Points 
Disease Activity Scales 
• Among those who achieved remission with induction infliximab, maintenance infliximab 
was more effective than episodic therapy at maintaining remission at week 50 in children 
with Crohn’s disease (RR, 1.35; 95% CI, 0.84 to 2.18). (SOE: Low) 
• Mesalamine and placebo did not differ in maintaining remission at 1 year in children with 
Crohn’s disease (RR, 0.90; 95% CI, 0.67 to 1.21). (SOE: Low) 
• We found insufficient evidence to determine the comparative effectiveness of other 
therapies alone or in combination to maintain remission in children with Crohn’s disease. 
We did not find any studies evaluating the effectiveness of thiopurines, methotrexate, 
corticosteroids, or sulfasalazine in children with Crohn’s disease. 
Surgeries 
• Mesalamine and placebo did not differ in maintaining remission and avoiding surgeries at 
year one in children with Crohn’s disease (no events observed in either arm). (SOE: Low) 
• We found insufficient evidence to determine the comparative effectiveness of other 
therapies alone or in combination in maintaining remission and avoiding surgeries in 
children with Crohn’s disease. We did not find any studies evaluating the effectiveness of 
biologics, thiopurines, methotrexate, corticosteroids, or sulfasalazine in children with 
Crohn’s disease. 
Mucosal Healing, Hospitalization, Reduction of Steroids, Fistula Response, 
and Patient-Reported Outcomes 
• We found insufficient evidence to determine the comparative effectiveness of therapies 
alone or in combination in maintaining remission with respect to mucosal healing, 
hospitalizations, reduction of steroids, fistula response, and patient-reported outcomes in 
children with Crohn’s disease. We did not find any studies evaluating the effectiveness of 
biologics, thiopurines, methotrexate, corticosteroids, or aminosalicylates in children with 
Crohn’s disease. 
 
Table 58 summarizes the evidence grades and specific conclusions for each comparison. 
Details of the evidence grades are in Appendix D, Table 21. 
 
218 
Table 58. Key findings and strength of evidence comparing pharmacologic therapies for the management of children with Crohn’s 
disease to maintain remission 
Comparison Disease Activity 
Scale 
Mucosal Healing Hospitalizations Surgeries Reduction of 
Steroids 
Fistula 
Response 
Patient-
Reported 
Outcomes 
Infliximab 
(maintenance vs. 
episodic therapy) 
Maintenance 
therapy favored; 
Low 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient 
Mesalamine vs. 
placebo  
Neither drug 
favored; 
Low 
Insufficient Insufficient Neither drug 
favored; 
Low 
Insufficient Insufficient Insufficient 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in 
the estimate of the effect. Mod = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may 
change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. Insufficient = Evidence is unavailable. 
We graded all other comparisons and outcomes as insufficient since there were no eligible studies. 
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Study Design and Population Characteristics 
Two RCTs compared the effectiveness of therapies alone or in combination to maintain 
remission in children with Crohn’s disease (Appendix D, Evidence Tables 22 and 23).194,195 One 
study evaluated mesalamine versus placebo,194 while another compared infliximab maintenance 
therapy versus episodic (or on-demand) therapy.195 
One study, examining mesalamine versus placebo, took place in Europe at multiple centers; 
the length of follow-up was 1 year.194 This RCT included 122 pediatric patients (18 years and 
younger) diagnosed with Crohn’s disease before the age of 16 years. The mean age was 11.8 
years. Seventy-three of 122 children (58 percent) were male. The mean disease duration was 0.8 
years. Only children with active Crohn’s disease were eligible (defined as HBI score greater than 
or equal to 5 or erythrocyte sedimentation rate (ESR) greater than or equal to 25 mm at 1 hour). 
The mean baseline HBI was 0.8, indicating that the study included the majority of children, 
based on ESR value. All disease activity levels were included in this study. However, the study 
excluded children if they had documented previous use of thiopurines or methotrexate. Disease 
locations were 12 percent ileal, 69 percent ileocolonic, and 19 percent colonic. Combining all 
disease locations, 32 percent of children also had perianal involvement. The study did not report 
smoking status, age at diagnosis, race, disease behavior, baseline IBDQ score, or CRP level. 
One open-label randomized study, examining different strategies of infliximab, took place in 
Europe at multiple centers; the length of follow-up was 1 year.195 The study population included 
40 patients enrolled between 2002 and 2005. The study included patients if they were between 7-
17 years of age with moderate-to-severe Crohn’s disease, based on HBI greater than or equal to 5 
and an ESR of greater than 20 mm/hour. Patients had to have prior resistance to thiopurines or 
methotrexate, as well as corticosteroids. The study prohibited prior anti-TNF use. All patients 
received induction dosing of infliximab 5 mg/kg intravenous at 0, 2, and 6 weeks. The study 
randomized those who achieved remission by week eight to receive maintenance infliximab at 5 
mg/kg every 8 weeks (Group A), or episodic (or on-demand) infliximab for patients who 
relapsed (Group B). The study defined remission as an HBI less than 5, ESR less than 20 mm/h, 
fistula closure [where applicable], and weaning completely from steroids. It defined relapse as an 
HBI greater than or equal to 5 and incomplete fistula closure.  
The mean age at diagnosis was 13.9, and mean duration of disease was 3.0 years. Twenty-
two patients (55 percent) were male. Twenty-seven patients had nonstricturing, nonpenetrating 
disease, while 13 had penetrating disease. At inclusion, all but four patients were on steroids, 37 
were on a thiopurine, and three were on methotrexate. Baseline HBI was 7.6. A total of 34 
patients went into clinical remission after induction dosing, and the study randomized 31 to 
maintenance, versus on-demand therapy. The study did not provide baseline characteristics for 
the randomized patients. 
Disease Activity Measures 
Infliximab Maintenance Versus Episodic Therapy 
One RCT195 examined clinical relapse at 50 weeks after randomization. The rate of remission 
at 50 weeks was 83 percent in the maintenance group and 61 percent in the episodic group (P < 
0.001). The rate of relapse over the course of the study was three of 13 (23 percent) and 11 of 12 
(92 percent), respectively (not intention-to-treat analysis). Notably, almost all patients in the 
episodic arm received infliximab at some point during the study (mean of 3.4 infusions 
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compared to six infusions in the maintenance arm), although at a later point in time (mean of 150 
days after randomization).  
Mesalamine Versus Placebo 
One RCT194 examined clinical relapse at 1 year (defined as HBI score of greater than or 
equal to 5) in 122 pediatric patients with active Crohn’s disease. The study randomized the 
patients after induction treatment (Appendix D, Evidence Table 24). The difference in relapse 
was not meaningful between children receiving 50 mg/kg per day of mesalamine and children 
receiving placebo. The 1-year relapse rate was 34 of 60 children (57 percent) receiving 
mesalamine, and 39 of 62 children (63 percent) receiving placebo. The average time without 
relapse was 8.6 months in the mesalamine group and 7.9 months in the placebo group, and was 
not clinically or statistically different between the two groups. 
Mucosal Healing 
Neither study looked at mucosal healing as an outcome of interest.  
Hospitalizations 
Neither study looked at hospitalizations as an outcome of interest.  
Surgeries 
Mesalamine Versus Placebo 
One RCT194 examined surgery for acute complications as an outcome of interest. At 1 year, 
the study reported no surgeries for children in either the 1 mg/kg per day mesalamine treatment 
group or the placebo group. 
Reduction of Steroids 
Neither study looked at reduction of steroids as an outcome of interest. 
Fistula Response 
Neither study looked at fistula response as an outcome of interest. 
Patient-Reported Outcomes 
Neither study looked at patient-reported outcomes as an outcome of interest. 
Study Quality 
The overall quality of one RCT194 was fair (Appendix D, Evidence Table 25). The study had 
adequate allocation sequence and concealment and adequate blinding, but the completeness of 
outcome data was unclear. The authors reported no conflict of interest. 
The overall quality of one RCT195 was poor. The study had adequate allocation sequence, but 
there was no blinding built into the study and outcome data was unclear with regard to relapse 
rates. The authors reported their conflicts of interest. 
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Key Question 3: Safety of Therapies in Children 
Key Points 
Mortality, Lymphoma, Other Cancers, Tuberculosis, Infusion- and Injection-
Site Reactions, and Bone Fractures 
• We found insufficient evidence to determine the comparative safety of therapies alone or 
in combination in children with Crohn’s disease. We did not find any studies reporting on 
mortality, lymphoma or other cancers, tuberculosis, infusion- and injection-site reactions, 
or bone fractures. 
Serious Infections 
• Infliximab maintenance therapy and episodic therapy did not differ in minimizing serious 
infections at 1 year in children with Crohn’s disease (no events reported). (SOE: Low) 
• Placebo was safer than 6-mercaptopurine in minimizing serious infections at 18 months 
in children with Crohn’s disease (RR, 3.1; 95% CI, 0.1 to 73.1). (SOE: Low) 
• We found insufficient evidence to determine the comparative safety of other therapies 
alone or in combination to minimize serious infections in children with Crohn’s disease. 
We found no studies evaluating other biologics, azathioprine, methotrexate, 
corticosteroids, or aminosalicylates in terms of serious infections among children with 
Crohn’s disease. 
Other Infections 
• Infliximab maintenance therapy and episodic therapy did not differ in minimizing other 
infections at 1 year in children with Crohn’s disease. (SOE: Low). 
• Budesonide was safer than prednisone in minimizing other infections at week eight in 
children with Crohn’s disease (RR, 0.2; 95% CI 0.01 to 3.8). (SOE: Low) 
• Budesonide and mesalamine combination therapy was safer than prednisone and 
mesalamine combination therapy in minimizing other infections at week 12 in children 
with Crohn’s disease (RR, 0.3; 95% CI, 0.01 to 5.7). (SOE: Low) 
• Prednisolone was safer than budesonide in minimizing other infections in children with 
Crohn’s disease (RR, 2.4; 95% CI 0.2 to 24.4). (SOE: Moderate)  
• We found insufficient evidence to determine the comparative safety of other therapies 
alone or in combination to minimize other infections in children with Crohn’s disease. 
• We did not find any studies evaluating other biologics, thiopurines, methotrexate, or 
aminosalicylates in children with Crohn’s disease. 
Height Change 
• Maintenance infliximab was more effective than episodic infliximab in allowing growth 
at 1 year in children with Crohn’s disease (z-score increased from -1.5 to -0.6 in the 
maintenance arm vs. -1.4 to -1.0 in the episodic arm). (SOE: Low) 
• 6-mercaptopurine and placebo did not differ at 6, 12, and 18 months in allowing growth 
in children with Crohn’s disease (6.8 cm vs. 5.3 cm after 18 months, respectively, 
P=0.3). (SOE: Low) 
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• Prednisone was more effective than placebo in allowing growth in children with Crohn’s 
disease. (SOE: Low) 
• Prednisone and budesonide did not differ in allowing growth at 6 months in children with 
Crohn’s disease (change in height percentile, 0.25 vs. -2.35 for budesonide and 
prednisone, respectively; P=0.1). (SOE: Low) 
• We found insufficient evidence to determine the comparative safety of other therapies 
alone or in combination to allow growth in children with Crohn’s disease. We did not 
find any studies evaluating the effects of other biologics, azathioprine, methotrexate, or 
aminosalicylates in children with Crohn’s disease. 
Weight Change 
• Maintenance infliximab was more effective than episodic infliximab in allowing weight 
gain at 1 year in children with Crohn’s disease (weight gain, 4.3 kg vs. -0.1 kg; P < 
0.001). (SOE: Low) 
• Infliximab was more effective than placebo in allowing weight gain in children with 
Crohn’s disease (fat mass to height z-score beta-coefficient, 0.29; 95% CI, 0.06 to 0.52). 
(SOE: Low) 
• Methotrexate was more effective than placebo in allowing weight gain in children with 
Crohn’s disease (fat mass to height z-score beta-coefficient, 0.30; 95% CI, 0.04 to 0.56). 
(SOE: Low) 
• Prednisone was more effective than placebo in allowing weight gain in children with 
Crohn’s disease (fat mass to height z-score beta-coefficient, 0.69; 95% CI, 0.12 to 1.26). 
(SOE: Low) 
• Prednisone was more effective than budesonide in allowing weight gain after 8 weeks in 
children with Crohn’s disease (weight gain, 4.6 vs. 2.5 kg for prednisone and budesonide, 
respectively; P < 0.05). (SOE: Low) 
• We found insufficient evidence to determine the comparative safety of other therapies 
alone or in combination to allow weight gain in children with Crohn’s disease. We did 
not find any studies evaluating the effects of natalizumab, adalimumab, certolizumab 
pegol, thiopurines, or aminosalicylates on weight in children with Crohn’s disease. 
 
Table 59 summarizes the evidence grades and specific conclusions for each comparison. 
Details of the evidence grades are in Appendix D, Table 21. 
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Table 59. Key findings and strength of evidence comparing pharmacologic therapies for the management of children with Crohn’s 
disease in terms of safety 
Comparison Mortality Lymphoma, 
Cervical 
Cancer, and 
Other 
Cancers 
Serious 
Infections 
Tuberculosis Other 
Infections 
Infusion- 
and 
Injection-
Site 
Reactions 
Bone 
Fractures 
Height 
Change 
Weight 
Change 
Infliximab vs. 
placebo 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Favors 
infliximab; Low 
Infliximab 
(maintenance 
vs. episodic 
therapy) 
Insufficient Insufficient Neither 
favored; Low 
Insufficient Neither 
favored; Low 
Insufficient Insufficient Maintenance 
infliximab 
favored; Low 
Maintenance 
infliximab 
favored; Low 
6-
Mercaptopurine 
and prednisone 
vs. prednisone 
alone 
Insufficient Insufficient Neither drug 
combination 
favored; 
Low 
Insufficient Insufficient Insufficient Insufficient Neither drug 
combination 
favored; Low 
Insufficient 
Methotrexate vs. 
placebo 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Favors 
methotrexate; 
Low 
Prednisone vs. 
placebo 
Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Insufficient Conflicting 
evidence; 
Low 
Favors 
prednisone; 
Low 
Budesonide vs. 
prednisone 
Insufficient Insufficient Insufficient Insufficient Neither drug 
favored; Low 
Insufficient Insufficient Neither drug 
favored; Low 
Favors 
prednisone; 
Low 
Budesonide and 
mesalamine vs. 
prednisone and 
mesalamine 
Insufficient Insufficient Insufficient Insufficient Neither drug 
combination 
favored; Low 
Insufficient Insufficient Insufficient Insufficient 
Budesonide vs. 
prednisolone 
Insufficient Insufficient Insufficient Insufficient Neither drug 
favored; Mod 
Insufficient Insufficient Insufficient Insufficient 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in 
the estimate of the effect. Mod = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may 
change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. Insufficient = Evidence is unavailable. 
We graded all other comparisons and outcomes as insufficient since there were no eligible studies. 
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Study Design and Population Characteristics 
Nine studies compared the safety of therapies alone or in combination in children with 
Crohn’s disease (Appendix D, Evidence Tables 22 and 23). Four studies were RCTs.190-192,195 
Two studies were prospective cohort studies,196,197 and three studies were retrospective cohort 
studies.198-200 One of the RCTs had a run-in period where both arms received induction 
infliximab; none of the RCTs were crossover studies. The studies took place in various countries 
(two in the United States, one in Canada, four in Europe, and two in Israel), and five studies were 
multi-centered trials.190-192,195,198 The length of followup ranged from 8 weeks to 43 months.  
The nine studies included pediatric patients exclusively, totaling 573 children. The mean age 
of children ranged from 12.7 to 13.9 years in seven studies (351 children).190-192,195,196,198,199 The 
mean disease duration ranged from 0.6 to 3.0 years in three studies (166 children).190,195,199 All 
nine studies reported the percent of male patients, which ranged from 33 to 100 percent. Two 
studies reported race; 51 of 55 children (93 percent) were white in one study,192 and eight of 78 
children (10 percent) were black in another study.199 Two studies (72 children) reported the mean 
age at diagnosis, which ranged from 7.0 to 13.9 years.196,197  
Five studies reported Crohn’s disease characteristics as disease location, severity, and 
baseline disease activity.190,192,197,199,200 The studies reported disease location for 333 children as 
follows: 14 percent (range: 3 to 42 percent) had ileal disease, 71 percent (range: 21 to 84 percent) 
had ileocolonic disease, 12 percent (range: 6 to 16 percent) had colonic disease, and 8 percent 
(range: 0 to 36 percent) had perianal disease. One study reported disease behavior; 27 patients 
had nonstricturing, nonpenetrating disease, while 13 had penetrating disease.195 Seven studies 
reported disease severity190-192,195,197-199 for 337 children as follows: 11 percent (range: 0 to 83 
percent) had mild disease, 50 percent (range: 0 to 100 percent) had mild-to-moderate disease, 
less than 1 percent (range: 0 to 6 percent) had moderate disease, 37 percent (range: 0 to 100 
percent) had moderate-to-severe disease, and less than 1 percent (range: 0 to 12 percent) had 
severe disease. Five studies reported a mean baseline PCDAI score ranging from 27.6 to 45.7190-
192,198,199 for 334 children. One study reported the mean baseline CDAI was 255 for 48 
children.190 Two studies reported the mean baseline HBI score was 7.5-7.6, in 95 children.192,195 
None of these studies reported on smoking status, baseline IBDQ score, or CRP level.  
The inclusion criteria were mostly the same among the studies except in regards to disease 
severity. All studies included mostly children, with a maximum age of 22 years. Five studies 
used Crohn’s disease severity for inclusion;190,192,195,198,201 the studies determined severity using 
physician assessment, PCDAI, CDAI, and HBI. Eight studies included only children with 
Crohn’s disease; one study included children with inflammatory bowel disease.197 One study 
excluded girls;196 all others included both sexes. 
Three studies, examining 6-mercaptopurine and prednisone192 and corticosteroids,190,191 
excluded children who had previously used thiopurines. Two studies, measuring growth,199,200 
excluded children who had an illness or were taking any other medications that could affect 
growth or development.  
Mortality 
No studies meeting our inclusion criteria reported on the outcome of mortality in children 
with Crohn’s disease.  
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Cancer 
No studies meeting our inclusion criteria reported on cancer rates in children with Crohn’s 
disease.  
Serious Infections 
Infliximab Maintenance Versus Episodic Therapy 
One RCT of 40 children reported on serious infections.195 Over the course of 1 year, none of 
the children in either arm developed a serious infection. 
Combination of 6-Mercaptopurine and Prednisone Versus Prednisone Alone 
One RCT of 55 children reported on serious infections (Table 60; Appendix D, Evidence 
Table 24).192 Over the course of the 18-month study, one of 27 children, receiving 1.5 mg/kg per 
day of 6-mercaptopurine and prednisone taper, developed an intra-abdominal abscess. None of 
28 children receiving a prednisone taper alone developed a serious infection.  
 
Table 60. Summary of the evidence comparing pharmacologic therapies for the management of children with 
Crohn’s disease in terms of serious infections 
Comparison 
Type of 
Infection 
Type of 
Studies 
Number of 
Studies Results Conclusions 
Strength of 
Evidence 
Infliximab 
(maintenance 
vs. episodic 
therapy) 
Serious 
infection 
RCT 1 0/18 
maintenance 
0/13 episodic 
Neither favored Low 
6-
Mercaptopurine 
and prednisone 
vs. prednisone 
alone 
Intra-
abdominal 
abscess 
Randomized 
controlled trial 
1 1/27 6-
mercaptopurine  
0/28 placebo 
Neither favored Low 
RCT = randomized controlled trial 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. 
Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence 
reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. 
Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the 
estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. 
Tuberculosis 
No studies meeting our inclusion criteria reported on tuberculosis rates in children with 
Crohn’s disease.  
Other Infections 
Four studies of 241 children with Crohn’s disease190,191,195,198 reported other infections during 
the course of their study (Table 61; Appendix D, Evidence Table 24). All but one study195 
compared some combination of corticosteroids. Two studies191,198 of 153 patients reported 
herpetic infections, all three of which occurred only in patients taking prednisone; none occurred 
in patients taking budesonide. One study190 on pharyngitis (48 patients) reported that two cases 
of pharyngitis in 22 patients in the budesonide treatment group, and one case in 26 patients in the 
prednisone treatment group.  
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Infliximab Maintenance Versus Episodic Therapy 
One study195 of 40 pediatric patients reported that there was no difference in infections (viral 
upper airway infections, gastroenteritis, herpes simplex lip infection, axillary bacterial abscess) 
between maintenance versus episodic therapy groups. They study did not provide a breakdown 
by treatment group. 
Budesonide Versus Prednisolone 
One RCT190 of 48 pediatric patients with mild-to-moderate Crohn’s disease, treated children 
with either budesonide or prednisolone. Over the 8-week course of the study, one of the 26 
children in the 1 mg/kg per day prednisolone taper treatment group developed pharyngitis, 
compared with two of the 22 children in the 9 mg per day budesonide taper treatment group.  
Budesonide Versus Prednisone 
One retrospective cohort study198 of 120 pediatric patients with mild-to-moderate Crohn’s 
disease, reviewed records of patients treated with either prednisone or budesonide. The study 
found two of the 58 children in the prednisone treatment group developed herpetic infections, 
compared with zero of the 62 children in the budesonide treatment group. There was no 
difference in herpetic infection rates between the two groups. 
Combination of Budesonide and Mesalamine Versus the Combination of 
Prednisone and Mesalamine 
One RCT,191 of 33 pediatric patients with mild-to-moderate Crohn’s disease, treated children 
with either 3 to 4 g per day of mesalamine and a 40 mg-per-day prednisone taper, or 3 to 4 g per 
day of mesalamine and a 9 mg-per-day budesonide taper. Over the 12-week course of the study, 
one of 14 children in the mesalamine and prednisone treatment group developed a herpetic 
infection, compared with zero of 19 children in the mesalamine and budesonide treatment group. 
There was no difference in herpetic infection rates between the two groups.  
 
Table 61. Summary of the evidence comparing pharmacologic therapies for the management of children with 
Crohn’s disease in terms of other infections 
Comparison 
Type of 
Infection 
Type of 
Studies 
Number of 
Studies Results Conclusions 
Strength of 
Evidence 
Budesonide vs. 
prednisolone 
Pharyngitis RCT 1190 2/22 budesonide 
1/26 prednisone  
Not statistically 
significant 
Moderate 
Budesonide vs. 
prednisone 
Herpetic 
infection 
Retrospective 
cohort study 
1198 0/62 budesonide 
2/58 prednisone  
Neither favored Low 
Combination 
budesonide + 
mesalamine vs. 
combination 
prednisone + 
mesalamine 
Herpetic 
infection 
RCT 1191 0/19 budesonide 
+ mesalamine 
1/14 prednisone 
+ mesalamine  
Neither favored Low 
RCT = randomized controlled trial 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. 
Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence 
reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. 
Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the 
estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. 
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Infusion- and Injection-Site Reactions 
No studies meeting our inclusion criteria reported infusion- or injection-site reactions in 
children with Crohn’s disease.  
Bone Fractures 
No studies meeting our inclusion criteria reported bone fractures in children with Crohn’s 
disease.  
Height Change 
Seven studies of 492 children reported on the effects on height (Table 62; Appendix D, 
Evidence Table 24).  
Infliximab Maintenance Versus Episodic Therapy 
One RCT of 40 children,195 comparing z-score for height and absolute height gain, 
randomized patients who went into remission after induction infliximab to receive maintenance 
dosing of infliximab versus episodic dosing for patients who relapse. The study followed patients 
for 50 weeks after randomization. Patients in the maintenance arm improved their z-score from  
-1.5 to -0.6, compared with an improvement from -1.4 to -1.0 in the episodic therapy group (P < 
0.001). Absolute height gain was 6.9 and 4.3 cm, respectively. 
Combination of 6-Mercaptopurine and Prednisone Versus Prednisone Alone  
One RCT of 55 children192 compared the linear growth of children treated with 1.5 mg/kg per 
day of 6-mercaptopurine and prednisone taper versus those who were treated with a prednisone 
taper alone. This study found no significant difference in linear growth between the two groups 
at 6, 12, or 18 months. From 0 to 6 months, the 6-mercaptopurine group (n=26) grew an average 
of 3.4 cm, and the placebo group (n=25) grew an average of 1.9 cm (P=0.06). From 6 to 12 
months, the 6-mercaptopurine group (n=23) grew an average of 0.7 cm, and the placebo group 
(n=24) grew an average of 1.3 cm (P=0.4). From 12 to 18 months, the 6-mercaptopurine group 
(n=23) grew an average of 2.8 cm, and the placebo group (n=24) grew an average of 2.3 cm 
(P=0.5). Overall, from 0 to 18 months, the 6-mercaptopurine group (n=23) grew an average of 
6.8 cm, and the placebo group (n=24) grew an average of 5.3 cm (P=0.3). 
Prednisone Versus Placebo 
Four studies196,197,199,200 of 277 children found mixed results when comparing the effect of 
prednisone versus placebo on linear growth in children. One study found children who had taken 
prednisone were shorter than those who had not taken prednisone, one study found that children 
who had taken prednisone were taller than those who had not taken prednisone, and two studies 
found no difference in height between children who had taken prednisone and those who had not.  
One prospective cohort study of 17 children196 compared the linear growth of nine boys with 
Crohn’s disease who were treated with alternate day prednisone (0.3 mg per kg) for longer than 3 
months, with eight boys with Crohn’s disease who had not been treated with alternate day 
prednisone for longer than 3 months. At the end of 2 years, both groups showed similar linear 
growth. 
One retrospective cohort study200 looked at 135 children with an early onset of Crohn’s 
disease. This study asked adults about their growth and medication use (men with onset of 
symptoms before age 22 years, and women with onset of symptoms before age 18 years). Eight 
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children had received corticosteroids before puberty and 19 children had received corticosteroids 
during puberty. Children who had received corticosteroids during puberty were significantly 
shorter than those who had not (P=0.005). This study also found that children with disease onset 
during puberty who had received corticosteroids were significantly shorter than those with 
disease onset during puberty that had not received corticosteroids (P=0.03).  
One prospective cohort study197 looked at 47 pediatric patients with either Crohn’s disease 
(n=18) or ulcerative colitis (n=29). This study found no significant difference in height standard 
deviation score (HSDS) or the height velocity standard deviation score (HVSDS) between those 
children who had received prednisone, compared with those children who had not received 
prednisone. The HSDS for children treated with prednisone was -0.50 at diagnosis, -0.47 after 1 
year, -0.24 after 2 years, -0.10 after 3 years, and +0.00 after 4 years. The HSDS for children not 
treated with prednisone was -0.20 at diagnosis, -0.31 after 1 year, -0.13 after 2 years, -0.09 after 
3 years, and +0.13 after 4 years. The HVSDS for children treated with prednisone was -1.20 at 
diagnosis, +0.29 after 1 year, +0.87 after 2 years, +1.47 after 3 years, and +0.78 after 4 years. 
The HVSDS for children not treated with prednisone was -0.01 at diagnosis, -0.26 after 1 year, 
+0.63 after 2 years, +0.16 after 3 years, and +1.25 after 4 years. 
One prospective cohort study199 looked at 78 patients (ages 5 to 21 years) with Crohn’s 
disease of varied severity and reported on height. This study performed a subgroup analysis on 
the 46 children who had completed four study visits, and found that children who had taken 
corticosteroids had a significantly lower height z-score than children who had not taken 
corticosteroids.  
Budesonide Versus Prednisone 
One retrospective cohort study198 compared the post-remission linear growth of 41 of 120 
children whose records included height measures. The children had mild-to-moderate Crohn’s 
disease and had received either prednisone or budesonide for at least 2 weeks. This study found 
no significant difference in the change of height percentile at 6 months between those children 
who had taken prednisone, compared with those children who had taken budesonide.  
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Table 62. Summary of the evidence comparing pharmacologic therapies for the management of children with 
Crohn’s disease in terms of height change 
Comparison 
Height 
Measure 
Type of 
Studies 
Number of 
Studies Results Conclusions 
Strength of 
Evidence 
Infliximab 
(maintenance 
vs. episodic 
therapy) 
Height z-
score 
RCT 1195 +0.9 
maintenance 
+0.4 episodic 
P < 0.001 Low 
Infliximab 
(maintenance 
vs. episodic 
therapy) 
Linear 
growth 
(cm) 
RCT 1195 6.9 
maintenance 
4.3 episodic 
P < 0.015 Low 
6-
Mercaptopurine 
vs. placebo 
Linear 
growth 
(cm) 
Randomized 
controlled trial 
1192 6.8 6-
mercaptopurine 
5.3 placebo 
P=0.3 Low 
Prednisone vs. 
placebo 
Linear 
growth 
over 2 
years (cm)  
Prospective 
cohort study 
1196 9.1 prednisone 
10.3 placebo 
NR Low 
Prednisone vs. 
placebo 
Height 
(cm) 
Retrospective 
cohort study 
1200 NR P=0.005 Low 
Prednisone vs. 
placebo 
HSDS Prospective 
cohort study 
1197 +0.00 
prednisone 
+0.13 placebo 
No difference Low 
Prednisone vs. 
placebo 
HVSDS Prospective 
cohort study 
1197 +0.78 
prednisone 
+1.25 placebo 
No difference Low 
Corticosteroids 
vs. placebo 
Height z-
score 
Retrospective 
cohort study 
1199 Beta-coefficient 
= -0.63; 95% 
CI, -1.00 to -
0.28 
P=0.0005 Low 
Budesonide vs. 
prednisone 
Change in 
height 
percentile 
Retrospective 
cohort study 
1198 +0.25 
budesonide 
 -2.35 
prednisone  
P=0.1 Low 
cm = centimeter; HSDS = height standard deviation score; HVSDS = height velocity standard deviation score; NR = not reported 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. 
Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence 
reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. 
Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the 
estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. 
Weight Change 
Two studies198,199 of 198 children reported on the outcome of weight (Table 63; Appendix D, 
Evidence Table 24). 
Infliximab Versus Placebo 
One prospective cohort study of 78 children with Crohn’s disease of varied severity199 
reported on the interaction of body mass and height. This study performed a subgroup analysis 
on the 46 children who had completed four study visits, and found that children who had taken 
infliximab had a significantly higher lean mass–height z-score than children who had not taken 
infliximab. This study also found that children who had taken infliximab had a significantly 
higher fat mass–height z-score than children who had not taken infliximab.  
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Infliximab Maintenance Versus Episodic Therapy 
One RCT of 40 children,195 comparing absolute weight gain, randomized patients who went 
into remission after induction infliximab to receive maintenance dosing of infliximab versus 
episodic dosing for patients who relapsed. Patients were followed for 50 weeks after 
randomization. Patients in the maintenance arm had an absolute mean weight gain of 4.3 +/- 5.4 
kg, compared to -0.1 +/- 5.7 kg in the episodic therapy group (P < 0.001). 
Methotrexate Versus Placebo 
The above cohort study199 also reported that children who had taken methotrexate had a 
significantly higher fat mass–height z-score than children who had not taken methotrexate.  
Corticosteroids Versus Placebo 
The above cohort study199 also reported that children who had taken corticosteroids had a 
significantly higher fat mass–height z score than those who had not taken corticosteroids.  
Budesonide Versus Prednisone 
One retrospective cohort study of 120 children198 looked at pediatric patients with mild-to-
moderate Crohn’s disease. This study looked at weight loss or gain in children who had received 
treatment with either prednisone or budesonide. After reviewing patient records, they found that 
those children who had received prednisone gained significantly more weight than those children 
who had received budesonide after 8 weeks.  
 
Table 63. Summary of the evidence comparing pharmacologic therapies for the management of children with 
Crohn’s disease in terms of weight change 
Comparison 
Weight 
Measure 
Type of 
Studies 
Number of 
Studies Results Conclusions 
Strength of 
Evidence 
Infliximab vs. 
placebo 
Lean mass 
– height z-
score 
Case-control 
study 
1199 Beta-coefficient, 
0.30; 95% CI, 
0.02 to 0.58 
P < 0.05 Low 
Infliximab vs. 
placebo 
Fat mass – 
height z-
score 
Case-control 
study 
1199 Beta-coefficient, 
0.29; 95% CI, 
0.06 to 0.52 
P < 0.05 Low 
Infliximab 
(maintenance 
vs. episodic 
therapy) 
Weight 
gain (kg) 
RCT 1195 4.3 maintenance 
-0.1 episodic 
P < 0.05 Low 
Methotrexate 
vs. placebo 
Fat mass – 
height z-
score 
Case-control 
study 
1199 Beta-coefficient, 
0.30; 95% CI, 
0.04 to 0.56 
P < 0.05 Low 
Corticosteroids 
vs. placebo 
Fat mass – 
height z-
score 
Case-control 
study 
1199 Beta-coefficient, 
0.69; 95% CI, 
0.12 to 1.26 
P < 0.05 Low 
Budesonide vs. 
prednisone 
Weight 
gain (kg) 
Retrospective 
cohort study 
1198 +2.54 kg 
budesonide +4.6 
kg prednisone  
P < 0.05 Low 
CI = confidence interval; kg = kilogram; RCT = randomized controlled trial 
Note: We defined the strength of the evidence as follows: High = High confidence that the evidence reflects the true effect. 
Further research is unlikely to change our confidence in the estimate of the effect. Mod = Moderate confidence that the evidence 
reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. 
Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the 
estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable. 
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Study Quality 
For serious infections (intra-abdominal abscess), the quality of the one RCT192 was good due 
to adequate allocation sequence and concealment, adequate blinding, and complete outcome data 
(Appendix D, Evidence Table 25). A pharmaceutical company supported this study.192 
For other infections (herpetic infections), the quality of one RCT191 was poor because the 
allocation sequence and concealment, blinding technique, and completeness of outcome data 
were unclear. The quality of the retrospective cohort study198 was fair due to good descriptions of 
outcomes, interventions, and patient characteristics. 
For other infections (pharyngitis), the quality of one study202 was good due to adequate 
allocation sequence and concealment, adequate blinding, and complete outcome data.  
For height change, seven studies192,195-200 had variable quality. The quality of one RCT192 was 
good due to adequate allocation sequence and concealment, adequate blinding, and complete 
outcome data. One RCT195 had poor quality because of absence of blinding. Two cohort 
studies198,199 had fair quality due to good descriptions of outcomes and patient characteristics. 
Two other cohort studies196,200 had poor quality due to study population selection bias. A 
pharmaceutical company supported one study.192 
For weight change, two cohort studies198,199 had fair quality with good descriptions of 
outcomes and patient characteristics. The one RCT195 had poor quality because of absence of 
blinding. 
  
232 
Discussion 
Key Findings and Clinical Implications 
The purpose of this review was to compare the effectiveness and safety of biologics, 
immunomodulators, corticosteroids, and aminosalicylates in the treatment of Crohn’s disease.  
This section provides a summary of the findings, compares the findings with related 
systematic reviews, lists limitations of the data and the approach, and suggests future directions. 
Summary of Key Findings for Adults 
Key Question 1. Induction of Remission Measured in Terms of 
Disease Activity 
Of the 78 comparisons with evidence, four resulted in high strength of evidence and 20 
resulted in moderate strength of evidence (see Table 6). Consistency of effect was based on a 
medication comparison having the same direction of effect for both disease activity (across 
evaluable time points) and for at least one other outcome. 
Infliximab was found to have the greatest consistency across the outcomes of disease 
activity, mucosal healing, fistula healing, and IBDQ when compared with placebo (based on two 
trials). It was also the only comparison that included a high SOE for a given outcome (fistula 
healing).  
Other consistent comparisons that included at least one outcome with a moderate SOE 
included: infliximab was favored over azathioprine for disease activity and mucosal healing 
(based on one trial), the combination of infliximab and azathioprine was favored over 
azathioprine alone for disease activity and mucosal healing (based on two trials), and the 
combination of infliximab and azathioprine was favored over infliximab alone for disease 
activity, mucosal healing (based on one trial). In all three of these comparisons, IBDQ was not 
different between treatment arms. 
Several placebo-controlled trials were also found to be consistent across outcomes. However, 
all the individual outcomes were rated as low SOE. The following interventions were favored 
over placebo: prednisone/6-methylprednisolone for disease activity and fistula healing (based on 
two trials), sulfasalazine for disease activity and fistula healing (based on two trials), and 
thiopurine for disease activity and fistula healing (based on one trial). Thiopurines and placebo 
did not differ in corticosteroid reduction and IBDQ. 
For head-to-head trails, the following comparisons were consistent across outcomes with all 
individual outcomes rated as low SOE: combination of infliximab and methotrexate favored over 
infliximab alone for disease activity, steroid reduction, and IBDQ (based on one trial), and 
corticosteroids favored over thiopurines for disease activity and fistula healing (based on one 
trial). 
Key Question 2. Maintenance of Remission Measured in Terms of 
Disease Activity 
Of the 55 comparisons with evidence, none resulted in high strength of evidence and 11 
resulted in moderate strength of evidence (see Table 21). Consistency of effect was based on a 
medication comparison having the same direction of effect for both disease activity (across 
evaluable time points) and for at least one other outcome.  
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Infliximab was found to have the greatest consistency across outcomes when compared with 
placebo for disease activity, mucosal healing, hospitalization, surgery, corticosteroid reduction, 
fistula healing, and IBDQ (based on three trials). Adalimumab was also favored over placebo for 
the outcomes of disease activity, hospitalization, surgery, and corticosteroid reduction (based on 
two trials); however, adalimumab was not favored over placebo for IBDQ.   
Other consistent comparisons with at least one outcome rated as moderate SOE included: 
natalizumab favored over placebo for disease activity, steroid reduction, and IBDQ (based on 
one trial), azathioprine over budesonide for disease activity and mucosal healing (based on one 
trial), and budesonide over aminosalicylates for disease activity and IBDQ (based on one trial). 
Thiopurines were consistently favored over placebo for disease activity and corticosteroid 
reduction (based on four trials); however, all the outcomes were rated as low SOE. 
Key Question 3. Safety 
The SOE for nearly every comparison was graded as insufficient or low for safety-related 
outcomes. Frequently, comparisons graded with low SOE did not favor either medication 
compared. We graded comparisons as high SOE for only two safety comparisons, both from a 
single RCT, and both for an outcome of infusion and injection-site reactions. One comparison 
favored oral azathioprine with placebo infusion over intravenous infliximab, and another favored 
placebo over intravenous azathioprine. 
Key Question 4. Patient-Reported Outcomes After Intestinal Resection 
We included one RCT that measured a patient-reported outcome (Inflammatory Bowel 
Disease Questionnaire [IBDQ]) after intestinal resection and no difference was found between 
azathioprine and mesalamine. Although the data were limited, patient-reported outcomes after 
intestinal resection had not been addressed in a previous systematic review.19 
Summary of Key Findings for Pediatrics 
Ten studies were identified that reported on pediatric outcomes. The SOE was graded as low 
or insufficient to support any medication to induce or maintain remission in pediatric Crohn’s 
disease for KQ1 and KQ2. No pediatric study reported on a serious adverse event such as 
mortality, progressive multifocal leukoencephalopathy, lymphoma, or other cancers. No 
pediatric study reported on a patient-reported outcome. 
Applicability of Remission Results for Adults 
Populations 
• The majority of trials enrolled only Caucasians. African Americans, Hispanics, and 
Asians were not well represented.  
• The median age at enrollment in most trials ranged between 25 and 40 years of age. 
Older persons were not well represented.  
• Mean duration of disease, with the exception of a few trials,45,48 was often greater than 10 
years. Understanding the effectiveness of medications on the natural history of disease, 
such as the proposed benefits of top-down compared with step-up therapy, requires trials 
with recently diagnosed patients. 
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Intervention 
• The doses and delivery methods of medications used sometimes differed across trials. 
Comparisons 
• There were very few direct comparisons of medications. 
Outcomes 
• Improvement in CDAI score is non-specific for Crohn’s disease. CDAI score also varies 
with irritable bowel-type symptoms.203 This may explain why many of the studies had 
high placebo rates of response and remission. 
• Few trials reported on outcomes other than the CDAI. Some outcomes such as mucosal 
healing and fistula response were frequently analyzed as subgroup analyses and not as 
primary endpoints. 
Timing 
• There were very few trials that evaluated endpoints beyond 1 year. For a lifelong disease, 
the amount of time represented by these trials is very short.  
Setting 
• Most trials took place in North America and Europe. Thus, results may not necessarily be 
transferred to other locales. 
Other—Conflict of Interest 
• In KQ1, of the 36 trials (82 percent) trials that reported on conflicts of interest, 86 percent 
received pharmaceutical support with 56 percent having pharmaceutical company 
employed co-authors. For the 25 trials (69 percent) reporting on conflicts of interest for 
KQ2, the figures were 80 percent and 44 percent, respectively.  
Applicability of Safety Results for Adults 
The non-RCTs that reported safety outcomes of interest did not have as many eligibility 
criteria as the RCTs. Very few non-RCTs had disease activity or disease location exclusions. 
Because observational studies made fewer restrictions on the patient populations, they likely 
apply to Crohn’s disease patients of all disease severities. Despite the differences in eligibility 
criteria, the RCTs and observational studies did not have meaningful differences in safety 
signals. The studies that included all IBD patients had similar safety findings as studies that 
included only Crohn’s disease patients or those studies that reported results for both Crohn’s 
disease and IBD patients. 
Pediatric Applicability 
The applicability of these studies was limited because of the small number of studies, with 
few participants per study. Also, very few medications were compared. The longest RCT had 
only 18 months of followup and the longest prospective study had less than 4 years of followup.  
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Comparison With Existing Guidelines and Systematic 
Reviews 
Several clinical guidelines have been developed based on comprehensive literature searches 
combined with expert opinion8,204-206 and numerous systematic reviews comparing treatments for 
Crohn’s disease have been performed.11,17,207-216 Although the findings of our systematic review 
are consistent with most of the published guidelines and reviews, we note a few differences in 
the methodology, strength of evidence and the findings. Our methodologic approach: 
• Searched publication databases without year of publication restrictions 
• Considered a clinically meaningful threshold to identify differences in treatments 
outcomes rather than relying on statistical significance 
• Abstracted information at multiple clinically relevant time points instead of focusing on 
the last time point reported 
• Included multiple outcomes associated with treatment aimed at achieving remission, 
instead of using the Crohn’s Disease Activity Index to measure response or remission and 
some safety events with occasional use of endoscopic healing and other outcomes 
• Specifically included mortality, progressive multifocal leukoencephalopathy, 
hepatosplenic-T-cell lymphoma, other lymphomas and cancers, and serious infections 
and infusion reactions, whereas many reviews consider more generic categories as 
reported in trials such as overall adverse events, serious adverse events, and infections 
• Required that all studies have a comparison group, allowed head-to-head trials, and 
allowed observational studies for safety outcomes 
• Did not include antibiotics and enteral nutrition as comparators of interest 
• Did not consider disease location in assessments in contrast with the clinical guidelines 
which often recommend different initial treatments depending on the location and extent 
of disease 
• Reviewed and graded the strength of evidence separately for safety and efficacy 
compared with considering the balance between safety and efficacy in a single grade of 
the SOE. 
 
The strength of evidence was generally graded the same or lower in our review compared 
with others. This difference might be due to the fact that the other studies pooled all comparisons 
regardless of study or statistical heterogeneity, whereas we only pooled studies when we felt 
studies were comparable and statistical heterogeneity was low, frequently leading to inconsistent 
and imprecise evidence. 
The major difference in findings between this review and others pertains to infliximab. Other 
reviews found that all TNF-alpha inhibitors are efficacious at inducing and maintaining 
remission. We also would come to this conclusion if we based results on the meta-analysis of 
TNF-alpha inhibitors that we performed at week 2 after induction. However, when we consider 
the clinically meaningful threshold for a difference in treatment effects and examine the 
consistency of efficacy across the different outcomes of interest, infliximab is the only TNF-
alpha inhibitor that is consistently favored over placebo at multiple time points and for multiple 
outcomes. 
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Limitations 
Our review has a number of limitations, most of which are related to the limitations of the 
available data. The major limitations in the data were:  
• Lack of head-to-head studies 
• Study heterogeneity limited meta-analyses 
• Inability to isolate patients with moderate-to-severe Crohn’s disease from those with mild 
disease 
• Potential measurement error as a result of abstracting data from figures 
• Limited reporting of results for the subgroup populations of interest 
• Short trial durations  
• Difficulty interpreting studies that compared the same drug delivered at different time 
points (i.e., on-demand versus maintenance therapy for biologics).  
 
The major limitations in our review methods were:  
• No standard existed to select a threshold of 10 percent to define a clinically meaningful 
difference between comparison groups  
• Trouble separating induction from maintenance studies (i.e., some studies that met 
criteria for induction had endpoints of 26 weeks or longer). 
Limitations in the Data 
Lack of Head-to-Head Studies 
There was a paucity of head-to-head studies, particularly for maintenance trials. Practitioners 
deciding between two maintenance therapies in patients with Crohn’s disease need to be aware 
that little evidence exists to make evidence-based treatment decisions. On initiation of this 
project, we knew that there were few head-to-head trials in the literature. However, we felt that it 
was important to systematically document the literature in order to better understand the gaps. 
Additionally, we had intended to perform a network meta-analysis in order to indirectly compare 
drug classes that have not been compared in the literature to help address the evidence gap 
resulting from direct comparisons of treatments. However, study heterogeneity and sparse data 
(few studies addressed each comparison of interest) prevented a network meta-analysis. 
Study Heterogeneity Limited Meta-Analyses 
One common source of heterogeneity was the variation in study designs, especially for the 
maintenance trials. For example, the studies of maintenance therapy varied in how they 
identified a patient’s eligibility for randomization to the study arms. Some of the maintenance 
trials had a run-in period where all patients received the active study medication followed by 
randomization of patients with a response to the study drug. Other maintenance trials enrolled 
patients that had a response to the study medication of interest in a previous remission trial or 
who had long-term inactive disease based on clinic visits.  
An additional source of heterogeneity was related to the baseline characteristics of the 
enrolled patients, particularly with use of previous and concurrent medication to treat Crohn’s 
disease. For example, many TNF-alpha inhibitor studies included both TNF-alpha inhibitor 
exposed and naïve patients. Additionally, maintenance studies varied with regard to the use of 
corticosteroids and other medications at randomization and throughout the trial.  
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Another source of heterogeneity was the use of varied definitions of remission. Among the 
studies, there were different disease activity scales and different disease activity scale thresholds 
for remission. For example, some studies required a change in corticosteroid dose and a change 
in disease activity to define remission whereas other studies considered remission a change in 
disease activity regardless of a decrease in corticosteroid dose.  
We also found heterogeneity in study duration, especially for the safety outcomes where 
results ranged from trial reports at 2 weeks to observational studies of over 5 years. Finally, we 
found it difficult to compare studies published prior to the 2000s and after as the study designs 
and reporting of the design details differed substantially. We often rated the newer studies as 
having lower risk of bias. 
Inability To Isolate Patients With Moderate-to-Severe Crohn’s Disease 
Our original intention was to look at patients with moderate-to-severe Crohn’s disease. 
However, we found that most induction of remission trials included patients with any active 
disease, including those with mild disease. Identifying patients with moderate-to-severe disease 
was even more of a challenge with maintenance of remission trials, where most studies 
randomized patients while in remission, so it was impossible to ascertain the original disease 
severity.  
Potential for Measurement Error for Time Points Other Than the 
Primary Outcome of Interest 
Because we included clinically meaningful time points of interest that may not have 
corresponded to the primary outcome of interest, we frequently abstracted data for these time 
points from figures. The article figures did not consistently display time points of assessment as 
reported in the study design and rarely included measures of variation for each time point. The 
lack of information on the variation of an outcome was especially pronounced for reporting of 
the IBDQ scores, and prevented us from performing statistical analyses of the difference in 
IBDQ scores between treatment groups. 
Subgroup Analyses Were Limited 
Most of the subgroup population analyses were limited by poor reporting of statistical 
interaction terms. This becomes particularly important as many studies allowed patients to use 
Crohn’s medications at randomization and throughout the study as long as the medication dose 
remained stable.  
Short Trial Durations 
The maintenance of remission evidence was limited to 2 years (104 weeks), a very brief 
period of time for a chronic condition. For many comparisons, especially the newer trials of 
biologics, the maximum trial duration was 1 year. For instance, the azathioprine and 6-
methylprednisolone were found to consistently outperform placebo at 1 and 2 years with 
azathioprine also reducing the need for corticosteroids at 6 months (the last reported time point 
available). However, the evidence for the other efficacious agents, natalizumab and infliximab, is 
limited to 1 year. The limited duration of trials for a relapsing and remitting chronic condition 
limits the information that health care providers can share with their patients regarding the 
efficacy of medications to treat Crohn’s disease. 
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Inclusion of Studies That Evaluated the Same Drug at Different Points 
in Time  
Per our methods, we excluded studies that compared different doses of the same medication 
unless a comparison to an additional medication was made. However, we came across TNF-
alpha inhibitor maintenance trials87,95,217 that were intended to compare episodic (on-demand) 
treatment with regularly scheduled treatment to mimic clinical practice. Additionally, the one 
study that directly addressed step-up versus top-down therapy examined different time points for 
introducing immune-based therapies such as thiopurines and infliximab.48 As a result, patients in 
both study arms may have received both classes of medications. Although these studies 
presented challenges in interpretation compared with more traditional trial designs, they were 
included because they are very applicable to clinical practice. 
Other Limitations of the Data 
Other limitations included: (a) most trials were sponsored by the manufacturer of the 
medications, which has been associated with the reporting of results that are more favorable than 
studies not supported by industry;218 (b) our analyses indicated the presence of publication bias 
as measured by Begg’s and Egger’s tests, especially for corticosteroids and aminosalicylates. 
Limitations in Our Review Method 
No Standard Existed To Define a Clinically Meaningful Difference 
Between Comparison Groups  
When we assessed the efficacy and safety of the medications, we sought to consider whether 
differences were clinically meaningful, instead of focusing on statistical significance. In the 
absence of a standard for a clinically meaningful absolute difference in remission rate for 
Crohn’s disease, we chose a relatively low absolute difference of 10 percent as the threshold for 
identifying a clinically meaningful difference in the induction and maintenance of remission 
outcomes. An example of this difference is that if 50 percent of placebo participants were in 
remission, 60 percent or more active medication participants had to be in remission to label the 
effect clinically meaningful. Although individual studies may have been designed to have only 
enough statistical power to detect larger differences in remission rates, we believed it was 
important to keep in mind that patients with the debilitating symptoms of Crohn’s disease might 
want to know whether a treatment could provide a modest 10 percent absolute increase in their 
chance at remission. If we had used a higher threshold for identifying a clinically meaningful 
difference in remission rates, fewer differences would have been considered clinically 
meaningful in this report.  
Because many of the adverse events are very rare, we did not assign a threshold for a 
clinically meaningful difference for safety. We relied on a statistically significant difference 
instead, which resulted in only two comparisons graded as high SOE, both with a greater than 10 
percent absolute difference between the treatment groups for the outcome of infusion- and 
injection-site reactions. 
Trouble Separating Induction From Maintenance Studies 
Our inclusion criteria arbitrarily defined eligibility for induction if patients had active disease 
at randomization and eligibility for maintenance if participants had inactive disease at 
randomization. However, we acknowledge that time points for induction trials after 12-16 weeks 
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are more consistent with maintenance studies. The alternative was to present the later time points 
of the induction trials with the maintenance trials, although we thought this would lead to 
unnecessary repetition of study and population characteristics. 
Other Limitations 
Other limitations included:  
• We excluded 223 non-English articles. 
• We only included information from peer-reviewed journals (excluding information 
reported in abstract-only form which has been documented to differ from the subsequent 
peer-reviewed article).219,220  
• We did not examine certain classes of medications including antibiotics or probiotics. We 
also did not examine other therapies such as enteral or parenteral feeding, as we felt this 
was out of the scope of this systematic review.  
Future Research Needs 
We found many gaps in the literature on medical therapy for Crohn’s disease. Most studies 
evaluated white adults under 50 years of age who often had been diagnosed at least 10 years 
prior to the start of the study. Further attention needs to be given to non-white populations, 
pediatric patients, older adults (over 50 years of age), newly diagnosed patients or those who 
have been on few medications for Crohn’s disease, and patients with severe Crohn’s disease 
(including those with complications including abscess and fistula formation).  
With regard to intervention and study design, we found few head-to-head trials involving 
TNF-alpha inhibitor agents and natalizumab. We also need further studies to evaluate the 
introduction of immunosuppressive therapy early in the disease course (top-down approach) 
versus more traditional step-up medication strategies as many physicians are beginning to use 
top-down treatment in the absence of strong evidence to support this treatment paradigm.  
Researchers need to design safety studies so they have sufficient power to detect clinically 
meaningful differences between medications. Randomized trials should also be adequately 
powered to compare specific, important safety events if they intend to report on safety outcomes. 
Keeping in mind the practical limitations of acquiring investigator-initiated funding, more trials 
that are independent of industry input in the design, analysis, interpretation, and design to 
publish, but with industry sponsorship, combined with investigators who are not paid consultants 
of industry could help minimize conflicts of interest. 
In terms of outcomes, more studies need to evaluate outcomes beyond disease activity, 
including mucosal healing, rates of hospitalization and surgery, fistula healing, and patient-
reported outcomes (including post-surgical studies). Given that Crohn’s disease may last many 
decades, we should extend outcomes for RCTs on maintenance therapy beyond 2 years. 
Observational studies for safety should be sufficiently long to observe safety outcomes, such as 
cancer, that may not manifest themselves for many years. 
Conclusions 
Infliximab was the only medication that was found to be consistently effective compared 
with placebo across a number of outcomes for both induction and maintenance of remission. For 
most medication comparisons, data was lacking on outcomes other than disease activity indices. 
In children, the evidence was insufficient to permit assessment of the consistency of medication 
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efficacy across outcomes. The quality of the safety evidence was poor due to poor reporting of 
the methods in trials and poor confounding control in observational studies. No strong or 
previously unidentified signals of harm were identified. Comparing Crohn’s disease medications 
directly using pragmatic clinical trials will help to understand the effectiveness of medications in 
clinical practice using outcomes other than the Crohn’s Disease Activity Index. 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
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Number of trials 
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Natalizumab vs. 
placebo–wk 12 
Disease 
activity 
measures 
3 (1444)32-34 Medium Consistent Direct Imprecise Favors natalizumab 
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SOE: Low 
Natalizumab vs. 
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Patient-
reported 
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Absolute between-group 
difference in change in mean 
IBDQ from baseline, 12 pts; 
placebo change in IBDQ, 15 pts 
 
SOE: Moderate 
Natalizumab + 
infliximab vs. 
infliximab–wks 2 
and 10 
Disease 
activity 
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1 (79)35 Low Unknown 
(single trial) 
Indirect 
 
Combination no 
longer used in 
clinical practice 
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RD across time points, 7% to 
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SOE: Low 
Natalizumab + 
infliximab vs. 
infliximab–wk 10 
Patient-
reported 
outcomes 
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Absolute between-group 
difference in change in mean 
IBDQ from baseline, 2 pts; 
infliximab change in IBDQ, 17 pts 
 
SOE: Low 
TNF vs. placebo–
wk 2 
Disease 
activity 
measures 
7 (2208)37-43 Medium Consistent Direct Precise Favors TNF 
Pooled RR, 1.8; 95% CI, 1.4 to 
2.4; placebo rate, 4 to 16% 
 
SOE: Moderate 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Adalimumab vs. 
placebo (160 mg 
x 1) –wk 2 
Disease 
activity 
measures 
2 (475)37 38 Low Consistent Direct Precise Favors adalimumab 
RD, 10% to 15%; placebo rate, 
6% to 14% 
 
SOE: High 
Adalimumab vs. 
placebo (≤ 80 mg 
x 1) –wk 2 
Disease 
activity 
measures 
2 (223)37 Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, 0% to 6%; placebo rate, 
14% 
 
SOE: Moderate 
Adalimumab vs. 
placebo–wk 4 
Fistula 
response 
1 (32)37 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -17% to 58%; placebo rate, 
17% 
 
SOE: Low 
Adalimumab vs. 
placebo–wk 4 
Patient-
reported 
outcomes 
2 (624)37 38 Low Consistent Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 2 to 15 pts; 
placebo change in IBDQ, 15 pts 
 
SOE: High 
Certolizumab 
pegol vs. 
placebo–wk 2, 12-
16 
Disease 
activity 
measures 
4 (1478)39-42 Medium Inconsistent Indirect 
 
IV formulation 
not presently 
approved41 
Imprecise Favors neither  
RD, -19% to 31%; placebo rate, 
8% to 32% 
 
SOE: Low 
Certolizumab 
pegol vs. 
placebo–wk 26 
Disease 
activity 
measures 
1 (331)39 High Unknown 
(single trial) 
Direct Precise Favors certolizumab pegol 
RD, 11%; placebo rate, 18% 
 
SOE: Low 
Certolizumab 
pegol vs. 
placebo–wk 26 
Fistula 
response 
1 (107)39  High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -1%; placebo rate, 31% 
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Certolizumab 
pegol vs. 
placebo–wks 12, 
26 
Patient-
reported 
outcomes 
2 (954)39 40 High Consistent Indirect 
 
Single dose for 
induction not 
presently used in 
practice40 
Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline across time 
points, 5 to 11 pts; placebo 
change in IBDQ, 18 to 21 pts 
 
SOE: Low 
Infliximab vs. 
placebo–wk 2 
Disease 
activity 
measures 
1 (106)43 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD, 16% to 34%; placebo rate, 
4% 
 
SOE: Moderate 
Infliximab vs. 
placebo–wk 12 
Disease 
activity 
measures 
1 (106)43 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Imprecise Favors infliximab 
RD, 10% to 22%; placebo rate, 
8% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 4 
Mucosal 
healing 
1 (30)49 High Unknown 
(single trial) 
Direct Precise Favors infliximab 
Absolute between-group 
difference in the change from 
baseline in CDEIS, 7.7; placebo 
difference, 0.9 
 
SOE: Low 
Infliximab vs. 
placebo–wk 6 
Fistula 
response 
1 (94)44 Low Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD, 25% to 42%; placebo rate, 
13% 
 
SOE: High 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Infliximab vs. 
placebo–wk 4 
Patient-
reported 
outcomes 
1 (83)43 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 31 pts; 
placebo change in IBDQ, 5 pts 
 
SOE: Moderate 
Infliximab vs. 
azathioprine–wks 
10, 26 
Disease 
activity 
measures 
1 (339)45 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD across time points, 13% to 
14%; azathioprine rate, 24% to 
30% 
 
SOE: Moderate 
Infliximab vs. 
azathioprine–wk 
26 
Mucosal 
healing 
1 (202)45  High Unknown 
(single trial) 
Direct Precise Favors infliximab 
RD in percentage of patients 
who achieved absence of 
mucosal ulcers, 13%; 
azathioprine rate, 17% 
 
SOE: Low  
Infliximab vs. 
azathioprine–wk 
26 
Patient-
reported 
outcomes 
1 (339)45  Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 9 pts; 
azathioprine change in IBDQ, 31 
pts 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
infliximab–wks 10, 
26 
Disease 
activity 
measures 
1 (338)45 Medium Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD across time points, 10% to 
13%; infliximab alone rate, 37% 
to 44% 
 
SOE: Moderate 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Infliximab + 
azathioprine vs. 
infliximab–wk 26 
Mucosal 
healing 
1 (200)45  High Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD in percentage of patients 
who achieved absence of 
mucosal ulcers, 14%; infliximab 
rate, 30% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
infliximab–wk 26 
Patient-
reported 
outcomes 
1 (338)45 Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 5 pts; 
infliximab change in IBDQ, 40 
pts 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
azathioprine–wks 
10-12, 24-26 
Disease 
activity 
measures 
2 (393)45 46 Medium Consistent Direct Precise Favors infliximab + azathioprine 
RD across time points, 12% to 
30%; azathioprine rate, 24% to 
44% 
 
SOE: Moderate 
Infliximab + 
azathioprine vs. 
azathioprine–wk 
26 
Mucosal 
healing 
1 (216)45 High Unknown 
(single trial) 
Direct Precise Favors infliximab + azathioprine 
RD in percentage of patients 
who achieved absence of 
mucosal ulcers, 27%; 
azathioprine rate, 17% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
azathioprine–wk 
26 
Patient-
reported 
outcomes 
1 (508)45 Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 14 pts; 
azathioprine change in IBDQ, 31 
pts 
 
SOE: Moderate 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Infliximab + 
azathioprine vs. 
steroids–wk 104 
Disease 
activity 
measures 
1 (129)48 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Imprecise Favors neither 
RD, 6%; corticosteroid rate, 49% 
 
SOE: Low 
Infliximab+ 
azathioprine vs. 
steroids–wk 104 
Mucosal 
healing 
1 (49)48  High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Precise Favors infliximab + azathioprine 
RD in percentage of patients with 
no ulcers, 43%; steroid rate, 30% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
steroids–wk 10 
Patient-
reported 
outcomes 
1 (129)48 High Unknown 
(single trial) 
Indirect 
 
Single dose for 
induction not 
presently used in 
practice 
Precise Favors infliximab + azathioprine 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 22 pts; 
steroids change in IBDQ, 37 pts 
 
SOE: Low 
Infliximab + 
methotrexate vs. 
infliximab–wks 2, 
12, 48 
Disease 
activity 
measures 
1 (19)47 High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
RD across time points, 17% to 
39%; infliximab rate, 25% to 50% 
 
SOE: Low 
Infliximab + 
methotrexate vs. 
infliximab–wk 48 
Reduction 
of steroids 
1 (13)47 High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
Reduction in prednisolone dose 
from baseline, 17 mg vs. 6 mg  
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Infliximab + 
methotrexate vs. 
infliximab–wk 4 
and 8 
Patient-
reported 
outcomes 
1 (19)47  High Unknown 
(single trial) 
Direct Imprecise Favors infliximab + methotrexate 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 22 pts; 
infliximab change in IBDQ, 28 
pts 
 
SOE: Low 
Thiopurine vs. 
placebo–wks 3-4, 
17-38 
Disease 
activity 
measures 
2 (158)56 57 High Inconsistent Indirect 
 
 
Imprecise Favors neither 
RD across time points, -5% to 
13%; placebo rate, 5% to 48% 
 
SOE: Low 
Thiopurine vs. 
placebo–wk 104 
Disease 
activity 
measures 
1 (33)60 High Unknown 
(single trial) 
Indirect Imprecise Favors 6-MP 
RD, 33%; placebo rate, 14% 
 
SOE: Low 
Thiopurines vs. 
placebo–wk 16 
Reduction 
of steroids 
1 (26)62  Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
Reduction in steroid dose from 
baseline, 7 mg vs. 12 mg  
 
SOE: Low 
Thiopurine vs. 
placebo–wk 17  
Fistula 
response 
1 (17)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD in perianal fistula closure, 
2%; placebo rate, 11% 
 
SOE: Low 
Thiopurine vs. 
placebo– 
wk 104 
Fistula 
response 
1 (46)60  High Unknown 
(single trial) 
Direct Imprecise Favors 6-MP 
RD in perianal fistula closure, 
25%; placebo rate, 6% 
 
SOE: Low 
Thiopurines vs. 
placebo–wk 8 and 
16 
Patient-
reported 
outcomes 
3 (116)57 61 62  Medium Inconsistent Direct Imprecise Favors neither 
Multiple measures; see text 
 
SOE: Low 
D-7 
Appendix D. Evidence Tables 
(reference list located in full report) 
 
Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Thiopurines vs. 
methotrexate 
(oral)–wks 4, 12, 
30-38 
Disease 
activity 
measures 
2 (89)52 57 Medium Inconsistent Indirect Imprecise Favors neither 
RD across time points, -1% to 
21%; placebo rate, 9% to 80% 
 
SOE: Low 
Azathioprine vs. 
prednisone–wks 
2, 13, 17 
Disease 
activity 
measures 
1 (144)56 High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD across time points, -24 to -
12%; prednisone rate, 27-77% 
 
SOE: Low 
Azathioprine vs. 
prednisone–wk 17 
Fistula 
response 
1 (18)55 High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD, -17%; prednisone rate, 30% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–wk 
2 
Disease 
activity 
measures 
1 (133)56 High Unknown 
(single trial) 
Direct Precise Favors sulfasalazine 
RD, -14%; sulfasalazine rate, 
20% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–wks 
13, 17 
Disease 
activity 
measures 
1 (133)56 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, 0% to 
6%; sulfasalazine rate, 32% to 
53% 
 
SOE: Low 
Azathioprine vs. 
sulfasalazine–wk 
17 
Fistula 
response 
1 (17)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -9%; sulfasalazine rate, 22% 
 
SOE: Low 
6-MP vs. ASA–
wks 12, 30 
Disease 
activity 
measures 
1 (23)52 High Unknown 
(single trial) 
Direct Precise Favors 6-MP 
RD across time points, 67% to 
80%; ASA rate, 14% 
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Azathioprine (IV 
and oral) vs. 
thiopurine (oral)–
wk 8, 16 
Disease 
activity 
measures 
1 (96)59 Medium Unknown 
(single trial) 
Indirect 
 
IV AZA is not 
presently used 
as a treatment 
Imprecise Favors neither 
RD across time points, 1% to 
4%; oral azathioprine alone rate, 
24% to 27% 
 
SOE: Low 
Azathioprine + 
steroid vs. 
steroid–wks 12, 
28 
Disease 
activity 
measures 
3 (186)51 53 54 Medium Inconsistent Direct Imprecise Favors azathioprine + steroid 
RD across time points, 10%; 
steroid rate, 28% to 63% 
 
SOE: Low 
Azathioprine + 
prednisone vs. 
methotrexate (IV 
followed by oral) + 
prednisone–wk 
13, 26 
Disease 
activity 
measures 
1 (54)58 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, -11% to 
7%; methotrexate + prednisone 
rate, 44% to 56% 
 
SOE: Low 
Azathioprine + 
prednisone vs. 
methotrexate (IV 
followed by oral) + 
prednisone–wk 26 
Fistula 
response 
1 (10)58  High Unknown 
(single trial) 
Direct Imprecise Favors methotrexate + 
prednisone 
RD in fistula closure, -42%; 
methotrexate + prednisone rate, 
67% 
 
SOE: Low 
Methotrexate 
(oral) vs. placebo–
wks 4, 12, 38 
Disease 
activity 
measures 
1 (52)57 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD across time points, -8% to 
3%; placebo rate, 5% to 46% 
 
SOE: Low 
Methotrexate 
(oral) vs. ASA–
wks 12, 30 
Disease 
activity 
measures 
1 (22)52 Medium Unknown 
(single trial) 
Direct Precise Favors methotrexate 
RD, 46% to 66%; ASA rate, 14% 
 
SOE: Moderate 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Methotrexate (IM) 
+ prednisone vs. 
placebo + 
prednisone–wk 16 
Disease 
activity 
measures 
1 (141)63 Medium 
 
Unknown 
(single trial) 
Direct Precise Favors methotrexate + 
prednisone 
RD, 20%; prednisone only rate, 
19% 
 
SOE: Moderate 
Methotrexate (IM) 
+ prednisone vs. 
placebo + 
prednisone–wk 16 
Patient-
reported 
outcomes 
1 (141)63  Medium Unknown 
(single trial) 
Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 15; 
prednisone only change in IBDQ, 
-8 
 
SOE: Moderate 
Budesonide (≥ 9 
mg) vs. placebo–
wk 2 
Disease 
activity 
measures 
2 (391)65 66 Medium Consistent Direct Precise Favors budesonide 
RD, 17% to 27%; placebo rate, 
11% to 13% 
 
SOE: Moderate 
Budesonide (< 9 
mg) vs. placebo–
wk 2 
Disease 
activity 
measures 
1 (128)66 Medium Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD, -1%; placebo rate, 11%  
 
SOE: Low 
Budesonide vs. 
placebo–wk 8 
Disease 
activity 
measures 
2 (458)65 66 Medium Consistent Direct Precise Favors budesonide 
RD across time points, 13% to 
31%; placebo rate, 20% to 33% 
 
SOE: Moderate 
Budesonide vs. 
placebo–wk 8 
Patient-
reported 
outcomes 
2 (458)65 66  High Consistent Direct Imprecise Favors neither 
Absolute between-group 
difference in change in IBDQ 
from baseline, 7 to 30; placebo 
change in IBDQ, 10 to 29 
 
SOE: Low 
Prednisone vs. 
placebo – wk 2 
Disease 
activity 
measures 
1 (162)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, 5%; placebo rate, 15% 
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
6-
methylprednisolon
e vs. placebo–wk 
3 
Disease 
activity 
measures 
1 (105)64 High Unknown 
(single study) 
Direct Precise Favors 6-methylprednisolone 
RD, 14%; placebo rate, 79% 
 
SOE: Low 
Steroid (6-methyl-
prednisolone, 
prednisone) vs. 
placebo–wks 16-
17, 104 
Disease 
activity 
measures 
2 (267)56 64 High Consistent Direct Precise Favors steroids 
RD across time points, 25% to 
47%; placebo rate, 8% to 42% 
 
SOE: Low 
Prednisone vs. 
placebo–wk 17 
Fistula 
response 
1 (19)55  High Unknown 
(single trial) 
Direct Imprecise Favors prednisone 
RD in fistula closure, 19%; 
placebo rate, 11%  
 
SOE: Low 
Budesonide vs. 
other steroid 
(prednisolone, 
prednisone)–wks 
2, 8 
Disease 
activity 
measures 
3 (557)67-69 Medium Consistent Direct Precise Favors neither 
Pooled RR at wk 8, 0.9; CI, 0.8 
to 1.0; steroid rate, 55% to 65% 
 
SOE: Moderate 
Budesonide vs. 
prednisone–wk 8 
Patient-
reported 
outcomes 
1 (201)67  Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline,  
-8; prednisone change in IBDQ, 
34 
 
SOE: Moderate 
Steroid vs. ASA–
wks 2-3, 12-17, 
54-104 
Disease 
activity 
measures 
7 (919)56 64 70-74 Medium Inconsistent Direct Imprecise Favors steroids 
RD across time points, -18% to 
30%; ASA rate, 6% to 87% 
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Prednisone vs. 
sulfasalazine 
Fistula 
healing 
2 (19)55 High Unknown 
(single trial) 
Direct Imprecise Favors neither 
RD in fistula closure, 9%; 
sulfasalazine rate, 22% 
 
SOE: Low 
Prednisone vs. 
ASA – wk 2 
Patient-
reported 
outcomes 
1 (50)73  Low Unknown 
(single trial) 
Direct Precise Favors prednisone 
Absolute between-group 
difference in Quality of Life Index 
from baseline, 16%; ASA 
improvement in Quality of Life 
Index, 7%  
 
SOE: High 
Prednisone vs. 
ASA – wk 12 
Patient-
reported 
outcomes 
1 (50)73  Low Unknown 
(single trial) 
Direct Imprecise Favors neither 
Absolute between-group 
difference in Quality of Life Index 
from baseline, 4%; ASA 
improvement in Quality of Life 
Index, 33% 
 
SOE: Moderate 
Prednisolone + 
sulfasalazine vs. 
placebo–wks 3,16, 
104 
Disease 
activity 
measures 
1 (114)64 High Unknown 
(single trial) 
Direct Precise Favors prednisolone + 
sulfasalazine 
RD across time points, 19% to 
47%; placebo rate, 8% to 79% 
 
SOE: Low 
Steroid + 
sulfasalazine vs. 
steroid–wks 3, 8-
16, 104 
Disease 
activity 
measures 
2 (192)64 75 Medium Consistent Direct Imprecise Favors neither 
RD across time points, 2% to 
19%; steroid rate, 33% to 93% 
 
SOE: Low 
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Evidence Table 1. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
induction of remission (KQ1) 
 
Comparison Outcome 
Number of trials 
(participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
Risk of bias Consistency Directness Precision 
Steroid + 
sulfasalazine vs. 
sulfasalazine–wks 
3, 16, 104 
Disease 
activity 
measures 
1 (110)64 High Consistent Direct Precise Favors steroids + sulfasalazine 
RD across time points, 11% to 
26%; sulfasalazine rate, 22% to 
87% 
 
SOE: Low 
ASA vs. placebo-
wks 2-3 
Disease 
activity 
measures 
5 (330)56 64 78 Medium Inconsistent Direct Imprecise Favors neither 
RD, -8 to 9%; placebo rate, 8 to 
79% 
 
SOE: Low  
ASA (mesalamine 
≥ 3.2 g daily or 
sulfasalazine) vs. 
placebo-wks 16-
17 
Disease 
activity 
measures 
5 (456)56 64 77 79 Medium Consistent Direct Imprecise Favors ASA 
RD, 12 to 25%; placebo rate, 18 
to 36% 
 
SOE: Low  
ASA (mesalamine 
< 3.2 g daily) vs. 
placebo-wk 16 
Disease 
activity 
measures 
5 (302)78 79 Medium Consistent Direct Imprecise Favors neither 
RD, 2 to 6%; placebo rate, 18 to 
25% 
 
SOE: Low  
Sulfasalazine vs. 
placebo – wk 104 
Disease 
activity 
measures 
1 (112)64 High Unknown 
(single trial) 
Direct Precise Favors sulfasalazine 
RD, 14%; placebo rate, 8% 
 
SOE: Low 
Sulfasalazine vs. 
placebo-wk 17 
Fistula 
response 
1 (18)55 High Unknown 
(single trial) 
Direct Imprecise Favors sulfasalazine 
RD in fistula closure, 11%; 
placebo rate, 11% 
 
SOE: Low 
6-MP = 6-mercaptopurine; ASA = aminosalicylates; CDEIS = Crohn’s Disease Endoscopic Index of Severity; CI = 95% confidence interval; IBDQ = Inflammatory Bowel Disease 
Questionnaire; IM = intramuscular; IV = intravenous; mg = milligrams; pts = points; RD = absolute risk difference; RR = relative risk; SOE = strength of evidence; steroid = 
corticosteroids; TNF = tumor necrosis factor-alpha inhibitor; TPMT = thiopurine methyltransferase; vs. = versus; wk = week 
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Evidence Table 2. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of inducing remission (KQ1) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Randomized controlled trials evaluating biologics 
Colombel, 
201045 
RCT, parallel 
arms 
Start year: 2005 
 
Duration of 
assigned 
treatment: 50 
weeks 
US, North 
America, 
Europe, Asia 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (abdominal surgery in past 6 
months), CDAI (219-451), previous use of corticosteroids, mesalamine or 
budesonide, no use of TNF-alpha inhibitors, methotrexate, 6-
mercaptopurine, azathioprine, moderate-severe disease, no short bowel 
syndrome, no ostomy, no abscess, no obstructive symptoms with 
strictures, no history of TB, no cancer, other criteria 
D'Haens, 
200848 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
Yes 
 
Yes 
Pediatrics, adults, CD only, CDAI (>200), no use of corticosteroids, 
antimetabolites, biological agents, active disease, not pregnant, no 
obstructive symptoms with strictures, no history of TB, no cancer, other 
criteria 
Gordon, 
200134 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Location: NR 
 
Number of 
centers NR 
No 
 
 
Adults, CD only, CDAI (150-451), no use of methotrexate, cyclosporin, 
tacrolimus, not pregnant, not nursing, using adequate contraception, no 
ostomy, no cancer, other criteria 
Hanauer, 
200637 
 
RCT, parallel 
arms 
Start year: 2002 
 
Duration of 
assigned 
treatment: 4 weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (extensive bowel resection (>100 
cm)), CDAI (220-450), no use of TNF-alpha inhibitors, moderate-severe 
disease, not pregnant, not nursing, using adequate contraception, no short 
bowel syndrome, no ostomy, no obstructive symptoms with strictures, no 
history of TB, no cancer, other criteria 
Lemann, 
200646 
RCT, parallel 
arms 
Start year: 2000 
 
Duration of 
assigned 
treatment: 24 
weeks 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, previous use of corticosteroids, prednisone, no use of 5-
aminosalicylate acids, TNF-alpha inhibitors, topical steroids, budesonide, 
active disease, not pregnant, not nursing, using adequate contraception, 
no abscess, no obstructive symptoms with strictures, no history of TB, 
other criteria 
 
Present, 
199944 
RCT, parallel 
arms 
Start year: 1996 
 
Duration of 
assigned 
treatment: 6 weeks 
US, Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, using adequate contraception, no abscess, 
other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Sandborn, 
200533 
 
 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 8 weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors in past 3 
months, no short bowel syndrome, no ostomy, no abscess, no obstructive 
symptoms with strictures, other criteria 
Sandborn, 
200739 
 
 
RCT, parallel 
arms 
Start year: 2003 
 
Duration of 
assigned 
treatment: 26 
weeks 
Worldwide 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), active disease, no short bowel 
syndrome, no ostomy, no abscess, no obstructive symptoms with 
strictures, no history of TB, no demyelinating disease, no cancer, other 
criteria 
Sandborn, 
200738 
 
 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 4 weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (bowel resection in past 6 months), 
CDAI (220-450), no use of adalimumab, active disease, not pregnant, not 
nursing, no short bowel syndrome, no ostomy, no obstructive symptoms 
with strictures, no history of TB, no demyelinating disease, other criteria 
Sandborn, 
201142 
RCT, parallel 
arms 
Start year: 2008 
 
Duration of 
assigned 
treatment: 6 weeks 
US, North 
America, 
Europe, Asia, 20 
countries all 
over 
 
Multicenter 
NR 
 
Adults, CD only, CDAI (220-450), previous use of TNF-alpha inhibitors, 
intravenous corticosteroids, other biological agent, no short bowel 
syndrome, no ostomy, no abscess, no history of TB, no demyelinating 
disease, no cancer, other criteria 
Sands, 200735 RCT, parallel 
arms 
Start year: 2002 
 
Duration of 
assigned 
treatment: NR 
US 
 
Multicenter 
No 
 
 
Adults, CD only, previous use of TNF-alpha inhibitors, no abscess, no 
obstructive symptoms with strictures, other criteria 
Schreiber, 
200540 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 8 weeks 
North America, 
Europe, Africa, 
Russia 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors, 
certolizumab pegol, sodium cromoglycate, mycophenolate, cyclosporin in 
past 4 weeks, TNF-alpha inhibitor with a biologic agent in past 12 weeks, 
moderate-severe disease, no abscess, no obstructive symptoms with 
strictures, no history of TB, other criteria 
D-15 
 
 
Evidence Table 2. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of inducing remission (KQ1) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Schroder, 
200647 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 48 
weeks 
Europe 
 
Single center 
No 
 
 
Adults, CD only, no use of TNF-alpha inhibitors, infliximab, active disease, 
other criteria 
Targan, 
199743 
 
 
RCT, parallel 
arms 
Start year: 1995 
 
Duration of 
assigned 
treatment: 12 
weeks 
US, North 
America, Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (proctocolectomy), CDAI (220-400), 
no use of cyclosporine, methotrexate or experimental agents in past 3 
months, no ostomy, no obstructive symptoms with strictures, other criteria 
Targan, 
200732 
 
 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 2004 
 
Duration of 
assigned 
treatment: 8 weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (total colectomy), CDAI (220-450), 
no use of TNF-alpha inhibitors, natalizumab, active disease (moderate-
severe), no short bowel syndrome, no ostomy, no abscess, no obstructive 
symptoms with strictures, other criteria 
Winter, 200441 RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe, Africa, 
Israel 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (extended bowel resection), CDAI 
(220-450), moderate-severe disease, no ostomy, no abscess, no 
obstructive symptoms with strictures, no history of TB, other criteria 
Randomized controlled trials evaluating thiopurines 
Ardizzone, 
200358 
RCT, parallel 
arms 
Start year: 1997 
 
Duration of 
assigned 
treatment: 6 
months 
Europe 
 
Single center 
No 
 
 
Adults, CD only, CDAI (>200), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no cancer, other criteria 
Candy, 199553 RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Africa 
 
Single center 
No 
 
 
Pediatrics, adults, CD only, no previous surgery (extensive surgery for 
CD), CDAI (>200), not pregnant, not nursing, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Ewe, 199354 RCT, parallel 
arms 
Start year: 1987 
 
Duration of 
assigned 
treatment: 4 
months 
Europe 
 
Single center 
No 
 
 
Adults, CD only, CDAI (>150), no use of thiopurines, perianal fistulizing, 
not pregnant, no abscess 
Klein, 197462 RCT, crossover Start year: NR 
 
Duration of 
assigned 
treatment: 4 
months 
US 
 
Single center 
Yes 
 
Yes 
Adults, CD only, other criteria 
Markowitz, 
2000192 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 18 
months 
US 
 
Multicenter 
No 
 
 
Pediatrics, CD only, moderate-severe disease, other criteria 
Mate-
Jimenez, 
200052 
RCT, parallel 
arms 
Start year: 1994 
 
Duration of 
assigned 
treatment: 26.5 
months 
Europe 
 
Single center 
No 
 
 
Pediatrics, adults, IBD, no previous surgery (extensive surgery), previous 
use of corticosteroids, not pregnant, not nursing, using adequate 
contraception, no abscess, other criteria 
Oren, 199757 RCT, parallel 
arms 
Start year: 1992 
 
Duration of 
assigned 
treatment: 9 
months 
Israel 
 
Multicenter 
No 
 
 
Adults, CD only, HBI (<7), previous use of corticosteroids, no use of 
immunomodulators in past 3 months, not pregnant, not nursing, using 
adequate contraception, no abscess, no obstructive symptoms with 
strictures, other criteria 
 
 
Present, 
198060 
RCT, parallel 
arms, crossover 
Start year: NR 
 
Duration of 
assigned 
treatment: 1 year 
US 
 
Single center 
Yes 
 
No 
Pediatrics, adults, CD only, active disease, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Reinisch, 
200851 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 12 
months 
North America, 
Europe, Africa, 
Russia 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (resection of >100 cm of small 
bowel), CDAI (220-450), previous use of corticosteroids, no use of 5-
aminosalicylate acids, TNF-alpha inhibitors, corticosteroids, methotrexate, 
corticosteroids for current flare >21 days prior to randomization, active 
disease, perianal fistulizing, no obstructive symptoms with strictures, other 
criteria 
Rhodes, 
197161 
RCT, crossover Start year: NR 
 
Duration of 
assigned 
treatment: 2 
months 
Location: NR 
 
Number of 
centers NR 
Yes 
 
No 
Pediatrics, adults, CD only 
Sandborn, 
199959 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1996 
 
Duration of 
assigned 
treatment: 16 
weeks 
US, North 
America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (> 100 cm ileum), CDAI (150-450), 
previous use of corticosteroids, no use of antibiotics, thiopurines, 
infliximab, adalimumab, certolizumab pegol, active disease (mild-
moderate), perianal fistulizing, no abscess, no obstructive symptoms with 
strictures, no cancer 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Randomized controlled trials evaluating methotrexate 
Feagan, 
199563 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1992 
 
Duration of 
assigned 
treatment: 16 
weeks 
US, North 
America 
 
Multicenter 
No 
 
 
CD only, previous use of prednisone, no use of prednisone > 10 mg/day, 
active disease, not pregnant, no cancer, other criteria 
 
 
Mate-
Jimenez, 
200052 
RCT, parallel 
arms 
Start year: 1994 
 
Duration of 
assigned 
treatment: 26.5 
months 
Europe 
 
Single center 
No 
 
 
Pediatrics, adults, IBD, no previous surgery (extensive surgery), previous 
use of corticosteroids, not pregnant, not nursing, using adequate 
contraception, no abscess, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Oren, 199757 RCT, parallel 
arms 
Start year: 1992 
 
Duration of 
assigned 
treatment: 9 
months 
Israel 
 
Multicenter 
No 
 
 
Adults, CD only, HBI (<7), previous use of corticosteroids, no use of 
immunomodulators in past 3 months, not pregnant, not nursing, using 
adequate contraception, no abscess, no obstructive symptoms with 
strictures, other criteria 
Randomized controlled trials evaluating corticosteroids 
Bar-Meir, 
199867 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 8 weeks 
Israel 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (150-350), no use of immunomodulators or 
corticosteroids in past 3 months, NSAIDs, no obstructive symptoms with 
strictures, other criteria 
Campieri, 
199768 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe, 
Australia 
 
Multicenter 
Yes 
 
 
Adults, CD only, no previous surgery (ileostomy or more extensive 
resection of the ileum (>100 cm)), CDAI (>200), active disease, no 
abscess, other criteria 
Escher, 
2004190 
RCT, parallel 
arms 
Start year: 1998 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, CD only, CDAI (>200), no use of corticosteroids, thiopurines, 
active disease, other criteria 
Greenberg, 
199466 
RCT, parallel 
arms 
Start year: 1991 
 
Duration of 
assigned 
treatment: 8 weeks 
North America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (>200), not pregnant, not nursing, no cancer, other 
criteria 
 
Gross, 199572 RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 8 weeks 
Europe 
 
Multicenter 
Yes 
 
No 
CD only, CDAI (150-350), other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Levine, 
2003191 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Israel 
 
Multicenter 
No 
 
 
Pediatrics, CD only, no previous surgery (in past 6 weeks), PCDAI (12.5-
40), no use of corticosteroids, thiopurines, active disease, other criteria 
Malchow, 
198464 
 
 
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Martin F, 
199073 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
North America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (200-450), previous use of corticosteroids, 
prednisone, no use of any medication taken for treatment for active CD in 
past month, active disease, not pregnant, not nursing, other criteria 
Prantera, 
199971 
RCT, parallel 
arms 
Start year: 1994 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (small bowel resection of >100 cm or 
colectomy or proctocolectomy), CDAI (180-350), no use of corticosteroids 
or other immunomodulators in past 3 months, mild-moderate disease, not 
pregnant, no short bowel syndrome, no obstructive symptoms with 
strictures, other criteria 
Rutgeerts, 
199469 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 10 
weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (ileostomy or small bowel resection 
>100 cm), CDAI (>200), no short bowel syndrome, no ostomy, no 
abscess, no obstructive symptoms with strictures, other criteria 
Schoon, 
2005185 
RCT, parallel 
arms 
Start year: 1996 
 
Duration of 
assigned 
treatment: 2 years 
Europe, Israel 
 
Multicenter 
 
 
No 
Adults, CD only, no previous surgery (gastric surgery or resection of >100 
cm of small bowel or of tissues distal to the mid-transverse colon), no use 
of hormone replacement therapy in past 6 months, bisphosphonates in 
past 6 months, androgens/anabolic steroids in past 6 months, no abscess, 
no obstructive symptoms with strictures, other criteria 
Singleton, 
197975 
 
 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 8 weeks 
US 
 
Multicenter 
Yes 
 
Yes 
CD only, CDAI (>150), active disease 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Thomsen, 
199870 
RCT, parallel 
arms 
Start year: 1994 
 
Duration of 
assigned 
treatment: 16 
weeks 
Europe, 
Australia, Africa 
 
Multicenter 
Yes 
 
No 
Adults, CD only, no previous surgery (resection of >100 cm of ileum or if 
need immediate surgery), CDAI (200-400), not pregnant, not nursing, no 
abscess, other criteria 
Tremaine, 
200265 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1995 
 
Duration of 
assigned 
treatment: 8 weeks 
US 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (200-450), mild-moderate disease, not pregnant, 
not nursing, no ostomy, other criteria 
Tromm, 
201174 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 8 weeks 
Europe, Israel 
 
Multicenter 
 
 
Adults, CD only, CDAI (200-400), no use of methotrexate, within 3 
monthsperianal fistulizing, no short bowel syndrome, no ostomy, no 
obstructive symptoms with strictures, other criteria 
Randomized controlled trials evaluating aminosalicylate acids 
Griffiths, 
1993221 
RCT, crossover Start year: 1988 
 
Duration of 
assigned 
treatment: 8 weeks 
North America 
 
Single center 
No 
 
 
Pediatrics, CD only, HBI (>4), other criteria 
Malchow, 
198464 
 
 
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Singleton, 
199379 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 16 
weeks 
US 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (151-400), mild-moderate disease, using adequate 
contraception, no ostomy, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence >80% 
in each study 
arm Inclusion criteria 
Singleton, 
1995222 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 16 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (ileostomies or colostomies), CDAI 
(150-400), not pregnant, using adequate contraception, other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Tremaine, 
199477 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 16 
weeks 
US 
 
Single center 
No 
 
 
Adults, CD only, no previous surgery (extensive small bowel resection with 
more than one half of the length of the small intestine removed), CDAI 
(150-450.9), mild-moderate disease, other criteria 
Abbreviations: CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; HBI= Harvey-Bradshaw Index; NR = not reported; RCT = randomized controlled trial; TB = 
tuberculosis; US = United States 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Randomized controlled trials evaluating biologics 
Colombel, 
201045 
Infliximab + 
Placebo, 169 
Route: IV + Oral 
Dose: 5 mg/kg 
every 8 weeks + 
NA every day 
Male, %: 49.7 
 
Race, % 
W: 86.4 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.2 
 
Age at 
enrollment 
Median: 35 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 37.9 
Colonic: 26.6 
 
Behavior NR 
 
CRP 
Median: 1.1 
CDAI 
Mean: 284.8 
5ASA: 51.5 
 
Corticosteroids: 
30.8 
 
Budesonide: 16.6 
NR NR 
Colombel, 
201045 
Azathioprine + 
Infliximab, 169 
Route: Oral + IV 
Dose: 2.5 mg/kg 
every day + 5 
mg/kg every 8 
weeks 
Male, %: 52.1 
 
Race, % 
W: 84 
 
Smoking, % 
Smoker, 38.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.2 
 
Age at 
enrollment 
Median: 34 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 43.2 
Colonic: 23.7 
 
Behavior NR 
 
CRP 
Median: 1 
CDAI 
Mean: 289.9 
5ASA: 50.3 
 
Corticosteroids: 
27.8 
 
Budesonide: 11.2 
NR NR 
Colombel, 
201045 
Azathioprine + 
Placebo, 170 
Route: Oral + IV 
Dose: 2.5 mg/kg 
every day + NA 
every 8 weeks 
Male, %: 52.9 
 
Race, % 
W: 86.5 
 
Smoking, % 
Smoker, 35.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.4 
 
Age at 
enrollment 
Median: 35 
Severity NR 
 
Location, % 
Ileal: 40 
Ileo-colonic: 40.6 
Colonic: 19.4 
 
Behavior NR 
 
CRP 
Median: 1 
CDAI 
Mean: 287.2 
5ASA: 61.2 
 
Corticosteroids: 
23.5 
 
Budesonide: 14.7 
NR NR 
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taken BEFORE 
study, % 
Medications 
taken FOR 
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D'Haens, 
200848 
Budesonide + 
(6)-
Methylprednisolo
ne, 64 
Route: Oral + 
Oral 
Dose: 9 mg 
every day + 32 
mg every day  
Male, %: 42.2 
 
Race, % 
W: 95.3 
 
Smoking, % 
Current smoker, 
35.9 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 28.7 
Severity NR 
 
Location, % 
Ileo-colonic: 43.8 
Colonic: 32.8 
 
Behavior NR 
 
CRP 
Median: 25 
CDAI 
Mean: 306 
 
IBDQ 
Mean: 136 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Budesonide 
5ASA: 3.1 NR 
D'Haens, 
200848 
Infliximab + 
Azathioprine, 65 
Route: IV + Oral 
Dose: 5 mg/kg + 
2-2.5 mg/kg 
Male, %: 33.8 
 
Race, % 
W: 98.5 
 
Smoking, % 
Current smoker, 
43.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30 
Severity NR 
 
Location, % 
Ileo-colonic: 47.7 
Colonic: 30.8 
 
Behavior NR 
 
CRP 
Median: 19 
CDAI 
Mean: 330 
 
IBDQ 
Mean: 122 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Azathioprine: 100 
 
Methylprednisolon
e 
5ASA: 4.6 NR 
Gordon, 
200134 
Natalizumab, 18 
Route: IV 
Dose: 3 mg/kg 
Male, %: 38.9 
 
Race, % 
W: 94.4 
A: 5.6 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.5 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileo-colonic: 27.8 
Colonic: 27.8 
Perianal: 27.8 
 
Behavior NR 
 
CRP 
Mean: 14 
CDAI 
Mean: 258 
Min: 122 
Max: 436 
 
IBDQ 
Mean: 121 
Min: 74 
Max: 167 
Corticosteroids: 
55.6 
 
Thiopurines: 33.3 
 
Mesalamine: 72.2 
 
Mesalamine alone: 
16.7 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Gordon, 
200134 
Placebo, 12 
Route: IV 
Dose: NA 
Male, %: 41.7 
 
Race, % 
W: 91.7 
A: 8.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.4 
 
Age at 
enrollment 
Mean: 34.4 
Severity NR 
 
Location, % 
Ileo-colonic: 33.3 
Colonic: 25 
Perianal: 33.3 
 
Behavior NR 
 
CRP 
Mean: 35 
CDAI 
Mean: 273 
Min: 191 
Max: 420 
 
IBDQ 
Mean: 118 
Min: 78 
Max: 144 
Corticosteroids: 75 
 
Thiopurines: 16.7 
 
Mesalamine: 75 
 
Mesalamine alone: 
16.7 
NR NR 
Hanauer, 
200637 
 
 
Placebo, 74 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Current smoker, 
38 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 68 
Ileo-colonic: 9 
Colonic: 19 
Perianal: 0 
 
Behavior NR 
 
CRP 
Mean: 1.8 
Median: 0.9 
Min: 0 
Max: 17.3 
CDAI 
Mean: 296 
 
IBDQ 
Median: 131 
Min: 52 
Max: 200 
5ASA: 50 
 
Antibiotics: 7 
 
Corticosteroids: 34 
 
Methotrexate: 1 
 
Thiopurines: 28.4 
 
Immunomodulator
s: 30 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 
200637 
 
 
Adalimumab, 75 
Route: SC 
Dose: 80 mg 
then 40 mg 
every 2 weeks 
Male, %: 33 
 
Race NR 
 
Smoking, % 
Current smoker, 
43 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 63 
Ileo-colonic: 9 
Colonic: 23 
Perianal: 1 
 
Behavior NR 
 
CRP 
Mean: 2 
Median: 0.9 
Min: 0 
Max: 14.9 
CDAI 
Mean: 301 
 
IBDQ 
Median: 128 
Min: 63 
Max: 200 
5ASA: 53 
 
Antibiotics: 9 
 
Corticosteroids: 43 
 
Methotrexate: 4 
 
Thiopurines: 25.3 
 
Immunomodulator
s: 28 
NR NR 
Hanauer, 
200637 
 
 
Adalimumab, 76 
Route: SC 
Dose: 160 mg 
then 80 mg 
every 2 weeks 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Current smoker, 
42 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 53 
Ileo-colonic: 11 
Colonic: 29 
Perianal: 1 
 
Behavior NR 
 
CRP 
Mean: 1.4 
Median: 0.7 
Min: 0 
Max: 9.3 
CDAI 
Mean: 295 
 
IBDQ 
Median: 127 
Min: 37 
Max: 192 
5ASA: 51 
 
Antibiotics: 5 
 
Corticosteroids: 32 
 
Methotrexate: 1 
 
Thiopurines: 27.6 
 
Immunomodulator
s: 29 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 
200637 
 
Adalimumab, 74 
Route: SC 
Dose: 40 mg 
then 20 mg 
every 2 weeks 
Male, %: 53 
 
Race NR 
 
Smoking, % 
Current smoker, 
34 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 61 
Ileo-colonic: 5 
Colonic: 31 
Perianal: 0 
 
Behavior NR 
 
CRP 
Mean: 1.6 
Median: 0.9 
Min: 0 
Max: 11.3 
CDAI 
Mean: 299 
 
IBDQ 
Median: 129 
Min: 81 
Max: 218 
5ASA: 50 
 
Antibiotics: 14 
 
Corticosteroids: 23 
 
Methotrexate: 5 
 
Thiopurines: 25.7 
 
Immunomodulator
s: 31 
NR NR 
Lemann, 
200646 
Infliximab + 
Azathioprine or 
6-MP, 57 
Route: IV 
Dose: 5 mg/kg + 
stable 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 10 
 
Age at 
enrollment 
Min: 22 
Max: 38 
Severity NR 
 
Location, % 
Ileal: 28.1 
Ileo-colonic: 50.9 
Colonic: 21.1 
Perianal: 33.3 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 47 
CDAI 
Min: 90 
Max: 281 
NR Thiopurines: 100 NR 
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characteristics 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Lemann, 
200646 
Placebo + 
Azathioprine or 
6-MP, 56 
Route: IV + Oral 
Dose: NA + 
stable mg/kg 
every day 
Male, %: 42.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 11 
 
Age at 
enrollment 
Min: 22 
Max: 36 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 48.2 
Colonic: 39.3 
Perianal: 10.7 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 35 
CDAI 
Min: 42 
Max: 262 
NR Thiopurines: 100 NR 
Present, 
199944 
Infliximab, 31 
Route: IV 
Dose: 5 mg/kg 
Male, %: 48.4 
 
Race, % 
W: 90.3 
B: 9.7 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 13.6 
 
Age at 
enrollment 
Mean: 41.2 
Severity NR 
 
Location, % 
Ileal: 22.6 
Ileo-colonic: 54.8 
Colonic: 22.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 184.4 
Median: 163 
 
Perianal DAI 
Median: 8 
5ASA: 54.8 
 
Antibiotics: 19.4 
 
Corticosteroids: 
38.7 
 
Thiopurines: 38.7 
NR NR 
Present, 
199944 
Placebo, 31 
Route: IV 
Male, %: 54.8 
 
Race, % 
W: 93.5 
B: 6.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12 
 
Age at 
enrollment 
Mean: 35.4 
Severity NR 
 
Location, % 
Ileal: 9.7 
Ileo-colonic: 61.3 
Colonic: 29 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 192.9 
Median: 162 
 
Perianal DAI 
Median: 9 
5ASA: 61.3 
 
Antibiotics: 35.5 
 
Corticosteroids: 
35.5 
 
Thiopurines: 29 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
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study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Present, 
199944 
Infliximab, 32 
Route: IV 
Dose: 10 mg/kg 
Male, %: 37.5 
 
Race, % 
W: 90.6 
B: 9.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11.5 
 
Age at 
enrollment 
Mean: 35 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 56.2 
Colonic: 31.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 184.9 
Median: 203 
 
Perianal DAI 
Median: 10 
5ASA: 50 
 
Antibiotics: 34.4 
 
Corticosteroids: 
31.2 
 
Thiopurines: 53.1 
NR NR 
Sandborn, 
200533 
 
Natalizumab, 
724 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 43 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
22.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.1 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 26.8 
Ileo-colonic: 51.5 
Colonic: 21.7 
 
Behavior NR 
 
CRP 
Mean: 20 
Median: 9 
Min: 0 
Max: 370 
CDAI 
Mean: 302 
5ASA: 47.4 
 
Antibiotics: 5.9 
 
Corticosteroids: 
37.4 
 
Methotrexate: 4.3 
 
Thiopurines: 29.8 
 
Prednisone: 27.2 
 
Budesonide: 10.9 
 
>/= 1 
corticosteroids or 
immunomodulator
s: 56.2 
 
Corticosteroids 
and 
immunomodulator
s: 15.3 
TNF-alpha 
inhibitors: 40.2 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200533 
 
 
Placebo, 181 
Route: IV 
Dose: NA every 
4 weeks 
Male, %: 40.3 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
24.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.16 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 26 
Ileo-colonic: 46.4 
Colonic: 27.1 
 
Behavior NR 
 
CRP 
Mean: 23 
Median: 12 
Min: 0 
Max: 127 
CDAI 
Mean: 303 
5ASA: 44.2 
 
Antibiotics: 6.6 
 
Corticosteroids: 
38.7 
 
Methotrexate: 3.3 
 
Thiopurines: 25.4 
 
Prednisone: 29.3 
 
Budesonide: 11 
 
>/= 1 
corticosteroid or 
immunomodulator
s: 55.2 
 
Corticosteroids 
and 
immunomodulator
s: 12.2 
TNF-alpha 
inhibitors: 38.1 
NR 
Sandborn, 
200739 
 
 
Placebo, 328 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 40 
 
Race NR 
 
Smoking, % 
Current smoker, 
33 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8 
Median: 5 
Min: 1 
Max: 40 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 77 
Severity NR 
 
Location, % 
Ileal: 27 
Ileo-colonic: 51 
Colonic: 23 
 
Behavior NR 
 
CRP 
Mean: 9 
Min: 2 
Max: 244 
CDAI 
Mean: 297 
Min: 161 
Max: 513 
Corticosteroids: 23 
 
Immunomodulator
s: 20 
 
Glucocorticoids + 
immunomodulator
s: 17 
 
Neither 
glucocorticoids nor 
immunomodulator
s: 40 
infliximab: 26 NR 
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Disease 
characteristics 
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Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200739 
 
 
Certolizumab 
pegol, 331 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Current smoker, 
31 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
Median: 5 
Min: 1 
Max: 44 
 
Age at 
enrollment 
Mean: 37 
Min: 18 
Max: 73 
Severity NR 
 
Location, % 
Ileal: 29 
Ileo-colonic: 45 
Colonic: 26 
 
Behavior NR 
 
CRP 
Mean: 8 
Min: 2 
Max: 205 
CDAI 
Mean: 300 
Min: 149 
Max: 491 
Corticosteroids: 22 
 
Immunomodulator
s: 21 
 
Glucocorticoids + 
immunomodulator
s: 17 
 
Neither 
glucocorticoids nor 
immunomodulator
s: 40 
infliximab: 30 NR 
Sandborn, 
200738 
 
Adalimumab, 
159 
Route: SC 
Male, %: 31.4 
 
Race NR 
 
Smoking, % 
Smoker, 34.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 70.4 
Colonic: 66 
Perianal: 17 
 
Behavior NR 
 
CRP 
Mean: 19 
CDAI 
Mean: 313 
 
IBDQ 
Mean: 120 
5ASA: 28.3 
 
Corticosteroids: 
34.6 
 
Immonomodulator: 
45.9 
NR NR 
Sandborn, 
200738 
 
 
Placebo, 166 
Route: SC 
Dose: NA 
Male, %: 39.2 
 
Race NR 
 
Smoking, % 
Smoker, 33.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 74.7 
Colonic: 68.1 
Perianal: 18.7 
 
Behavior NR 
 
CRP 
Mean: 20 
CDAI 
Mean: 313 
 
IBDQ 
Mean: 124 
5ASA: 36.1 
 
Corticosteroids: 44 
 
Immunomodulator
s: 51.2 
NR NR 
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Disease 
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index 
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taken during 
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taken BEFORE 
study, % 
Medications 
taken FOR 
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Sandborn, 
201142 
Certolizumab 
pegol, 223 
Route: SC Dose: 
400 mg every 2 
weeks 
Male, %: 47.1  
 
Race NR  
 
Smoking NR  
 
CD NR 
Age at diagnosis 
NR  
 
Disease duration 
Mean: 7.5  
 
Age at 
enrollment NR 
Severity NR  
 
Location, % Ileal: 
28.3 Ileo- 
colonic: 40.4 
Colonic: 29.1  
 
Behavior, % 
Inflammatory: 75.3 
Stricturing: 14.8 
Penetrating: 9  
 
CRP Mean: 9.41 
CDAI Mean: 
262.1  
 
HBI Mean: 9.8  
 
IBDQ Mean: 
126.5 
Corticosteroids: 
43.5  
Immunomodulator
s: 34.5  
corticosteroid or 
IMM: 62.3  
corticosteroid and 
IMM: 15.7  
neither 
corticosteroid nor 
IMM: 37.7 
NR NR 
Sandborn, 
201142 
Placebo, 215 
Route: SC Dose: 
400 mg every 2 
weeks 
Male, %: 41.9  
 
Race NR  
 
Smoking NR  
 
CD NR 
Age at diagnosis 
NR  
 
Disease duration 
Mean: 7  
 
Age at 
enrollment Min: 
18 Max: 70 
Severity NR  
 
Location, % Ileal: 
26.5 Ileo-colonic: 
41.4 Colonic: 28.4  
 
Behavior, % 
Inflammatory: 76.7 
Stricturing: 15.8 
Penetrating: 7.4  
 
CRP Mean: 9.02 
CDAI Mean: 
292.7  
 
HBI Mean: 9.7  
 
IBDQ Mean: 
122.1 
Corticosteroids: 
45.6  
Immunomodulator
s: 31.2  
corticosteroid or 
IMM: 62.3  
corticosteroid and 
IMM: 14.4  
neither 
corticosteroid nor 
IMM: 37.7 
NR NR 
Sands, 
200735 
Placebo + 
Infliximab, 27 
Route: IV + IV 
Dose: NA every 
4 weeks + 5 
mg/kg every 8 
weeks 
Male, %: 63 
 
Race, % 
W: 85.2 
B: 7.4 
Other: 7.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Min: 0 
Max: 36 
 
Age at 
enrollment 
Mean: 38.9 
Min: 19 
Max: 72 
Severity NR 
 
Location, % 
Ileal: 14.8 
Ileo-colonic: 55.6 
Colonic: 29.6 
 
Behavior NR 
 
CRP 
Mean: 5.9 
Min: 0 
Max: 49 
CDAI 
Mean: 243.6 
Min: 150 
Max: 366 
5ASA: 37 
 
Antibiotics: 18.5 
 
Corticosteroids: 
29.6 
 
Azathioprine, 6-
mercaptopurine, or 
methotrexate: 55.6 
NR NR 
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Medications 
taken FOR 
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Sands, 
200735 
Natalizumab + 
Infliximab, 52 
Route: IV + IV 
Dose: 300 mg 
every 4 weeks + 
5 mg/kg every 8 
weeks 
Male, %: 46.2 
 
Race, % 
W: 94.2 
B: 3.8 
Other: 1.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12.5 
 
Age at 
enrollment 
Mean: 39.9 
Min: 20 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 21.2 
Ileo-colonic: 53.8 
Colonic: 25 
 
Behavior NR 
 
CRP 
Mean: 6.5 
Min: 0 
Max: 71 
CDAI 
Mean: 263.8 
Min: 129 
Max: 545 
5ASA: 46.2 
 
Antibiotics: 19.2 
 
Corticosteroids: 
26.9 
 
Azathioprine, 6-
mercaptopurine, or 
methotrexate: 50 
NR NR 
Schreiber, 
200540 
Certolizumab 
pegol, 72 
Route: SC 
Dose: 200 mg 
every 4 weeks 
Male, %: 30.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.84 
Min: 0 
Max: 30.7 
 
Age at 
enrollment 
Mean: 40.1 
Min: 19 
Max: 71 
Severity NR 
 
Location, % 
Ileal: 70.8 
Perianal: 31.9 
 
Behavior NR 
 
CRP 
Mean: 6.5 
Min: 0.2 
Max: 127 
IBDQ 
Mean: 122.9 
5ASA: 44.4 
 
Antibiotics: 9.7 
 
Corticosteroids: 
40.3 
 
Methotrexate: 5.6 
 
Thiopurines: 34.7 
 
Immunomodulator
s: 40.3 
 
Anti-diarrheals: 
22.2 
 
Codeine and 
derivatives: 6.9 
 
Azathioprine: 31.9 
 
6-MP: 2.8 
TNF-alpha 
inhibitors: 23.6 
NR 
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Schreiber, 
200540 
Certolizumab 
pegol, 74 
Route: SC 
Dose: 100 mg 
every 4 weeks 
Male, %: 47.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.73 
Min: 0 
Max: 31.8 
 
Age at 
enrollment 
Mean: 33.5 
Min: 18 
Max: 56 
Severity NR 
 
Location, % 
Ileal: 77 
Perianal: 27 
 
Behavior NR 
 
CRP 
Mean: 6.2 
Min: 0.2 
Max: 141 
IBDQ 
Mean: 132.2 
5ASA: 50 
 
Antibiotics: 8.1 
 
Corticosteroids: 
32.4 
 
Methotrexate: 5.4 
 
Immunomodulator
s: 35.1 
 
Anti-diarrheals: 
25.7 
 
Codeine and 
derivatives: 6.8 
 
Azathioprine: 17.6 
 
6-MP: 12.2 
TNF-alpha 
inhibitors: 24.3 
NR 
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Schreiber, 
200540 
Placebo, 73 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 32.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.95 
Min: 0.1 
Max: 27.6 
 
Age at 
enrollment 
Mean: 35.8 
Min: 19 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 74 
Perianal: 31.5 
 
Behavior NR 
 
CRP 
Mean: 7.3 
Min: 0.3 
Max: 86.1 
IBDQ 
Mean: 122.9 
5ASA: 39.7 
 
Antibiotics: 9.6 
 
Corticosteroids: 
39.7 
 
Methotrexate: 6.8 
 
Immunomodulator
s: 35.6 
 
Anti-diarrheals: 
13.7 
 
Codeine and 
derivatives: 8.2 
 
Azathioprine: 23.3 
 
6-MP: 5.5 
TNF-alpha 
inhibitors: 21.9 
NR 
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Schreiber, 
200540 
Certolizumab 
pegol, 72 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 44.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.43 
Min: 0.2 
Max: 26.5 
 
Age at 
enrollment 
Mean: 35.9 
Min: 18 
Max: 67 
Severity NR 
 
Location, % 
Ileal: 77.8 
Perianal: 29.2 
 
Behavior NR 
 
CRP 
Mean: 7.7 
Min: 0.4 
Max: 128.2 
IBDQ 
Mean: 126.5 
5ASA: 38.9 
 
Antibiotics: 8.3 
 
Corticosteroids: 
30.6 
 
Methotrexate: 4.2 
 
Immunomodulator
s: 37.5 
 
Anti-diarrheals: 
16.7 
 
Codeine and 
derivatives: 2.8 
 
Azathioprine: 30.6 
 
6-MP: 2.8 
TNF-alpha 
inhibitors: 16.7 
NR 
Schroder, 
200647 
Infliximab, 8 
Route: IV 
Dose: 5 mg/kg 
every 2 weeks 
Male, %: 25 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.6 
 
Age at 
enrollment 
Mean: 36.5 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 62.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 293 
 
IBDQ 
Mean: 106 
5ASA: 37.5 
 
Corticosteroids: 
87.5 
NR NR 
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Schroder, 
200647 
Methotrexate + 
Infliximab, 11 
Route: IV + IV 
Dose: 20 mg 
every 1 week + 5 
mg/kg every 2 
weeks 
Male, %: 54.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.2 
 
Age at 
enrollment 
Mean: 31.6 
Severity NR 
 
Location, % 
Ileal: 9.1 
Ileo-colonic: 63.6 
Colonic: 9.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 251 
 
IBDQ 
Mean: 113 
5ASA: 18.2 
 
Corticosteroids: 
72.7 
NR NR 
Targan, 
199743 
 
 
Infliximab, 28 
Route: IV 
Dose: 10 mg/kg 
Male, %: 46 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11.5 
 
Age at 
enrollment 
Mean: 39.3 
Severity NR 
 
Location, % 
Ileal: 14 
Ileo-colonic: 50 
Colonic: 36 
 
Behavior NR 
 
CRP 
Mean: 23.2 
CDAI 
Mean: 318 
 
IBDQ 
Mean: 116 
5ASA: 64 
 
Corticosteroids: 
57.1 
 
Thiopurines: 28 
 
Prednisolone < 20 
mg/day: 29 
 
Prednisolone >/= 
20 mg/day: 29 
NR NR 
Targan, 
199743 
 
 
Placebo, 25 
Route: IV 
Dose: NA 
Male, %: 60 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.4 
 
Age at 
enrollment 
Mean: 38.5 
Severity, % 
Mod-sev disease: 
100 
 
Location, % 
Ileal: 32 
Ileo-colonic: 40 
Colonic: 28 
 
Behavior NR 
 
CRP 
Mean: 12.8 
CDAI 
Mean: 288 
 
IBDQ 
Mean: 128 
5ASA: 68 
 
Corticosteroids: 64 
 
Thiopurines: 44 
 
Prednisolone < 
20mg/day: 40 
 
Prednisolone >/= 
20 mg/day: 24 
NR NR 
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Targan, 
199743 
 
 
Infliximab, 27 
Route: IV 
Dose: 5 mg/kg 
Male, %: 52 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12.5 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 11 
Ileo-colonic: 56 
Colonic: 33 
 
Behavior NR 
 
CRP 
Mean: 22.1 
CDAI 
Mean: 312 
 
IBDQ 
Mean: 122 
5ASA: 59 
 
Corticosteroids: 56 
 
Thiopurines: 34 
 
Prednisolone < 
20mg/day: 30 
 
Prednisolone >/= 
20 mg: 26 
NR NR 
Targan, 
199743 
 
 
Infliximab, 28 
Route: IV 
Dose: 20 mg/kg 
Male, %: 46 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 13.5 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 7 
Ileo-colonic: 68 
Colonic: 25 
 
Behavior NR 
 
CRP 
Mean: 22.4 
CDAI 
Mean: 307 
 
IBDQ 
Mean: 118 
5ASA: 46 
 
Corticosteroids: 
60.7 
 
Thiopurines: 43 
 
Prednisolone < 
20mg/day: 36 
 
Prednisolone >/= 
20 mg /day: 25 
NR NR 
Targan, 
200732 
 
 
Natalizumab, 
259 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 41 
 
Race, % 
W: 95 
H: 1 
B: 1 
A: 1 
not specified: 3 
 
Smoking, % 
>10 
cigarettes/day, 
22 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.1 
 
Age at 
enrollment 
Mean: 38.1 
Severity, % 
Severe disease: 
32 
 
Location, % 
Ileal: 22 
Ileo-colonic: 52 
Colonic: 27 
 
Behavior NR 
 
CRP 
Mean: 23 
CDAI 
Mean: 303.9 
 
IBDQ 
Mean: 123.6 
5ASA: 49 
 
Antibiotics: 7 
 
Corticosteroids: 42 
 
Immunomodulator
s: 37 
TNF-alpha 
inhibitors: 50 
NR 
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Targan, 
200732 
 
 
Placebo, 250 
Route: IV 
Dose: NR every 
4 weeks 
Male, %: 41 
 
Race, % 
W: 94 
H: 1 
B: 2 
A: 1 
not specified: 2 
 
Smoking, % 
>10 
cigarettes/day, 
19 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
 
Age at 
enrollment 
Mean: 37.7 
Severity, % 
Severe disease: 
28 
 
Location, % 
Ileal: 26 
Ileo-colonic: 48 
Colonic: 26 
 
Behavior NR 
 
CRP 
Mean: 23.4 
CDAI 
Mean: 299.5 
 
IBDQ 
Mean: 122.5 
5ASA: 48 
 
Antibiotics: 5 
 
Corticosteroids: 38 
 
Immunomodulator
s: 38 
TNF-alpha 
inhibitors: 45 
NR 
Winter, 
200441 
Certolizumab 
pegol, 25 
Route: IV 
Dose: 5 mg/kg 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.52 
Min: 0.69 
Max: 17.0 
 
Age at 
enrollment 
Mean: 36.4 
Min: 21 
Max: 61 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 48 
 
Corticosteroids: 24 
 
Immunomodulator
s: 44 
TNF-alpha 
inhibitors: 23 
NR 
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Winter, 
200441 
Placebo, 25 
Route: IV 
Dose: NA 
Male, %: 24 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.74 
Min: 0.1 
Max: 21.9 
 
Age at 
enrollment 
Mean: 32.1 
Min: 18 
Max: 56 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 40 
 
Corticosteroids: 28 
 
Immunomodulator
s: 44 
TNF-alpha 
inhibitors: 13 
NR 
Winter, 
200441 
Certolizumab 
pegol, 2 
Route: IV 
Dose: 1.25 
mg/kg 
Male, %: 0 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.28 
Min: 7.7 
Max: 10.9 
 
Age at 
enrollment 
Mean: 36.5 
Min: 31 
Max: 42 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 0 
 
Corticosteroids: 50 
 
Immunomodulator
s: 0 
TNF-alpha 
inhibitors: 50 
NR 
Winter, 
200441 
Certolizumab 
pegol, 23 
Route: IV 
Dose: 20 mg/kg 
Male, %: 44 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.94 
Min: 1.3 
Max: 18.9 
 
Age at 
enrollment 
Mean: 33.3 
Min: 19 
Max: 60 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 39 
 
Corticosteroids: 26 
 
Immunomodulator
s: 44 
TNF-alpha 
inhibitors: 30 
NR 
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Winter, 
200441 
Certolizumab 
pegol, 17 
Route: IV 
Dose: 10 mg/kg 
Male, %: 35 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.20 
Min: 0.9 
Max: 26.0 
 
Age at 
enrollment 
Mean: 40.3 
Min: 18 
Max: 64 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 53 
 
Corticosteroids: 35 
 
Immunomodulator
s: 53 
TNF-alpha 
inhibitors: 29 
NR 
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Randomized controlled trials evaluating thiopurines 
Ardizzone, 
200358 
Methotrexate, 27 
Route: IV for first 
3 months, then 
oral 
Dose: 25 mg 
every 1 week 
Male, %: 48.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.38 
Min: 0.25 
Max: 7.08 
 
Age at 
enrollment 
Mean: 37 
Min: 25 
Max: 54 
Severity NR 
 
Location, % 
Colonic: 15 
 
Behavior NR 
 
CRP 
Mean: 8.03 
Min: 4 
Max: 54 
CDAI 
Mean: 213.36 
Min: 210 
Max: 390 
Corticosteroids: 
100 
5ASA: 100 
 
Antibiotics: 7.4 
 
Corticosteroids: 
100 
 
Immunomodulat
ors (AZA/6-MP, 
CyA): 14.8 
NR 
Ardizzone, 
200358 
Azathioprine, 27 
Route: Oral 
Dose: 2 mg/kg 
every day 
Male, %: 55.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.77 
Min: 0.67 
Max: 17 
 
Age at 
enrollment 
Mean: 31 
Min: 18 
Max: 60 
Severity NR 
 
Location, % 
Colonic: 22 
 
Behavior NR 
 
CRP 
Mean: 8.75 
Min: 5 
Max: 73 
CDAI 
Mean: 225.96 
Min: 205 
Max: 408 
Corticosteroids: 
100 
5ASA: 100 
 
Antibiotics: 7.4 
 
Corticosteroids: 
100 
 
Immunomodulat
ors (AZA/6-MP, 
CyA): 7.4 
NR 
D-42 
 
 
Evidence Table 3. Population characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic therapies 
for the management of moderate to severe Crohn’s disease in terms of inducing remission (KQ1) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Candy, 
199553 
Placebo + 
Prednisolone, 30 
Route: Oral + 
Oral 
Dose: NA + 1 
mg/kg every day 
Male, %: 37 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 3.7 
Min: 0.1 
Max: 18.7 
 
Age at 
enrollment 
Median: 31.8 
Min: 21 
Max: 62 
Severity, % 
Severe disease: 
43 
 
Location, % 
Ileal: 20 
Ileo-colonic: 63.3 
Colonic: 16.7 
 
Behavior NR 
 
CRP 
Median: 3.9 
Min: 2.8 
Max: 5.3 
CDAI 
Median: 282 
Min: 240 
Max: 356 
Corticosteroids: 
100 
Corticosteroids 
 
corticosteroids in 
the last 6 
months: 63 
 
no previous 
corticosteroids: 7 
 
 
NR 
Candy, 
199553 
Azathioprine + 
Prednisolone, 33 
Route: Oral + 
Oral 
Dose: 2.5 mg/kg 
every day + 1 
mg/kg every day 
Male, %: 21 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.6 
Min: 0.1 
Max: 19.3 
 
Age at 
enrollment 
Median: 33.9 
Min: 15 
Max: 60 
Severity, % 
Severe disease: 
52 
 
Location, % 
Ileal: 24.2 
Ileo-colonic: 60.6 
Colonic: 15.2 
 
Behavior NR 
 
CRP 
Median: 5.4 
Min: 2.9 
Max: 7.3 
CDAI 
Median: 301 
Min: 264 
Max: 358 
Corticosteroids: 
100 
 
Thiopurines: 100 
corticosteroids in 
previous 6-12 
mo: 67 
 
no previous 
corticosteroids: 
15 
 
 
NR 
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Ewe, 199354 Placebo + 
Prednisolone, 21 
Dose: 60 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.3 
Min: 18 
Max: 48 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 285 
NR 5ASA: 28.6 
 
5-ASA + GCs: 
38.1 
NR 
Ewe, 199354 Azathioprine + 
Prednisolone, 21 
Dose: 2.5 mg/kg 
every day + 60 
mg every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.4 
 
Age at 
enrollment 
Mean: 27.3 
Min: 18 
Max: 43 
Severity NR 
 
Location, % 
Ileal: 4.8 
Ileo-colonic: 66.7 
Colonic: 28.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 290 
NR 5ASA: 33.3 
 
5-ASA + GCs: 
57.1 
NR 
Klein, 197462 Azathioprine, 13 
Route: Oral 
Dose: 3 mg/kg 
every 24 hours 
Male, %: 61.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.8 
 
Age at 
enrollment 
Mean: 29 
Severity NR 
 
Location, % 
Ileal: 30.8 
Ileo-colonic: 53.8 
Colonic: 15.4 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Klein, 197462 Placebo, 13 
Route: Oral 
Dose: NA 
Male, %: 69.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.2 
 
Age at 
enrollment 
Mean: 31 
Severity NR 
 
Location, % 
Ileal: 46.2 
Ileo-colonic: 46.2 
Colonic: 7.7 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Markowitz, 
2000192 
Placebo + 
Prednisone, 28 
Dose: 40 mg 
every day 
Male, %: 64.3 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.4 
Severity NR 
 
Location, % 
Ileal: 3.6 
Ileo-colonic: 78.6 
Colonic: 17.9 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 44.7 
 
HBI 
Mean: 7.4 
 
partial HB 
Mean: 6.5 
NR NR NR 
Markowitz, 
2000192 
6-MP + 
Prednisone, 27 
Dose: 1.5 mg/kg 
every day + 40 
mg every day 
Male, %: 55.6 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 14.8 
Ileo-colonic: 70.4 
Colonic: 14.8 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 46.7 
 
HBI 
Mean: 7.7 
 
partial HB 
Mean: 6.6 
NR NR NR 
Mate-
Jimenez, 
200052 
5-ASA, 7 
Route: Oral 
Dose: 3 g every 
day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 85.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 14.3 
Perianal: 14.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 215 
Corticosteroids: 
100 
NR NR 
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Mate-
Jimenez, 
200052 
6-MP, 16 
Route: Oral 
Dose: 1.5 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 75 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 37.5 
Perianal: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 191 
Corticosteroids: 
100 
NR NR 
Mate-
Jimenez, 
200052 
Methotrexate, 15 
Route: Oral 
Dose: 15 mg 
every 1 week 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 66.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.3 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 40 
Perianal: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 200 
Corticosteroids: 
100 
NR NR 
Oren, 199757 Methotrexate + 
Placebo, 26 
Route: Oral + 
Oral 
Dose: 12.5 mg 
every 1 week + 
NA every 24 
hours 
Male, %: 53.8 
 
Race NR 
 
Smoking, % 
Present smoker, 
24 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.5 
 
Age at 
enrollment 
Mean: 38.2 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 29.2 
Colonic: 37.5 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 9 
5ASA: 72 
 
Corticosteroids: 80 
Corticosteroids: 
100 
 
Immunomodulat
ors: 12 
NR 
Oren, 199757 Placebo + 
Placebo, 26 
Route: Oral + 
Oral 
Dose: NA every 
24 hours + NA 
every 1 week 
Male, %: 46.2 
 
Race NR 
 
Smoking, % 
Present smoker, 
32 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.77 
 
Age at 
enrollment 
Mean: 33.43 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 25 
Colonic: 25 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 7.8 
5ASA: 69 
 
Corticosteroids: 73 
Corticosteroids: 
100 
 
Immunomodulat
ors: 15 
NR 
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Oren, 199757 6-MP + Placebo, 
32 
Route: Oral + 
Oral 
Dose: 50 mg 
every 24 hours + 
NA every 1 week 
Male, %: 54.8 
 
Race NR 
 
Smoking, % 
Present smoker, 
33.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.43 
 
Age at 
enrollment 
Mean: 34.03 
Severity NR 
 
Location, % 
Ileal: 46.7 
Ileo-colonic: 40 
Colonic: 13.3 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 8.7 
5ASA: 63 
 
Corticosteroids: 79 
Corticosteroids: 
100 
 
Immunomodulat
ors: 27 
NR 
Present, 
198060 
Placebo 
Route: Oral 
Dose: NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Present, 
198060 
6-MP 
Route: Unknown 
Dose: 1.5 mg/kg 
every 24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Reinisch, 
200851 
Placebo + 
Prednisone, 29 
Route: Oral + 
Oral 
Dose: NA every 
day + 1mg/kg or 
>/= 40mg every 
day 
Male, %: 55.2 
 
Race NR 
 
Smoking, % 
Smoker, 34.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 0.6 
Min: 0 
Max: 14.9 
 
Age at 
enrollment 
Median: 39.5 
Min: 18 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 82.8 
Colonic: 58.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 280 
Min: 230 
Max: 432 
 
IBDQ 
Median: 120 
Min: 70 
Max: 147 
NR NR Corticosteroids: 
96.6 
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Reinisch, 
200851 
Azathioprine + 
Prednisone, 52 
Route: Oral + 
Oral 
Dose: 2.5 mg/kg 
every day + 1 
mg/kg or >/= 40 
mg every day 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Smoker, 30.8 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 1.2 
Min: 0 
Max: 20.3 
 
Age at 
enrollment 
Median: 38.5 
Min: 19 
Max: 74 
Severity NR 
 
Location, % 
Ileal: 71.2 
Colonic: 73.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 282 
Min: 225 
Max: 435 
 
IBDQ 
Median: 126 
Min: 46 
Max: 198 
NR NR Corticosteroids: 
96.2 
Rhodes, 
197161 
Placebo, 16 
Route: Oral 
Dose: NA 
Male, %: 75 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 16 
 
Age at 
enrollment 
Min: 14 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 37.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
18.8 
 
Sulfasalazine: 
18.8 
NR NR 
Rhodes, 
197161 
Azathioprine, 16 
Route: Oral 
Dose: 4 mg/kg 
every 24 hours 
Male, %: 75 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 14 
 
Age at 
enrollment 
Min: 14 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 37.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Sulfasalazine: 
18.8 
 
Prednisolone: 18.8 
NR NR 
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Sandborn, 
199959 
Azathioprine + 
Azathioprine, 51 
Route: IV + Oral 
Dose: 40 mg/kg 
+ 2 mg/kg every 
day 
Male, %: 47.1 
 
Race NR 
 
Smoking, % 
Smoker, 43.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 7.1 
Min: 0 
Max: 28 
 
Age at 
enrollment 
Median: 33 
Min: 19 
Max: 63 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 52.9 
Colonic: 13.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 244 
Min: 89 
Max: 424 
 
IBDQ 
Median: 127 
Min: 73 
Max: 183 
NR NR NR 
Sandborn, 
199959 
Placebo + 
Azathioprine, 45 
Route: Oral 
Dose: 2 mg/kg 
every day 
Male, %: 55.6 
 
Race NR 
 
Smoking, % 
Smoker, 35.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.6 
Min: 0 
Max: 35 
 
Age at 
enrollment 
Median: 35 
Min: 19 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 17.8 
Ileo-colonic: 60 
Colonic: 22.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 245 
Min: 142 
Max: 476 
 
IBDQ 
Median: 123 
Min: 77 
Max: 182 
NR NR NR 
Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kgs 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
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Summers, 
197956 
 
 
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
Summers, 
197956 
 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg. every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
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Randomized controlled trials evaluating methotrexate 
Feagan, 
199563 
Placebo + 
Prednisone, 47 
Route: IM + Oral 
Dose: NA every 
1 week + every 
day 
Male, %: 55 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 47 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 98 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 17 
Ileo-colonic: 64 
Colonic: 19 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 190 
 
IBDQ 
Mean: 159 
Hydrocortisone 
ointment 
NR NR 
Feagan, 
199563 
Methotrexate + 
Prednisone, 94 
Route: IM + Oral 
Dose: 25 mg 
every 1 week 
Male, %: 54 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 49 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 93 
 
Age at 
enrollment 
Mean: 34 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 52 
Colonic: 16 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181 
 
IBDQ 
Mean: 162 
NR NR NR 
Mate-
Jimenez, 
200052 
5-ASA, 7 
Route: Oral 
Dose: 3 g every 
day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 85.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 14.3 
Perianal: 14.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 215 
Corticosteroids: 
100 
NR NR 
Mate-
Jimenez, 
200052 
Methotrexate, 15 
Route: Oral 
Dose: 15 mg 
every 1 week 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 66.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.3 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 40 
Perianal: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 200 
Corticosteroids: 
100 
NR NR 
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Mate-
Jimenez, 
200052 
6-MP, 16 
Route: Oral 
Dose: 1.5 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 75 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 37.5 
Perianal: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 191 
Corticosteroids: 
100 
NR NR 
Oren, 199757 Placebo + 
Placebo, 26 
Route: Oral + 
Oral 
Dose: NA every 
24 hours + NA 
every week 
Male, %: 46.2 
 
Race NR 
 
Smoking, % 
Present smoker, 
32 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.77 
 
Age at 
enrollment 
Mean: 33.43 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 25 
Colonic: 25 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 7.8 
5ASA: 69 
 
Corticosteroids: 73 
Corticosteroids: 
100 
 
Immunomodulat
ors: 15 
NR 
Oren, 199757 6-MP + Placebo, 
32 
Route: Oral + 
Oral 
Dose: 50 mg 
every 24 hours + 
NA every 1 week 
Male, %: 54.8 
 
Race NR 
 
Smoking, % 
Present smoker, 
33.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.43 
 
Age at 
enrollment 
Mean: 34.03 
Severity NR 
 
Location, % 
Ileal: 46.7 
Ileo-colonic: 40 
Colonic: 13.3 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 8.7 
5ASA: 63 
 
Corticosteroids: 79 
Corticosteroids: 
100 
 
Immunomodulat
ors: 27 
NR 
Oren, 199757 Methotrexate + 
Placebo, 26 
Route: Oral + 
Oral 
Dose: 12.5 mg 
every 1 week + 
NA every 24 
hours 
Male, %: 53.8 
 
Race NR 
 
Smoking, % 
Present smoker, 
24 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.5 
 
Age at 
enrollment 
Mean: 38.2 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 29.2 
Colonic: 37.5 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 9 
5ASA: 72 
 
Corticosteroids: 80 
Corticosteroids: 
100 
 
Immunomodulat
ors: 12 
NR 
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Randomized controlled trials evaluating corticosteroids 
Bar-Meir, 
199867 
Prednisone + 
Placebo, 101 
Route: Oral + 
Oral 
Dose: 40mg 
every 24 hours + 
NA every 8 
hours 
Male, %: 50.5 
 
Race NR 
 
Smoking, % 
Smoker, 30.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5 
 
Age at 
enrollment 
Mean: 32.8 
Severity NR 
 
Location, % 
Colonic: 16.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 265 
 
IBDQ 
Mean: 131.2 
NR 5ASA: 81.2 
 
Antibiotics: 34.7 
 
Corticosteroids: 
37.6 
NR 
Bar-Meir, 
199867 
Budesonide + 
Placebo, 100 
Route: Oral 
Dose: 3 mg 
every 8 hours + 
NA every day 
Male, %: 53 
 
Race NR 
 
Smoking, % 
Smoker, 30 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5 
 
Age at 
enrollment 
Mean: 32.7 
Severity NR 
 
Location, % 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 264 
 
IBDQ 
Mean: 136.8 
NR 5ASA: 80 
 
Antibiotics: 28 
 
Corticosteroids: 
33 
NR 
Campieri, 
199768 
Budesonide + 
Placebo, 58 
Route: Oral + 
Oral 
Dose: 9 mg 
every day + NA 
every 24 hours 
Male, %: 36.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.3 
Min: 0 
Max: 30 
 
Age at 
enrollment 
Mean: 36 
Min: 17 
Max: 71 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 277 
Min: 121 
Max: 476 
Corticosteroids: 
100 
NR NR 
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Campieri, 
199768 
Prednisolone + 
Placebo, 58 
Route: Oral + 
Oral 
Dose: 40 mg 
every day + NA 
every 12 hours 
Male, %: 39.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.7 
Min: 0 
Max: 27 
 
Age at 
enrollment 
Mean: 36 
Min: 19 
Max: 70 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 279 
Min: 202 
Max: 458 
Corticosteroids: 
100 
NR NR 
Campieri, 
199768 
Budesonide + 
Placebo, 61 
Route: Oral + 
Oral 
Dose: 4.5 mg 
every 12 hours + 
NA every 24 
hours 
Male, %: 45.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.9 
Min: 0 
Max: 37 
 
Age at 
enrollment 
Mean: 38 
Min: 20 
Max: 71 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 274 
Min: 107 
Max: 465 
Corticosteroids: 
100 
NR NR 
Escher, 
2004190 
Prednisolone, 26 
Dose: 1 mg/kg 
every day 
Male, %: 69.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.8 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 26.9 
Ileo-colonic: 65.4 
Colonic: 3.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 268 
 
PCDAI 
Mean: 45 
NR NR NR 
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Escher, 
2004190 
Budesonide, 22 
Dose: 9 mg 
every day 
Male, %: 31.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.6 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 59.1 
Ileo-colonic: 31.8 
Colonic: 9.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 239 
 
PCDAI 
Mean: 39 
NR NR NR 
Greenberg, 
199466 
Placebo, 66 
Route: Oral 
Dose: NA every 
12 hours 
Male, %: 37.9 
 
Race NR 
 
Smoking, % 
Smoker, 57.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.3 
 
Age at 
enrollment 
Median: 32 
Min: 19 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 84.8 
Ileo-colonic: 15.2 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 287 
 
IBDQ 
Median: 130 
Loperamide Corticosteroids: 
38 
NR 
Greenberg, 
199466 
Budesonide, 67 
Route: Oral 
Dose: 1.5 mg 
every 12 hours 
Male, %: 29.9 
 
Race NR 
 
Smoking, % 
Smoker, 49 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5.3 
 
Age at 
enrollment 
Median: 30 
Severity NR 
 
Location, % 
Ileal: 81 
Ileo-colonic: 19 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 10 
CDAI 
Median: 293 
 
IBDQ 
Median: 131 
Loperamide Corticosteroids: 
45 
NR 
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Greenberg, 
199466 
Budesonide, 61 
Route: Oral 
Dose: 4.5 mg 
every 12 hours 
Male, %: 38 
 
Race NR 
 
Smoking, % 
Smoker, 46 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5.9 
 
Age at 
enrollment 
Median: 37 
Severity NR 
 
Location, % 
Ileal: 84 
Ileo-colonic: 16 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 296 
 
IBDQ 
Median: 125 
Loperamide Corticosteroids: 
43 
NR 
Greenberg, 
199466 
Budesonide, 64 
Route: Oral 
Dose: 7.5 mg 
every 12 hours 
Male, %: 45.3 
 
Race NR 
 
Smoking, % 
Smoker, 47 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.1 
 
Age at 
enrollment 
Median: 31 
Severity NR 
 
Location, % 
Ileal: 88 
Ileo-colonic: 12 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 285 
 
IBDQ 
Median: 130 
Loperamide Corticosteroids: 
47 
NR 
Gross, 
199572 
(6)-
Methylprednisolo
ne, 16 
Route: Oral 
Dose: 48 mg/day 
every 24 hours 
Male, %: 31.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.6 
 
Age at 
enrollment 
Mean: 31.9 
Severity NR 
 
Location, % 
Ileal: 75 
Colonic: 93.8 
 
Behavior NR 
 
CRP 
Mean: 3.9 
CDAI 
Mean: 236.2 
Corticosteroids: 
100 
Previous therapy 
(not specified): 
62.5 
NR 
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Gross, 
199572 
5-ASA (Salofalk), 
15 
Route: Oral 
Dose: 1.5 g 
every 8 hours 
Male, %: 40 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.4 
 
Age at 
enrollment 
Mean: 26.4 
Severity NR 
 
Location, % 
Ileal: 86.7 
Colonic: 73.3 
 
Behavior NR 
 
CRP 
Mean: 5.3 
CDAI 
Mean: 251.5 
5ASA: 100 Previous therapy 
(not specified): 
26.7 
NR 
Levine, 
2003191 
Budesonide + 
Mesalamine, 19 
Dose: 3 mg 
every 8 hours + 
3-4 g every day 
Male, %: 68.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 29.3 
NR NR NR 
Levine, 
2003191 
Prednisone + 
Mesalamine, 14 
Dose: 40 mg 
every day + 3-4 
g every day 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.15 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 28.9 
NR NR NR 
Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
NR 
D-57 
 
 
Evidence Table 3. Population characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic therapies 
for the management of moderate to severe Crohn’s disease in terms of inducing remission (KQ1) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
 
NR 
Malchow, 
198464 
 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR sulfasalazine: 88 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3 
NR 
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Malchow, 
198464 
 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
Malchow, 
198464 
 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
NR 
Malchow, 
198464 
 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
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INDUCTION, % 
Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
Martin F, 
199073 
Prednisone, 28 
Route: Oral 
Dose: 40 mg 
every 24 hours 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.4 
 
Age at 
enrollment 
Mean: 30.6 
Severity NR 
 
Location, % 
Ileal: 64.3 
Ileo-colonic: 35.7 
 
Behavior, % 
Inflammatory: 100 
 
CRP NR 
CDAI 
Mean: 291 
 
QOLI 
Mean: 129 
NR Prednisone: 21.4 NR 
Martin F, 
199073 
5-ASA (Salofalk), 
22 
Route: Oral 
Dose: 250 mg 
every 8 hours 
Male, %: 40.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.3 
 
Age at 
enrollment 
Mean: 29.2 
Min: 19 
Max: 60 
Severity NR 
 
Location, % 
Ileal: 54.5 
Ileo-colonic: 45.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 295 
 
QOLI 
Mean: 134 
NR Corticosteroids: 
31.8 
NR 
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Prantera, 
199971 
Mesalamine 
(Asacol), 28 
Route: Oral 
Dose: 4 g every 
day 
Male, %: 53.5 
 
Race NR 
 
Smoking, % 
Smoker, 42.85 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.3 
 
Age at 
enrollment 
Mean: 32.4 
Severity NR 
 
Location, % 
Ileal: 75 
Ileo-colonic: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 222 
Min: 204 
Max: 241 
NR 5ASA: 57.14 NR 
Prantera, 
199971 
Mesalamine 
(Asacol), 35 
Route: Oral 
Dose: 4 g every 
day 
Male, %: 57.14 
 
Race NR 
 
Smoking, % 
Smoker, 48.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.1 
 
Age at 
enrollment 
Mean: 36.8 
Severity NR 
 
Location, % 
Ileal: 71.4 
Ileo-colonic: 28.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 220 
Min: 205 
Max: 244 
NR 5ASA: 60 NR 
Prantera, 
199971 
(6)-
Methylprednisolo
ne, 31 
Route: Oral 
Dose: 40 mg 
Male, %: 58.06 
 
Race NR 
 
Smoking, % 
Smoker, 41.9 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.3 
 
Age at 
enrollment 
Mean: 38.3 
Severity NR 
 
Location, % 
Ileal: 74.2 
Ileo-colonic: 25.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 233 
Min: 216 
Max: 257 
NR 5ASA: 58.06 NR 
Rutgeerts, 
199469 
Prednisolone + 
Placebo, 88 
Route: Oral + 
Oral 
Dose: 40 mg 
every 24 hours + 
NA every day 
Male, %: 42 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP 
Mean: 23 
CDAI 
Mean: 279 
 
HBI 
Mean: 9.3 
NR NR NR 
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Rutgeerts, 
199469 
Budesonide + 
Placebo, 88 
Route: Oral + 
Oral 
Dose: 9 mg 
every 24 hours 
Male, %: 34.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
 
Age at 
enrollment 
Mean: 35 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP 
Mean: 25 
CDAI 
Mean: 275 
 
HBI 
Mean: 9.3 
NR NR NR 
Schoon, 
2005185 
Prednisolone, 
134 
Route: Oral 
Dose: 40 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Vitamin D: 15 
 
Calcium: 51 
NR NR 
Schoon, 
2005185 
Budesonide, 137 
Route: Oral 
Dose: 9 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Vitamin D: 12 
 
Calcium: 46 
NR NR 
Singleton, 
197975 
 
 
Sulfasalazine + 
Prednisone, 43 
Route: Oral + 
Unknown 
Dose: 1g per 
15kg body 
weight to 5g max 
every day + 
every day 
Male, %: 47 
 
Race, % 
W: 86 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30 
Severity NR 
 
Location, % 
Ileo-colonic: 56 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 239 
NR 5ASA: 51 
 
Corticosteroids: 
47 
NR 
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Singleton, 
197975 
 
 
Placebo + 
Prednisone, 46 
Route: Unknown 
+ Oral 
Dose: NA + 
every day 
Male, %: 46 
 
Race, % 
W: 89 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.9 
Severity NR 
 
Location, % 
Ileo-colonic: 55 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 236.3 
NR 5ASA: 54 
 
Corticosteroids: 
52 
NR 
Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kgs 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
Summers, 
197956 
  
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
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Summers, 
197956 
 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
Thomsen, 
199870 
Mesalamine 
(Pentasa), 89 
Route: Oral 
Dose: 2 g every 
12 hours 
Male, %: 31.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 4.6 
 
Age at 
enrollment 
Median: 31 
Severity NR 
 
Location, % 
Ileal: 56.2 
Ileo-colonic: 39.3 
Colonic: 4.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 278 
Min: 193 
Max: 394 
Opiates & 
loperamide 
5ASA 
 
Corticosteroids 
 
Immunomodulat
ors 
NR 
Thomsen, 
199870 
Budesonide + 
Placebo, 93 
Route: Oral + 
Oral 
Dose: 9 mg 
every day + NA 
every day 
Male, %: 32.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.1 
 
Age at 
enrollment 
Median: 34 
Severity NR 
 
Location, % 
Ileal: 60.2 
Ileo-colonic: 38.7 
Colonic: 1.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 266 
Min: 166 
Max: 398 
Opiates & 
loperamide 
5ASA 
 
Corticosteroids 
 
Immunomodulat
ors 
NR 
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Tremaine, 
200265 
Budesonide, 79 
Route: Oral 
Dose: 4.5 mg 
every 12 hours 
Male, %: 44.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Median: 7.1 
 
Age at 
enrollment 
Mean: 39 
Median: 38 
Severity, % 
Mild-mod disease: 
100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 279 
Median: 270 
Min: 166 
Max: 437 
NR NR NR 
Tremaine, 
200265 
Placebo, 41 
Route: Oral 
Dose: NA every 
day 
Male, %: 43.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Median: 8.2 
 
Age at 
enrollment 
Mean: 37 
Median: 36 
Severity, % 
Mild-mod disease: 
100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 271 
Median: 253 
Min: 197 
Max: 425 
NR NR NR 
Tremaine, 
200265 
Budesonide, 80 
Route: Oral 
Dose: 9 mg 
every day 
Male, %: 23.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11.9 
Median: 9.2 
 
Age at 
enrollment 
Mean: 41 
Median: 36 
Severity, % 
Mild-mod disease: 
100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 280 
Median: 268 
Min: 199 
Max: 484 
NR NR NR 
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Tromm, 
201174 
Budesonide, 154 
Route: Oral 
Dose: two 
administrations 
of 9mg total 
every 1 days 
Male, %: 53.2  
 
Race, % W: 99.4  
 
Smoking, % No 
smoking 
defintion 
abstracted, 30.5  
 
CD NR 
Age at diagnosis 
NR  
 
Disease duration 
Mean: 6.1  
 
Age at 
enrollment 
Mean: 36.8 
Severity NR  
 
Location NR  
 
Behavior NR  
 
CRP Mean: 15.4 
CDAI Mean: 
265.6 
Thiopurines: 3.2 NR NR 
Tromm, 
201174 
Mesalamine 
(Salofalk), 153 
Route: Oral 
Dose: 3 x 1.5 
g/day 
Male, %: 50.3  
 
Race, % W: 99.3  
 
Smoking, % No 
smoking 
defintion 
abstracted, 25.5  
 
CD NR 
Age at diagnosis 
NR  
 
Disease duration 
Mean: 5.9  
 
Age at 
enrollment 
Mean: 37.8 
Severity NR  
 
Location NR  
 
Behavior NR  
 
CRP Mean: 16.6 
CDAI Mean: 
267.2 
Thiopurines: 3.3 NR NR 
Randomized controlled trials evaluating aminosalicylate acids 
Griffiths, 
1993221 
Mesalamine 
(Pentasa), 7 
Route: Oral 
Dose: 50 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 188.3 
 
HBI 
Mean: 3.71 
NR NR NR 
Griffiths, 
1993221 
Placebo, 6 
Route: Oral 
Dose: NA every 
day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 182.5 
 
HBI 
Mean: 3.5 
NR NR NR 
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Malchow, 
198464 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR Sulfasalazine: 
88.0 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3  
NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
NR 
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Malchow, 
198464 
 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
Malchow, 
198464 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR Sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
 
NR 
Malchow, 
198464 
 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
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Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
NR 
Malchow, 
198464 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
Singleton, 
199379 
Mesalamine 
(Pentasa), 75 
Route: Oral 
Dose: 2 g every 
day 
Male, %: 39 
 
Race NR 
 
Smoking, % 
Smoker, 41 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.6 
Min: 0 
Max: 33 
 
Age at 
enrollment 
Mean: 36 
Min: 20 
Max: 70 
Severity NR 
 
Location, % 
Ileal: 40 
Ileo-colonic: 35 
Colonic: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 265 
Min: 133 
Max: 409 
 
HBI 
Mean: 8.8 
Min: 3 
Max: 18 
 
Van Hees index 
Mean: 155 
Min: 97 
Max: 249 
NR 5ASA: 15 
 
Corticosteroids: 
21 
NR 
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Singleton, 
199379 
Mesalamine 
(Pentasa), 80 
Route: Oral 
Dose: 1 g every 
day 
Male, %: 36 
 
Race NR 
 
Smoking, % 
Smoker, 40 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.4 
Min: 0 
Max: 28 
 
Age at 
enrollment 
Mean: 36 
Min: 18 
Max: 67 
Severity NR 
 
Location, % 
Ileal: 38 
Ileo-colonic: 38 
Colonic: 23 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 271 
Min: 168 
Max: 388 
 
HBI 
Mean: 9 
Min: 3 
Max: 17 
 
Van Hees index 
Mean: 158 
Min: 72 
Max: 224 
NR 5ASA: 18 
 
Corticosteroids: 
16 
NR 
Singleton, 
199379 
Placebo, 80 
Route: Oral 
Dose: NA every 
day 
Male, %: 41 
 
Race NR 
 
Smoking, % 
Smoker, 50 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.5 
Min: 0 
Max: 38 
 
Age at 
enrollment 
Mean: 37 
Min: 16 
Max: 75 
Severity NR 
 
Location, % 
Ileal: 45 
Ileo-colonic: 36 
Colonic: 19 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 277 
Min: 112 
Max: 460 
 
HBI 
Mean: 9.8 
Min: 4 
Max: 20 
 
Van Hees index 
Mean: 154 
Min: 91 
Max: 279 
NR 5ASA: 25 
 
Corticosteroids: 
26 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Singleton, 
199379 
Mesalamine 
(Pentasa), 75 
Route: Oral 
Dose: 4 g every 
day 
Male, %: 27 
 
Race NR 
 
Smoking, % 
Smoker, 29 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.9 
Min: 0 
Max: 45 
 
Age at 
enrollment 
Mean: 37 
Min: 19 
Max: 76 
Severity NR 
 
Location, % 
Ileal: 44 
Ileo-colonic: 36 
Colonic: 19 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 260 
Min: 86 
Max: 381 
 
HBI 
Mean: 8.6 
Min: 1 
Max: 16 
 
Van Hees index 
Mean: 157 
Min: 80 
Max: 232 
NR 5ASA: 17 
 
Corticosteroids: 
20 
NR 
Singleton, 
1995222 
Placebo, 80 
Route: Unknown 
Dose: NA every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Singleton, 
1995222 
Mesalamine 
(Pentasa), 75 
Route: Oral 
Dose: 2 g every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Singleton, 
1995222 
Mesalamine 
(Pentasa), 75 
Route: Oral 
Dose: 4 g every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Singleton, 
1995222 
Mesalamine 
(Pentasa), 80 
Route: Oral 
Dose: 1 g every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Summers, 
197956 
 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg. every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
Summers, 
197956 
 
 
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kg 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
Tremaine, 
199477 
Mesalamine 
(Asacol), 20 
Route: Oral 
Dose: 800 mg 
every 6 hours 
Male, %: 35 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 3.5 
Min: 0.33 
Max: 25 
 
Age at 
enrollment 
Median: 31 
Min: 20 
Max: 62 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 231.7 
NR NR Corticosteroids: 
65 
 
Thiopurines: 0 
 
: 30 
 
: 30 
 
: 0 
 
: 10 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Tremaine, 
199477 
Placebo, 18 
Route: Oral 
Dose: NA every 
6 hours 
Male, %: 66.66 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5 
Min: 0.58 
Max: 13 
 
Age at 
enrollment 
Median: 38 
Min: 22 
Max: 65 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 204.8 
NR NR Corticosteroids: 
50 
 
Thiopurines: 0 
 
: 38.9 
 
: 16.7 
 
: 11.1 
 
: 5.6 
Abbreviations: 5ASA = 5-aminosalicylic acid; 6-MP = 6-mercaptopurine; A = Asian: B = African American; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CRP 
= C-reactive protein; DAI = disease activity index; g = grams; H = Hispanic; HBI = Harvey-Bradshaw Index; IBDQ = Inflammatory Bowel Disease Questionnaire; IV = 
intravenous; kg = kilogram; Max. = maximum; mg = milligram; Min. = minimum; Mod-sev = moderate to severe; NA = not applicable; NR = not reported; SC = subcutaneous; 
TNF = tumor necrosis factor; W = White 
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Evidence Table 4. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
inducing remission (KQ1) 
 
Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
55 / 169 (32.5%) 
Incidence  
30 / 170 (17.6%) P: 0.001 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 26 
wks 
NA 
Yes 
Incidence  
81 / 169 (47.9%) 
Incidence  
54 / 170 (31.8%) P: 0.002 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 50 
wks 
NA 
Yes 
Incidence  
64 / 169 (38%) 
Incidence  
41 / 170 (24%) P: 0.006 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Endoscopic healing 
(Absence of ulcers) 
@ 26 wks 
NA 
No 
Incidence  
28 / 93 (30%) 
Incidence  
18 / 109 (17%) P: 0.02 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
B: Mean, 126.7 (SD, 30) 
F-B: Mean, 39.9 (SD, 37) 
G1-G2: -8.5 
B: Mean, 122.1 (SD, 30) 
F-B: Mean, 31.4 (SD, 35) 
G1-G2: -8.5 P: 0.05 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
F-B: Mean, 27.7 (SD, 26) 
G1-G2: -7.6 
F-B: Mean, 20.1 (SD, 24) 
G1-G2: -7.6 P: 0.007 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
50 wks 
NA 
No 
F-B: Mean, 51.6 (SD, 33) 
G1-G2: -8.6 
F-B: Mean, 43 (SD, 33) 
G1-G2: -8.6 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 26 
wks 
NA 
Yes 
Incidence  
75 / 169 (44.4%) 
Incidence  
51 / 170 (30%) P: 0.006 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 50 
wks 
NA 
Yes 
Incidence  
59 / 169 (35%) 
Incidence  
41 / 170 (24%) P: 0.03 
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Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 6 
wks 
NA 
Yes 
Incidence  
50 / 169 (29.6%) 
Incidence  
24 / 170 (14.1%) 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
62 / 169 (36.7%) 
Incidence  
30 / 170 (17.6%) P: 
<0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 26 
wks 
NA 
Yes 
Incidence  
102 / 169 (60.4%) 
Incidence  
54 / 170 (31.8%) P: 
<0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 50 
wks 
NA 
Yes 
Incidence  
80 / 169 (47%) 
Incidence  
41 / 170 (24%) P: <0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Endoscopic healing 
(Absence of ulcers) 
@ 26 wks 
NA 
No 
Incidence  
47 / 107 (44%) 
Incidence  
18 / 109 (17%) 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
F-B: Mean, 31.4 (SD, 30) 
G1-G2: -11.3 
F-B: Mean, 20.1 (SD, 24) 
G1-G2: -11.3 P: <0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
B: Mean, 125.3 (SD, 29) 
F-B: Mean, 45.2 (SD, 36) 
G1-G2: -13.8 
B: Mean, 122.1 (SD, 30) 
F-B: Mean, 31.4 (SD, 35) 
G1-G2: -13.8 P: <0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
HR QoL (IBDQ) @ 
50 wks 
NA 
No 
F-B: Mean, 56.4 (SD, 33) 
G1-G2: -13.4 
F-B: Mean, 43 (SD, 33) 
G1-G2: -13.4 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 50 
wks 
NA 
Yes 
Incidence  
78 / 168 (46%) 
Incidence  
41 / 170 (24%) P: <0.001 
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Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 6 
wks 
NA 
Yes 
Incidence  
55 / 169 (32.5%) 
Incidence  
24 / 170 (14.1%) P: 
<0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Azathioprine + placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + NA 
every 8 wks 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 26 
wks 
NA 
Yes 
Incidence  
96 / 169 (56.8%) 
Incidence  
51 / 170 (30%) P: <0.001 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
62 / 169 (36.7%) 
Incidence  
55 / 169 (32.5%) P: 0.38 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
CDAI (Remission: 
CDAI < 150) @ 26 
wks 
NA 
Yes 
Incidence  
102 / 169 (60.4%) 
Incidence  
81 / 169 (47.9%) P: 0.02 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
CDAI (Remission: 
CDAI < 150) @ 50 
wks 
NA 
Yes 
Incidence  
80 / 169 (47%) 
Incidence  
64 / 169 (38%) P: 0.08 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Endoscopic healing 
(Absence of ulcers) 
@ 26 wks 
NA 
No 
Incidence  
47 / 107 (44%) 
Incidence  
28 / 93 (30%) P: 0.06 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
B: Mean, 125.3 (SD, 29) 
F-B: Mean, 45.2 (SD, 36) 
G1-G2: -5.3 
B: Mean, 126.7 (SD, 30) 
F-B: Mean, 39.9 (SD, 37) 
G1-G2: -5.3 P: 0.13 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
F-B: Mean, 31.4 (SD, 30) 
G1-G2: -3.7 
F-B: Mean, 27.7 (SD, 26) 
G1-G2: -3.7 P: 0.31 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
HR QoL (IBDQ) @ 
50 wks 
NA 
No 
F-B: Mean, 56.4 (SD, 33) 
G1-G2: -4.8 
F-B: Mean, 51.6 (SD, 33) 
G1-G2: -4.8 
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Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 26 
wks 
NA 
Yes 
Incidence  
96 / 169 (56.8%) 
Incidence  
75 / 169 (44.4%) P: 0.02 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 50 
wks 
NA 
Yes 
Incidence  
78 / 168 (46%) 
Incidence  
59 / 169 (35%) P: 0.04 
Colombel, 
201045 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg daily + 5 
mg/kg every 8 wks 
Infliximab + placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA daily 
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 6 
wks 
NA 
Yes 
Incidence  
55 / 169 (32.5%) 
Incidence  
50 / 169 (29.6%) P: 0.55 
Reinisch, 
200851 
Azathioprine + prednisone 
Route: Oral + Oral 
Dose: 2.5 mg/kg daily + 1 
mg/kg or ≥ 40 mg daily 
Placebo + prednisone 
Route: Oral + Oral 
Dose: NA daily + 1mg/kg or 
≥ 40mg daily 
HR QoL (IBDQ) @ 4 
wks 
NA 
No 
F-B: Median, 43 
G1-G2: -3 
F-B: Median, 40 
G1-G2: -3 
D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
CDAI (Remission: 
CDAI<150, absence 
of intestinal 
resection, absence 
of corticosteroid 
therapy) @ 104 wks 
NA 
Yes 
Incidence  
32 / 64 (50%) 
Incidence  
36 / 65 (55%) P: 0.431 
D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
CDAI (Remission: 
CDAI<150, absence 
of intestinal 
resection, absence 
of corticosteroid 
therapy) @ 26 wks 
NA 
Yes 
Incidence  
23 / 64 (36%)  
Incidence  
39 / 65 (60%) P: 0.0062 
D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
CDAI (Remission: 
CDAI<150, absence 
of intestinal 
resection, absence 
of corticosteroid 
therapy) @ 52 wks 
NA 
Yes 
Incidence  
27 / 64 (42%)  
Incidence  
40 / 65 (62%) P: 0.0278 
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D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
CDAI (Remission: 
CDAI<150, absence 
of intestinal 
resection, absence 
of corticosteroid 
therapy) @ 14 wks 
NA 
Yes 
Incidence  
20 / 64 (32%) 
Incidence  
42 / 65 (65%) P: 0.0001 
D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Endoscopic healing 
(Absence of ulcers) 
@ 104 wks 
NA 
NR 
Incidence  
7 / 23 (30%) 
Incidence  
19 / 26 (73%) P: 0.0028 
D'Haens, 
200848 
Budesonide + (6)-
methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg daily + 32 mg 
daily 
Infliximab + azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Endoscopic healing 
(SES-CD) @ 104 
wks 
NA 
NR 
F: Mean, 3.1 (SD, 2.9) P: 
<0.001 
F: Mean, 0.7 (SD, 1.5) P: 
<0.001 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
86 / 331 (26%) 
Incidence  
66 / 328 (20%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
43 / 331 (13%) 
Incidence  
26 / 328 (8%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 26 
wks 
NA 
Yes 
Incidence  
95 / 327 (29%) 
Incidence  
59 / 326 (18%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ 
response (≥16-pt 
increase)) @ 26 wks 
NA 
Yes 
Incidence  
140 / 331 (42%) 
Incidence  
108 / 328 (33%) P: 0.01 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
26 wks 
NA 
Yes 
F-B: Mean, 26.4 (SD, 35) 
G1-G2: -5.9 
F-B: Mean, 20.5 (SD, 33) 
G1-G2: -5.9 P: 0.03 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Perianal disease 
(Complete fistula 
closure) @ 26 wks 
NA 
Yes 
Incidence  
14 / 46 (30%) 
Incidence  
19 / 61 (31%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA  
NA 
Incidence  
97 / 259 (38%) 
Incidence  
63 / 250 (25%) P: 0.001 
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Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA  
NA 
Incidence  
68 / 259 (26%) 
Incidence  
40 / 250 (16%) P: 0.002 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
HR QoL (IBDQ) @ 
12 wks 
NA  
NA 
B: Mean, 123.6 (SD, 31) 
F-B: Mean, 26.7 (SD, 32) 
P: <0.001 
B: Mean, 122.5 (SD, 28) 
F-B: Mean, 15.2 (SD, 29) 
G1-G2: -11.5 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
 (Complete fistula 
closure) @ 4 wks 
NA  
NA 
Incidence  
1 / 20 (5%) 
Incidence  
2 / 25 (8%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
34 / 159 (21%) 
Incidence  
12 / 166 (7%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
10 / 159 (6%) 
Incidence  
6 / 166 (4%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
HR QoL (IBDQ) @ 4 
wks 
NA  
NA 
F: Mean, 150 P: <0.001 F: Mean, 139 P: <0.001 
Sands, 200735 Natalizumab + infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
CDAI (Remission: 
CDAI < 150) 
NA 
Yes 
Incidence  
24 / 52 (46%) 
Incidence  
11 / 27 (41%) 
Sands, 200735 Natalizumab + infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
HR QoL (IBDQ) @ 6 
wks 
NA 
Yes 
F-B: 12.3 
G1-G2: -3.2 
F-B: 9.1 
G1-G2: -3.2 
Sands, 200735 Natalizumab + infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
HR QoL (IBDQ) @ 
10 wks 
NA 
Yes 
F-B: Mean, 18.7 
G1-G2: -1.4 
F-B: Mean, 17.3 
G1-G2: -1.4 
Lemann, 
200646 
Infliximab + azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable  
Endoscopic healing 
(Absence of ulcers) 
@ 24 wks 
NA 
Yes 
Incidence  
3 / 11 (27%) 
Incidence  
3 / 9 (33%) P: 0.77 
Lemann, 
200646 
Infliximab + azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable  
Endoscopic healing 
(CDEIS) @ 24 wks 
NA 
NR 
F-B: Median, -6.9 (IQR, -
9.5 to -4.1) 
G1-G2: 5.7 
F-B: Median, -1.2 (IQR, -
4.4 to 1.5) 
G1-G2: 5.7 P: 0.05 
Lemann, 
200646 
Infliximab + azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable  
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 12 
wks 
NA 
Yes 
Incidence  
41 / 55 (75%) 
OR: 4.9 (2.2 to 11)  
Incidence  
21 / 56 (38%) 
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Lemann, 
200646 
Infliximab + azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable  
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 24 
wks 
NA 
Yes 
Incidence  
31 / 54 (57%) 
OR: 3.3 (1.5 to 7.4) 
P: 0.003  
Incidence  
15 / 52 (29%) P: 0.003 
Lemann, 
200646 
Infliximab + azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable  
Steroid free (steroid-
free remission 
(CDAI < 150)) @ 52 
wks 
NA 
Yes 
Incidence  
22 / 55 (40%) 
OR: 2.4 (1 to 5.7) 
P: 0.04  
Incidence  
11 / 51 (22%) P: 0.04 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 1 
wk 
NA 
Yes 
Incidence  
12 / 74 (16%) 
Incidence  
5 / 74 (7%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
13 / 74 (18%) 
Incidence  
9 / 74 (12%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 1 
wk 
NA 
Yes 
B: Mean, 129 
F: Mean, 14314 
B: Mean, 131 
F: Mean, 14110 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Mean, 129 
F: Mean, 147 P: NS18 
B: Mean, 131 
F: Mean, 147 P: NS16 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(50% fistula closure) 
@ 4 wks 
NA 
Yes 
Incidence  
3 / 4 (75%) 
Incidence  
2 / 6 (33%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(Complete fistula 
closure) @ 4 wks 
NA 
Yes 
Incidence  
3 / 4 (75%) 
Incidence  
1 / 6 (17%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 1 
wk 
NA 
Yes 
Incidence  
10 / 75 (13%) 
Incidence  
5 / 74 (7%) P: NS 
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Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
18 / 75 (24%) 
Incidence  
9 / 74 (12%) P: NS 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 1 
wk 
NA 
Yes 
B: Mean, 128 
F: Mean, 146 
F-B: Mean: 18 
B: Mean, 131 
F: Mean, 141 
F-B: Mean: 10 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Mean, 128 
F: Mean, 157 P: <0.0529 
B: Mean, 131 
F: Mean, 147 P: <0.0516 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(50% fistula closure) 
@ 4 wks 
NA 
Yes 
Incidence  
2 / 10 (20%) 
Incidence  
2 / 6 (33%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(Complete fistula 
closure) @ 4 wks 
NA 
Yes 
Incidence  
0 / 10 (0%) 
Incidence  
1 / 6 (17%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 1 
wk 
NA 
Yes 
Incidence  
12 / 76 (16%) 
Incidence  
5 / 74 (7%) P: NS 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
27 / 76 (36%) 
Incidence  
9 / 74 (12%) P: 0.001 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 1 
wk 
NA 
Yes 
B: Mean, 127 
F: Mean, 14619 
B: Mean, 131 
F: Mean, 14110 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Mean, 127 
F: Mean, 157 P: <0.0530 
B: Mean, 131 
F: Mean, 147 P: <0.0516 
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Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(50% fistula closure) 
@ 4 wks 
NA 
Yes 
Incidence  
1 / 12 (8%) 
Incidence  
2 / 6 (33%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(Complete fistula 
closure) @ 4 wks 
NA 
Yes 
Incidence  
0 / 12 (0%) 
Incidence  
1 / 6 (17%) 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
7 / 11 (64%) 
Incidence  
2 / 8 (25%) P: 0.16 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
9 / 11 (82%) 
Incidence  
4 / 8 (50%) P: 0.32 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 48 
wks 
NA 
Yes 
Incidence  
5 / 11 (45%) 
Incidence  
2 / 8 (25%) P: 0.63 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 113 (SD, 23) 
F: Mean, 160 
F-B: Mean: 47 
B: Mean, 106 (SD, 17) 
F: Mean, 135 
F-B: Mean: 29 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
B: Mean, 113 (SD, 23) 
F: Mean, 172 
F-B: Mean: 59 
B: Mean, 106 (SD, 17) 
F: Mean, 140 
F-B: Mean: 34 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
HR QoL (IBDQ) @ 
48 wks 
NA 
Yes 
B: Mean, 113 (SD, 23) 
F: Mean, 165 
F-B: Mean: 52 
B: Mean, 106 (SD, 17) 
F: Mean, 130 
F-B: Mean: 24 
Schroder, 
200647 
Methotrexate + infliximab 
Route: IV + IV 
Dose: 20 mg weekly + 5 
mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
Steroid free 
(Discontinued 
corticosteroids) @ 
48 wks 
NA 
Yes 
Incidence  
7 / 7 (100%) 
Incidence  
2 / 6 (33%) P: 0.02 
Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
101 / 724 (14%) 
Incidence  
18 / 181 (10%) 
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Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 10 
wks 
NA 
Yes 
Incidence  
268 / 724 (37%) 
Incidence  
54 / 181 (30%) P: 0.12 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
13 / 74 (18%) 
Incidence  
6 / 73 (8%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
20 / 74 (27%) 
Incidence  
17 / 73 (23.3%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 132.2 
F-B: Mean, 16.6 
G1-G2: -6 
B: Mean, 122.9 
F-B: Mean, 10.6 
G1-G2: -6 P: <0.05 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
B: Mean, 132.2 
F-B: 22 
G1-G2: -6 
B: Mean, 122.9 
F-B: 16 
G1-G2: -6 P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 2 wks 
NA 
Yes 
Incidence  
24 / 73 (32.9%) 
Incidence  
13 / 73 (17.8%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 12 wks 
NA 
Yes 
Incidence  
28 / 73 (38.4%) 
Incidence  
17 / 73 (23.3%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
7 / 72 (10%) 
Incidence  
6 / 73 (8%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
14 / 72 (19.4%) 
Incidence  
17 / 73 (23.3%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 122.9 
F-B: Mean, 21.8 
G1-G2: -11.2 
B: Mean, 122.9 
F-B: Mean, 10.6 
G1-G2: -11.2 P: <0.05 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
B: Mean, 122.9 
F-B: 20 
G1-G2: -4 
B: Mean, 122.9 
F-B: 16 
G1-G2: -4 P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 2 wks 
NA 
Yes 
Incidence  
14 / 72 (19.4%) 
Incidence  
13 / 73 (17.8%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 12 wks 
NA 
Yes 
Incidence  
17 / 72 (23.6%) 
Incidence  
17 / 73 (23.3%) P: NS 
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Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
13 / 72 (18%) 
Incidence  
6 / 73 (8%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
19 / 72 (26.4%) 
Incidence  
17 / 73 (23.3%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 2 wks 
NA 
Yes 
Incidence  
20 / 72 (27.8%) 
Incidence  
13 / 73 (17.8%) P: NS 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ > 
170) @ 12 wks 
NA 
Yes 
Incidence  
28 / 72 (38.9%) 
Incidence  
17 / 73 (23.3%) P: <0.05 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 2 
wks 
NA  
NA 
B: Mean, 126.5 (SD, 25) 
F-B: Mean, 22.8 
G1-G2: -12.2 
B: Mean, 122.9 (SD, 27) 
F-B: Mean, 10.6 
G1-G2: -12.2 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
12 wks 
NA 
NR 
B: Mean, 126.5 (SD, 25) 
F: Mean, 156.4 (SD, 37) 
F-B: Mean, 29.9 
B: Mean, 122.9 (SD, 27) 
F: Mean, 140.5 (SD, 36) 
F-B: Mean, 17.6 
G1-G2: -14 P: <0.05 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
9 / 25 (35%) 
Incidence  
4 / 25 (16%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
8 / 25 (32%) 
Incidence  
8 / 25 (32%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
8 / 17 (47.1%) 
Incidence  
4 / 25 (16%) P: 0.041 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
4 / 17 (23.5%) 
Incidence  
8 / 25 (32%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
5 / 23 (20%) 
Incidence  
4 / 25 (16%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
3 / 23 (12%) 
Incidence  
8 / 25 (32%) 
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Ardizzone, 
200358 
Methotrexate 
Route: IV for first 3 mos 
then oral 
Dose: 25 mg weekly 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg daily 
Steroid free 
(Remission: CDAI < 
150) @ 12 wks 
NA 
Yes 
Incidence  
12 / 27 (44%) 
Incidence  
9 / 27 (33%) 
Ardizzone, 
200358 
Methotrexate 
Route: IV for first 3 mos 
then oral 
Dose: 25 mg weekly 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg daily 
Perianal disease 
(Complete fistula 
closure) @ 24 wks 
NA 
NR 
Incidence  
4 / 6 (67%) 
Incidence  
1 / 4 (25%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
No 
Incidence  
31 / 78 (40%) 
Incidence  
5 / 40 (13%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
No 
Incidence  
41 / 78 (53%) 
Incidence  
13 / 40 (33%) P: >0.05 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
treatment benefit 
(CDAI <150 or 100 
pt drop)) @ 2 wks 
NA 
No 
Incidence  
45 / 78 (58%) 
Incidence  
11 / 40 (27%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
treatment benefit 
(CDAI <150 or 100 
pt drop)) @ 8 wks 
NA 
No 
Incidence  
50 / 78 (64%) 
Incidence  
18 / 40 (44%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA daily 
HR QoL (IBDQ) @ 8 
wks 
NA 
No 
F-B: numerical 
improvements in total 
score', 34.1 (SD, 35.2) 
F-B: numerical 
improvements in total 
score', 29.3 (SD, 35.7) 
G1-G2: -4.8 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
No 
Incidence  
24 / 79 (31%) 
Incidence  
5 / 40 (13%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
No 
Incidence  
37 / 79 (48%) 
Incidence  
13 / 40 (33%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
treatment benefit 
(CDAI <150 or 100 
pt drop)) @ 2 wks 
NA 
No 
Incidence  
38 / 79 (48%) 
Incidence 
11 / 40 (27%) 
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Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
treatment benefit 
(CDAI <150 or 100 
pt drop)) @ 8 wks 
NA 
No 
Incidence  
52 / 79 (66%) 
Incidence 
18 / 40 (44%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg daily 
Placebo 
Route: Oral 
Dose: NA daily 
HR QoL (IBDQ) @ 8 
wks 
NA 
No 
F-B: numerical 
improvements in total 
score', 36.3 (SD, 32.5) 
F-B: numerical 
improvements in total 
score', 29.3 (SD, 35.7) 
G1-G2: -7 
Gordon, 
200134 
Natalizumab 
Route: IV 
Dose: 3 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
7 / 18 (39%) 
Incidence  
1 / 12 (8%) P: 0.1 
Gordon, 
200134 
Natalizumab 
Route: IV 
Dose: 3 mg/kg 
Placebo 
Route: IV 
Dose: NA 
HR QoL (IBDQ) @ 4 
wks 
NA 
NR 
F-B: Mean, 19 P: 0.004  
Mate-Jimenez, 
200052 
Methotrexate 
Route: Oral 
Dose: 15 mg weekly 
6-MP 
Route: Oral 
Dose: 1.5 mg/kg daily 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration) @ 30 
wks 
NA 
NR 
Incidence  
12 / 15 (80%) 
Incidence  
15 / 16 (93.7%) 
Mate-Jimenez, 
200052 
Methotrexate 
Route: Oral 
Dose: 15 mg weekly 
6-MP 
Route: Oral 
Dose: 1.5 mg/kg daily 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration) @ 
106 wks 
NA 
No 
Incidence  
8 / 15 (53%) 
Incidence  
8 / 16 (50%) 
Mate-Jimenez, 
200052 
ASA 
Route: Oral 
Dose: 3 g daily 
6-MP 
Route: Oral 
Dose: 1.5 mg/kg daily 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration)@ 30 
wks 
NA 
NR 
Incidence  
1 / 7 (14%) 
Incidence  
15 / 16 (93.7%) 
Mate-Jimenez, 
200052 
ASA 
Route: Oral 
Dose: 3 g daily 
6-MP 
Route: Oral 
Dose: 1.5 mg/kg daily 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration) @ 
106 wks 
NA 
No 
Incidence  
0 / 7 (0%) 
Incidence  
8 / 16 (50%) 
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Mate-Jimenez, 
200052 
ASA 
Route: Oral 
Dose: 3 g daily 
Methotrexate 
Route: Oral 
Dose: 15 mg weekly 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration)@ 30 
wks 
NA 
NR 
Incidence  
1 / 7 (14%) 
Incidence  
12 / 15 (80%) 
Mate-Jimenez, 
200052 
ASA 
Route: Oral 
Dose: 3 g daily 
Methotrexate 
Route: Oral 
Dose: 15 mg weekly 
Steroid free 
(Remission: CDAI < 
150 and normal 
serum orosmucoid 
concentration)@ 
106 wks 
NA 
No 
Incidence  
0 / 7 (0%) 
Incidence  
8 / 15 (53%) 
Sandborn, 
199959 
Azathioprine + azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
daily 
Placebo + azathioprine 
Route: IV + Oral 
Dose: NA + 2 mg/kg daily 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
13 / 51 (25%) 
Incidence  
11 / 45 (24%) P: 0.906 
Sandborn, 
199959 
Azathioprine + azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
daily 
Placebo + azathioprine 
Route: IV + Oral 
Dose: NA + 2 mg/kg daily 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
11 / 51 (22%) 
Incidence  
10 / 45 (22%) P: 0.939 
Sandborn, 
199959 
Azathioprine + azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
daily 
Placebo + azathioprine 
Route: IV + Oral 
Dose: NA + 2 mg/kg daily 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
16 / 51 (31%) 
Incidence  
12 / 45 (27%) P: 0.615 
Prantera, 
199971 
(6)-Methylprednisolone 
Route: Oral 
Dose: 40 mg 
Mesalamine (Asacol) 
Route: Oral (tablets) 
Dose: 4 g daily 
CDAI (Remission: 
CDAI < 150) @ 3 
wks 
NA 
Yes 
Incidence  
19 / 31 (61%) 
Incidence  
16 / 35 (46%) 
Prantera, 
199971 
(6)-Methylprednisolone 
Route: Oral 
Dose: 40 mg 
Mesalamine (Asacol) 
Route: Oral (tablets) 
Dose: 4 g daily 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
19 / 31 (61%) 
Incidence  
21 / 35 (60%) 
Prantera, 
199971 
(6)-Methylprednisolone 
Route: Oral 
Dose: 40 mg 
Mesalamine (Asacol) 
Route: Oral (granules) 
Dose: 4 g daily 
CDAI (Remission: 
CDAI < 150) @ 3 
wks 
NA 
Yes 
Incidence  
19 / 31 (61%) 
Incidence  
17 / 28 (61%) 
Prantera, 
199971 
(6)-Methylprednisolone 
Route: Oral 
Dose: 40 mg 
Mesalamine (Asacol) 
Route: Oral (granules) 
Dose: 4 g daily 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
19 / 31 (61%) 
Incidence  
22 / 28 (79%) 
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Bar-Meir, 
199867 
Prednisone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 8 hrs 
Budesonide + placebo 
Route: Oral 
Dose: 3 mg every 8 hrs + 
NA daily 
HR QoL (SF-36, 
physical score) @ 8 
wks 
NA 
Yes 
B: Mean, 40.8 (SD, 16.3) 
F: Mean, 62.3 (SD, 22) 
F-B: 21.5 
G1-G2: 8 
B: Mean, 44.8 (SD, 16.2) 
F: Mean, 58.3 (SD, 20.9) 
F-B: 13.5 
Bar-Meir, 
199867 
Prednisone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 8 hrs 
Budesonide + placebo 
Route: Oral 
Dose: 3 mg every 8 hrs + 
NA daily 
HR QoL (SF-36, 
mental score) @ 8 
wks 
NA 
Yes 
B: Mean, 42.2 (SD, 19.7) 
F: Mean, 60.9 (SD, 23.1)  
F-B: 18.7 
G1-G2: 8 
B: Mean, 46.5 (SD, 18.9) 
F: Mean, 56.9 (SD, 20.7)  
F-B: 10.4 
Bar-Meir, 
199867 
Prednisone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 8 hrs 
Budesonide + placebo 
Route: Oral 
Dose: 3 mg every 8 hrs + 
NA daily 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 130.1 (SD, 32) 
F: Mean, 164.4 (SD, 36)  
F-B: Mean, 34.3 
G1-G2: 8 
B: Mean, 135.9 (SD, 28) 
F: Mean, 162 (SD, 34)  
F-B: Mean, 26.1 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
30 / 83 (36%) 
Incidence  
39 / 89 (44%) 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
18 / 50 (36%) 
Incidence  
48 / 77 (62%) 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
HR QoL (PGWB) @ 
2 wks 
NA  
NA 
B: 83 
F: Mean, 95 P: <0.05 
B: 81 
F: Mean, 98 P: <0.05 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
HR QoL 
(Psychological 
General Well-Being 
index) @ 16 wks 
NA 
Yes 
B: Mean, 83 
F: Mean, 95 P: 0.01 
F-B: Mean, 9 (SD, 21) P: 
0.0025 
G1-G2: 11.4 
B: Mean, 81 
F: Mean, 101 P: 0.01 
F-B: Mean, 20.4 (SD, 24) 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
HR QoL (physician's 
global evaluation 
score) @ 2 wks 
NA 
Yes 
B: Mean, 2.2 
F: Mean, 1.7 P: <0.01  
F-B: Mean, -0.5 
B: Mean, 2.2 
F: Mean, 1.3 P: <0.01  
F-B: Mean, -0.9 
Thomsen, 
199870 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g every 12 hrs 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA daily 
HR QoL (physician's 
global assessment) 
@ 16 wks 
NA 
Yes 
B: Mean, 2.2 
F: 1.8 P: <0.001 
B: Mean, 2.2 
F: 1.2 P: <0.001 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 4 wks 
NA 
Yes 
Incidence  
0 / 32 (0%) 
Incidence  
1 / 26 (5%) 
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Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 16 wks 
NA 
Yes 
Incidence  
10 / 32 (30%) 
Incidence  
7 / 26 (28%) 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI < 3 and not on 
steroids) @ 38 wks 
NA 
Yes 
Incidence  
13 / 32 (41%) 
Incidence  
12 / 26 (46%) 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Relapse rate: 
HBI increased by 3+ 
points and/or 
require restarting 
steroid treatment at 
>300 mg/mo) @ 38 
wks 
NA 
No 
Incidence  
5 / 13 (38%) 
Incidence  
4 / 12 (33%) 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 4 wks 
NA 
NR 
B: Mean, 0 
F: Mean, 0.8 
F-B: 0.8 
B: Mean, 0 
F: Mean, 0.8 
F-B: 0.8 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 16 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.2 
F-B: 1.2 
B: Mean, 0 
F: Mean, 1 
F-B: 1 
Oren, 199757 6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 38 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.3 
F-B: 1.3 
B: Mean, 0 
F: Mean, 1 
F-B: 1 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 4 wks 
NA 
Yes 
Incidence  
2 / 26 (8%) 
Incidence  
1 / 26 (5%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 16 wks 
NA 
Yes 
Incidence  
8 / 26 (30%) 
Incidence  
7 / 26 (28%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI < 3 and not on 
steroids) @ 38 wks 
NA 
Yes 
Incidence  
10 / 26 (38%) 
Incidence  
12 / 26 (46%) 
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Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HBI (Relapse rate: 
HBI increased by 3+ 
points and/or 
require restarting 
steroid treatment at 
>300mg/mo) @ 38 
wks 
NA 
No 
Incidence  
1 / 10 (10%) 
Incidence  
4 / 12 (33%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 4 wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.2 
F-B: 1.2 
B: Mean, 0 
F: Mean, 0.8 
F-B: 0.8 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 16 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.2 
F-B: 1.2 
B: Mean, 0 
F: Mean, 1 
F-B: 1 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
Placebo + placebo 
Route: Oral + Oral 
Dose: NA every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 38 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 2.7 
F-B: 2.7 
B: Mean, 0 
F: Mean, 1 
F-B: 1 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 4 wks 
NA 
Yes 
Incidence  
2 / 26 (8%) 
Incidence  
0 / 32 (0%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI<3 and not on 
steroids) @ 16 wks 
NA 
Yes 
Incidence  
8 / 26 (30%) 
Incidence  
10 / 32 (30%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HBI (Remission: 
HBI < 3 and not on 
steroids) @ 38 wks 
NA 
Yes 
Incidence  
10 / 26 (38%) 
Incidence  
13 / 32 (41%) 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HBI (Relapse rate: 
HBI increased by 3+ 
points and/or 
require restarting 
steroid treatment at 
>300mg/mo) @ 38 
wks 
NA 
No 
Incidence  
1 / 10 (10%) 
Incidence  
5 / 13 (38%) 
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Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 4 wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.2  
F-B: Mean, 1.2 
B: Mean, 0 
F: Mean, 0.8  
F-B: Mean, 0.8 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 16 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 1.2  
F-B: Mean, 1.2 
B: Mean, 0 
F: Mean, 1.2  
F-B: Mean, 1.2 
Oren, 199757 Methotrexate + placebo 
Route: Oral + Oral 
Dose: 12.5 mg weekly + 
NA every 24 hrs 
6-MP + placebo 
Route: Oral + Oral 
Dose: 50 mg every 24 hrs + 
NA weekly 
HR QoL (Treatment 
Goal Score for 
Wellbeing) @ 38 
wks 
NA 
NR 
B: Mean, 0 
F: Mean, 2.7  
F-B: Mean, 2.7 
B: Mean, 0 
F: Mean, 1.3  
F-B: Mean, 1.3 
Targan, 199743 Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
No 
Incidence  
10 / 26 (37%) 
Incidence  
1 / 24 (4%) 
Targan, 199743 Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
No 
Incidence  
8 / 27 (30%) 
Incidence  
2 / 25 (8%) 
Targan, 199743 Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Endoscopic healing 
(CDEIS) @ 4 wks 
NA 
Yes 
B: Mean, 15 (SE, 7) 
F: Mean, 6 (SE, 5) P: 
<0.01  
F-B: Mean, -8.7 
B: Mean, 8 (SE, 6) 
F: Mean, 7 (SE, 5) P: 
<0.01  
F-B: Mean, -0.9 
Targan, 199743 Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
HR QoL (IBDQ) @ 4 
wks 
NA 
No 
B: Mean, 122 (SD, 29) 
F: Mean, 168 (SD, 36)  
F-B: Mean, 46 
B: Mean, 128 (SD, 29) 
F: Mean, 133 (SD, 28)  
F-B: Mean, 5 P: <0.001 
Targan, 199743 Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
No 
Incidence  
5 / 23 (20%) 
Incidence  
1 / 24 (4%) P: NS 
Targan, 199743 Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
No 
Incidence  
5 / 28 (18%) 
Incidence  
2 / 25 (8%) 
Targan, 199743 Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Endoscopic healing 
(CDEIS) @ 4 wks 
NA 
Yes 
B: Mean, 11 (SE, 8) 
F: Mean, 4 (SE, 5) P: 
<0.01  
F-B: Mean, -6.3 
B: Mean, 8 (SE, 6) 
F: Mean, 7 (SE, 5) P: 
<0.01  
F-B: Mean, -0.9 
Targan, 199743 Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
HR QoL (IBDQ) @ 4 
wks 
NA 
No 
B: Mean, 116 (SD, 23) 
F: Mean, 146 (SD, 41)  
F-B: Mean, 30 
B: Mean, 128 (SD, 29) 
F: Mean, 133 (SD, 28)  
F-B: Mean, 5 P: 0.02 
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Targan, 199743 Infliximab 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
No 
Incidence  
6 / 28 (20%) 
Incidence  
1 / 24 (4%) P: NS 
Targan, 199743 Infliximab 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
No 
Incidence  
7 / 28 (25%) 
Incidence  
2 / 25 (8%) 
Targan, 199743 Infliximab 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Endoscopic healing 
(CDEIS) @ 4 wks 
NA 
Yes 
B: Mean, 13.3 (SE, 6.9) 
F: Mean, 5.2 (SE, 2.8) P: 
<0.01  
F-B: Mean, -8.1 
B: Mean, 8.4 (SE, 6.3) 
F: Mean, 7.5 (SE, 5.4) P: 
<0.01  
F-B: Mean, -0.9 
Targan, 199743 Infliximab 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
HR QoL (IBDQ) @ 4 
wks 
NA 
No 
B: Mean, 118 (SD, 28) 
F: Mean, 149 (SD, 35)  
F-B: Mean, 31 
B: Mean, 128 (SD, 29) 
F: Mean, 133 (SD, 28)  
F-B: Mean, 5 P: 0.03 
Campieri, 
199768 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 4.5 mg every 12 hrs 
+ NA every 24 hrs 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
NR 
Incidence  
16 / 61 (27%) 
Incidence  
21 / 58 (37%) 
Campieri, 
199768 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 4.5 mg every 12 hrs 
+ NA every 24 hrs 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
NR 
Incidence  
31 / 61 (51%) 
Incidence  
31 / 58 (53%) 
Campieri, 
199768 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA 
every 24 hrs 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
NR 
Incidence  
28 / 58 (48%) 
Incidence  
21 / 58 (37%) 
Campieri, 
199768 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg daily + NA 
every 24 hrs 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg daily + NA 
every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
NR 
Incidence  
34 / 58 (58%) 
Incidence  
31 / 58 (53%) 
Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg daily 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg daily + 1 
mg/kg daily 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
19 / 30 (63%) 
Incidence  
24 / 33 (73%) P: 0.6 
Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg daily 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg daily + 1 
mg/kg daily 
CDAI (Remission: 
CDAI < 150) @ 60 
wks 
NA  
NA 
Incidence  
2 / 30 (7%) 
Incidence  
14 / 33 (42%) P: 0.001 
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Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg daily 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg daily + 1 
mg/kg daily 
CDAI (Remission: 
CDAI<175) @ 64 
wks 
NA 
Yes 
Incidence  
14 / 33 (42%) 
RR: 6.36 (1.6 to 25.7) 
Incidence  
2 / 30 (7%) P: 0.001 
Gross, 199572 (6)-Methylprednisolone 
Route: Oral 
Dose: 48 mg/d every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 1.5 g every 8 hrs 
CDAI (Remission: 
CDAI<150 and 60-pt 
drop) @ 2 wks 
NA 
Yes 
Incidence  
1 / 16 (8%) 
Incidence  
1 / 15 (8%) 
Gross, 199572 (6)-Methylprednisolone 
Route: Oral 
Dose: 48 mg/d every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 1.5 g every 8 hrs 
CDAI (Remission: 
CDAI<150 and 60-pt 
drop) @ 8 wks 
NA 
Yes 
Incidence  
9 / 16 (56.3%) 
Incidence  
6 / 15 (40%) P: 0.5867 
Feagan, 
199563 
Methotrexate + prednisone 
Route: IM + Oral 
Dose: 25 mg weekly 
Placebo + prednisone 
Route: IM + Oral 
Dose: NA weekly + daily 
CDAI (Remission: 
discontinuation of 
prednisone therapy 
and CDAI ≤ 150 pts) 
@ 16 wks 
NA 
Yes 
Incidence  
37 / 94 (39%) 
RR: 1.95 (1.09 to 3.48) 
P: 0.025 vs. main 
Incidence  
9 / 47 (19%) P: 0.025 
Feagan, 
199563 
Methotrexate + prednisone 
Route: IM + Oral 
Dose: 25 mg weekly 
Placebo + prednisone 
Route: IM + Oral 
Dose: NA weekly + daily 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 162 
F: Mean, 167  
F-B: Mean, 5 
B: Mean, 159 
F: Mean, 161  
F-B: Mean, 2 
Feagan, 
199563 
Methotrexate + prednisone 
Route: IM + Oral 
Dose: 25 mg weekly 
Placebo + prednisone 
Route: IM + Oral 
Dose: NA weekly + daily 
HR QoL (IBDQ) @ 
16 wks 
NA 
Yes 
B: Mean, 162 (SE, 17) 
F: Mean, 169 (SE, 4) P: 
<.002  
F-B: Mean, 7 
B: Mean, 159 (SE, 5) 
F: Mean, 151 (SE, 6) P: 
<.002  
F-B: Mean, -8 
Tremaine, 
199477 
Mesalamine (Asacol) 
Route: Oral 
Dose: 800 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
CDAI (Remission: 
CDAI<150 and 70 pt 
drop) @ 16 wks 
NA 
Yes 
Incidence  
9 / 20 (45%) 
Incidence  
4 / 18 (22%) 
Rutgeerts, 
199469 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg every 24 hrs + 
NA daily 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg every 24 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
48 / 88 (56%) 
Incidence  
39 / 88 (45%) P: 0.22 
Rutgeerts, 
199469 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 40 mg every 24 hrs + 
NA daily 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 9 mg every 24 hrs 
CDAI (Remission: 
CDAI < 150) @ 10 
wks 
NA 
Yes 
Incidence  
58 / 88 (66%) 
Incidence  
47 / 88 (53%) P: 0.12 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
7 / 67 (10%) 
Incidence  
7 / 66 (11%) 
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Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
22 / 67 (33%) 
Incidence  
13 / 66 (20%) P: 0.13 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI >150 and 60-
pt increase) 
NA  
NA 
Event rate  
124 events 
Event rate  
39 events 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI >150 and 60-
pt increase) @ 52 
wks 
NA  
NA 
Incidence  
23 / 33 (70%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 131 
F: Mean, 142  
F-B: Mean, 11 
B: Mean, 130 
F: Mean, 141  
F-B: Mean, 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 131 
F: Mean, 140  
F-B: Mean, 9 
B: Mean, 130 
F: Mean, 141  
F-B: Mean, 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
12 wks 
NA  
NA 
B: Mean, 185 (SD, 21) 
F: Mean, 170 (SD, 39)  
F-B: Mean, -15 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35)  
F-B: Mean, -27 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
52 wks 
NA  
NA 
B: Mean, 185 (SD, 21) 
F: Mean, 156 (SD, 39)  
F-B: Mean, -29 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38)  
F-B: Mean, -31 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI >150 and 60-
pt increase) 
NA  
NA 
Event rate  
178 days 
Event rate  
39 events / ds 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI >150 and 60-
pt increase) @ 52 
wks 
NA  
NA 
Incidence  
22 / 36 (61%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
21 / 61 (34%) 
Incidence  
7 / 66 (11%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
31 / 61 (51%) 
Incidence  
13 / 66 (20%) P: <0.001 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 125 
F: Mean, 157 P: 0.0002  
F-B: Mean, 32 
B: Mean, 130 
F: Mean, 141 P: 0.0002  
F-B: Mean, 11 
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Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 125 
F: Mean, 166 P: <0.001  
F-B: Mean, 41 
B: Mean, 130 
F: Mean, 141 P: <0.001  
F-B: Mean, 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
12 wks 
NA  
NA 
B: Mean, 184 (SD, 24) 
F: Mean, 172 (SD, 35)  
F-B: Mean, -12 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35)  
F-B: Mean, -27 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
52 wks 
NA  
NA 
B: Mean, 184 (SD, 24) 
F: Mean, 161 (SD, 36)  
F-B: Mean, -23 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38)  
F-B: Mean, -31 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
17 / 64 (27%) 
Incidence  
7 / 66 (11%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
28 / 64 (43%) 
Incidence  
13 / 66 (20%) P: 0.009 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 130 
F: Mean, 155 P: 0.006  
F-B: Mean, 25 
B: Mean, 130 
F: Mean, 141 P: 0.006  
F-B: Mean, 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 130 
F: Mean, 154 P: 0.012  
F-B: Mean, 24 
B: Mean, 130 
F: Mean, 141 P: 0.012  
F-B: Mean, 11 
Ewe, 199354 Azathioprine + 
prednisolone 
Dose: 2.5 mg/kg daily + 60 
mg daily 
Placebo + prednisolone 
Dose: 60 mg daily 
CDAI (Remission: 
CDAI < 150) 
NA 
NR 
Incidence  
16 / 21 (76%) 
Incidence  
8 / 21 (38%) P: 0.061 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
25 / 42 (60%) 
Incidence  
32 / 42 (75%) P: ns 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period) @ 104 wks 
NA 
No 
Incidence  
45 / 75 (60%) 
 P: NS 
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Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
56 / 75 (75%) 
 P: <0.05 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
49 / 75 (65%) 
 P: <0.05 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: IV 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
25 / 38 (65%) 
Incidence  
32 / 42 (75%) P: ns 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
40 / 75 (53%) 
 P: <0.001 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
49 / 75 (65%) 
 P: <0.001 
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Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
38 / 75 (50%) 
 P: NS 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
32 / 42 (75%) P: <0.05 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
48 / 74 (65%) 
 P: <0.001 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
48 / 74 (65%) 
 P: NS 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
49 / 75 (65%) 
Incidence  
51 / 68 (75%) 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
56 / 75 (75%) 
Incidence  
61 / 68 (90%) 
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Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
45 / 75 (60%) 
Incidence  
44 / 68 (65%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
40 / 75 (53%) 
Incidence  
51 / 68 (75%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
49 / 75 (65%) 
Incidence  
61 / 68 (90%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
38 / 75 (50%) 
Incidence  
44 / 68 (65%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
51 / 68 (75%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period) @ 104 wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
44 / 68 (65%) 
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Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
61 / 68 (90%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: IV 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
25 / 38 (65%) 
Incidence  
25 / 42 (60%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
25 / 42 (60%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
40 / 75 (53%) 
Incidence  
49 / 75 (65%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
49 / 75 (65%) 
Incidence  
56 / 75 (75%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
38 / 75 (50%) 
Incidence  
45 / 75 (60%) 
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Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
49 / 75 (65%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
56 / 75 (75%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
45 / 75 (60%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: IV 
Dose: 48 mg every 24 hrs 
CDAI (Relapse rate: 
failure to fall to less 
than 150 points or 
rise to above 150) 
@ 104 wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
25 / 38 (65%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
CDAI (Relapse rate: 
increase to more 
than 150 or in 
patients with active 
disease at 
randomization did 
not fall to less than 
150 after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
23 / 38 (60%) 
Incidence  
40 / 75 (53%) 
D-101 
 
 
Evidence Table 4. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
inducing remission (KQ1) 
 
Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
CDAI (Relapse rate: 
rise of CDAI to over 
150 during the study 
period.) @ 104 wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
38 / 75 (50%) 
Malchow, 
198464 
Sulfasalazine + 
prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
CDAI (Relapse rate: 
CDAI not coming 
down to less than 
150 even after 2 AP 
treatments) @ 104 
wks 
NA 
No 
Incidence  
48 / 74 (65%) 
Incidence  
49 / 75 (65%) 
Present, 
198060 
6-MP 
Route: Unknown 
Dose: 1.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Steroid free 
(stopping steroid 
use in patients) @ 
104 wks 
NA 
No 
Incidence  
24 / 44 (55%) 
Incidence  
14 / 39 (36%) 
Singleton, 
197975 
Sulfasalazine + prednisone 
Route: Oral + Unknown 
Dose: 1g per 15kg body 
weight to 5g max daily + 
daily 
Placebo + prednisone 
Route: Unknown + Oral 
Dose: NA + daily 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
NR 
Incidence  
25 / 43 (57%) 
Incidence  
35 / 46 (76%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs daily 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
5 / 74 (7%) 
Incidence  
4 / 77 (5%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs daily 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
11 / 74 (15%) 
Incidence  
17 / 77 (22%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs daily 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
39 / 74 (53%) 
Incidence  
38 / 77 (50%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs daily 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
33 / 74 (45%) 
Incidence  
23 / 77 (30%) P: 0.08 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs daily 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
2 / 9 (22%) 
Incidence  
1 / 9 (11%) 
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Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
dose of prednisone is 
1/4mg/kg, if CDAI = 150-
300 then prednisone was 
dosed at 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
11 / 85 (13%) 
Incidence  
4 / 77 (5%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
25 / 85 (29%) 
Incidence  
17 / 77 (22%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
66 / 85 (78%) 
Incidence  
38 / 77 (50%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
51 / 85 (60%) 
Incidence  
23 / 77 (30%) P: <0.0001 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
dose of prednisone is 
1/4mg/kg, if CDAI = 150-
300 then prednisone was 
dosed at 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
3 / 10 (30%) 
Incidence  
1 / 9 (11%) 
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Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
13 / 59 (22%) 
Incidence  
17 / 77 (22%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
1 / 59 (2%) 
Incidence  
4 / 77 (5%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
25 / 59 (43%) 
Incidence  
23 / 77 (30%) P: 0.17 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
32 / 59 (55%) 
Incidence  
38 / 77 (50%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 8 (12%) 
Incidence  
1 / 9 (11%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
25 / 85 (29%) 
Incidence  
11 / 74 (15%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
11 / 85 (13%) 
Incidence  
5 / 74 (7%) 
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Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
66 / 85 (78%) 
Incidence  
39 / 74 (53%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
51 / 85 (60%) 
Incidence  
33 / 74 (45%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
3 / 10 (30%) 
Incidence  
2 / 9 (22%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
1 / 59 (2%) 
Incidence  
5 / 74 (7%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
13 / 59 (22%) 
Incidence  
11 / 74 (15%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
25 / 59 (43%) 
Incidence  
33 / 74 (45%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
32 / 59 (55%) 
Incidence  
39 / 74 (53%) 
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Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 8 (12%) 
Incidence  
2 / 9 (22%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
13 / 59 (22%) 
Incidence  
25 / 85 (29%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
CDAI (Remission: 
CDAI < 150) @1 wk 
NA 
Yes 
Incidence  
1 / 59 (2%) 
Incidence  
11 / 85 (13%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
25 / 59 (43%) 
Incidence  
51 / 85 (60%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
CDAI (Remission: 
CDAI < 150) @ 17 
wks 
NA 
No 
Incidence  
32 / 59 (55%) 
Incidence  
66 / 85 (78%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 then 1/2mg/kg, if CDAI 
>300 then 3/4mg/kg every 
24 hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 8 (12%) 
Incidence  
3 / 10 (30%) 
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Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
(Relapse rate: 
Cumulative 
probability of 
relapse after 6 mos 
relapse clinically 
defined) @ 24 wks 
NA 
No 
G1-G2: Mean, 0% G1-G2: Mean, 25% P: 
<0.01 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
(Relapse rate: 
Cumulative 
probability of 
relapse after 6 mos 
relapse clinically 
defined) @ 52 wks 
NA 
No 
G1-G2: Mean, 5% G1-G2: Mean, 41% P: 
<0.01 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Unnamed disease 
activity score (Score 
change from 
baseline) @ 52 wks 
NA 
No 
F-B: Mean, 0.63 P: <0.05 
G1-G2: 1.8 
F-B: Mean, 2.46 
G1-G2: 1.8 
Klein, 197462 Azathioprine 
Route: Oral 
Dose: 3 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Reduction of 
steroids (reduction 
in the average dose 
of prednisone) @ 16 
wks 
NA 
No 
B: Mean, 13.3 (SD, 3.5) 
F: Mean, 6.3 (SD, 1.6)  
F-B: Mean, -7 
B: Mean, 19.8 (SD, 5.9) 
F: Mean, 7.8 (SD, 3)  
F-B: Mean, -12 
Klein, 197462 Azathioprine 
Route: Oral 
Dose: 3 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Reduction of 
steroids (reduction 
in the dose of 
prednisone) @ 32 
wks 
NA 
No 
B: Mean, 4.4 
F: Mean, 1.7  
F-B: Mean, -2.7 
B: Mean, 5.2 
F: Mean, 5  
F-B: Mean, -0.2 
Klein, 197462 Azathioprine 
Route: Oral 
Dose: 3 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
HR QoL (subjective 
feeling of 
improvement) @ 16 
wks 
NA 
No 
Incidence  
6 / 13 (46%) 
Incidence  
6 / 13 (46%) 
Klein, 197462 Azathioprine 
Route: Oral 
Dose: 3 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
HR QoL (subjective 
feeling of no 
change) @ 16 wks 
NA 
No 
Incidence  
5 / 13 (38%) 
Incidence  
5 / 13 (38%) 
Rhodes, 
197161 
Azathioprine 
Route: Oral 
Dose: 4 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
HR QoL (Subjective 
feeling of being 
better after 
treatment) @ 8 wks 
NA 
NR 
Incidence  
0 / 8 (0%) 
Incidence  
0 / 7 (0%) 
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Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Rhodes, 
197161 
Azathioprine 
Route: Oral 
Dose: 4 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
HR QoL (subjective 
feeling of being 
worse after 
treatment) @ 8 wks 
NA 
No 
Incidence  
2 / 8 (25%) 
Incidence  
1 / 7 (14%) 
Rhodes, 
197161 
Azathioprine 
Route: Oral 
Dose: 4 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
HR QoL (Subjective 
feeling of 'No 
difference' after 
treatment) @ 8 wks 
NA 
No 
Incidence  
6 / 8 (75%) 
Incidence  
6 / 7 (86%) 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 1 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
50-point drop and a 
final CDAI < 151) @ 
16 wks 
NA 
Yes 
Incidence  
18 / 80 (23%) 
Incidence  
14 / 80 (18%) 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 1 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
HBI (Absolute HBI) 
@ 16 wks 
NA 
Yes 
F-B: Mean, -0.4 (SE, 0.5) F-B: Mean, -0.9 (SE, 0.5) 
G1-G2: -0.5 P: NS 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
50-point drop and a 
final CDAI < 151) @ 
16 wks 
NA 
Yes 
Incidence  
18 / 75 (24%) 
Incidence  
14 / 80 (18%) P: NS 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 2 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
HBI (Absolute HBI) 
@ 16 wks 
NA 
Yes 
F-B: Mean, -1.2 (SE, 0.5) F-B: Mean, -0.9 (SE, 0.5) 
G1-G2: 0.3 P: NS 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 4 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
CDAI (Remission: 
50-point drop and a 
final CDAI < 151) @ 
16 wks 
NA 
Yes 
Incidence  
32 / 75 (43%) 
Incidence  
14 / 80 (18%) P: 0.0017 
Singleton, 
199379 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 4 g daily 
Placebo 
Route: Oral 
Dose: NA daily 
HBI (Absolute HBI) 
@ 16 wks 
NA 
Yes 
F-B: Mean, -2.8 (SE, 0.5) F-B: Mean, -0.9 (SE, 0.5) 
G1-G2: 1.9 P: 0.0054 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Perianal disease 
activity index) @ 2 
wks 
NA 
No 
B: Median, 8 (IQR, 7 to 
10) 
F: Median, 6 (IQR, 3 to 7) 
P: 0.02 
B: Median, 9 (IQR, 7 to 
10.5) 
F: Median, 8 (IQR, 6 to 
10) P: 0.02 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Perianal Disease 
Activity Index) @ 18 
wks 
NA 
No 
B: Median, 8 (IQR, 7 to 
10) 
F: Median, 4 (IQR, 1 to 7) 
P: 0.05 
B: Median, 9 (IQR, 7 to 
10.5) 
F: Median, 7 (IQR, 4 to 9) 
P: 0.05 
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Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(50% fistula closure) 
@ 18 wks 
NA 
Yes 
Incidence  
21 / 31 (68%) 
Incidence  
8 / 31 (26%) P: 0.002 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Complete fistula 
closure) @ 18 wks 
NA 
Yes 
Incidence  
17 / 31 (55%) 
Incidence  
4 / 31 (13%) P: 0.001 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Perianal disease 
activity index) @ 2 
wks 
NA 
No 
B: Median, 10 (IQR, 8 to 
12) 
F: Median, 6 (IQR, 4 to 8) 
P: 0.04 
B: Median, 9 (IQR, 7 to 
10.5) 
F: Median, 8 (IQR, 6 to 
10) P: 0.04 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Perianal Disease 
Activity Index) @ 18 
wks 
NA 
No 
B: Median, 10 (IQR, 8 to 
12) 
F: Median, 5 (IQR, 3 to 8) 
P: 0.14 
B: Median, 9 (IQR, 7 to 
10.5) 
F: Median, 7 (IQR, 4 to 9) 
P: 0.14 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(50% fistula closure) 
@ 18 wks 
NA 
Yes 
Incidence  
18 / 31 (58%) 
Incidence  
8 / 31 (26%) P: 0.02 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Perianal disease 
(Complete fistula 
closure) @ 18 wks 
NA 
Yes 
Incidence  
12 / 32 (38%) 
Incidence  
4 / 31 (13%) P: 0.04 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
No 
Incidence  
12 / 26 (46%) 
Incidence  
9 / 19 (47%) 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University quality of 
life index) @ 2 wks 
NA 
No 
G1-G2: Mean, 24 G1-G2: Mean, 6 P: 
<0.005 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life index) @ 12 wks 
NA  
NA 
G1-G2: Mean, 38 G1-G2: Mean, 36 P: NS 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life - Bowel 
symptoms) @ 12 
wks 
NA  
NA 
G1-G2: Mean, 38 G1-G2: Mean, 38 P: NS 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life index - 
Emotional function) 
@ 12 wks 
NA 
No 
G1-G2: Mean, 26 G1-G2: Mean, 26 P: NS 
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Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life index - Social 
Function) @ 12 wks 
NA 
No 
G1-G2: Mean, 38 G1-G2: Mean, 44 P: NS 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life index - systemic 
symptoms) @ 2 wks 
NA 
No 
G1-G2: Mean, 42 G1-G2: Mean, 2 P: <0.05 
Martin F, 
199073 
Prednisone 
Route: Oral 
Dose: 40 mg every 24 hrs 
ASA (Salofalk) 
Route: Oral 
Dose: 250 mg every 8 hrs 
HR QoL (McMaster 
University Quality of 
life index - systemic 
symptoms) @ 12 
wks 
NA 
No 
G1-G2: Mean, 50 G1-G2: Mean, 48 P: NS 
Schreiber, 
201142 
Certolizumab pegol 
Route: SC 
Dose: 400 mg sc once 
Placebo Remission (CDAI < 
150) @ 2 wks 
NA 
Yes 
Incidence 
50 / 215 (23%) 
Incidence 
33 / 209 (16%) P = 0.03 
Schreiber, 
201142 
Certolizumab pegol 
Route: SC 
Dose: 400 mg sc once 
Placebo HR QoL (IBDQ 
Remission) @ 2 
wsks 
NA 
Yes 
55 / 215 (26%) 38 / 209 (18%) P = 0.059 
Abbreviations: 95% CI = 95% Confidence Interval; 6-MP = 6-Mercaptopurine; @ = at; AP = Acute Phase; ASA = Aminosalicylates; CDAI = Crohn’s Disease Activity Index; 
CDEIS = Crohn’s Disease Endoscopic Index of Severity; g = gram; g/kgs = gram/kilograms; HBI = Harvey-Bradshaw Index; HR QoL= Health-related Quality of Life; hrs = 
hours; IBDQ = Inflammatory Bowel Disease Questionnaire; IFX= Infliximab; IM = intramuscular; IV= intravenous; IQR= inter-quartile range; kg = kilogram; Max. = maximum; 
mg = milligram; mg/d = milligram/day; mg/kg = milligram/kilogram; mg/mo = milligram/month; Min. = minimum; Mo/mos= month(s); NA = Not Applicable; NR= Not 
Reported; NS = not significant; OR: Odds Ratio; PGWB = Psychological General Well-Being; P = p-value; pt = point; SES-CD = Simplified Endoscopic Activity Score for 
Crohn’s Disease; SC = subcutaneous; SD = standard deviation; SE= standard error; Steroid free = steroid-free remission; TNF = tumor necrosis factor; TPMT= thiopurine 
methyltransferase; UTD = unable to determine; and wks = weeks.  
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Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Randomized controlled trials evaluating biologics 
Colombel, 
201045  
Yes Yes Yes Yes Yes Yes Yes Fair 
D'Haens, 200848  Yes Yes No Unclear No Yes No Poor 
Gordon, 200134  Unclear Yes Yes Yes No Yes Yes Poor 
Hanauer, 200637  Yes Yes Yes Yes Yes Yes Yes Good 
Lemann, 200646  Yes Yes Yes Yes Yes Yes No Good 
Present, 199944  Yes Yes Yes Yes Yes Yes Yes Good 
Sandborn, 
200533  
Yes Yes Yes Unclear Yes Yes Yes Fair 
Sandborn, 
200739  
Yes Yes Yes Yes No Yes Yes Poor 
Sandborn, 
200738  
Yes Yes Yes Yes Yes Yes Yes Good 
Sands, 200735  Yes Yes Yes Yes Yes Yes Yes Good 
Schreiber, 
200540  
Yes Yes Yes Unclear Yes Yes Yes Fair 
Schreiber, 
201142 
Yes Yes  Yes Unclear No Yes Yes Fair 
Schroder, 
200647  
Unclear Unclear No Unclear No No No Poor 
Targan, 199743  Yes Yes Yes Unclear No Yes Yes Fair 
Targan, 200732  Yes Yes Yes Yes Yes Yes Yes Good 
Winter, 200441  Unclear Unclear Yes Yes No Yes Yes Fair 
Randomized controlled trials evaluating thiopurines 
Ardizzone, 
200358  
Yes Yes No Yes Yes UTD NA Good 
Candy, 199553  Unclear Yes Unclear Unclear Yes UTD NA Fair 
Ewe, 199354  Unclear Unclear Unclear Yes Yes Yes UTD Poor 
Klein, 197462  Unclear Unclear Yes Yes Unclear Yes UTD Fair 
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Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Lemann, 200646  Yes Yes Yes Yes Yes Yes UTD Good 
Markowitz, 
2000192  
Yes Yes Yes Yes Yes No NA Good 
Mate-Jimenez, 
200052  
Unclear Unclear Unclear Yes Yes No NA Good 
O'Donoghue, 
1978100  
Unclear Unclear Yes Yes Yes UTD NA Good 
Oren, 199757  Unclear Unclear Yes Yes Unclear No NA Fair 
Present, 198060  Yes Unclear Unclear No No UTD UTD Poor 
Reinisch, 200851  Yes Unclear Unclear Yes No Yes Yes Fair 
Rhodes, 197161  Unclear Unclear Yes Yes No Yes UTD Poor 
Sandborn, 
199959  
Yes Yes Yes Unclear Yes UTD NA Fair 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Randomized controlled trials evaluating methotrexate 
Feagan, 199563  Unclear Unclear Yes Yes Unclear Yes No Fair 
Mate-Jimenez, 
200052  
Unclear Unclear Unclear Yes Yes No NA Good 
Oren, 199757  Unclear Unclear Yes Yes Unclear No NA Fair 
Randomized controlled trials evaluating corticosteroids 
Bar-Meir, 199867  Yes Yes Yes Yes No UTD NA Good 
Campieri, 
199768  
Unclear Unclear Yes Unclear Yes Yes Yes Fair 
Escher, 2004190  Yes Yes Yes Yes Yes Yes Yes Good 
Greenberg, 
199466  
Unclear Unclear Unclear Unclear No Yes Yes Fair 
Gross, 199572  Unclear Yes Yes Yes No Yes UTD Poor 
Levine, 2003191  Unclear Unclear Unclear Unclear Unclear UTD NA Poor 
Malchow, 
198464  
Unclear Yes Yes No No Yes UTD Fair 
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Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Martin F, 199073  Yes Yes Yes Yes Yes UTD NA Good 
Prantera, 199971  Yes Yes Yes Yes Unclear No NA Fair 
Rutgeerts, 
199469  
Yes Yes Yes Yes Yes Yes UTD Good 
Schoon, 2005185  Yes Yes No Yes No Yes Yes Poor 
Singleton, 
197975  
Unclear Unclear Yes Yes Yes No NA Good 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Thomsen, 
199870  
Yes Yes Yes No No Yes Yes Poor 
Tremaine, 
200265  
Yes Yes Yes No No Yes Yes Poor 
Randomized controlled trials evaluating 5-aminosalicylate acids 
Griffiths, 1993221  Yes Unclear Yes No Yes Yes UTD Fair 
Malchow, 
198464  
Unclear Yes Yes No No Yes UTD Fair 
Singleton, 
199379  
Unclear Unclear Yes Yes Yes UTD NA Good 
Singleton, 
1995222  
Unclear Unclear Unclear Yes Yes Yes Yes Fair 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Tremaine, 
199477  
Unclear Unclear Yes Yes Yes Yes UTD Fair 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Study Quality Criteria: Criteria for a judgment of “GOOD” (i.e. low risk of bias): These studies have the least bias and results are considered valid- A study that adheres mostly to 
the commonly held concepts of high quality including the following: a) A formal randomized controlled study; b)Clear description of the population, setting, interventions, and 
comparison groups; c) Appropriate measurements of outcomes; d) Appropriate statistical and analytic methods and reporting; e) No reporting errors; f) Low dropout rate; and g) 
Clear reporting of dropouts. Criteria for a judgment of “FAIR”: a) These studies are susceptible to some bias, but it is not sufficient to invalidate the results; b) do not meet all the 
criteria required for a rating of good qualities because they have some deficiencies, but no flaw is likely to cause major bias; and c) The study may be missing information, making 
it difficult to assess limitations and potential problems. Criteria for a judgment of “POOR” (i.e. high risk of bias): a) These studies have significant flaws that imply biases of 
various types that may invalidate the results; b) Have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.  
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Natalizumab vs. 
placebo–wk 48 
Disease activity 
measures 
1 (339)33 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
RD, 33%; placebo rate, 22%  
 
SOE: Moderate 
Natalizumab vs. 
placebo–wk 48 
Reduction of 
steroids 
1 (143)33 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
RD, 27%; placebo rate, 15%  
 
SOE: Moderate 
Natalizumab vs. 
placebo–wk 48 
Patient-reported 
outcomes 
1 (217)81 Medium Unknown 
(single study) 
Direct Precise Favors natalizumab 
Absolute between-group 
difference in change in mean 
IBDQ from randomization to 
induction trial, 19 pts; placebo 
change in mean IBDQ, -23 pts  
 
SOE: Moderate 
Adalimumab vs. 
placebo–wk 52 
Disease activity 
measures 
2 (554)82 83 95 High Consistent Direct Precise Favors adalimumab 
RD range, 11% to 39%; placebo 
rate range, 12% to 44% 
 
SOE: Low 
Adalimumab vs. 
placebo–wk 52 
Hospitalization 1 (778)90 Medium Unknown 
(single study) 
Direct Precise Favors adalimumab for all-
cause hospitalizations 
Favors neither for Crohn’s 
disease related hospitalizations 
RD range, -6% to -13%; 
placebo rate range, 16% to 25% 
 
SOE: Moderate 
Adalimumab vs. 
placebo–wk 52 
Surgery 1 (778)90 Medium Unknown 
(single study) 
Direct Precise Favors neither 
RD, -3.4%; placebo rate, 3.8%  
 
SOE: Moderate 
Adalimumab vs. 
placebo–wk 52 
Reduction of 
steroids 
2 (219)82 83  High Consistent Direct Precise Favors adalimumab 
RD, 10% to 31%; placebo rate, 
6% to 57%  
 
SOE: Low 
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Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Adalimumab vs. 
placebo–wk 52 
Patient-reported 
outcomes 
2 (554)95 96 High Consistent Direct Precise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from randomization, 14 to 
22 pts; placebo mean change, -
10 to -25 pts  
 
SOE: Low 
CP vs. placebo–
wk 18 
Disease activity 
measures 
1 (428)84 Medium Unknown 
(single study) 
Indirect Precise Favors CP 
RD, 19%; placebo rate, 29% 
 
SOE: Low 
CP vs. placebo–
wk 18 
Patient-reported 
outcomes 
1 (424)84 Medium Unknown 
(single study) 
Indirect Precise Favors neither 
Difference in final adjusted 
mean IBDQ, 8 pts; final placebo 
mean, 163 pts 
 
SOE: Low 
Infliximab vs. 
placebo–wk 52 
Disease activity 
measures 
1 (573)86 94 High Unknown 
(single study) 
Direct Imprecise Favors neither among all 
randomized 
Favors infliximab among 
responders to induction 
RD range, 6% to 25%; placebo 
rate, 15% to 35% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 52 
Mucosal healing 1(58)91 94 High Unknown 
(single study) 
Direct Precise Favors infliximab 
RD, 26% to 43%; placebo rate, 
7% to 18% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 40, 
52 
Hospitalization 2 (855)92 94  Medium Consistent Direct Precise Favors infliximab 
Crohn’s disease-related 
hospitalizations per 100 
patients, 9 to 23 in infliximab 
group, 19 to 38 in placebo 
group  
 
SOE: Moderate 
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Infliximab vs. 
placebo–wk 52 
Surgery 1 (573)94  Medium Unknown 
(single study) 
Direct Precise Favors neither 
Rate of Crohn’s disease-related 
surgery, 3%; placebo rate, 8% 
 
SOE: Moderate 
Infliximab vs. 
placebo (patients 
with fistulas) –wk 
40 
Surgery 1 (195)92 Medium Unknown 
(single study) 
Direct Precise Favors infliximab 
Rate of Crohn’s disease-related 
surgery per 100 patients, 65; 
placebo rate per 100 patients, 
126 
 
SOE: Moderate 
Infliximab vs. 
placebo–wk 52 
Reduction of 
steroids 
1 (325)86  High Unknown 
(single study) 
Direct Precise Favors infliximab 
RD, 20%; placebo rate, 9% 
 
SOE: Low 
Infliximab vs. 
placebo–wk 40 
Fistula 
response 
1 (282)87  Medium Unknown 
(single study) 
Indirect Precise Favors infliximab 
RD, 17%; placebo rate, 19%  
 
SOE: Low 
Infliximab vs. 
placebo–wks 36-
52 
Patient-reported 
outcomes 
3 (603)85 87 93  High Inconsistent Direct Imprecise Favors infliximab 
Absolute between-group 
difference in change in median 
IBDQ -5 to 23 pts; placebo 
mean change, -31 to 9 pts  
 
SOE: Low 
Infliximab + 
azathioprine vs. 
infliximab–wk 
104 
Disease activity 
measures 
1 (80)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Absolute difference [with regard 
to need for infliximab stoppage 
or change in dosage interval], 
5%; infliximab alone rate, 55% 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
infliximab–wk 
104 
Mucosal healing 1 (49)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD for absence of ulcers, 3%; 
infliximab alone rate, 61% 
 
SOE: Low 
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Infliximab + 
azathioprine vs. 
infliximab–wk 
104 
Patient-reported 
outcomes 
1 (80)89 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Difference in overall median 
IBDQ, -2 pts; infliximab only 
median, 176 pts 
 
SOE: Low 
Infliximab + 
azathioprine vs. 
infliximab + 
hydrocortisone 
IV 
premedication–
wk 52, 104 
Disease activity 
measures 
1 (46)88 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD across time points, -5%; 
infliximab and hydrocortisone 
rate range, 77% to 84% 
 
SOE: Low  
Azathioprine (1 
mg/kg/d) vs. 
placebo - wks 
52, 104 
Disease activity 
measures 
1 (155)56 Medium Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, -11 to 5%; placebo rate, 40 
to 64% 
 
SOE: Low 
Azathioprine (1.7 
to 2.1 mg/kg/d) 
vs. placebo - wks 
52, 78, 104 
Disease activity 
measures 
3 (163)98 100 101 Medium Inconsistent Direct Imprecise Favors azathioprine 
RD, 13 to 39%; placebo rate, 47 
to 79% 
 
SOE: Low 
Azathioprine vs. 
placebo - wk 26 
Reduction of 
steroids 
1 (20)104  Medium Unknown 
(single study) 
Indirect Precise Favors azathioprine 
Absolute reduction in 
prednisone use from baseline, 
9.4 mg; placebo reduction, 6.1 
mg  
 
SOE: Low 
Azathioprine vs. 
budesonide - wk 
52 
Disease activity 
measures 
1 (77)102 Medium Unknown 
(single study) 
Direct Imprecise Favors azathioprine 
RD, 15%; budesonide rate, 64% 
 
SOE: Low 
Azathioprine vs. 
prednisone - wk 
52 
Disease activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors azathioprine 
RD, 12%; prednisone rate, 57%  
 
SOE: Low 
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Azathioprine vs. 
prednisone - wk 
104 
Disease activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
Wk 104: RD, -3%; corticosteroid 
rate, 32% 
 
SOE: Low 
Azathioprine vs. 
budesonide - wk 
52 
Mucosal healing 1 (77)102  Medium Unknown 
(single study) 
Direct Precise Favors azathioprine 
RD for absence of ulcers, 55%; 
budesonide rate, 5% 
 
SOE: Moderate 
Azathioprine vs. 
sulfasalazine - 
wks 52, 104 
Disease activity 
measures 
1 (115)56 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD range, -2% to 7%; 
sulfasalazine rate range, 31% to 
62% 
 
SOE: Low 
Methotrexate 
(intramuscular) 
vs. placebo – wk 
40 
Disease activity 
measures 
1 (76)105 Medium Unknown 
(single study) 
Indirect Precise Favors methotrexate 
RD, 26%; placebo rate, 39% 
 
SOE: Low 
Budesonide vs. 
placebo--wk 52 
Disease activity 
measures 
5 (557)106 108-111 Medium Inconsistent Direct Imprecise Favors neither 
3mg pooled RR, 1.0; CI, 0.8 to 
1.2; placebo rate, 33% to 40% 
 
6mg pooled RR, 1.2; CI, 0.9 to 
1.5; placebo rate, 33% to 42% 
 
SOE: Low 
Budesonide vs. 
placebo--wks 13 
and 52 
Patient-reported 
outcomes 
2 (122)107 111 Medium Consistent Direct Imprecise Favors neither 
Absolute between-group 
difference in change in mean 
IBDQ from baseline, 2 to 11 pts; 
placebo mean change, -4 to -31 
pts  
 
SOE: Low 
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Prednisone vs. 
placebo--wks 54 
and 104 
Disease activity 
measures 
1 (162)56 High Unknown 
(single study) 
Direct Imprecise Neither favored 
RD across time points, 0% to 
9%; placebo rate, 59% to 72% 
 
SOE: Low 
6-
methylprednisolo
ne vs. placebo--
wks 54 and 104 
Disease activity 
measures 
1 (118)64 High Unknown 
(single study) 
Direct Imprecise Favors 6-methylprednisolone 
RD across time points, 11% to 
12%; placebo rate, 32% to 48% 
 
SOE: Low 
Budesonide vs. 
mesalamine--wk 
52 
Disease activity 
measures 
1 (57)113 Medium Unknown 
(single study) 
Direct Precise Favors budesonide 
RD, 27%; mesalamine rate, 
18% 
 
SOE: Moderate 
Budesonide vs. 
mesalamine--wk 
52 
Patient-reported 
outcomes 
1 (57)113 Medium Unknown 
(single study) 
Direct Precise Favors budesonide 
Absolute between-group 
difference in change in mean 
IBDQ, 30 to 36 pts; mesalamine 
mean change, -51 to -76 pts  
 
SOE: Moderate 
Prednisone or 6-
methylprednisolo
ne vs. 
sulfasalazine --
wks 54, 104 
Disease activity 
measures 
2 (248)56 64 High Consistent Direct Imprecise Favors neither 
RD across time points, 5% to 
9%; ASA rate, 37% to 67% 
 
SOE: Low 
6-
methylprednisolo
ne + 
sulfasalazine vs. 
placebo--wks 54, 
104 
Disease activity 
measures 
1 (108)64 High Unknown 
(single study) 
Direct Imprecise Favors neither 
RD across time points, 2% to 
5%; placebo rate, 32% to 48% 
 
SOE: Low 
Steroids + 
sulfasalazine vs. 
steroids--wks 26-
54, 104 
Disease activity 
measures 
2 (181)64 75 Medium Inconsistent Direct Imprecise Favors neither 
RD across time points, -9% to  
-6%; steroid rate, 22% to 60% 
 
SOE: Low 
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Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
Comparison Outcome Number of trials 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
6- Disease activity 1(119)64 High Unknown Direct Imprecise Favors neither 
methylprednisolo measures (single study) RD, -3% to -2%; sulfasalazine 
ne + rate, 37% to 55% 
sulfasalazine vs.  
sulfasalazine-- SOE: Low 
wks 54, 104 
Mesalamine Disease activity 2 (309)117 119 High Consistent Direct Imprecise Favors mesalamine (controlled-
(controlled-
 release) vs. 
measures release) 
RD, 7 to 11%; placebo rate, 22 
placebo—wks to 58% 
48, 52  
SOE: Low 
Mesalamine Disease activity 1 (161)122 Low Unknown Direct Imprecise Favors neither 
(controlled-
 release) vs. 
measures (single study) RD, 6%; placebo rate, 
 
58% 
placebo—wk 104 SOE: Moderate 
Mesalamine Patient-reported 1 (246)117  Medium Unknown Direct Imprecise Favors neither 
(controlled- outcomes (single study) Absolute between-group 
release), vs. difference in change in mean 
placebo--wk 48 IBDQ, 1 pt; placebo mean 
change, -14 pts 
 
SOE: Low 
Mesalamine (pH-
 release) vs. 
Disease activity 
measures 
7 (756)115 118 120 
121 123 125 126 
Medium Inconsistent Direct Precise  Favors mesalamine (pH-
release) 
placebo—wk 52 RR, 1.1; 95% CI, 1.0 to 1.3 
 
SOE: Low 
Mesalamine (pH-
 release) vs. 
Disease activity 
measures 
1 (117)118 High Unknown 
(single study) 
Direct Imprecise Favors placebo 
RD, -17%; placebo rate, 42% 
placebo—wk 104  
SOE: Low 
Mesalamine (pH-
 release) vs. 
Disease activity 
measures 
1 (59)121 Medium Unknown 
(single study) 
Direct Imprecise Favors mesalamine (pH-
release) 
placebo—wk 208 RD, 18%; placebo rate, 29% 
 
SOE: Low 
D-120 
 
Evidence Table 6. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
maintenance of remission (KQ2) 
 
 
Abbreviations: ASA = aminosalicylates; CI = 95% confidence interval; CP = certolizumab pegol; HR = hazard ratio; IBDQ = Inflammatory Bowel Disease Questionnaire; IV = 
intravenous; mg = milligrams; NA = not applicable; OR = odds ratio; pts = points; RD = risk difference; RR = relative risk; SOE = strength of evidence; Steroids = corticosteroids; 
vs = versus; wk = weeks 
The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the 
estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may 
change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. Insufficient = Evidence is unavailable. 
Olsalazine vs. 
placebo—wk 52 
Disease activity 
measures 
1 (328)116 Low Unknown 
(single study) 
Direct Imprecise Favors neither 
RD, 2%; placebo rate, 74% 
 
SOE: Moderate 
Sulfasalazine vs. 
placebo—wks 
54, 104 
Disease activity 
measures 
2 (274)56 64 High Inconsistent Direct Imprecise Favors neither 
RD, -5 to 7%; placebo rate, 32 
to 72% 
 
SOE: Low 
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Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Randomized controlled trials evaluating biologics 
Colombel, 
200782 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2003 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of adalimumab, moderate-
severe disease, not pregnant, not nursing, using adequate contraception, 
no short bowel syndrome, no ostomy, no obstructive symptoms with 
strictures, no history of TB, no demyelinating disease, no cancer, other 
criteria 
Feagan, 
200781 
 
 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 48 
weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<220), no short bowel syndrome, no ostomy, no 
abscess, no obstructive symptoms with strictures, other criteria 
Feagan, 
200890 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2003 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (bowel resection in past 6 months), 
CDAI (220-450), no use of adalimumab, moderate-severe disease, not 
pregnant, not nursing, using adequate contraception, no short bowel 
syndrome, no ostomy, no obstructive symptoms with strictures, no history 
of TB, no demyelinating disease, no cancer, other criteria 
Hanauer, 
200286 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1999 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, 
Europe, Israel 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-400), previous use of antibiotics, 5-
aminosalicylate acids, corticosteroids, thiopurines, methotrexate, no use 
of TNF-alpha inhibitors, infliximab, other criteria 
Mantzaris, 
200988 
RCT, parallel 
arms with a 6-
week run-in 
period 
Start year: NR 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Number of 
centers NR 
Yes 
 
Yes 
Adults, CD only, CDAI (>180), active disease, not pregnant, not nursing, 
no history of TB, other criteria 
Rutgeerts, 
199985 
RCT, parallel 
arms with a 16-
week run-in 
period 
Start year: 1995 
 
Duration of 
assigned 
treatment: 36 
weeks 
US, North 
America, Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (proctocolectomy or total colectomy), 
CDAI (220-400), no ostomy, no obstructive symptoms with strictures, 
other criteria 
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Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Sandborn, 
200783 
 
 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2002 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), in remission for >4 weeks, inactive disease, 
using adequate contraception, other criteria 
Sands, 
200487 
RCT, parallel 
arms with a 14-
week run-in 
period 
Start year: 2000 
 
Duration of 
assigned 
treatment: 40 
weeks 
US, North 
America, 
Europe, Israel 
 
Multicenter 
No 
 
 
Adults, CD only, no use of infliximab, no abscess, no obstructive 
symptoms with strictures, other criteria 
Schreiber, 
200784 
RCT, parallel 
arms with a 6-
week run-in 
period 
Start year: 2004 
 
Duration of 
assigned 
treatment: 18 
weeks 
Worldwide 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors, 
infliximab, adalimumab, certolizumab pegol, no short bowel syndrome, no 
ostomy, no abscess, no obstructive symptoms with strictures, no history of 
TB, no demyelinating disease, no cancer, other criteria 
Van Assche, 
200889 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, adults, CD only, previous use of methotrexate, infliximab, 
immunosuppressives (azathioprine/6-MP or methotrexate), perianal 
fistulizing, not pregnant, not nursing, other criteria 
Randomized controlled trials evaluating thiopurines 
Candy, 
199553 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Africa 
 
Single center 
No 
 
 
Pediatrics, adults, CD only, no previous surgery (extensive surgery for 
Crohn's disease), CDAI (>200), not pregnant, not nursing, other criteria 
Lemann, 
200598 
RCT, parallel 
arms 
Start year: 1995 
 
Duration of 
assigned 
treatment: 18 
months 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (except limited perianal surgery in 
past 42 months), CDAI (<150), in remission for >42 months, previous use 
of azathioprine, no use of antibiotics, 5-aminosalicylate acids, 
corticosteroids, inactive disease, other criteria 
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Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Mantzaris, 
2009102 
RCT, parallel 
arms 
Start year: 1998 
 
Duration of 
assigned 
treatment: 1.5 
years 
Europe 
 
Number of 
centers NR 
Yes 
 
Yes 
Adults, CD only, no previous surgery (intestinal resection), CDAI (<150), 
previous use of corticosteroids, no use of infliximab, mesalamine-only 
maintenance therapy, effective prior treatment with azathioprine, perianal 
fistulizing, not pregnant, not nursing, no history of TB, other criteria 
O'Donoghue, 
1978100 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 6 
months 
Europe 
 
Single center 
Yes 
 
Yes 
Adults, CD only, in remission for >6 months, previous use of azathioprine, 
inactive disease 
Rosenberg, 
1975104 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 26 
weeks 
US 
 
Single center 
Yes 
 
Yes 
Adults, CD only, previous use of corticosteroids, not pregnant, not nursing, 
other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Vilien, 
2004101 
RCT, parallel 
arms 
Start year: 2000 
 
Duration of 
assigned 
treatment: 1 year 
Location: NR 
 
Number of 
centers NR 
No 
 
 
CD only, no previous surgery (in past 3 months), previous use of 
thiopurines, azathioprine, no use of corticosteroids, inactive disease, other 
criteria 
Willoughby 
JM, 197199 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 24 
weeks 
Europe 
 
Single center 
No 
 
 
CD only, previous use of corticosteroids, active and inactive disease 
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Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Randomized controlled trials evaluating methotrexate 
Feagan, 
2000105 
RCT, parallel 
arms 
Start year: 1993 
 
Duration of 
assigned 
treatment: NR 
US, North 
America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, previous use of methotrexate, inactive disease, not 
pregnant, no cancer, other criteria 
Randomized controlled trials evaluating corticosteroids 
Bergman, 
1976223 
RCT, parallel 
arms 
Start year: 1969 
 
Duration of 
assigned 
treatment: 33 
weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no use of corticosteroids, salazopyrine, azathioprine, 
other criteria 
Brignola, 
1988112 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 1983 
 
Duration of 
assigned 
treatment: 6 
months 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), LI >100, other criteria 
Cortot, 
2001107 
RCT, parallel 
arms 
Start year: 1996 
 
Duration of 
assigned 
treatment: 22 
weeks 
Europe, Asia, 
Africa 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (resection of ileum of >100 cm or 
who require immediate surgery), CDAI (<201), previous use of 
corticosteroids, inactive disease, not pregnant, not nursing, no ostomy, no 
abscess, no history of TB, other criteria 
de Franchis, 
1997118 
RCT, parallel 
arms with a 4-8-
week run-in 
period 
Start year: 1991 
 
Duration of 
assigned 
treatment: 24 
months 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (<150), previous use of corticosteroids, no use of 
immunomodulators in past 3 months, not pregnant, not nursing, no 
obstructive symptoms with strictures, other criteria 
Ferguson, 
1998108 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
months 
Europe, 
Australia 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (ileostomy or previous small bowel 
resection of >100 cm), CDAI (<150), inactive disease, not pregnant, not 
nursing, no ostomy, no abscess, other criteria 
D-125 
 
 
Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Greenberg, 
199466 
RCT, parallel 
arms 
Start year: 1991 
 
Duration of 
assigned 
treatment: 8 weeks 
North America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (>200), not pregnant, not nursing, no cancer, other 
criteria 
Greenberg, 
1996111 
RCT, parallel 
arms with a 8-
week run-in 
period 
Start year: 1992 
 
Duration of 
assigned 
treatment: 52 
weeks 
North America 
 
Multicenter 
Yes 
 
No 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, not nursing, 
no ostomy, no cancer, other criteria 
Gross, 
1998109 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: NR 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (<150), in remission for >8 weeks, previous use of 
prednisolone 
Hanauer, 
2005106 
RCT, parallel 
arms 
Start year: 1995 
 
Duration of 
assigned 
treatment: 52 
weeks 
US 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (ileostomy, colostomy, gastric 
surgery other than for closure of perforation or selective vagotomy or 
resection of ileum >100cm), CDAI (<150), in remission for >10 weeks, no 
use of immunomodulators in past 90 days, corticosteroids in past 14 days, 
mesalamine or NSAIDs for more than 3 consecutive days, inactive 
disease, not pregnant, not nursing, no history of TB, no cancer, other 
criteria 
Issenman, 
1993196 
Prospective 
cohort 
Start year: NR  
 
Mean followup 
duration: 2 years 
North America 
 
Single center 
NA Pediatrics, CD only, males, active disease 
Lofberg, 
1996110 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
months 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (ilestomy or prior small bowel 
resection >100 cm), CDAI (<150), no short bowel syndrome, no ostomy, 
other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Malchow, 
198464 
 
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Mantzaris, 
2003113 
RCT, parallel 
arms with a 1-
month run-in 
period 
Start year: 1994 
 
Duration of 
assigned 
treatment: 1 year 
Europe 
 
Single center 
No 
 
 
Adults, CD only, no previous surgery (intestinal resection), CDAI (<150), 
no use of mesalamine maintenance therapy, azathioprine unless 
withdrawn at least 3 months before start of trial due to side effects, 
inactive disease, not pregnant, not nursing, other criteria 
Singleton, 
197975 
 
 
RCT, parallel 
arms with a 8-
week run-in 
period 
Start year: NR 
 
Duration of 
assigned 
treatment: 6 
months 
US 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (<150), previous use of prednisone, sulfasalazine 
and prednisone, inactive disease, other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Randomized controlled trials evaluating aminosalicylates 
Arber, 
1995121 
RCT, parallel 
arms 
Start year: 1991 
 
Duration of 
assigned 
treatment: 12 
months 
Israel 
 
Multicenter 
Yes 
 
Yes 
CD only, HBI (<4), in remission for >6 months, other criteria 
Bresci G, 
1995125 
RCT, parallel 
arms with a 6-
week run-in 
period 
Start year: 1988 
 
Duration of 
assigned 
treatment: 4 years 
Europe 
 
Single center 
Yes 
 
Yes 
Adults, CD only, no previous surgery , CDAI (<150), Laboratory Index (LI) 
<100, inactive disease, not pregnant, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Brignola, 
1992124 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 4 
months 
Location: NR 
 
Single center 
Yes 
 
Yes 
CD only, CDAI (<150), Laboratory activity (LA) >100, in remission for >4 
weeks, no use of corticosteroids, corticosteroids in past 4 weeks, inactive 
disease 
Cezard, 
2009194 
RCT, parallel 
arms 
Start year: 1991 
 
Duration of 
assigned 
treatment: 1 year 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, CD only, HBI (>5), no use of 5-aminosalicylate acids, 
thiopurines, methotrexate, active disease, other criteria 
Gendre, 
1993122 
RCT, parallel 
arms 
Start year: 1985 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
Yes 
 
Yes 
CD only, CDAI (<150), in remission for >24 months, no use of 
corticosteroids, corticosteroids and immunomodulators in past month, 
inactive disease, not pregnant, other criteria 
Mahmud, 
2001116 
RCT, parallel 
arms 
Start year: 1992 
 
Duration of 
assigned 
treatment: 52 
weeks 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), in remission for >1 months, no use of 
corticosteroids, thiopurines, immunomodulators (other than ASA) not 
pregnant, not nursing, no obstructive symptoms with strictures, other 
criteria 
Malchow, 
198464 
 
 
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Prantera, 
1992123 
RCT, parallel 
arms 
Start year: 1988 
 
Duration of 
assigned 
treatment: 12 
months 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (<150), perianal fistulizing, no obstructive 
symptoms with strictures, other criteria 
D-128 
 
 
Evidence Table 7. Study design characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic 
therapies for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Prantera, 
2005115 
RCT, parallel 
arms with a 8-
week run-in 
period 
Start year: 2000 
 
Duration of 
assigned 
treatment: 12 
months 
Europe 
 
Multicenter 
No 
 
 
CD only, CDAI (150-400), mild-moderate disease, other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Sutherland, 
1997117 
RCT, parallel 
arms 
Start year: 1990 
 
Duration of 
assigned 
treatment: 11 
months 
North America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (proctocolectomy or history of >3 
resections in the last 10 years), CDAI (<150), no use of azathioprine, 6-
MP or cyclosporine in past 90 days, steroids in past 30 days, mesalamine 
or metronidazole in past 7 days, perianal fistulizing, no short bowel 
syndrome, no cancer, other criteria 
Thomson, 
1990224 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
months 
North America, 
Europe, Africa 
 
Multicenter 
Yes 
 
Yes 
Pediatrics, CD only, CDAI (<150), no use of azathioprine, metronidazole, 
no ostomy, no obstructive symptoms with strictures, other criteria 
Thomson, 
1995120 
RCT, parallel 
arms 
Start year: 1988 
 
Duration of 
assigned 
treatment: 12 
months 
US, North 
America, 
Europe, Asia, 
Africa 
 
Multicenter 
Yes 
 
No 
Adults, CD only, no previous surgery (ileostomy, colostomy, or bowel 
resection with >100 cm of bowel removed; or bowel resection in past 3 
months), CDAI (<150), no use of azathioprine, immunomodulators or 
systemic corticosteroids in past month, not pregnant, not nursing, using 
adequate contraception, no short bowel syndrome, no obstructive 
symptoms with strictures, no cancer, other criteria 
Wellmann W, 
1988126 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 1 year 
Europe 
 
Number of 
centers NR 
Yes 
 
Yes 
CD only, CDAI (<120), in remission for >3 months, no use of 
corticosteroids, corticosteroids in past 3 months, inactive disease 
Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; NA = not applicable; NR = not 
reported; RCT = randomized controlled trial; TAS = Trial of Adjunctive Sulfasalazine in Crohn's disease; TB = tuberculosis; US = United States 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Randomized controlled trials evaluating biologics 
Colombel, 
200782 
Adalimumab, 
157 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 39 
 
Race NR 
 
Smoking, % 
Current smoker, 
32 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location, % 
Ileal: 76 
Ileo-colonic: 54 
Colonic: 76 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 160 
 
IBDQ 
Mean: 165 
5ASA: 69 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 12 
 
Thiopurines: 38 
 
Immunomodulator
s: 50 
TNF-alpha 
inhibitors: 45 
Adalimumab: 
100 
Colombel, 
200782 
Adalimumab, 
172 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 36 
 
Race NR 
 
Smoking, % 
Current smoker, 
34 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.4 
Severity NR 
 
Location, % 
Ileal: 73 
Ileo-colonic: 47 
Colonic: 73 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 155 
 
IBDQ 
Mean: 175 
5ASA: 38 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 10 
 
Thiopurines: 36 
 
Immunomodulator
s: 45 
TNF-alpha 
inhibitors: 50 
Adalimumab: 
100 
Colombel, 
200782 
Placebo, 170 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 38 
 
Race NR 
 
Smoking, % 
Current smoker, 
37 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location, % 
Ileal: 66 
Ileo-colonic: 44 
Colonic: 76 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 170 
 
IBDQ 
Mean: 165 
5ASA: 46 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 8 
 
Thiopurines: 42 
 
Immunomodulator
s: 49 
TNF-alpha 
inhibitors: 48 
Adalimumab: 
100 
D-131 
 
 
Evidence Table 8. Population characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic therapies 
for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Feagan, 
200781 
 
 
Placebo, 33 
Route: IV 
Dose: NA every 
4 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Feagan, 
200781 
 
 
Placebo, 171 
Route: IV 
Dose: NA every 
4 weeks 
Male, %: 34.5 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
26.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.7 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 23.4 
Ileo-colonic: 49.7 
Colonic: 26.9 
 
Behavior NR 
 
CRP 
Mean: 9.4 
Median: 3.9 
Min: 0 
Max: 120 
CDAI 
Mean: 118 
 
IBDQ 
Mean: 121 
5ASA: 54.4 
 
Antibiotics: 5.8 
 
Corticosteroids: 
44.4 
 
Methotrexate: 4.7 
 
Thiopurines: 30.4 
 
Prednisone: 31.6 
 
Budesonide: 14 
 
>/= 1 
corticosteroid or 
immunomodulator
s: 60.2 
 
Corticosteroids 
and 
immunosuppressa
nts: 19.3 
TNF-alpha 
inhibitors: 39.8 
Natalizumab: 
100 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Feagan, 
200781 
 
 
Natalizumab, 
168 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 45.8 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
16.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.9 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 24.4 
Ileo-colonic: 50.6 
Colonic: 25 
 
Behavior NR 
 
CRP 
Mean: 8.9 
Median: 4.3 
Min: 0 
Max: 97 
CDAI 
Mean: 105 
 
IBDQ 
Mean: 125 
5ASA: 45.2 
 
Antibiotics: 8.9 
 
Corticosteroids: 
39.9 
 
Methotrexate: 4.8 
 
Thiopurines: 32.1 
 
Prednisone: 26.2 
 
Budesonide: 12.5 
 
>/= 1 
corticosteroid or 
immunomodulator
s: 57.1 
 
Corticosteroids 
and 
immunosuppressa
nts: 17.9 
TNF-alpha 
inhibitors: 32.7 
Natalizumab: 
100 
Feagan, 
200781 
 
 
Natalizumab, 35 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Feagan, 
200890 
Placebo, 261 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 37.9 
 
Race, % 
W: 94.3 
B: 3.1 
A: 1.1 
Other: 1.5 
 
Smoking, % 
Smoker, 36.8 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 209 
Corticosteroids: 41 NR Adalimumab: 
100 
Feagan, 
200890 
Adalimumab, 
257 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 38.9 
 
Race, % 
W: 89.9 
B: 4.7 
A: 2.7 
Other: 2.7 
 
Smoking, % 
Smoker, 34.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 209 
Corticosteroids: 
41.6 
NR Adalimumab: 
100 
Feagan, 
200890 
Adalimumab, 
260 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 37.3 
 
Race, % 
W: 94.2 
B: 2.7 
A: 1.5 
Other: 1.5 
 
Smoking, % 
Smoker, 35.4 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 195 
Corticosteroids: 
38.1 
NR Adalimumab: 
100 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 
200286 
Placebo, 110 
Route: IV 
Dose: NA every 
8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 155 
Median: 160 
 
IBDQ 
Mean: 170 
Median: 173 
5ASA 
 
Corticosteroids 
 
Immunomodulator
s 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
Hanauer, 
200286 
Infliximab, 113 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 154 
Median: 156 
 
IBDQ 
Mean: 170 
Median: 169 
5ASA 
 
Corticosteroids 
 
Immunomodulator
s 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
Hanauer, 
200286 
Infliximab, 112 
Route: IV 
Dose: 10 mg/kg 
every 8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 152 
Median: 151 
 
IBDQ 
Mean: 168 
Median: 173 
5ASA 
 
Corticosteroids 
 
Immunomodulator
s 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Mantzaris, 
200988 
Hydrocortisone + 
Infliximab, 23 
Route: IV 
Dose: 250 mg 
every 8 weeks + 
5 mg/kg every 8 
weeks 
Male, %: 52.2 
 
Race NR 
 
Smoking, % 
Smoker, 47.8 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 35 
Min: 20 
Max: 57 
Severity NR 
 
Location, % 
Ileal: 30.4 
Ileo-colonic: 47.8 
Colonic: 21.7 
 
Behavior, % 
Inflammatory: 100 
 
CRP NR 
CDAI 
Mean: 298 
NR 5ASA: 91.3 
 
Corticosteroids: 
69.6 
 
budesonide: 34.8 
 
NO azathioprine: 
26.1 
 
topical ASA: 17.4 
 
: 26.1 
Infliximab: 100 
Mantzaris, 
200988 
Azathioprine + 
Infliximab, 23 
Route: Oral + IV 
Dose: 2.0-2.5 
mg/kg every day 
+ 5 mg/kg every 
8 weeks 
Male, %: 47.8 
 
Race NR 
 
Smoking, % 
Smoker, 43.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Min: 21 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 26.1 
Ileo-colonic: 56.5 
Colonic: 17.4 
 
Behavior, % 
Inflammatory: 100 
 
CRP NR 
CDAI 
Mean: 287 
NR 5ASA: 87 
 
Corticosteroids: 
69.6 
 
budesonide: 34.8 
 
NO azathioprine: 
100 
 
topical ASA: 13 
 
: 100 
Infliximab: 100 
Rutgeerts, 
199985 
Infliximab, 37 
Route: IV 
Dose: 10 mg/kg 
every 8 weeks 
Male, %: 40.5 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9.4 
Min: 1.1 
Max: 30.8 
 
Age at 
enrollment 
Median: 34 
Min: 20 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 13.5 
Ileo-colonic: 62.2 
Colonic: 24.3 
 
Behavior NR 
 
CRP 
Median: 0.5 
CDAI 
Median: 175 
 
IBDQ 
Median: 165 
NR NR TNF-alpha 
inhibitors: 91.9 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Rutgeerts, 
199985 
Placebo, 36 
Route: Unknown 
Dose: NA every 
8 weeks 
Male, %: 63.9 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 12.1 
Min: 0.3 
Max: 32.8 
 
Age at 
enrollment 
Median: 39 
Min: 20 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 13.9 
Ileo-colonic: 47.2 
Colonic: 38.9 
 
Behavior NR 
 
CRP 
Median: 0.4 
CDAI 
Median: 170 
 
IBDQ 
Median: 170 
NR NR TNF-alpha 
inhibitors: 97.2 
Sandborn, 
200783 
 
 
Placebo, 18 
Route: SC 
Dose: NA every 
1 week 
Male, %: 33 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 67 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.24 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 188 
5ASA: 44 
 
Antibiotics: 6 
 
Corticosteroids: 56 
 
Methotrexate: 6 
 
Thiopurines: 11.1 
 
Immunomodulator
s: 17 
NR TNF-alpha 
inhibitors: 100 
Sandborn, 
200783 
 
Adalimumab, 18 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 56 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.13 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 191 
5ASA: 67 
 
Antibiotics: 0 
 
Corticosteroids: 50 
 
Methotrexate: 0 
 
Thiopurines: 28 
 
Immunomodulator
s: 28 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200783 
 
 
Adalimumab, 19 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 37 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 68 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.73 
 
Age at 
enrollment 
Mean: 34 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 187 
5ASA: 74 
 
Antibiotics: 0 
 
Corticosteroids: 47 
 
Methotrexate: 0 
 
Thiopurines: 21 
 
Immunomodulator
s: 21 
NR NR 
Sands, 
200487 
Infliximab, 96 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Male, %: 55 
 
Race NR 
 
Smoking, % 
Current smoker, 
45 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 10.5 
Min: 0.2 
Max: 32.2 
 
Age at 
enrollment 
Median: 37 
Severity NR 
 
Location, % 
Ileal: 19 
Ileo-colonic: 46 
Colonic: 35 
 
Behavior NR 
 
CRP 
Median: 0.6 
IBDQ 
Median: 155 
5ASA: 43 
 
Antibiotics: 29 
 
Corticosteroids: 26 
 
Methotrexate: 1 
 
Thiopurines: 30 
Antibiotics: 96 
 
Methotrexate: 5 
 
Thiopurines: 72 
 
cyclosporine or 
tacrolimus: 3 
Infliximab: 100 
Sands, 
200487 
Placebo, 99 
Route: IV 
Dose: NA every 
8 weeks 
Male, %: 48 
 
Race NR 
 
Smoking, % 
Current smoker, 
38 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 12.3 
Min: 0.5 
Max: 31.6 
 
Age at 
enrollment 
Median: 36 
Severity NR 
 
Location, % 
Ileal: 16 
Ileo-colonic: 54 
Colonic: 30 
 
Behavior NR 
 
CRP 
Median: 0.7 
IBDQ 
Median: 168 
5ASA: 49 
 
Antibiotics: 26 
 
Corticosteroids: 30 
 
Methotrexate: 2 
 
Thiopurines: 35 
Antibiotics: 93 
 
Methotrexate: 8 
 
Thiopurines: 64 
 
cyclosporine or 
tacrolimus: 7 
Infliximab: 100 
D-138 
 
 
Evidence Table 8. Population characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic therapies 
for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Schreiber, 
200784 
Certolizumab 
pegol, 216 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 43 
 
Race NR 
 
Smoking, % 
Current smoker, 
30 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9 
Median: 7 
Min: 1 
Max: 33 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 67 
Severity NR 
 
Location, % 
Ileal: 22 
Ileo-colonic: 51 
Colonic: 27 
 
Behavior, % 
Inflammatory: 67.4 
Stricturing: 11.6 
Penetrating: 20.9 
 
CRP 
Mean: 10 
Min: 2 
Max: 183 
CDAI 
Mean: 306 
Min: 179 
Max: 504 
Corticosteroids: 22 
 
Immunomodulator
s: 27 
 
Glucocorticoids + 
immunomodulator
s: 13 
 
Neither 
glucocoricoids nor 
immunosuppresive
s: 38 
5ASA: 34.4 
 
Corticosteroids: 
49.3 
 
Immunomodulat
ors: 21.4 
 
infliximab: 24 
Certolizumab 
pegol: 100 
Schreiber, 
200784 
Placebo, 212 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 52 
 
Race NR 
 
Smoking, % 
Current smoker, 
36 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
Median: 5 
Min: 1 
Max: 43 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 25 
Ileo-colonic: 46 
Colonic: 29 
 
Behavior, % 
Inflammatory: 67.1 
Stricturing: 9.5 
Penetrating: 23.3 
 
CRP 
Mean: 10 
Min: 2 
Max: 244 
CDAI 
Mean: 301 
Min: 183 
Max: 583 
Corticosteroids: 21 
 
Immunomodulator
s: 25 
 
Glucocorticoids + 
immunomodulator
s: 16 
 
Neither 
glucocorticoids nor 
immunomodulator
s: 38 
5ASA: 34.3 
 
Corticosteroids: 
46.7 
 
Immunomodulat
ors: 20.5 
 
infliximab: 24 
Certolizumab 
pegol: 100 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Van Assche, 
200889 
Infliximab + 
Immunomodulat
or, 40 
Route: IV + Oral 
Dose: 5 mg/kg 
every 8 weeks + 
see below 
Male, %: 42.5 
 
Race NR 
 
Smoking, % 
Smoker, 45 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 1 
Max: 36 
 
Age at 
enrollment 
Mean: 35.6 
Severity NR 
 
Location, % 
Colonic: 32.5 
 
Behavior NR 
 
CRP 
Median: 3.4 
CDAI 
Mean: 137.6 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
Van Assche, 
200889 
Infliximab, 40 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Male, %: 47.5 
 
Race NR 
 
Smoking, % 
Smoker, 47.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 2 
Max: 25 
 
Age at 
enrollment 
Mean: 35.4 
Severity NR 
 
Location, % 
Colonic: 12.5 
 
Behavior NR 
 
CRP 
Median: 3.2 
CDAI 
Mean: 138.1 
TNF-alpha 
inhibitors: 100 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
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Medications 
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Randomized controlled trials evaluating thiopurines 
Candy, 
199553 
Placebo + 
Prednisolone, 30 
Route: Oral + 
Oral 
Dose: NA + 1 
mg/kg every day 
Male, %: 37 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 3.7 
Min: 0.1 
Max: 18.7 
 
Age at 
enrollment 
Median: 31.8 
Min: 21 
Max: 62 
Severity, % 
Severe disease: 
43 
 
Location, % 
Ileal: 20 
Ileo-colonic: 63.3 
Colonic: 16.7 
 
Behavior NR 
 
CRP 
Median: 3.9 
Min: 2.8 
Max: 5.3 
CDAI 
Median: 282 
Min: 240 
Max: 356 
Corticosteroids: 
100 
Corticosteroids 
 
corticosteroids in 
the last 6 
months: 63 
 
no previous 
corticosteroids: 7 
 
: 7 
NR 
Candy, 
199553 
Azathioprine + 
Prednisolone, 33 
Route: Oral + 
Oral 
Dose: 2.5 mg/kg 
every day + 1 
mg/kg every day 
Male, %: 21 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.6 
Min: 0.1 
Max: 19.3 
 
Age at 
enrollment 
Median: 33.9 
Min: 15 
Max: 60 
Severity, % 
Severe disease: 
52 
 
Location, % 
Ileal: 24.2 
Ileo-colonic: 60.6 
Colonic: 15.2 
 
Behavior NR 
 
CRP 
Median: 5.4 
Min: 2.9 
Max: 7.3 
CDAI 
Median: 301 
Min: 264 
Max: 358 
Corticosteroids: 
100 
 
Thiopurines: 100 
corticosteroids in 
previous 6-12 
mo: 67 
 
no previous 
corticosteroids: 
15 
 
: 15 
NR 
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taken BEFORE 
study, % 
Medications 
taken FOR 
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Lemann, 
200598 
Azathioprine, 40 
Route: Oral 
Dose: as taken 
before 
enrollment every 
day 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11 
 
Age at 
enrollment 
Mean: 40 
Severity NR 
 
Location, % 
Ileal: 13 
Ileo-colonic: 40 
Colonic: 48 
Perianal: 43 
 
Behavior NR 
 
CRP 
Mean: 5.3 
CDAI 
Mean: 41 
 
CDEIS 
Mean: 2.5 
Corticosteroids 
<10mg/day: 8 
azathioprine: 100 NR 
Lemann, 
200598 
Placebo, 43 
Route: Oral 
Dose: NA every 
day 
Male, %: 42 
 
Race NR 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 9 
Ileo-colonic: 51 
Colonic: 40 
Perianal: 44 
 
Behavior NR 
 
CRP 
Mean: 6.9 
CDAI 
Mean: 39 
 
CDEIS 
Mean: 2.4 
Corticosteroids 
<10mg/day: 5 
azathioprine: 100 NR 
Mantzaris, 
2009102 
Budesonide, 39 
Route: Oral 
Dose: 09-Jun mg 
every day 
Male, %: 43.6 
 
Race NR 
 
Smoking, % 
Smoker, 92.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.9 
 
Age at 
enrollment 
Median: 34.5 
Min: 19 
Max: 62 
Severity, % 
Remission: 100 
 
Location, % 
Ileo-colonic: 66.7 
Colonic: 33.3 
 
Behavior, % 
Inflammatory: 100 
 
CRP NR 
CDAI 
Mean: 129 
 
CDEIS 
Mean: 7.1 
NR Corticosteroids: 
100 
Corticosteroids: 
100 
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Mantzaris, 
2009102 
Azathioprine, 38 
Route: Oral 
Dose: 2.0-2.5 
mg/kg every day 
Male, %: 44.7 
 
Race NR 
 
Smoking, % 
Smoker, 92.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.8 
 
Age at 
enrollment 
Median: 34.3 
Min: 19 
Max: 59 
Severity, % 
Remission: 100 
 
Location, % 
Ileo-colonic: 63.2 
Colonic: 36.8 
 
Behavior, % 
Inflammatory: 100 
 
CRP NR 
CDAI 
Mean: 132 
 
CDEIS 
Mean: 7.2 
NR Corticosteroids: 
100 
Corticosteroids: 
100 
O'Donoghue, 
1978100 
Azathioprine, 24 
Route: Oral 
Dose: 2 mg/kg 
every 24 hours 
Male, %: 45.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.25 
Min: 1.5 
Max: 20 
 
Age at 
enrollment 
Mean: 40 
Min: 21 
Max: 78 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 41.7 
Colonic: 45.8 
 
Behavior NR 
 
CRP NR 
Unnamed clinical 
scoring system 
Mean: 2.33 
Min: 0 
Max: 9 
Corticosteroids 
and/or 
sulfasalazine: 33.3 
NR Thiopurines: 100 
O'Donoghue, 
1978100 
Placebo, 27 
Route: Oral 
Dose: NA 
Male, %: 40.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.05 
Min: 1.5 
Max: 15 
 
Age at 
enrollment 
Mean: 40.5 
Min: 22 
Max: 65 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 25.9 
Ileo-colonic: 11.1 
Colonic: 63 
 
Behavior NR 
 
CRP NR 
Unnamed clinical 
scoring system 
Mean: 2 
Min: 0 
Max: 7 
Prednisolone and 
sulfasalazine 
collectively: 25.9 
NR Thiopurines: 100 
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taken BEFORE 
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Rosenberg, 
1975104 
Azathioprine, 10 
Route: Oral 
Dose: 2 mg/kg 
every 24 hours 
Male, %: 60 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.6 
Severity NR 
 
Location, % 
Ileal: 30 
Ileo-colonic: 70 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics: 20 
 
Corticosteroids: 
100 
 
Sulfasalazine: 40 
Corticosteroids: 
100 
NR 
Rosenberg, 
1975104 
Placebo, 10 
Route: Oral 
Dose: NA 
Male, %: 40 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.3 
Severity NR 
 
Location, % 
Ileal: 10 
Ileo-colonic: 90 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics: 40 
 
Corticosteroids: 
100 
 
Sulfasalazine: 30 
Corticosteroids: 
100 
NR 
Summers, 
197956 
 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
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Summers, 
197956 
 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
Summers, 
197956 
 
 
Prednisone, 61 
Route: Oral 
Dose: 04-Jan 
mg/kg every 24 
hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
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Vilien, 
2004101 
Discontinued 
azathioprine, 15 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5.9 
Min: 0 
Max: 36 
 
Age at 
enrollment 
Median: 47 
Min: 23 
Max: 73 
Severity NR 
 
Location, % 
Colonic: 20 
 
Behavior NR 
 
CRP 
Median: 25 
Min: 20 
Max: 174 
CDAI 
Median: 61 
Min: 15 
Max: 166 
NR NR NR 
Vilien, 
2004101 
Azathioprine, 14 
Route: Unknown 
Dose: NR every 
day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 4.9 
Min: 0.1 
Max: 19.4 
 
Age at 
enrollment 
Median: 33 
Min: 22 
Max: 63 
Severity NR 
 
Location, % 
Colonic: 28.6 
 
Behavior NR 
 
CRP 
Median: 54 
Min: 25 
Max: 395 
CDAI 
Median: 81 
Min: 1 
Max: 176 
NR NR NR 
Willoughby 
JM, 197199 
Prednisolone + 
Azathioprine, 5 
Route: Oral + 
Oral 
Dose: Patient 
continued on the 
current steroid 
dose required to 
maintain 
remission every 
24 hours + 2 
mg/kg every 24 
weeks 
Male, %: 20 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.4 
 
Age at 
enrollment 
Mean: 32.8 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 60 
Ileo-colonic: 40 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
Not named 
Mean: 3.2 
NR Corticosteroids: 
100 
NR 
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Willoughby 
JM, 197199 
Prednisolone + 
Placebo, 6 
Route: Oral + 
Oral 
Dose: 60 mg 
every day + NA 
every 24 hours 
Male, %: 33.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.8 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 33.3 
Colonic: 16.7 
 
Behavior NR 
 
CRP NR 
Not named 
Mean: 7.8 
NR NR NR 
Willoughby 
JM, 197199 
Prednisolone + 
Azathioprine, 6 
Route: Oral + 
Oral 
Dose: 60 mg 
every 24 hours + 
4 mg/kg every 24 
hours 
Male, %: 16.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.8 
 
Age at 
enrollment 
Mean: 29.2 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 66.7 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
Not named 
Mean: 10.7 
NR NR NR 
Willoughby 
JM, 197199 
Prednisolone + 
Placebo, 5 
Route: Oral + 
Oral 
Dose: current 
dose the patient 
is taking to keep 
him free of 
relapse every 24 
hours + NA 
every 24 hours 
Male, %: 60 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.6 
 
Age at 
enrollment 
Mean: 33.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 40 
Ileo-colonic: 60 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
Not named 
Mean: 1.8 
NR Corticosteroids: 
100 
NR 
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Randomized controlled trials evaluating methotrexate 
Feagan, 
2000105 
Methotrexate, 40 
Route: IM 
Dose: 15 mg 
every 1 week 
Male, %: 40 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 50 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.33 
 
Age at 
enrollment 
Mean: 32 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 45 
Ileo-colonic: 28 
Colonic: 28 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94 
NR NR Methotrexate: 
100 
Feagan, 
2000105 
Placebo, 36 
Route: IM 
Dose: NA every 
1 week 
Male, %: 61 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 84 
 
Age at 
enrollment 
Mean: 34 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 31 
Ileo-colonic: 44 
Colonic: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 84 
NR Methotrexate: 
100 
 
Thiopurines: 3 
Methotrexate: 
100 
Randomized controlled trials evaluating corticosteroids 
Bergman, 
1976223 
Sulfasalazine + 
Prednisone, 49 
Route: Oral + 
Oral 
Dose: 3 g every 
24 hours + 15 
mg every 24 
hours 
Male, %: 40.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.9 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Bergman, 
1976223 
No treatment, 35 Male, %: 51.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Brignola, 
1988112 
Placebo, 9 
Route: Unknown 
Dose: NA 
Male, %: 22.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 44.4 
Colonic: 22.2 
 
Behavior NR 
 
CRP 
Mean: 2.3 
Disease activity 
index NR 
Folic acid 
 
Iron 
 
Calcium 
NR Corticosteroids: 
44.4 
Brignola, 
1988112 
(6)-
Methylprednisolo
ne, 9 
Route: Unknown 
Dose: 0.25 
mg/kg every 24 
hours 
Male, %: 66.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 28 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 33.3 
Colonic: 33.3 
 
Behavior NR 
 
CRP 
Mean: 2.5 
Disease activity 
index NR 
Folic acid 
 
Iron 
 
Calcium 
NR Corticosteroids: 
44.4 
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Cortot, 
2001107 
Placebo, 58 
Route: Unknown 
Dose: NA every 
day 
Male, %: 34.5 
 
Race, % 
W: 91.4 
Mixed: 8.6 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.1 
Min: 1 
Max: 26 
 
Age at 
enrollment 
Mean: 32 
Min: 18 
Max: 66 
Severity NR 
 
Location, % 
Ileal: 51.7 
Ileo-colonic: 48.3 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 109 
Min: -50 
Max: 192 
5ASA: 48.3 
 
Corticosteroids: 
100 
 
Thiopurines: 8.6 
NR NR 
Cortot, 
2001107 
Budesonide, 59 
Route: Oral 
Dose: 6 mg 
every day 
Male, %: 47.5 
 
Race, % 
W: 91.5 
Mixed: 8.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.9 
Min: 1 
Max: 25 
 
Age at 
enrollment 
Mean: 35 
Min: 19 
Max: 71 
Severity NR 
 
Location, % 
Ileal: 47.5 
Ileo-colonic: 49.2 
Colonic: 3.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 103 
Min: -14 
Max: 208 
5ASA: 49.2 
 
Corticosteroids: 
100 
 
Thiopurines: 15.3 
NR NR 
de Franchis, 
1997118 
Placebo + (6)-
Methylprednisolo
ne, 59 
Route: Oral + 
Oral 
Dose: NA every 
8 hours + every 
24 hours 
Male, %: 59.3 
 
Race NR 
 
Smoking, % 
Present smoker, 
34 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4 
Min: 0.0027 
Max: 17.9 
 
Age at 
enrollment 
Mean: 35.8 
Min: 18 
Max: 66 
Severity NR 
 
Location, % 
Ileal: 28.8 
Ileo-colonic: 39 
Colonic: 32.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 70.5 
Corticosteroids: 
100 
NR Corticosteroids: 
100 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
de Franchis, 
1997118 
ASA + (6)-
Methylprednisolo
ne, 58 
Route: Oral + 
Oral 
Dose: 1000 mg 
every 8 hours + 
every 24 hours 
Male, %: 46.6 
 
Race NR 
 
Smoking, % 
Present smoker, 
38 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
Min: 0.0027 
Max: 14.9 
 
Age at 
enrollment 
Mean: 39.6 
Min: 18 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 27.6 
Ileo-colonic: 43.1 
Colonic: 29.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 71.2 
5ASA: 100 
 
Corticosteroids: 
100 
NR Corticosteroids: 
100 
Ferguson, 
1998108 
Placebo, 27 
Route: Oral 
Dose: NA every 
day 
Male, %: 40.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.8 
Min: 0 
Max: 27 
 
Age at 
enrollment 
Mean: 34 
Min: 19 
Max: 61 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 90 
Min: 0 
Max: 155 
NR NR Budesonide: 
59.3 
 
Prednisolone: 
40.7 
Ferguson, 
1998108 
Budesonide + 
Placebo, 26 
Route: Oral + 
Oral 
Dose: 3 mg 
every day + NA 
every day 
Male, %: 53.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.7 
Min: 0 
Max: 27 
 
Age at 
enrollment 
Mean: 37 
Min: 20 
Max: 71 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 75 
Min: 0 
Max: 138 
NR NR Budesonide: 
80.8 
 
Prednisolone: 
19.2 
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Medications 
taken FOR 
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Ferguson, 
1998108 
Budesonide, 22 
Route: Oral 
Dose: 6 mg 
every day 
Male, %: 40.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.3 
Min: 0 
Max: 30 
 
Age at 
enrollment 
Mean: 37 
Min: 20 
Max: 63 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 102 
Min: 15 
Max: 210 
NR NR Budesonide: 
63.6 
 
Prednisolone: 
36.4 
Greenberg, 
199466 
Budesonide, 64 
Route: Oral 
Dose: 7.5 mg 
every 12 hours 
Male, %: 45.3 
 
Race NR 
 
Smoking, % 
Smoker, 47 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.1 
 
Age at 
enrollment 
Median: 31 
Severity NR 
 
Location, % 
Ileal: 88 
Ileo-colonic: 12 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 285 
 
IBDQ 
Median: 130 
Loperamide Corticosteroids: 
47 
NR 
Greenberg, 
199466 
Placebo, 66 
Route: Oral 
Dose: NA every 
12 hours 
Male, %: 37.9 
 
Race NR 
 
Smoking, % 
Smoker, 57.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.3 
 
Age at 
enrollment 
Median: 32 
Min: 19 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 84.8 
Ileo-colonic: 15.2 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 287 
 
IBDQ 
Median: 130 
Loperamide Corticosteroids: 
38 
NR 
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Greenberg, 
199466 
Budesonide, 67 
Route: Oral 
Dose: 1.5 mg 
every 12 hours 
Male, %: 29.9 
 
Race NR 
 
Smoking, % 
Smoker, 49 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5.3 
 
Age at 
enrollment 
Median: 30 
Severity NR 
 
Location, % 
Ileal: 81 
Ileo-colonic: 19 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 10 
CDAI 
Median: 293 
 
IBDQ 
Median: 131 
Loperamide Corticosteroids: 
45 
NR 
Greenberg, 
199466 
Budesonide, 61 
Route: Oral 
Dose: 4.5 mg 
every 12 hours 
Male, %: 38 
 
Race NR 
 
Smoking, % 
Smoker, 46 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 5.9 
 
Age at 
enrollment 
Median: 37 
Severity NR 
 
Location, % 
Ileal: 84 
Ileo-colonic: 16 
Colonic: 0 
 
Behavior NR 
 
CRP 
Median: 4 
CDAI 
Median: 296 
 
IBDQ 
Median: 125 
Loperamide Corticosteroids: 
43 
NR 
Greenberg, 
1996111 
Placebo, 36 
Route: Oral 
Dose: NA every 
day 
Male, %: 38.9 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.7 
Min: 0.2 
Max: 29 
 
Age at 
enrollment 
Mean: 34 
Min: 19 
Max: 60 
Severity, % 
Remission: 91.7 
 
Location, % 
Ileal: 89 
Ileo-colonic: 11 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 115 
Min: 28 
Max: 246 
 
IBDQ 
Mean: 181 
Min: 69 
Max: 198 
Loperamide NR Placebo: 8.3 
 
Budesonide 
3mg: 11.1 
 
Budesonide 
9mg: 61.1 
 
Budesonide 
15mg: 19.4 
D-153 
 
 
Evidence Table 8. Population characteristics of randomized controlled trials reporting on the effectiveness of pharmacologic therapies 
for the management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
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Greenberg, 
1996111 
Budesonide, 33 
Route: Oral 
Dose: 3 mg 
every day 
Male, %: 30.3 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8 
Min: 0.2 
Max: 23 
 
Age at 
enrollment 
Mean: 37 
Min: 22 
Max: 62 
Severity, % 
Remission: 90.9 
 
Location, % 
Ileal: 88 
Ileo-colonic: 12 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 96 
Min: 20 
Max: 160 
 
IBDQ 
Mean: 185 
Min: 76 
Max: 179 
Loperamide NR Placebo: 9.1 
 
Budesonide 
3mg: 21.2 
 
Budesonide 
9mg: 48.5 
 
Budesonide 
15mg: 21.2 
Greenberg, 
1996111 
Budesonide, 36 
Route: Oral 
Dose: 6 mg 
every day 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.7 
Min: 0.2 
Max: 26 
 
Age at 
enrollment 
Mean: 36 
Min: 19 
Max: 63 
Severity, % 
Remission: 97.2 
 
Location, % 
Ileal: 81 
Ileo-colonic: 19 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 102 
Min: 15 
Max: 154 
 
IBDQ 
Mean: 184 
Min: 68 
Max: 197 
Loperamide NR Placebo: 13.9 
 
Budesonide 
3mg: 19.4 
 
Budesonide 
9mg: 41.7 
 
Budesonide 
15mg: 25 
Gross, 
1998109 
Placebo, 95 
Route: Oral 
Dose: NA every 
24 hours 
Male, %: 38.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5 
 
Age at 
enrollment 
Mean: 32 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 66 
NR NR Corticosteroids: 
100 
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Gross, 
1998109 
Budesonide, 84 
Route: Oral 
Dose: 3 mg 
every 24 hours 
Male, %: 42.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.5 
 
Age at 
enrollment 
Mean: 32 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 65 
NR NR Corticosteroids: 
100 
Hanauer, 
2005106 
Budesonide, 54 
Route: Oral 
Dose: 6 mg 
every day 
Male, %: 31.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 40.5 
Min: 18 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 68.5 
Ileo-colonic: 31.5 
Colonic: 1.9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 97.4 
Max: 150 
NR NR Budesonide: 
79.6 
 
Placebo: 20.4 
Hanauer, 
2005106 
Placebo, 54 
Route: Oral 
Dose: NA every 
day 
Male, %: 44.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 40.3 
Min: 18 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 72.2 
Ileo-colonic: 29.6 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 87.4 
Max: 150 
NR NR Budesonide: 87 
 
Placebo: 13 
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Medications 
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Issenman, 
1993196 
Discontinued 
corticosteroids, 8 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD, %: 212.5 
Age at diagnosis 
Mean: 13.2 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.2 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Issenman, 
1993196 
Prednisone, 9 
Route: Oral 
Dose: 2 mg/kg 
every day 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 14.5 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.5 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 64.1 
Corticosteroids: 
100 
5ASA NR 
Lofberg, 
1996110 
Budesonide, 32 
Route: Oral 
Dose: 6 mg 
every 24 hours 
Male, %: 46.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.7 
 
Age at 
enrollment 
Mean: 37 
Min: 21 
Max: 71 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 72 
Ileo-colonic: 28 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 88 
NR NR Budesonide: 28 
 
Prednisolone: 72 
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INDUCTION, % 
Lofberg, 
1996110 
Budesonide, 31 
Route: Oral 
Dose: 3 mg 
every 24 hours 
Male, %: 32.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.4 
 
Age at 
enrollment 
Mean: 33 
Min: 18 
Max: 69 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 71 
Ileo-colonic: 29 
Colonic: 0 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 104 
NR NR Budesonide: 65 
 
Prednisolone: 35 
Lofberg, 
1996110 
Placebo, 27 
Route: Oral 
Dose: NA every 
24 hours 
Male, %: 40.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.7 
 
Age at 
enrollment 
Mean: 35 
Min: 22 
Max: 52 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 78 
Ileo-colonic: 19 
Colonic: 4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 107 
NR NR Prednisolone: 52 
 
Budesonide: 48 
Malchow, 
198464 
 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR sulfasalazine: 88 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3 
 
: 54.7 
NR 
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Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
: 59.5 
NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
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Malchow, 
198464 
 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
 
: 55.4 
NR 
Malchow, 
198464 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
 
: 47.8 
NR 
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INDUCTION, % 
Malchow, 
198464 
 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
Mantzaris, 
2003113 
Mesalamine 
(Salofalk), 28 
Route: Unknown 
Dose: 1 g every 
8 hours 
Male, %: 42.9 
 
Race NR 
 
Smoking, % 
Smoker, 82 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.2 
 
Age at 
enrollment 
Mean: 31.8 
Min: 19 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 54 
Ileo-colonic: 28 
Colonic: 18 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 138 
 
IBDQ 
Mean: 186 
Corticosteroids: 
100 
Thiopurines: 43 NR 
Mantzaris, 
2003113 
Budesonide, 29 
Route: Unknown 
Dose: 6 mg 
every day 
Male, %: 44.8 
 
Race NR 
 
Smoking, % 
Smoker, 86 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment 
Mean: 34.1 
Min: 20 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 52 
Ileo-colonic: 38 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 139 
 
IBDQ 
Mean: 188 
Corticosteroids: 
100 
Thiopurines: 41 NR 
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Singleton, 
197975 
 
 
Placebo + 
Prednisone, 18 
Route: Oral + 
Oral 
Dose: NA + 0.25 
mg/kg every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR Corticosteroids: 
100 
 
Placebo: 100 
Singleton, 
197975 
 
 
Sulfasalazine + 
Prednisone, 16 
Route: Oral + 
Unknown 
Dose: 1g/15kg to 
5g max every 
day + 0.25 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR Corticosteroids: 
100 
 
Placebo: 100 
Singleton, 
197975 
 
 
Sulfasalazine + 
Prednisone, 13 
Route: Oral + 
Oral 
Dose: 1g per 
15kg body wt to 
max of 5g/day 
every day + 0.25 
mg/kg every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR 5ASA: 100 
 
Corticosteroids: 
100 
Singleton, 
197975 
 
Placebo + 
Prednisone, 12 
Route: Oral + 
Oral 
Dose: NA + 0.25 
mg/kg every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR 5ASA: 100 
 
Corticosteroids: 
100 
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Summers, 
197956 
 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
Summers, 
197956 
 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Prednisone, 61 
Route: Oral 
Dose: 04-Jan 
mg/kg every 24 
hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
Randomized controlled trials evaluating aminosalicylates 
Arber, 
1995121 
Placebo, 31 
Route: Oral 
Dose: NA every 
24 hours 
Male, %: 58 
 
Race NR 
 
Smoking, % 
Present smoker, 
19.31 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 61.2 
Ileo-colonic: 33.58 
Colonic: 12.9 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 2.3 
NR NR 5ASA: 64.5 
 
Sulfasalazine: 
22.58 
 
None: 12.9 
Arber, 
1995121 
ASA, 28 
Route: Oral 
Dose: 1 g every 
day 
Male, %: 67.85 
 
Race NR 
 
Smoking, % 
Present smoker, 
17.85 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 60.71 
Ileo-colonic: 17.85 
Colonic: 14.28 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 2.2 
5ASA: 100 NR 5ASA: 71.42 
 
Sulfasalazine: 
10.71 
 
None: 14.3 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Bresci G, 
1995125 
ASA, 33 
Route: Unknown 
Dose: 2.4 g 
every 24 hours 
Male, %: 54.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.2 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 66.7 
Ileo-colonic: 33.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 54 
 
CDEIS 
Mean: 3 
NR Corticosteroids: 
87.9 
NR 
Bresci G, 
1995125 
Placebo, 33 
Route: Unknown 
Dose: NA 
Male, %: 69.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.4 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 51.5 
Ileo-colonic: 48.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 48 
 
CDEIS 
Mean: 2.6 
NR Corticosteroids: 
93.9 
NR 
Brignola, 
1992124 
Placebo, 22 
Route: Oral 
Dose: NA every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 40.9 
Ileo-colonic: 59.1 
 
Behavior NR 
 
CRP 
Mean: 2.4 
CDAI 
Mean: 75 
NR Corticosteroids: 
45.5 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Brignola, 
1992124 
ASA (Pentasa), 
22 
Route: Oral 
Dose: 2 g every 
24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.2 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 45.5 
Ileo-colonic: 54.5 
 
Behavior NR 
 
CRP 
Mean: 2.2 
CDAI 
Mean: 82 
NR Corticosteroids: 
40.9 
NR 
Cezard, 
2009194 
Placebo, 62 Male, %: 58 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.6 
 
Age at 
enrollment 
Mean: 11.6 
Severity NR 
 
Location, % 
Ileal: 11 
Ileo-colonic: 69 
Colonic: 19 
Perianal: 31 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 0.9 
NR NR NR 
Cezard, 
2009194 
Mesalamine 
(Pentasa), 60 
Dose: 50 mg/kg 
every day 
Male, %: 62 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.1 
 
Age at 
enrollment 
Mean: 12 
Severity NR 
 
Location, % 
Ileal: 13 
Ileo-colonic: 68 
Colonic: 18 
Perianal: 33 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 0.7 
NR NR NR 
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Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Gendre, 
1993122 
Mesalamine 
(Pentasa), 80 
Route: Oral 
Dose: 500 mg 
every 6 hours 
Male, %: 41 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 11 
Ileo-colonic: 60 
Colonic: 29 
Perianal: 11 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR unspecified 
medication use 
in the last 1 
month prior to 
the study: 25 
NR 
Gendre, 
1993122 
Placebo, 81 
Route: Oral 
Dose: NA every 
6 hours 
Male, %: 53 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 12 
Ileo-colonic: 54 
Colonic: 33 
Perianal: 14 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR just mentioned 
as medications 
in the prior 1 
month but not 
specified: 32 
NR 
Mahmud, 
2001116 
Olsalazine, 167 
Route: Oral 
Dose: 2 g every 
day 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 32.9 
 
Disease duration 
Mean: 7.18 
 
Age at 
enrollment 
Mean: 40 
Severity NR 
 
Location, % 
Ileo-colonic: 53.3 
Colonic: 94 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 59.8 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Mahmud, 
2001116 
Placebo, 160 
Route: Oral 
Dose: NA every 
day 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 31.9 
 
Disease duration 
Mean: 6.56 
 
Age at 
enrollment 
Mean: 38.4 
Severity NR 
 
Location, % 
Ileo-colonic: 49.4 
Colonic: 96.9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 55.8 
NR NR NR 
Malchow, 
198464 
 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
: 59.5 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 
198464 
 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
 
: 55.4 
NR 
Malchow, 
198464 
 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR sulfasalazine: 88 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3 
 
: 54.7 
NR 
Malchow, 
198464 
 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
 
: 47.8 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 
198464 
 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
Malchow, 
198464 
 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
Prantera, 
1992123 
Placebo, 61 
Route: Oral 
Dose: NA every 
8 hours 
Male, %: 62 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.8 
 
Age at 
enrollment 
Mean: 36.6 
Severity NR 
 
Location, % 
Ileal: 52 
Ileo-colonic: 30 
Colonic: 18 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 49 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
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taken during 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Prantera, 
1992123 
ASA (Asacol), 64 
Route: Oral 
Dose: 800 mg 
every 8 hours 
Male, %: 62 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.2 
 
Age at 
enrollment 
Mean: 35.2 
Severity NR 
 
Location, % 
Ileal: 59 
Ileo-colonic: 30 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 55 
5ASA: 100 NR NR 
Prantera, 
2005115 
Mesalamine 
(Asacol), 23 
Route: Oral 
Dose: 4 g 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 100 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR Methylprednisolo
ne: 100 
Prantera, 
2005115 
Placebo, 17 
Route: Unknown 
Dose: NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 100 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR Methylprednisolo
ne: 100 
Summers, 
197956 
 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
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Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Prednisone, 61 
Route: Oral 
Dose: 04-Jan 
mg/kg every 24 
hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
Summers, 
197956 
 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
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taken BEFORE 
study, % 
Medications 
taken FOR 
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Sutherland, 
1997117 
Placebo, 128 
Route: Oral 
Dose: NA every 
6 hours 
Male, %: 45 
 
Race NR 
 
Smoking, % 
Smoker, 35 
 
CD NR 
Age at diagnosis 
Mean: 29 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 49.2 
Ileo-colonic: 50 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 75.2 
 
IBDQ 
Mean: 193 
NR NR NR 
Sutherland, 
1997117 
Mesalamine 
(Pentasa), 118 
Route: Oral 
Dose: 750 mg 
every 6 hours 
Male, %: 40 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 29.7 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 49.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 74.5 
 
IBDQ 
Mean: 193.4 
NR NR NR 
Thomson, 
1995120 
Placebo, 43 
Route: Oral 
Dose: NA every 
12 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 70 
NR NR NR 
Thomson, 
1995120 
Placebo, 105 
Route: Oral 
Dose: NA every 
12 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 56.9 
NR NR NR 
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Disease activity 
index 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Thomson, 
1995120 
Mesalamine, 36 
Route: Oral 
Dose: 1.5 g 
every 12 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 74.7 
NR NR NR 
Thomson, 
1995120 
Mesalamine, 102 
Route: Oral 
Dose: 1.5 g 
every 12 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 61.7 
NR NR NR 
Thomson, 
1990224 
5-ASA, 101 
Dose: 500 mg 
every 8 hours 
Male, %: 42.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6 
 
Age at 
enrollment 
Mean: 34.1 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI Mean: 51.8 NR sulphasalazine: 
15.8 
Thomson, 
1990224 
Thomson, 
1990224 
Placebo, 105 
Route: Oral 
Dose: NA every 
8 hours 
Male, %: 45.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.3 
 
Age at 
enrollment 
Mean: 37.4 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI Mean: 60.1 NR sulphasalazine: 
16.2 
Thomson, 
1990224 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Wellmann W, 
1988126 
mesalamine 
(NR), 31 
Route: Oral 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 35.5 
Ileo-colonic: 29 
Colonic: 35.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Wellmann W, 
1988126 
Placebo, 35 
Route: Oral 
Dose: NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 31.4 
Ileo-colonic: 28.6 
Colonic: 40 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Abbreviations: ASA = Aminosalicylates; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; CRP = C-
reactive protein; g = gram; HBI = Harvey-Bradshaw Index; IBDQ = Inflammatory Bowel Disease Questionnaire; IBDQ = Inflammatory Bowel Disease Questionnaire; IV = 
intravenous; kg = kilogram; Max. = maximum; mg = milligram; Min. = minimum; NA = not applicable; NR = not reported; SC = subcutaneous; TNF = tumor necrosis factor; W = 
white 
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maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Mantzaris, 
200988 
Hydrocortisone + infliximab 
Route: IV 
Dose: 250 mg every 8 wks 
+ 5 mg/kg every 8 wks 
Azathioprine + infliximab 
Route: Oral + IV 
Dose: 2.0-2.5 mg/kg every 
1 d + 5 mg/kg every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 104 
wks 
NA 
Yes 
Incidence  
18 / 23 (78%) 
Incidence  
17 / 23 (74%) P: 1 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 6-9 mg every 1 d 
CDAI (Relapse rate 
definition: CDAI 
increase >100 and 
>150 total) @ 52 
wks 
NA 
Yes 
Incidence  
8 / 38 (21%) 
Incidence  
14 / 39 (36%) P: 0.2 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 6-9 mg every 1 d 
CDAI (Relapse rate 
definition: CDAI 
increase >100 and 
>150 total) @ 78 
wks 
NA 
Yes 
Incidence  
9 / 38 (24%) 
Incidence  
25 / 39 (64%) P: 0.03 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 6-9 mg every 1 d 
Endoscopic healing 
(CDEIS) @ 52 wks 
NA 
Yes 
B: Mean, 7.2 (SD, 3.1) 
F: Mean, 1.62 (SD, 2.58) 
P: <0.0001 
F-B: Mean, -5.58 P: 
<0.001 
G1-G2: 5.7 
B: Mean, 7.1 (SD, 3.5) 
F: Mean, 7.2 (SD, 3.2) P: 
<0.0001 
F-B: Mean, 0.1 P: 1 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 6-9 mg every 1 d 
Endoscopic healing 
(complete or near 
complete mucosal 
healing') @ 52 wks 
NA 
Yes 
Incidence  
32 / 38 (83%) 
Incidence  
9 / 39 (24%) P: 0.0001 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 6-9 mg every 1 d 
AHS-average 
histology score @ 
52 wks 
NA 
Yes 
B: Mean, 5.92 (SD, 1.7) 
F: Mean, 2.92 (SD, 1.93) 
P: <0.01 
F-B: Mean, -3 (SD, 0.23) 
P: <0.01 
G1-G2: 3.3 
B: Mean, 5.72 (SD, 1.63) 
F: Mean, 6.01 (SD, 1.72) 
P: <0.01 
F-B: Mean, 0.29 (SD, 
0.09) P: 0.31 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Need for surgery 
(CD-related 
surgeries except for 
drainage of abscess 
and placement of a 
seton - responders) 
@ 52 wks 
NA 
No 
Incidence  
1 / 172 (0.6%) 
Incidence  
7 / 170 (4.1%) 
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maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations - 
responders) @ 52 
wks 
NA 
No 
Incidence  
25 / 172 (14.3%) 
RH: 0.47 (0.25 to 0.89) 
vs. main 
Incidence  
42 / 170 (24.8%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations - 
responders) @ 52 
wks 
NA 
No 
Incidence  
17 / 172 (9.7%) 
RH: 0.55 (0.25 to 1.22) 
vs. main 
Incidence  
23 / 170 (13.4%) P: 0.12 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Need for surgery 
(CD-related 
surgeries except for 
drainage of abscess 
and placement of a 
seton - responders) 
@ 52 wks 
NA 
No 
Incidence  
0 / 157 (0%) 
Incidence  
7 / 170 (4.1%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations - 
responders) @ 52 
wks 
NA 
No 
Incidence  
4 / 157 (2.8%) 
RH: 0.15 (0.04 to 0.51) 
vs. main 
Incidence  
23 / 170 (13.4%) P: <0.01 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations - 
responders) @ 52 
wks 
NA 
No 
Incidence  
9 / 157 (5.6%) 
RH: 0.16 (0.06 to 0.39) 
vs. main 
Incidence  
42 / 170 (24.8%) P: <0.02 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Need for surgery 
(major CD-related 
surgeries, excluding 
drainage of abscess 
and placement of a 
seton) @ 52 wks 
NA 
Yes 
Incidence  
1 / 260 (0.4%) 
Incidence  
10 / 261 (3.8%) 
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Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
16 / 260 (6%) 
Incidence  
26 / 261 (10%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations) @ 
8 wks 
NA 
Yes 
Incidence  
14 / 260 (5.2%) 
Incidence  
34 / 261 (13.1%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
8 wks 
NA  
NA 
Incidence  
7 / 260 (2.8%) 
Incidence  
23 / 261 (9%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
21 / 260 (8%) 
RH: 0.5 (0.26 to 0.94) 
P: 0.03 vs. main 
Incidence  
40 / 261 (15.5%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
32 / 260 (12.2%) 
Hazard ratio: 0.45 (0.27 
to 0.75) 
P: 0.003 vs. main 
Incidence  
66 / 261 (25.2%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Need for surgery 
(major CD-related 
surgeries, excluding 
drainage of abscess 
and placement of a 
seton) @ 52 wks 
NA 
Yes 
Incidence  
2 / 257 (0.8%) 
Incidence  
10 / 261 (3.8%) P: <0.05 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations) @ 
8 wks 
NA 
Yes 
Incidence  
13 / 257 (4.9%) 
Incidence  
34 / 261 (13.1%) P: <0.01 
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maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
8 wks 
NA  
NA 
Incidence  
9 / 257 (3.4%) 
Incidence  
23 / 261 (9%) P: <0.02 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
14 / 257 (5.6%) 
RH: 0.34 (0.17 to 0.68) 
P: 0.002 vs. main 
Incidence  
40 / 261 (15.5%) 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations (all-
cause 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
26 / 257 (10%) 
Hazard ratio: 0.36 (0.21 
to 0.62) vs. main 
Incidence  
66 / 261 (25.2%) P: <0.01 
Feagan, 
200890 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Number of 
hospitalizations 
(CD-related 
hospitalizations) @ 
52 wks 
NA 
Yes 
Incidence  
13 / 257 (5%) 
Incidence  
26 / 261 (10%) 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
CDAI (Absolute 
CDAI) @ 104 wks 
NA 
Yes 
F: Median, 104 (IQR, 55 
to 165) 
F: Median, 92 (IQR, 34 to 
164) 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Endoscopic healing 
(SES-CD) @ 104 
wks 
NA  
NA 
F: Median, 2.5 F: Median, 1 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Endoscopic healing 
(Absence of ulcers) 
@ 104 wks 
NA 
NR 
Incidence  
14 / 23 (61%) 
Incidence  
16 / 25 (64%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Remission) 
@ 4 wks 
NA 
No 
Incidence  
30 / 130 (23%) 
Incidence  
35 / 120 (29%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Remission) 
@ 16 wks 
NA 
No 
Incidence  
61 / 130 (47%) 
Incidence  
80 / 120 (67%) 
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Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Remission: 
Maintenance of 
remission) @ 48 
wks 
NA 
No 
Incidence  
79 / 130 (61%) 
Incidence  
102 / 120 (85%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL: Global 
Assessment) @ 12 
wks 
NA 
Yes 
F: Mean, 44.2 P: 0.032 F: Mean, 30.3 P: 0.032 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Relapse rate) 
@ 4 wks 
NA 
Yes 
Incidence  
20 / 168 (12%) 
Incidence  
31 / 170 (18%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Relapse rate) 
@ 16 wks 
NA 
Yes 
Incidence  
57 / 168 (34%) 
Incidence  
102 / 170 (60%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Relapse rate) 
@ 48 wks 
NA 
Yes 
Incidence  
77 / 168 (46%) 
Incidence  
136 / 170 (80%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
Incidence  
123 / 168 (73%) 
B: 185 
F: Mean, 181 P: <0.01 
F-B: Mean, 51.6 (SD, 31) 
G1-G2: -7.8 
Incidence  
80 / 171 (46.9%) 
B: 178 
F: Mean, 163 P: <0.01 
F-B: Mean, 43.8 (SD, 35) 
G1-G2: -7.8 P: <0.01 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
48 wks 
NA 
Yes 
Incidence  
120 / 168 (71.3%) 
B: Mean, 185 
F: Mean, 181 P: <0.001 
F-B: Mean, 53.9 (SD, 
33.6) 
G1-G2: -18.4 
Incidence  
68 / 171 (40%) 
B: Mean, 178 
F: Mean, 157 P: <0.001 
F-B: Mean, 35.5 (SD, 
40.3) 
G1-G2: -18.4 P: <0.001 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (SF-36, 
MCS) @ 12 wks 
NA 
Yes 
B: Mean, 49.5 
F: Mean, 49.5 P: <0.01 
F-B: Mean, 8.6 (SD, 10.5) 
G1-G2: -0.6 
B: Mean, 49 
F: Mean, 44.5 P: <0.01 
F-B: Mean, 8 (SD, 11) 
G1-G2: -0.6 P: NS 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (SF-36, 
MCS) @ 48 wks 
NA 
Yes 
B: Mean, 49.5 
F: Mean, 50 P: <0.001 
F-B: Mean, 12.6 (SE, 9.4) 
G1-G2: -5.8 
B: Mean, 49 
F: Mean, 44 P: <0.001 
F-B: Mean, 6.8 (SE, 9.5) 
G1-G2: -5.8 P: <0.001 
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Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (SF-36, 
PCS) @ 12 wks 
NA 
Yes 
B: Mean, 46.5 
F: Mean, 46 P: 0.011 
F-B: Mean, 12.5 (SD, 8.5) 
G1-G2: -3.7 
B: Mean, 45.5 
F: Mean, 43 P: 0.011 
F-B: Mean, 8.8 (SD, 8.9) 
G1-G2: -3.7 P: <0.01 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
HR QoL (SF-36, 
PCS) @ 48 wks 
NA 
Yes 
B: Mean, 46.5 
F: Mean, 46 P: <0.001 
F-B: Mean, 12.6 (SD, 9.4) 
G1-G2: -5.8 
B: Mean, 45.5 
F: Mean, 41.5 P: <0.001 
F-B: Mean, 6.8 (SD, 9.5) 
G1-G2: -5.8 P: <0.001 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Median time to loss 
of remission  
NA 
NR 
Event rate  
336 days 
Event rate  
86 days 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Relapse rate) 
@ 24 wks 
NA 
No 
Incidence  
16 / 35 (46%) 
Incidence  
15 / 33 (45%) P: 0.58 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
CDAI (Relapse rate) 
@ 48 wks 
NA 
No 
Incidence  
18 / 35 (51%) 
Incidence  
21 / 33 (64%) P: 0.16 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Response: 
100 pt drop) @ 18 
wks 
NA 
Yes 
Incidence  
135 / 216 (63%) 
Incidence  
76 / 212 (36%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
CDAI (Remission: 
CDAI < 150) @ 18 
wks 
NA 
Yes 
Incidence  
103 / 216 (48%) 
Incidence  
60 / 212 (29%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ) @ 
18 wks 
NA 
Yes 
F: Mean, 175.7 (SD, 
29.24) P: 0.001 
F: Mean, 167.9 (SD, 
32.19) P: 0.001 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ 
remission (total 
score ≥170 pts)) @ 
18 wks 
NA 
Yes 
Incidence  
99 / 213 (46.5%) 
Incidence  
55 / 210 (26.2%) P: 0.001 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ 
response (≥ 16 pt 
increase)) @ 18 wks 
NA 
Yes 
Incidence  
129 / 213 (61%) 
Incidence  
90 / 210 (43%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (IBDQ 
response (≥ 16 pt 
increase)) @ 18 wks 
NA 
Yes 
Incidence  
129 / 216 (60%) 
Incidence  
90 / 212 (43%) 
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collection 
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Results, Group 1 Results, Group 2 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (SF-36 
MCS response 
(+3.9 pts)) @ 18 
wks 
NA 
Yes 
Incidence  
92 / 208 (44.2%) 
Incidence  
67 / 207 (32.4%) P: 0.016 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (SF-36 
MCS) @ 18 wks 
NA 
Yes 
F: Mean, 46.9 (SD, 
11.53) P: 0.001 
F: Mean, 45.2 (SD, 
11.83) P: 0.001 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (SF-36 
PCS response (+4.1 
pts)) @ 18 wks 
NA 
Yes 
Incidence  
107 / 209 (51.2%) 
Incidence  
70 / 207 (33.8%) P: 0.001 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (SF-36 
PCS) @ 18 wks 
NA 
Yes 
F: Mean, 48.1 (SD, 8.17) 
P: 0.014 
F: Mean, 46.4 (SD, 7.69) 
P: 0.014 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (WPAI:CD 
Presenteeism) @ 18 
wks 
NA 
Yes 
F-B: Mean, 4.3 (SD, 23.6) 
P: NS 
F-B: Mean, 13.7 (SD, 
30.5) P: <0.001 
G1-G2: Mean, 9.4 (95% 
CI, 2.1 to 16.8) P: 0.013 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (WPAI:CD 
Daily activity 
impairment) @ 18 
wks 
NA 
Yes 
F-B: Mean, 5.1 (SD, 29.4) 
P: <0.05G1-G2: Mean,  
F-B: Mean, 15.3 (SD, 30) 
P: <0.001 
G1-G2: Mean, 10.2 (95% 
CI, 4.3 to 16.1) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (WPAI:CD 
Absenteeism) @ 18 
wks 
NA 
Yes 
F-B: Mean, 4 (SD, 25.1) 
P: NSG1-G2: Mean,  
F-B: Mean, 10.3 (SD, 
23.8) P: <0.001 
G1-G2: Mean, 6.3 (95% 
CI, -0.5 to 13.2) P: 0.07 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (WPAI:CD 
Overall work 
impairment) @ 18 
wks 
NA 
Yes 
F-B: Mean, 5.1 (SD, 24.4) 
P: <0.05G1-G2: Mean,  
F-B: Mean, 16.1 (SD, 
32.2) P: <0.001 
G1-G2: Mean, 11 (95% 
CI, 2.8 to 19.2) P: 0.01 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (EQ-5D 
VAS response (9.2-
pt increase)) @ 18 
wks 
NA 
Yes 
Incidence  
115 / 211 (57.2%) 
Incidence  
77 / 203 (37.9%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (EQ-5D 
VAS) @ 18 wks 
NA 
Yes 
F: Mean, 74.6 (SD, 
17.13) P: 0.002 
F: Mean, 70.2 (SD, 
18.07) P: 0.002 
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Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (Normal 
life) @ 18 wks 
NA 
Yes 
Incidence  
46 / 215 (21.4%) 
Incidence  
27 / 210 (12.9%) P: 0.019 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
HR QoL (QALY) @ 
18 wks 
NA 
Yes 
F: Mean, 0.25 (SD, 0.1) 
P: 0.001 
F: Mean, 0.21 (SD, 0.11) 
P: 0.001 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Perianal disease 
(Complete fistula 
closure) @ 18 wks 
NA 
Yes 
Incidence  
15 / 28 (54%) 
Incidence  
13 / 30 (43%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 4 
wks 
NA 
Yes 
Incidence  
15 / 19 (79%) 
Incidence  
12 / 18 (67%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 16 
wks 
NA 
Yes 
Incidence  
18 / 19 (94%) 
Incidence  
11 / 18 (61%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
15 / 19 (79%) 
Incidence  
10 / 18 (56%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 4 wks 
NA 
Yes 
Incidence  
17 / 19 (89%) 
Incidence  
16 / 18 (89%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 16 
wks 
NA 
Yes 
Incidence  
18 / 19 (95%) 
Incidence  
15 / 18 (83%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
15 / 19 (79%) 
Incidence  
13 / 18 (72%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
F-B: Mean, -150.8 (95% 
CI, -202 to -99.8) 
G1-G2: 31.2 
F-B: Mean, -119.6 (95% 
CI, -174 to -65.1) 
G1-G2: 31.2 P: <0.05 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
16 / 19 (85%) 
Incidence  
10 / 18 (55%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
17 / 19 (91%) 
Incidence  
9 / 18 (51%) 
D-182 
 
 
Evidence Table 9. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
15 / 19 (79%) 
Incidence  
8 / 18 (44%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 
16 wks 
NA 
Yes 
B: Mean, 187 
F: Mean, 177-10 
B: Mean, 188 
F: Mean, 171-17 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 187 
F: Mean, 178.4-8.6 
B: Mean, 188 
F: Mean, 162.4-25.6 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Mean, 187 
F: Mean, 181 P: NS-6 
B: Mean, 188 
F: Mean, 179 P: NS-9 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Steroid free 
(completely 
discontinued 
steroids) @ 52 wks 
NA 
Yes 
Incidence  
4 / 6 (67%) 
Incidence  
4 / 7 (56%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 4 
wks 
NA 
Yes 
Incidence  
16 / 18 (89%) 
Incidence  
12 / 18 (67%) P: NS 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 16 
wks 
NA 
Yes 
Incidence  
15 / 18 (84%) 
Incidence  
11 / 18 (61%) P: NS 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
100pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
16 / 18 (89%) 
Incidence  
10 / 18 (56%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 4 wks 
NA 
Yes 
Incidence  
18 / 18 (100%) 
Incidence  
16 / 18 (89%) P: NS 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 16 
wks 
NA 
Yes 
Incidence  
17 / 18 (95%) 
Incidence  
15 / 18 (83%) P: NS 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Response: 
70pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
16 / 18 (89%) 
Incidence  
13 / 18 (72%) P: NS 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
16 / 18 (89%) 
Incidence  
10 / 18 (55%) 
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Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
15 / 18 (83%) 
Incidence  
9 / 18 (51%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
15 / 18 (83%) 
Incidence  
8 / 18 (44%) P: <0.05 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
F-B: Mean, -197.7 (95% 
CI, -248 to -147) 
G1-G2: 78.1 
F-B: Mean, -119.6 (95% 
CI, -174 to -65.1) 
G1-G2: 78.1 P: <0.05 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Mean, 191 
F: Mean, 187 P: NS-4 
B: Mean, 188 
F: Mean, 179 P: NS-9 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 
16 wks 
NA 
Yes 
B: Mean, 191 
F: Mean, 186-5 
B: Mean, 188 
F: Mean, 171-17 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 191 
F: Mean, 185.6-5.4 
B: Mean, 188 
F: Mean, 162.4-25.6 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Steroid free 
(completely 
discontinued 
steroids) @ 52 wks 
NA 
Yes 
Incidence  
7 / 8 (88%) 
Incidence  
4 / 7 (56%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
70 pt drop) @ 22 
wks 
NA 
Yes 
Incidence  
93 / 172 (54.1%) 
Incidence  
48 / 170 (28.2%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
70 pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
74 / 172 (43%) 
Incidence  
30 / 170 (17.6%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 2 wks 
NA 
Yes 
B: Mean, 155 
F: Mean, 150 
F-B: -5 
B: Mean, 170 
F: Mean, 175  
F-B: 5 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 16 wks 
NA 
Yes 
B: Mean, 155 
F: Mean, 135  
F-B: -20 
B: Mean, 170 
F: Mean, 165  
F-B: -5 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 155 
F: Mean, 100 
F-B: -55 
B: Mean, 170 
F: Mean, 135 
F-B: -35 
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Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
100 pt drop) @ 22 
wks 
NA 
Yes 
Incidence  
89 / 172 (51.7%) 
Incidence  
45 / 170 (26.5%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
100 pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
71 / 172 (41.3%) 
Incidence  
28 / 170 (16.5%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
98 / 172 (57%) 
Incidence  
56 / 170 (33%) P: 0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
74 / 172 (43%) 
Incidence  
36 / 170 (21%) P: 0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
62 / 172 (36%) 
Incidence  
20 / 170 (12%) P: 0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Zung Self-
Rating Depression 
Scale) @ 8 wks 
NA 
Yes 
B: Mean, 44.9 (SD, 10.7) 
F: Mean, 43.4 (SD, 11) 
F-B: -1.5 
B: Mean, 46.1 (SD, 11.9) 
F: Mean, 47.4 (SD, 12.8) 
F-B: 1.3 P: <0.01 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Zung Self-
Rating Depression 
Scale) @ 52 wks 
NA 
Yes 
B: Mean, 44.9 (SD, 10.7) 
F: Mean, 43.7 (SD, 11)  
F-B: -1.2 
B: Mean, 46.1 (SD, 11.9) 
F: Mean, 47.9 (SD, 13.1)  
F-B: 1.8 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (FACIT-
Fatigue Scale 
Scores) @ 8 wks 
NA 
Yes 
B: Mean, 35.6 (SD, 10.6) 
F: Mean, 38.2 (SD, 10.5) 
F-B: 2.6 
B: Mean, 34.6 (SD, 11.3) 
F: Mean, 33.4 (SD, 12.2)  
F-B: -1.2 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (FACIT- 
Fatigue Scale 
Scores) @ 52 wks 
NA 
Yes 
B: Mean, 35.6 (SD, 10.6) 
F: Mean, 36.8 (SD, 11.2) 
F-B: 1.2 
B: Mean, 34.6 (SD, 11.3) 
F: Mean, 32.5 (SD, 12.6)  
F-B: -2.1 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 171 
F: Mean, 175 P: <0.001  
F-B: 4 
B: Mean, 168 
F: Mean, 160 P: <0.001  
F-B: -8 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 171 
F: Mean, 177 P: <0.0001  
F-B: 6 
B: Mean, 168 
F: Mean, 159 P: <0.0001  
F-B: -9 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
MCS) @ 8 wks 
NA 
Yes 
B: Mean, 46.2 (SD, 10.4) 
F: Mean, 48.4 (SD, 10.7) 
F-B: 2.2 
B: Mean, 47.4 (SD, 10.4) 
F: Mean, 46.2 (SD, 11) 
F-B: -1.2 P: NS 
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Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
MCS) @ 52 wks 
NA 
Yes 
B: Mean, 46.2 (SD, 10.4) 
F: Mean, 48.7 (SD, 10.5) 
F-B: 2.5 
B: Mean, 47.4 (SD, 10.4) 
F: Mean, 45.9 (SD, 11.2)  
F-B: -1.5 P: <0.05 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36, 
MCS - +5 pt 
increase) @ 52 wks 
NA 
Yes 
Incidence  
94 / 140 (67%) 
Incidence  
57 / 106 (54%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
PCS) @ 8 wks 
NA 
Yes 
B: Mean, 44.5 (SD, 7.8) 
F: Mean, 46.9 (SD, 8.6)  
F-B: 2.4 
B: Mean, 44.3 (SD, 8.9) 
F: Mean, 44.5 (SD, 9)  
F-B: 0.2 P: <0.01 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
PCS) @ 52 wks 
NA 
Yes 
B: Mean, 44.5 (SD, 7.8) 
F: Mean, 47.5 (SD, 8.5) 
F-B: 3 
B: Mean, 44.3 (SD, 8.9) 
F: Mean, 45.3 (SD, 8.6)  
F-B: 1 P: <0.05 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36, 
PCS - +5 pt 
increase) @ 52 wks 
NA 
Yes 
Incidence  
108 / 140 (77%) 
Incidence  
65 / 106 (61%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Abdominal 
pain VAS) @ 8 wks 
NA 
Yes 
B: Mean, 27.8 (SD, 19.4) 
F: Mean, 24 (SD, 21.2) 
F-B: -3.8 
B: Mean, 28.3 (SD, 19.5) 
F: Mean, 32.9 (SD, 24.5)  
F-B: 4.6 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Abdominal 
pain VAS) @ 52 
wks 
NA  
NA 
B: Mean, 27.8 (SD, 19.4) 
F: Mean, 23.9 (SD, 22.4)  
F-B: -3.9 
B: Mean, 28.3 (SD, 19.5) 
F: Mean, 36 (SD, 26.5)  
F-B: 7.7 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(Mean number of 
draining fistulas/ 
day) @ 52 wks 
NA 
No 
Event rate  
0.93 events among 1 d 
Event rate  
1.15 events among 1 d 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Steroid free 
(corticosteroid-free 
remission (CDAI < 
150)) @ 22 wks 
NA 
Yes 
Incidence  
20 / 58 (35%) 
Incidence  
2 / 66 (3%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Steroid free 
(corticosteroid-free 
remission (CDAI < 
150)) @ 52 wks 
NA 
Yes 
Incidence  
17 / 58 (29%) 
Incidence  
4 / 66 (6%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
70 pt drop) @ 22 
wks 
NA 
Yes 
Incidence  
88 / 157 (56.1%) 
Incidence  
48 / 170 (28.2%) P: 
<0.001 
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Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
70 pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
77 / 157 (49%) 
Incidence  
30 / 170 (17.6%) P: 
<0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 2 wks 
NA 
Yes 
B: Mean, 165 
F: Mean, 160  
F-B: -5 
B: Mean, 170 
F: Mean, 175  
F-B: 5 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 16 wks 
NA 
Yes 
B: Mean, 165 
F: Mean, 120  
F-B: -45 
B: Mean, 170 
F: Mean, 165  
F-B: -5 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 165 
F: Mean, 80  
F-B: -85 
B: Mean, 170 
F: Mean, 135  
F-B: -35 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
100 pt drop) @ 22 
wks 
NA 
Yes 
Incidence  
82 / 157 (52.2%) 
Incidence  
45 / 170 (26.5%) P: 
<0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Response: 
100 pt drop) @ 52 
wks 
NA 
Yes 
Incidence  
75 / 157 (47.8%) 
Incidence  
28 / 170 (16.5%) P: 
<0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
66 / 157 (42%) 
Incidence  
56 / 170 (33%) P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
71 / 157 (45%) 
Incidence  
36 / 170 (21%) P: 0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
65 / 157 (41%) 
Incidence  
20 / 170 (12%) P: 0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (FACIT- 
Fatigue Scale 
Scores) @ 8 wks 
NA 
Yes 
B: Mean, 34.2 (SD, 11.2) 
F: Mean, 34.6 (SD, 11.5)  
F-B: 0.4 
B: Mean, 34.6 (SD, 11.3) 
F: Mean, 33.4 (SD, 12.2)  
F-B: -1.2 P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (FACIT- 
Fatigue Scale 
Scores) @ 52 wks 
NA 
Yes 
B: Mean, 34.2 (SD, 11.2) 
F: Mean, 35 (SD, 12.7)  
F-B: 0.8 
B: Mean, 34.6 (SD, 11.3) 
F: Mean, 32.5 (SD, 12.6)  
F-B: -2.1 P: <0.05 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 167 
F: Mean, 170 P: <0.05  
F-B: 3 
B: Mean, 168 
F: Mean, 160 P: <0.05  
F-B: -8 
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Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 167 
F: Mean, 171 P: <0.01  
F-B: 4 
B: Mean, 168 
F: Mean, 159 P: <0.01  
F-B: -9 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Zung Self-
Rating Depression 
Scale) @ 8 wks 
NA 
Yes 
B: Mean, 47 (SD, 11.2) 
F: Mean, 46.1 (SD, 11.5) 
F-B: -0.9 
B: Mean, 46.1 (SD, 11.9) 
F: Mean, 47.4 (SD, 12.8)  
F-B: 1.3 P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Zung Self-
Rating Depression 
Scale) @ 52 wks 
NA 
Yes 
B: Mean, 47 (SD, 11.2) 
F: Mean, 45.9 (SD, 12.3)  
F-B: -1.1 
B: Mean, 46.1 (SD, 11.9) 
F: Mean, 47.9 (SD, 13.1)  
F-B: 1.8 P: <0.05 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
PCS) @ 8 wks 
NA 
Yes 
B: Mean, 43.7 (SD, 8.4) 
F: Mean, 46 (SD, 8.6)  
F-B: 2.3 
B: Mean, 44.3 (SD, 8.9) 
F: Mean, 44.5 (SD, 9)  
F-B: 0.2 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
PCS) @ 52 wks 
NA 
Yes 
B: Mean, 43.7 (SD, 8.4) 
F: Mean, 47.1 (SD, 9.4)  
F-B: 3.4 
B: Mean, 44.3 (SD, 8.9) 
F: Mean, 45.3 (SD, 8.6)  
F-B: 1 P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
MCS) @ 8 wks 
NA 
Yes 
B: Mean, 45.7 (SD, 9.3) 
F: Mean, 46.1 (SD, 11.9)  
F-B: 0.4 
B: Mean, 47.4 (SD, 10.4) 
F: Mean, 46.2 (SD, 11)  
F-B: -1.2 P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (SF-36 
MCS) @ 52 wks 
NA 
Yes 
B: Mean, 45.7 (SD, 9.3) 
F: Mean, 46.5 (SD, 12.4)  
F-B: 0.8 
B: Mean, 47.4 (SD, 10.4) 
F: Mean, 45.9 (SD, 11.2)  
F-B: -1.5 P: NS 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Abdominal 
pain VAS) @ 8 wks 
NA 
Yes 
B: Mean, 31 (SD, 18.7) 
F: Mean, 27.8 (SD, 23.1)  
F-B: -3.2 
B: Mean, 28.3 (SD, 19.5) 
F: Mean, 32.9 (SD, 24.5)  
F-B: 4.6 P: <0.05 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
HR QoL (Abdominal 
pain VAS) @ 52 
wks 
NA  
NA 
B: Mean, 31 (SD, 18.7) 
F: Mean, 26.7 (SD, 24.2)  
F-B: -4.3 
B: Mean, 28.3 (SD, 19.5) 
F: Mean, 36 (SD, 26.5)  
F-B: 7.7 P: <0.001 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Perianal disease 
(Mean number of 
draining 
fistulas/day) @ 52 
wks 
NA 
No 
Event rate  
0.65 events among 1 d 
Event rate  
1.15 events among 1 d 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Steroid free 
(corticosteroid-free 
remission (CDAI < 
150)) @ 22 wks 
NA 
Yes 
Incidence  
22 / 74 (30%) 
Incidence  
2 / 66 (3%) P: <0.001 
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Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Steroid free 
(corticosteroid-free 
remission (CDAI < 
150)) @ 52 wks 
NA 
Yes 
Incidence  
17 / 74 (23%) 
Incidence  
4 / 66 (6%) P: 0.008 
Lemann, 
200598 
Azathioprine 
Route: Oral 
Dose: as taken before 
enrollment every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI > 250, a CDAI 
between 150-250 on 
3 consecutive wks 
with an increase 
≥75 pts, or the need 
for surgery (with the 
exception of limited 
perianal surgery)) @ 
78 wks 
NA 
Yes 
Incidence  
3 / 40 (7.9%) 
Incidence  
9 / 43 (21.3%) P: 0.195 
Lemann, 
200598 
Azathioprine 
Route: Oral 
Dose: as taken before 
enrollment every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Remission 
duration) 
NA 
Yes 
Event rate  
17.3 months 
Event rate  
15.9 months 
Prantera, 
2005115 
Mesalamine (Asacol) 
Route: Oral 
Dose: 4 g 
Placebo 
Route: Unknown 
Dose: NA 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
NR 
Incidence  
3 / 23 (13%) 
Incidence  
3 / 17 (18%) 
Hanauer, 
2005106 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI≥150 plus 
increase of ≥60 pts 
or clinical 
deterioration) @ 13 
wks 
NA  
NA 
Incidence  
14 / 55 (25%) 
Incidence  
21 / 55 (38%) 
Hanauer, 
2005106 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI≥150 plus 
increase of ≥60 pts 
or clinical 
deterioration) @ 52 
wks 
NA 
Yes 
Incidence  
26 / 55 (47%) 
Incidence  
32 / 55 (58%) 
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Vilien, 2004101 Discontinued azathioprine Azathioprine 
Route: Unknown 
Dose: NR every 1 d 
CDAI (Relapse rate: 
CDAI ≥ 75 increase 
and CDAI >150 or 
any increased 
disease activity 
requiring new 
medical or surgical 
treatment) @ 52 
wks 
NA 
NR 
Incidence  
8 / 15 (53%) 
Incidence  
2 / 14 (14%) 
Mantzaris, 
2003113 
Mesalamine (Salofalk) 
Route: Unknown 
Dose: 1 g every 8 hrs 
Budesonide 
Route: Unknown 
Dose: 6 mg every 1 d 
CDAI (Relapse rate: 
>150 and >100 from 
baseline) @ 52 wks 
NA 
NR 
Incidence  
23 / 28 (82%) 
Incidence  
16 / 29 (55%) P: 0.045 
Mantzaris, 
2003113 
Mesalamine (Salofalk) 
Route: Unknown 
Dose: 1 g every 8 hrs 
Budesonide 
Route: Unknown 
Dose: 6 mg every 1 d 
HR QoL (IBDQ) @ 
52 wks 
NA 
NR 
G1-G2: Mean, 113 (SD, 
33) 
G1-G2: Mean, 150 (SD, 
44; 15.93 to 58.07) 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Absolute 
CDAI) @ 16 wks 
NA 
Yes 
F-B: Median, -42 F-B: Median, -16 
G1-G2: 26 P: 0.004 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Absolute 
CDAI) @ 40 wks 
NA 
Yes 
F-B: Median, -40 F-B: Median, -15 
G1-G2: 25 P: 0.04 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
16 wks 
NA 
Yes 
F-B: Median, 14 F-B: Median, 4 
G1-G2: -10 P: 0.002 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
40 wks 
NA 
Yes 
F-B: Median, 10 F-B: Median, 5 
G1-G2: -5 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(All surgeries) @ 40 
wks 
NA 
Yes 
Event rate  
49 events among 100 
persons 
Event rate  
100 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(All patients and 
surgeries) @ 40 wks 
NA 
Yes 
Event rate  
65 events among 100 
persons 
Event rate  
126 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(Major surgeries) @ 
40 wks 
NA 
Yes 
Event rate  
2 events among 100 
persons 
Event rate  
16 events among 100 
persons 
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Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(Major surgeries) @ 
40 wks 
NA 
Yes 
Event rate  
2 events among 100 
persons 
Event rate  
11 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(Inpatient surgeries 
and procedures) @ 
40 wks 
NA 
Yes 
Event rate  
16 events among 100 
persons 
Event rate  
55 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(Inpatient surgeries 
and procedures) @ 
40 wks 
NA 
Yes 
Event rate  
7 events among 100 
persons 
Event rate  
41 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Need for surgery 
(not specified) @ 40 
wks 
NA 
Yes 
Incidence  
1 / 96 (1%) 
Incidence  
0 / 99 (0%) 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Number of 
hospitalizations 
(mean number of 
hospitalizations per 
100 patients) @ 40 
wks 
NA 
Yes 
Event rate  
19 events among 100 
persons 
Event rate  
32 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Number of 
hospitalizations 
(mean number of 
hospitalizations per 
100 patients) @ 40 
wks 
NA 
Yes 
Incidence  
7 / 96 (7.3%) 
Event rate  
11 events among 100 
persons 
Incidence  
18 / 99 (18.2%) 
Event rate  
31 events among 100 
persons 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Number of 
hospitalizations 
(mean number of 
hospitalization days) 
@ 40 wks 
NA 
Yes 
0.5  2.5  
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Number of 
hospitalizations 
(mean number of 
hospitalization days) 
@ 40 wks 
NA 
Yes 
1.6  2.3  
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Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Perianal disease 
(50% fistula closure) 
@ 40 wks 
NA 
Yes 
Incidence  
9 / 43 (21%) 
Incidence  
7 / 44 (16%) 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Perianal disease 
(50% fistula closure) 
@ 40 wks 
NA 
Yes 
Incidence  
46 / 91 (42%) 
Incidence  
23 / 98 (23%) P: 0.001 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Perianal disease 
(Complete fistula 
closure) @ 40 wks 
NA 
Yes 
Incidence  
33 / 91 (36%) 
Incidence  
19 / 98 (19%) P: 0.009 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Perianal disease 
(Loss of response, 
defined as 
recrudescence of 
draining fistulas, the 
need for a change in 
medication, or need 
for additional 
medication, the 
need for surgery, or 
discontinuation of 
study due to lack of 
efficacy) @ 40 wks 
NA 
Yes 
Incidence  
40 / 96 (42%) 
Incidence  
61 / 99 (62%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 30 
wks 
NA  
NA 
Incidence  
44 / 113 (39%) 
Incidence  
23 / 110 (21%) P: 0.003 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
34 / 113 (30%) 
Incidence  
16 / 110 (15%) P: 0.007 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop & at least 
25% reduction) @ 
28 wks 
NA 
Yes 
Incidence  
62 / 113 (55%) 
Incidence  
30 / 110 (27%) P: 0.002 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop & at least 
25% reduction) @ 
52 wks 
NA 
Yes 
Incidence  
44 / 113 (39%) 
Incidence  
20 / 110 (18%) P: 0.001 
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Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
MCS) @ 30 wks 
NA 
Yes 
F-B: Mean, 4.6 
G1-G2: -1.7 
F-B: Mean, 2.9 
G1-G2: -1.7 P: NS 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
MCS) @ 52 wks 
NA 
Yes 
F-B: Mean, 5.1 
G1-G2: -3.1 
F-B: Mean, 2 
G1-G2: -3.1 P: NS 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
PCS) @ 28 wks 
NA 
Yes 
F-B: Mean, 7.3 
G1-G2: -4.2 
F-B: Mean, 3.1 
G1-G2: -4.2 P: <0.01 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
PCS) @ 52 wks 
NA 
Yes 
F-B: Mean, 6.1 
G1-G2: -3.6 
F-B: Mean, 2.5 
G1-G2: -3.6 P: <0.05 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
28 wks 
NA 
Yes 
B: Mean, 170 (SD, 26) 
F-B: Mean, 27.1 
G1-G2: -13.1 
B: Mean, 170 (SD, 29) 
F-B: Mean, 14 
G1-G2: -13.1 P: <0.05 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 170 (SD, 26) 
F-B: Mean, 22.1 
G1-G2: -13.2 
B: Mean, 170 (SD, 29) 
F-B: Mean, 8.9 
G1-G2: -13.2 P: <0.05 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Steroid free 
(Steroid-free 
remission) @ 52 
wks 
NA 
Yes 
OR: 4.2 (1.5 to 11.5) vs. 
main 
 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop in CDAI 
& at least 25% 
reduction) @ 28 wks 
NA 
Yes 
Incidence  
67 / 112 (60%) 
Incidence  
30 / 110 (27%) P: <0.001 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop & at least 
25% reduction) @ 
52 wks 
NA 
Yes 
Incidence  
53 / 112 (47%) 
Incidence  
20 / 110 (18%) P: <0.001 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 30 
wks 
NA  
NA 
Incidence  
50 / 112 (45%) 
Incidence  
23 / 110 (21%) P: 0.002 
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Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 52 
wks 
NA 
Yes 
Incidence  
45 / 112 (40%) 
Incidence  
16 / 110 (15%) P: <0.001 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
MCS) @ 30 wks 
NA 
Yes 
F-B: Mean, 4.9 
G1-G2: -2 
F-B: Mean, 2.9 
G1-G2: -2 P: NS 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
MCS) @ 52 wks 
NA 
Yes 
F-B: Mean, 5.8 
G1-G2: -3.8 
F-B: Mean, 2 
G1-G2: -3.8 P: <0.05 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
PCS) @ 28 wks 
NA 
Yes 
F-B: Mean, 7.3 
G1-G2: -4.2 
F-B: Mean, 3.1 
G1-G2: -4.2 P: <0.01 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (SF-36 
PCS) @ 52 wks 
NA 
Yes 
F-B: Mean, 7.2 
G1-G2: -4.7 
F-B: Mean, 2.5 
G1-G2: -4.7 P: <0.01 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
28 wks 
NA 
Yes 
B: Mean, 168 (SD, 31) 
F-B: Mean, 31.7 
G1-G2: -17.7 
B: Mean, 170 (SD, 29) 
F-B: Mean, 14 
G1-G2: -17.7 P: <0.01 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 168 (SD, 31) 
F-B: Mean, 30.2 
G1-G2: -21.3 
B: Mean, 170 (SD, 29) 
F-B: Mean, 8.9 
G1-G2: -21.3 P: <0.001 
Mahmud, 
2001116 
Olsalazine 
Route: Oral 
Dose: 2 g every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI >150 or 60-pt 
increase) @ 52 wks 
NA 
NR 
Incidence  
40 / 167 (24%) 
Incidence  
42 / 161 (26.1%) 
Mahmud, 
2001116 
Olsalazine 
Route: Oral 
Dose: 2 g every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
Clinical relapse 
(need for additional 
therapy or surgery 
in exceptional 
situations where 
CDAI criteria are not 
fulfilled) @ 52 wks 
NA 
NR 
Incidence  
15 / 167 (9%) 
Incidence  
17 / 161 (10.6%) 
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Cortot, 2001107 Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Unknown 
Dose: NA every 1 d 
CDAI (Relapse rate: 
>200 and 60 pt 
increase) @ 13 wks 
NA 
NR 
Incidence  
19 / 59 (32%) 
Incidence  
38 / 58 (65%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Absolute 
CDAI) @ 4 wks 
NA 
Yes 
B: Median, 175 
F: Median, 105 
B: Median, 170 
F: Median, 160 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Absolute 
CDAI) @ 16 wks 
NA 
Yes 
B: Median, 175 
F: Median, 102 
B: Median, 170 
F: Median, 192 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Absolute 
CDAI) @ 36 wks 
NA 
Yes 
B: Median, 175 
F: Median, 150 
B: Median, 170 
F: Median, 200 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop) @ 4 wks 
NA 
Yes 
Incidence  
30 / 37 (80%) 
Incidence  
28 / 36 (77%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop) @ 16 
wks 
NA 
Yes 
Incidence  
27 / 37 (73%) 
Incidence  
21 / 36 (58%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Response: 
70 pt drop) @ 36 
wks 
NA 
Yes 
Incidence  
20 / 37 (53%) 
Incidence  
11 / 36 (30%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 4 
wks 
NA 
Yes 
Incidence  
22 / 37 (59%) 
Incidence  
14 / 36 (40%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 16 
wks 
NA 
Yes 
Incidence  
22 / 37 (60%) 
Incidence  
11 / 36 (30%) 
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Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (Remission: 
CDAI < 150) @ 36 
wks 
NA 
Yes 
Incidence  
14 / 37 (37%) 
Incidence  
7 / 36 (20%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
CDAI (time to loss 
of response) 
NA 
Yes 
48 wks 37 wks P: 0.057 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 4 
wks 
NA 
Yes 
B: Median, 166 
F: Median, 180 
B: Median, 168 
F: Median, 166 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
16 wks 
NA 
Yes 
B: Median, 166 
F: Median, 180 
B: Median, 168 
F: Median, 160 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
HR QoL (IBDQ) @ 
36 wks 
NA 
Yes 
B: Median, 166 
F: Median, 158 
B: Median, 168 
F: Median, 137 
Ferguson, 
1998108 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 3 mg every 1 d + NA 
every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI > 150 and 60-
pt increase, or any 
deterioration 
requiring a different 
medicine or surgery) 
@ 52 wks 
NA 
Yes 
Incidence  
12 / 26 (46%) 
Incidence  
16 / 27 (60%) 
Ferguson, 
1998108 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 3 mg every 1 d + NA 
every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 75 
F-B: Mean, 71 
G1-G2: -3 
B: Mean, 90 
F-B: Mean, 68 
G1-G2: -3 
Ferguson, 
1998108 
Budesonide + placebo 
Route: Oral + Oral 
Dose: 3 mg every 1 d + NA 
every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
Median time to 
relapse) 
NA 
Yes 
335 days 310 days 
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Ferguson, 
1998108 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI > 150 and 60-
pt increase, or any 
deterioration 
requiring a different 
medicine or surgery) 
@ 52 wks 
NA 
Yes 
Incidence  
11 / 22 (48%) 
Incidence  
16 / 27 (60%) 
Ferguson, 
1998108 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 102 
F-B: Mean, 14 
G1-G2: 54 
B: Mean, 90 
F-B: Mean, 68 
G1-G2: 54 
Ferguson, 
1998108 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate 
definition: Median 
time to relapse) 
NA 
Yes 
275 days 310 days 
Gross, 1998109 Budesonide 
Route: Oral 
Dose: 3 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI<150 on 2 
consecutive wks) @ 
52 wks 
NA 
Yes 
Incidence  
56 / 84 (66.7%) 
Incidence  
62 / 95 (65.3%) 
de Franchis, 
1997118 
ASA + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 1000 mg every 8 hrs 
+ every 24 hrs 
Placebo + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: NA every 8 hrs + 
every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥60 
pts increase, and 
increase in at least 
2 of 3 acute phase 
reactants) @ 4 wks 
NA 
NR 
Incidence  
58 / 59 (98%) 
B: Mean, 70.5 (SD, 4.5) 
Incidence  
57 / 58 (98%) 
B: Mean, 71.2 (SD, 4.9) 
de Franchis, 
1997118 
ASA + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 1000 mg every 8 hrs 
+ every 24 hrs 
Placebo + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: NA every 8 hrs + 
every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥60 
pts increase, and 
increase in at least 
2 of 3 acute phase 
reactants) @ 16 wks 
NA 
NR 
Incidence  
16 / 58 (27%) 
Incidence  
10 / 59 (17%) 
de Franchis, 
1997118 
ASA + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 1000 mg every 8 hrs 
+ every 24 hrs 
Placebo + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: NA every 8 hrs + 
every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥60 
pts increase, and 
increase in at least 
2 of 3 acute phase 
reactants) @ 52 wks 
NA 
NR 
Incidence  
34 / 58 (58.3%) 
Incidence  
31 / 59 (52.2%) 
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Sutherland, 
1997117 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 750 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pts increase, or 
diagnosed flare up 
or need for steroids 
or hospitalization) @ 
12 wks 
NA 
No 
Incidence  
14 / 118 (12%) 
Incidence  
28 / 128 (22%) 
Sutherland, 
1997117 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 750 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pts increase, or 
diagnosed flare up 
or need for steroids 
or hospitalization) @ 
48 wks 
NA 
No 
Incidence  
41 / 118 (35%) 
Incidence  
55 / 128 (43%) 
Sutherland, 
1997117 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 750 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
CDAI (Absolute 
CDAI) @ 48 wks 
NA 
No 
B: Mean, 74.5 (SE, 3.7) 
F: Mean, 91.5 
F-B: Mean, 17 P: 0.02 
G1-G2: 18 
B: Mean, 75.2 (SE, 4) 
F: Mean, 110 
F-B: Mean, 35 P: 0.001 
G1-G2: 18 
Sutherland, 
1997117 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 750 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
HR QoL (IBDQ) @ 
48 wks 
NA 
No 
B: Mean, 193.4 (SE, 1.9) 
F: Mean, 180-13.4 
B: Mean, 193 (SE, 1.8) 
F: Mean, 179-14 
Sutherland, 
1997117 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 750 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
Time to relapse (not 
specified) 
NA 
No 
119 days 109 days 
Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 3 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥ 
60 pt increase) @ 
12 wks 
NA 
NR 
Incidence  
14 / 31 (45%) 
Incidence  
12 / 27 (44%) 
Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 3 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥ 
60 pt increase) @ 
52 wks 
NA 
NR 
Incidence  
23 / 31 (74%) 
Incidence  
17 / 27 (63%) 
Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 3 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Median time 
to relapse) 
NA 
NR 
175 days 146 days 
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Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 6 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥ 
60 pt increase) @ 
12 wks 
NA 
NR 
Incidence  
6 / 32 (19%) 
Incidence  
12 / 27 (44%) 
Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 6 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI > 150 and ≥ 
60 pt increase) @ 
52 wks 
NA 
NR 
Incidence  
19 / 32 (59%) 
Incidence  
17 / 27 (63%) 
Lofberg, 
1996110 
Budesonide 
Route: Oral 
Dose: 6 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Median time 
to relapse) 
NA 
NR 
271 days 146 days 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Median time 
to relapse ([CDAI 
≥150 + 60 pt 
increase] OR 
withdrawn because 
of medical or 
surgical treatment)) 
NA 
Yes 
124 days 39 days 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI ≥150 and ≥ 
60-pt increase or 
medical or surgical 
intervention) @ 52 
wks 
NA 
Yes 
Incidence  
23 / 33 (70%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 12 wks 
NA  
NA 
B: Mean, 96 (SD, 40) 
F: Mean, 155 (SD, 88) P: 
NS 
F-B: 59 
B: Mean, 115 (SD, 40) 
F: Mean, 197 (SD, 99) P: 
NS 
F-B: 82 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 96 (SD, 40) 
F: Mean, 209 (SD, 106) 
P: NS 
F-B: 113 
B: Mean, 115 (SD, 40) 
F: Mean, 210 (SD, 119) 
P: NS 
F-B: 95 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
B: Mean, 185 (SD, 21) 
F: Mean, 170 (SD, 39) P: 
NS-15 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35) P: 
NS 
F-B: -27 
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Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 3 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 185 (SD, 21) 
F: Mean, 156 (SD, 39) P: 
NS 
F-B: -29 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38) P: 
NS 
F-B: -31 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 12 wks 
NA  
NA 
B: Mean, 102 (SD, 36) 
F: Mean, 141 (SD, 87) P: 
NS 
F-B: 39 
B: Mean, 115 (SD, 40) 
F: Mean, 197 (SD, 99) P: 
NS 
F-B: 82 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Absolute 
CDAI) @ 52 wks 
NA 
Yes 
B: Mean, 102 (SD, 36) 
F: Mean, 182 (SD, 128) 
P: NS 
F-B: 80 
B: Mean, 115 (SD, 40) 
F: Mean, 210 (SD, 119) 
P: NS95 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
CDAI (Relapse rate: 
CDAI ≥150 and ≥ 
60-pt increase or 
medical or surgical 
intervention) @ 52 
wks 
NA 
Yes 
Incidence  
22 / 36 (61%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
Median time to 
relapse ([CDAI ≥150 
+ 60 pt increase] 
OR withdrawn 
because of medical 
or surgical 
treatment) 
NA 
Yes 
178 days 39 days P: 0.024 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
HR QoL (IBDQ) @ 
12 wks 
NA 
Yes 
B: Mean, 184 (SD, 24) 
F: Mean, 172 (SD, 35) P: 
NS 
F-B: -12 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35) P: 
NS 
F-B: -27 
Greenberg, 
1996111 
Budesonide 
Route: Oral 
Dose: 6 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
HR QoL (IBDQ) @ 
52 wks 
NA 
Yes 
B: Mean, 184 (SD, 24) 
F: Mean, 161 (SD, 36) P: 
NS 
F-B: -23 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38) P: 
NS 
F-B: -31 
Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (colitis/ 
ileocolitis only)) @ 4 
wks 
NA 
Yes 
Incidence  
10 / 102 (10%) 
Incidence  
15 / 105 (14%) 
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Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (colitis/ 
ileocolitis only)) @ 
12 wks 
NA 
Yes 
Incidence  
13 / 102 (13%) 
Incidence  
18 / 105 (17%) 
Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (colitis/ 
ileocolitis only)) @ 
52 wks 
Active 
Yes 
Yes 
Incidence  
28 / 102 (27%) 
HR: 0.694 (0.289 to 
1.666) 
P: 0.4501 vs. main 
Incidence  
33 / 105 (31%) 
Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (ileitis 
only)) @ 4 wks 
NA 
Yes 
Incidence  
4 / 36 (12%) 
Incidence  
3 / 43 (8%) P: NS 
Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (ileitis 
only)) @ 12 wks 
NA 
Yes 
Incidence  
6 / 36 (18%) 
Incidence  
8 / 43 (19%) P: NS P: NS 
Thomson, 
1995120 
Mesalamine 
Route: Oral 
Dose: 1.5 g every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI>150 and ≥ 60 
pt increase (ileitis 
only)) @ 52 wks 
NA 
Yes 
Incidence  
14 / 36 (40%) 
HR: 0.433 (0.1 to 1.878) 
P: 0.2634 vs. main 
Incidence  
10 / 43 (23%) P: NS 
Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg every 
1 d 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg every 1 d 
CDAI (Absolute 
CDAI) @ 64 wks 
NA 
Yes 
B: Median, 301 (IQR, 264 
to 358) 
F-B: Median, -191.5 (IQR, 
45.5 to 256.5) P: 0.06 
G1-G2: 141.5 
B: Median, 282 (IQR, 240 
to 356) 
F-B: Median, -50 (IQR, 8 
to 222) 
Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg every 
1 d 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg every 1 d 
CDAI (Remission: 
CDAI < 150) @ 12 
wks 
NA 
Yes 
Incidence  
19 / 30 (63%) 
Incidence  
24 / 33 (73%) P: 0.6 
Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg every 
1 d 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg every 1 d 
CDAI (Remission: 
CDAI < 150) @ 60 
wks 
NA  
NA 
Incidence  
2 / 30 (7%) 
Incidence  
14 / 33 (42%) P: 0.001 
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Candy, 199553 Placebo + prednisolone 
Route: Oral + Oral 
Dose: NA + 1 mg/kg every 
1 d 
Azathioprine + 
prednisolone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg every 1 d 
CDAI (Remission: 
CDAI<175) @ 64 
wks 
NA 
Yes 
Incidence  
14 / 33 (42%) 
RR: 6.36 (1.6 to 25.7) vs. 
main 
Incidence  
2 / 30 (7%) P: 0.001 
Arber, 1995121 ASA 
Route: Oral 
Dose: 1 g every 1 d 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
HBI (Relapse rate: 
>4 increase) @ 4 
wks 
NA 
Yes 
Incidence  
0 / 28 (0%) 
Incidence  
4 / 31 (14%) 
Arber, 1995121 ASA 
Route: Oral 
Dose: 1 g every 1 d 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
HBI (Relapse rate: 
>4 increase) @ 16 
wks 
NA 
Yes 
Incidence  
1 / 28 (3%) 
Incidence  
7 / 31 (21%) 
Arber, 1995121 ASA 
Route: Oral 
Dose: 1 g every 1 d 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
HBI (Relapse rate: 
>4 increase) @ 52 
wks 
NA 
Yes 
Incidence  
8 / 28 (27%) 
Incidence  
17 / 31 (55%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI<150 and ≥60 
pt increase) @ 52 
wks 
NA  
NA 
Incidence  
23 / 33 (70%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Time to 
relapse) 
NA  
NA 
124 days 39 days 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Absolute 
CDAI) @ 12 wks 
NA  
NA 
B: Mean, 96 (SD, 40) 
F: Mean, 155 (SD, 88) 
F-B: 59 
B: Mean, 115 (SD, 40) 
F: Mean, 197 (SD, 99)  
F-B: 82 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Absolute 
CDAI) @ 52 wks 
NA  
NA 
B: Mean, 96 (SD, 40) 
F: Mean, 209 (SD, 106)  
F-B: 113 
B: Mean, 115 (SD, 40) 
F: Mean, 210 (SD, 119)  
F-B: 95 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
7 / 67 (10%) 
Incidence  
7 / 66 (11%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
22 / 67 (33%) 
Incidence  
13 / 66 (20%) P: 0.13 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 131 
F: Mean, 142  
F-B: 11 
B: Mean, 130 
F: Mean, 141  
F-B: 11 
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Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 131 
F: Mean, 140  
F-B: 9 
B: Mean, 130 
F: Mean, 141  
F-B: 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
12 wks 
NA  
NA 
B: Mean, 185 (SD, 21) 
F: Mean, 170 (SD, 39)  
F-B: -15 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35)  
F-B: -27 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 1.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
52 wks 
NA  
NA 
B: Mean, 185 (SD, 21) 
F: Mean, 156 (SD, 39)  
F-B: -29 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38)  
F-B: -31 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
21 / 61 (34%) 
Incidence  
7 / 66 (11%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
31 / 61 (51%) 
Incidence  
13 / 66 (20%) P: <0.001 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Time to 
relapse) 
NA  
NA 
178 days 39 days 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Relapse rate: 
CDAI<150 and ≥60 
pt increase) @ 52 
wks 
NA  
NA 
Incidence  
22 / 36 (61%) 
Incidence  
24 / 36 (67%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Absolute 
CDAI) @ 12 wks 
NA  
NA 
B: Mean, 102 (SD, 36) 
F: Mean, 141 (SD, 87)  
F-B: 39 
B: Mean, 115 (SD, 40) 
F: Mean, 197 (SD, 99)  
F-B: 82 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Absolute 
CDAI) @ 52 wks 
NA  
NA 
B: Mean, 102 (SD, 36) 
F: Mean, 182 (SD, 128)  
F-B: 80 
B: Mean, 115 (SD, 40) 
F: Mean, 210 (SD, 119)  
F-B: 95 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 125 
F: Mean, 157 P: 0.0002  
F-B: 32 
B: Mean, 130 
F: Mean, 141 P: 0.0002  
F-B: 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 125 
F: Mean, 166 P: <0.001  
F-B: 41 
B: Mean, 130 
F: Mean, 141 P: <0.001  
F-B: 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
12 wks 
NA  
NA 
B: Mean, 184 (SD, 24) 
F: Mean, 172 (SD, 35)  
F-B: -12 
B: Mean, 181 (SD, 19) 
F: Mean, 154 (SD, 35)  
F-B: -27 
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Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 
52 wks 
NA  
NA 
B: Mean, 184 (SD, 24) 
F: Mean, 161 (SD, 36)  
F-B: -23 
B: Mean, 181 (SD, 19) 
F: Mean, 150 (SD, 38)  
F-B: -31 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 2 
wks 
NA 
Yes 
Incidence  
17 / 64 (27%) 
Incidence  
7 / 66 (11%) 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
CDAI (Remission: 
CDAI < 150) @ 8 
wks 
NA 
Yes 
Incidence  
28 / 64 (43%) 
Incidence  
13 / 66 (20%) P: 0.009 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 2 
wks 
NA 
Yes 
B: Mean, 130 
F: Mean, 155 P: 0.006  
F-B: 25 
B: Mean, 130 
F: Mean, 141 P: 0.006  
F-B: 11 
Greenberg, 
199466 
Budesonide 
Route: Oral 
Dose: 7.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 12 hrs 
HR QoL (IBDQ) @ 8 
wks 
NA 
Yes 
B: Mean, 130 
F: Mean, 154 P: 0.012  
F-B: 24 
B: Mean, 130 
F: Mean, 141 P: 0.012  
F-B: 11 
Gendre, 
1993122 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 500 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
Clinical relapses 
and surgical 
complications 
(Relapse rate: CDAI 
>250 or CDAI 
between 150 - 250 
but over the 
baseline value by 
>50 pts with 
confirmation 2 wks 
later and surgery for 
acute complications) 
NA 
NR 
Incidence  
29 / 80 (36%) 
Incidence  
34 / 81 (42%) 
Gendre, 
1993122 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 500 mg every 6 hrs 
Placebo 
Route: Oral 
Dose: NA every 6 hrs 
Probability of 
relapse or acute 
complication as a 
function of treatment 
and stratum 
(Relapse rate: CDAI 
> 300 or between 
150 - 300 if the 
increase was 50 
within 1 year) 
NA 
NR 
Incidence  
17 / 31 (55%) 
Incidence  
23 / 33 (71%) 
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Prantera, 
1992123 
ASA (Asacol) 
Route: Oral 
Dose: 800 mg every 8 hrs 
Placebo 
Route: Oral 
Dose: NA every 8 hrs 
CDAI (Relapse rate: 
CDAI > 150 and 100 
pt increase) @ 12 
wks 
NA 
Yes 
Incidence  
8 / 64 (12%) 
Incidence  
13 / 61 (22%) 
Prantera, 
1992123 
ASA (Asacol) 
Route: Oral 
Dose: 800 mg every 8 hrs 
Placebo 
Route: Oral 
Dose: NA every 8 hrs 
CDAI (Relapse rate: 
CDAI > 150 and 100 
pt increase) @ 52 
wks 
NA 
Yes 
Incidence  
22 / 64 (34%) 
Incidence  
34 / 61 (55%) P: 0.02 
Brignola, 
1992124 
ASA (Pentasa) 
Route: Oral 
Dose: 2 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
ileocolonic sub-
group) @ 16 wks 
NA 
No 
Incidence  
8 / 11 (73%) 
Incidence  
7 / 13 (54%) 
Brignola, 
1992124 
ASA (Pentasa) 
Route: Oral 
Dose: 2 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
CDAI >100 pt 
increase or >150 for 
more than 2 wks) @ 
16 wks 
NR 
Yes 
No 
Incidence  
11 / 21 (52%) 
Incidence  
13 / 22 (59%) 
Brignola, 
1992124 
ASA (Pentasa) 
Route: Oral 
Dose: 2 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA every 24 hrs 
CDAI (Relapse rate: 
ileal subgroup) @ 
16 wks 
NA 
No 
Incidence  
3 / 10 (30%) 
Incidence  
6 / 9 (67%) 
Brignola, 
1988112 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 0.25 mg/kg every 24 
hrs 
Placebo 
Route: Unknown 
Dose: NA 
CDAI (Relapse rate: 
Relapse after LI 
normalization to less 
than 100) 
NA 
NR 
Incidence  
5 / 7 (71%) 
Incidence  
2 / 3 (67%) 
Brignola, 
1988112 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 0.25 mg/kg every 24 
hrs 
Placebo 
Route: Unknown 
Dose: NA 
CDAI (Relapse rate: 
100 pt increase or 
CDAI >150 for more 
than 2 wks) @ 24 
wks 
NA 
NR 
Incidence  
1 / 9 (11%) 
Incidence  
7 / 9 (78%) 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
(Relapse rate: 
cumulative 
probability of 
relapse (clinically 
defined)) @ 24 wks 
NA 
No 
G1-G2: Mean, 0% G1-G2: Mean, 25% P: 
<0.01 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
(Relapse rate: 
cumulative 
probability of 
relapse (clinically 
defined)) @ 52 wks 
NA 
No 
G1-G2: Mean, 5% G1-G2: Mean, 41% P: 
<0.01 
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O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Unnamed disease 
activity score 
(Absolute score) @ 
52 wks 
NA 
No 
F-B: Mean, 0.63 P: <0.05 
G1-G2: 1.8 
F-B: Mean, 2.46 
G1-G2: 1.8 
Bergman, 
1976223 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 3 g every 24 hrs + 15 
mg every 24 hrs 
No treatment (Relapse rate: 
determined by X ray 
evidence) @ 132 
wks 
NA 
No 
Incidence  
16 / 49 (33%) 
Incidence  
10 / 35 (29%) 
Bergman, 
1976223 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 3 g every 24 hrs + 15 
mg every 24 hrs 
No treatment (Relapse rate: 
determined by X ray 
evidence) @ 52 wks 
NA 
No 
Incidence  
7 / 49 (14%) 
Incidence  
4 / 35 (11%) 
Bergman, 
1976223 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 3 g every 24 hrs + 15 
mg every 24 hrs 
No treatment (Relapse rate: 
determined by X ray 
evidence of 
recurrence between 
1 to 2 years of 
surgery) 
NA 
No 
Incidence  
8 / 42 (19%) 
Incidence  
4 / 31 (13%) 
Bergman, 
1976223 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 3 g every 24 hrs + 15 
mg every 24 hrs 
No treatment (Relapse rate: X ray 
evidence of relapse 
between 2 to 3 
years after surgery) 
NA 
No 
Incidence  
1 / 34 (3%) 
Incidence  
2 / 27 (7%) 
Bergman, 
1976223 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 3 g every 24 hrs + 15 
mg every 24 hrs 
No treatment (Relapse rate: 
Number of 
recurrences during 
study period) @ 132 
wks 
NA 
No 
Incidence  
9 / 31 (29%) 
Incidence  
2 / 13 (15%) 
Rosenberg, 
1975104 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Reduction of 
steroids (average 
reduction of 
prednisolone 
between groups) @ 
26 wks 
NA  
NA 
B: Mean, 19.1 
F: Mean, 3.6 P: <0.05 
F-B: -15.5 
B: Mean, 17.3 
F: Mean, 11.2 
F-B: -6.1 
Rosenberg, 
1975104 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Steroid free (Taper 
and stopping 
steroids) @ 26 wks 
NA 
NR 
Incidence  
5 / 10 (50%) 
Incidence  
3 / 10 (30%) 
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Feagan, 
2000105 
Methotrexate 
Route: IM 
Dose: 15 mg every 1 wks 
Placebo 
Route: IM 
Dose: NA every 1 wks 
CDAI (Relapse rate: 
CDAI increase of 
100 OR initiation of 
prednisone or 
antimetabolite) @ 4 
wks 
NA  
NA 
Incidence  
4 / 40 (10%) 
Incidence  
7 / 36 (20%) 
Feagan, 
2000105 
Methotrexate 
Route: IM 
Dose: 15 mg every 1 wks 
Placebo 
Route: IM 
Dose: NA every 1 wks 
CDAI (Relapse rate: 
CDAI increase of 
100 pts OR initiation 
of prednisone or 
antimetabolite) @ 
16 wks 
NA  
NA 
Incidence  
12 / 40 (29%) 
Incidence  
15 / 36 (42%) 
Feagan, 
2000105 
Methotrexate 
Route: IM 
Dose: 15 mg every 1 wks 
Placebo 
Route: IM 
Dose: NA every 1 wks 
CDAI (Relapse rate: 
CDAI increase of 
100 pts OR initiation 
of prednisone or 
antimetabolite) @ 
40 wks 
NA 
No 
Incidence  
14 / 40 (35%) 
Incidence  
22 / 36 (61%) P: 0.04 
Bresci G, 
1995125 
ASA 
Route: Unknown 
Dose: 2.4 g every 24 hrs 
Placebo 
Route: Unknown 
Dose: NA 
CDAI (Relapse rate: 
CDAI ≥ 150 or 100-
pt increase and LI ≥ 
100) 
NA 
No 
Incidence  
17 / 32 (53.1%) 
Incidence  
22 / 31 (70.9%) 
Wellmann W, 
1988126 
mesalamine (NR) 
Route: Oral 
Dose: NR 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI ≥150) @ 52 
wks 
NA 
No 
Incidence  
10 / 31 (32%) 
Incidence  
14 / 35 (40%) 
Willoughby 
JM, 197199 
Prednisolone + 
azathioprine 
Route: Oral + Oral 
Dose: 60 mg every 24 hrs + 
4 mg/kg every 24 hrs 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 60 mg every 1 d + 
NA every 24 hrs 
Other index: (not 
specified) @ 24 wks 
NA 
No 
B: Mean, 10.7 
F: Mean, 2.3 
F-B: -8.4 
B: Mean, 7.8 
F: Mean, 8 
F-B: 0.2 
Willoughby 
JM, 197199 
Prednisolone + 
azathioprine 
Route: Oral + Oral 
Dose: current + 2 mg/kg 
every 24 wks 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: 60 mg every 1 d + 
NA every 24 hrs 
Other index: (not 
specified) @ 24 wks 
NA 
No 
B: Mean, 3.2 
F: Mean, 4.4 
F-B: 1.2 
B: Mean, 7.8 
F: Mean, 8 
F-B: 0.2 
D-207 
 
 
Evidence Table 9. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Willoughby 
JM, 197199 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: current dose + NA 
every 24 hrs 
Prednisolone + 
azathioprine 
Route: Oral + Oral 
Dose: 60 mg every 24 hrs + 
4 mg/kg every 24 hrs 
Other index: (not 
specified) @ 24 wks 
NA 
No 
B: Mean, 1.8 
F: Mean, 8.6 
F-B: 6.8 
B: Mean, 10.7 
F: Mean, 2.3 
F-B: -8.4 
Willoughby 
JM, 197199 
Prednisolone + 
azathioprine 
Route: Oral + Oral 
Dose: current dose + 2 
mg/kg every 24 wks 
Prednisolone + placebo 
Route: Oral + Oral 
Dose: current dose the 
patient is taking to keep 
him free of relapse every 
24 hrs + NA every 24 hrs 
Other index: (not 
specified) @ 24 wks 
NA 
No 
B: Mean, 3.2 
F: Mean, 4.4 
F-B: 1.2 
B: Mean, 1.8 
F: Mean, 8.6 
F-B: 6.8 
Singleton, 
197975 
Sulfasalazine + prednisone 
Route: Oral + Unknown 
Dose: 1g/15kg to 5g max 
every 1 d + 0.25 mg/kg 
every 1 d 
Placebo + prednisone 
Route: Oral + Oral 
Dose: NA + 0.25 mg/kg 
every 1 d 
CDAI (Remission: 
CDAI < 150) @ 24 
wks 
NA 
NR 
Incidence  
3 / 16 (19%) 
Incidence  
2 / 18 (11%) 
Singleton, 
197975 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 1g/15kg to 5g max 
every 1 d + 0.25 mg/kg 
every 1 d 
Placebo + prednisone 
Route: Oral + Oral 
Dose: NA + 0.25 mg/kg 
every 1 d 
CDAI (Remission: 
CDAI < 150) @ 24 
wks 
NA 
NR 
Incidence  
3 / 13 (23%) 
Incidence  
2 / 18 (11%) 
Singleton, 
197975 
Placebo + prednisone 
Route: Oral + Oral 
Dose: NA + 0.25 mg/kg 
every 1 d 
Sulfasalazine + prednisone 
Route: Oral + Unknown 
Dose: 1g/15kg to 5g max 
every 1 d + 0.25 mg/kg 
every 1 d 
CDAI (Remission: 
CDAI < 150) @ 24 
wks 
NA 
NR 
Incidence  
4 / 12 (33%) 
Incidence  
3 / 16 (19%) 
Singleton, 
197975 
Sulfasalazine + prednisone 
Route: Oral + Oral 
Dose: 1g/15kg to 5g max 
every 1 d + 0.25 mg/kg 
every 1 d 
Placebo + prednisone 
Route: Oral + Oral 
Dose: NA + 0.25 mg/kg 
every 1 d 
CDAI (Remission: 
CDAI < 150) @ 24 
wks 
NA 
NR 
Incidence  
3 / 13 (23%) 
Incidence  
4 / 12 (33%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
8 / 58 (13%) 
Incidence  
11 / 101 (11%) 
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Evidence Table 9. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
19 / 58 (33%) 
Incidence  
27 / 101 (27%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 6 (17%) 
Incidence  
2 / 7 (29%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
9 / 61 (15%) 
Incidence  
11 / 101 (11%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
18 / 61 (29%) 
Incidence  
27 / 101 (27%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 2 (50%) 
Incidence  
2 / 7 (29%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
9 / 54 (16%) 
Incidence  
11 / 101 (11%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
16 / 54 (29%) 
Incidence  
27 / 101 (27%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
0 / 3 (0%) 
Incidence  
2 / 7 (29%) 
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Evidence Table 9. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
9 / 61 (15%) 
Incidence  
8 / 58 (13%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
18 / 61 (29%) 
Incidence  
19 / 58 (33%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
1 / 2 (50%) 
Incidence  
1 / 6 (17%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
9 / 54 (16%) 
Incidence  
8 / 58 (13%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
16 / 54 (29%) 
Incidence  
19 / 58 (33%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1/2 g/ 15 kg every 24 
hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
0 / 3 (0%) 
Incidence  
1 / 6 (17%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 16 wks 
NA 
Yes 
Incidence  
9 / 54 (16%) 
Incidence  
9 / 61 (15%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
CDAI (Relapse rate: 
CDAI>150 and 
≥100-pt increase, 
plus other criteria) 
@ 52 wks 
NA 
Yes 
Incidence  
16 / 54 (29%) 
Incidence  
18 / 61 (29%) 
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Evidence Table 9. Effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in terms of 
maintaining remission (KQ2) 
 
Author, year 
 
Group1 Group2 Outcome 
(definition) 
Adverse 
event 
collection 
/ ITT 
Results, Group 1 Results, Group 2 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 04-Jan mg/kg every 
24 hrs 
Perianal disease 
(Complete fistula 
closure) @ 104 wks 
NA 
No 
Incidence  
0 / 3 (0%) 
Incidence  
1 / 2 (50%) 
Abbreviations: 95% CI = 95% Confidence Interval; 6-MP = 6-Mercaptopurine; @ = at; AE = adverse events; AP = Acute Phase; ASA = Aminosalicylates; CD = Crohn’s Disease; 
CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; d= day; EQ-5D VAS = EuroQol (EQ-5D), a generic health index comprises a 
five-part questionnaire and a visual analogue self-rating scale; FACIT = functional assessment of chronic illness therapy; g = gram; g/kgs = gram/kilograms; h = hour; HBI = 
Harvey-Bradshaw Index; HR QoL= Health-related Quality of Life; hrs = hours; IBDQ = Inflammatory Bowel Disease Questionnaire; IFX= Infliximab; IM = intramuscular; IV= 
intravenous; IQR= inter-quartile range; ITT = intention to treat; kg = kilogram; Max. = maximum; MCS = Mental Component Score; mg = milligram; mg/d = milligram/day; 
mg/kg = milligram/kilogram; mg/mo = milligram/month; Min. = minimum; Mo/mos= month(s); NA = Not Applicable; NR= Not Reported; NS = not significant; OR: Odds Ratio; 
PCS = Physical Component Score; PGWB = Psychological General Well-Being; P = p-value; pt = point; QALY = Quality-Adjusted Life Year; rx = reaction; SC = subcutaneous; 
SD = standard deviation; SE= standard error; SES-CD = Simplified Endoscopic Activity Score for Crohn’s Disease; SF = Short Form; Steroid free = steroid-free remission; TNF = 
tumor necrosis factor; TPMT= thiopurine methyltransferase; UTD = unable to determine; VAS = visual analog scale; and wks = weeks; WPAI:CD = Work Productivity and 
Activity Impairment: Crohn's Disease.  
.  
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Evidence Table 10. Study quality of randomized controlled trials reporting on the effectiveness of pharmacologic therapies for the 
management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Randomized controlled trials evaluating biologics 
Colombel, 
200782  
Yes Yes Yes No No Yes Yes Poor 
Feagan, 200393 Yes Yes Yes No No Yes Yes Poor 
Feagan, 200781  Yes Yes Yes Unclear No Yes Yes Fair 
Feagan, 200890  Yes Yes Yes Yes No Yes Yes Fair 
Hanauer, 200286  Yes Yes Yes No No Yes Yes Poor 
Lichtenstein, 
200592 
Yes Yes Yes Unclear Yes Yes Yes Fair 
Mantzaris, 
200988  
Unclear No No No Yes No No Poor 
Rutgeerts, 
199985  
Yes Yes Yes No Yes Yes Yes Fair 
Rutgeerts, 
200494 
Yes Yes Yes No Yes Yes Yes  Poor 
Sandborn, 
200533 
Yes Yes Yes Unclear No Yes Yes Fair 
Sandborn, 
200783  
Yes Yes Yes Yes Yes Yes Yes Fair 
Sands, 200487  Yes Yes Yes Yes Yes Yes Yes Fair 
Schreiber, 
200784  
Yes Yes Yes Yes Yes Yes Yes Fair 
Van Assche, 
200889  
Yes Yes No Yes No No No Poor 
Randomized controlled trials evaluating thiopurines 
Candy, 199553  Unclear Yes Unclear Unclear Yes UTD NA Fair 
Lemann, 200598  Yes Yes Yes Yes Yes Yes UTD Good 
Mantzaris, 
2009102  
Yes Yes No No Yes UTD NA Fair 
O'Donoghue, 
1978100  
Unclear Unclear Yes Yes Yes UTD NA Good 
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Evidence Table 10. Study quality of randomized controlled trials reporting on the effectiveness of pharmacologic therapies for the 
management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Rosenberg, 
1975104  
Unclear Yes Yes Yes Yes Yes UTD Good 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Vilien, 2004101  Yes Yes No Yes Yes UTD NA Good 
Willoughby JM, 
197199  
Yes Yes Yes Yes Yes UTD NA Good 
Randomized controlled trials evaluating methotrexate 
Feagan, 2000105  Yes Yes Yes No No Yes No Fair 
Randomized controlled trials evaluating corticosteroids 
Bergman, 
1976223  
Yes No No Yes No Yes NA Poor 
Brignola, 1988112  Unclear Unclear Unclear Yes No UTD NA Fair 
Cortot, 2001107  Yes Yes Yes Yes Yes Yes Yes Good 
de Franchis, 
1997118  
Yes Yes Yes No Yes Yes UTD Poor 
Ferguson, 
1998108  
Yes Yes Yes Yes No Yes Yes Good 
Greenberg, 
199466  
Unclear Unclear Unclear Unclear No Yes Yes Fair 
Greenberg, 
1996111  
Yes Unclear Unclear Unclear No Yes Yes Poor 
Gross, 1998109  Unclear Unclear Yes Yes No Yes UTD Fair 
Hanauer, 
2005106  
Yes Unclear Unclear Unclear No Yes Yes Fair 
Lofberg, 1996110  Yes Yes Yes Yes Yes Yes UTD Good 
Malchow, 198464  Unclear Yes Yes No No Yes UTD Fair 
Mantzaris, 
2003113  
Unclear Unclear No Yes Yes UTD NA Fair 
Singleton, 
197975  
Unclear Yes Yes Yes Yes No NA Good 
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Evidence Table 10. Study quality of randomized controlled trials reporting on the effectiveness of pharmacologic therapies for the 
management of moderate to severe Crohn’s disease in terms of maintaining remission (KQ2) 
 
Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Randomized controlled trials evaluating 5-aminosalicylate acids 
Arber, 1995121  Yes Yes Yes Unclear Yes UTD NA Fair 
Bresci G, 
1995125  
No No Unclear Yes Yes UTD NA Fair 
Brignola, 1992124  Unclear Yes Yes Yes Yes Yes No Good 
Cezard, 2009194  Yes Yes Yes Unclear Yes No NA Fair 
Gendre, 1993122  Unclear Unclear Yes Yes Yes No NA Good 
Mahmud, 
2001116  
Yes Yes Yes Yes Yes Yes UTD Good 
Malchow, 198464  Unclear Yes Yes No No Yes UTD Fair 
Prantera, 
1992123  
Unclear Unclear Yes Yes Yes  NA Good 
Prantera, 
2005115  
Unclear Unclear Unclear No No Yes Yes Poor 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Sutherland, 
1997117  
Yes Yes Yes No Unclear UTD NA Poor 
Thomson, 
1995120  
Yes Yes Yes Unclear Unclear Yes UTD Poor 
Wellmann W, 
1988126  
Unclear Yes Yes Yes Yes UTD NA Good 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Study Quality Criteria: Criteria for a judgment of “GOOD” (i.e. low risk of bias): These studies have the least bias and results are considered valid- A study that adheres mostly to 
the commonly held concepts of high quality including the following: a) A formal randomized controlled study; b)Clear description of the population, setting, interventions, and 
comparison groups; c) Appropriate measurements of outcomes; d) Appropriate statistical and analytic methods and reporting; e) No reporting errors; f) Low dropout rate; and g) 
Clear reporting of dropouts. Criteria for a judgment of “FAIR”: a) These studies are susceptible to some bias, but it is not sufficient to invalidate the results; b) do not meet all the 
criteria required for a rating of good qualities because they have some deficiencies, but no flaw is likely to cause major bias; and c) The study may be missing information, making 
it difficult to assess limitations and potential problems. Criteria for a judgment of “POOR” (i.e. high risk of bias):a) These studies have significant flaws that imply biases of 
various types that may invalidate the results; b) Have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.  
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
TNF-alpha 
inhibitor vs no 
TNF-alpha 
inhibitor 
Mortality 12 RCTs 
3,896 CD 
1 prospective 
2 retrospective 
6,464 CD 
1,409 IBD 
Moderate Consistent Direct Very imprecise Neither favored 
Observational RR range 
0.8 – 4.3 
Low 
 
Infliximab + IMM 
vs infliximab 
Mortality 3 RCTs 
535 CD 
 
3 retrospective 
1 unclear 
690 CD 
221 IBD 
High Inconsistent Direct Very imprecise Neither favored 
Low 
Infliximab + IMM 
vs IMM 
Mortality 1 RCT 
340 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Infliximab + 
corticosteroids 
vs infliximab 
Mortality 2 retrospective 
71 CD 
100 IBD 
High NA Direct Very imprecise Neither favored 
Low 
Infliximab vs 
IMM 
Mortality 1 RCT 
324 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Natalizumab vs 
placebo 
Mortality 3 RCTs 
1,414 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
IMM vs no IMM Mortality 3 RCTs 
425 CD 
 
2 prospective 
2 retrospective 
11,829 CD 
19,486 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observational RR range 
0.7 – 1.3 Low 
Azathioprine vs 
corticosteroids 
Mortality 2 RCTs 
336 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
Azathioprine vs 
sulfasalazine 
Mortality 1 RCT 
245 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Azathioprine + 
prednisone vs 
prednisone 
Mortality 1 RCT 
81 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Corticosteroids 
vs no 
corticosteroids 
Mortality 2 RCTs 
547 CD 
 
1 prospective 
3 retrospective 
15,070 CD 
554 IBD 
High Inconsistent Direct Imprecise No corticosteroids favored 
Observational RR range 
1.0 – 2.5 
Low 
Corticosteroids 
vs ASA 
Mortality 2 RCTs 
508 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
Corticosteroids 
+ ASA vs 
placebo, 
corticosteroids 
or ASA 
Mortality 1 RCT 
452 CD 
 
Moderate NA Direct Very imprecise Neither favored 
Low 
ASA vs no ASA Mortality 4 RCTs 
674 CD 
 
1 retrospective 
3,241 CD 
Moderate Inconsistent Direct Imprecise Neither favored 
Observational RR 0.7 
Low 
TNF-alpha 
inhibitor vs no 
TNF-alpha 
inhibitor 
Lymphoma 8 RCTs 
2,704 CD 
  
3 retrospective 
9,389 CD 
1,409 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
Observational RR range 
0.6 – 1.7 
Low 
 
TNF-alpha 
inhibitor + IMM + 
steroids vs no 
therapy 
Lymphoma 1 retrospective 
NR CD 
High NA Direct Very imprecise Neither favored  
Low 
Infliximab + IMM 
vs infliximab 
Lymphoma 1 retrospective 
100 IBD 
High NA Direct Very imprecise Neither favored 
Low 
TNF-alpha 
inhibitor + IMM 
vs no therapy 
Lymphoma 1 retrospective 
NR CD 
High NA Direct Imprecise Neither favored 
Observational RR = 1.5 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Infliximab + 
corticosteroids 
vs infliximab 
Lymphoma 1 retrospective 
100 IBD 
High NA Direct Very imprecise Neither favored 
Low 
TNF-alpha 
inhibitor + 
corticosteroids 
vs no therapy 
Lymphoma 1 retrospective 
NR CD 
High NA Direct Very imprecise Neither favored 
Low 
Natalizumab vs 
placebo 
Lymphoma 3 RCTs 
1,414 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
Natalizumab + 
infliximab vs 
infliximab 
Lymphoma 1 RCT 
79 CD 
Low NA Direct Very imprecise Neither favored 
Low 
IMM vs no IMM Lymphoma 1 prospective 
4 retrospective 
1 case-control 
8,581 CD 
54,939 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observational RR range 
0.3 – 5.3 Low 
IMM + 
corticosteroids 
vs no therapy 
Lymphoma 1 retrospective 
NR CD 
High NA Direct Very imprecise Neither favored 
Low 
Azathioprine + 
ASA vs 
azathioprine 
Lymphoma 1 retrospective 
104 CD 
High NA Direct Very imprecise Neither favored 
Low 
Corticosteroids 
vs no therapy 
Lymphoma 1 retrospective 
NR CD 
High NA Direct Very imprecise Neither favored 
Observation HR 1.0 
Low 
Corticosteroids 
vs no 
corticosteroids 
Lymphoma 1 retrospective 
15,164 IBD 
 
High NA Direct Imprecise Neither favored 
Observational OR 1.0 
Low 
ASA vs no ASA Lymphoma 1 retrospective 
15,164 IBD 
 
High NA Direct Imprecise Neither favored 
Observational OR 1.0 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
TNF-alpha 
inhibitor vs no 
TNF-alpha 
inhibitor 
Cervical cancer 1 RCT 
371 CD women 
 
3 retrospective 
1,567 IBD women 
High Inconsistent Direct Imprecise Neither favored; Low 
IMM vs no IMM Cervical cancer 4 retrospective 
1,942 IBD women 
High Inconsistent Direct Imprecise Neither favored; Low 
Corticosteroids 
vs no 
corticosteroids 
Cervical cancer 2 retrospective 
1,205 IBD women 
High Inconsistent Direct Imprecise Neither favored; Low 
ASA vs no ASA Cervical cancer 1 retrospective 
1,165 IBD women 
High NA Direct Imprecise Neither favored; Low 
TNF-alpha 
inhibitor vs no 
TNF-alpha 
inhibitor 
Cancers 8 RCTs 
3,393 CD 
3 retrospective 
1,966 CD 
1,409 IBD 
1 case-control 
1,935 CD 
Moderate Inconsistent Direct Imprecise Neither favored 
Observational RR range 
0.2 – 3.6 
Low 
TNF-alpha 
inhibitor + IMM + 
steroids vs no 
therapy 
Cancers 1 retrospective 
8,581 CD 
High NA Direct Imprecise Neither favored 
Observational RR 0.7 – 
0.9 
Low 
TNF-alpha 
inhibitor + IMM 
versus no TNF-
alpha inhibitor + 
no IMM 
Cancers 1 case-control 
1,935 CD 
High NA Direct Precise No TNF + No IMM favored 
Observational RR range 
5.9 – 6.8 
Low 
Infliximab + IMM 
vs infliximab 
Cancers 3 RCTs 
441 CD 
2 retrospective 
573 CD 
100 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
Observational RR 2.9 
Low 
Infliximab + IMM 
vs IMM 
Cancers 2 RCTs 
435 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
TNF-alpha 
inhibitor + IMM 
vs no therapy 
Cancers 1 retrospective 
8,581 CD 
High NA Direct Imprecise Neither favored 
Observational RR range 
0.9 – 1.1 
Low 
Infliximab + 
corticosteroids 
vs infliximab 
Cancers 2 retrospective 
221 IBD 
High NA Direct Very imprecise Neither favored 
Low 
TNF-alpha 
inhibitor + 
corticosteroids 
vs no therapy 
Cancers 1 retrospective 
8,581 CD 
High NA Direct Imprecise Neither favored 
Observational RR range 
0.3 – 0.6  
Low 
Infliximab vs 
IMM 
Cancers 1 RCT 
324 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Natalizumab vs 
placebo 
Cancers 3 RCTs 
1,414 CD 
Moderate Consistent Direct Very imprecise Neither favored 
Low 
Natalizumab + 
infliximab vs 
infliximab 
Cancers 1 RCT 
79 CD 
Low NA Direct Very imprecise Neither favored 
Low 
IMM vs no IMM Cancers 1 RCT 
291 CD 
1 prospective 
 3 retrospective 
 5 case-control 
10,551 CD 
39,527 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observational RR range 0 
– 10.8 
Low 
IMM + 
corticosteroids 
vs no therapy 
Cancers 1 retrospective 
8,581 CD 
High NA Direct Very imprecise Neither favored 
Low 
Azathioprine vs 
prednisone 
Cancers 1 RCT 
259 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Azathioprine vs 
sulfasalazine 
Cancers 1 RCT 
245 CD 
Moderate NA Direct Very imprecise Neither favored 
Low 
Azathioprine + 
ASA vs 
azathioprine 
Cancers 1 retrospective 
104 CD 
High NA Direct Very imprecise Neither favored 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Corticosteroids 
vs no 
corticosteroids 
Cancers 1 RCT 
324 CD 
1 retrospective 
3 case-control 
8,616 CD 
1,584 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observation RR range 1.0 
– 1.6 
Low 
Prednisone vs 
sulfasalazine 
Cancers 1 RCT 
278 CD 
 
Moderate NA Direct Very imprecise Neither favored 
Low 
ASA vs no ASA Cancers 1 RCT 
310 CD 
1 retrospective 
3 case-control 
35 CD 
10.328 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observational RR 0.2 – 
1.2  
Low 
TNF-alpha 
inhibitor versus 
no TNF-alpha 
inhibitor 
Infections 13 RCTs 
4,059 CD 
1 prospective 
1 retrospective 
1 case-control 
6,290 CD 
1,709 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RCT RR range 0.3 – 5.5 
Observational RR range 
0.7 – 11.1 
Low 
Infliximab + IMM 
vs infliximab 
Infections 3 RCTs 
607 CD 
1 retrospective 
1 uclear 
57 CD 
121 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RR range 0.8 – 3.2 
Low 
Infliximab + IMM 
vs IMM 
Infections 2 RCTs 
340 CD 
 
1 retrospective 
10,141 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RR 1.1 
Low 
Infliximab + IMM 
vs 
corticosteroids 
Infections 1 RCT 
129 CD 
Moderate NA Direct Imprecise Neither favored 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Infliximab vs 
IMM 
Infections 1 RCT 
324 CD 
1 retrospective 
3.404 IBD 
Moderate NA Direct Imprecise Neither favored 
RCT RR range 0.9 – 1.0 
Observational RR range 
0.7 – 1.1 
Low 
TNF-alpha 
inhibitor + IMM 
vs no therapy 
Infections 1 retrospective 
1 case-control 
8,581 CD 
300 IBD 
High NA Direct Imprecise Neither favored 
RR range 0.7 – 4.8 
Low 
TNF-alpha 
inhibitor + IMM + 
corticosteroids 
vs no therapy 
Infections 1 retrospective 
1 case control 
8,581 CD 
300 IBD 
High NA Direct Imprecise Neither favored 
RR range 2.4 – 4.1 
Low 
TNF-alpha 
inhibitor + 
corticosteroids 
vs no therapy 
Infections 1 retrospective 
8,581 CD 
High NA Direct Imprecise Neither favored 
RR range 0.7 – 5.6 
Low 
Natalizumab 
versus placebo 
Infections 3 RCTs 
1,414 CD 
Moderate  Inconsistent Direct Imprecise Neither favored 
RR range 0.3 – 1.3 
Low 
Natalizumab + 
infliximab vs 
infliximab 
Infections 1 RCT 
79 CD 
Moderate NA Direct Imprecise Neither favored 
RR 0.9 
Low 
IMM vs no IMM Infections 3 RCTs 
463 CD 
1 retrospective, 1 
prospective 
6253 CD 
302 IBD 
Moderate NA Direct Imprecise Neither favored 
RR range 0.6 – 2.0 
Low 
IMM vs no 
therapy 
Infections 1 retrospective 
2 case-control 
10,141 CD 
2,538 IBD 
High NA Direct Imprecise Neither favored 
RR range 0.6 – 4.1 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
IMM vs 
corticosteroids 
Infections 2 RCTs 
336 CD 
1 retrospective 
10,141 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RR range 0.3 – 2.9 
Low 
Azathioprine vs 
sulfasalazine 
Infections 1 RCT 
245 CD 
Moderate NA Direct Imprecise Neither favored 
RR 0.6 
Low 
IMM + steroids 
vs steroids 
Infections 3 RCTs 
263 CD 
Moderate Inconsistent Direct Imprecise Neither favored 
RR range 0.9 – 1.3 
Low 
Azathioprine + 
ASA vs 
azathioprine 
Infections 1 retrospective 
199 IBD 
High NA Direct Very imprecise Neither favored 
Low 
IMM + 
corticosteroids 
vs no therapy 
Infections 1 retrospective 
2 case-control 
8,581 CD 
2,538 IBD 
High NA Direct  Imprecise Neither favored 
RR range 1.2 – 17.5 
Low 
Corticosteroids 
vs no 
corticosteroids 
Infections 2 RCTs 
362 CD 
1 prospective 1 
retrospective 
6,253 CD 
554 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RR range 0.4 – 2.9 
Low 
Corticosteroids 
vs no therapy 
Infections 1 retrospecitvie 
2 case-control  
8,581 CD 
2,538 IBD 
High NA Direct Imprecise Neither favored 
RR range 0.9 – 3.4 
Low 
Corticosteroids 
vs ASA 
Infections 2 RCTs 
216 CD 
Moderate NA Direct Imprecise Neither favored 
RR range 0.4 – 2.8 
Low 
Prednisone + 
sulfasalazine vs 
prednisone 
Infections 1 RCT 
89 CD 
Moderate NA Direct Precise PRED + SUL favored 
RR = 0.3 
Moderate 
Sulfasalazine vs 
placebo 
Infections 1 RCT 
159 CD 
Moderate NA Direct Imprecise Neither favored 
RR range 1.1 – 1.8 
Low 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Mesalamine vs 
no therapy 
Infections 1 case-control 
2,238 IBD 
High NA Direct Imprecise Neither favored 
RR 0.9 
Low 
TNF-alpha 
inhibitor vs 
placebo 
Tuberculosis 5 RCTs 
2,374 CD 
Moderate Consistent Direct Imprecise 4 cases observed in TNF 
treated, 0 in untreated 
Low 
Infliximab + 
azathioprine vs 
infliximab 
Tuberculosis 1 RCT 
340 CD 
Moderate NA Direct Imprecise 1 case in infliximab + 
azathioprine, 0 in 
infliximab 
Low 
Infliximab + IMM 
vs IMM 
Tuberculosis 1 RCT 
342 CD 
Moderate NA Direct Imprecise 1 case in infliximab + 
azathioprine, 0 in 
infliximab  
Low 
TNF-alpha 
inhibitor vs 
placebo 
Infusion and 
injection-site 
reactions 
13 RCTs 
4,389 CD 
Moderate Inconsistent Direct Precise Placebo favored for 
infliximab and 
adalimumab 
RCT RR range 1.1 – 3.2 
Low 
 
Neither favored for CP  
RCT RR range 0.2 – 6.4  
Low 
Infliximab + IMM 
vs infliximab 
Infusion and 
injection-site 
reactions 
3 RCTs 
468 CD 
1 prospective  
8 retrospective 
1,025 CD 
1,184 IBD 
Moderate Inconsistent Direct Imprecise Neither favored 
RCT RR range 0.3 – 1.5 
Observational RR range 
0.3 – 1.4 
Low 
Infliximab + IMM 
vs IMM 
Infusion and 
injection-site 
reactions 
2 RCTs 
453 CD 
Moderate Inconsistent Direct Imprecise Neither favored 
RCT RR 0.9 
Low 
Infliximab vs 
azathioprine 
Infusion and 
injection-site 
reactions 
1 RCT 
324 CD 
Low NA Direct Precise Azathioprine favored 
RCT RR 3.0 
High 
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Evidence Table 11. Number of studies and subjects, strength of evidence domains, magnitude of effect, and strength of evidence for 
safety (KQ3) 
 
Comparison Outcome Number of studies 
(Participants) 
Domains pertaining to strength of evidence Magnitude of effect 
 
Strength of evidence 
   Risk of bias Consistency Directness Precision  
Infliximab + 
thiopurines vs 
infliximab + 
methotrexate 
Infusion and 
injection-site 
reactions 
1 prospective  
2 retrospective  
291 CD 144 IBD 
High Inconsistent Direct Imprecise Neither favored 
Observational RR range 
0.8 – 1.4 
Low 
Infliximab + 
steroids vs 
infliximab + no 
steroids 
Infusion and 
injection-site 
reactions 
3 retrospective  
964 IBD 
High Inconsistent Direct Imprecise Neither favored 
Low 
Natalizumab vs 
placebo 
Infusion and 
injection-site 
reactions 
3 RCTs 
1,414 CD 
Moderate Inconsistent Direct Imprecise Neither favored 
RCT RR range 0.8 – 1.5 
Low 
Natalizumab + 
infliximab vs 
infliximab 
Infusion and 
injection-site 
reactions 
1 RCT 
79 CD 
High NA Direct Very imprecise Neither favored 
Low 
Azathioprine vs 
placebo 
Infusion and 
injection-site 
reactions 
1 RCT 
96 CD 
Low NA Direct Precise Placebo favored 
RCT RR 5.8 
High 
Budesonide vs. 
Prednisolone 
Fractures 1 RCT 
271 CD 
Low NA Direct Imprecise Neither favored 
Moderate 
Corticosteroids 
vs. no 
corticosteroids 
Fractures 3 
207 CD 
554 IBD 
High Consistent Direct Imprecise Neither favored 
Low 
ASA = aminosalicylate; CD = Crohn’s disease; CP = certolizumab pegol; HR = hazard ratio; IBD = inflammatory bowel disease; IMM = immunomodulator; NA = not applicable 
because only one study reported; NR = not reported; OR = odds ratio; RCT = randomized controlled trial; RR = relative risk, Steroids = corticosteroids; TNF = tumor necrosis 
factor; vs = versus 
The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further research is unlikely to change our confidence in the 
estimate of the effect. Moderate = Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of the effect and may 
change the estimate. Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of the effect and is likely to 
change the estimate. Insufficient = Evidence is unavailable. 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Studies evaluating biologics 
af 
Bjorkesten, 
2011163 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration:  11.5 
months 
Europe 
 
Single center 
NA Adults, CD only, previous use of infliximabactive disease, other criteria 
Biancone, 
2006149 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration: 48-60 
months 
Europe 
 
Multicenter 
NA CD only, other criteria 
Caspersen, 
2008225 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration: 29.1 
months 
Europe 
 
Multicenter 
NA NR 
Chaparro, 
2011160 
ENEIDA 
Prospective 
cohort 
Start year: NR 
Mean followup 
duration: 11 
months 
 
Median followup 
duration: 11 
months 
Europe 
 
Multicenter 
NA CD only, other criteria 
Clare, 
2009181 
Prospective 
cohort 
Start year: 2004 
 
Followup duration: 
NR 
Europe 
 
Single center 
NA IBD 
Colombel, 
2004137 
Retrospective 
cohort 
Start year: 1998 
 
Median followup 
duration: 17 
months 
US 
 
Multicenter 
NA CD only 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Colombel, 
200782 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2003 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of adalimumab, moderate-
severe disease, not pregnant, not nursing, using adequate contraception, 
no short bowel syndrome, no ostomy, no obstructive symptoms with 
strictures, no history of TB, no demyelinating disease, no cancer, other 
criteria 
Colombel, 
200995 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2009 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (bowel resection in past 6 months), 
CDAI (220-450), no use of adalimumabmoderate-severe disease, not 
pregnant, not nursing, using adequate contraception, no short bowel 
syndrome, no ostomy, no obstructive symptoms with strictures, no history 
of TB, no demyelinating disease, no cancer, other criteria 
Colombel, 
201045 
RCT, parallel 
arms 
Start year: 2005 
 
Duration of 
assigned 
treatment: 50 
weeks 
US, North 
America, 
Europe, Asia 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (abdominal surgery in past 6 
months), CDAI (219-451), previous use of corticosteroids, mesalamine or 
budesonide, no use of TNF-alpha inhibitors, methotrexate, 6-
mercaptopurine, azathioprine, moderate-severe disease, no short bowel 
syndrome, no ostomy, no abscess, no obstructive symptoms with 
strictures, no history of TB, no cancer, other criteria 
Cottone, 
2011150 
Retrospective 
cohort 
Start year: 2000  
 
Mean followup 
duration: 26 
months 
Europe 
 
Multicenter 
NA Adults, IBD, previous use of infliximab, other criteria 
Crombe, 
2011226 
EPIMAD 
Retrospective 
cohort 
Start year: 1988 
 
Median followup 
duration: 32 
months 
Europe 
 
Multicenter 
NA Pediatrics, CD only, previous use of infliximab, other criteria 
de Vries, 
2008227 
Other study 
design 
Start year: 1999 
 
Median followup 
duration: 9 years 
Europe 
 
Single center 
NA Pediatrics, adults, IBD, no use of infliximab 
D'Haens, 
200848 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
Yes 
 
Yes 
Pediatrics, adults, CD only, CDAI (>200), no use of corticosteroids, 
antimetabolites, biological agents, active disease, not pregnant, no 
obstructive symptoms with strictures, no history of TB, no cancer, other 
criteria 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Domenech, 
2010228 
Prospective 
cohort 
Start year: 1999 
 
Median followup 
duration: 76-198 
months 
Europe 
 
Single center 
NA IBD, other criteria 
Feagan, 
200781 
 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 48 
weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<220), no short bowel syndrome, no ostomy, no 
abscess, no obstructive symptoms with strictures, other criteria 
Fidder, 
2009153 
Retrospective 
cohort 
Start year: 1994 
 
Median followup 
duration: 58-144 
months 
Europe 
 
Single center 
NA IBD 
Hamzaoglu, 
2010164 
Retrospective 
cohort 
Start year: 1998 
 
Median followup 
duration: 14.3 
months 
US 
 
Single center 
NA CD only 
Hanauer, 
200286 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1999 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, 
Europe, Israel 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-400), previous use of antibiotics, 5-
aminosalicylate acids, corticosteroids, thiopurines, methotrexate, no use 
of TNF-alpha inhibitors, infliximab, other criteria 
Hanauer, 
200637 
 
 
RCT, parallel 
arms 
Start year: 2002 
 
Duration of 
assigned 
treatment: 4 weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (extensive bowel resection (>100 
cm)), CDAI (220-450), no use of TNF-alpha inhibitors, moderate-severe 
disease, not pregnant, not nursing, using adequate contraception, no 
short bowel syndrome, no ostomy, no obstructive symptoms with 
strictures, no history of TB, no cancer, other criteria 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Keshavarzia
n, 2007182 
Retrospective 
cohort 
Start year: 2003 
Mean followup 
duration: 2.3 years 
 
Median followup 
duration: 2.3 years 
US 
 
Multicenter 
NA CD only, other criteria 
Kinney, 
2003162 
Retrospective 
cohort 
Start year: 1998  
 
Mean followup 
duration: 52 weeks 
US 
 
Single center 
NA CD only, other criteria 
Lawrance, 
2010165 
Retrospective 
cohort 
Start year: 1999 
 
Average duration: 
NR 
Australia, New 
Zealand 
 
Multicenter 
NA IBD, previous use of TNF-alpha inhibitors, other criteria 
Lee, 2011184 Retrospective 
cohort 
Start year: 2009 
 
Average duration: 
NR 
North America 
 
Multicenter 
NA IBD, other criteria 
Lees, 
2009145 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration: 2.4 years 
Europe 
 
Multicenter 
NA Pediatrics, adults, IBD, not pregnant, other criteria 
Lemann, 
200646 
RCT, parallel 
arms 
Start year: 2000 
 
Duration of 
assigned 
treatment: 24 
weeks 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, previous use of corticosteroids, prednisone, no use of 5-
aminosalicylate acids, TNF-alpha inhibitors, topical steroids, budesonide, 
active disease, not pregnant, not nursing, using adequate contraception, 
no abscess, no obstructive symptoms with strictures, no history of TB, 
other criteria 
Lichtenstein, 
2006131 
 
Prospective 
cohort 
Start year: 1999 
Mean followup 
duration: 1.9 years 
US, North 
America 
 
Multicenter 
NA Adults, CD only, other criteria 
Lichtiger, 
2010161 
Other study 
design 
Start year: 2006  
 
Mean followup 
duration: 18 weeks 
 
US 
 
Multicenter 
NA Adults, CD only, previous use of infliximab, no use of adalimumab, 
natalizumab, adalimumab, anakinra, moderate-severe disease, not 
pregnant, not nursing, using adequate contraception, no demyelinating 
disease, no cancer, other criteria 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Lofberg, 
2011158 
CARE 
Prospective 
cohort 
Start year: 2006 
 
Average duration: 
NR 
Europe 
 
Multicenter 
NA Adults, CD only, HBI (>7), no use of TNF-alpha inhibitors, adalimumab, 
natalizumab, not pregnant, not nursing, using adequate contraception, no 
short bowel syndrome, no ostomy, no abscess, no obstructive symptoms 
with strictures, no history of TB, no demyelinating disease, no cancer, 
other criteria 
Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Retrospective 
cohort 
Start year: 2003  
 
Mean followup 
duration: 12 
months 
Europe 
 
Single center 
NA Pediatrics, CD only, other criteria 
Mantzaris, 
200988 
RCT, parallel 
arms with a 6-
week run-in 
period 
Start year: NR 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Number of 
centers NR 
Yes 
 
Yes 
Adults, CD only, CDAI (>180), active disease, not pregnant, not nursing, 
no history of TB, other criteria 
Marehbian, 
2009168 
Retrospective 
cohort 
Start year: 2002 
 
Average duration: 
NR 
US 
 
Single center 
NA CD only, other criteria 
Mortimore, 
2001174 
 
 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration:16.4 
weeks 
Australia 
 
Multicenter 
NA CD only, other criteria 
Moss, 
2008148 
Retrospective 
cohort 
Start year: 2000 
 
Median followup 
duration: 35 
months 
US 
 
Single center 
NA CD only, other criteria 
Moss, 
2010147 
Retrospective 
cohort 
Start year: 2000 
 
Median followup 
duration: 34 
months 
US 
 
Single center 
NA CD only, active disease 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Orlando, 
2005128 
 
 
Prospective 
cohort 
Start year: 1999 
 
Median followup 
duration: NR 
Europe 
 
Multicenter 
NA No abscess, no obstructive symptoms with strictures, no cancer, other 
criteria 
Present, 
199944 
RCT, parallel 
arms 
Start year: 1996 
 
Duration of 
assigned 
treatment: 6 weeks 
US, Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, using adequate contraception, no abscess, 
other criteria 
Ricart, 
2001138 
Retrospective 
cohort 
Start year: 1998 
 
Median followup 
duration: 34 weeks 
US 
 
Single center 
NA CD only, other criteria 
Rudolph, 
2008175 
Retrospective 
cohort 
Start year: NR 
 
Average duration: 
NR 
US 
 
Single center 
NA CD only, no use of TNF-alpha inhibitors, other criteria 
Rutgeerts, 
199985 
RCT, parallel 
arms with a 16-
week run-in 
period 
Start year: 1995 
 
Duration of 
assigned 
treatment: 36 
weeks 
US, North 
America, Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (proctocolectomy or total colectomy), 
CDAI (220-400), no ostomy, no obstructive symptoms with strictures, 
other criteria 
Sandborn, 
200533 
 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 8 weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors in past 3 
months, no short bowel syndrome, no ostomy, no abscess, no obstructive 
symptoms with strictures, other criteria 
Sandborn, 
200739 
 
RCT, parallel 
arms 
Start year: 2003 
 
Duration of 
assigned 
treatment: 26 
weeks 
Worldwide 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), active disease, no short bowel 
syndrome, no ostomy, no abscess, no obstructive symptoms with 
strictures, no history of TB, no demyelinating disease, no cancer, other 
criteria 
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Evidence Table 12. Study design characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Sandborn, 
200738 
 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 4 weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (bowel resection in past 6 months), 
CDAI (220-450), no use of adalimumab, active disease, not pregnant, not 
nursing, no short bowel syndrome, no ostomy, no obstructive symptoms 
with strictures, no history of TB, no demyelinating disease, other criteria 
Sandborn, 
200783 
 
 
RCT, parallel 
arms with a 4-
week run-in 
period 
Start year: 2002 
 
Duration of 
assigned 
treatment: 52 
weeks 
US, North 
America, Europe 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), in remission for >4 weeks, inactive disease, 
using adequate contraception, other criteria 
Sands, 
200487 
RCT, parallel 
arms with a 14-
week run-in 
period 
Start year: 2000 
 
Duration of 
assigned 
treatment: 40 
weeks 
US, North 
America, 
Europe, Israel 
 
Multicenter 
No 
 
 
Adults, CD only, no use of infliximab, no abscess, no obstructive 
symptoms with strictures, other criteria 
Sands, 
200735 
RCT, parallel 
arms 
Start year: 2002 
 
Duration of 
assigned 
treatment: NR 
US 
 
Multicenter 
No 
 
 
Adults, CD only, previous use of TNF-alpha inhibitors, no abscess, no 
obstructive symptoms with strictures, other criteria 
Schneeweiss
, 2009230 
Retrospective 
cohort 
Start year: 2001  
 
Mean followup 
duration: 1.3 years 
North America 
 
Multicenter 
NA IBD, no cancer, other criteria 
Schreiber, 
200540 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 8 weeks 
North America, 
Europe, Africa, 
Russia 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors, 
certolizumab pegol, sodium cromoglycate, mycophenolate, cyclosporin in 
past 4 weeks, TNF-alpha inhibitor with a biologic agent in past 12 weeks, 
moderate-severe disease, no abscess, no obstructive symptoms with 
strictures, no history of TB, other criteria 
Schreiber, 
200784 
RCT, parallel 
arms with a 6-
week run-in 
period 
Start year: 2004 
 
Duration of 
assigned 
treatment: 18 
weeks 
Worldwide 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (220-450), no use of TNF-alpha inhibitors, 
infliximab, adalimumab, certolizumab pegol, no short bowel syndrome, no 
ostomy, no abscess, no obstructive symptoms with strictures, no history of 
TB, no demyelinating disease, no cancer, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Schroder, 
200647 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 48 
weeks 
Europe 
 
Single center 
No 
 
 
Adults, CD only, no use of TNF-alpha inhibitors, infliximab, active disease, 
other criteria 
Seiderer, 
2004173 
Retrospective 
cohort 
Start year: 2000 
 
Median followup 
duration: 26 
months 
Europe 
 
Single center 
NA Adults, IBD, other criteria 
Sokol, 
2010129 
MICISTA 
Registry--
part of 
French group 
Other study 
design 
Start year: NR 
 
Median followup 
duration: 30 
months 
Europe 
 
Single center 
NA IBD, other criteria 
Sprakes, 
2011159 
Leeds 
Prospective 
cohort 
Start year: 2007 
 
Median followup 
duration: 10 
months 
Europe 
 
Single center 
NA CD only, previous use of infliximab, other criteria 
Swoger, 
2010140 
Mayo clinic 
Retrospective 
cohort 
Start year: 2003 
 
Median followup 
duration: 13.7 
months 
US 
Single center 
NA Adults, CD only, previous use of , other criteria 
Targan, 
200732 
 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 2004 
 
Duration of 
assigned 
treatment: 8 weeks 
US, North 
America, 
Europe, 
Australia, Africa 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (total colectomy), CDAI (220-450), 
no use of TNF-alpha inhibitors, natalizumab, active disease (moderate-
severe), no short bowel syndrome, no ostomy, no abscess, no obstructive 
symptoms with strictures, other criteria 
Thayu, 
2010199 
Case-control 
study 
Start year: NR 
Mean followup 
duration: 43 
months 
US 
 
Single center 
NA Pediatrics, CD only, no use of any medications affecting growth and 
development, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Van Assche, 
200889 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, adults, CD only, previous use of methotrexate, infliximab, 
immunosuppressives (azathioprine/6-MP or methotrexate), perianal 
fistulizing, not pregnant, not nursing, other criteria 
Vavricka, 
2010132 
FACTS II 
Other study 
design 
Start year: 2008  
 
Mean followup 
duration: 26 weeks 
Europe 
Multicenter 
NA CD only, active disease, other criteria 
Vermeire, 
2007154 
Prospective 
cohort 
Start year: 2000 
 
Median followup 
duration: 4 weeks 
Europe 
 
Multicenter 
NA CD only, other criteria 
Winter, 
200441 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe, Africa, 
Israel 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (extended bowel resection), CDAI 
(220-450), moderate-severe disease, no ostomy, no abscess, no 
obstructive symptoms with strictures, no history of TB, other criteria 
Studies evaluating thiopurines 
Beaugerie, 
2009130 
Prospective 
cohort 
Start year: 2004 
 
Median followup 
duration: 35 
months 
Europe 
 
Multicenter 
NA Pediatrics, adults, IBD, other criteria 
Campbell, 
2001146 
Retrospective 
cohort 
Start year:  
 
Median followup 
duration: 4.3 years 
Europe 
 
Single center 
NA IBD, other criteria 
Ewe, 199354 RCT, parallel 
arms 
Start year: 1987 
 
Duration of 
assigned 
treatment: 4 
months 
Europe 
 
Single center 
No 
 
 
Adults, CD only, CDAI (>150), no use of thiopurines, perianal fistulizing, 
not pregnant, no abscess 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Farrell, 
2000231 
 
 
Retrospective 
cohort 
Start year: 1990 
 
Median followup 
duration: 8 years 
Europe 
 
Single center 
NA Other criteria 
Fraser, 
2002232 
Retrospective 
cohort 
Start year: NR 
 
Mean followup 
duration: 13.7 
years 
Australia 
 
Single center 
NA IBD, other criteria 
Govani, 
2010157 
Retrospective 
cohort 
Start year: 2000 
 
Median followup 
duration: 73 weeks 
US 
 
Multicenter 
NA Adults, IBD, other criteria 
Hutfless, 
2007151 
 
 
Retrospective 
cohort 
Start year: 1996 
 
Median followup 
duration: 6.8 years 
US 
 
Multicenter 
NA CD only, other criteria 
Kane, 
2008141 
Retrospective 
cohort 
Start year: 2004 
 
Average duration: 
NR 
US 
 
Single center 
NA IBD, females, other criteria 
Lees, 
2009144 
Retrospective 
cohort 
Start year: NR 
 
Average duration: 
NR 
Europe 
 
Single center 
NA IBD, females, other criteria 
Lemann, 
200598 
RCT, parallel 
arms 
Start year: 1995 
 
Duration of 
assigned 
treatment: 18 
months 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (except limited perianal surgery in 
past 42 months), CDAI (<150), in remission for >42 months, previous use 
of azathioprine, no use of antibiotics, 5-aminosalicylate acids, 
corticosteroids, inactive disease, other criteria 
Lemann, 
200646 
RCT, parallel 
arms 
Start year: 2000 
 
Duration of 
assigned 
treatment: 24 
weeks 
Europe 
 
Multicenter 
No 
 
 
Adults, CD only, previous use of corticosteroids, prednisone, no use of 5-
aminosalicylate acids, TNF-alpha inhibitors, topical steroids, budesonide, 
active disease, not pregnant, not nursing, using adequate contraception, 
no abscess, no obstructive symptoms with strictures, no history of TB, 
other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Lewis, 
2001136 
 
 
Retrospective 
cohort 
Start year: 1988  
 
Mean followup 
duration: 3.7 years 
Europe 
 
Multicenter 
NA IBD, other criteria 
Lichtenstein, 
2006131 
 
 
Prospective 
cohort 
Start year: 1999 
Mean followup 
duration: 1.9 years 
US, North 
America 
 
Multicenter 
NA Adults, CD only, other criteria 
Maher, 
2009176 
Retrospective 
cohort 
Start year: 2005 Africa 
 
Single center 
NA IBD, other criteria 
Mantzaris, 
2009102 
RCT, parallel 
arms 
Start year: 1998 
 
Duration of 
assigned 
treatment: 1.5 
years 
Europe 
 
Number of 
centers NR 
Yes 
 
Yes 
Adults, CD only, no previous surgery (intestinal resection), CDAI (<150), 
previous use of corticosteroids, no use of infliximab, mesalamine-only 
maintenance therapy, effective prior treatment with azathioprine, perianal 
fistulizing, not pregnant, not nursing, no history of TB, other criteria 
Marehbian, 
2009168 
Retrospective 
cohort 
Start year: 2002 
 
Average duration: 
NR 
US 
 
Single center 
NA CD only, other criteria 
Markowitz, 
2000192 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 18 
months 
US 
 
Multicenter 
No 
 
 
Pediatrics, CD only, moderate-severe disease, other criteria 
O'Donoghue, 
1978100 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 6 
months 
Europe 
 
Single center 
Yes 
 
Yes 
Adults, CD only, in remission for >6 months, previous use of azathioprine, 
inactive disease 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Reinisch, 
200851 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 12 
months 
North America, 
Europe, Africa, 
Russia 
 
Multicenter 
No 
 
 
Adults, CD only, no previous surgery (resection of >100 cm of small 
bowel), CDAI (220-450), previous use of corticosteroids, no use of 5-
aminosalicylate acids, TNF-alpha inhibitors, corticosteroids, methotrexate, 
corticosteroids for current flare >21 days prior to randomization, active 
disease, perianal fistulizing, no obstructive symptoms with strictures, other 
criteria 
Sandborn, 
199959 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1996 
 
Duration of 
assigned 
treatment: 16 
weeks 
US, North 
America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, no previous surgery (> 100 cm ileum), CDAI (150-450), 
previous use of corticosteroids, no use of antibiotics, thiopurines, 
infliximab, adalimumab, certolizumab pegol, active disease (mild-
moderate), perianal fistulizing, no abscess, no obstructive symptoms with 
strictures, no cancer 
Schneeweiss
, 2009230 
Retrospective 
cohort 
Start year: 2001  
 
Mean followup 
duration: 1.3 years 
North America 
 
Multicenter 
NA IBD, no cancer, other criteria 
Seksik, 
2009155 
Prospective 
cohort 
Start year: 2003  
 
Mean followup 
duration: 0.9 years 
Europe 
 
Single center 
NA Adults, IBD, other criteria 
Shah, 
2008156 
Retrospective 
cohort 
Start year: NR 
 
Followup duration: 
NR 
Europe 
 
Multicenter 
NA IBD, previous use of 5-aminosalicylate acids, other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Summers, 
197956 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Tay, 2003233 Retrospective 
cohort 
Start year: 1998 
 
Average duration: 
NR 
US 
 
Single center 
NA No previous surgery (first resection with anastomosis or strictureplasty), 
no ostomy 
van Schaik, 
2011234 
Netherlands 
claims 
database 
Retrospective 
cohort 
Start year: 2001 
 
Average duration: 
NR 
Europe 
Multicenter 
NA Adults, IBD, no previous surgery  (subtotal or total colectomy), no cancer, 
other criteria 
Studies evaluating methotrexate 
Feagan, 
199563 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1992 
 
Duration of 
assigned 
treatment: 16 
weeks 
US, North 
America 
 
Multicenter 
No 
 
 
CD only, previous use of prednisone, no use of prednisone > 10 mg/day, 
active disease, not pregnant, no cancer, other criteria 
Feagan, 
2000105 
RCT, parallel 
arms 
Start year: 1993 
 
Duration of 
assigned 
treatment: NR 
US, North 
America 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, previous use of methotrexate, inactive disease, not 
pregnant, no cancer, other criteria 
Thayu, 
2010199 
Case-control 
study 
Start year: NR  
 
Mean followup 
duration: 43 
months 
US 
 
Single center 
NA Pediatrics, CD only, no use of any medications affecting growth and 
development, other criteria 
Studies evaluating corticosteroids 
Alemzadeh, 
2002200 
Retrospective 
cohort 
Start year: NR 
 
Followup duration: 
NR 
Europe 
 
Single center 
NA Pediatrics, CD only, other criteria 
Campieri, 
199768 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe, 
Australia 
 
Multicenter 
Yes 
 
 
Adults, CD only, no previous surgery (ileostomy or more extensive 
resection of the ileum (>100 cm)), CDAI (>200), active disease, no 
abscess, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Escher, 
2004190 
RCT, parallel 
arms 
Start year: 1998 
 
Duration of 
assigned 
treatment: 12 
weeks 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, CD only, CDAI (>200), no use of corticosteroids, thiopurines, 
active disease, other criteria 
Goldstein, 
1967142 
Retrospective 
cohort 
Start year: 1946 
 
Average duration: 
NR 
US 
 
Single center 
NA IBD, other criteria 
Hutfless, 
2007151 
 
 
Retrospective 
cohort 
Start year: 1996 
 
Median followup 
duration: 6.8 years 
US 
 
Multicenter 
NA CD only, other criteria 
Issenman, 
1993196 
Prospective 
cohort 
Start year: NR  
 
Mean followup 
duration: 2 years 
North America 
 
Single center 
NA Pediatrics, CD only, males, active disease 
Levine, 
2002198 
Case-control 
study 
Start year: NR 
 
Followup duration: 
NR 
Israel 
 
Multicenter 
NA Pediatrics, CD only, PCDAI (12.5-40), no use of thiopurines, mild-
moderate disease, other criteria 
Levine, 
2003191 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Israel 
 
Multicenter 
No 
 
 
Pediatrics, CD only, no previous surgery (in past 6 weeks), PCDAI (12.5-
40), no use of corticosteroids, thiopurines, active disease, other criteria 
Lewis, 
2001136 
 
 
Retrospective 
cohort 
Start year: 1988 
Mean followup 
duration: 3.7 years 
Europe 
 
Multicenter 
NA IBD, other criteria 
Lichtenstein, 
2006131 
 
Prospective 
cohort 
Start year: 1999 
Mean followup 
duration: 1.9 years 
US, North 
America 
 
Multicenter 
NA Adults, CD only, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Malchow, 
198464 
 
 
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Mantzaris, 
2003113 
RCT, parallel 
arms with a 1-
month run-in 
period 
Start year: 1994 
 
Duration of 
assigned 
treatment: 1 years 
Europe 
 
Single center 
No 
 
 
Adults, CD only, no previous surgery (intestinal resection), CDAI (<150), 
no use of mesalamine maintenance therapy, azathioprine unless 
withdrawn at least 3 months before start of trial due to side effects, 
inactive disease, not pregnant, not nursing, other criteria 
Saha, 
1998197 
Prospective 
cohort 
Start year: 1982 
 
Followup duration: 
NR 
Europe 
 
Single center 
NA Pediatrics, IBD 
Schoon, 
2005185 
RCT, parallel 
arms 
Start year: 1996 
 
Duration of 
assigned 
treatment: 2 years 
Europe, Israel 
 
Multicenter 
 
 
No 
Adults, CD only, no previous surgery (gastric surgery or resection of >100 
cm of small bowel or of tissues distal to the mid-transverse colon), no use 
of hormone replacement therapy in past 6 months, bisphosphonates in 
past 6 months, androgens/anabolic steroids in past 6 months, no abscess, 
no obstructive symptoms with strictures, other criteria 
Siffledeen, 
2007127 
Other study 
design 
Start year: 2000 
 
Average duration: 
NR 
North America 
 
Single center 
NA Adults, CD only, no short bowel syndrome, other criteria 
Singleton, 
197975 
 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 8 weeks 
US 
 
Multicenter 
Yes 
 
Yes 
CD only, CDAI (>150), active disease 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Thayu, 
2010199 
Case-control 
study 
Start year: NR 
Mean followup 
duration: 43 
months 
US 
 
Single center 
NA Pediatrics, CD only, no use of any medications affecting growth and 
development, other criteria 
Tremaine, 
200265 
RCT, parallel 
arms with a 2-
week run-in 
period 
Start year: 1995 
 
Duration of 
assigned 
treatment: 8 weeks 
US 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, CDAI (200-450), mild-moderate disease, not pregnant, 
not nursing, no ostomy, other criteria 
Tromm, 
201174 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 8 weeks 
Europe, Israel 
 
Multicenter 
 
 
Adults, CD only, CDAI (200-400), no use of methotrexate, within 3 
months, perianal fistulizing, no short bowel syndrome, no ostomy, no 
obstructive symptoms with strictures, other criteria 
Studies evaluating 5-aminosalicylate acids 
Bernstein, 
2011235 
University of 
Manitoba 
Retrospective 
cohort 
Start year: 1995 
 
Average duration: 
NR 
North America 
 
Multicenter 
NA IBD, other criteria 
Hutfless, 
2007151 
 
Retrospective 
cohort 
Start year: 1996 
 
Median followup 
duration: 6.8 years 
US 
 
Multicenter 
NA CD only, other criteria 
Lewis, 
2001136 
 
 
Retrospective 
cohort 
Start year: 1988 
Mean followup 
duration: 3.7 years 
Europe 
 
Multicenter 
NA IBD, other criteria 
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Author, year Study design 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Malchow, 
198464 
  
RCT, parallel 
arms 
Start year: 1975 
 
Duration of 
assigned 
treatment: 6 weeks 
Europe 
 
Multicenter 
Yes 
 
Yes 
Adults, CD only, not pregnant, no abscess, no obstructive symptoms with 
strictures, other criteria 
Summers, 
197956 
 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 17 
weeks 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (>150), active disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Summers, 
197956 
 
RCT, parallel 
arms 
Start year: 1971 
 
Duration of 
assigned 
treatment: 24 
months 
US 
 
Multicenter 
No 
 
 
Adults, CD only, CDAI (<150), inactive disease, not pregnant, no abscess, 
no obstructive symptoms with strictures, no history of TB, other criteria 
Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; IBD = irritable bowel disease; mg = milligram; NA = not applicable; 
NR = not reported; RCT = randomized controlled trial; TB = tuberculosis; TNF = tumor necrosis factor; US = United States 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Studies evaluating biologics 
af Bjorkesten, 
2011163 
Infliximab + 
Never user 
corticosteroids, 
30 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg + NA 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors 
Immunomodulat
ors 
NR 
af Bjorkesten, 
2011163 
Infliximab + 
Corticosteroid, 
41 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg + NR 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors 
Immunomodulat
ors 
NR 
af Bjorkesten, 
2011163 
Infliximab + 
Never user 
immunomodulat
or, 8 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg + NA 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids Corticosteroids NR 
af Bjorkesten, 
2011163 
Infliximab + 
immumodulator, 
63 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg + NR 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids Corticosteroids NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Biancone, 
2006149 
No infliximab + 
6-
MP/azathioprine/
methotrexate, 
186 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Biancone, 
2006149 
Infliximab + No 
immunomodulat
ors, 191 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Biancone, 
2006149 
Infliximab, 404 
Route: IV 
Male, %: 53 
 
Race NR 
 
Smoking, % 
Smoker, 36 
 
CD NR 
Age at diagnosis 
Median: 28 
Min: 7 
Max: 80 
 
Disease duration 
Median: 10 
Min: 1 
Max: 62 
 
Age at 
enrollment 
Median: 41 
Min: 13 
Max: 82 
Severity NR 
 
Location, % 
Ileal: 25 
Ileo-colonic: 42 
Colonic: 31 
 
Behavior, % 
Inflammatory: 36 
Stricturing: 5 
Penetrating: 59 
 
CRP NR 
Disease activity 
index NR 
Methotrexate: 5 
 
Thiopurines: 95 
Methotrexate NR 
Biancone, 
2006149 
Certolizumab 
pegol + 6-
MP/azathioprine/
methotrexate, 
213 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Biancone, 
2006149 
Never user 
infliximab, 404 
Male, %: 53 
 
Race NR 
 
Smoking, % 
Smoker, 36 
 
CD NR 
Age at diagnosis 
Median: 29 
Min: 9 
Max: 81 
 
Disease duration 
NR 
 
Age at 
enrollment 
Median: 40 
Min: 14 
Max: 82 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 43 
Colonic: 33 
 
Behavior, % 
Inflammatory: 44 
Stricturing: 13 
Penetrating: 43 
 
CRP NR 
Disease activity 
index NR 
Methotrexate: 3 
 
Thiopurines: 97 
Methotrexate NR 
Biancone, 
2006149 
No infliximab + 
6-
MP/azathioprine/
methotrexate, 
218 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Caspersen, 
2008225 
Infliximab + 
Azathioprine 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Caspersen, 
2008225 
Infliximab + 
Corticosteroid 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Caspersen, 
2008225 
Infliximab 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Chaparro, 
2011160 
Adalimumab + 
IMM, 247 Dose: 
2+ induction 
doses with a 
primary 
response 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Disease  
behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors: 100 
NR NR 
Chaparro, 
2011160 
Adalimumab + 
no IMM, 133 
Dose: 2+ 
induction doses 
with a primary 
response 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR TNF-alpha 
inhibitors 
NR 
Clare, 2009181 Infliximab, 37 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Clare, 2009181 Infliximab + 
Immunomodulat
or 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Clare, 2009181 Infliximab + 
Azathioprine, 86 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Clare, 2009181 Infliximab + 
Methotrexate 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
Never user 
corticosteroids, 
azathioprine, 6-
MP, 
methotrexate, 37 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
Thiopurine, 374 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
Methotrexate, 53 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Colombel, 
2004137 
Infliximab + 
Corticosteroids 
and either 
azathioprine, 6-
MP, or 
methotrexate, 
111 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
Corticosteroid, 
156 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
corticosteroids, 
6-MP, 
azathioprine, or 
methotrexate, 
463 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
2004137 
Infliximab + 
Corticosteroid, 
45 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Colombel, 
2004137 
Infliximab + 
Thiopurine, 316 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Colombel, 
200782 
Adalimumab, 
172 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 36 
 
Race NR 
 
Smoking, % 
Current smoker, 
34 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.4 
Severity NR 
 
Location, % 
Ileal: 73 
Ileo-colonic: 47 
Colonic: 73 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 155 
 
IBDQ 
Mean: 175 
5ASA: 38 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 10 
 
Thiopurines: 36 
 
Immunomodulat
ors: 45 
TNF-alpha 
inhibitors: 50 
Adalimumab: 
100 
Colombel, 
200782 
Adalimumab, 
157 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 39 
 
Race NR 
 
Smoking, % 
Current smoker, 
32 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location, % 
Ileal: 76 
Ileo-colonic: 54 
Colonic: 76 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 160 
 
IBDQ 
Mean: 165 
5ASA: 69 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 12 
 
Thiopurines: 38 
 
Immunomodulat
ors: 50 
TNF-alpha 
inhibitors: 45 
Adalimumab: 
100 
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Colombel, 
200782 
Placebo, 170 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 38 
 
Race NR 
 
Smoking, % 
Current smoker, 
37 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location, % 
Ileal: 66 
Ileo-colonic: 44 
Colonic: 76 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 170 
 
IBDQ 
Mean: 165 
5ASA: 46 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate: 8 
 
Thiopurines: 42 
 
Immunomodulat
ors: 49 
TNF-alpha 
inhibitors: 48 
Adalimumab: 
100 
Colombel, 
200995 
Adalimumab, 
260 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 37.3 
 
Race, % 
W: 94.2 
B: 2.7 
A: 1.5 
Other: 1.5 
 
Smoking, % 
Current smoker, 
35.4 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 7.9 
Min: 0.3 
Max: 44.1 
 
Age at 
enrollment 
Mean: 36.8 
Severity NR 
 
Location, % 
Ileal: 75.4 
Ileo-colonic: 50.4 
Colonic: 73.9 
 
Behavior NR 
 
CRP 
Median: 0.9 
CDAI 
Median: 302 
 
IBDQ 
Median: 124 
5ASA: 36.9 
 
Corticosteroids: 
41.9 
 
Immonomodulat
or: 43.1 
TNF-alpha 
inhibitors: 51.2 
Adalimumab: 
100 
Colombel, 
200995 
Placebo, 261 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 37.9 
 
Race, % 
W: 94.3 
B: 3.1 
A: 1.2 
Other: 1.5 
 
Smoking, % 
Current smoker, 
36.8 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 8.4 
Min: 0.3 
Max: 40.3 
 
Age at 
enrollment 
Mean: 36.9 
Severity NR 
 
Location, % 
Ileal: 69 
Ileo-colonic: 47.9 
Colonic: 76.6 
 
Behavior NR 
 
CRP 
Median: 1 
CDAI 
Median: 306 
 
IBDQ 
Median: 125 
5ASA: 44.4 
 
Corticosteroids: 
43.7 
 
Immonomodulat
or: 51 
TNF-alpha 
inhibitors: 49.8 
Adalimumab: 
100 
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Colombel, 
200995 
Adalimumab, 
257 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 38.9 
 
Race, % 
W: 89.9 
B: 4.7 
A: 2.7 
Other: 2.7 
 
Smoking, % 
Current smoker, 
34.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 7.9 
Min: 0.3 
Max: 38.8 
 
Age at 
enrollment 
Mean: 37.8 
Severity NR 
 
Location, % 
Ileal: 75.9 
Ileo-colonic: 51.4 
Colonic: 73.5 
 
Behavior NR 
 
CRP 
Median: 0.9 
CDAI 
Median: 299 
 
IBDQ 
Median: 122 
5ASA: 36.6 
 
Corticosteroids: 
45.1 
 
Immonomodulat
or: 47.1 
TNF-alpha 
inhibitors: 49.4 
Adalimumab: 
100 
Colombel, 
201045 
Infliximab + 
Placebo, 169 
Route: IV + Oral 
Dose: 5 mg/kg 
every 8 weeks + 
NA every day 
Male, %: 49.7 
 
Race, % 
W: 86.4 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.2 
 
Age at 
enrollment 
Median: 35 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 37.9 
Colonic: 26.6 
 
Behavior NR 
 
CRP 
Median: 1.1 
CDAI 
Mean: 284.8 
5ASA: 51.5 
 
Corticosteroids: 
30.8 
 
Budesonide: 
16.6 
NR NR 
Colombel, 
201045 
Azathioprine + 
Infliximab, 169 
Route: Oral + IV 
Dose: 2.5 mg/kg 
every day + 5 
mg/kg every 8 
weeks 
Male, %: 52.1 
 
Race, % 
W: 84 
 
Smoking, % 
Smoker, 38.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.2 
 
Age at 
enrollment 
Median: 34 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 43.2 
Colonic: 23.7 
 
Behavior NR 
 
CRP 
Median: 1 
CDAI 
Mean: 289.9 
5ASA: 50.3 
 
Corticosteroids: 
27.8 
 
Budesonide: 
11.2 
NR NR 
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Colombel, 
201045 
Azathioprine + 
Placebo, 170 
Route: Oral + IV 
Dose: 2.5 mg/kg 
every day + NA 
every 8 weeks 
Male, %: 52.9 
 
Race, % 
W: 86.5 
 
Smoking, % 
Smoker, 35.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.4 
 
Age at 
enrollment 
Median: 35 
Severity NR 
 
Location, % 
Ileal: 40 
Ileo-colonic: 40.6 
Colonic: 19.4 
 
Behavior NR 
 
CRP 
Median: 1 
CDAI 
Mean: 287.2 
5ASA: 61.2 
 
Corticosteroids: 
23.5 
 
Budesonide: 
14.7 
NR NR 
Cottone, 2011150 Never user 
Biologics, 116 
Route: Unknown 
Dose: NR 
Male, %: 60.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 70 Min: 
65 Max: 80 
Severity NR 
 
Location, % Ileal: 
34.5 Ileo-colonic: 
37.9 Colonic: 3.4 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
89.7 
NR NR 
Cottone, 2011150 TNF-alpha, 58 
Route: Unknown 
Dose: NR 
Male, %: 60.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 71 Min: 
65 Max: 84 
Severity NR 
 
Location, % Ileal: 
34.5 Ileo-colonic: 
37.9 Colonic: 3.4 
 
Behavior NR 
 
CRP NR 
CDAI Median: 
211 Min: 149 
Max: 439 
Corticosteroids: 
93.1 
Immunomodulat
ors: 25.9 
NR NR 
Crombe, 2011226 Infliximab + 
immunomodulat
or, 103 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg every 8 
weeks + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids 
NR NR 
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Crombe, 2011226 Infliximab + no 
IMM, 17 Route: 
Unknown Dose: 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis  
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids 
NR NR 
de Vries, 2008227 Infliximab + No 
corticosteroids, 
45 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors 
NR NR 
de Vries, 2008227 Infliximab + 
Corticosteroid, 
102 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors 
NR NR 
de Vries, 2008227 Infliximab + No 
immunomodulat
or, 54 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
de Vries, 2008227 Infliximab + 
Immunomodulat
or, 93 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
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D'Haens, 200848 Infliximab + 
Azathioprine, 65 
Route: IV + Oral 
Dose: 5 mg/kg + 
2-2.5 mg/kg 
Male, %: 33.8 
 
Race, % 
W: 98.5 
 
Smoking, % 
Current smoker, 
43.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30 
Severity NR 
 
Location, % 
Ileo-colonic: 47.7 
Colonic: 30.8 
 
Behavior NR 
 
CRP 
Median: 19 
CDAI 
Mean: 330 
 
IBDQ 
Mean: 122 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Azathioprine: 
100 
 
Methylprednisolo
ne 
5ASA: 4.6 NR 
D'Haens, 200848 Budesonide + 
(6)-
Methylprednisolo
ne, 64 
Route: Oral + 
Oral 
Dose: 9 mg 
every day + 32 
mg every day 
Male, %: 42.2 
 
Race, % 
W: 95.3 
 
Smoking, % 
Current smoker, 
35.9 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 28.7 
Severity NR 
 
Location, % 
Ileo-colonic: 43.8 
Colonic: 32.8 
 
Behavior NR 
 
CRP 
Median: 25 
CDAI 
Mean: 306 
 
IBDQ 
Mean: 136 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Budesonide 
5ASA: 3.1 NR 
Domenech, 
2010228 
Infliximab + No 
concomitant 
immunomodulat
or, 15 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Domenech, 
2010228 
Infliximab + 
Thiopurines or 
methotrexate, 61 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR Corticosteroids NR 
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taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Feagan, 200781 
 
 
Natalizumab, 
168 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 45.8 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
16.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.9 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 24.4 
Ileo-colonic: 50.6 
Colonic: 25 
 
Behavior NR 
 
CRP 
Mean: 8.9 
Median: 4.3 
Min: 0 
Max: 97 
CDAI 
Mean: 105 
 
IBDQ 
Mean: 125 
5ASA: 45.2 
 
Antibiotics: 8.9 
 
Corticosteroids: 
39.9 
 
Methotrexate: 
4.8 
 
Thiopurines: 
32.1 
 
Prednisone: 26.2 
 
Budesonide: 
12.5 
 
>/= 1 
corticosteroid or 
immunomodulat
ors: 57.1 
 
Corticosteroids 
and 
immunomodulat
ors: 17.9 
TNF-alpha 
inhibitors: 32.7 
Natalizumab: 
100 
Feagan, 200781 
 
 
Natalizumab, 35 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Feagan, 200781 
 
 
Placebo, 171 
Route: IV 
Dose: NA every 
4 weeks 
Male, %: 34.5 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
26.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.7 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 23.4 
Ileo-colonic: 49.7 
Colonic: 26.9 
 
Behavior NR 
 
CRP 
Mean: 9.4 
Median: 3.9 
Min: 0 
Max: 120 
CDAI 
Mean: 118 
 
IBDQ 
Mean: 121 
5ASA: 54.4 
 
Antibiotics: 5.8 
 
Corticosteroids: 
44.4 
 
Methotrexate: 
4.7 
 
Thiopurines: 
30.4 
 
Prednisone: 31.6 
 
Budesonide: 14 
 
>/= 1 
corticosteroid or 
immunomodulat
ors: 60.2 
 
Corticosteroids 
and 
immunosuppress
ants: 19.3 
TNF-alpha 
inhibitors: 39.8 
Natalizumab: 
100 
Feagan, 200781 
 
 
Placebo, 33 
Route: IV 
Dose: NA every 
4 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Fidder, 2009153 Infliximab, 743 
Route: IV 
Dose: NR 
Male, %: 43 
 
Race NR 
 
Smoking NR 
 
CD, %: 80.3 
Age at diagnosis 
Median: 24 
 
Disease duration 
Median: 7 
 
Age at 
enrollment 
Median: 35 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
27 
 
Methotrexate: 23 
 
Thiopurines: 67 
 
No thiopurines, 
methotrexate, 
cyclosporin: 18 
 
Cyclosporin: 0 
NR NR 
Fidder, 2009153 Never user 
infliximab, 666 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD, %: 79.4 
Age at diagnosis 
Median: 26 
 
Disease duration 
Median: 8 
 
Age at 
enrollment 
Median: 34 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
66 
 
Methotrexate: 6 
 
Thiopurines: 58 
 
No thiopurines, 
methotrexate, 
cyclosporin: 42 
 
Cyclosporin: 6 
NR NR 
Hamzaoglu, 
2010164 
Infliximab + 
Corticosteroid, 
50 Route: IV + 
Unknown 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hamzaoglu, 
2010164 
Infliximab + aza, 
6mo or mtx, 62 
Route: IV + 
Unknown Dose: 
NR 
Male, %: 44 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 14.2 
Min: 1 Max: 39 
 
Age at 
enrollment 
Mean: 43.6 Min: 
19 Max: 81 
Severity NR 
Location, % Ileal: 
17.7 Ileo-colonic: 
116.1 Colonic: 
79 
Behavior NR 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hamzaoglu, 
2010164 
Infliximab + no 
steroid, 6mp, 
aza, mtx, 160 
Route: IV 
Male, %: 40 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 13.8 
 
Age at 
enrollment 
Mean: 41.1 
Severity NR 
Location, % Ileal: 
10 Ileo-colonic: 
47.5 Colonic: 
38.1 
Behavior NR 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hamzaoglu, 
2010164 
Infliximab + 
steroid + 
6mp/aza/mtx, 25 
Route: IV + 
Unknown 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
Location NR 
Behavior NR 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hanauer, 200286 Placebo, 110 
Route: IV 
Dose: NA every 
8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 155 
Median: 160 
 
IBDQ 
Mean: 170 
Median: 173 
5ASA 
 
Corticosteroids 
 
Immunomodulat
ors 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 200286 Infliximab, 113 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 154 
Median: 156 
 
IBDQ 
Mean: 170 
Median: 169 
5ASA 
 
Corticosteroids 
 
Immunomodulat
ors 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
Hanauer, 200286 Infliximab, 112 
Route: IV 
Dose: 10 mg/kg 
every 8 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 152 
Median: 151 
 
IBDQ 
Mean: 168 
Median: 173 
5ASA 
 
Corticosteroids 
 
Immunomodulat
ors 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
Infliximab: 100 
Hanauer, 200637 
 
 
Adalimumab, 75 
Route: SC 
Dose: 80 mg 
then 40 mg 
every 2 weeks 
Male, %: 33 
 
Race NR 
 
Smoking, % 
Current smoker, 
43 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 63 
Ileo-colonic: 9 
Colonic: 23 
Perianal: 1 
 
Behavior NR 
 
CRP 
Mean: 2 
Median: 0.9 
Min: 0 
Max: 14.9 
CDAI 
Mean: 301 
 
IBDQ 
Median: 128 
Min: 63 
Max: 200 
5ASA: 53 
 
Antibiotics: 9 
 
Corticosteroids: 
43 
 
Methotrexate: 4 
 
Thiopurines: 
25.3 
 
Immunomodulat
ors: 28 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 200637 
 
 
Placebo, 74 
Route: SC 
Dose: NA every 
2 weeks 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Current smoker, 
38 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 68 
Ileo-colonic: 9 
Colonic: 19 
Perianal: 0 
 
Behavior NR 
 
CRP 
Mean: 1.8 
Median: 0.9 
Min: 0 
Max: 17.3 
CDAI 
Mean: 296 
 
IBDQ 
Median: 131 
Min: 52 
Max: 200 
5ASA: 50 
 
Antibiotics: 7 
 
Corticosteroids: 
34 
 
Methotrexate: 1 
 
Thiopurines: 
28.4 
 
Immunomodulat
ors: 30 
NR NR 
Hanauer, 200637 
 
 
Adalimumab, 76 
Route: SC 
Dose: 160 mg 
then 80 mg 
every 2 weeks 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Current smoker, 
42 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 53 
Ileo-colonic: 11 
Colonic: 29 
Perianal: 1 
 
Behavior NR 
 
CRP 
Mean: 1.4 
Median: 0.7 
Min: 0 
Max: 9.3 
CDAI 
Mean: 295 
 
IBDQ 
Median: 127 
Min: 37 
Max: 192 
5ASA: 51 
 
Antibiotics: 5 
 
Corticosteroids: 
32 
 
Methotrexate: 1 
 
Thiopurines: 
27.6 
 
Immunomodulat
ors: 29 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Hanauer, 200637 
 
 
Adalimumab, 74 
Route: SC 
Dose: 40 mg 
then 20 mg 
every 2 weeks 
Male, %: 53 
 
Race NR 
 
Smoking, % 
Current smoker, 
34 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 61 
Ileo-colonic: 5 
Colonic: 31 
Perianal: 0 
 
Behavior NR 
 
CRP 
Mean: 1.6 
Median: 0.9 
Min: 0 
Max: 11.3 
CDAI 
Mean: 299 
 
IBDQ 
Median: 129 
Min: 81 
Max: 218 
5ASA: 50 
 
Antibiotics: 14 
 
Corticosteroids: 
23 
 
Methotrexate: 5 
 
Thiopurines: 
25.7 
 
Immunomodulat
ors: 31 
NR NR 
Keshavarzian, 
2007182 
Immunomodulat
ors + Infliximab, 
322 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Keshavarzian, 
2007182 
Never user 
immunomodulat
ors + Infliximab, 
125 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Kinney, 2003162 Infliximab + 
Methotrexate, 23 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 13 
 
Age at 
enrollment 
Mean: 43 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
NR NR 
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Disease 
characteristics 
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taken BEFORE 
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Medications 
taken FOR 
INDUCTION, % 
Kinney, 2003162 Infliximab + 
Thiopurine, 58 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12 
 
Age at 
enrollment 
Mean: 40 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
NR NR 
Kinney, 2003162 Infliximab, 36 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 15 
 
Age at 
enrollment 
Mean: 46 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
NR NR 
Lawrance, 
2010165 
TNF-alpha + 
Never user 
corticosteroids 
OR thio/mtx, 44 
Route: IV or SC 
Dose: 5 mg/kg 
for infliximab 
160/80 mg for 
adalimumab + 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lawrance, 
2010165 
TNF-alpha + 
Corticosteroid, 
36 Route: IV or 
SC + Unknown 
Dose: 5 mg/kg 
for infliximab 
160/80 mg for 
adalimumab + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Lawrance, 
2010165 
TNF-alpha + 
steroid + 
aza/6mp/mtx, 
232 Route: IV or 
SC + Unknown 
Dose: 5 mg/kg 
for infliximab 
160/80 mg for 
adalimumab + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lawrance, 
2010165 
TNF-alpha + 
aza/6mp/mtx, 
177 Route: IV or 
SC Dose: 5 
mg/kg for 
infliximab 160/80 
mg for 
adalimumab + 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lee, 2011184 Infliximab + 
Immunosupress
ants, 116 Route: 
IV Dose: 5 
mg/kg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lee, 2011184 Infliximab + No 
IMM 
(AZA,6mp/MTX), 
97 Route: IV 
Dose: 5 mg/kg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lee, 2011184 Infliximab + No 
premed with 
steroids or, 47 
Route: IV Dose: 
5 mg/kg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lee, 2011184 Infliximab + 
steroid premed, 
171 Dose: 5 
mg/kg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 2009145 Infliximab + 
Corticosteroid, 
32 
Route: IV + 
Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 2009145 Infliximab + 
Azathioprine, 51 
Route: IV 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lees, 2009145 Adalimumab, 30 Male, %: 36.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Median: 32.3 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 2009145 Infliximab + 
Never user 
concomitant 
azathioprine/6-
MP/methotrexate
/corticosteroids, 
19 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 2009145 Infliximab + 
Azathioprine/6-
MP/methotrexate 
+ corticosteroids, 
55 
Route: IV + 
Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lemann, 200646 Infliximab + 
Azathioprine or 
6-MP, 57 
Route: IV 
Dose: 5 mg/kg + 
stable 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 10 
 
Age at 
enrollment 
Min: 22 
Max: 38 
Severity NR 
 
Location, % 
Ileal: 28.1 
Ileo-colonic: 50.9 
Colonic: 21.1 
Perianal: 33.3 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 47 
CDAI 
Min: 90 
Max: 281 
NR Thiopurines: 100 NR 
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Lemann, 200646 Placebo + 
Azathioprine or 
6-MP, 56 
Route: IV + Oral 
Dose: NA + 
stable mg/kg 
every day 
Male, %: 42.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 11 
 
Age at 
enrollment 
Min: 22 
Max: 36 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 48.2 
Colonic: 39.3 
Perianal: 10.7 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 35 
CDAI 
Min: 42 
Max: 262 
NR Thiopurines: 100 NR 
Lichtenstein, 
2006131 
 
 
Immunomodulat
or, 3764 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
No reported 
prednisone 
usage, 2396 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
Prednisone, 
3894 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lichtenstein, 
2006131 
 
No 
immunomodulat
ors, 2526 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
Never user 
infliximab, 3111 
Route: IV 
Male, %: 40.8 
 
Race, % 
W: 89.3 
H: 1.4 
B: 6.2 
A: 0.3 
Other: 0.6 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.9 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 47.9 
Mod-sev 
disease: 10.3 
Severe disease: 
0.6 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 35.4 
Colonic: 28 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors: 32.2 
 
Prednisone: 16.1 
 
Narcotic 
analgesics: 5.4 
NR NR 
Lichtenstein, 
2006131 
 
 
Infliximab, 3179 
Route: IV 
Male, %: 40.5 
 
Race, % 
W: 88.8 
H: 1.2 
B: 7.2 
A: 0.5 
Other: 0.7 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.7 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 50.1 
Mod-sev 
disease: 30.8 
Severe disease: 
2.5 
 
Location, % 
Ileal: 25.1 
Ileo-colonic: 43.2 
Colonic: 28.2 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Prednisone: 27.4 
 
Immunomodulat
or: 49.4 
 
narcotic 
analgesic: 9.8 
NR NR 
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Lichtiger, 
2010161 
Adalimumab + 
Never user ASA, 
434 Route: SC + 
Unknown Dose: 
40 mg every 2 
weeks + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics 
Corticosteroids 
Methotrexate 
Thiopurines 
5ASA 
Antibiotics 
TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
Lichtiger, 
2010161 
Adalimumab + 
immunomodulat
or, 277 Route: 
SC + Unknown 
Dose: 40 mg 
every 2 weeks + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Antibiotics 
Corticosteroids 
NR NR 
Lichtiger, 
2010161 
Adalimumab + 5-
ASA, 239 Route: 
SC + Unknown 
Dose: 40 mg 
every 2 weeks + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics 
Corticosteroids 
Methotrexate 
Thiopurines 
5ASA 
Antibiotics 
TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
Lichtiger, 
2010161 
Adalimumab + 
Never user 
immunomodulat
or, 396 Route: 
SC + Unknown 
Dose: 40 mg 
every 2 weeks + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Antibiotics 
Corticosteroids 
NR NR 
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Lichtiger, 
2010161 
Adalimumab + 
Corticosteroid, 
285 Route: SC + 
Unknown Dose: 
40 mg every 2 
weeks + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Antibiotics 
Methotrexate 
Thiopurines 
NR NR 
Lichtiger, 
2010161 
Adalimumab + 
Never user 
corticosteroids, 
388 Route: SC + 
Unknown Dose: 
40 mg every 2 
weeks + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics 
Methotrexate 
Thiopurines 
NR NR 
Lofberg, 2011158 
CARE 
Adalimumab + 
steroid +/- IMM, 
706 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP Median: 1.1 
HBI Median: 10 Corticosteroids NR NR 
Lofberg, 2011158 
CARE 
Adalimumab + 
no steroid no 
IMM, 239 Dose: 
160,80,40 mg 
every 2 weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Malik, 2011229 
Royal Hospital 
Sick Children 
Infliximab + 
steroid, 15 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis  
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Methotrexate NR NR 
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Malik, 2011229 
Royal Hospital 
Sick Children 
Infliximab + no 
steroid, 13 
Route: IV Dose: 
5 mg/kg every 2 
weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Methotrexate NR NR 
Malik, 2011229 
Royal Hospital 
Sick Children 
Infliximab + 
Methotrexate, 21 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Malik, 2011229 
Royal Hospital 
Sick Children 
Infliximab + no 
MTX, 7 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Mantzaris, 
200988 
Hydrocortisone + 
Infliximab, 23 
Route: IV 
Dose: 250 mg 
every 8 weeks + 
5 mg/kg every 8 
weeks 
Male, %: 52.2 
 
Race NR 
 
Smoking, % 
Smoker, 47.8 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 35 
Min: 20 
Max: 57 
Severity NR 
 
Location, % 
Ileal: 30.4 
Ileo-colonic: 47.8 
Colonic: 21.7 
 
Behavior, % 
Inflammatory: 
100 
 
CRP NR 
CDAI 
Mean: 298 
NR 5ASA: 91.3 
 
Corticosteroids: 
69.6 
 
budesonide: 
34.8 
 
NO azathiprine: 
26.1 
 
topical ASA: 
17.4 
 
: 26.1 
Infliximab: 100 
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Mantzaris, 
200988 
Azathioprine + 
Infliximab, 23 
Route: Oral + IV 
Dose: 2.0-2.5 
mg/kg every day 
+ 5 mg/kg every 
8 weeks 
Male, %: 47.8 
 
Race NR 
 
Smoking, % 
Smoker, 43.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Min: 21 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 26.1 
Ileo-colonic: 56.5 
Colonic: 17.4 
 
Behavior, % 
Inflammatory: 
100 
 
CRP NR 
CDAI 
Mean: 287 
NR 5ASA: 87 
 
Corticosteroids: 
69.6 
 
budesonide: 
34.8 
 
NO azathiprine: 
100 
 
topical ASA: 13 
 
: 100 
Infliximab: 100 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Thiopurine + 
TNF-alpha 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Never user 
corticosteroids, 
azathioprine/6-
MP/methotrexate
, TNF-alpha 
inhibitor or 
combination of 
these drugs 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: Total 
sample NR, but 
n CD was 0 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
TNF-alpha + 
Corticosteroid 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Corticosteroid + 
TNF-alpha 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Thiopurine + 
TNF-alpha 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Mortimore, 
2001174 
 
 
Infliximab + No 
concomitant 
immunosuppress
ive, 15 
Route: IV + 
Unknown 
Dose: 5 mg/kg + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Mortimore, 
2001174 
 
 
Infliximab, 42 
Route: IV 
Dose: 5 mg/kg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Methotrexate: 
21.4 
 
Thiopurines: 81 
 
Mycophenolate: 
4.8 
NR NR 
Moss, 2008148 Infliximab + 
Corticosteroid, 
86 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Moss, 2008148 Infliximab + No 
steroids, 201 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Moss, 2008148 Infliximab + No 
immunomodulat
or at initiation, 
172 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Moss, 2008148 Infliximab + 
Thiopurine, 115 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Moss, 2010147 Infliximab + 6-
MP, 62 
Route: IV 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Moss, 2010147 Infliximab, 61 
Route: IV 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Moss, 2010147 Infliximab, 61 
Route: IV 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Moss, 2010147 Infliximab, 61 
Route: IV 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
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Moss, 2010147 Infliximab, 61 
Route: IV 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
Orlando, 2005128 
 
 
Infliximab + 
Immunomodulat
or (unspecified), 
211 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
NR NR 
Orlando, 2005128 
 
 
Infliximab + No 
concomitant 
immunomodulat
ors, 362 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Antibiotics 
 
Corticosteroids 
NR NR 
Present, 199944 Infliximab, 32 
Route: IV 
Dose: 10 mg/kg 
Male, %: 37.5 
 
Race, % 
W: 90.6 
B: 9.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11.5 
 
Age at 
enrollment 
Mean: 35 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 56.2 
Colonic: 31.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 184.9 
Median: 203 
 
Perianal DAI 
Median: 10 
5ASA: 50 
 
Antibiotics: 34.4 
 
Corticosteroids: 
31.2 
 
Thiopurines: 
53.1 
NR NR 
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Present, 199944 Infliximab, 31 
Route: IV 
Dose: 5 mg/kg 
Male, %: 48.4 
 
Race, % 
W: 90.3 
B: 9.7 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 13.6 
 
Age at 
enrollment 
Mean: 41.2 
Severity NR 
 
Location, % 
Ileal: 22.6 
Ileo-colonic: 54.8 
Colonic: 22.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 184.4 
Median: 163 
 
Perianal DAI 
Median: 8 
5ASA: 54.8 
 
Antibiotics: 19.4 
 
Corticosteroids: 
38.7 
 
Thiopurines: 
38.7 
NR NR 
Present, 199944 Placebo, 31 
Route: IV 
Male, %: 54.8 
 
Race, % 
W: 93.5 
B: 6.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12 
 
Age at 
enrollment 
Mean: 35.4 
Severity NR 
 
Location, % 
Ileal: 9.7 
Ileo-colonic: 61.3 
Colonic: 29 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 192.9 
Median: 162 
 
Perianal DAI 
Median: 9 
5ASA: 61.3 
 
Antibiotics: 35.5 
 
Corticosteroids: 
35.5 
 
Thiopurines: 29 
NR NR 
Ricart, 2001138 Infliximab + 
Corticosteroid, 
44 
Route: IV + 
Unknown 
Dose: 5 mg/kg + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
NR 
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Ricart, 2001138 Infliximab + 
Never user 
corticosteroid, 56 
Route: IV + 
Unknown 
Dose: 5 mg/kg + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
NR 
Ricart, 2001138 Infliximab + 
Never user 
immunomodulat
ors, 5 
Route: IV + 
Unknown 
Dose: 5 mg/kg + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
NR 
Ricart, 2001138 Infliximab + 
Immunomodulat
ors, 95 
Route: IV + 
Unknown 
Dose: 5 mg/kg + 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
5ASA 
 
Antibiotics 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Immunomodulat
ors 
NR 
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Rudolph, 2008175 Infliximab + 
Never user 
immunomodulat
or at start of 
infliximab, 71 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids Corticosteroids 
 
Immunomodulat
ors 
NR 
Rudolph, 2008175 Infliximab + 
Immunomudulat
or, 127 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Rutgeerts, 
199985 
Infliximab, 37 
Route: IV 
Dose: 10 mg/kg 
every 8 weeks 
Male, %: 40.5 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9.4 
Min: 1.1 
Max: 30.8 
 
Age at 
enrollment 
Median: 34 
Min: 20 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 13.5 
Ileo-colonic: 62.2 
Colonic: 24.3 
 
Behavior NR 
 
CRP 
Median: 0.5 
CDAI 
Median: 175 
 
IBDQ 
Median: 165 
NR NR TNF-alpha 
inhibitors: 91.9 
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Rutgeerts, 
199985 
Placebo, 36 
Route: Unknown 
Dose: NA every 
8 weeks 
Male, %: 63.9 
 
Race, % 
W: 100 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 12.1 
Min: 0.3 
Max: 32.8 
 
Age at 
enrollment 
Median: 39 
Min: 20 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 13.9 
Ileo-colonic: 47.2 
Colonic: 38.9 
 
Behavior NR 
 
CRP 
Median: 0.4 
CDAI 
Median: 170 
 
IBDQ 
Median: 170 
NR NR TNF-alpha 
inhibitors: 97.2 
Russell, 2011236 Adalimumab + 
no IMM (Thio or 
MTX) +/- steroid, 
24 Route: 
Unknown + 
Unknown Dose: 
40 mg every 15 
days + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 283.3 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
Russell, 2011236 Adalimumab + 
IMM (Thio or 
MTX) +/- steroid, 
46 Route: 
Unknown + 
Unknown Dose: 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
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characteristics 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200533 
 
Natalizumab, 
724 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 43 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
22.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.1 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 26.8 
Ileo-colonic: 51.5 
Colonic: 21.7 
 
Behavior NR 
 
CRP 
Mean: 20 
Median: 9 
Min: 0 
Max: 370 
CDAI 
Mean: 302 
5ASA: 47.4 
 
Antibiotics: 5.9 
 
Corticosteroids: 
37.4 
 
Methotrexate: 
4.3 
 
Thiopurines: 
29.8 
 
Prednisone: 27.2 
 
Budesonide: 
10.9 
 
>/= 1 
corticosteroids or 
immunomodulat
ors: 56.2 
 
Corticosteroids 
and 
immunosuppress
ants: 15.3 
TNF-alpha 
inhibitors: 40.2 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200533 
 
 
Placebo, 181 
Route: IV 
Dose: NA every 
4 weeks 
Male, %: 40.3 
 
Race NR 
 
Smoking, % 
>10 
cigarettes/day, 
24.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.16 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 26 
Ileo-colonic: 46.4 
Colonic: 27.1 
 
Behavior NR 
 
CRP 
Mean: 23 
Median: 12 
Min: 0 
Max: 127 
CDAI 
Mean: 303 
5ASA: 44.2 
 
Antibiotics: 6.6 
 
Corticosteroids: 
38.7 
 
Methotrexate: 
3.3 
 
Thiopurines: 
25.4 
 
Prednisone: 29.3 
 
Budesonide: 11 
 
>/= 1 
corticosteroid or 
immunomodulat
ors: 55.2 
 
Corticosteroids 
and 
immunosuppress
ants: 12.2 
TNF-alpha 
inhibitors: 38.1 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200739 
 
 
Placebo, 328 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 40 
 
Race NR 
 
Smoking, % 
Current smoker, 
33 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8 
Median: 5 
Min: 1 
Max: 40 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 77 
Severity NR 
 
Location, % 
Ileal: 27 
Ileo-colonic: 51 
Colonic: 23 
 
Behavior NR 
 
CRP 
Mean: 9 
Min: 2 
Max: 244 
CDAI 
Mean: 297 
Min: 161 
Max: 513 
Corticosteroids: 
23 
 
Immunomodulat
ors: 20 
 
Glucocorticoids 
+ 
immunomodulat
ors: 17 
 
Neither 
glucocorticoids 
nor 
immunomodulat
ors: 40 
infliximab: 26 NR 
Sandborn, 
200739 
 
 
Certolizumab 
pegol, 331 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Current smoker, 
31 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
Median: 5 
Min: 1 
Max: 44 
 
Age at 
enrollment 
Mean: 37 
Min: 18 
Max: 73 
Severity NR 
 
Location, % 
Ileal: 29 
Ileo-colonic: 45 
Colonic: 26 
 
Behavior NR 
 
CRP 
Mean: 8 
Min: 2 
Max: 205 
CDAI 
Mean: 300 
Min: 149 
Max: 491 
Corticosteroids: 
22 
 
Immunomodulat
ors: 21 
 
Glucocorticoids 
+ 
immunomodulat
ors: 17 
 
Neither 
glucocorticoids 
nor 
immunomodulat
ors: 40 
infliximab: 30 NR 
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Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200738 
 
Placebo, 166 
Route: SC 
Dose: NA 
Male, %: 39.2 
 
Race NR 
 
Smoking, % 
Smoker, 33.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 37 
Severity NR 
 
Location, % 
Ileal: 74.7 
Colonic: 68.1 
Perianal: 18.7 
 
Behavior NR 
 
CRP 
Mean: 20 
CDAI 
Mean: 313 
 
IBDQ 
Mean: 124 
5ASA: 36.1 
 
Corticosteroids: 
44 
 
Immunomodulat
ors: 51.2 
NR NR 
Sandborn, 
200738 
 
 
Adalimumab, 
159 
Route: SC 
Male, %: 31.4 
 
Race NR 
 
Smoking, % 
Smoker, 34.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 39 
Severity NR 
 
Location, % 
Ileal: 70.4 
Colonic: 66 
Perianal: 17 
 
Behavior NR 
 
CRP 
Mean: 19 
CDAI 
Mean: 313 
 
IBDQ 
Mean: 120 
5ASA: 28.3 
 
Corticosteroids: 
34.6 
 
Immonomodulat
or: 45.9 
NR NR 
Sandborn, 
200783 
 
 
Adalimumab, 18 
Route: SC 
Dose: 40 mg 
every 1 week 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 56 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.13 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 191 
5ASA: 67 
 
Antibiotics: 0 
 
Corticosteroids: 
50 
 
Methotrexate: 0 
 
Thiopurines: 28 
 
Immunomodulat
ors: 28 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
200783 
 
 
Placebo, 18 
Route: SC 
Dose: NA every 
1 week 
Male, %: 33 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 67 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.24 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 188 
5ASA: 44 
 
Antibiotics: 6 
 
Corticosteroids: 
56 
 
Methotrexate: 6 
 
Thiopurines: 
11.1 
 
Immunomodulat
ors: 17 
NR TNF-alpha 
inhibitors: 100 
Sandborn, 
200783 
 
 
Adalimumab, 19 
Route: SC 
Dose: 40 mg 
every 2 weeks 
Male, %: 37 
 
Race NR 
 
Smoking, % 
Patients who 
smoked, 68 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.73 
 
Age at 
enrollment 
Mean: 34 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
IBDQ 
Mean: 187 
5ASA: 74 
 
Antibiotics: 0 
 
Corticosteroids: 
47 
 
Methotrexate: 0 
 
Thiopurines: 21 
 
Immunomodulat
ors: 21 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sandborn, 
201142 
Certolizumab 
pegol, 223 
Route: SC Dose: 
400 mg every 2 
weeks 
Male, %: 47.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % Ileal: 
28.3 Ileo-colonic: 
40.4 Colonic: 
29.1 
 
Behavior, % 
Inflammatory: 
75.3 Stricturing: 
14.8 Penetrating: 
9 
 
CRP Mean: 9.41 
CDAI Mean: 
262.1 
HBI Mean: 9.8 
IBDQ Mean: 
126.5 
Corticosteroids: 
43.5 
Immunomodulat
ors: 34.5 
corticosteroid or 
IMM: 62.3 
corticosteroid 
and IMM: 15.7 
neither 
corticosteroid 
nor IMM: 37.7 
NR NR 
Sandborn, 
201142 
Placebo, 215 
Route: SC Dose: 
400 mg every 2 
weeks 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
 
Age at 
enrollment Min: 
18 Max: 70 
Severity NR 
 
Location, % Ileal: 
26.5 Ileo-colonic: 
41.4 Colonic: 
28.4 
 
Behavior, % 
Inflammatory: 
76.7 Stricturing: 
15.8 Penetrating: 
7.4 
 
CRP Mean: 9.02 
CDAI Mean: 
292.7 
HBI Mean: 9.7 
IBDQ Mean: 
122.1 
Corticosteroids: 
45.6 
Immunomodulat
ors: 31.2 
corticosteroid or 
IMM: 62.3 
corticosteroid 
and IMM: 14.4 
neither 
corticosteroid 
nor IMM: 37.7 
NR NR 
Sands, 200487 Placebo, 99 
Route: IV 
Dose: NA every 
8 weeks 
Male, %: 48 
 
Race NR 
 
Smoking, % 
Current smoker, 
38 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 12.3 
Min: 0.5 
Max: 31.6 
 
Age at 
enrollment 
Median: 36 
Severity NR 
 
Location, % 
Ileal: 16 
Ileo-colonic: 54 
Colonic: 30 
 
Behavior NR 
 
CRP 
Median: 0.7 
IBDQ 
Median: 168 
5ASA: 49 
 
Antibiotics: 26 
 
Corticosteroids: 
30 
 
Methotrexate: 2 
 
Thiopurines: 35 
Antibiotics: 93 
 
Methotrexate: 8 
 
Thiopurines: 64 
 
cyclosporine or 
tacrolimus: 7 
Infliximab: 100 
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Disease 
characteristics 
Disease activity 
index 
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study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Sands, 200487 Infliximab, 96 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Male, %: 55 
 
Race NR 
 
Smoking, % 
Current smoker, 
45 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
Median: 10.5 
Min: 0.2 
Max: 32.2 
 
Age at 
enrollment 
Median: 37 
Severity NR 
 
Location, % 
Ileal: 19 
Ileo-colonic: 46 
Colonic: 35 
 
Behavior NR 
 
CRP 
Median: 0.6 
IBDQ 
Median: 155 
5ASA: 43 
 
Antibiotics: 29 
 
Corticosteroids: 
26 
 
Methotrexate: 1 
 
Thiopurines: 30 
Antibiotics: 96 
 
Methotrexate: 5 
 
Thiopurines: 72 
 
cyclosporine or 
tacrolimus: 3 
Infliximab: 100 
Sands, 200735 Placebo + 
Infliximab, 27 
Route: IV + IV 
Dose: NA every 
4 weeks + 5 
mg/kg every 8 
weeks 
Male, %: 63 
 
Race, % 
W: 85.2 
B: 7.4 
Other: 7.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Min: 0 
Max: 36 
 
Age at 
enrollment 
Mean: 38.9 
Min: 19 
Max: 72 
Severity NR 
 
Location, % 
Ileal: 14.8 
Ileo-colonic: 55.6 
Colonic: 29.6 
 
Behavior NR 
 
CRP 
Mean: 5.9 
Min: 0 
Max: 49 
CDAI 
Mean: 243.6 
Min: 150 
Max: 366 
5ASA: 37 
 
Antibiotics: 18.5 
 
Corticosteroids: 
29.6 
 
Azathioprine, 6-
mercaptopurine, 
or methotrexate: 
55.6 
NR NR 
Sands, 200735 Natalizumab + 
Infliximab, 52 
Route: IV + IV 
Dose: 300 mg 
every 4 weeks + 
5 mg/kg every 8 
weeks 
Male, %: 46.2 
 
Race, % 
W: 94.2 
B: 3.8 
Other: 1.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12.5 
 
Age at 
enrollment 
Mean: 39.9 
Min: 20 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 21.2 
Ileo-colonic: 53.8 
Colonic: 25 
 
Behavior NR 
 
CRP 
Mean: 6.5 
Min: 0 
Max: 71 
CDAI 
Mean: 263.8 
Min: 129 
Max: 545 
5ASA: 46.2 
 
Antibiotics: 19.2 
 
Corticosteroids: 
26.9 
 
Azathioprine, 6-
mercaptopurine, 
or methotrexate: 
50 
NR NR 
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Medications 
taken FOR 
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Schneeweiss, 
2009230 
Corticosteroid, 
7258 
Route: Unknown 
Dose: NR 
Male, %: 45.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 41.5 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
TNF-alpha 
inhibitors 
 
Methotrexate 
 
Thiopurines 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
NR 
Schneeweiss, 
2009230 
Immunomodulat
or, 2883 
Route: Unknown 
Dose: NR 
Male, %: 46.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38.6 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
NR 
Schneeweiss, 
2009230 
Infliximab, 521 
Route: Unknown 
Dose: NR 
Male, %: 45.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
NR 
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Schreiber, 
200540 
Certolizumab 
pegol, 72 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 44.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.43 
Min: 0.2 
Max: 26.5 
 
Age at 
enrollment 
Mean: 35.9 
Min: 18 
Max: 67 
Severity NR 
 
Location, % 
Ileal: 77.8 
Perianal: 29.2 
 
Behavior NR 
 
CRP 
Mean: 7.7 
Min: 0.4 
Max: 128.2 
IBDQ 
Mean: 126.5 
5ASA: 38.9 
 
Antibiotics: 8.3 
 
Corticosteroids: 
30.6 
 
Methotrexate: 
4.2 
 
Immunomodulat
ors: 37.5 
 
Anti-diarrheals: 
16.7 
 
Codeine and 
derivatives: 2.8 
 
Azathioprine: 
30.6 
 
6-MP: 2.8 
TNF-alpha 
inhibitors: 16.7 
NR 
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Schreiber, 
200540 
Certolizumab 
pegol, 74 
Route: SC 
Dose: 100 mg 
every 4 weeks 
Male, %: 47.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.73 
Min: 0 
Max: 31.8 
 
Age at 
enrollment 
Mean: 33.5 
Min: 18 
Max: 56 
Severity NR 
 
Location, % 
Ileal: 77 
Perianal: 27 
 
Behavior NR 
 
CRP 
Mean: 6.2 
Min: 0.2 
Max: 141 
IBDQ 
Mean: 132.2 
5ASA: 50 
 
Antibiotics: 8.1 
 
Corticosteroids: 
32.4 
 
Methotrexate: 
5.4 
 
Immunomodulat
ors: 35.1 
 
Anti-diarrheals: 
25.7 
 
Codeine and 
derivatives: 6.8 
 
Azathioprine: 
17.6 
 
6-MP: 12.2 
TNF-alpha 
inhibitors: 24.3 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
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Schreiber, 
200540 
Certolizumab 
pegol, 72 
Route: SC 
Dose: 200 mg 
every 4 weeks 
Male, %: 30.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.84 
Min: 0 
Max: 30.7 
 
Age at 
enrollment 
Mean: 40.1 
Min: 19 
Max: 71 
Severity NR 
 
Location, % 
Ileal: 70.8 
Perianal: 31.9 
 
Behavior NR 
 
CRP 
Mean: 6.5 
Min: 0.2 
Max: 127 
IBDQ 
Mean: 122.9 
5ASA: 44.4 
 
Antibiotics: 9.7 
 
Corticosteroids: 
40.3 
 
Methotrexate: 
5.6 
 
Thiopurines: 
34.7 
 
Immunomodulat
ors: 40.3 
 
Anti-diarrheals: 
22.2 
 
Codeine and 
derivatives: 6.9 
 
Azathioprine: 
31.9 
 
6-MP: 2.8 
TNF-alpha 
inhibitors: 23.6 
NR 
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Schreiber, 
200540 
Placebo, 73 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 32.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.95 
Min: 0.1 
Max: 27.6 
 
Age at 
enrollment 
Mean: 35.8 
Min: 19 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 74 
Perianal: 31.5 
 
Behavior NR 
 
CRP 
Mean: 7.3 
Min: 0.3 
Max: 86.1 
IBDQ 
Mean: 122.9 
5ASA: 39.7 
 
Antibiotics: 9.6 
 
Corticosteroids: 
39.7 
 
Methotrexate: 
6.8 
 
Immunomodulat
ors: 35.6 
 
Anti-diarrheals: 
13.7 
 
Codeine and 
derivatives: 8.2 
 
Azathioprine: 
23.3 
 
6-MP: 5.5 
TNF-alpha 
inhibitors: 21.9 
NR 
Schreiber, 
200784 
Certolizumab 
pegol, 216 
Route: SC 
Dose: 400 mg 
every 4 weeks 
Male, %: 43 
 
Race NR 
 
Smoking, % 
Current smoker, 
30 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9 
Median: 7 
Min: 1 
Max: 33 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 67 
Severity NR 
 
Location, % 
Ileal: 22 
Ileo-colonic: 51 
Colonic: 27 
 
Behavior, % 
Inflammatory: 
67.4 
Stricturing: 11.6 
Penetrating: 20.9 
 
CRP 
Mean: 10 
Min: 2 
Max: 183 
CDAI 
Mean: 306 
Min: 179 
Max: 504 
Corticosteroids: 
22 
 
Immunomodulat
ors: 27 
 
Glucocorticoids 
+ 
immunomodulat
ors: 13 
 
Neither 
glucocoricoids 
nor 
immunomodulat
ors: 38 
5ASA: 34.4 
 
Corticosteroids: 
49.3 
 
Immunomodulat
ors: 21.4 
 
infliximab: 24 
Certolizumab 
pegol: 100 
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Schreiber, 
200784 
Placebo, 212 
Route: SC 
Dose: NA every 
4 weeks 
Male, %: 52 
 
Race NR 
 
Smoking, % 
Current smoker, 
36 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7 
Median: 5 
Min: 1 
Max: 43 
 
Age at 
enrollment 
Mean: 38 
Min: 18 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 25 
Ileo-colonic: 46 
Colonic: 29 
 
Behavior, % 
Inflammatory: 
67.1 
Stricturing: 9.5 
Penetrating: 23.3 
 
CRP 
Mean: 10 
Min: 2 
Max: 244 
CDAI 
Mean: 301 
Min: 183 
Max: 583 
Corticosteroids: 
21 
 
Immunomodulat
ors: 25 
 
Glucocorticoids 
+ 
immunomodulat
ors: 16 
 
Neither 
glucocorticoids 
nor 
immunosuppress
ives: 38 
5ASA: 34.3 
 
Corticosteroids: 
46.7 
 
Immunomodulat
ors: 20.5 
 
infliximab: 24 
Certolizumab 
pegol: 100 
Schroder, 200647 Methotrexate + 
Infliximab, 11 
Route: IV + IV 
Dose: 20 mg 
every 1 week + 5 
mg/kg every 2 
weeks 
Male, %: 54.5 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.2 
 
Age at 
enrollment 
Mean: 31.6 
Severity NR 
 
Location, % 
Ileal: 9.1 
Ileo-colonic: 63.6 
Colonic: 9.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 251 
 
IBDQ 
Mean: 113 
5ASA: 18.2 
 
Corticosteroids: 
72.7 
NR NR 
Schroder, 200647 Infliximab, 8 
Route: IV 
Dose: 5 mg/kg 
every 2 weeks 
Male, %: 25 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.6 
 
Age at 
enrollment 
Mean: 36.5 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 62.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 293 
 
IBDQ 
Mean: 106 
5ASA: 37.5 
 
Corticosteroids: 
87.5 
NR NR 
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Seiderer, 
2004173 
Infliximab + 6-
MP, 18 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
NR NR 
Seiderer, 
2004173 
Infliximab + No 
azathioprine/6-
MP at first 
infusion, 18 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
NR NR 
Seiderer, 
2004173 
Infliximab + 
Corticosteroid, 
42 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Thiopurines 
NR NR 
Seiderer, 
2004173 
Infliximab + 
Thiopurine, 82 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
NR NR 
Seiderer, 
2004173 
Infliximab + 
Azathioprine, 64 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
NR NR 
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Sokol, 2010129 
MICISTA 
Registry--part of 
French group 
Infliximab + 
Other immunwith 
azathioprine or 
methotrexate 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration  
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Sokol, 2010129 
MICISTA 
Registry--part of 
French group 
Infliximab + No 
immunomod 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Sprakes, 2011159 
Leeds 
Adalimumab + 
Corticosteroid, 
25 Route: 
Unknown + 
Unknown Dose: 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors 
TNF-alpha 
inhibitors 
NR 
Sprakes, 2011159 
Leeds 
Adalimumab + 
Immunomodulan
ts (Not 
specified), 21 
Route: Unknown 
+ Unknown 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors 
Corticosteroids NR 
Sprakes, 2011159 
Leeds 
Adalimumab + 
No steroids, 19 
Route: Unknown 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors 
Immunomodulat
ors 
NR 
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Sprakes, 2011159 
Leeds 
Adalimumab + 
No IMM, 23 
Route: Unknown 
Dose: 160 mg 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids TNF-alpha 
inhibitors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
Corticosteroid, 
69 Route: 
Unknown + 
Unknown Dose: 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Thiopurines 
Immunomodulat
ors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
Never user 
immunomodulat
or, 48 Route: 
Unknown + 
Unknown Dose: 
NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
Never user 
corticosteroids, 
49 Route: 
Unknown + 
Unknown Dose: 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
Median age, 
years (range)a 
35.7 (18β€“69)  
Corticosteroids/b
udesonide and  
AZA/6-MP/MTX, 
42 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Swoger, 2010140 
Mayo clinic 
Adalimumab + 
Corticosteroids/b
udesonide and  
aAZA/6-MP/MTX 
and infliximab, 
10 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
No therapy, 
monotherapy or 
2 of 
Corticosteroids/b
udesonide and  
aAZA/6-MP/MTX 
and infliximab, 
108 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
no therapy or 
monotherapy 
with 
Corticosteroids/b
udesonide and  
AZA/6-MP/MTX, 
76 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Swoger, 2010140 
Mayo clinic 
Adalimumab + 
immunomodulat
or, 70 Route: 
Unknown + 
Unknown Dose: 
NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
5ASA 
TNF-alpha 
inhibitors 
Corticosteroids 
Immunomodulat
ors 
NR 
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Targan, 200732 
 
Placebo, 250 
Route: IV 
Dose: NR every 
4 weeks 
Male, %: 41 
 
Race, % 
W: 94 
H: 1 
B: 2 
A: 1 
not specified: 2 
 
Smoking, % 
>10 
cigarettes/day, 
19 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
 
Age at 
enrollment 
Mean: 37.7 
Severity, % 
Severe disease: 
28 
 
Location, % 
Ileal: 26 
Ileo-colonic: 48 
Colonic: 26 
 
Behavior NR 
 
CRP 
Mean: 23.4 
CDAI 
Mean: 299.5 
 
IBDQ 
Mean: 122.5 
5ASA: 48 
 
Antibiotics: 5 
 
Corticosteroids: 
38 
 
Immunomodulat
ors: 38 
TNF-alpha 
inhibitors: 45 
NR 
Targan, 200732 
 
Natalizumab, 
259 
Route: IV 
Dose: 300 mg 
every 4 weeks 
Male, %: 41 
 
Race, % 
W: 95 
H: 1 
B: 1 
A: 1 
not specified: 3 
 
Smoking, % 
>10 
cigarettes/day, 
22 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.1 
 
Age at 
enrollment 
Mean: 38.1 
Severity, % 
Severe disease: 
32 
 
Location, % 
Ileal: 22 
Ileo-colonic: 52 
Colonic: 27 
 
Behavior NR 
 
CRP 
Mean: 23 
CDAI 
Mean: 303.9 
 
IBDQ 
Mean: 123.6 
5ASA: 49 
 
Antibiotics: 7 
 
Corticosteroids: 
42 
 
Immunomodulat
ors: 37 
TNF-alpha 
inhibitors: 50 
NR 
Thayu, 2010199 Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Thayu, 2010199 Infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Corticosteroid Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Methotrexate Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Tromm, 201174 Mesalamine 
(Salofalk), 153 
Route: Oral 
Dose: 3 x 1.5 
g/day 
Male, %: 50.3 
 
Race, % W: 99.3 
 
Smoking, % No  
smoking 
defintion  
abstracted, 25.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.9 
 
Age at 
enrollment 
Mean: 37.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP Mean: 16.6 
CDAI Mean: 
267.2 
Thiopurines: 3.3 NR NR 
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Tromm, 201174 Budesonide, 154 
Route: Oral 
Dose: two 
administrations 
of 9mg total 
every 1 days 
Male, %: 53.2 
 
Race, % W: 99.4 
 
Smoking, % No 
smoking 
defintion 
abstracted, 30.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.1 
 
Age at 
enrollment 
Mean: 36.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP Mean: 15.4 
CDAI Mean: 
265.6 
Thiopurines: 3.2 NR NR 
Van Assche, 
200889 
Infliximab, 40 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Male, %: 47.5 
 
Race NR 
 
Smoking, % 
Smoker, 47.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 2 
Max: 25 
 
Age at 
enrollment 
Mean: 35.4 
Severity NR 
 
Location, % 
Colonic: 12.5 
 
Behavior NR 
 
CRP 
Median: 3.2 
CDAI 
Mean: 138.1 
TNF-alpha 
inhibitors: 100 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
Van Assche, 
200889 
Infliximab + 
Immunomodulat
or, 40 
Route: IV + Oral 
Dose: 5 mg/kg 
every 8 weeks + 
see below 
Male, %: 42.5 
 
Race NR 
 
Smoking, % 
Smoker, 45 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 1 
Max: 36 
 
Age at 
enrollment 
Mean: 35.6 
Severity NR 
 
Location, % 
Colonic: 32.5 
 
Behavior NR 
 
CRP 
Median: 3.4 
CDAI 
Mean: 137.6 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
Vermeire, 
2007154 
Infliximab + 
Methotrexate, 50 
Route: IV + IM or 
SC 
Dose: NR + 15 
mg every 1 week 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR Thiopurines NR 
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Vermeire, 
2007154 
Infliximab + 
Thiopurine, 65 
Route: IV + 
Unknown 
Dose: NR + See 
Comments every 
day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Vermeire, 
2007154 
Infliximab + 
Thiopurine or 
methotrexate, 
115 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Vermeire, 
2007154 
Infliximab + No 
concomitant 
methotrexate or 
azathioprine/6-
MP, 59 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + 
Budesonide, 5 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids 
Methotrexate 
Thiopurines 
budesonide: 100 
NR NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + No 5asa, 
59 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 0 
Corticosteroids 
Methotrexate 
Thiopurines 
NR NR 
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Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + No 
Budesonide, 55 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids 
Methotrexate 
Thiopurines 
budesonide: 0 
NR NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + 
Corticosteroid, 4 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis  
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
100 
5ASA 
Corticosteroids 
Methotrexate 
Thiopurines 
NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + No 
steroids, 56 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids: 
0 
Methotrexate 
Thiopurines 
NR NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + 
Thiopurine, 9 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
Corticosteroids 
Methotrexate 
Thiopurines: 100 
NR NR 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + No Thio, 
51 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Thiopurines: 100 5ASA 
Corticosteroids 
Methotrexate 
Thiopurines 
NR 
D-300 
 
Evidence Table 13. Population characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Vavricka, 
2010132 
FACTS II 
Certolizumab 
pegol + 5-ASA, 1 
Route: SC Dose: 
400 mg every 2 
weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 100 
Corticosteroids 
Methotrexate 
Thiopurines 
NR NR 
Winter, 200441 Placebo, 25 
Route: IV 
Dose: NA 
Male, %: 24 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.74 
Min: 0.1 
Max: 21.9 
 
Age at 
enrollment 
Mean: 32.1 
Min: 18 
Max: 56 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 40 
 
Corticosteroids: 
28 
 
Immunomodulat
ors: 44 
TNF-alpha 
inhibitors: 13 
NR 
Winter, 200441 Certolizumab 
pegol, 25 
Route: IV 
Dose: 5 mg/kg 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.52 
Min: 0.69 
Max: 17.0 
 
Age at 
enrollment 
Mean: 36.4 
Min: 21 
Max: 61 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 48 
 
Corticosteroids: 
24 
 
Immunomodulat
ors: 44 
TNF-alpha 
inhibitors: 23 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
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study, % 
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taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Winter, 200441 Certolizumab 
pegol, 17 
Route: IV 
Dose: 10 mg/kg 
Male, %: 35 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.20 
Min: 0.9 
Max: 26.0 
 
Age at 
enrollment 
Mean: 40.3 
Min: 18 
Max: 64 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 53 
 
Corticosteroids: 
35 
 
Immunomodulat
ors: 53 
TNF-alpha 
inhibitors: 29 
NR 
Winter, 200441 Certolizumab 
pegol, 23 
Route: IV 
Dose: 20 mg/kg 
Male, %: 44 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.94 
Min: 1.3 
Max: 18.9 
 
Age at 
enrollment 
Mean: 33.3 
Min: 19 
Max: 60 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 39 
 
Corticosteroids: 
26 
 
Immunomodulat
ors: 44 
TNF-alpha 
inhibitors: 30 
NR 
Winter, 200441 Certolizumab 
pegol, 2 
Route: IV 
Dose: 1.25 
mg/kg 
Male, %: 0 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.28 
Min: 7.7 
Max: 10.9 
 
Age at 
enrollment 
Mean: 36.5 
Min: 31 
Max: 42 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 0 
 
Corticosteroids: 
50 
 
Immunomodulat
ors: 0 
TNF-alpha 
inhibitors: 50 
NR 
Studies evaluating thiopurines 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
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taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Beaugerie, 
2009130 
Thiopurine, 8676 
Dose: NR 
Male, %: 43 
 
Race NR 
 
Smoking NR 
 
CD, %: 76.1 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 53.3 
Colonic: 59.3 
Perianal: 24.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors: 10 
 
Methotrexate: 
7.5 
 
Cyclosporin, 
mycophenolate 
mofetil, or 
cyclophosamide: 
1.6 
TNF-alpha 
inhibitors: 21.3 
 
Methotrexate: 
15.3 
NR 
Beaugerie, 
2009130 
Never user 
thiopurine, 
10810 
Dose: NA 
Male, %: 47 
 
Race NR 
 
Smoking NR 
 
CD, %: 48 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 42.3 
Severity NR 
 
Location, % 
Ileal: 33.3 
Colonic: 30.5 
Perianal: 7.3 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors: 0.6 
 
Methotrexate: 
0.4 
 
Cyclosporin, 
mycophenolate 
mofetil, or 
cyclophosamide: 
0.6 
TNF-alpha 
inhibitors: 0.9 
 
Methotrexate: 
0.6 
NR 
Campbell, 
2001146 
Azathioprine, 56 
Route: Unknown 
Dose: 1.8 mg/kg 
Male, %: 53.6 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38 
Severity NR 
 
Location, % 
Ileal: 26.8 
Ileo-colonic: 26.8 
Colonic: 46.4 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
25 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Campbell, 
2001146 
Azathioprine + 5-
ASA, 48 
Route: Unknown 
+ Unknown 
Dose: 1.7 mg/kg 
+ NR 
Male, %: 31.2 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 40 
Severity NR 
 
Location, % 
Ileal: 16.7 
Ileo-colonic: 18.8 
Colonic: 64.6 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
20.8 
NR NR 
Ewe, 199354 Placebo + 
Prednisolone, 21 
Dose: 60 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.3 
Min: 18 
Max: 48 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 285 
NR 5ASA: 28.6 
 
5-ASA + GCs: 
38.1 
NR 
Ewe, 199354 Azathioprine + 
Prednisolone, 21 
Dose: 2.5 mg/kg 
every day + 60 
mg every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.4 
 
Age at 
enrollment 
Mean: 27.3 
Min: 18 
Max: 43 
Severity NR 
 
Location, % 
Ileal: 4.8 
Ileo-colonic: 66.7 
Colonic: 28.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 290 
NR 5ASA: 33.3 
 
5-ASA + GCs: 
57.1 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Farrell, 2000231 
 
 
Immunomodulat
ors, 238 
Route: Unknown 
Dose: NR 
Male, %: 44 
 
Race NR 
 
Smoking NR 
 
CD, %: 46 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 9.4 
 
Age at 
enrollment 
Mean: 39.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Farrell, 2000231 
 
 
Never used 
immunomodulat
ors, 544 
Male, %: 49 
 
Race NR 
 
Smoking NR 
 
CD, %: 28 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.3 
 
Age at 
enrollment 
Mean: 46.1 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Fraser, 2002232 Never user 
azathioprine, 
1578 
Male, %: 47 
 
Race NR 
 
Smoking NR 
 
CD, %: 37 
Age at diagnosis 
Mean: 35.1 
 
Disease duration 
Mean: 13.7 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 17.7 
Ileo-colonic: 18.6 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Fraser, 2002232 Azathioprine, 
626 
Route: Unknown 
Dose: NR 
Male, %: 46.6 
 
Race NR 
 
Smoking NR 
 
CD, %: 43.3 
Age at diagnosis 
Mean: 31.9 
 
Disease duration 
Mean: 13.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Disease 
characteristics 
Disease activity 
index 
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taken during 
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Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Govani, 2010157 Thiopurine + no 
steroid, 11 
Route: Unknown 
Dose: NR 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Govani, 2010157 Thiopurine + 
Corticosteroid, 
16 Route: 
Unknown + 
Unknown Dose: 
NR + NR 
Gender NR 
Race NR 
Smoking NR 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
 Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Never user 
immunomodulat
or, 2798 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
Never user 5-
aminosalicylate 
acid, 675 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Immunomodulat
or, 443 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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study, % 
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taken BEFORE 
study, % 
Medications 
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Hutfless, 2007151 
 
 
Never user 
corticosteroid, 
1073 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Corticosteroid, 
2168 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
5-ASA, 2566 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Kane, 2008141 Never user 
immunnomodula
tors, 17 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Kane, 2008141 Immunomodulat
ors, 23 
Route: Unknown 
Dose: NR 
Male, %: 0 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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taken BEFORE 
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Medications 
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Lees, 2009144 Immunomodulat
or, 105 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 2009144 Never user 
immunomodulat
or, 234 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lemann, 200598 Azathioprine, 40 
Route: Oral 
Dose: as taken 
before 
enrollment every 
day 
Male, %: 47 
 
Race NR 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11 
 
Age at 
enrollment 
Mean: 40 
Severity NR 
 
Location, % 
Ileal: 13 
Ileo-colonic: 40 
Colonic: 48 
Perianal: 43 
 
Behavior NR 
 
CRP 
Mean: 5.3 
CDAI 
Mean: 41 
 
CDEIS 
Mean: 2.5 
Corticosteroids 
<10mg/day: 8 
azathioprine: 
100 
NR 
Lemann, 200598 Placebo, 43 
Route: Oral 
Dose: NA every 
day 
Male, %: 42 
 
Race NR 
 
Smoking, % 
Smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 9 
Ileo-colonic: 51 
Colonic: 40 
Perianal: 44 
 
Behavior NR 
 
CRP 
Mean: 6.9 
CDAI 
Mean: 39 
 
CDEIS 
Mean: 2.4 
Corticosteroids 
<10mg/day: 5 
azathioprine: 
100 
NR 
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Medications 
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Lemann, 200646 Placebo + 
Azathioprine or 
6-MP, 56 
Route: IV + Oral 
Dose: NA + 
stable mg/kg 
every day 
Male, %: 42.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 11 
 
Age at 
enrollment 
Min: 22 
Max: 36 
Severity NR 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 48.2 
Colonic: 39.3 
Perianal: 10.7 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 35 
CDAI 
Min: 42 
Max: 262 
NR Thiopurines: 100 NR 
Lemann, 200646 Infliximab + 
Azathioprine or 
6-MP, 57 
Route: IV 
Dose: 5 mg/kg + 
stable 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 10 
 
Age at 
enrollment 
Min: 22 
Max: 38 
Severity NR 
 
Location, % 
Ileal: 28.1 
Ileo-colonic: 50.9 
Colonic: 21.1 
Perianal: 33.3 
 
Behavior NR 
 
CRP 
Min: 4 
Max: 47 
CDAI 
Min: 90 
Max: 281 
NR Thiopurines: 100 NR 
Lewis, 2001136 
 
 
Never user 
mesalamine 
(NR), 7931 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
 
Never user 
corticosteroid, 
11000 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Thiopurine, 837 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
azathioprine/6-
MP, 5768 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 15087 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
 
Immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 77 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Mesalamine 
(NR), 7233 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Corticosteroid, 
4064 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
No 
immunomodulat
ors, 2526 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lichtenstein, 
2006131 
 
 
No reported 
prednisone 
usage, 2396 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
Immunomodulat
or, 3764 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
Infliximab, 3179 
Route: IV 
Male, %: 40.5 
 
Race, % 
W: 88.8 
H: 1.2 
B: 7.2 
A: 0.5 
Other: 0.7 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.7 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 50.1 
Mod-sev 
disease: 30.8 
Severe disease: 
2.5 
 
Location, % 
Ileal: 25.1 
Ileo-colonic: 43.2 
Colonic: 28.2 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Prednisone: 27.4 
 
Immunomodulat
or: 49.4 
 
narcotic 
analgesic: 9.8 
NR NR 
D-312 
 
Evidence Table 13. Population characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
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Lichtenstein, 
2006131 
 
Never user 
infliximab, 3111 
Route: IV 
Male, %: 40.8 
 
Race, % 
W: 89.3 
H: 1.4 
B: 6.2 
A: 0.3 
Other: 0.6 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.9 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 47.9 
Mod-sev 
disease: 10.3 
Severe disease: 
0.6 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 35.4 
Colonic: 28 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors: 32.2 
 
Prednisone: 16.1 
 
Narcotic 
analgesics: 5.4 
NR NR 
Lichtenstein, 
2006131 
 
 
Prednisone, 
3894 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Maher, 2009176 Azathioprine, 16 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Antibiotics 
 
Corticosteroids 
NR NR 
Maher, 2009176 Never user, 60 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Mantzaris, 
2009102 
Azathioprine, 38 
Route: Oral 
Dose: 2.0-2.5 
mg/kg every day 
Male, %: 44.7 
 
Race NR 
 
Smoking, % 
Smoker, 92.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.8 
 
Age at 
enrollment 
Median: 34.3 
Min: 19 
Max: 59 
Severity, % 
Remission: 100 
 
Location, % 
Ileo-colonic: 63.2 
Colonic: 36.8 
 
Behavior, % 
Inflammatory: 
100 
 
CRP NR 
CDAI 
Mean: 132 
 
CDEIS 
Mean: 7.2 
NR Corticosteroids: 
100 
Corticosteroids: 
100 
Mantzaris, 
2009102 
Budesonide, 39 
Route: Oral 
Dose: 1-9 mg 
every day 
Male, %: 43.6 
 
Race NR 
 
Smoking, % 
Smoker, 92.3 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.9 
 
Age at 
enrollment 
Median: 34.5 
Min: 19 
Max: 62 
Severity, % 
Remission: 100 
 
Location, % 
Ileo-colonic: 66.7 
Colonic: 33.3 
 
Behavior, % 
Inflammatory: 
100 
 
CRP NR 
CDAI 
Mean: 129 
 
CDEIS 
Mean: 7.1 
NR Corticosteroids: 
100 
Corticosteroids: 
100 
Marehbian, 
2009168 
Thiopurine + 
TNF-alpha 
Route: Unknown 
+ Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Marehbian, 
2009168 
Thiopurine + 
TNF-alpha 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Never user 
corticosteroids, 
azathioprine/6-
MP/methotrexate
, TNF-alpha 
inhibitor or 
combination of 
these drugs 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: Total 
sample NR, but 
n CD was 0 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Marehbian, 
2009168 
TNF-alpha + 
Corticosteroid 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Marehbian, 
2009168 
Corticosteroid + 
TNF-alpha 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Markowitz, 
2000192 
6-MP + 
Prednisone, 27 
Dose: 1.5 mg/kg 
every day + 40 
mg every day 
Male, %: 55.6 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 14.8 
Ileo-colonic: 70.4 
Colonic: 14.8 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 46.7 
 
HBI 
Mean: 7.7 
 
partial HB 
Mean: 6.6 
NR NR NR 
Markowitz, 
2000192 
Placebo + 
Prednisone, 28 
Dose: 40 mg 
every day 
Male, %: 64.3 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.4 
Severity NR 
 
Location, % 
Ileal: 3.6 
Ileo-colonic: 78.6 
Colonic: 17.9 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 44.7 
 
HBI 
Mean: 7.4 
 
partial HB 
Mean: 6.5 
NR NR NR 
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O'Donoghue, 
1978100 
Placebo, 27 
Route: Oral 
Dose: NA 
Male, %: 40.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.05 
Min: 1.5 
Max: 15 
 
Age at 
enrollment 
Mean: 40.5 
Min: 22 
Max: 65 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 25.9 
Ileo-colonic: 11.1 
Colonic: 63 
 
Behavior NR 
 
CRP NR 
Unnamed clinical 
scoring system 
Mean: 2 
Min: 0 
Max: 7 
Prednisolone 
and 
sulfasalazine 
collectively: 25.9 
NR Thiopurines: 100 
O'Donoghue, 
1978100 
Azathioprine, 24 
Route: Oral 
Dose: 2 mg/kg 
every 24 hours 
Male, %: 45.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.25 
Min: 1.5 
Max: 20 
 
Age at 
enrollment 
Mean: 40 
Min: 21 
Max: 78 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 12.5 
Ileo-colonic: 41.7 
Colonic: 45.8 
 
Behavior NR 
 
CRP NR 
Unnamed clinical 
scoring system 
Mean: 2.33 
Min: 0 
Max: 9 
Corticosteroids 
and/or 
sulfasalazine: 
33.3 
NR Thiopurines: 100 
Reinisch, 200851 Azathioprine + 
Prednisone, 52 
Route: Oral + 
Oral 
Dose: 2.5 mg/kg 
every day + 1 
mg/kg or >/= 40 
mg every day 
Male, %: 50 
 
Race NR 
 
Smoking, % 
Smoker, 30.8 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 1.2 
Min: 0 
Max: 20.3 
 
Age at 
enrollment 
Median: 38.5 
Min: 19 
Max: 74 
Severity NR 
 
Location, % 
Ileal: 71.2 
Colonic: 73.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 282 
Min: 225 
Max: 435 
 
IBDQ 
Median: 126 
Min: 46 
Max: 198 
NR NR Corticosteroids: 
96.2 
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Reinisch, 200851 Placebo + 
Prednisone, 29 
Route: Oral + 
Oral 
Dose: NA every 
day + 1mg/kg or 
>/= 40mg every 
day 
Male, %: 55.2 
 
Race NR 
 
Smoking, % 
Smoker, 34.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 0.6 
Min: 0 
Max: 14.9 
 
Age at 
enrollment 
Median: 39.5 
Min: 18 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 82.8 
Colonic: 58.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 280 
Min: 230 
Max: 432 
 
IBDQ 
Median: 120 
Min: 70 
Max: 147 
NR NR Corticosteroids: 
96.6 
Sandborn, 
199959 
Azathioprine + 
Azathioprine, 51 
Route: IV + Oral 
Dose: 40 mg/kg 
+ 2 mg/kg every 
day 
Male, %: 47.1 
 
Race NR 
 
Smoking, % 
Smoker, 43.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 7.1 
Min: 0 
Max: 28 
 
Age at 
enrollment 
Median: 33 
Min: 19 
Max: 63 
Severity NR 
 
Location, % 
Ileal: 33.3 
Ileo-colonic: 52.9 
Colonic: 13.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 244 
Min: 89 
Max: 424 
 
IBDQ 
Median: 127 
Min: 73 
Max: 183 
NR NR NR 
Sandborn, 
199959 
Placebo + 
Azathioprine, 45 
Route: Oral 
Dose: 2 mg/kg 
every day 
Male, %: 55.6 
 
Race NR 
 
Smoking, % 
Smoker, 35.6 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 6.6 
Min: 0 
Max: 35 
 
Age at 
enrollment 
Median: 35 
Min: 19 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 17.8 
Ileo-colonic: 60 
Colonic: 22.2 
 
Behavior NR 
 
CRP NR 
CDAI 
Median: 245 
Min: 142 
Max: 476 
 
IBDQ 
Median: 123 
Min: 77 
Max: 182 
NR NR NR 
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Schneeweiss, 
2009230 
Corticosteroid, 
7258 
Route: Unknown 
Dose: NR 
Male, %: 45.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 41.5 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
TNF-alpha 
inhibitors 
 
Methotrexate 
 
Thiopurines 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
NR 
Schneeweiss, 
2009230 
Immunomodulat
or, 2883 
Route: Unknown 
Dose: NR 
Male, %: 46.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 38.6 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
NR 
Schneeweiss, 
2009230 
Infliximab, 521 
Route: Unknown 
Dose: NR 
Male, %: 45.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
5ASA 
 
Antibiotics 
 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
NR 
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Seksik, 2009155 Never user 
azathioprine, 61 
Route: Unknown 
Dose: NR 
Male, %: 41 
 
Race NR 
 
Smoking NR 
 
CD, %: 67.2 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 12.6 
 
Age at 
enrollment 
Mean: 40.8 
Min: 21.4 
Max: 76.8 
Severity NR 
 
Location, % 
Ileal: 45.9 
Ileo-colonic: 13.1 
Colonic: 8.2 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 77 
 
Corticosteroids: 
5 
 
Azathioprine: 0 
 
Infliximab: 0 
NR NR 
Seksik, 2009155 Azathioprine, 
169 
Route: Unknown 
Dose: NR 
Male, %: 42.6 
 
Race NR 
 
Smoking NR 
 
CD, %: 71.6 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 13.1 
 
Age at 
enrollment 
Mean: 37.7 
Min: 17.8 
Max: 71.8 
Severity NR 
 
Location, % 
Ileal: 22.5 
Ileo-colonic: 30.8 
Colonic: 17.8 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
5ASA: 0 
 
Corticosteroids: 
14 
 
Azathioprine: 
100 
 
Infliximab: 4 
NR NR 
Shah, 2008156 Azathioprine + 
Never user 
mesalamine, 95 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 69.5 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Shah, 2008156 Azathioprine + 
Mesalamine 
(NR), 104 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 53.8 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
Summers, 
197956 
 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg. every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
Summers, 
197956 
 
 
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
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Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kgs 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
Summers, 
197956 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
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Summers, 
197956 
 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
Summers, 
197956 
 
 
Prednisone, 61 
Route: Oral 
Dose: 1-4 mg/kg 
every 24 hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
Tay, 2003233 Any 
immunomodulat
or, 72 
Route: Unknown 
Male, %: 40.3 
 
Race NR 
 
Smoking, % 
Smoker, 1.4 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Min: 19 
Max: 51 
Severity NR 
 
Location, % 
Ileal: 2.8 
Ileo-colonic: 1.4 
Colonic: 1.4 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors: 5.6 
NR NR 
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Tay, 2003233 No 
immunomodulat
or, 28 
Route: Unknown 
Male, %: 46.4 
 
Race NR 
 
Smoking, % 
Smoker, 7.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Min: 28 
Max: 60 
Severity NR 
 
Location, % 
Ileal: 14.3 
Ileo-colonic: 10.7 
Colonic: 3.6 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
van Schaik, 
2011234 
Netherlands 
claims database 
5-ASA + Never 
user thiopurines, 
973 Route: 
Unknown Dose: 
1.2 g every 1 
days 
Male, %: 43 
 
Race NR 
 
Smoking NR 
 
CD, %: 46 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3 
 
Age at 
enrollment 
Mean: 43 
 Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
van Schaik, 
2011234 
Netherlands 
claims database 
Thiopurine + 
Never user asa, 
314 Route: 
Unknown Dose: 
50 mg every 1 
days 
Male, %: 42 
 
Race NR 
 
Smoking NR 
 
CD, %: 39 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.8 
Age at 
enrollment 
Mean: 42 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
van Schaik, 
2011234 
Netherlands 
claims database 
5-ASA + 
Thiopurine, 456 
Route: Unknown 
+ Unknown 
Dose: 1.2 g + 50 
mg every 1 days 
Male, %: 42 
 
Race NR 
 
Smoking NR 
 
CD, %: 47 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.3 
Age at 
enrollment 
Mean: 44 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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van Schaik, 
2011234 
Netherlands 
claims database 
Never user ASA 
or thiopurine or 
didn't meet 
dose/duration 
requirement, 835 
Route: Unknown 
Dose: NR 
Male, %: 43 
 
Race NR 
 
Smoking NR 
 
CD, %: 43 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.9 
 
Age at 
enrollment 
Mean: 43 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Studies evaluating methotrexate 
Feagan, 199563 Placebo + 
Prednisone, 47 
Route: IM + Oral 
Dose: NA every 
1 week + every 
day 
Male, %: 55 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 47 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 98 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location, % 
Ileal: 17 
Ileo-colonic: 64 
Colonic: 19 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 190 
 
IBDQ 
Mean: 159 
Hydrocortisone 
ointment 
NR NR 
Feagan, 199563 Methotrexate + 
Prednisone, 94 
Route: IM + Oral 
Dose: 25 mg 
every 1 week 
Male, %: 54 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 49 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 93 
 
Age at 
enrollment 
Mean: 34 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 52 
Colonic: 16 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181 
 
IBDQ 
Mean: 162 
NR NR NR 
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Feagan, 2000105 Methotrexate, 40 
Route: IM 
Dose: 15 mg 
every 1 week 
Male, %: 40 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 50 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.33 
 
Age at 
enrollment 
Mean: 32 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 45 
Ileo-colonic: 28 
Colonic: 28 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94 
NR NR Methotrexate: 
100 
Feagan, 2000105 Placebo, 36 
Route: IM 
Dose: NA every 
1 week 
Male, %: 61 
 
Race NR 
 
Smoking, % 
Cigarette 
smoker, 42 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 84 
 
Age at 
enrollment 
Mean: 34 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 31 
Ileo-colonic: 44 
Colonic: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 84 
NR Methotrexate: 
100 
 
Thiopurines: 3 
Methotrexate: 
100 
Thayu, 2010199 Infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Thayu, 2010199 Corticosteroid Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Methotrexate Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Studies evaluating corticosteroids 
Alemzadeh, 
2002200 
Placebo, 108 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Alemzadeh, 
2002200 
Corticosteroid, 
27 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Campieri, 199768 Budesonide + 
Placebo, 61 
Route: Oral + 
Oral 
Dose: 4.5 mg 
every 12 hours + 
NA every 24 
hours 
Male, %: 45.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 7.9 
Min: 0 
Max: 37 
 
Age at 
enrollment 
Mean: 38 
Min: 20 
Max: 71 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 274 
Min: 107 
Max: 465 
Corticosteroids: 
100 
NR NR 
Campieri, 199768 Prednisolone + 
Placebo, 58 
Route: Oral + 
Oral 
Dose: 40 mg 
every day + NA 
every 12 hours 
Male, %: 39.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6.7 
Min: 0 
Max: 27 
 
Age at 
enrollment 
Mean: 36 
Min: 19 
Max: 70 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 279 
Min: 202 
Max: 458 
Corticosteroids: 
100 
NR NR 
Campieri, 199768 Budesonide + 
Placebo, 58 
Route: Oral + 
Oral 
Dose: 9 mg 
every day + NA 
every 24 hours 
Male, %: 36.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 8.3 
Min: 0 
Max: 30 
 
Age at 
enrollment 
Mean: 36 
Min: 17 
Max: 71 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 277 
Min: 121 
Max: 476 
Corticosteroids: 
100 
NR NR 
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Escher, 2004190 Budesonide, 22 
Dose: 9 mg 
every day 
Male, %: 31.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.6 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 59.1 
Ileo-colonic: 31.8 
Colonic: 9.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 239 
 
PCDAI 
Mean: 39 
NR NR NR 
Escher, 2004190 Prednisolone, 26 
Dose: 1 mg/kg 
every day 
Male, %: 69.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.8 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 26.9 
Ileo-colonic: 65.4 
Colonic: 3.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 268 
 
PCDAI 
Mean: 45 
NR NR NR 
Goldstein, 
1967142 
Corticosteroid, 
430 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Goldstein, 
1967142 
Never user 
corticosteroids/A
CTH, 124 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Hutfless, 2007151 
 
 
Corticosteroid, 
2168 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Immunomodulat
or, 443 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Never user 
immunomodulat
or, 2798 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
Never user 5-
aminosalicylic 
acid, 675 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
5-ASA, 2566 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Hutfless, 2007151 
 
Never user 
corticosteroid, 
1073 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Issenman, 
1993196 
Discontinued 
corticosteroids, 8 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD, %: 212.5 
Age at diagnosis 
Mean: 13.2 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.2 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Issenman, 
1993196 
Prednisone, 9 
Route: Oral 
Dose: 2 mg/kg 
every day 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 14.5 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.5 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 64.1 
Corticosteroids: 
100 
5ASA NR 
Levine, 2002198 Budesonide, 62 
Dose: 9 mg 
every day 
Male, %: 59.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.1 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 25.8 
NR immunosuppress
ives: 29 
NR 
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Levine, 2002198 Prednisone, 58 
Dose: 40 mg 
every day 
Male, %: 60.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.7 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 29.6 
NR immunosuppress
ives: 20.6 
NR 
Levine, 2003191 Prednisone + 
Mesalamine, 14 
Dose: 40 mg 
every day + 3-4 
g every day 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.15 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 28.9 
NR NR NR 
Levine, 2003191 Budesonide + 
Mesalamine, 19 
Dose: 3 mg 
every 8 hours + 
3-4 g every day 
Male, %: 68.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 29.3 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
azathioprine/6-
MP, 5768 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
 
Never user 
immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 15087 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 77 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Thiopurine, 837 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Mesalamine 
(NR), 7233 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
 
Corticosteroid, 
4064 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
corticosteroid, 
11000 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
mesalamine 
(NR), 7931 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
Infliximab, 3179 
Route: IV 
Male, %: 40.5 
 
Race, % 
W: 88.8 
H: 1.2 
B: 7.2 
A: 0.5 
Other: 0.7 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.7 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 50.1 
Mod-sev 
disease: 30.8 
Severe disease: 
2.5 
 
Location, % 
Ileal: 25.1 
Ileo-colonic: 43.2 
Colonic: 28.2 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Prednisone: 27.4 
 
Immunomodulat
or: 49.4 
 
narcotic 
analgesic: 9.8 
NR NR 
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Lichtenstein, 
2006131 
 
 
No reported 
prednisone 
usage, 2396 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
Prednisone, 
3894 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
 
No 
immunomodulat
ors, 2526 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lichtenstein, 
2006131 
 
Immunomodulat
or, 3764 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lichtenstein, 
2006131 
 
Never user 
infliximab, 3111 
Route: IV 
Male, %: 40.8 
 
Race, % 
W: 89.3 
H: 1.4 
B: 6.2 
A: 0.3 
Other: 0.6 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10.9 
 
Age at 
enrollment NR 
Severity, % 
Mild-mod 
disease: 47.9 
Mod-sev 
disease: 10.3 
Severe disease: 
0.6 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 35.4 
Colonic: 28 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulat
ors: 32.2 
 
Prednisone: 16.1 
 
Narcotic 
analgesics: 5.4 
NR NR 
Malchow, 198464 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
Malchow, 198464 
 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
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study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 198464 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
Malchow, 198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
 
NR 
Malchow, 198464 
 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
 
 
NR 
Malchow, 198464 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR sulfasalazine: 88 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3 
 
 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 198464 
 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
 
 
NR 
Malchow, 198464 
 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 
113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
Mantzaris, 
2003113 
Budesonide, 29 
Route: Unknown 
Dose: 6 mg 
every day 
Male, %: 44.8 
 
Race NR 
 
Smoking, % 
Smoker, 86 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment 
Mean: 34.1 
Min: 20 
Max: 62 
Severity NR 
 
Location, % 
Ileal: 52 
Ileo-colonic: 38 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 139 
 
IBDQ 
Mean: 188 
Corticosteroids: 
100 
Thiopurines: 41 NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Mantzaris, 
2003113 
Mesalamine 
(Salofalk), 28 
Route: Unknown 
Dose: 1 g every 
8 hours 
Male, %: 42.9 
 
Race NR 
 
Smoking, % 
Smoker, 82 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.2 
 
Age at 
enrollment 
Mean: 31.8 
Min: 19 
Max: 65 
Severity NR 
 
Location, % 
Ileal: 54 
Ileo-colonic: 28 
Colonic: 18 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 138 
 
IBDQ 
Mean: 186 
Corticosteroids: 
100 
Thiopurines: 43 NR 
Saha, 1998197 Prednisone Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Saha, 1998197 Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Schoon, 2005185 Budesonide, 137 
Route: Oral 
Dose: 9 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Vitamin D: 12 
 
Calcium: 46 
NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Schoon, 2005185 Prednisolone, 
134 
Route: Oral 
Dose: 40 mg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Vitamin D: 15 
 
Calcium: 51 
NR NR 
Siffledeen, 
2007127 
Never user 
corticosteroids 
during year 
before DXA 
scan, 107 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Siffledeen, 
2007127 
Corticosteroid, 
109 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Singleton, 
197975 
 
Placebo + 
Prednisone, 46 
Route: Unknown 
+ Oral 
Dose: NA + 
every day 
Male, %: 46 
 
Race, % 
W: 89 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.9 
Severity NR 
 
Location, % 
Ileo-colonic: 55 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 236.3 
NR 5ASA: 54 
 
Corticosteroids: 
52 
NR 
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Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Singleton, 
197975 
 
 
Sulfasalazine + 
Prednisone, 43 
Route: Oral + 
Unknown 
Dose: 1g per 
15kg body 
weight to 5g max 
every day + 
every day 
Male, %: 47 
 
Race, % 
W: 86 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30 
Severity NR 
 
Location, % 
Ileo-colonic: 56 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 239 
NR 5ASA: 51 
 
Corticosteroids: 
47 
NR 
Summers, 
197956 
 
 
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kgs 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
D-341 
 
Evidence Table 13. Population characteristics of randomized controlled trials and observational studies reporting on the safety of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease (KQ3) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg. every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
Summers, 
197956 
 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
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Disease 
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index 
Medications 
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Medications 
taken BEFORE 
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Medications 
taken FOR 
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Summers, 
197956 
 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
Summers, 
197956 
 
Prednisone, 61 
Route: Oral 
Dose: 1-4 mg/kg 
every 24 hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
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taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Thayu, 2010199 Methotrexate Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 2010199 Corticosteroid Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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taken BEFORE 
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Medications 
taken FOR 
INDUCTION, % 
Tremaine, 
200265 
Placebo, 41 
Route: Oral 
Dose: NA every 
day 
Male, %: 43.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Median: 8.2 
 
Age at 
enrollment 
Mean: 37 
Median: 36 
Severity, % 
Mild-mod 
disease: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 271 
Median: 253 
Min: 197 
Max: 425 
NR NR NR 
Tremaine, 
200265 
Budesonide, 80 
Route: Oral 
Dose: 9 mg 
every day 
Male, %: 23.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 11.9 
Median: 9.2 
 
Age at 
enrollment 
Mean: 41 
Median: 36 
Severity, % 
Mild-mod 
disease: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 280 
Median: 268 
Min: 199 
Max: 484 
NR NR NR 
Tremaine, 
200265 
Budesonide, 79 
Route: Oral 
Dose: 4.5 mg 
every 12 hours 
Male, %: 44.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 10 
Median: 7.1 
 
Age at 
enrollment 
Mean: 39 
Median: 38 
Severity, % 
Mild-mod 
disease: 100 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 279 
Median: 270 
Min: 166 
Max: 437 
NR NR NR 
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Medications 
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Studies evaluating 5-aminosalicylate acids 
Bernstein, 
2011235 
University of 
Manitoba 
5-ASA, 5787 
Route: Oral 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Bernstein, 
2011235 
University of 
Manitoba 
Never user ASA, 
2957 Route: 
Unknown Dose: 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Never user 
corticosteroid, 
1073 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Immunomodulat
or, 443 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Hutfless, 2007151 
 
Never user 
immunomodulat
or, 2798 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
Never user 5-
aminosalicylate 
acid, 675 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
5-ASA, 2566 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Hutfless, 2007151 
 
 
Corticosteroid, 
2168 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
Never user 
mesalamine 
(NR), 7931 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
 
Never user 
corticosteroid, 
11000 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Thiopurine, 837 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
azathioprine/6-
MP, 5768 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Never user 
immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 15087 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lewis, 2001136 
 
Immunosuppres
ants (defined as 
either 
methotrexate, 
cyclosporine, 
tacrolimus or 
mycophenolate 
mofetil), 77 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Mesalamine 
(NR), 7233 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lewis, 2001136 
 
 
Corticosteroid, 
4064 
Route: Unknown 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Malchow, 198464 
 
 
Sulfasalazine + 
Prednisolone, 74 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 41.9 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 32.4 
Ileo-colonic: 46 
Colonic: 21.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 148.2 
NR Sulfasalazine: 
83.8 
 
Prednisolone: 
59.5 
 
Azathioprine: 6.8 
 
: 59.5 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 198464 
 
(6)-
Methylprednisolo
ne, 75 
Route: Unknown 
Dose: 48 mg 
every 24 hours 
Male, %: 50.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 32.5 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 159.9 
NR Sulfasalazine: 
81.3 
 
Prednisolone: 
55.4 
 
Azathioprine: 4 
 
: 55.4 
NR 
Malchow, 198464 
 
Sulfasalazine, 75 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 48 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 31.2 
Severity NR 
 
Location, % 
Ileal: 32 
Ileo-colonic: 48 
Colonic: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 165.2 
NR sulfasalazine: 88 
 
Prednisolone: 
54.7 
 
Azathioprine: 5.3 
 
: 54.7 
NR 
Malchow, 198464 
 
Sulfasalazine, 42 
Route: Oral 
Dose: 3 g every 
24 hours 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 33.1 
Severity NR 
 
Location, % 
Ileal: 62.4 
Ileo-colonic: 
113.3 
Colonic: 62.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 181.9 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Malchow, 198464 
 
Placebo, 68 
Route: Oral 
Dose: NA 
Male, %: 44.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 29.1 
Severity NR 
 
Location, % 
Ileal: 33.8 
Ileo-colonic: 45.6 
Colonic: 20.6 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 161.4 
NR sulfasalazine: 
92.6 
 
Prednisolone: 
47.8 
 
Azathioprine: 4.4 
 
: 47.8 
NR 
Malchow, 198464 
 
Placebo, 42 
Route: Oral 
Dose: NA 
Male, %: 35.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.1 
Severity NR 
 
Location, % 
Ileal: 23.8 
Ileo-colonic: 52.4 
Colonic: 23.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 178.2 
NR NR NR 
Malchow, 198464 
 
Sulfasalazine + 
Prednisolone, 38 
Route: Oral + 
Unknown 
Dose: 3 g every 
24 hours + 48 
mg every 24 
hours 
Male, %: 42.1 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30.2 
Severity NR 
 
Location, % 
Ileal: 23.7 
Ileo-colonic: 52.6 
Colonic: 23.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 185.3 
NR NR NR 
Malchow, 198464 
 
(6)-
Methylprednisolo
ne, 38 
Route: IV 
Dose: 48 mg 
every 24 hours 
Male, %: 47.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 26.1 
Severity NR 
 
Location, % 
Ileal: 31.6 
Ileo-colonic: 57.9 
Colonic: 10.5 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 147.4 
NR NR NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Sulfasalazine, 74 
Route: Oral 
Dose: 1g/15kgs 
every 24 hours 
Male, %: 65.7 
 
Race, % 
W: 93.2 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.42 
 
Age at 
enrollment 
Mean: 29.6 
Severity NR 
 
Location, % 
Ileal: 23 
Ileo-colonic: 66.2 
Colonic: 10.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 256.2 
NR Corticosteroids: 
38.4 
 
sulfasalazine: 
51.1 
NR 
Summers, 
197956 
 
 
Placebo, 77 
Route: Oral 
Dose: NA 
Male, %: 45.5 
 
Race, % 
W: 93.5 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.97 
 
Age at 
enrollment 
Mean: 33.7 
Severity NR 
 
Location, % 
Ileal: 32.5 
Ileo-colonic: 55.8 
Colonic: 11.7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 241.9 
NR Corticosteroids: 
37.7 
 
sulfasalazine: 
35.1 
NR 
Summers, 
197956 
 
Prednisone, 85 
Route: Oral 
Dose: If 
CDAI<150 then 
dose of 
prednisone is 
1/4mg/kg, if 
CDAI = 150-300 
then prednisone 
was dosed at 
1/2mg/kg, if 
CDAI >300 then 
prednisone is 
3/4mg/kg. every 
24 hours 
Male, %: 52.9 
 
Race, % 
W: 92.9 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.48 
 
Age at 
enrollment 
Mean: 31.8 
Severity NR 
 
Location, % 
Ileal: 30.6 
Ileo-colonic: 60 
Colonic: 9.4 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 243.4 
NR Corticosteroids: 
24.7 
 
Sulfasalazine: 
30.6 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Azathioprine, 59 
Route: Oral 
Dose: 2.5 mg/kg 
every 24 hours 
Male, %: 52.5 
 
Race, % 
W: 89.8 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.25 
 
Age at 
enrollment 
Mean: 29.8 
Severity NR 
 
Location, % 
Ileal: 40.7 
Ileo-colonic: 44.1 
Colonic: 15.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 240.7 
NR Corticosteroids: 
37.3 
 
Sulfasalazine: 
30.5 
NR 
Summers, 
197956 
 
Azathioprine, 54 
Route: Oral 
Dose: 1 mg/kg 
every 24 hours 
Male, %: 57.4 
 
Race, % 
W: 94.4 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.99 
 
Age at 
enrollment 
Mean: 31 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 37 
Ileo-colonic: 56 
Colonic: 7 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 85.9 
NR NR Corticosteroids: 
31.5 
Summers, 
197956 
 
 
Placebo, 101 
Route: Oral 
Dose: NA 
Male, %: 53.5 
 
Race, % 
W: 94.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 2.84 
 
Age at 
enrollment 
Mean: 31.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 43 
Ileo-colonic: 48 
Colonic: 9 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 83.5 
NR NR Corticosteroids: 
31.7 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Summers, 
197956 
 
 
Sulfasalazine, 58 
Route: Oral 
Dose: 1/2 g/ 15 
kg every 24 
hours 
Male, %: 53.4 
 
Race, % 
W: 98.3 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.11 
 
Age at 
enrollment 
Mean: 32.2 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 50 
Ileo-colonic: 40 
Colonic: 10 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 89.4 
NR NR Corticosteroids: 
32.8 
Summers, 
197956 
 
Prednisone, 61 
Route: Oral 
Dose: 1-4 mg/kg 
every 24 hours 
Male, %: 50.8 
 
Race, % 
W: 95.1 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.37 
 
Age at 
enrollment 
Mean: 32.6 
Severity, % 
Remission: 100 
 
Location, % 
Ileal: 46 
Ileo-colonic: 43 
Colonic: 11 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 94.8 
NR NR Corticosteroids: 
34.4 
Abbreviations: 5-ASA = 5-aminosalicylic acid; 6-MP = 6-mercaptopurine; A = Asian; B = African American; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; 
CRP = C-reactive protein; H = Hispanic; IBDQ = Inflammatory Bowel Disease Questionnaire; IV = intravenous; kg = kilogram; Max. = maximum; mg = milligram; Min. = 
minimum; NR = not reported; SC = subcutaneous; W = White 
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Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Infusion and injection-
site rx (any adverse 
event that occurred 
during or within 1 hour 
after infusion) @ 54 wks 
NR 
No 
No 
Incidence  
27 / 163 (17%) 
Incidence  
9 / 161 (6%) P: 0.002 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Mortality (NR) @ 54 
wks 
NR 
No 
Yes 
Incidence  
0 / 163 (0%) 
Incidence  
1 / 161 (1%) 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Other cancers (colon 
cancer) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 163 (0%) 
Incidence  
2 / 161 (1%) 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Other infections 
(serious and non-
serious) @ 54 wks 
NR 
No 
No 
Incidence  
75 / 163 (46%) 
Incidence  
73 / 161 (45%) P: 0.91 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Serious infections 
(sepsis) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 163 (0%) 
Incidence  
1 / 161 (1%) 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Serious infections (NR) 
@ 54 wks 
NR 
No 
No 
Incidence  
8 / 163 (5%) 
Incidence  
9 / 161 (6%) P: 0.81 
Colombel, 
201045 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
TB (NR) @ 54 wks NR 
No 
No 
Incidence  
0 / 163 (0%) 
Incidence  
0 / 161 (0%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Infusion and injection-
site rx (any adverse 
event that occurred 
during or within 1 hour 
after infusion) @ 54 wks 
NR 
No 
No 
Incidence  
9 / 179 (5%) 
Incidence  
9 / 161 (6%) P: 1 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Mortality (NR) @ 54 
wks 
NR 
No 
Yes 
Incidence  
0 / 179 (0%) 
Incidence  
1 / 161 (1%) 
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Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Other cancers (colon 
cancer) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 179 (0%) 
Incidence  
2 / 161 (1%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Other infections 
(serious and non-
serious) @ 54 wks 
NR 
No 
No 
Incidence  
75 / 179 (42%) 
Incidence  
73 / 161 (45%) P: 0.58 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Serious infections 
(sepsis) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 179 (0%) 
Incidence  
1 / 161 (1%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
Serious infections (NR) 
@ 54 wks 
NR 
No 
No 
Incidence  
7 / 179 (4%) 
Incidence  
9 / 161 (6%) P: 0.61 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Azathioprine + Placebo 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ NA every 8 wks 
TB (NR) @ 54 wks NR 
No 
No 
Incidence  
1 / 179 (1%) 
Incidence  
0 / 161 (0%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Infusion and injection-
site rx (any adverse 
event that occurred 
during or within 1 hour 
after infusion) @ 54 wks 
NR 
No 
No 
Incidence  
9 / 179 (5%) 
Incidence  
27 / 163 (17%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Mortality (NR) @ 54 
wks 
NR 
No 
Yes 
Incidence  
0 / 179 (0%) 
Incidence  
0 / 163 (0%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Other cancers (colon 
cancer) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 179 (0%) 
Incidence  
0 / 163 (0%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Other infections 
(serious and non-
serious) @ 54 wks 
NR 
No 
No 
Incidence  
75 / 179 (42%) 
Incidence  
75 / 163 (46%) P: 0.45 
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Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Serious infections (NR) 
@ 54 wks 
NR 
No 
No 
Incidence  
7 / 179 (4%) 
Incidence  
8 / 163 (5%) P: 0.79 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
Serious infections 
(sepsis) @ 54 wks 
NR 
No 
No 
Incidence  
0 / 179 (0%) 
Incidence  
0 / 163 (0%) 
Colombel, 
201045 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.5 mg/kg every 1 d 
+ 5 mg/kg every 8 wks 
Infliximab + Placebo 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks 
+ NA every 1 d 
TB (NR) @ 54 wks NR 
No 
No 
Incidence  
1 / 179 (1%) 
Incidence  
0 / 163 (0%) 
Mantzaris, 
200988 
Hydrocortisone + Infliximab 
Route: IV 
Dose: 250 mg every 8 wks 
+ 5 mg/kg every 8 wks 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.0-2.5 mg/kg every 
1 d + 5 mg/kg every 8 wks 
Infusion and injection-
site rx (NR) 
NR 
No  
NA 
Incidence  
1 / 23 (4%) 
Incidence  
0 / 23 (0%) 
Mantzaris, 
200988 
Hydrocortisone + Infliximab 
Route: IV 
Dose: 250 mg every 8 wks 
+ 5 mg/kg every 8 wks 
Azathioprine + Infliximab 
Route: Oral + IV 
Dose: 2.0-2.5 mg/kg every 
1 d + 5 mg/kg every 8 wks 
Mortality (NR) NR 
No  
NA 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 23 (0%) 
Beaugerie, 
2009130 
Thiopurine 
Dose: NR 
Never user thiopurine 
Dose: NA 
Lymphoma 
(lymphoproliferative 
disorder, including 
lymphoma) @ 156 wks 
Passive 
No  
NA 
Incidence  
17 / 8676 (0%) 
RH: 5.26 (2.2 to 12.6) 
P: 0.0002 vs. main 
Incidence  
6 / 10810 (0%) 
Beaugerie, 
2009130 
Thiopurine 
Dose: NR 
Never user thiopurine 
Dose: NA 
Mortality (NR) @ 156 
wks 
Passive 
No  
NA 
Incidence  
91 / 8676 (1%) 
Incidence  
95 / 10810 (1%) 
Beaugerie, 
2009130 
Thiopurine 
Dose: NR 
Never user thiopurine 
Dose: NA 
Other cancers (NR) @ 
156 wks 
Passive 
No  
NA 
Incidence  
155 / 8676 (2%) 
Incidence  
134 / 10810 (1%) 
Lees, 2009144 Immunomodulator 
Route: Unknown 
Dose: NR 
Never user 
immunomodulator 
Cervical cancer 
(cervical 
adenocarcinoma) 
Passive 
No  
NA 
Incidence  
0 / 105 (0%) 
Incidence  
1 / 234 (0%) 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
OR: 0.3 (0.1 to 0.8) 
P: 0.02 vs. main 
 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
OR: 0.3 (0.1 to 0.8) 
P: 0.02 vs. main 
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Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Other cancers (NR) Passive 
No  
NA 
Incidence  
1 / 62 (2%) 
Incidence  
0 / 61 (0%) 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Other cancers (NR) Passive 
No  
NA 
Incidence  
1 / 62 (2%) 
Incidence  
0 / 61 (0%) 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Other infections (NR) @ 
8 wks 
Passive 
No 
No 
Incidence  
0 / 62 (0%) 
Incidence  
2 / 61 (3%) 
Moss, 2010147 Infliximab + 6-MP 
Route: IV 
Infliximab 
Route: IV 
Other infections (NR) @ 
8 wks 
Passive 
No 
No 
Incidence  
0 / 62 (0%) 
Incidence  
2 / 61 (3%) 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
0 events / 379 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
0 events / 379 pys 
RH: 1.07 (0.87 to 1.31) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
72 events / 379 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
25 events / 379 pys 
RH: 3.2 (2.12 to 4.84) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
9 events / 379 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
3 events / 379 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
3 events / 911 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
3 events / 911 pys 
RH: 1.17 (0.99 to 1.38) 
vs. main 
Event rate  
2115 events / 15673 
pys 
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Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
5 events / 911 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
17 events / 911 pys 
RH: 1.06 (0.64 to 1.77) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
95 events / 911 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
Thiopurine 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
6 events / 911 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
2 events / 292 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
2 events / 292 pys 
RH: 0.95 (0.7 to 1.29) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
3 events / 292 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
4 events / 292 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
48 events / 292 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
TNF-alpha 
Route: Unknown 
Dose: NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
11 events / 292 pys 
RH: 2.03 (1.1 to 3.77) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
0 events / 19 pys 
Event rate  
64 events / 15673 pys 
D-359 
 
 
Evidence Table 14. Safety of pharmacologic therapies for the management of Crohn’s disease (KQ3) 
 
Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
0 events / 19 pys 
RH: 0.97 (0.66 to 1.43) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
6 events / 19 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
0 events / 19 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
2 events / 19 pys 
RH: 4.75 (2.73 to 8.27) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
TNF-alpha + Corticosteroid Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
0 events / 19 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
0 events / 142 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
11 events / 142 pys 
RH: 0.32 (0.04 to 2.28) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
2 events / 142 pys 
RH: 5.62 (1.38 to 22.9) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
27 events / 142 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
1 events / 142 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
Corticosteroid + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
3 events / 142 pys 
Event rate  
123 events / 15673 pys 
D-360 
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Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
1 events / 162 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
20 events / 162 pys 
RH: 1.13 (0.72 to 1.78) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
23 events / 162 pys 
Event rate  
1833 events / 15673 
pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
3 events / 162 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
15 events / 162 pys 
RH: 0.71 (0.17 to 2.87) 
vs. main 
Event rate  
305 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
4 events / 162 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Lymphoma (ICD9 code 
available on request) 
Passive 
No  
NA 
Event rate  
0 events / 31 pys 
Event rate  
64 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other cancers (solid 
tumors) 
Passive 
No 
NR 
Event rate  
3 events / 31 pys 
RH: 0.89 (0.33 to 2.38) 
vs. main 
Event rate  
2115 events / 15673 
pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(Herpes zoster) 
Passive 
No  
NA 
Event rate  
1 events / 31 pys 
Event rate  
123 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections (herpes 
simplex) 
Passive 
No  
NA 
Event rate  
0 events / 31 pys 
Event rate  
134 events / 15673 pys 
Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(opportunistic infection 
or candidiasis or TB) 
Passive 
No  
NA 
Event rate  
2 events / 31 pys 
RH: 3.61 (0.9 to 14.56) 
vs. main 
Event rate  
305 events / 15673 pys 
D-361 
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Marehbian, 
2009168 
Thiopurine + TNF-alpha 
Dose: NR + NR 
Never user of steroids, 
IMM, TNF, or combination 
of these drugs 
Other infections 
(sepsis) 
Passive 
No  
NA 
Event rate  
9 events / 31 pys 
Event rate  
1833 events / 15673 
pys 
Schneeweiss, 
2009230 
Infliximab 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Other infections 
(C.difficile) 
Passive 
No  
NA 
Event rate  
0 events / 682.1 pys 
Event rate  
14 events / 3971.9 pys 
Schneeweiss, 
2009230 
Infliximab 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Other infections 
(bacteriaemia) 
Passive 
No  
NA 
Event rate  
5 events / 678.1 pys 
RH: 1.41 (0.47 to 4.24) 
vs. main 
Event rate  
15 events / 3973.4 pys 
Schneeweiss, 
2009230 
Infliximab 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Serious infections 
(bacteriaemia/ 
septicaemia, 
pneumonia, 
osteomyelitis, 
pyelonephritis, 
meningitis, encephalitis 
or endocarditis) 
Passive 
No  
NA 
Event rate  
6 events / pys 
Event rate  
27 events / 3963.8 pys 
Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Other infections 
(bacteriaemia) 
Passive 
No  
NA 
Event rate  
17 events / 4077.3 pys 
RH: 1.12 (0.52 to 2.41) 
vs. main 
Event rate  
15 events / 3973.4 pys 
Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Other infections 
(C.difficile) 
Passive 
No  
NA 
Event rate  
57 events / 4063.4 pys 
Event rate  
14 events / 3971.9 pys 
Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Serious infections 
(bacteriaemia/ 
septicaemia, 
pneumonia, 
osteomyelitis, 
pyelonephritis, 
meningitis, encephalitis 
or endocarditis) 
Passive 
No  
NA 
Event rate  
32 events / 4065.8 pys 
Event rate  
27 events / 3963.8 pys 
Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Infliximab 
Route: Unknown 
Dose: NR 
Other infections 
(bacteriaemia) 
Passive 
No  
NA 
Event rate  
17 events / 4077.3 pys 
Event rate  
5 events / 678.1 pys 
Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Infliximab 
Route: Unknown 
Dose: NR 
Other infections 
(C.difficile) 
Passive 
No  
NA 
Event rate  
57 events / 4063.4 pys 
Event rate  
0 events / 682.1 pys 
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Schneeweiss, 
2009230 
Corticosteroid 
Route: Unknown 
Dose: NR 
Infliximab 
Route: Unknown 
Dose: NR 
Serious infections 
(bacteriaemia/ 
septicaemia, 
pneumonia, 
osteomyelitis, 
pyelonephritis, 
meningitis, encephalitis 
or endocarditis) 
Passive 
No  
NA 
Event rate  
32 events / 4065.8 pys 
Event rate  
6 events / pys 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
NA 
Yes 
Incidence  
67 / 260 (25.8%) 
Incidence  
36 / 261 (13.8%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Mortality (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 260 (0%) 
Incidence  
0 / 261 (0%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other cancers 
(malignant neoplasm) 
@ 52 wks 
Active 
Yes 
Incidence  
0 / 260 (0%) 
Incidence  
1 / 261 (0.4%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(opportunistic infection) 
@ 52 wks 
NA 
Yes 
Incidence  
1 / 260 (0.4%) 
Incidence  
5 / 261 (2%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(infectious adverse 
event) @ 52 wks 
NA 
Yes 
Incidence  
153 / 260 (58.9%) 
Incidence  
148 / 261 (56.7%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections (NR) 
@ 52 wks 
NA 
Yes 
Incidence  
10 / 260 (3.9%) 
Incidence  
13 / 261 (5%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
TB (NR) @ 52 wks NA 
Yes 
Incidence  
1 / 260 (0%) 
Incidence  
0 / 261 (0%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
NA 
Yes 
Incidence  
66 / 257 (25.7%) 
Incidence  
36 / 261 (13.8%) P: 
<0.001 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Mortality (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 257 (0%) 
Incidence  
0 / 261 (0%) 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other cancers 
(malignant neoplasm) 
@ 52 wks 
Active 
Yes 
Incidence  
0 / 257 (0%) 
Incidence  
1 / 261 (0.4%) P: NS 
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Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(infectious adverse 
event) @ 52 wks 
NA 
Yes 
Incidence  
161 / 257 (62.7%) 
Incidence  
148 / 261 (56.7%) P: 
NS 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(opportunistic infection) 
@ 52 wks 
NA 
Yes 
Incidence  
5 / 257 (2%) 
Incidence  
5 / 261 (2%) P: NS 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections (NR) 
@ 52 wks 
NA 
Yes 
Incidence  
12 / 257 (4.7%) 
Incidence  
13 / 261 (5%) P: NS 
Colombel, 
200995 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
TB (NR) @ 52 wks NA 
Yes 
Incidence  
1 / 257 (0%) 
Incidence  
0 / 261 (0%) 
Seksik, 
2009155 
Azathioprine 
Route: Unknown 
Dose: NR 
Never user azathioprine 
Route: Unknown 
Dose: NR 
Other infections (upper 
respiratory tract 
infections) 
Active 
Yes  
NA 
Event rate  
2.2 events / 1 pys 
Event rate  
2.1 events / 1 pys P: 
0.77 
Seksik, 
2009155 
Azathioprine 
Route: Unknown 
Dose: NR 
Never user azathioprine 
Route: Unknown 
Dose: NR 
Other infections 
(herpes-virus skin and 
genital lesions) 
Active 
Yes  
NA 
Incidence  
29 / 169 (17.2%) 
Event rate  
1 events / 1 pys 
Incidence  
2 / 61 (3.3%) 
Event rate  
0.2 events / 1 pys P: 
0.04 
Maher, 2009176 Azathioprine Never user Other infections (CMV) Active 
No  
NA 
Event rate  
2 events / 12 persons 
Event rate  
7 events / 60 persons 
Clare, 2009181 Infliximab + Azathioprine 
Route: IV 
Dose: NR 
Infliximab 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (rash, 
breathlessness, 
wheeze, headache, 
dizziness, nausea, 
nonspecific symptoms 
of feeling unwell, drop 
in systolic, 
bronchospasm) 
Active 
Yes  
NA 
 OR: 0.89 (0.27 to 2.97) 
P: 0.85 vs. comp 
D-364 
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Clare, 2009181 Infliximab + 
Immunomodulator 
Infliximab 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (rash, 
breathlessness, 
wheeze, headache, 
dizziness, nausea, 
nonspecific symptoms 
of feeling unwell, drop 
in systolic, 
bronchospasm) 
Active 
Yes  
NA 
OR: 1.41 (0.26 to 7.69) 
P: 0.69 vs. main 
 
Clare, 2009181 Infliximab + Methotrexate 
Route: IV 
Dose: NR 
Infliximab + Azathioprine 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (rash, 
breathlessness, 
wheeze, headache, 
dizziness, nausea, 
nonspecific symptoms 
of feeling unwell, drop 
in systolic, 
bronchospasm) 
Active 
Yes  
NA 
OR: 1.21 (0.49 to 3.03) 
P: 0.68 vs. main 
 
de Vries, 
2008227 
Infliximab + Corticosteroid Infliximab + No 
corticosteroids 
Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
4 / 102 (4%) 
Incidence  
5 / 45 (11%) 
de Vries, 
2008227 
Infliximab + Corticosteroid Infliximab + No 
corticosteroids 
Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 102 (18%) 
Incidence  
18 / 45 (40%) 
D-365 
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de Vries, 
2008227 
Infliximab + No 
immunomodulator 
Infliximab + No 
corticosteroids 
Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
2 / 54 (4%) 
Incidence  
5 / 45 (11%) 
de Vries, 
2008227 
Infliximab + No 
immunomodulator 
Infliximab + No 
corticosteroids 
Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 54 (33%) 
Incidence  
18 / 45 (40%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + No 
corticosteroids 
Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
7 / 93 (8%) 
Incidence  
5 / 45 (11%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + No 
corticosteroids 
Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 93 (19%) 
Incidence  
18 / 45 (40%) 
de Vries, 
2008227 
Infliximab + No 
immunomodulator 
Infliximab + Corticosteroid Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
2 / 54 (4%) 
Incidence  
4 / 102 (4%) 
D-366 
 
 
Evidence Table 14. Safety of pharmacologic therapies for the management of Crohn’s disease (KQ3) 
 
Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
de Vries, 
2008227 
Infliximab + No 
immunomodulator 
Infliximab + Corticosteroid Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 54 (33%) 
Incidence  
18 / 102 (18%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + Corticosteroid Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
7 / 93 (8%) 
Incidence  
4 / 102 (4%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + Corticosteroid Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 93 (19%) 
Incidence  
18 / 102 (18%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + No 
immunomodulator 
Other cancers (paper or 
electronic chart review: 
CRC basal cell 
carcinoma, melanoma, 
breast cancer, 
squamous cell 
carcinoma, carcinoid 
tumor and lymphangitis 
carcinomatosa) 
Passive 
No  
NA 
Incidence  
7 / 93 (8%) 
Incidence  
2 / 54 (4%) 
de Vries, 
2008227 
Infliximab + 
Immunomodulator 
Infliximab + No 
immunomodulator 
Serious infections 
(hospitalization for 
infection from paper 
and electronic medical 
records) 
Passive 
No  
NA 
Incidence  
18 / 93 (19%) 
Incidence  
18 / 54 (33%) 
Mantzaris, 
2009102 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 d 
Budesonide 
Route: Oral 
Dose: 09-Jun mg every 1 d 
Other infections (NR) NR 
No  
NA 
Incidence  
25 / 38 (66%) 
Incidence  
14 / 39 (36%) 
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Caspersen, 
2008225 
Infliximab + Azathioprine 
Route: IV 
Dose: NR 
Infliximab 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Event rate  
63 events / 2079 other 
denominator 
Event rate  
83 events / 1272 other 
denominator 
Caspersen, 
2008225 
Infliximab + Corticosteroid Infliximab 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Event rate  
33 events / 611 other 
denominator 
Event rate  
83 events / 1272 other 
denominator 
Caspersen, 
2008225 
Infliximab + Corticosteroid Infliximab + Azathioprine 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Event rate  
33 events / 611 other 
denominator 
Event rate  
63 events / 2079 other 
denominator 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Infusion and injection-
site rx (acute infusion 
reaction) 
Passive 
No  
NA 
Incidence  
115 / 682 (17%) 
 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Infusion and injection-
site rx (delayed-type 
hypersensitivity 
reaction) 
Passive 
No  
NA 
Incidence  
50 / 682 (7%) 
 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Lymphoma (chart 
review) 
Passive 
No  
NA 
Incidence  
3 / 743 (0%) 
Incidence  
5 / 666 (1%) 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Mortality (chart review) Passive 
No  
NA 
Incidence  
12 / 743 (2%) 
Event rate  
12 events / 743 persons 
Incidence  
16 / 666 (2%) 
Event rate  
16 events / 666 persons 
OR: 1.33 (0.56 to 3) 
P: 0.45 vs. comp 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Other cancers 
(malignancies, non-
melanoma skin 
cancers) 
Passive 
No  
NA 
Incidence  
21 / 734 (3%) 
Event rate  
23 events / 3775 pys 
OR: 0.97 (0.56 to 1.65) 
P: 0.91 vs. main 
Incidence  
30 / 666 (5%) 
Event rate  
42 events / 6704 pys 
Fidder, 2009153 Infliximab 
Route: IV 
Dose: NR 
Never user infliximab Serious infections (chart 
review -- requiring 
hospitalization, 
prolonged 
hospitalization, fatal, 
life-threatening or led to 
significant disability) 
Passive 
No  
NA 
Incidence  
48 / 743 (6%) 
Event rate  
59 events / 743 persons 
Incidence  
62 / 666 (9%) 
Event rate  
77 events / 666 persons 
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Reinisch, 
200851 
Azathioprine + Prednisone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg or ≥40 mg every 
1 d 
Placebo + Prednisone 
Route: Oral + Oral 
Dose: NA every 1 d + 
1mg/kg or ≥ 40mg every 1 
d 
Mortality (NR) @ 28 
wks 
NR 
No 
No 
Incidence  
0 / 52 (0%) 
Incidence  
0 / 28 (0%) 
Reinisch, 
200851 
Azathioprine + Prednisone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg or ≥ 40 mg every 
1 d 
Placebo + Prednisone 
Route: Oral + Oral 
Dose: NA every 1 d + 
1mg/kg or ≥ 40mg every 1 
d 
Other infections 
(perianal abscess) @ 
28 wks 
NR 
No  
NA 
Incidence  
0 / 52 (0%) 
Incidence  
3 / 28 (11%) 
Reinisch, 
200851 
Azathioprine + Prednisone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg or ≥ 40 mg every 
1 d 
Placebo + Prednisone 
Route: Oral + Oral 
Dose: NA every 1 d + 
1mg/kg or ≥ 40mg every 1 
d 
Other infections 
(perianal abscess) @ 
28 wks 
NR 
No 
No 
Incidence  
0 / 52 (0%) 
Incidence  
3 / 28 (11%) 
Reinisch, 
200851 
Azathioprine + Prednisone 
Route: Oral + Oral 
Dose: 2.5 mg/kg every 1 d 
+ 1 mg/kg or ≥ 40 mg every 
1 d 
Placebo + Prednisone 
Route: Oral + Oral 
Dose: NA every 1 d + 
1mg/kg or ≥ 40mg every 1 
d 
Other infections 
(Nasopharyngitis) @ 28 
wks 
NR 
No 
No 
Incidence  
7 / 52 (13%) 
Incidence  
3 / 28 (11%) 
Moss, 2008148 Infliximab + Corticosteroid 
Dose: NR + NR 
Infliximab + No 
immunomodulator at 
initiation 
Route: Unknown 
Dose: NR 
Infusion and injection-
site rx (Development of 
new symptoms within 1-
2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
18 / 86 (21%) 
Incidence  
38 / 172 (22%) 
Moss, 2008148 Infliximab + Thiopurine 
Dose: NR + NR 
Infliximab + No 
immunomodulator at 
initiation 
Route: Unknown 
Dose: NR 
Infusion and injection-
site rx (Development of 
new symptoms within 1-
2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
13 / 115 (11%) 
OR: 0.3 (0.2 to 0.9) 
P: 0.007 vs. main 
Incidence  
38 / 172 (22%) 
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Moss, 2008148 Infliximab + No steroids Infliximab + No 
immunomodulator at 
initiation 
Route: Unknown 
Dose: NR 
Infusion and injection-
site rx (Development of 
new symptoms within 1-
2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
33 / 201 (16%) 
Incidence  
38 / 172 (22%) 
Moss, 2008148 Infliximab + Thiopurine 
Dose: NR + NR 
Infliximab + Corticosteroid 
Dose: NR + NR 
Infusion and injection-
site rx (Development of 
new symptoms within 
BE 1-2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
13 / 115 (11%) 
Incidence  
18 / 86 (21%) 
Moss, 2008148 Infliximab + No steroids Infliximab + Corticosteroid 
Dose: NR + NR 
Infusion and injection-
site rx (Development of 
new symptoms within 
BE 1-2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
33 / 201 (16%) 
Incidence  
18 / 86 (21%) 
Moss, 2008148 Infliximab + No steroids Infliximab + Thiopurine 
Dose: NR + NR 
Infusion and injection-
site rx (Development of 
new symptoms within 
BE 1-2 h of an infusion 
(acute), or in the 14 d 
after (delayed) an 
infusion) 
Passive 
No  
NA 
Incidence  
33 / 201 (16%) 
Incidence  
13 / 115 (11%) 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
Immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Infusion and injection-
site rx (NR) @ 104 wks 
NR 
Yes 
NR 
Incidence  
1 / 40 (2%) 
Incidence  
1 / 40 (3%) 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
Immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Mortality (sudden 
cardiac death) @ 104 
wks 
NR 
Yes 
NR 
Incidence  
1 / 40 (2%) 
Incidence  
0 / 40 (0%) 
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Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
Immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Other cancers (renal 
cell carcinoma) @ 104 
wks 
NR 
Yes 
NR 
Incidence  
0 / 40 (0%) 
Incidence  
1 / 40 (2%) 
Van Assche, 
200889 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Infliximab + 
Immunomodulator 
Route: IV + Oral 
Dose: 5 mg/kg every 8 wks  
Other infections (NR) @ 
104 wks 
NR 
Yes 
NR 
Incidence  
4 / 40 (10%) 
Incidence  
5 / 40 (12%) 
Shah, 2008156 Azathioprine + Mesalamine 
(NR) 
Azathioprine + Never user 
mesalamine 
Other infections (NR) Passive 
No  
NA 
Event rate  
2 events / 104 persons 
Event rate  
2 events / 95 persons 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections 
(vaginal infections) 
NA  
NA 
Incidence  
7 / 64 (11%) 
Incidence  
7 / 65 (11%) P: 1 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections 
(gastrointestinal 
infection) 
NA  
NA 
Incidence  
13 / 64 (20%) 
Incidence  
12 / 65 (18%) P: 0.83 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections (upper 
respiratory tract 
infection) 
NA  
NA 
Incidence  
20 / 64 (31%) 
Incidence  
22 / 65 (34%) P: 0.85 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections (urinary 
tract infections) 
NA  
NA 
Incidence  
6 / 64 (9%) 
Incidence  
6 / 65 (9%) P: 1 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections (eye 
infections) 
NA  
NA 
Incidence  
3 / 64 (5%) 
Incidence  
4 / 65 (6%) P: 1 
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D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Other infections 
(common cold) 
NR  
NA 
Incidence  
31 / 64 (48%) 
Incidence  
26 / 65 (40%) P: 0.38 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Serious infections 
(pneumonia) 
NA  
NA 
Incidence  
0 / 64 (0%) 
Incidence  
1 / 65 (2%) P: 1 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Serious infections 
(perianal abscess or 
fistula) 
NA  
NA 
Incidence  
7 / 64 (11%) 
Incidence  
3 / 65 (5%) P: 0.21 
D'Haens, 
200848 
Budesonide + (6)-
Methylprednisolone 
Route: Oral + Oral 
Dose: 9 mg every 1 d + 32 
mg every 1 d 
Infliximab + Azathioprine 
Route: IV + Oral 
Dose: 5 mg/kg + 2-2.5 
mg/kg 
Serious infections 
(Hepatitis C) 
NA  
NA 
Incidence  
1 / 64 (2%) 
Incidence  
0 / 65 (0%) P: 0.5 
Hutfless, 
2007151 
ASA 
Route: Unknown 
Dose: NR 
Never user 5-
aminosalicylate acid 
Mortality (All-cause 
mortality) 
Passive 
No  
NA 
Incidence  
175 / 2566 (7%) 
OR: 0.7 (0.5 to 1.1) vs. 
main 
Incidence  
56 / 675 (8%) 
Hutfless, 
2007151 
Immunomodulator 
Route: Unknown 
Dose: NR 
Never user 
immunomodulator 
Route: Unknown 
Dose: NR 
Mortality (All-cause 
mortality) 
Passive 
No  
NA 
Incidence  
37 / 443 (8%) 
OR: 1.3 (0.9 to 1.9) vs. 
main 
Incidence  
194 / 2798 (7%) 
Hutfless, 
2007151 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user corticosteroid 
Route: Unknown 
Dose: NR 
Mortality (All-cause 
mortality) 
Passive 
No  
NA 
Incidence  
157 / 2168 (7%) 
OR: 1 (0.7 to 1.4) vs. 
main 
Incidence  
74 / 1073 (7%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Infusion and injection-
site rx (Any adverse 
event occurring within 2 
hrs of the infusion) @ 
48 wks 
Active 
Yes 
Yes 
Incidence  
14 / 214 (7%) 
Incidence  
18 / 214 (8%) 
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Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Lymphoma (NR) @ 48 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 214 (0%) 
Incidence  
0 / 214 (0%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Mortality (NR) @ 48 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 214 (0%) 
Incidence  
0 / 214 (0%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Other cancers (Basal 
cell carcinoma) @ 48 
wks 
Active 
Yes 
Yes 
Incidence  
1 / 214 (0%) 
Incidence  
1 / 214 (0%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Other infections (NR) @ 
48 wks 
Active 
Yes 
Yes 
Incidence  
132 / 214 (62%) 
Incidence  
119 / 214 (56%) 
Feagan, 
200781 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Serious infections 
(abscesses, sepsis, 
pneumonia, meningitis, 
gastroenteritis) @ 48 
wks 
Active 
Yes 
Yes 
Incidence  
6 / 214 (3%) 
Incidence  
5 / 214 (2%) 
Kane, 2008141 Immunomodulators 
Route: Unknown 
Dose: NR 
Never user 
immunnomodulators 
Route: Unknown 
Dose: NR 
Cervical cancer 
(Glandular or squamous 
carcinoma of the cervix) 
Passive  
NA 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 17 (0%) 
Rudolph, 
2008175 
Infliximab + 
Immunomudulator 
Infliximab + Never user 
immunomodulator at start 
of infliximab 
Infusion and injection-
site rx (occurring within 
1 h after infusion) 
Passive 
No  
NA 
Event rate  
6 events  
Event rate  
9 events  
Rudolph, 
2008175 
Infliximab + 
Immunomudulator 
Infliximab + Never user 
immunomodulator at start 
of infliximab 
Serious infections (NR) Passive 
No  
NA 
Event rate  
1 events  
Event rate  
0 events  
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Infusion and injection-
site rx (NR) @ 18 wks 
Active 
Yes 
Yes 
Incidence  
6 / 216 (3%) 
Incidence  
31 / 212 (15%) P: 0.003 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Mortality (NR) @ 18 
wks 
Active 
Yes  
NA 
Incidence  
0 / 216 (0%) 
Incidence  
0 / 212 (0%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Other cancers (any 
neoplasm) @ 18 wks 
Active 
Yes  
NA 
Incidence  
0 / 216 (0%) 
Incidence  
0 / 212 (0%) 
Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Serious infections (NR) 
@ 18 wks 
Active 
Yes  
NA 
Incidence  
6 / 216 (3%) 
Incidence  
2 / 212 (1%) 
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Schreiber, 
200784 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
TB (NR) @ 18 wks Active 
Yes 
Yes 
Incidence  
1 / 216 (0%) 
Incidence  
0 / 212 (0%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Cervical cancer 
(cervical carcinoma, 
stage 0) @ 26 wks 
Active 
Yes 
Yes 
Incidence  
0 / 331 (0%) 
Incidence  
1 / 329 (0%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Infusion and injection-
site rx (occurred at 
injection site and 
temporally related to 
injection) @ 26 wks 
Active 
Yes 
Yes 
Incidence  
9 / 331 (3%) 
Incidence  
47 / 329 (14%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Lymphoma (Hodgkin's 
lymphoma) @ 26 wks 
Active 
Yes 
Yes 
Incidence  
0 / 331 (0%) 
Incidence  
1 / 329 (0%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Mortality (NR) @ 26 
wks 
Passive 
Yes 
Yes 
Incidence  
1 / 331 (0%) 
Incidence  
0 / 329 (0%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Other cancers (any 
neoplasm (benign, 
malignant, or 
unspecified, including 
cysts and polyps)) @ 26 
wks 
Active 
Yes 
Yes 
Incidence  
2 / 331 (1%) 
Incidence  
0 / 329 (0%) 
Sandborn, 
200739 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Serious infections (NR) 
@ 26 wks 
Active 
Yes 
Yes 
Incidence  
7 / 331 (2%) 
Event rate  
9 events 
Incidence  
3 / 329 (1%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Infusion and injection-
site rx (Hypersensitivity 
reactions within 24 hrs 
of infusion) 
Passive 
Yes 
No 
Incidence  
10 / 260 (4%) 
Incidence  
1 / 250 (2%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Infusion and injection-
site rx (occurring within 
2 hrs of infusion) 
Active 
No 
No 
Incidence  
23 / 260 (9%) 
Incidence  
17 / 250 (7%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Lymphoma (B cell 
lymphoma) 
Active 
Yes  
NA 
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Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Mortality (NR) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 260 (0%) 
Incidence  
0 / 250 (0%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Other cancers (Basal 
cell carcinoma) 
Active 
No 
No 
Incidence  
1 / 260 (1%) 
Incidence  
0 / 250 (0%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Other infections (occur 
in > 2% of patients in 
either treatment groups) 
Active 
No 
No 
Incidence  
9 / 260 (35%) 
Incidence  
75 / 250 (30%) 
Targan, 200732 Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NR every 4 wks 
Serious infections (NR) 
@ 12 wks 
Active 
No 
No 
Incidence  
13 / 260 (5%) 
Incidence  
24 / 250 (10%) 
Siffledeen, 
2007127 
Corticosteroid Never user corticosteroids 
during year before DXA 
scan 
Fractures (Height 
reduction >20% and a 
loss of surface area 
>10%, in the presence 
of a biconcave, crush, 
or wedge deformity as 
measured by DXA 
scan) 
Active 
No  
NA 
Incidence  
25 / 105 (24%) 
Incidence  
17 / 102 (17%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
Infusion and injection-
site rx (NR) 
Active 
No  
NA 
Incidence  
17 / 159 (11%) 
Incidence  
17 / 166 (10%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
Mortality (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 159 (0%) 
Incidence  
0 / 166 (0%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
Other cancers (Solid 
tumors or hematologic 
cancer) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 159 (0%) 
Incidence  
0 / 166 (0%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
Other infections (NR) Active  
NA 
Incidence  
26 / 159 (16%) 
Incidence  
39 / 166 (23%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
Serious infections (NR) Active 
No  
NA 
Incidence  
0 / 159 (0%) 
Incidence  
4 / 166 (2%) 
Sandborn, 
200738 
Adalimumab 
Route: SC 
Placebo 
Route: SC 
Dose: NA 
TB (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 159 (0%) 
Incidence  
0 / 166 (0%) 
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Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
1 / 19 (5%) 
Incidence  
2 / 18 (12%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Lymphoma (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Mortality (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other cancers 
(squamous cell 
carcinoma) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
1 / 18 (5%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(nasopharyngitis) @ 52 
wks 
Active 
Yes 
Yes 
Incidence  
5 / 19 (26%) 
Incidence  
7 / 18 (39%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(sinusitis) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
4 / 19 (21%) 
Incidence  
1 / 18 (6%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(treatment-emergent 
infectious adverse 
events) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
14 / 19 (74%) 
Incidence  
15 / 18 (83%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Serious infections (NR) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
TB (NR) @ 52 wks NA 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 18 (0%) 
Incidence  
2 / 18 (12%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Lymphoma (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Mortality (NR) @ 52 
wks 
NA 
Yes 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
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Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other cancers 
(squamous cell 
carcinoma) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 19 (0%) 
Incidence  
1 / 18 (5%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(nasopharyngitis) @ 52 
wks 
Active 
Yes 
Yes 
Incidence  
2 / 18 (11%) 
Incidence  
7 / 18 (39%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(sinusitis) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
1 / 18 (6%) 
Incidence  
1 / 18 (6%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Other infections 
(treatment-emergent 
infectious adverse 
events) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
6 / 18 (33%) 
Incidence  
15 / 18 (83%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
Serious infections (NR) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Sandborn, 
200783 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 1 wks 
TB (NR) @ 52 wks NA 
Yes 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(abscess) @ 52 wks 
Active 
Yes  
NA 
Incidence  
3 / 260 (1.2%) 
Incidence  
5 / 261 (1.9%) 
Colombel, 
200782 
Adalimumab 
Route: SC 
Dose: 40 mg every 1 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(abscess) @ 52 wks 
Active 
Yes  
NA 
Incidence  
5 / 257 (1.9%) 
Incidence  
5 / 261 (1.9%) P: NS 
Vermeire, 
2007154 
Infliximab + Methotrexate 
Route: IV + IM or SC 
Dose: NR + 15 mg every 1 
wks 
Infliximab + No concomitant 
methotrexate or thiopurine 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
7 / 50 (14%) 
Incidence  
24 / 59 (40%) 
Vermeire, 
2007154 
Infliximab + Thiopurine 
Route: IV + Unknown 
Dose: NR + See 
Comments every 1 d 
Infliximab + No concomitant 
methotrexate or thiopurine 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
12 / 65 (18%) 
Incidence  
24 / 59 (40%) 
Vermeire, 
2007154 
Infliximab + Thiopurine or 
methotrexate 
Infliximab + No concomitant 
methotrexate or thiopurine 
Route: IV 
Dose: NR 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
18 / 115 (16%) 
Incidence  
24 / 59 (40%) P: 0.04 
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Vermeire, 
2007154 
Infliximab + Thiopurine 
Route: IV + Unknown 
Dose: NR + See 
Comments every 1 d 
Infliximab + Methotrexate 
Route: IV + IM or SC 
Dose: NR + 15 mg every 1 
wks 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
12 / 65 (18%) 
Incidence  
7 / 50 (14%) P: >0.05 
Vermeire, 
2007154 
Infliximab + Thiopurine or 
methotrexate 
Infliximab + Methotrexate 
Route: IV + IM or SC 
Dose: NR + 15 mg every 1 
wks 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
18 / 115 (16%) 
Incidence  
7 / 50 (14%) 
Vermeire, 
2007154 
Infliximab + Thiopurine or 
methotrexate 
Infliximab + Thiopurine 
Route: IV + Unknown 
Dose: NR + See 
Comments every 1 d 
Infusion and injection-
site rx (NR) 
Passive 
No  
NA 
Incidence  
18 / 115 (16%) 
Incidence  
12 / 65 (18%) 
Sands, 200735 Natalizumab + Infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + Infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
Lymphoma (NR) @ 20 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 52 (0%) 
Incidence  
0 / 27 (0%) 
Sands, 200735 Natalizumab + Infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + Infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
Other infections (upper 
resp. tract infection) 
NR 
No 
NR 
Incidence  
3 / 52 (6%) 
Incidence  
1 / 27 (4%) 
Sands, 200735 Natalizumab + Infliximab 
Route: IV + IV 
Dose: 300 mg every 4 wks 
+ 5 mg/kg every 8 wks 
Placebo + Infliximab 
Route: IV + IV 
Dose: NA every 4 wks + 5 
mg/kg every 8 wks 
Other infections 
(nasopharyngitis) 
NR 
NR 
Incidence  
5 / 52 (10%) 
Incidence  
3 / 27 (11%) 
Lichtenstein, 
2006131 
Infliximab 
Route: IV 
Never user infliximab 
Route: IV 
Mortality (NR) Passive 
Yes  
NA 
Incidence  
29 / 3179 (1%) 
OR: 1.015 (0.531 to 
1.942) 
P: 0.96 vs. main 
Incidence  
26 / 3111 (1%) 
Lichtenstein, 
2006131 
Infliximab 
Route: IV 
Never user infliximab 
Route: IV 
Mortality (NR) Passive 
Yes  
NA 
Event rate  
0.53 events / 100 pys 
RR: 1.24 (0.729 to 
2.102) 
P: 0.43 vs. main 
Event rate  
0.43 events / 100 pys  
Lichtenstein, 
2006131 
Infliximab 
Route: IV 
Never user infliximab 
Route: IV 
Serious infections (NR) Active 
Yes  
NA 
Event rate  
1.37 events / 100 pys 
RR: 2.15 (1.442 to 3.21) 
vs. main 
Event rate  
0.65 events / 100 pys 
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Lichtenstein, 
2006131 
Infliximab 
Route: IV 
Never user infliximab 
Route: IV 
Serious infections (NR) Active 
Yes  
NA 
Incidence  
69 / 2933 (2%) 
OR: 0.991 (0.641 to 
1.535) 
P: 0.97 vs. main 
Incidence  
37 / 3320 (1%) 
Lichtenstein, 
2006131 
No reported prednisone 
usage 
Route: Unknown 
Dose: NR 
Prednisone 
Route: Unknown 
Dose: NR 
Mortality (NR) NR 
Yes  
NA 
Incidence  
23 / 3894 (1%) 
Incidence  
30 / 2396 (1%) 
OR: 2.096 (1.147 to 
3.832) 
P: 0.016 vs. comp 
Lichtenstein, 
2006131 
No reported prednisone 
usage 
Route: Unknown 
Dose: NR 
Prednisone 
Route: Unknown 
Dose: NR 
Serious infections (NR) Active 
Yes  
NA 
Incidence  
45 / 4111 (1%) 
Incidence  
61 / 2142 (3%) 
OR: 2.212 (1.464 to 
3.342) vs. comp 
Lichtenstein, 
2006131 
No immunomodulators 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Mortality (NR) Passive 
Yes  
NA 
Incidence  
26 / 2526 (1%) 
Incidence  
27 / 3764 (1%) 
OR: 0.731 (0.398 to 
1.34) 
P: 0.31 vs. comp 
Lichtenstein, 
2006131 
No immunomodulators 
Route: Unknown 
Dose: NR 
Immunomodulator 
Route: Unknown 
Dose: NR 
Serious infections (NR) Active 
Yes  
NA 
Incidence  
48 / 2775 (2%) 
Incidence  
58 / 3478 (2%) 
OR: 0.782 (0.519 to 
1.179) 
P: 0.24 vs. comp 
Lemann, 
200646 
Infliximab + Azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + Azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable mg/kg 
every 1 d 
Mortality (NR) @ 52 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 57 (0%) 
Incidence  
0 / 56 (0%) 
Lemann, 
200646 
Infliximab + Azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + Azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable mg/kg 
every 1 d 
Other cancers (NR) @ 
52 wks 
Active 
Yes 
Yes 
Incidence  
0 / 57 (0%) 
Incidence  
0 / 56 (0%) 
Lemann, 
200646 
Infliximab + Azathioprine or 
6-MP 
Route: IV 
Dose: 5 mg/kg + stable 
Placebo + Azathioprine or 
6-MP 
Route: IV + Oral 
Dose: NA + stable mg/kg 
every 1 d 
Other infections 
(infections) @ 24 wks 
NR 
No 
NR 
Event rate  
18 events 
Event rate  
16 events 
D-379 
 
 
Evidence Table 14. Safety of pharmacologic therapies for the management of Crohn’s disease (KQ3) 
 
Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Infusion and injection-
site rx (NR) @ 4 wks 
NA 
Yes 
Incidence  
19 / 74 (26%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Lymphoma (NR) @ 4 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Mortality (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
1 / 74 (1%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections (NR) @ 
4 wks 
Active 
Yes 
Yes 
Incidence  
8 / 74 (10%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(opportunistic 
infections) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(abscess) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections (NR) 
@ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
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Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 40 mg then 20 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
TB (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Infusion and injection-
site rx (NR) @ 4 wks 
NA 
Yes 
Incidence  
18 / 75 (24%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Lymphoma (NR) @ 4 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Mortality (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(opportunistic 
infections) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
1 / 74 (1%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections (NR) @ 
4 wks 
Active 
Yes 
Yes 
Incidence  
13 / 75 (17%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(abscess) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
D-381 
 
 
Evidence Table 14. Safety of pharmacologic therapies for the management of Crohn’s disease (KQ3) 
 
Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections (NR) 
@ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 80 mg then 40 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
TB (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 75 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Infusion and injection-
site rx (NR) @ 4 wks 
NA 
Yes 
Incidence  
29 / 76 (38%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Lymphoma (NR) @ 4 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 76 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Mortality (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 76 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(opportunistic 
infections) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
0 / 76 (0%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
2 / 76 (3%) 
Incidence  
1 / 74 (1%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Other infections (NR) @ 
4 wks 
Active 
Yes 
Yes 
Incidence  
16 / 76 (21%) 
Incidence  
12 / 74 (16%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections (NR) 
@ 4 wks 
Active 
Yes 
Yes 
Incidence  
2 / 76 (3%) 
Incidence  
0 / 74 (0%) 
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Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(abscess) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
1 / 76 (1%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
Serious infections 
(pneumonia) @ 4 wks 
Active 
Yes 
Yes 
Incidence  
1 / 76 (1%) 
Incidence  
0 / 74 (0%) 
Hanauer, 
200637 
Adalimumab 
Route: SC 
Dose: 160 mg then 80 mg 
every 2 wks 
Placebo 
Route: SC 
Dose: NA every 2 wks 
TB (NR) @ 4 wks Active 
Yes 
Yes 
Incidence  
0 / 76 (0%) 
Incidence  
0 / 74 (0%) 
Schroder, 
200647 
Methotrexate + Infliximab 
Route: IV + IV 
Dose: 20 mg every 1 wks + 
5 mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
Other cancers (NR) @ 
48 wks 
Active 
Yes 
Yes 
Incidence  
0 / 11 (0%) 
Incidence  
0 / 8 (0%) 
Schroder, 
200647 
Methotrexate + Infliximab 
Route: IV + IV 
Dose: 20 mg every 1 wks + 
5 mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
Other infections (NR) @ 
48 wks 
Active 
Yes 
Yes 
Incidence  
2 / 11 (18%) 
Incidence  
1 / 8 (12%) P: 1 
Schroder, 
200647 
Methotrexate + Infliximab 
Route: IV + IV 
Dose: 20 mg every 1 wks + 
5 mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
Other infections 
(respiratory tract 
infections) @ 48 wks 
Active 
Yes 
Yes 
Incidence  
4 / 11 (36%) 
Incidence  
1 / 8 (12%) P: 0.34 
Schroder, 
200647 
Methotrexate + Infliximab 
Route: IV + IV 
Dose: 20 mg every 1 wks + 
5 mg/kg every 2 wks 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 2 wks 
Serious infections (NR) 
@ 48 wks 
Active 
Yes 
Yes 
Incidence  
0 / 11 (0%) 
Incidence  
0 / 8 (0%) 
Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Infusion and injection-
site rx (occurring within 
2 hrs of infusion) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
83 / 723 (11%) 
Incidence  
14 / 181 (8%) 
Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Lymphoma (NR) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 724 (0%) 
Incidence  
0 / 181 (0%) 
Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Mortality (NR) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
2 / 724 (0%) 
Incidence  
0 / 181 (0%) 
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Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Other infections 
(influenza, sinusitis, 
candidiasis, viral 
infections and herpes 
zoster / others) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
352 / 723 (49%) 
Incidence  
78 / 181 (43%) 
Sandborn, 
200533 
Natalizumab 
Route: IV 
Dose: 300 mg every 4 wks 
Placebo 
Route: IV 
Dose: NA every 4 wks 
Serious infections 
(abscess, sepsis, 
pneumonia, meningitis, 
gastroenteritis) @ 12 
wks 
Active 
Yes 
Yes 
Incidence  
12 / 723 (2%) 
Incidence  
4 / 181 (2%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Infusion and injection-
site rx (NR) 
NR 
No 
NR 
Incidence  
5 / 74 (6.8%) 
Incidence  
2 / 73 (2.7%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Lymphoma (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Mortality (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 100 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
TB (NR) @ 12 wks Active 
No 
Yes 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Infusion and injection-
site rx (NR) 
NR 
No 
NR 
Incidence  
4 / 72 (5.6%) 
Incidence  
2 / 73 (2.7%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Lymphoma (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Mortality (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 200 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
TB (NR) @ 12 wks Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Infusion and injection-
site rx (NR) 
NR 
No 
NR 
Incidence  
2 / 72 (2.7%) 
Incidence  
2 / 73 (2.7%) 
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Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Lymphoma (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
Mortality (NR) @ 12 
wks 
Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Schreiber, 
200540 
Certolizumab pegol 
Route: SC 
Dose: 400 mg every 4 wks 
Placebo 
Route: SC 
Dose: NA every 4 wks 
TB (NR) @ 12 wks Active 
No 
Yes 
Incidence  
0 / 72 (0%) 
Incidence  
0 / 73 (0%) 
Biancone, 
2006149 
Infliximab 
Route: IV 
Never user infliximab Lymphoma (non-
Hodgkin’s lymphoma 
from chart review) 
Passive 
No  
NA 
Incidence  
0 / 404 (0%) 
Incidence  
1 / 404 (0%) 
Biancone, 
2006149 
Infliximab 
Route: IV 
Never user infliximab Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
Hodgkin’s lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
9 / 404 (2%) 
OR: 1.33 (0.46 to 3.84) 
P: 0.4 vs. main 
Incidence  
7 / 404 (2%) 
Biancone, 
2006149 
Infliximab + No 
immunomodulators 
Never user infliximab Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
2 / 191 (1%) 
Incidence  
7 / 404 (2%) 
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Biancone, 
2006149 
Infliximab + No 
immunomodulators 
Certolizumab pegol + 6-
MP/azathioprine/methotrex
ate 
Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
2 / 191 (1%) 
Incidence  
7 / 213 (3%) 
Biancone, 
2006149 
No infliximab + 6-
MP/azathioprine/methotrex
ate 
Certolizumab pegol + 6-
MP/azathioprine/methotrex
ate 
Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
3 / 218 (1%) 
Incidence  
7 / 213 (3%) 
Biancone, 
2006149 
No infliximab + 6-
MP/azathioprine/methotrex
ate 
Certolizumab pegol + 6-
MP/azathioprine/methotrex
ate 
Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
4 / 186 (2%) 
Incidence  
7 / 213 (3%) 
D-386 
 
 
Evidence Table 14. Safety of pharmacologic therapies for the management of Crohn’s disease (KQ3) 
 
Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Biancone, 
2006149 
No infliximab + 6-
MP/azathioprine/methotrex
ate 
Infliximab + No 
immunomodulators 
Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
3 / 218 (1%) 
Incidence  
2 / 191 (1%) 
Biancone, 
2006149 
No infliximab + 6-
MP/azathioprine/methotrex
ate 
Infliximab + No 
immunomodulators 
Other cancers (from 
charts: 
cholagiocarcinoma, 
anal carcinoma, breast 
cancer, leukemia, non-
hod lymphoma, 
baslioma, laryngeal 
carcinoma, 
adenocarcinoma 
cecum, spinaloma,) 
Passive 
No  
NA 
Incidence  
4 / 186 (2%) 
Incidence  
2 / 191 (1%) 
Lemann, 
200598 
Azathioprine 
Route: Oral 
Dose: as taken before 
enrollment every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
Mortality (NR) @ 48 
wks 
NR 
No 
Yes 
Incidence  
1 / 40 (2%) 
Incidence  
0 / 43 (0%) 
Orlando, 
2005128 
Infliximab + 
Immunomodulator 
(unspecified) 
Infliximab + No concomitant 
immunomodulators 
Mortality (within 12 wks 
(of first or last infusion--
unclear)) 
NR 
No  
NA 
Incidence  
0 / 211 (0%) 
Incidence  
0 / 362 (0%) 
Orlando, 
2005128 
Infliximab + 
Immunomodulator 
(unspecified) 
Infliximab + No concomitant 
immunomodulators 
Other cancers (anal 
adenocarcinoma, breast 
adenocarcinoma, 
laryngeal carcinoma, 
leukemia, biliary duct 
carcinoma, skin 
carcinoma) 
NR 
No  
NA 
Incidence  
6 / 211 (3%) 
Incidence  
2 / 362 (1%) 
Schoon, 
2005185 
Prednisolone 
Route: Oral 
Dose: 40 mg every 1 d 
Budesonide 
Route: Oral 
Dose: 9 mg every 1 d 
Fractures (traumatic 
and atraumatic 
fractures at all sites) @ 
104 wks 
Active 
Yes 
Yes 
Event rate  
3 events  
Event rate  
3 events 
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Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Infusion and injection-
site rx (NR) @ 12 wks 
Active 
Yes 
No 
Incidence  
0 / 2 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Mortality (NR) @ 12 
wks 
Active 
Yes 
No 
Incidence  
0 / 2 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections 
(Opportunistic 
infections) @ 12 wks 
Passive 
Yes 
No 
Incidence  
0 / 2 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections (NR) @ 
12 wks 
Active 
Yes 
No 
Incidence  
13 / 68 (19.1%) 
Incidence  
3 / 24 (12.5%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections (NR) @ 
4 wks 
Active 
Yes 
No 
Incidence  
8 / 68 (11.8%) 
Incidence  
2 / 24 (8.3%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Serious infections 
(perianal abscess) @ 
12 wks 
Active 
Yes 
No 
Incidence  
0 / 2 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 1.25 mg/kg 
Placebo 
Route: IV 
Dose: NA 
TB (NR) @ 12 wks Active 
Yes 
No 
Incidence  
0 / 2 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Infusion and injection-
site rx (NR) @ 12 wks 
Active 
Yes 
No 
Incidence  
0 / 26 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Mortality (NR) @ 12 
wks 
Active 
Yes 
No 
Incidence  
0 / 26 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections 
(Opportunistic 
infections) @ 12 wks 
Passive 
Yes 
No 
Incidence  
0 / 26 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Serious infections 
(perianal abscess) @ 
12 wks 
Active 
Yes 
No 
Incidence  
0 / 26 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Dose: NA 
TB (NR) @ 12 wks Active 
Yes 
No 
Incidence  
0 / 26 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Infusion and injection-
site rx (NR) @ 12 wks 
Active 
Yes 
No 
Incidence  
0 / 17 (0%) 
Incidence  
0 / 24 (0%) 
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Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Mortality (NR) @ 12 
wks 
Active 
Yes 
No 
Incidence  
0 / 17 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections 
(Opportunistic 
infections) @ 12 wks 
Passive 
Yes 
No 
Incidence  
0 / 17 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Serious infections 
(perianal abscess) @ 
12 wks 
Active 
Yes 
No 
Incidence  
0 / 17 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Dose: NA 
TB (NR) @ 12 wks Active 
Yes 
No 
Incidence  
0 / 17 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Infusion and injection-
site rx (NR) @ 12 wks 
Active 
Yes 
No 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Mortality (NR) @ 12 
wks 
Active 
Yes 
No 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Other infections 
(Opportunistic 
infections) @ 12 wks 
Passive 
Yes 
No 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
Serious infections 
(perianal abscess) @ 
12 wks 
Active 
Yes 
No 
Incidence  
1 / 23 (4%) 
Incidence  
0 / 24 (0%) 
Winter, 200441 Certolizumab pegol 
Route: IV 
Dose: 20 mg/kg 
Placebo 
Route: IV 
Dose: NA 
TB (NR) @ 12 wks Active 
Yes 
No 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 24 (0%) 
Seiderer, 
2004173 
Infliximab + Azathioprine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Infusion and injection-
site rx (NR) 
Active 
No  
NA 
Incidence  
2 / 64 (3%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Azathioprine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Mortality (from chart 
review) 
Passive 
No  
NA 
Incidence  
0 / 64 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Azathioprine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other cancers 
(malignancy from 
medical record review) 
Passive 
No  
NA 
Incidence  
0 / 64 (0%) 
Incidence  
0 / 18 (0%) 
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Seiderer, 
2004173 
Infliximab + Azathioprine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other infections 
(varicella-zoster, 
bacterial uncomplicated 
pneumonia, E coli, 
sepsis) 
Passive 
No  
NA 
Incidence  
3 / 64 (5%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + 6-MP Infliximab + No 
azathioprine/6-MP at first 
infusion 
Infusion and injection-
site rx (NR) 
Active 
No  
NA 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + 6-MP Infliximab + No 
azathioprine/6-MP at first 
infusion 
Mortality (from chart 
review) 
Passive 
No  
NA 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + 6-MP Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other cancers 
(malignancy from 
medical record review) 
Passive 
No  
NA 
Incidence  
0 / 18 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + 6-MP Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other infections 
(varicella-zoster, 
bacterial uncomplicated 
pneumonia, E coli, 
sepsis) 
Passive 
No  
NA 
Incidence  
1 / 18 (6%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Thiopurine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Infusion and injection-
site rx (NR) 
Active 
No  
NA 
Incidence  
2 / 82 (2%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Thiopurine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Mortality (from chart 
review) 
Passive 
No  
NA 
Incidence  
0 / 82 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Thiopurine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other cancers 
(malignancy from 
medical record review) 
Passive 
No  
NA 
Incidence  
0 / 82 (0%) 
Incidence  
0 / 18 (0%) 
Seiderer, 
2004173 
Infliximab + Thiopurine Infliximab + No 
azathioprine/6-MP at first 
infusion 
Other infections 
(varicella-zoster, 
bacterial uncomplicated 
pneumonia, E coli, 
sepsis) 
Passive 
No  
NA 
Incidence  
4 / 82 (5%) 
Incidence  
0 / 18 (0%) 
Mantzaris, 
2003113 
Mesalamine (Salofalk) 
Route: Unknown 
Dose: 1 g every 8 hrs 
Budesonide 
Route: Unknown 
Dose: 6 mg every 1 d 
Other infections (NR) @ 
52 wks 
Active 
No  
NA 
Event rate  
16 events  
Event rate  
19 events  
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Infusion and injection-
site rx (NR) @ 54 wks 
Active 
Yes 
Yes 
Incidence  
22 / 138 (16%) 
Incidence  
24 / 144 (17%) 
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Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Mortality (NR) @ 40 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 139 (0%) 
Incidence  
0 / 143 (0%) 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other cancers (Any 
cancer) @ 40 wks 
Active 
Yes 
Yes 
Incidence  
0 / 139 (0%) 
Incidence  
0 / 143 (0%) 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other infections 
(infections requiring 
antimicrobial treatment) 
@ 40 wks 
Active 
Yes 
Yes 
Incidence  
47 / 138 (34%) 
Incidence  
39 / 144 (27%) P: 0.2 
Sands, 200487 Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Serious infections (NR) 
@ 40 wks 
Active 
Yes 
Yes 
Incidence  
4 / 138 (3%) 
Incidence  
9 / 144 (6%) P: 0.18 
Tay, 2003233 Any immunomodulator 
Route: Unknown 
No immunomodulator 
Route: Unknown 
Serious infections 
(IASC) @ 44 wks 
Active 
Yes  
NA 
Incidence  
4 / 72 (6%) 
Incidence  
4 / 28 (14%) P: 0.1 
Kinney, 
2003162 
Infliximab + Thiopurine 
Dose: NR + NR 
Infliximab 
Route: Unknown 
Dose: NR 
Mortality (NR) Passive 
No  
NA 
Incidence  
0 / 58 (0%) 
Incidence  
1 / 36 (3%) 
Kinney, 
2003162 
Infliximab + Methotrexate 
Dose: NR + NR 
Infliximab 
Route: Unknown 
Dose: NR 
Mortality (NR) Passive 
No  
NA 
Incidence  
0 / 23 (0%) 
Incidence  
1 / 36 (3%) 
Kinney, 
2003162 
Infliximab + Methotrexate 
Dose: NR + NR 
Infliximab + Thiopurine 
Dose: NR + NR 
Mortality (NR) Passive 
No  
NA 
Incidence  
0 / 23 (0%) 
Incidence  
0 / 58 (0%) 
Fraser, 
2002232 
Azathioprine 
Route: Unknown 
Dose: NR 
Never user azathioprine Lymphoma (Histology 
described) 
Passive 
No  
NA 
Incidence  
3 / 626 (0%) 
Incidence  
5 / 1578 (0%) 
Fraser, 
2002232 
Azathioprine 
Route: Unknown 
Dose: NR 
Never user azathioprine Other cancers (NR) Passive 
No  
NA 
Event rate  
31 events 
Event rate  
77 events  
Fraser, 
2002232 
Azathioprine 
Route: Unknown 
Dose: NR 
Never user azathioprine Other cancers (NR) Passive 
No  
NA 
Incidence  
30 / 626 (5%) 
Incidence  
70 / 1578 (4%) 
Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 9 mg every 1 d 
Placebo 
Route: Oral 
Dose: NA every 1 d 
Other infections 
(respiratory infection) 
Active 
Yes 
No 
Incidence  
8 / 80 (10%) 
Incidence  
5 / 41 (13%) 
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Tremaine, 
200265 
Budesonide 
Route: Oral 
Dose: 4.5 mg every 12 hrs 
Placebo 
Route: Oral 
Dose: NA every 1 d 
Other infections 
(respiratory infection) 
Active 
Yes 
No 
Incidence  
2 / 79 (2%) 
Incidence  
5 / 41 (13%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
44 / 193 (23%) 
Incidence  
17 / 188 (9%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Lymphoma (natural-
killer-cell lymphoma) @ 
52 wks 
Active 
No 
Yes 
Incidence  
0 / 193 (0%) 
Incidence  
1 / 188 (1%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Mortality (NR) @ 52 
wks 
Active 
Yes 
Yes 
Incidence  
3 / 193 (2%) 
Incidence  
0 / 188 (0%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other cancers (any type 
of cancer) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
3 / 193 (2%) 
Incidence  
2 / 188 (1%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other infections 
(infection requiring 
antimicrobial treatment) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
64 / 193 (33%) 
Incidence  
70 / 188 (37%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Serious infections (NR) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
8 / 193 (4%) 
Incidence  
8 / 188 (4%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 5 mg/kg every 8 wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
TB (NR) @ 52 wks Active 
Yes 
Yes 
Incidence  
1 / 193 (1%) 
Incidence  
0 / 188 (0%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Infusion and injection-
site rx (NR) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
36 / 192 (19%) 
Incidence  
17 / 188 (9%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Lymphoma (natural-
killer-cell lymphoma) @ 
52 wks 
Active 
No 
Yes 
Incidence  
0 / 192 (0%) 
Incidence  
1 / 188 (1%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Mortality (NR) @ 52 
wks 
Active 
Yes 
Yes 
Incidence  
0 / 192 (0%) 
Incidence  
0 / 188 (0%) 
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Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other cancers (any type 
of cancer) @ 52 wks 
Active 
Yes 
Yes 
Incidence  
1 / 192 (1%) 
Incidence  
2 / 188 (1%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Other infections 
(infection requiring 
antimicrobial treatment) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
52 / 192 (27%) 
Incidence  
70 / 188 (37%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
Serious infections (NR) 
@ 52 wks 
Active 
Yes 
Yes 
Incidence  
6 / 192 (3%) 
Incidence  
8 / 188 (4%) 
Hanauer, 
200286 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: IV 
Dose: NA every 8 wks 
TB (NR) @ 52 wks Active 
Yes 
Yes 
Incidence  
0 / 192 (0%) 
Incidence  
0 / 188 (0%) 
Campbell, 
2001146 
Azathioprine + ASA 
Dose: 1.7 mg/kg + NR 
Azathioprine 
Route: Unknown 
Dose: 1.8 mg/kg 
Other cancers (NR) Passive 
No  
NA 
Incidence  
1 / 48 (2%) 
Incidence  
0 / 56 (0%) 
Lewis, 2001136 Thiopurine Never user azathioprine/6-
MP 
Lymphoma (ICD code 
verified by physician 
questionnaire in most 
cases) 
Passive 
No  
NA 
  
Lewis, 2001136 Thiopurine Never user azathioprine/6-
MP 
Lymphoma (ICD code 
verified by physician 
questionnaire in most 
cases) 
Passive 
No  
NA 
Incidence  
0 / 837 (0%) 
Incidence  
7 / 5768 (0%) 
Lewis, 2001136 Never user corticosteroid 
Route: Unknown 
Dose: NR 
Corticosteroid 
Route: Unknown 
Dose: NR 
Lymphoma (ICD code 
verified by physician 
questionnaire in most 
cases) 
Passive 
No  
NA 
Incidence  
11 / 11000 (0%) 
Incidence  
4 / 4064 (0%) 
Lewis, 2001136 Never user mesalamine 
(NR) 
Route: Unknown 
Dose: NR 
Mesalamine (NR) 
Route: Unknown 
Dose: NR 
Lymphoma (ICD code 
verified by physician 
questionnaire in most 
cases) 
Passive 
No  
NA 
Incidence  
8 / 7931 (0%) 
Incidence  
7 / 7233 (0%) 
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Lewis, 2001136 Never user 
immunosuppresants 
(defined as either 
methotrexate, cyclosporine, 
tacrolimus or 
mycophenolate mofetil) 
Route: Unknown 
Dose: NR 
Immunosuppresants 
(defined as either 
methotrexate, cyclosporine, 
tacrolimus or 
mycophenolate mofetil) 
Route: Unknown 
Dose: NR 
Lymphoma (ICD code 
verified by physician 
questionnaire in most 
cases) 
Passive 
No  
NA 
Incidence  
14 / 15087 (0%) 
Incidence  
1 / 77 (1%) 
Mortimore, 
2001174 
Infliximab + No concomitant 
immunosuppressive 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Serious infections 
(Pneumocystis carinii 
pneumonia) 
Passive 
No  
NA 
Incidence  
1 / 15 (7%) 
Incidence  
0 / 42 (0%) 
Ricart, 2001138 Infliximab + Corticosteroid 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Infliximab + Never user 
corticosteroid 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Serious infections 
(Either pneumonia, 
varicella or candida 
esophagitis) 
Active 
No  
NA 
Incidence  
2 / 44 (5%) 
Incidence  
4 / 56 (7%) 
Ricart, 2001138 Infliximab + 
Immunomodulators 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Infliximab + Never user 
immunomodulators 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Infusion and injection-
site rx (NR) 
Active 
No  
NA 
Incidence  
18 / 95 (19%) 
Incidence  
1 / 5 (20%) 
Ricart, 2001138 Infliximab + 
Immunomodulators 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Infliximab + Never user 
immunomodulators 
Route: IV + Unknown 
Dose: 5 mg/kg + NR 
Serious infections 
(Either pneumonia, 
varicella or candida 
esophagitis) 
Active 
No  
NA 
Incidence  
5 / 95 (5%) 
Incidence  
1 / 5 (20%) 
Farrell, 2000231 Immunomodulators 
Route: Unknown 
Dose: NR 
Never used 
immunomodulators 
Lymphoma (Non-
Hodgkins Lymphoma) 
Passive 
No  
NA 
Incidence  
4 / 238 (2%) 
Incidence  
0 / 544 (0%) P: 0.002 
Farrell, 2000231 Immunomodulators 
Route: Unknown 
Dose: NR 
Never used 
immunomodulators 
Other cancers 
(colorectal cancer, skin 
cancers, lymphoma and 
'Other' Cancers) 
Passive 
No  
NA 
Incidence  
14 / 238 (6%) 
Incidence  
16 / 544 (3%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
Lymphoma (B cell 
lymphoma) @ 36 wks 
Active 
Yes 
No 
Incidence  
0 / 37 (0%) 
Incidence  
1 / 36 (3%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
Mortality (NR) @ 36 
wks 
Active 
No 
Yes 
Incidence  
0 / 37 (0%) 
Incidence  
1 / 36 (3%) 
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Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
Other infections 
(Bronchitis) @ 36 wks 
Active 
Yes 
Yes 
Incidence  
6 / 37 (16.2%) 
Incidence  
3 / 36 (8.3%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
Other infections 
(pharyngitis) @ 36 wks 
Active 
Yes 
No 
Incidence  
7 / 37 (18.9%) 
Incidence  
1 / 36 (2.8%) 
Rutgeerts, 
199985 
Infliximab 
Route: IV 
Dose: 10 mg/kg every 8 
wks 
Placebo 
Route: Unknown 
Dose: NA every 8 wks 
Other infections (Upper 
respiratory infections) 
Active 
Yes 
Yes 
Incidence  
9 / 37 (24.3%) 
Incidence  
6 / 36 (16.7%) 
Sandborn, 
199959 
Azathioprine + Azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
every 1 d 
Placebo + Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 1 d 
Infusion and injection-
site rx (NR) 
Active 
Yes 
Yes 
Incidence  
11 / 51 (22%) 
Incidence  
1 / 45 (2%) P: 0.005 
Sandborn, 
199959 
Azathioprine + Azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
every 1 d 
Placebo + Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 1 d 
Other infections 
(pneumonia) 
Active 
Yes 
Yes 
Incidence  
0 / 51 (0%) 
Incidence  
2 / 45 (4%) P: 0.217 
Sandborn, 
199959 
Azathioprine + Azathioprine 
Route: IV + Oral 
Dose: 40 mg/kg + 2 mg/kg 
every 1 d 
Placebo + Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 1 d 
Other infections (viral 
lower respiratory 
infection) 
Active 
Yes 
Yes 
Incidence  
6 / 51 (12%) 
Incidence  
6 / 45 (13%) P: 1 
Campieri, 
199768 
Budesonide + Placebo 
Route: Oral + Oral 
Dose: 4.5 mg every 12 hrs 
+ NA every 24 hrs 
Prednisolone + Placebo 
Route: Oral + Oral 
Dose: 40 mg every 1 d + 
NA every 12 hrs 
Weight (kg) @ 8 wks Active 
Yes 
Yes 
B: Mean, 63 
F-B: Mean, 0 
G1-G2: 2.1 
B: Mean, 61 
F-B: Mean, 2.1 
G1-G2: 2.1 
Campieri, 
199768 
Budesonide + Placebo 
Route: Oral + Oral 
Dose: 9 mg every 1 d + NA 
every 24 hrs 
Prednisolone + Placebo 
Route: Oral + Oral 
Dose: 40 mg every 1 d + 
NA every 12 hrs 
Weight (kg) @ 8 wks Active 
Yes 
Yes 
B: Mean, 63 
F-B: Mean, 1 
G1-G2: 1.1 
B: Mean, 61 
F-B: Mean, 2.1 
G1-G2: 1.1 
Feagan, 
199563 
Methotrexate + Prednisone 
Route: IM + Oral 
Dose: 25 mg every 1 wks 
Placebo + Prednisone 
Route: IM + Oral 
Dose: NA every 1 wks + 
every 1 d 
Other infections 
(influenza like illness or 
pneumonia probably 
due to mycoplasma) 
NR 
No 
Yes 
Incidence  
11 / 94 (12%) 
Incidence  
6 / 47 (13%) 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
0 / 117 (0%) 
Incidence  
0 / 110 (0%) 
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Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
1 / 75 (1%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
3 / 75 (4%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
2 / 113 (2%) 
Incidence  
0 / 110 (0%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
0 / 75 (0%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
0 / 75 (0%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
0 / 112 (0%) 
Incidence  
0 / 110 (0%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
2 / 74 (3%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
1 / 74 (1%) 
Incidence  
1 / 68 (1%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
2 / 113 (2%) 
Incidence  
0 / 117 (0%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
0 / 75 (0%) 
Incidence  
1 / 75 (1%) 
Malchow, 
198464 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
0 / 75 (0%) 
Incidence  
3 / 75 (4%) 
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Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
0 / 112 (0%) 
Incidence  
0 / 117 (0%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
2 / 74 (3%) 
Incidence  
3 / 75 (4%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 3 g every 24 hrs 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
1 / 74 (1%) 
Incidence  
1 / 75 (1%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Mortality (NR) @ 104 
wks 
NR 
No 
No 
Incidence  
0 / 112 (0%) 
Incidence  
2 / 113 (2%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Serious infections 
(abscesses) @ 104 wks 
NA 
No 
Incidence  
2 / 74 (3%) 
Incidence  
0 / 75 (0%) 
Malchow, 
198464 
Sulfasalazine + 
Prednisolone 
Route: Oral + Unknown 
Dose: 3 g every 24 hrs + 48 
mg every 24 hrs 
(6)-Methylprednisolone 
Route: Unknown 
Dose: 48 mg every 24 hrs 
Serious infections 
(abscesses) @ 6 wks 
NA 
No 
Incidence  
1 / 74 (1%) 
Incidence  
0 / 75 (0%) 
Singleton, 
197975 
Sulfasalazine + Prednisone 
Route: Oral + Unknown 
Dose: 1g per 15kg body 
weight to 5g max every 1 d 
+ every 1 d 
Placebo + Prednisone 
Route: Unknown + Oral 
Dose: NA + every 1 d 
Other infections (NR) @ 
8 wks 
Active 
No 
NR 
Incidence  
19 / 43 (44%) 
Incidence  
33 / 46 (72%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
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Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
3 / 74 (4%) 
Incidence  
5 / 77 (6%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
0 / 74 (0%) 
Incidence  
0 / 77 (0%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
3 / 74 (4%) 
Incidence  
5 / 77 (6%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
10 / 74 (14%) 
Incidence  
10 / 77 (13%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 85 (2%) 
Incidence  
5 / 77 (6%) 
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Adverse 
event 
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Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
27 / 85 (32%) 
Incidence  
10 / 77 (13%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
1 / 85 (1%) 
Incidence  
5 / 77 (6%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
1 / 85 (1%) 
Incidence  
0 / 77 (0%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 59 (3%) 
Incidence  
0 / 77 (0%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
2 / 59 (3%) 
Incidence  
5 / 77 (6%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
5 / 59 (8%) 
Incidence  
10 / 77 (13%) 
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Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
4 / 59 (7%) 
Incidence  
5 / 77 (6%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
1 / 85 (1%) 
Incidence  
3 / 74 (4%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
27 / 85 (32%) 
Incidence  
10 / 74 (14%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
1 / 85 (1%) 
Incidence  
0 / 74 (0%) 
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Summers, 
197956 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 85 (2%) 
Incidence  
3 / 74 (4%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
5 / 59 (8%) 
Incidence  
10 / 74 (14%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
4 / 59 (7%) 
Incidence  
3 / 74 (4%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 59 (3%) 
Incidence  
0 / 74 (0%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Sulfasalazine 
Route: Oral 
Dose: 1g/15kgs every 24 
hrs 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
2 / 59 (3%) 
Incidence  
3 / 74 (4%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Mortality (NR) @ 17 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
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Adverse 
event 
collection 
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Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Mortality (NR) @ 104 
wks 
Active 
Yes 
No 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Other infections (Other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 59 (3%) 
Incidence  
1 / 85 (1%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Other infections 
(Perianal abscess) @ 
104 wks 
NA 
No 
Incidence  
2 / 59 (3%) 
Incidence  
1 / 85 (1%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Other infections 
(Infections) @ 17 wks 
NA 
No 
Incidence  
5 / 59 (8%) 
Incidence  
27 / 85 (32%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 2.5 mg/kg every 24 
hrs 
Prednisone 
Route: Oral 
Dose: If CDAI<150 then 
1/4mg/kg, if CDAI = 150-
300 1/2mg/kg, if CDAI >300 
then 3/4mg/kg every 24 hrs 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
4 / 59 (7%) 
Incidence  
2 / 85 (2%) 
O'Donoghue, 
1978100 
Azathioprine 
Route: Oral 
Dose: 2 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (Not defined) 
@ 52 wks 
NR 
No 
Yes 
Incidence  
1 / 24 (4%) 
Incidence  
0 / 27 (0%) 
Goldstein, 
1967142 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user 
corticosteroids/ACTH 
Fractures (NR) NR 
No  
NA 
Incidence  
6 / 430 (1%) 
Incidence  
0 / 124 (0%) 
Goldstein, 
1967142 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user 
corticosteroids/ACTH 
Mortality (Suicide) NR 
No  
NA 
Incidence  
4 / 430 (1%) 
Incidence  
0 / 124 (0%) 
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Goldstein, 
1967142 
Corticosteroid 
Route: Unknown 
Dose: NR 
Never user 
corticosteroids/ACTH 
Other infections (NR) NR 
No  
NA 
Incidence  
95 / 430 (22%) 
Incidence  
17 / 124 (14%) 
Keshavarzian, 
2007182 
Immunomodulators + 
Infliximab 
Never user 
immunomodulators + 
Infliximab 
Route: Unknown 
Dose: NR 
Infusion and injection-
site rx  
Passive 
No  
NA 
Incidence  
57 / 322 (18%) 
OR: 0.65 (0.4 to 1.07) 
P: 0.118 vs. main 
Incidence  
31 / 125 (25%) P: 0.118 
Keshavarzian, 
2007182 
Immunomodulators + 
Infliximab 
Never user 
immunomodulators + 
Infliximab 
Route: Unknown 
Dose: NR 
Infusion and injection-
site rx 
Passive 
No  
NA 
Event rate  
91 events  
OR: 0.39 (0.3 to 0.52) 
vs. main 
Event rate  
135 events  
Feagan, 
2000105 
Methotrexate 
Route: IM 
Dose: 15 mg every 1 wks 
Placebo 
Route: IM 
Dose: NA every 1 wks 
Other infections 
(serious or not 
infections including viral 
respiratory infection and 
influenza like illness) @ 
40 wks 
Active 
No 
Yes 
Incidence  
2 / 40 (5%) 
Incidence  
3 / 36 (8%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Infusion and injection-
site rx (during infusion 
or within 2 hrs of 
infusion: dizziness, 
fever, headache, chest 
pain with flushing) 
Active 
Yes 
Incidence  
4 / 63 (6%) 
Incidence  
0 / 31 (0%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Mortality (All-cause 
mortality) @ 18 wks 
Active 
No  
NA 
Incidence  
0 / 31 (0%) 
Incidence  
0 / 31 (0%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Other infections 
(pneumonia, abscess or 
upper respiratory 
infection) @ 18 wks 
Active 
No 
Yes 
Incidence  
3 / 31 (10%) 
Incidence  
3 / 31 (10%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 5 mg/kg 
Placebo 
Route: IV 
Serious infections 
(Either pneumonia or 
abscess formation) @ 
18 wks 
Active 
No  
NA 
Incidence  
2 / 31 (6%) 
Incidence  
1 / 31 (3%) 
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Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Infusion and injection-
site rx (during infusion 
or within 2 hrs of 
infusion: dizziness, 
fever, headache, chest 
pain with flushing) 
Active 
Yes 
 Incidence  
0 / 31 (0%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Mortality (All-cause 
mortality) @ 18 wks 
Active 
No  
NA 
Incidence  
0 / 32 (0%) 
Incidence  
0 / 31 (0%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Other infections 
(pneumonia, abscess or 
upper respiratory 
infection) @ 18 wks 
Active 
No 
Yes 
Incidence  
11 / 32 (34%) 
Incidence  
3 / 31 (10%) 
Present, 
199944 
Infliximab 
Route: IV 
Dose: 10 mg/kg 
Placebo 
Route: IV 
Serious infections 
(Either pneumonia or 
abscess formation) @ 
18 wks 
Active 
No  
NA 
Incidence  
6 / 32 (19%) 
Incidence  
1 / 31 (3%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
0 / 58 (0%) 
Incidence  
1 / 101 (1%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 58 (3%) 
Incidence  
1 / 101 (1%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
17 / 58 (29%) 
Incidence  
19 / 101 (19%) 
Summers, 
197956 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
2 / 58 (3%) 
Incidence  
0 / 101 (0%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
3 / 61 (5%) 
Incidence  
1 / 101 (1%) 
D-404 
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Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 61 (3%) 
Incidence  
1 / 101 (1%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
8 / 61 (13%) 
Incidence  
19 / 101 (19%) P: NS 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
1 / 61 (2%) 
Incidence  
0 / 101 (0%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
1 / 54 (2%) 
Incidence  
1 / 101 (1%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 54 (4%) 
Incidence  
1 / 101 (1%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
17 / 54 (31%) 
Incidence  
19 / 101 (19%) P: NS 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Placebo 
Route: Oral 
Dose: NA 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
1 / 54 (2%) 
Incidence  
0 / 101 (0%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
3 / 61 (5%) 
Incidence  
2 / 58 (3%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 61 (3%) 
Incidence  
0 / 58 (0%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
8 / 61 (13%) 
Incidence  
17 / 58 (29%) 
Summers, 
197956 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
1 / 61 (2%) 
Incidence  
2 / 58 (3%) 
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Author, year Group1 Group2 Outcome (definition) 
Adverse 
event 
collection 
/ ITT Results, Group 1 Results, Group 2 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
17 / 54 (31%) 
Incidence  
17 / 58 (29%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 54 (4%) 
Incidence  
2 / 58 (3%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
1 / 54 (2%) 
Incidence  
0 / 58 (0%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Sulfasalazine 
Route: Oral 
Dose: .5 g/ 15 kg every 1 d 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
1 / 54 (2%) 
Incidence  
2 / 58 (3%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Mortality (NR) @ 104 
wks 
Active 
Yes 
Yes 
Event rate  
0 events 
Event rate  
0 events 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Other infections (total 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
2 / 54 (4%) 
Incidence  
3 / 61 (5%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Other infections (other 
abscess) @ 104 wks 
Active 
Yes  
NA 
Incidence  
1 / 54 (2%) 
Incidence  
2 / 61 (3%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Other infections 
(Infection) @ 104 wks 
Active 
Yes 
No 
Incidence  
17 / 54 (31%) 
Incidence  
8 / 61 (13%) 
Summers, 
197956 
Azathioprine 
Route: Oral 
Dose: 1 mg/kg every 24 hrs 
Prednisone 
Route: Oral 
Dose: 1-4 mg/kg every 1 d 
Serious infections 
(Perianal abscess) @ 
104 wks 
Active 
Yes 
No 
Incidence  
1 / 54 (2%) 
Incidence  
1 / 61 (2%) 
Abbreviations: 95% CI = 95% Confidence Interval; 6-MP = 6-Mercaptopurine; @ = at; AE = adverse events; AP = Acute Phase; ASA = Aminosalicylates; CD = Crohn’s Disease; 
CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; d= day; DXA Scan = bone density test also called densitometry; EQ-5D VAS = 
EuroQol (EQ-5D), a generic health index comprises a five-part questionnaire and a visual analogue self-rating scale; FACIT = functional assessment of chronic illness therapy; g = 
gram; g/kgs = gram/kilograms; h = hour; HBI = Harvey-Bradshaw Index; HR QoL= Health-related Quality of Life; hrs = hours; IBDQ = Inflammatory Bowel Disease 
Questionnaire; ICD = International Code of Diseases; ICD9 = International Code of Diseases Version 9; IFX= Infliximab; IM = intramuscular; IMM = Immunomodulator; IV= 
intravenous; IQR= inter-quartile range; ITT = intention to treat; kg = kilogram; Max. = maximum; MCS = Mental Component Score; mg = milligram; mg/d = milligram/day; 
mg/kg = milligram/kilogram; mg/mo = milligram/month; Min. = minimum; Mo/mos= month(s); NA = Not Applicable; NR= Not Reported; NS = not significant; OR: Odds Ratio; 
PCS = Physical Component Score; PGWB = Psychological General Well-Being; P = p-value; pt = point; pys = person years; QALY = Quality-Adjusted Life Year; RH = relative 
hazard; rx = reaction; SC = subcutaneous; SD = standard deviation; SE= standard error; SES-CD = Simplified Endoscopic Activity Score for Crohn’s Disease; SF = Short Form; 
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Steroid free = steroid-free remission; TNF = tumor necrosis factor alpha inhibitor; TPMT= thiopurine methyltransferase; UTD = unable to determine; VAS = visual analog scale; 
and wks = weeks; WPAI:CD = Work Productivity and Activity Impairment: Crohn's Disease.  
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Evidence Table 15. Quality of randomized controlled trials reporting on the safety of pharmacologic therapies for the management of 
moderate to severe Crohn’s disease (KQ3) 
 
Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Randomized controlled trials evaluating biologics 
Colombel, 
200782  
Yes Yes Unclear No Unclear Yes Yes Fair 
Colombel, 
200995  
Yes Yes No Yes No Yes Yes Poor 
Colombel, 
201045  
Unclear Yes Yes Yes Yes Yes Yes Good 
D'Haens, 200848  Yes Yes No Yes Yes Yes No Fair 
Feagan, 200781  Yes Yes Yes Unclear Unclear Yes Yes Fair 
Hanauer, 200286  Unclear Yes Yes Yes Unclear Yes Yes Fair 
Hanauer, 200637  Yes Yes Yes Yes Yes Yes Yes Good 
Lemann, 200646  Yes Yes Yes Yes Yes Yes UTD Good 
Mantzaris, 
200988  
Unclear No No Yes Yes No NA Fair 
Present, 199944  Yes Yes Unclear Unclear Yes Yes Yes Fair 
Rutgeerts, 
199985  
Yes Yes Yes Yes Unclear Yes Yes Fair 
Sandborn, 
200533  
Yes Yes Yes Unclear Yes Yes Yes Good 
Sandborn, 
200739  
Yes Yes Yes Yes Yes Yes Yes Good 
Sandborn, 
200738  
Yes Yes Yes Yes Yes Yes Yes Good 
Sandborn, 
200783  
Yes Yes No Yes Unclear Yes Yes Fair 
Sands, 200487  Yes Yes Yes Yes Yes Yes Yes Good 
Sands, 200735  Unclear Unclear Yes Yes Yes Yes UTD Good 
Schreiber, 
200540  
Yes Yes No Yes Yes Yes UTD Good 
Schreiber, 
200784  
Yes Yes Yes Yes Yes Yes Yes Good 
Schroder, 
200647  
Unclear Unclear Unclear No Yes No NA Fair 
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Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Targan, 200732  Unclear Yes Yes Yes Unclear Yes Yes Good 
Van Assche, 
200889  
Unclear Yes No Yes Yes No NA Good 
Winter, 200441  Unclear Unclear Yes Yes No Yes Yes Poor 
Randomized controlled trials evaluating thiopurines 
Ewe, 199354  Unclear Unclear Unclear Yes Yes Yes UTD Poor 
Lemann, 200598  Yes Yes Yes Yes Yes Yes UTD Good 
Lemann, 200646  Yes Yes Yes Yes Yes Yes UTD Good 
Mantzaris, 
2009102  
Yes Yes No No Yes UTD NA Fair 
Markowitz, 
2000192  
Yes Yes Yes Yes Yes No NA Good 
O'Donoghue, 
1978100  
Unclear Unclear Yes Yes Yes UTD NA Good 
Reinisch, 200851  Yes Unclear Unclear Yes No Yes Yes Fair 
Sandborn, 
199959  
Yes Yes Yes Unclear Yes UTD NA Fair 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Randomized controlled trials evaluating methotrexate 
Feagan, 199563  Unclear Unclear Yes Yes Unclear Yes No Fair 
Feagan, 2000105  Yes Yes Yes No No Yes No Fair 
Randomized controlled trials evaluating corticosteroids 
Campieri, 199768  Unclear Unclear Yes Unclear Yes Yes Yes Fair 
Escher, 2004190  Yes Yes Yes Yes Yes Yes Yes Good 
Levine, 2003191  Unclear Unclear Unclear Unclear Unclear UTD NA Poor 
Malchow, 198464 Unclear Yes Yes No No Yes UTD Fair 
Mantzaris, 
2003113  
Unclear Unclear No Yes Yes UTD NA Fair 
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Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Schoon, 2005185  Yes Yes No Yes No Yes Yes Poor 
Singleton, 
197975  
Unclear Unclear Yes Yes Yes No NA Good 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Tremaine, 
200265  
Yes Yes Yes No No Yes Yes Poor 
Randomized controlled trials evaluating 5-aminosalicylate acids 
Malchow, 198464  Unclear Yes Yes No No Yes UTD Fair 
Summers, 
197956  
Yes Yes No Yes No Yes NA Fair 
Summers, 
197956  
Yes Yes Unclear Yes Unclear No NA Poor 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Study Quality Criteria: Criteria for a judgment of “GOOD” (i.e. low risk of bias): These studies have the least bias and results are considered valid- A study that adheres mostly to 
the commonly held concepts of high quality including the following: a) A formal randomized controlled study; b)Clear description of the population, setting, interventions, and 
comparison groups; c) Appropriate measurements of outcomes; d) Appropriate statistical and analytic methods and reporting; e) No reporting errors; f) Low dropout rate; and g) 
Clear reporting of dropouts. Criteria for a judgment of “FAIR”: a) These studies are susceptible to some bias, but it is not sufficient to invalidate the results; b) do not meet all the 
criteria required for a rating of good qualities because they have some deficiencies, but no flaw is likely to cause major bias; and c) The study may be missing information, making 
it difficult to assess limitations and potential problems. Criteria for a judgment of “POOR” (i.e. high risk of bias): a) These studies have significant flaws that imply biases of 
various types that may invalidate the results; b) Have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.  
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Evidence Table 16. Quality of observational studies reporting on the safety of pharmacologic therapies for the management of moderate 
to severe Crohn’s disease (KQ3) 
 
Author, year 
Main outcomes / 
Patient 
characteristics / 
Interventions 
described 
Distribution of 
confounders 
described 
Study groups 
from same 
population 
Losses to 
followup 
accounted for 
Adequate 
adjustment for 
confounding 
Overall study 
quality* 
Pharmaceutical 
support / 
Company 
involvement in 
design, conduct 
or reporting 
Cohort studies evaluating biologics 
Biancone, 2006149 No / Yes / No Yes Yes No Yes Poor No / NA 
Caspersen, 
2008225 
Yes / Yes / Yes Yes Yes No No Poor Yes / UTD 
Clare, 2009181 Yes / Yes / No Yes Yes No No Poor UTD / NA 
Colombel, 2004137 Yes / No / Yes No Yes No No Poor Yes / UTD 
de Vries, 2008227 Yes / Yes / No No Yes No No Poor Yes / No 
Domenech, 
2010228 
Yes / Yes / Yes Yes Yes No No Poor Yes / No 
Fidder, 2009153 Yes / Yes / No Yes No UTD UTD Poor No / NA 
Fidder, 2009153 Yes / Yes / Yes Yes No No No Poor No / NA 
Keshavarzian, 
2007182 
Yes / Yes / Yes No Yes No No Poor Yes / Yes 
Kinney, 2003162 Yes / No / Yes No Yes No No Poor UTD / NA 
Lees, 2009145 No / No / No No No No No Poor Yes / No 
Lichtenstein, 
2006131 
Yes / Yes / Yes Yes Yes Yes Yes Good Yes / Yes 
Lichtenstein, 
2006131 
No / No / No Yes No Yes Yes Poor Yes / Yes 
Marehbian, 
2009168 
No / No / Yes No Yes Yes No Poor Yes / Yes 
Mortimore, 2001174 No / Yes / Yes No Yes No No Poor UTD / NA 
Moss, 2008148 Yes / Yes / Yes Yes Yes Yes Yes Good Yes / No 
Moss, 2010147 No / No / No No Yes No UTD Poor Yes / No 
Orlando, 2005128 No / Yes / No No Yes No No Poor No / NA 
Ricart, 2001138 No / Yes / Yes Yes Yes No No Poor Yes / No 
Rudolph, 2008175 No / Yes / Yes Yes Yes Yes Yes Fair UTD / NA 
Rudolph, 2008175 No / Yes / Yes Yes Yes Yes No Fair UTD / NA 
Schneeweiss, 
2009230 
Yes / Yes / Yes Yes Yes Yes Yes Good Yes / No 
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Author, year 
Main outcomes / 
Patient 
characteristics / 
Interventions 
described 
Distribution of 
confounders 
described 
Study groups 
from same 
population 
Losses to 
followup 
accounted for 
Adequate 
adjustment for 
confounding 
Overall study 
quality* 
Pharmaceutical 
support / 
Company 
involvement in 
design, conduct 
or reporting 
Seiderer, 2004173 No / Yes / Yes No Yes No No Poor UTD / NA 
Thayu, 2010199 Yes / Yes / UTD Yes UTD Yes Yes Fair No / NA 
Vermeire, 2007154 No / Yes / Yes No Yes Yes No Poor Yes / No 
Cohort studies evaluating thiopurines 
Beaugerie, 2009130 Yes / Yes / Yes Yes Yes Yes Yes Good Yes / No 
Campbell, 2001146 No / No / Yes Yes UTD No No Poor  UTD 
Farrell, 2000231 No / No / Yes No Yes No No Poor UTD / NA 
Fraser, 2002232 No / No / No Yes Yes UTD UTD Poor UTD / NA 
Hutfless, 2007151 Yes / Yes / Yes Yes Yes UTD Yes Good UTD / NA 
Kane, 2008141 Yes / No / Yes Yes No No No Poor No / NA 
Lees, 2009144 Yes / Yes / Yes Yes Yes No No Poor Yes / UTD 
Lewis, 2001136 Yes / Yes / Yes Yes Yes Yes No Poor Yes / UTD 
Lichtenstein, 
2006131 
Yes / Yes / Yes Yes Yes Yes Yes Good Yes / Yes 
Lichtenstein, 
2006131 
No / No / No Yes No Yes Yes Poor Yes / Yes 
Maher, 2009176 Yes / No / No No UTD No No Poor UTD / NA 
Marehbian, 
2009168 
No / No / Yes No Yes Yes No Poor Yes / Yes 
Schneeweiss, 
2009230 
Yes / Yes / Yes Yes Yes Yes Yes Good Yes / No 
Seksik, 2009155 No / Yes / Yes Yes UTD Yes No Poor No / NA 
Shah, 2008156 No / No / Yes No Yes No No Poor No / NA 
Tay, 2003233 Yes / Yes / Yes Yes Yes Yes Yes Good UTD / NA 
Cohort studies evaluating methotrexate 
Thayu, 2010199 Yes / Yes / UTD Yes UTD Yes Yes Fair No / NA 
Cohort studies evaluating corticosteroids 
Alemzadeh, 
2002200 
Yes / Yes / Yes No UTD UTD No Poor No / NA 
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Author, year 
Main outcomes / 
Patient 
characteristics / 
Interventions 
described 
Distribution of 
confounders 
described 
Study groups 
from same 
population 
Losses to 
followup 
accounted for 
Adequate 
adjustment for 
confounding 
Overall study 
quality* 
Pharmaceutical 
support / 
Company 
involvement in 
design, conduct 
or reporting 
Goldstein, 1967142 No / No / Yes No No No No Poor UTD / NA 
Hutfless, 2007151 Yes / Yes / Yes Yes Yes UTD Yes Good UTD / NA 
Levine, 2002198 Yes / Yes / Yes Yes Yes UTD Yes Fair No / NA 
Lewis, 2001136 Yes / Yes / Yes Yes Yes Yes No Poor Yes / UTD 
Lichtenstein, 
2006131 
Yes / Yes / Yes Yes Yes Yes Yes Good Yes / Yes 
Lichtenstein, 
2006131 
No / No / No Yes No Yes Yes Poor Yes / Yes 
Saha, 1998197 Yes / Yes / Yes No Yes UTD UTD Poor No / NA 
Siffledeen, 2007127 Yes / Yes / Yes Yes Yes UTD No Poor Yes / UTD 
Thayu, 2010199 Yes / Yes / UTD Yes UTD Yes Yes Fair No / NA 
Cohort studies evaluating 5-aminosalicylate acids 
Hutfless, 2007151 Yes / Yes / Yes Yes Yes UTD Yes Good UTD / NA 
Lewis, 2001136 Yes / Yes / Yes Yes Yes Yes No Poor Yes / UTD 
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Case-control studies 
Armstrong, 2010133 Yes / Yes / Yes Yes Yes No Yes Poor No / NA 
Bernstein, 2003186 Yes / Yes / Yes Yes No No No Poor UTD / NA 
Gupta, 2006135 Yes / Yes / Yes Yes Yes Yes Yes Good No / No 
Hutfless, 2008152 Yes / Yes / Yes Yes Yes Yes Yes Good No / NA 
Lashner, 1992143 Yes / Yes / Yes Yes Yes Yes Yes Good UTD / UTD 
Lewis, 2001136 Yes / Yes / Yes Yes Yes Yes No Poor Yes / UTD 
Long, 2010170 Yes / Yes / Yes Yes Yes Yes Yes Good No / NA 
Tang, 2010172 Yes / Yes / Yes No No No No Poor Yes / UTD 
Terdiman, 2007171 No / No / No No UTD Yes No Poor Yes / UTD 
Toruner, 2008139 Yes / Yes / Yes Yes Yes Yes Yes Good UTD / NA 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Overall study quality: Good indicates all "YES" responses in reporting, selection bias, and confounding domains of questionnaire. Fair indicates mostly "YES" for Reporting and 
all "YES" for Selection Bias and Confounding bias. Poor indicates at least 1 "NO" or "Unable to determine" for selection or confounding bias. 
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Evidence Table 17. Study design characteristics of randomized controlled trials and observational studies reporting on the 
effectiveness of pharmacologic therapies to prevent post-operative recurrence in Crohn’s disease in terms of patient-reported 
outcomes (KQ4) 
 
Author, 
year Study design1 
Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm Inclusion criteria 
Myrelid, 
2006189 
Prospective 
cohort 
Start year: 1989 
 
Median followup 
duration: 84.7 
months 
Europe 
 
Single center 
NA CD only, previous surgery , previous use of azathioprine or 6-MP, 
other criteria 
Reinisch, 
2010188 
RCT, parallel 
arms 
Start year: 2002 
 
Duration of 
assigned 
treatment: 52 
weeks 
Europe, Asia 
 
Multicenter 
Yes 
 
No 
Adults, CD only, previous surgery (resection of terminal ileum and 
partial colectomy with ileoclonic anastomosis), CDAI (<200), in 
remission for >1 weeks, no use of antibiotics, TNF-alpha inhibitors, 
corticosteroids, immunomodulators, NSAIDs other than paracetamol 
or low-dose aspirin, moderate-severe disease, no short bowel 
syndrome, smokers and non smokers, other criteria 
Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; NA = not applicable; NSAID = non-steroidal anti-inflammatory drug; 
RCT = randomized controlled trial; TNF = tumor necrosis factor 
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of pharmacologic therapies to prevent post-operative recurrence in Crohn’s disease in terms of patient-reported outcomes (KQ4) 
 
Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Myrelid, 2006189 Azathioprine, 28 
Route: Unknown 
Dose: NR 
Male, %: 35.7 
 
Race NR 
 
Smoking, % 
Smoker, 10.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 13 
Min: 0 
Max: 34 
 
Age at 
enrollment 
Median: 34.5 
Min: 17 
Max: 71 
Severity NR 
 
Location, % 
Ileal: 7.1 
Ileo-colonic: 71.4 
Colonic: 21.4 
Perianal: 50 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Thiopurines: 100 NR NR 
Myrelid, 2006189 azathioprine or 
6-MP intolerant 
group, 14 
Male, %: 35.7 
 
Race NR 
 
Smoking, % 
Smoker, 0 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 12.5 
Min: 0 
Max: 36 
 
Age at 
enrollment 
Median: 38 
Min: 19 
Max: 64 
Severity NR 
 
Location, % 
Ileal: 28.6 
Ileo-colonic: 57.1 
Colonic: 14.3 
Perianal: 42.9 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR Immunomodulat
ors: 100 
NR 
Reinisch, 
2010188 
Mesalamine 
(Salofalk), 37 
Route: Oral 
Dose: 4 g every 
day 
Male, %: 54.1 
 
Race NR 
 
Smoking, % 
Smoker, 54.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 36 
Severity NR 
 
Location NR 
 
Behavior, % 
Inflammatory: 
16.2 
Stricturing: 40.5 
Penetrating: 43.2 
 
CRP NR 
CDAI 
Mean: 102 
Median: 93 
Min: -10 
Max: 204 
 
Screening 
Rutgeerts score 
Mean: 2.97 
 
IBDQ 
Mean: 175.2 
NSAIDs: 27 5ASA: 73 
 
TNF-alpha 
inhibitors: 2.7 
 
Corticosteroids: 
78.3 
 
Thiopurines: 
21.6 
 
other 
NR 
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Author, year Intervention, n Demographics Age, in years 
Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Reinisch, 
2010188 
Azathioprine, 41 
Route: Oral 
Dose: 2.0-2.5 
mg/kg every day 
Male, %: 58.5 
 
Race NR 
 
Smoking, % 
Smoker, 41.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 35.5 
Severity NR 
 
Location NR 
 
Behavior, % 
Inflammatory: 
9.8 
Stricturing: 24.4 
Penetrating: 65.9 
 
CRP 
Mean: 0.59 
CDAI 
Mean: 70 
Median: 72 
Min: -29 
Max: 209 
 
Screening 
Rutgeerts Score 
Mean: 3.17 
 
IBDQ 
Mean: 191.2 
NSAIDS: 29.3 5ASA: 78 
 
TNF-alpha 
inhibitors: 4.9 
 
Corticosteroids: 
78 
 
Thiopurines: 
14.6 
 
other 
NR 
Abbreviations: 5-ASA = 5-aminosalicylic acid; CD = Crohn’s disease; CRP = C-reactive protein; IBDQ = Inflammatory Bowel Disease Questionnaire; Max. = maximum; Min. = 
minimum; NR = not reported; NSAIDs = non-steroidal anti-inflammatory drug; TNF = tumor necrosis factor 
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Evidence Table 19. Effectiveness of pharmacologic therapies to prevent post-operative recurrence in Crohn’s disease in terms of 
patient-reported outcomes (KQ4) 
 
Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Reinisch, 
2010188 
Azathioprine 
Route: Oral 
Dose: 2.0-2.5 mg/kg every 
1 days 
Mesalamine (Salofalk) 
Route: Oral 
Dose: 4 g every 1 days 
HR QoL (IBDQ) @ 
52 weeks 
NA 
Yes 
F-B: Mean, 9 (SD, 17.7) 
G1-G2: -4 
F-B: Mean, 5 (SD, 27.4) 
P: 0.4565 
G1-G2: -4 
Myrelid, 
2006189 
Azathioprine 
Route: Unknown 
Dose: NR 
Azathioprine or 6-MP 
intolerant group 
HR QoL (Patients' 
perceived health 
assessed by visual 
analogue scale ) @ 
21.3 weeks 
Active 
No  
NA 
F: Mean, 65.4 (95% CI, 0 
to 99.4)  
F: Mean, 55.5 (95% CI, 
14.6 to 98.6) P: NS 
6-MP = 6-mercaptopurine; AE = adverse events; CI = confidence interval; F-B = change score; g = grams; G1-G2 = change score in group 1 minus the change score in group 2;  
HR QoL = health-related quality of life; IBDQ = Inflammatory Bowel Disease Questionnaire; ITT = intention-to-treat analysis; mg/kg = milligrams per kilogram;  
NA = not applicable; NR = not reported; NS = not significant; SD = standard deviation 
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Evidence Table 20. Quality of randomized controlled trials reporting on the effectiveness of pharmacologic therapies to prevent post-
operative recurrence in Crohn’s disease in terms of patient-reported outcomes (KQ4) 
 
Author, year 
Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate Blinding 
Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Reinisch, 
2010188  
Yes Yes  Yes Yes No NA Good 
Abbreviations: NA = not applicable  
*Study Quality Criteria: Criteria for a judgment of “GOOD” (i.e. low risk of bias): These studies have the least bias and results are considered valid- A study that adheres mostly to 
the commonly held concepts of high quality including the following: a) A formal randomized controlled study; b)Clear description of the population, setting, interventions, and 
comparison groups; c) Appropriate measurements of outcomes; d) Appropriate statistical and analytic methods and reporting; e) No reporting errors; f) Low dropout rate; and g) 
Clear reporting of dropouts. Criteria for a judgment of “FAIR”: a) These studies are susceptible to some bias, but it is not sufficient to invalidate the results; b) do not meet all the 
criteria required for a rating of good qualities because they have some deficiencies, but no flaw is likely to cause major bias; and c) The study may be missing information, making 
it difficult to assess limitations and potential problems. Criteria for a judgment of “POOR” (i.e. high risk of bias): a) These studies have significant flaws that imply biases of 
various types that may invalidate the results; b) Have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.  
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Evidence Table 21. Number of studies and subjects, strength of evidence domains, magnitude of effect, and 
strength of evidence for the comparative effectiveness and safety of therapies among pediatrics 
 
Number of 
Studies 
(Participants) 
Domains Pertaining to Strength of Evidence Strength of 
Evidence 
 Risk of Bias Consistency Directness Precision Other 
concerns 
 
INDUCTION OF REMISSION 
Combination of a 6-mercaptopurine and prednisone versus prednisone alone 
1192 
(55)  
Moderate NA Direct Imprecise  Low  
Budesonide versus prednisolone 
1190 
(48) 
Low NA Direct Imprecise  Moderate 
Prednisone and mesalamine versus budesonide and mesalamine 
1191 
(33) 
High NA Direct Imprecise  Low 
MAINTAIN REMISSION 
Mesalamine versus placebo 
1194 
(122) 
High NA Direct Imprecise  Low 
 
SERIOUS INFECTIONS 
6-Mercaptopurine and prednisone versus prednisone alone 
1192 
(55) 
Moderate NA Direct Imprecise  Low 
OTHER INFECTIONS 
Prednisone versus budesonide 
1198 
(120) 
High NA Direct Imprecise  Low 
Budesonide versus prednisolone 
1190 
(48) 
Low NA Direct Imprecise  Moderate 
Prednisone and mesalamine versus budesonide and mesalamine 
1191 
(33) 
High NA 
 
Direct Imprecise  Low 
HEIGHT CHANGE 
6-mercaptopurine versus placebo 
1192 
(55) 
Moderate NA Direct Imprecise  Low 
Prednisone versus placebo 
4196 197 199 200 
(277)  
High NA Direct Imprecise  Low 
Prednisone versus budesonide 
1198 
(120) 
High NA 
 
Direct Imprecise  Low 
WEIGHT CHANGE 
Infliximab versus placebo 
1199  
(78) 
High NA Direct Imprecise  Low 
Methotrexate versus placebo 
1199 
(78) 
High NA Direct Imprecise  Low 
Corticosteroids versus placebo 
1199 
(78) 
High NA Direct Imprecise  Low 
Prednisone versus budesonide 
1198 
(120) 
High NA Direct Imprecise  Low 
RCT = randomized controlled trial; NA = not applicable, consistency is not applicable when a single study reported comparison 
and outcome 
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Evidence Table 21. Number of studies and subjects, strength of evidence domains, magnitude of effect, and 
strength of evidence for the comparative effectiveness and safety of therapies among pediatrics 
 
The strength of the evidence was defined as follows: High = High confidence that the evidence reflects the true effect. Further 
research is unlikely to change our confidence in the estimate of the effect. Moderate = Moderate confidence that the evidence 
reflects the true effect. Further research may change our confidence in the estimate of the effect and may change the estimate. 
Low = Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the 
estimate of the effect and is likely to change the estimate. Insufficient = Evidence is unavailable.  
N=total N for all studies in each comparison. This is not necessarily the N for analysis because the N for analysis often was not 
stated for each outcome. 
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Evidence Table 22. Study design characteristics of randomized controlled trials and observational studies reporting on the 
effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Study design1 Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm 
Inclusion criteria 
Alemzadeh, 
2002200 
Retrospective 
cohort 
Start year: NR 
 
Followup duration: 
NR 
Europe 
 
Single center 
NA Pediatrics, CD only, other criteria 
Beaugerie, 
2009130 
Prospective 
cohort 
Start year: 2004 
 
Median followup 
duration: 35 
months 
Europe 
 
Multicenter 
NA Pediatrics, adults, IBD, other criteria 
Candy, 
199553 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Africa 
 
Single center 
No 
 
 
Pediatrics, adults, CD only, no previous surgery (extensive surgery for 
Crohn's disease), CDAI (>200), not pregnant, not nursing, other criteria 
Cezard, 
2009194 
RCT, parallel 
arms 
Start year: 1991 
 
Duration of 
assigned 
treatment: 1 years 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, CD only, HBI (>5), no use of 5-aminosalicylate acids, 
thiopurines, methotrexate, active disease, other criteria 
Crombe, 
2011226 
EPIMAD 
Retrospective 
cohort 
Start year: 1988 
 
Median followup 
duration: 32 
months 
Europe 
 
Multicenter 
NA Pediatrics, CD only, previous use of infliximab, other criteria 
de Vries, 
2008227 
Other study 
design 
Start year: 1999 
 
Median followup 
duration: 9 years 
Europe 
 
Single center 
NA Pediatrics, adults, IBD, no use of infliximab 
D'Haens, 
200848 
RCT, parallel 
arms 
Start year: 2001 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
Yes 
 
Yes 
Pediatrics, adults, CD only, CDAI (>200), no use of corticosteroids, 
antimetabolites, biological agents, active disease, not pregnant, no 
obstructive symptoms with strictures, no history of TB, no cancer, other 
criteria 
Escher, 
2004190 
RCT, parallel 
arms 
Start year: 1998 
 
Duration of 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, CD only, CDAI (>200), no use of corticosteroids, thiopurines, 
active disease, other criteria 
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Evidence Table 22. Study design characteristics of randomized controlled trials and observational studies reporting on the 
effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Study design1 Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm 
Inclusion criteria 
assigned 
treatment: 12 
weeks 
Griffiths, 
1993221 
RCT, crossover Start year: 1988 
 
Duration of 
assigned 
treatment: 8 weeks 
North America 
 
Single center 
No 
 
 
Pediatrics, CD only, HBI (>4), other criteria 
Issenman, 
1993196 
Prospective 
cohort 
Start year: NR 
Mean followup 
duration: 2 years 
North America 
 
Single center 
NA Pediatrics, CD only, males, active disease 
Lees, 
2009145 
Retrospective 
cohort 
Start year: 1999 
 
Median followup 
duration: 2.4 years 
Europe 
 
Multicenter 
NA Pediatrics, adults, IBD, not pregnant, other criteria 
Levine, 
2002198 
Case-control 
study 
Start year: NR 
 
Followup duration: 
NR 
Israel 
 
Multicenter 
NA Pediatrics, CD only, PCDAI (12.5-40), no use of thiopurines, mild-
moderate disease, other criteria 
Levine, 
2003191 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 12 
weeks 
Israel 
 
Multicenter 
No 
 
 
Pediatrics, CD only, no previous surgery (in past 6 weeks), PCDAI (12.5-
40), no use of corticosteroids, thiopurines, active disease, other criteria 
Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Retrospective 
cohort 
Start year: 2003  
 
Mean followup 
duration: 12 
months 
Europe 
 
Single center 
NA Pediatrics, CD only, other criteria 
Markowitz, 
2000192 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
treatment: 18 
months 
US 
 
Multicenter 
No 
 
 
Pediatrics, CD only, moderate-severe disease, other criteria 
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Evidence Table 22. Study design characteristics of randomized controlled trials and observational studies reporting on the 
effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Study design1 Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm 
Inclusion criteria 
Mate-
Jimenez, 
200052 
RCT, parallel 
arms 
Start year: 1994 
 
Duration of 
assigned 
treatment: 26.5 
months 
Europe 
 
Single center 
No 
 
 
Pediatrics, adults, IBD, no previous surgery (extensive surgery), previous 
use of corticosteroids, not pregnant, not nursing, using adequate 
contraception, no abscess, other criteria 
Present, 
198060 
RCT, parallel 
arms, crossover 
Start year: NR 
 
Duration of 
assigned 
treatment: 1 years 
US 
 
Single center 
Yes 
 
No 
Pediatrics, adults, CD only, active disease, other criteria 
Rhodes, 
197161 
RCT, crossover Start year: NR 
 
Duration of 
assigned 
treatment: 2 
months 
Location: NR 
 
Number of 
centers NR 
Yes 
 
No 
Pediatrics, adults, CD only 
Russell, 
2011236 
Prospective 
cohort 
Start year: 2008 
 
Median followup 
duration: 0.8 years 
Europe 
Multicenter 
NA Pediatrics, IBD, other criteria 
Saha, 
1998197 
Prospective 
cohort 
Start year: 1982 
 
Followup duration: 
NR 
Europe 
 
Single center 
NA Pediatrics, IBD 
Thayu, 
2010199 
Case-control 
study 
Start year: NR  
 
Mean followup 
duration: 43 
months 
US 
 
Single center 
NA Pediatrics, CD only, no use of any medications affecting growth and 
development, other criteria 
Thayu, 
2010237 
CHOP 
Prospective 
cohort 
Start year: NR US 
Single center 
NA Pediatrics, CD only, other criteria 
Thomson, 
1990224 
RCT, parallel 
arms 
Start year: NR 
 
Duration of 
assigned 
North America, 
Europe, Africa 
Multicenter 
Yes 
Yes 
Pediatrics, CD only, CDAI (<150), no use of azathioprine, metronidazole, 
no ostomy, no obstructive symptoms with strictures, other criteria 
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Evidence Table 22. Study design characteristics of randomized controlled trials and observational studies reporting on the 
effectiveness of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Study design1 Start year of 
enrollment / 
Length of 
followup 
Location / 
Multicenter 
Adherence 
reported / 
Adherence 
>80% in each 
study arm 
Inclusion criteria 
treatment: 12 
months 
Van Assche, 
200889 
RCT, parallel 
arms 
Start year: 2004 
 
Duration of 
assigned 
treatment: 2 years 
Europe 
 
Multicenter 
No 
 
 
Pediatrics, adults, CD only, previous use of methotrexate, infliximab, 
immunosuppressives (azathioprine/6-MP or methotrexate), perianal 
fistulizing, not pregnant, not nursing, other criteria 
Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; IBD = irritable bowel disease; PCDAI 
= Pediatric Crohn’s Disease Activity Index; NR = not reported; RCT = randomized controlled trial; TB = tuberculosis; US = United States 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Alemzadeh, 
2002200 
Placebo, 108 Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Alemzadeh, 
2002200 
Corticosteroid, 
27 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Beaugerie, 
2009130 
Never user 
thiopurine, 
10810 
Dose: NA 
Male, %: 47 
 
Race NR 
 
Smoking NR 
 
CD, %: 48 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 42.3 
Severity NR 
 
Location, % 
Ileal: 33.3 
Colonic: 30.5 
Perianal: 7.3 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors: 0.6 
 
Methotrexate: 0.4 
 
Cyclosporin, 
mycophenolate 
mofetil, or 
cyclophosamide: 
0.6 
TNF-alpha 
inhibitors: 0.9 
 
Methotrexate: 
0.6 
NR 
Beaugerie, 
2009130 
Thiopurine, 8676 
Dose: NR 
Male, %: 43 
 
Race NR 
 
Smoking NR 
 
CD, %: 76.1 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Ileal: 53.3 
Colonic: 59.3 
Perianal: 24.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
TNF-alpha 
inhibitors: 10 
 
Methotrexate: 7.5 
 
Cyclosporin, 
mycophenolate 
mofetil, or 
cyclophosamide: 
1.6 
TNF-alpha 
inhibitors: 21.3 
 
Methotrexate: 
15.3 
NR 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Candy, 
199553 
Azathioprine + 
Prednisolone, 33 
Route: Oral + 
Oral 
Dose: 2.5 mg/kg 
every day + 1 
mg/kg every day 
Male, %: 21 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 2.6 
Min: 0.1 
Max: 19.3 
 
Age at 
enrollment 
Median: 33.9 
Min: 15 
Max: 60 
Severity, % 
Severe disease: 
52 
 
Location, % 
Ileal: 24.2 
Ileo-colonic: 60.6 
Colonic: 15.2 
 
Behavior NR 
 
CRP 
Median: 5.4 
Min: 2.9 
Max: 7.3 
CDAI 
Median: 301 
Min: 264 
Max: 358 
Corticosteroids: 
100 
 
Thiopurines: 100 
corticosteroids in 
previous 6-12 
mo: 67 
 
no previous 
corticosteroids: 
15 
 
: 15 
NR 
Candy, 
199553 
Placebo + 
Prednisolone, 30 
Route: Oral + 
Oral 
Dose: NA + 1 
mg/kg every day 
Male, %: 37 
 
Race NR 
 
Smoking, % 
Smoker, 67 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 3.7 
Min: 0.1 
Max: 18.7 
 
Age at 
enrollment 
Median: 31.8 
Min: 21 
Max: 62 
Severity, % 
Severe disease: 
43 
 
Location, % 
Ileal: 20 
Ileo-colonic: 63.3 
Colonic: 16.7 
 
Behavior NR 
 
CRP 
Median: 3.9 
Min: 2.8 
Max: 5.3 
CDAI 
Median: 282 
Min: 240 
Max: 356 
Corticosteroids: 
100 
Corticosteroids 
 
corticosteroids in 
the last 6 
months: 63 
 
no previous 
corticosteroids: 7 
 
: 7 
NR 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Cezard, 
2009194 
Placebo, 62 Male, %: 58 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.6 
 
Age at 
enrollment 
Mean: 11.6 
Severity NR 
 
Location, % 
Ileal: 11 
Ileo-colonic: 69 
Colonic: 19 
Perianal: 31 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 0.9 
NR NR NR 
Cezard, 
2009194 
Mesalamine 
(Pentasa), 60 
Dose: 50 mg/kg 
every day 
Male, %: 62 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 1.1 
 
Age at 
enrollment 
Mean: 12 
Severity NR 
 
Location, % 
Ileal: 13 
Ileo-colonic: 68 
Colonic: 18 
Perianal: 33 
 
Behavior NR 
 
CRP NR 
HBI 
Mean: 0.7 
NR NR NR 
Crombe, 
2011226 
EPIMAD 
Infliximab + 
immunomodulato
r, 103 Route: 
Unknown + 
Unknown Dose: 
5 mg/kg every 8 
weeks + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR  Disease activity 
index NR 
5ASA 
Corticosteroids 
NR NR 
Crombe, 
2011226 
EPIMAD 
Infliximab + no 
IMM, 17 Route: 
Unknown Dose: 
NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
NR NR Disease activity 
index NR 
5ASA 
Corticosteroids 
NR NR 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
de Vries, 
2008227 
Infliximab + 
Immunomodulat
or, 93 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
de Vries, 
2008227 
Infliximab + No 
corticosteroids, 
45 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulator
s 
NR NR 
de Vries, 
2008227 
Infliximab + No 
immunomodulato
r, 54 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids NR NR 
de Vries, 
2008227 
Infliximab + 
Corticosteroid, 
102 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Immunomodulator
s 
NR NR 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
D'Haens, 
200848 
Budesonide + 
(6)-
Methylprednisolo
ne, 64 
Route: Oral + 
Oral 
Dose: 9 mg 
every days + 32 
mg every day 
Male, %: 42.2 
 
Race, % 
W: 95.3 
 
Smoking, % 
Current smoker, 
35.9 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 28.7 
Severity NR 
 
Location, % 
Ileo-colonic: 43.8 
Colonic: 32.8 
 
Behavior NR 
 
CRP 
Median: 25 
CDAI 
Mean: 306 
 
IBDQ 
Mean: 136 
TNF-alpha 
inhibitors 
 
Corticosteroids 
 
Methotrexate 
 
Thiopurines 
 
Budesonide 
5ASA: 3.1 NR 
D'Haens, 
200848 
Infliximab + 
Azathioprine, 65 
Route: IV + Oral 
Dose: 5 mg/kg + 
2-2.5 mg/kg 
Male, %: 33.8 
 
Race, % 
W: 98.5 
 
Smoking, % 
Current smoker, 
43.1 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 30 
Severity NR 
 
Location, % 
Ileo-colonic: 47.7 
Colonic: 30.8 
 
Behavior NR 
 
CRP 
Median: 19 
CDAI 
Mean: 330 
 
IBDQ 
Mean: 122 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Azathioprine: 100 
 
Methylprednisolon
e 
5ASA: 4.6 NR 
Escher, 
2004190 
Prednisolone, 26 
Dose: 1 mg/kg 
every day 
Male, %: 69.2 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.8 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 26.9 
Ileo-colonic: 65.4 
Colonic: 3.8 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 268 
 
PCDAI 
Mean: 45 
NR NR NR 
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Evidence Table 23. Population characteristics of randomized controlled trials and observational studies reporting on the effectiveness 
of pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Intervention, n Demographics Age, in years Disease 
characteristics 
Disease activity 
index 
Medications 
taken during 
study, % 
Medications 
taken BEFORE 
study, % 
Medications 
taken FOR 
INDUCTION, % 
Escher, 
2004190 
Budesonide, 22 
Dose: 9 mg 
every day 
Male, %: 31.8 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 0.6 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 59.1 
Ileo-colonic: 31.8 
Colonic: 9.1 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 239 
 
PCDAI 
Mean: 39 
NR NR NR 
Griffiths, 
1993221 
Mesalamine 
(Pentasa), 7 
Route: Oral 
Dose: 50 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 188.3 
 
HBI 
Mean: 3.71 
NR NR NR 
Griffiths, 
1993221 
Placebo, 6 
Route: Oral 
Dose: NA every 
day 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 182.5 
 
HBI 
Mean: 3.5 
NR NR NR 
Issenman, 
1993196 
Discontinued 
corticosteroids, 8 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD, %: 212.5 
Age at diagnosis 
Mean: 13.2 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.2 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Issenman, 
1993196 
Prednisone, 9 
Route: Oral 
Dose: 2 mg/kg 
every days 
Male, %: 100 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
Mean: 14.5 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.5 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 64.1 
Corticosteroids: 
100 
5ASA NR 
Lees, 
2009145 
Adalimumab, 30 Male, %: 36.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Median: 32.3 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 
2009145 
Infliximab + 
Azathioprine, 51 
Route: IV 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 
2009145 
Infliximab + 
Corticosteroid, 
32 
Route: IV + 
Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Lees, 
2009145 
Infliximab + 
Azathioprine/6-
MP/methotrexate 
+ corticosteroids, 
55 
Route: IV + 
Unknown 
Dose: NR + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Lees, 
2009145 
Infliximab + 
Never user 
concomitant 
azathioprine/6-
MP/methotrexate
/corticosteroids, 
19 
Route: IV 
Dose: NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 100 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Levine, 
2002198 
Budesonide, 62 
Dose: 9 mg 
every day 
Male, %: 59.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.1 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 25.8 
NR immunomodulato
rs: 29 
NR 
Levine, 
2002198 
Prednisone, 58 
Dose: 40 mg 
every day 
Male, %: 60.3 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.7 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 29.6 
NR immunomodulato
rs: 20.6 
NR 
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Levine, 
2003191 
Prednisone + 
Mesalamine, 14 
Dose: 40 mg 
every day + 3-4 
g every day 
Male, %: 50 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 14.15 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 28.9 
NR NR NR 
Levine, 
2003191 
Budesonide + 
Mesalamine, 19 
Dose: 3 mg 
every 8 hours + 
3-4 g every day 
Male, %: 68.4 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.8 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 29.3 
NR NR NR 
Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Infliximab + no 
steroid, 13 
Route: IV Dose: 
5 mg/kg every 2 
weeks 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Methotrexate NR NR 
Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Infliximab + 
Methotrexate, 21 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Corticosteroids NR NR 
Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Infliximab + no 
MTX, 7 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Corticosteroids NR NR 
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Malik, 
2011229 
Royal 
Hospital Sick 
Children 
Infliximab + 
steroid, 15 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Methotrexate NR NR 
Markowitz, 
2000192 
6-MP + 
Prednisone, 27 
Dose: 1.5 mg/kg 
every day + 40 
mg every day 
Male, %: 55.6 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13 
Severity NR 
 
Location, % 
Ileal: 14.8 
Ileo-colonic: 70.4 
Colonic: 14.8 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 46.7 
 
HBI 
Mean: 7.7 
 
partial HB 
Mean: 6.6 
NR NR NR 
Markowitz, 
2000192 
Placebo + 
Prednisone, 28 
Dose: 40 mg 
every day 
Male, %: 64.3 
 
Race, % 
W: 93 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment 
Mean: 13.4 
Severity NR 
 
Location, % 
Ileal: 3.6 
Ileo-colonic: 78.6 
Colonic: 17.9 
 
Behavior NR 
 
CRP NR 
PCDAI 
Mean: 44.7 
 
HBI 
Mean: 7.4 
 
partial HB 
Mean: 6.5 
NR NR NR 
Mate-
Jimenez, 
200052 
6-MP, 16 
Route: Oral 
Dose: 1.5 mg/kg 
every day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 75 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 37.5 
Perianal: 25 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 191 
Corticosteroids: 
100 
NR NR 
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Mate-
Jimenez, 
200052 
Methotrexate, 15 
Route: Oral 
Dose: 15 mg 
every 1 week 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 66.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 4.3 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 40 
Perianal: 20 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 200 
Corticosteroids: 
100 
NR NR 
Mate-
Jimenez, 
200052 
5-ASA, 7 
Route: Oral 
Dose: 3 g every 
day 
Gender NR 
 
Race NR 
 
Smoking, % 
Smoker, 85.7 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 3.5 
 
Age at 
enrollment NR 
Severity NR 
 
Location, % 
Colonic: 14.3 
Perianal: 14.3 
 
Behavior NR 
 
CRP NR 
CDAI 
Mean: 215 
Corticosteroids: 
100 
NR NR 
Present, 
198060 
6-MP 
Route: Unknown 
Dose: 1.5 mg/kg 
every 24 hours 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Present, 
198060 
Placebo 
Route: Oral 
Dose: NA 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Rhodes, 
197161 
Azathioprine, 16 
Route: Oral 
Dose: 4 mg/kg 
every 24 hours 
Male, %: 75 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 14 
 
Age at 
enrollment 
Min: 14 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 37.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Sulfasalazine: 
18.8 
 
Prednisolone: 18.8 
NR NR 
Rhodes, 
197161 
Placebo, 16 
Route: Oral 
Dose: NA 
Male, %: 75 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Min: 1 
Max: 16 
 
Age at 
enrollment 
Min: 14 
Max: 69 
Severity NR 
 
Location, % 
Ileal: 50 
Ileo-colonic: 37.5 
Colonic: 12.5 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
Corticosteroids: 
18.8 
 
Sulfasalazine: 
18.8 
NR NR 
Russell, 
2011236 
Adalimumab + 
no IMM (Thio or 
MTX) +/- steroid, 
24 Route: 
Unknown + 
Unknown Dose: 
40 mg every 15 
days + NR 
Gender NR 
 
Race NR 
 
Smoking NR 
 
CD, %: 283.3 
NR NR Disease activity 
index NR 
Corticosteroids TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
Russell, 
2011236 
Adalimumab + 
IMM (Thio or 
MTX) +/- steroid, 
46 Route: 
Unknown + 
Unknown Dose: 
NR 
Gender NR 
Race NR 
Smoking NR 
CD NR 
NR NR Disease activity 
index NR 
Corticosteroids TNF-alpha 
inhibitors 
Corticosteroids 
Methotrexate 
Thiopurines 
Immunomodulat
ors 
NR 
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Saha, 
1998197 
Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Saha, 
1998197 
Prednisone Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 
2010199 
Infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 
2010199 
Placebo Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
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Thayu, 
2010199 
Corticosteroid Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 
2010199 
Methotrexate Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
NR 
 
Age at 
enrollment NR 
Severity NR 
 
Location NR 
 
Behavior NR 
 
CRP NR 
Disease activity 
index NR 
NR NR NR 
Thayu, 
2010237 
CHOP 
Corticosteroid Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Corticosteroids: 
100 
NR NR 30 
Thayu, 
2010237 
CHOP 
No infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
NR NR NR 30 
Thayu, 
2010237 
CHOP 
No MTX Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
NR NR NR 30 
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Thayu, 
2010237 
CHOP 
Infliximab Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
infliximab: 100 NR NR 30 
Thayu, 
2010237 
CHOP 
Methotrexate Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
Methotrexate: 100 NR NR 30 
Thayu, 
2010237 
CHOP 
No steroids Gender NR 
 
Race NR 
 
Smoking NR 
 
CD NR 
NR NR Disease activity 
index NR 
NR NR NR 30 
Thomson, 
1990224 
Placebo, 105 
Route: Oral 
Dose: NA every 
8 hours 
Male, %: 45.7 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 5.3 
 
Age at 
enrollment 
Mean: 37.4 
NR CDAI Mean: 60.1 NR sulphasalazine: 
16.2 
NR 2 
Thomson, 
1990224 
5-ASA, 101 
Dose: 500 mg 
every 8 hours 
Male, %: 42.6 
 
Race NR 
 
Smoking NR 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Mean: 6 
 
Age at 
enrollment 
Mean: 34.1 
NR CDAI Mean: 51.8 NR sulphasalazine: 
15.8 
NR 2 
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Van Assche, 
200889 
Infliximab, 40 
Route: IV 
Dose: 5 mg/kg 
every 8 weeks 
Male, %: 47.5 
 
Race NR 
 
Smoking, % 
Smoker, 47.5 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 2 
Max: 25 
 
Age at 
enrollment 
Mean: 35.4 
Severity NR 
 
Location, % 
Colonic: 12.5 
 
Behavior NR 
 
CRP 
Median: 3.2 
CDAI 
Mean: 138.1 
TNF-alpha 
inhibitors: 100 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
Van Assche, 
200889 
Infliximab + 
Immunomodulat
or, 40 
Route: IV + Oral 
Dose: 5 mg/kg 
every 8 weeks + 
see below 
Male, %: 42.5 
 
Race NR 
 
Smoking, % 
Smoker, 45 
 
CD NR 
Age at diagnosis 
NR 
 
Disease duration 
Median: 9 
Min: 1 
Max: 36 
 
Age at 
enrollment 
Mean: 35.6 
 
Severity NR 
 
Location, % 
Colonic: 32.5 
 
Behavior NR 
 
CRP 
Median: 3.4 
CDAI 
Mean: 137.6 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
TNF-alpha 
inhibitors: 100 
 
Methotrexate 
 
Thiopurines 
NR 
 
 
Abbreviations: 5ASA = 5-aminosalicylic acid; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CRP = C-reactive protein; g = gram; HBI = Harvey-Bradshaw 
Index; Max. = maximum; Min. = minimum; NA = not applicable; NR = not reported; TNF = tumor necrosis factor 
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Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Thayu, 2010199 Infliximab Placebo Weight (Fat mass - 
height z score) 
NA  
NA 
Beta-coefficient, 0.29 
(95% CI, 0.06 to 0.52) 
 P: <0.05 
Thayu, 2010199 Infliximab Placebo Weight (lean mass - 
height z score) 
Active 
Yes  
NA 
Beta-coefficient, 0.30 
(95% CI, 0.02 to 0.58) 
 P: <0.05 
Thayu, 2010199 Corticosteroid Placebo Weight (Fat mass - 
height z score) 
Active 
Yes  
NA 
Beta-coefficient, 0.69 
(95% CI, 0.12 to 1.26) 
 P: <0.05 
Thayu, 2010199 Methotrexate Placebo Weight (Fat mass - 
height z score) 
Active 
Yes  
NA 
Beta-coefficient, 0.30 
(95% CI, 0.04 to 0.56) 
 P: <0.05 
Cezard, 
2009194 
Mesalamine (Pentasa) 
Dose: 50 mg/kg every 1 
day 
Placebo HBI (Relapse rate: 
HBI >5) 
Active 
No 
NR 
Incidence  
29 / 60 (57%) 
Incidence  
35 / 62 (63%) 
Escher, 
2004190 
Prednisolone 
Dose: 1 mg/kg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
CDAI (Absolute 
CDAI) @ 8 weeks 
NA 
Yes 
G1-G2: Mean, 97 G1-G2: Mean, 149; P: 
0.047 
Escher, 
2004190 
Prednisolone 
Dose: 1 mg/kg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
CDAI (Absolute 
CDAI) @ 4 weeks 
NA 
Yes 
  P: 0.034 
Escher, 
2004190 
Prednisolone 
Dose: 1 mg/kg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
CDAI (Remission: 
CDAI < 150) @ 8 
weeks 
NA 
Yes 
Incidence  
17 / 24 (71%) 
Incidence  
12 / 22 (55%); P: 0.25 
Escher, 
2004190 
Prednisolone 
Dose: 1 mg/kg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
Other infections 
(pharyngitis) 
Active 
Yes 
Yes 
Incidence  
1 / 26 (4%) 
Incidence  
2 / 22 (9%) 
Levine, 
2003191 
Prednisone + mesalamine 
Dose: 40 mg every 1 day + 
3-4 g every 1 day 
Budesonide + mesalamine 
Dose: 3 mg every 8 hours + 
3-4 g every 1 day 
Other infections 
(herpetic skin 
infection) 
Active 
Yes 
Yes 
Incidence  
1 / 14 (7%) 
Incidence  
0 / 19 (0%) 
Levine, 
2003191 
Prednisone + mesalamine 
Dose: 40 mg every 1 day + 
3-4 g every 1 day 
Budesonide + mesalamine 
Dose: 3 mg every 8 hours + 
3-4 g every 1 day 
PCDAI (Remission 
definition: PCDAI 
<10) @ 4 weeks 
NA 
Yes 
Incidence  
8 / 14 (57%) 
Incidence  
9 / 19 (47%) 
Levine, 
2003191 
Prednisone + mesalamine 
Dose: 40 mg every 1 day + 
3-4 g every 1 day 
Budesonide + mesalamine 
Dose: 3 mg every 8 hours + 
3-4 g every 1 day 
PCDAI (Remission 
definition: PCDAI 
<10) @ 8 weeks 
NA 
Yes 
Incidence  
6 / 14 (43%) 
Incidence  
8 / 19 (42%) 
Levine, 
2003191 
Prednisone + Mesalamine 
Dose: 40 mg every 1 days 
+ 3-4 g every 1 day 
Budesonide + Mesalamine 
Dose: 3 mg every 8 hours + 
3-4 g every 1 day 
PCDAI (Remission 
definition: PCDAI 
<10) @ 12 weeks 
NA 
Yes 
Incidence  
7 / 14 (50%) 
Incidence 
9 / 19 (47%) 
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Alemzadeh, 
2002200 
Corticosteroid Placebo Height (not 
specified) 
Active 
Yes  
NA 
  P: 0.007 
Alemzadeh, 
2002200 
Corticosteroid Placebo Height (not 
specified) 
Active 
Yes  
NA 
  P: 0.005 
Levine, 
2002198 
Prednisone 
Dose: 40 mg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
Height (post-
remission linear 
growth in 
percentiles) @ 24 
weeks 
NR 
No  
NA 
G1-G2: -2.35 G1-G2: 0.25; P: 0.1 
Levine, 
2002198 
Prednisone 
Dose: 40 mg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
Other infections 
(herpetic infections) 
NR 
No  
NA 
Incidence  
2 / 58 (3%) 
Incidence  
0 / 62 (0%) 
Levine, 
2002198 
Prednisone 
Dose: 40 mg every 1 day 
Budesonide 
Dose: 9 mg every 1 day 
Weight (weight gain 
in kg) @ 8 weeks 
NR 
No  
NA 
G1-G2: Mean, 4.6 G1-G2: Mean, 2.54; P: 
<0.01 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
days+ 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
HBI (Remission 
definition: <3) @ 4 
weeks 
NA 
Yes 
Incidence  
25 / 27 (93%) 
Incidence  
22 / 28 (79%) 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
HBI (Remission 
definition: HBI< 3) 
NA 
Yes 
Incidence  
24 / 27 (89%) 
Incidence  
25 / 28 (89%) 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
HBI (Relapse rate 
definition: HBI ≥ 4) 
@ 24 weeks 
NA 
Yes 
Incidence  
(4%) 
Incidence  
(28%) 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
HBI (Relapse rate 
definition: HBI ≥ 4) 
NA 
Yes 
Incidence  
(9%) 
Incidence  
(47%) P: 0.007 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
Height (linear 
growth (cm)) @ 24 
weeks 
Active 
Yes 
Yes 
G1-G2: 3.4 (2.9) G1-G2: 1.9 (2.4); P: 0.06 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
Height (linear 
growth (cm)) @ 78 
weeks 
Active 
Yes 
Yes 
G1-G2: 6.8 (4.1) G1-G2: 5.3 (4); P: 0.3 
Markowitz, 
2000192 
6-MP + prednisone 
Dose: 1.5 mg/kg every 1 
day + 40 mg every 1 day 
Placebo + prednisone 
Dose: 40 mg every 1 day 
Need for surgery 
(not specified) @ 78 
weeks 
NA 
Yes 
Incidence  
1 / 27 (4%) 
Incidence  
3 / 28 (11%); P: 0.63 
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Evidence Table 24. Outcomes from randomized controlled trials and observational studies reporting on the effectiveness of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Saha, 1998197 Prednisone Placebo Height (height 
standard deviation 
score) @ 208 weeks 
Active 
Yes  
NA 
F-B: Mean, 0 F-B: Mean, 0.13 
Saha, 1998197 Prednisone Placebo Height (height 
standard deviation 
score) @ 156 weeks 
Active 
Yes  
NA 
F-B: Mean, -0.1 F-B: Mean, -0.09 
Saha, 1998197 Prednisone Placebo Height (height 
standard deviation 
score) 
Active 
Yes  
NA 
F-B: Mean, -0.47 F-B: Mean, -0.31 
Saha, 1998197 Prednisone Placebo Height (height 
standard deviation 
score) @ 104 weeks 
Active 
Yes  
NA 
F-B: Mean, -0.24 F-B: Mean, -0.13 
Issenman, 
1993196 
Discontinued 
corticosteroids 
Prednisone 
Route: Oral 
Dose: 2 mg/kg every 1 day 
Height (cm) @ 104 
weeks 
Active 
No  
NA 
B: Mean, 155.8 (SD, 
19.1) 
F-B: Mean, 10.3 (SD, 6) 
G1-G2: -1.2 
B: Mean, 159.5 (SD, 
13.4) 
F-B: Mean, 9.1 (SD, 4.6) 
Issenman, 
1993196 
Discontinued 
corticosteroids 
Prednisone 
Route: Oral 
Dose: 2 mg/kg every 1 day 
Height (height 
velocity >10% (cm/ 
2 years)) @ 104 
weeks 
Active 
No  
NA 
Incidence  
6 / 8 (75%) 
Incidence  
9 / 9 (100%) 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
CDAI (Absolute 
CDAI) @ 8 weeks 
NA 
Yes 
B: Mean, 188.3 (SE, 
20.9) 
F: Mean, 152.3 (SE, 31.4) 
F-B: Mean, -36 (SE, 38.1) 
G1-G2: 112 
B: Mean, 182.5 (SE, 
21.6) 
F: Mean, 258.4 (SE, 49.4) 
F-B: Mean, 76 (SE, 38) 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
CDAI (Response: 
50-pt drop in CDAI) 
@ 8 weeks 
NA 
Yes 
Incidence  
3 / 7 (43%) 
Incidence  
0 / 6 (0%) 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
HBI (Absolute HBI) 
@ 8 weeks 
NA 
Yes 
B: Mean, 3.71 (SE, 0.61) 
F: Mean, 3.43 (SE, 1.21) 
F-B: Mean, -0.29 (SE, 
1.36) 
G1-G2: 3.5 
B: Mean, 3.5 (SE, 0.99) 
F: Mean, 6.67 (SE, 1.82) 
F-B: Mean, 3.17 (SE, 
1.62) 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
HBI (Response: 
significant decrease 
in HBI) @ 8 weeks 
NA 
Yes 
Incidence  
3 / 7 (43%) 
Incidence  
0 / 6 (0%) 
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Evidence Table 24. Outcomes from randomized controlled trials and observational studies reporting on the effectiveness of 
pharmacologic therapies for the management of moderate to severe Crohn’s disease in children 
 
Author, year Group1 Group2 
Outcome 
(definition) 
AE 
collection 
/ ITT Results, Group 1 Results, Group 2 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
Lloyd-Still index 
(Response: Lloyd-
Still improvement) 
@ 8 weeks 
NA  
NA 
Incidence  
4 / 7 (57%) 
Incidence  
2 / 6 (33%) 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
Lloyd-Still index 
(absolute score) @ 
8 weeks 
NA 
Yes 
B: Mean, 71.1 (SE, 4.72) 
F: Mean, 75 (SE, 4.45) 
F-B: Mean, 3.86 (SE, 
3.69) 
G1-G2: -8.7 
B: Mean, 75.2 (SE, 4.93) 
F: Mean, 70.4 (SE, 2.36) 
F-B: Mean, -4.8 (SE, 
4.47) 
G1-G2: -8.7 P: 0.171 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 day 
van Hees index 
(absolute score) @ 
8 weeks 
NA 
Yes 
B: Mean, 175.1 (SE, 6.8) 
F: Mean, 175.7 (SE, 12.3) 
F-B: Mean, 0.6 (SE, 17.4) 
G1-G2: 5.3 
B: Mean, 171.4 (SE, 
13.1) 
F: Mean, 177.3 (SE, 10.1) 
F-B: Mean, 5.86 (SE, 
10.4) 
G1-G2: 5.3 P: 0.475 
Griffiths, 
1993221 
Mesalamine (Pentasa) 
Route: Oral 
Dose: 50 mg/kg every 1 
day 
Placebo 
Route: Oral 
Dose: NA every 1 days 
van Hees index 
(Response: 
significant decrease 
in van Hees index) 
@ 8 weeks 
NA 
Yes 
Incidence  
4 / 7 (57%) 
Incidence  
1 / 6 (17%) 
AE = adverse events; B = baseline value; CDAI = Crohn’s Disease Activity Index; CI = confidence interval; cm = centimeter; F = final values; F-B = change score; g = grams;  
G1-G2 = change score in group 1 minus the change score in group 2; HBI = Harvey-Bradshaw Index; ITT = intention-to-treat analysis; mg = milligrams; mg/kg = milligrams per 
kilogram; NA = not applicable; NR = not reported; PCDAI = Pediatric Crohn’s Disease Activity Index; pt = point; SD = standard deviation; SE = standard error 
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Evidence Table 25. Quality of randomized controlled trials reporting on the effectiveness of pharmacologic therapies for the 
management of moderate to severe Crohn’s disease in children 
 
Author, year Allocation 
sequence 
adequate 
Allocation 
concealment 
adequate 
Blinding Incomplete 
outcome data 
Other potential 
threats 
Pharmaceutical 
support 
Company 
involvement in 
design, 
conduct or 
reporting 
Overall study 
quality* 
Cezard, 2009194  Yes Yes Yes Unclear Yes No NA Fair 
Escher, 2004190  Yes Yes Yes Yes Yes Yes Yes Good 
Griffiths, 1993221  Yes Unclear Yes No Yes Yes UTD Fair 
Levine, 2003191  Unclear Unclear Unclear Unclear Unclear UTD NA Poor 
Markowitz, 
2000192  
Yes Yes Yes Yes Yes No NA Good 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Study Quality Criteria: Criteria for a judgment of “GOOD” (i.e. low risk of bias): These studies have the least bias and results are considered valid- A study that adheres mostly to 
the commonly held concepts of high quality including the following: a) A formal randomized controlled study; b)Clear description of the population, setting, interventions, and 
comparison groups; c) Appropriate measurements of outcomes; d) Appropriate statistical and analytic methods and reporting; e) No reporting errors; f) Low dropout rate; and g) 
Clear reporting of dropouts. Criteria for a judgment of “FAIR”: a) These studies are susceptible to some bias, but it is not sufficient to invalidate the results; b) do not meet all the 
criteria required for a rating of good qualities because they have some deficiencies, but no flaw is likely to cause major bias; and c) The study may be missing information, making 
it difficult to assess limitations and potential problems. Criteria for a judgment of “POOR” (i.e. high risk of bias): a) These studies have significant flaws that imply biases of 
various types that may invalidate the results; b) Have serious errors in design, analysis, or reporting; large amounts of missing information; or discrepancies in reporting.  
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Evidence Table 26. Quality of observational studies reporting on the effectiveness of pharmacologic therapies for the management of 
moderate to severe Crohn’s disease in children 
 
Author, year 
Main outcomes / 
Patient 
characteristics / 
Interventions 
described 
Distribution of 
confounders 
described 
Study groups 
from same 
population 
Losses to 
followup 
accounted for 
Adequate 
adjustment for 
confounding 
Overall study 
quality* 
Pharmaceutical 
support / 
Company 
involvement in 
design, conduct 
or reporting 
Alemzadeh, 
2002200 
Yes / Yes / Yes No UTD UTD No Poor No / NA 
Levine, 2002198 Yes / Yes / Yes Yes Yes UTD Yes Fair No / NA 
Saha, 1998197 Yes / Yes / Yes No Yes UTD UTD Poor No / NA 
Thayu, 2010199 Yes / Yes / UTD Yes UTD Yes Yes Fair No / NA 
Abbreviations: NA = not applicable; UTD = unable to determine 
*Overall study quality: Good indicates all "YES" responses in reporting, selection bias, and confounding domains of questionnaire. Fair indicates mostly "YES" for Reporting and 
all "YES" for Selection Bias and Confounding bias. Poor indicates at least 1 "NO" or "Unable to determine" for selection or confounding bias. 
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 Appendix E. Additional Meta-Analyses 
Figure 1. Pooled relative risk of remission* at week 2 comparing a TNF-alpha inhibitor with placebo by trials that allowed and did not 
allow prior TNF-alpha inhibitor use 
ADA = adalimumab; CI = confidence interval; CP = certolizumab pegol; IFX = infliximab; RR = relative risk; TNF = tumor necrosis factor-alpha inhibitor  
* In all trials, remission was defined as a Crohn’s Disease Activity Index less than 150. 
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E-1 
 Boxes indicate individual trial point estimates. The box size denotes the weight of the trial, with larger boxes contributing more to the pooled estimate. The width of the horizontal 
lines represents the 95% confidence intervals for each trial. The diamond at the bottom of the graph indicates the 95% confidence interval for the random-effects pooled estimate. 
Test for heterogeneity: Q = 2.22 with 2 degrees of freedom (p = 0.33); Q = 3.54 with 3 degrees of freedom (p = 0.32); Q = 7.41 with 6 degrees of freedom (p = 0.29) 
I-squared statistic = 10%; 15%; 19% 
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 Appendix F. Summary of Studies Comparing the 
Safety of Pharmacologic Therapies Among Patients 
With Inflammatory Bowel Disease 
(reference list located in full report) 
Mortality 
Infliximab Versus No Infliximab 
One retrospective study of inflammatory bowel disease patients (80 percent Crohn’s disease) 
compared 743 users of infliximab followed a median of 5 years to 666 never users of a biologic 
followed a median of 12 years.153 Safety was assessed using chart review and physician and 
patient contact. Two percent mortality was observed in both groups and an OR was provided 
(OR, 0.8; 95% CI, 0.3 to 1.8), although concomitant medications, disease severity, or other 
demographic or disease characteristics may not have been accounted for in the analysis. One of 
these deaths was from progressive multifocal leukoencephalopathy (PML), which is described in 
further detail in the PML section of the main report.33 167 This study153 may have underestimated 
the relative risk of cancer and death among patients treated with infliximab because of a flaw 
known as immortal time bias resulting from differential exclusion of followup time in the study 
groups.238 
Combination of Infliximab and Immunomodulators Versus 
Infliximab 
Two single center studies of 221 patients (92 percent173 and 81 percent129 Crohn’s disease) 
reported mortality in inflammatory bowel disease patients for the combination of infliximab and 
thiopurines versus infliximab.129 173 Concomitant medications were reported at the time of the 
first infliximab infusion. No deaths were reported in either study. 
Combination of Infliximab and Corticosteroids Versus Infliximab 
The same center reported no deaths among 42 users of infliximab and corticosteroids users or 
among 58 users of infliximab without corticosteroids.173 
Thiopurines Versus No Thiopurines 
A prospective study included 19,846 inflammatory bowel disease patients (60 percent 
Crohn’s disease) seen by 817 adult and pediatric gastroenterologists in France.130 One percent 
mortality was observed in thiopurine users and never users followed for up to three years (Peto 
OR, 1.2; 95% CI, 0.9 to 1.6). The study also reported mortality among those receiving a 
thiopurine at study entry (46 deaths, <1 percent), discontinuing a thiopurine prior to study entry 
(45 deaths, 2 percent), or never receiving thiopurines (95 deaths, <1 percent). The study reported 
a p-value less than 0.0006 for a difference in the comparison between these three groups.  
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 Corticosteroids Versus No Corticosteroids 
One retrospective cohort of 554 inflammatory bowel disease patients evaluated mortality in 
users and non-users of corticosteroids or corticotrophin using a chart review of patients seen at 
the study center between 1946 and 1965.142 Suicide was recorded in four of 430 corticosteroid 
users compared with zero of 124 non-users.  
Lymphoma 
Infliximab Versus Never User of Biologics 
One retrospective study including 1,409 inflammatory bowel disease patients aimed to 
evaluate the long term safety of infliximab at their center.153 The study compared 743 infliximab 
users followed for 5 years with 666 never users of a biologic followed for 12 years. Two 
lymphoma cases were reported among infliximab users and three lymphoma cases in never users 
of biologics corresponding to less than 1 percent lymphoma in each group.153 The corresponding 
Peto OR was 0.6 (95% CI, 0.1 to 3.5).153 This study153 may have underestimated the relative risk 
of cancer and death among patients treated with infliximab because of a flaw known as immortal 
time bias resulting from differential exclusion of followup time in the study groups.238 
Combination of Infliximab and Immunomodulators Versus 
Infliximab 
One retrospective study of 100 inflammatory bowel disease patients reported no cases of 
lymphoma over 26 months median followup.173  
Combination of Infliximab and Corticosteroids Versus Infliximab 
One retrospective study of 100 inflammatory bowel disease patients reported no cases of 
lymphoma over 26 months median followup.173 
Immunomodulators Versus No Immunomodulators 
Four observational studies including 37,943 inflammatory bowel disease patients compared 
immunomodulators with no immunomodulators and reported on lymphoma.130 133 231 232 One 
prospective study aimed to assess the risk of lymphoproliferative disorders in inflammatory 
bowel disease patients with thiopurine use over 3 years of followup.130 Sixty percent of the 
11,759 patients had Crohn’s disease. One non-Hodgkin’s lymphoma and 22 non-Hodgkin’s 
lymphoproliferative disorder cases were reported. The study reported an adjusted HR of 5.3 
(95% CI, 2.2 to 12.6) for incident lymphoproliferative disorder between thiopurine users and 
thiopurine non-users. 
One case-control study133 and one retrospective study232 including 17,675 patients reported 
the association between azathioprine and lymphoma. The case-control study compared 
azathioprine users versus non-users.133 Fifteen of 15,471 inflammatory bowel disease cases had 
codes indicating lymphoma. The age and smoking adjusted OR comparing azathioprine users 
with non-users was 3.2 (95% CI, 1.0 to 10.2). For each tertile increase in azathioprine exposure, 
the odds of lymphoma increased by 37 percent (age and smoking adjusted OR, 1.4; 95% CI, 0.8 
to 2.4). This database may include cases that have been reported in other studies included in this 
review.136 239 A retrospective study reported three cases of lymphoma among 626 (< 1 percent) 
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 patients with azathioprine use recorded in their charts compared with five lymphoma cases 
among 1,578 inflammatory bowel disease patients with no history of azathioprine use.232 Thirty-
nine percent of patients had Crohn’s disease. One Crohn’s disease patient who had not been 
treated with azathioprine had lymphoma.  
A retrospective study of inflammatory bowel disease patients (34 percent Crohn’s disease) 
reported four non-Hodgkin’s lymphoma cases among 238 patients with a record of azathioprine, 
methotrexate, or cyclosporine in their medical records compared with zero cases among 544 
patients with no reported history of azathioprine, methotrexate or cyclosporine.231 One of the 
lymphoma cases had Crohn’s disease. 
Corticosteroids Versus No Corticosteroids 
The retrospective study including 15,164 inflammatory bowel disease patients that could 
include overlapping lymphoma patients as another study also reported lymphoma by 
corticosteroid use.136 Less than 1 percent of the corticosteroid and no corticosteroid groups had 
lymphoma. The corresponding Peto OR is 1.0 (95% CI, 0.3 to 3.1). 
Mesalamine Versus No Mesalamine 
The same study reported lymphoma by mesalamine use in inflammatory bowel disease 
patients.136 The Peto OR for mesalamine versus no mesalamine is 1.0 (95% CI, 0.3 to 2.6). 
Cervical Cancer 
Infliximab Versus No Infliximab 
Two retrospective studies including 1,205 female inflammatory bowel disease patients 
reported cervical cancer by infliximab use.141 152 A retrospective study within a case-control 
study of women with inflammatory bowel disease who had received at least one Papanicolaou 
(Pap) test reported that none of the 10 cervical cancer cases (defined as cervical intraepithelial 
neoplasia grade III or greater) used infliximab within three years of their cancer compared with 
11 of 1,155 (1 percent) inflammatory bowel disease women who had normal Pap tests.152 
Another retrospective study within a case-control study included 40 inflammatory bowel disease 
patients with at least one normal Pap test prior to inflammatory bowel disease diagnosis and two 
Pap tests after inflammatory bowel disease diagnosis. No case of cervical cancer was 
observed.141 None of the seven women with a record of infliximab use in their charts and none of 
the 33 women with no recorded infliximab use was diagnosed with cervical cancer.141 
TNF-Alpha Inhibitor Versus No TNF-Alpha Inhibitor 
One retrospective study within a case-control study including 362 patients compared 
infliximab or adalimumab use with no use with risk of cervical dysplasia as recorded in 
pathology records.144 The study included women diagnosed with inflammatory bowel disease 
prior to age 60 who had no history of abnormal cervical smears prior to inflammatory bowel 
disease diagnosis and at least one cervical smear after inflammatory bowel disease diagnosis. 
One cervical adenocarcinoma was reported among the 362 women with inflammatory bowel 
disease. None of 33 women with adalimumab or infliximab use were diagnosed with cervical 
cancer compared with one of 329 (<1 percent) women with no record of use.144 
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 Immunomodulators Versus No Immunomodulators 
Four retrospective studies including 1,942 patients reported cervical cancer by 
immunomodulators use.141 144 152 231 One study reported immunomodulators use within 3 years 
among three of 10 (30 percent) cervical cancer cases compared with 123 of 1,155 (11 percent) 
non-cases (age, ethnicity, and smoking adjusted OR, 3.5; 95% CI, 0.8 to 14.5).152 Other 
medications were not accounted for in the analyses. Another study reported that cervical cancer 
was diagnosed in 0 of 107 women with a record of thiopurine use for at least three months 
compared with one of 233 women with no thiopurine use or less than three months of thiopurine 
use.144 This study also reported no cervical cancer cases among 13 users of methotrexate for at 
least three months compared with the same single cervical cancer case among the 349 (<1 
percent) women with no use or less than three months of methotrexate use.144 A study reported 
that none of the 22 women with a record of thiopurine use in their charts and none of the 18 
women with no recorded thiopurine use was diagnosed with cervical cancer.141 Methotrexate use 
was not recorded in any of the 40 charts. 
One study did not aim to study cervical cancer but specifically reported that cervical cancer 
was not an observed cancer among those reported. The retrospective study of inflammatory 
bowel disease patients reported no cervical cancer cases among 238 patients with a record of 
azathioprine, methotrexate, or cyclosporine in their medical records as well as no cervical cancer 
cases among 544 with no reported history of azathioprine, methotrexate, or cyclosporine. Of the 
included patients, 375 were women.231  
Corticosteroids Versus No Corticosteroids 
Two retrospective studies including 1,205 patients reported cervical cancer by corticosteroid 
use.141 152 One study reported corticosteroid use within 3 years among seven of 10 (70 percent) 
cervical cancer cases compared with 508 of 1,155 (44 percent) non-cases (age, ethnicity, and 
smoking adjusted OR, 2.8; 95% CI, 0.7 to 11.0).152 One invasive cervical cancer was reported. 
The invasive cervical cancer case had ulcerative colitis. Another study reported that none of the 
12 women with a record of greater than 15 mg of prednisone use in their charts and none of the 
28 women having less than 15 mg prednisone use was diagnosed with cervical cancer.141 
Aminosalicylates Versus No Aminosalicylates 
A study reported aminosalicylate use within 3 years among 8 of 10 (80 percent) cervical 
cancer cases compared with 769 of 1,155 (67 percent) non-cases (age, ethnicity, and smoking 
adjusted OR, 1.7; 95% CI, 0.3 to 8.0).152 
Colorectal Cancer 
Immunomodulators Versus No Immunomodulators 
A pooled registry study of 1,149 inflammatory bowel disease patients reported colorectal 
neoplasia in two patients receiving thiopurines without aminosalicylates compared to 14 cases 
among patients who had never received thiopurines nor aminosalicylates (adjusted HR 0.1; 95% 
CI 0.0 – 0.8).234  
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 Combination of Immunomodulators With Aminosalicylates Versus 
Never User of These Medications 
A pooled registry study of 1,149 inflammatory bowel disease patients reported colorectal 
neoplasia in one patient who received thiopurines with aminosalicylates (0.3 cases per 1,000 
person-years compared to 14 cases among patients who had never received thiopurines nor 
aminosalicylates (2.9 cases per 1,000 person-years).234  
Aminosalicylates Versus No Aminosalicylates 
Two retrospective studies including 10,552 inflammatory bowel disease patients compared 
aminsalicylate use to never use with risk of colorectal cancer.234 235 Neither study found a 
statistically significance association with colorectal cancer risk. The effect estimates suggested 
modest effects of aminosalicylates in opposite directions. The Dutch pooled registry study 
reported that aminosalicylates were associated with a decreased risk of cancer (adjusted HR 0.6; 
95% CI 0.2 – 1.4)234 compared to a slightly elevated effect in the Canadian study (adjusted HR 
1.2; 95% CI 0.8 – 1.7).235 The inconsistent effects may be partly explained by the adjustments in 
the analyses. Both studies adjusted for demographics, but the Dutch study also adjusted for 
disease location, dysplasia hx, surgery hx, folic acid use, calcium use, other medication use and 
type of inflammatory bowel disease.234 
Other Cancers 
Infliximab Versus No Infliximab 
One retrospective study of 1,409 inflammatory bowel disease patients (80 percent Crohn’s 
disease) compared infliximab with never user of a biologic and reported on cancer risk.153 Three 
percent of the infliximab group (21 cancers among 743 patients contributing 3,775 person-years) 
and 5 percent of the never users of biologics (30 of 666 patients contributing 6,704 person-years) 
had cancer. The study reported an adjusted OR of 1.0 (95% CI, 0.6 to 1.7). An unadjusted rate 
ratio corresponding to the events and person-time provided was 3.6 (95% CI, 1.9 to 6.4). This 
study153 may have underestimated the relative risk of cancer and death among patients treated 
with infliximab because of a flaw known as immortal time bias resulting from differential 
exclusion of followup time in the study groups.238 
Combination of Infliximab and Immunomodulators Versus 
Infliximab 
Two single center studies of 221 patients (92 percent173 and 81 percent129 Crohn’s disease) 
reported on cancer in inflammatory bowel disease patients for the combination of infliximab and 
thiopurines versus infliximab.129 173 Concomitant medications were reported at the time of the 
first infliximab infusion. No cancers were reported in either study. 
Combination of Infliximab and Corticosteroids Versus Infliximab 
The same retrospective study of 100 inflammatory bowel disease patients reported no cancers 
during the 26-month median study period comparing 42 patients taking infliximab and a 
corticosteroid with 58 patients taking infliximab without a corticosteroid.173 
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 Other Combinations With Infliximab 
One retrospective study of 147 inflammatory bowel disease patients met the inclusion criteria 
but the cancer cases’ concomitant medications may be misclassified as described above.227 Nine 
cancers were reported. The cancers occurred in seven of 93 patients taking infliximab and an 
immunomodulator (with or without corticosteroids) and two of 54 (4 percent) patients taking 
infliximab without an immunomodulator. When examining concomitant corticosteroids (with or 
without immunomodulators), the cancers occurred in four of 102 (4 percent) patients taking 
infliximab and a corticosteroid compared with five of 45 (11 percent) patients taking infliximab 
without a corticosteroid.  
Immunomodulators Versus No Immunomodulators 
Four observational studies including 37,943 inflammatory bowel disease patients compared 
immunomodulators with no immunomodulators and reported on cancer risk.130 133 231 232 A 
prospective study of 19,486 patients followed a median of 35 months reported cancers in 2 
percent of current or previous thiopurine users and 1 percent of never users of thiopurine.130 The 
study reported P < 0.0006 for a difference in the comparison between these three groups. The 
corresponding Peto OR comparing ever with never users was 1.4 (95% CI, 1.1 to 1.8).  
A retrospective study (39 percent Crohn’s disease) with 13.7 mean years of followup 
reported cancers in 5 percent of the 626 azathioprine patients and 4 percent of the 1,578 no 
azathioprine group. The corresponding Peto OR was 1.1 (95% CI, 0.7 to 1.7).232 Another 
retrospective study with 8 years median followup reported 14 (6 percent) cancers in 238 ever 
users of thiopurines, methotrexate, or cyclosporine and 16 (3 percent) cancers in 544 who had 
not used these medications according to chart review. The corresponding Peto OR was 2.1 (95% 
CI, 0.9 to 4.6).231 
A case-control study comparing inflammatory bowel disease cancer cases with inflammatory 
bowel disease patients without cancer reported that 11 percent of cancer patients had been 
prescribed azathioprine compared with 13 percent of controls.133 After excluding 43 non-
melanoma skin cancers (azathioprine versus no azathioprine OR, 1.0), there were 392 incident 
cases of cancer among 15,471 inflammatory bowel disease patients with at least one year of 
relevant data between 1987 and 2001. After adjusting for age and smoking, the OR was 1.1 (95% 
CI, 0.8 to 1.5). Although the number of Crohn’s disease patients and their azathioprine use was 
not reported, the azathioprine versus no azathioprine OR in Crohn’s disease was reported as 1.1 
(95% CI, 0.7 to 1.8), although it is unclear if this relationship was adjusted.  
Infections 
Infliximab Versus No Infliximab 
A retrospective study of 1,409 inflammatory bowel disease patients (80 percent Crohn’s 
disease) reported serious infections that required hospitalization, prolonged hospitalization, led to 
significant disability, or were life-threatening or fatal.153 Serious infections within 12 weeks of 
the last infliximab infusion were reported in 48 (6 percent) of 743 infliximab users (5 years of 
followup) compared with 62 (9 percent) of 666 never users of a biologic (12 years of followup). 
The corresponding Peto OR was 0.7 (95% CI, 0.5 to 1.0).  
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 Combination of Infliximab With Immunomodulators Versus 
Infliximab 
The retrospective study of 1,409 inflammatory bowel disease patients (80 percent Crohn’s 
disease) reported that non-serious infections were not affected by methotrexate or thiopurine use, 
although the magnitude of the association was not reported.153 No infections requiring 
hospitalization were observed in a hospital-based registry of 121 patients (81 percent Crohn’s 
disease).129 
Combination of Infliximab With Corticosteroids Versus Infliximab 
The retrospective study of 1,409 inflammatory bowel disease patients (80 percent Crohn’s 
disease) reported non-serious infections were more likely to occur during periods when 
corticosteroids were used (OR 2.7, 95% CI 1.2 to 6.1).153 
Other Combinations With Infliximab 
Two retrospective studies including 247 inflammatory bowel disease patients met the 
inclusion criteria but the concomitant medications of the patients with infections may be 
misclassified as described in the mortality section.173 227 One retrospective study of 100 
inflammatory bowel disease patients (92 Crohn’s disease) reported infections in four of 82 
patients receiving infliximab and a thiopurine compared with no infections in 18 patients 
receiving infliximab without a thiopurine.173 Examining the combination of infliximab and 
corticosteroids in these same 100 patients, infections occurred in zero of 42 patients on 
infliximab and corticosteroids and four of 58 patients on infliximab without a corticosteroid. The 
observed infections were varicella-zoster, pneumonia, E. coli, and sepsis. The study also reported 
that no opportunistic infections were observed. Another retrospective study of 147 patients (138 
Crohn’s disease) followed a median of 9 years reported serious infection requiring 
hospitalization in 19 percent of 93 patients taking infliximab and an immunomodulator and 33 
percent of 54 patients taking infliximab without an immunomodulator.227 In the same 147 
patients, serious infections were reported in 18 percent of 102 patients taking infliximab and 
corticosteroids and 40 percent of 45 patients taking infliximab without corticosteroids. Among 
these 36 patients, there were 57 unique hospitalizations with infection as the main reason for the 
hospitalization.227 
Immunomodulators Versus No Immunomodulators 
Two studies including 302 inflammatory bowel disease patients compared 
immunomodulators with no immunomodulators and reported on infections.155 176 A prospective 
study reported specific benign infections (benign upper respiratory infections and human 
papillomavirus and herpes simplex virus cutaneous infections) among 230 inflammatory bowel 
disease patients (162 Crohn’s disease) with well-controlled disease.155 Azathioprine use was 
assessed by chart review over an average of one year of followup. Active ascertainment of 
infections was performed by physical exams at each visit, with use of standardized forms for 
benign infections. Inflammatory bowel disease patients with and without use of azathioprine 
averaged two upper respiratory tract infections per year. Azathioprine users were more likely to 
have a flare-up of human papillomavirus or herpes simplex virus than patients not on 
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 azathioprine (1 flare per year among azathioprine users versus 0.2 flares per year among non-
users).  
One retrospective study including 72 patients (23 Crohn’s disease) tested for 
cytomegalovirus infections in intestinal biopsies taken from inpatients with active inflammatory 
bowel disease.176 They reported that 17 percent (2 out of 12) of patients with azathioprine use 
had cytomegalovirus infection compared with 12 percent (7 out of 60) of patients without 
azathioprine use.176 Two of the eight cytomegalovirus infection positive patients had Crohn’s 
disease.  
Immunomodulators Versus Corticosteroids 
One study including 10,141 inflammatory bowel disease patients compared 
immunomodulators with corticosteroids and reported on infections.230 Because the study 
reported rate ratios comparing corticosteroids with immunomodulators, the comparisons reported 
here also compared corticosteroids with immunomodulators. The number of serious infections 
requiring hospitalization (as identified by ICD-9-CM codes) was 32 in corticosteroid users 
(4,066 person-years) compared with 27 in immunomodulator users (3,964 person-years). They 
adjusted for age, gender, inflammatory bowel disease type, year of diagnosis, mean comorbidity 
index, number of doctor visits, and number of medications, and reported a serious infection rate 
ratio of 1.1 (95% CI, 0.6 to 1.9) comparing corticosteroids (with or without infliximab) with 
immunomodulators. The rate ratio comparing corticosteroids only with immunomodulators only 
for serious infections was 1.2 (95% CI, 0.7 to 2.1). Clostridium difficile (C. difficile) was a non-
serious infection of interest. The number of C. difficile infections was 57 in corticosteroid users 
(4,063 patient-years) compared with 14 in immunomodulator users (3,972 patient-years). The 
adjusted rate ratio comparing corticosteroids (with or without infliximab) with 
immunomodulators was 3.4 (95% CI, 1.9 to 6.1). The adjusted rate ratio comparing 
corticosteroids alone with immunomodulators alone was 2.7 (95% CI, 1.5 to 4.6). 
A retrospective study of 27 users of thiopurines with or without corticosteroids (41 percent 
Crohn’s disease) reported that almost 20 percent of both groups had infections including two 
cases of shingles and one case each of EBV viremia, PCP pneumonia, and viral meningitis.157 
Combination of Azathioprine and Aminosalicylates Versus 
Azathioprine 
One retrospective study including 199 inflammatory bowel disease patients (122 Crohn’s 
disease) reported that 2 percent (2 out of 104) of inflammatory bowel disease patients who filled 
prescriptions for both azathioprine and aminosalicylates at the hospital pharmacy had an 
infection reported in their charts compared with 2 percent (2 out of 95) of patients who filled 
prescriptions for azathioprine alone.156 The severity and type of infection were not defined.  
Corticosteroids Versus No Corticosteroids 
One retrospective cohort including 554 inflammatory bowel disease patients reported 
infections in corticosteroid or corticotrophin users and non-users according to a chart review of 
patients seen at the hospital clinic between 1946 and 1965.142 Infections of unspecified severity 
or type were recorded in 17 of 124 (14 percent) corticosteroid or corticotrophin non-users 
compared with 95 of 430 (22 percent) corticosteroid or corticotrophin users. The corresponding 
Peto OR was 1.7 (95% CI, 1.0 to 2.8).  
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 Infusion and Injection-Site Reactions 
Combination of Infliximab and Immunomodulators Versus 
Infliximab 
Five observational studies including 1,189 inflammatory bowel disease patients compared a 
combination of infliximab and immunomodulators with infliximab alone and reported infusion 
reactions.173 181 225 228 A retrospective study of 144 inflammatory bowel disease patients (139 
Crohn’s disease) who received 30 minutes to 1 hour of infusion instead of the standard 2 hours 
did not report the number of patients who experienced infusion reaction but did report an OR of 
1.4 comparing a combination of infliximab and immunomodulators (thiopurines or methotrexate) 
with infliximab without immunomodulators (95% CI, 0.3 to 7.7) after adjustment for unspecified 
factors.181 The unadjusted OR comparing a combination of infliximab and thiopurines with 
infliximab was 1.1 (95% CI, 0.3 to 3.7).  
Another retrospective study of 1 hour compared to 2 hour infusions reported 3 percent of 
patients who received immunosuppressants had an infusion reaction compared to 9 percent of 
patients who received infliximab alone.184 
A retrospective study that followed inflammatory bowel disease patients for 8 months to 17 
years reported a p-value only comparing a combination of infliximab and immunomodulators 
with infliximab. Patients who received the combination of infliximab and immunomodulators 
were less likely to have any adverse event within 24 hours of infusion than patients receiving 
infliximab without immunomodulators (univariate P = 0.002).228 
A retrospective study of 651 inflammatory bowel disease patients reported 63 infusion 
reactions in 2,079 (3 percent) infliximab and immunomodulator infusions and 83 infusion 
reactions in 1,272 (7 percent) infliximab without immunomodulator infusions (during or within 2 
hours after infusion).225 A retrospective study of 100 inflammatory bowel disease patients (92 
with Crohn’s disease) reported infusion reactions in two of 82 patients using infliximab and a 
thiopurine compared with zero of 18 patients using infliximab without a thiopurine.173 Both 
patients who experienced an infusion reaction had Crohn’s disease. 
Combination of Infliximab and Thiopurines Versus Combination of 
Infliximab and Methotrexate 
The retrospective study of 144 inflammatory bowel disease patients receiving 30 minute to 1-
hour infusions instead of 2-hour infusions reported an unadjusted OR for infusion reaction 
comparing a combination of infliximab and methotrexate or prednisolone with a combination of 
infliximab and thiopurines of 1.2 (95% CI, 0.5 to 3.0).181 
Combination of Infliximab and Corticosteroids Versus Infliximab 
Three retrospective studies including 989 inflammatory bowel disease patients compared 
infusion reactions in patients who received a combination of infliximab and corticosteroids 
versus infliximab without corticosteroids.173 225 A study of 100 inflammatory bowel disease 
patients (92 Crohn’s disease) reported two Crohn’s disease patients experiencing an infusion 
reaction in 58 patients receiving infliximab and corticosteroids versus zero in 42 patients 
receiving infliximab without corticosteroids.173 A retrospective study of 651 inflammatory bowel 
disease patients reported 33 infusion reactions in 611 infusions of infliximab with corticosteroids 
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 compared with 113 infusion reactions in 2,750 infusions of infliximab without corticosteroids.225 
A retrospective study of 1 hour compared to 2 hour infusions reported 6 percent of patients who 
received corticosteroid premedication had an infusion reaction compared to 4 percent of patients 
who received infliximab alone.184 
Bone Fractures 
Corticosteroids Versus No Corticosteroids 
One retrospective cohort (n = 554) evaluated bone fractures in inflammatory bowel disease 
patients using a corticosteroid or corticotrophin compared with non-users according to a chart 
review of patients seen at the hospital clinic between 1946 and 1965.142 A pathologic fracture 
was recorded in zero of 124 corticosteroid non-users compared with six of 430 corticosteroid 
users (1 percent).  
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 Appendix G. Subgroup Analysis Tables 
(reference list located in full report) 
 
Table 1. Comparative effectiveness of pharmacologic therapies to induce remission in sub-populations of patients with Crohn’s disease 
Subgroup Remission Steroid-free remission Other outcomes 
Baseline CRP Remission = CDAI < 150 at week 438 
Baseline CRP < 10 mg/L  
Placebo (7%)  
Adalimumab (18%) 
Baseline CRP > 10 mg/L  
Placebo (7%) 
Adalimumab (25%) 
(P = 0.67) 
 
Remission = CDAI < 150 at week 437 
Baseline CRP < 1mg/dL 
Placebo (16%) 
Adalimumab 40mg/20mg (14%) 
Adalimumab 80mg/40mg (21%) 
Adalimumab 160mg/80mg (31%) 
Baseline CRP ≥1mg/dL 
Placebo (7%) 
Adalimumab 40mg/20mg (23%) 
Adalimumab 80mg/40mg (27%) 
Adalimumab 160mg/80mg (43%) 
Corticosteroid-free remission (CDAI < 
150) at week 2645 
Baseline CRP <0.8 mg/dL 
Infliximab + azathioprine (51%; OR = 
2.0; P = 0.05)  
Infliximab (40%; OR = 1.3; P = 0.43) 
Azathioprine (34%; ref) 
Baseline CRP ≥ 0.8 mg/dL 
Infliximab + azathioprine (64%; OR = 
4.6; P < 0.001)  
Infliximab (48%; OR = 2.4; P = 0.004) 
Azathioprine (28%; ref) 
 
 
Corticosteroid use Remission = CDAI < 150 at week 438 
Baseline corticosteroid use  
Placebo (4%) 
Adalimumab (33%) 
No baseline corticosteroid use 
Placebo (10%)  
Adalimumab (15%) 
(P = 0.01) 
 
Corticosteroid-free remission (CDAI < 
150) at week 2645 
Baseline steroid use <20 mg 
Infliximab + azathioprine (56%; OR = 
2.7; P < 0.001)  
Infliximab (43%; OR = 1.6; P = 0.08) 
Azathioprine (33%; ref) 
Baseline steroid use ≥20 mg 
Infliximab + azathioprine (61%; OR = 
6.9; P < 0.001)  
Infliximab (49%; OR = 4.3; P = 0.01) 
Azathioprine (18%; ref) 
Reduction of ≥ 50% in number of 
draining fistulas44 
Concomitant oral corticosteroid use of 20 
mg/day 
Placebo (20%) 
Infliximab (67%; OR = 8.0; P = 0.14) 
Concomitant oral corticosteroid use of 
<20 mg/day  
Placebo (17%) 
Infliximab (53%; OR = 5.7; P = 0.15) 
No concomitant oral corticosteroid use 
Placebo (30%) 
Infliximab (64%; OR = 4.2; P = 0.01) 
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 Subgroup Remission Steroid-free remission Other outcomes 
Immunomodulator use Remission = CDAI < 150 at week 438 
Baseline immunomodulator (AZA, MP, 
MTX) use 
Placebo (7%) 
Adalimumab (22%) 
No baseline immunomodulator (AZA, 
MP, MTX) use 
Placebo (7%) 
Adalimumab (21%) 
(P = 0.88) 
 
Remission = CDAI < 150 at week 437 
Concomitant immunomodulator (AZA, 
MP, MTX) use 
Placebo (9%) 
Adalimumab 40mg/20mg (22%) 
Adalimumab 80mg/40mg (10%) 
Adalimumab 160mg/80mg (36%) 
No concomitant immunomodulator (AZA, 
MP, MTX) use 
Placebo (13%) 
Adalimumab 40mg/20mg (16%) 
Adalimumab 80mg/40mg (30%) 
Adalimumab 160mg/80mg (35%) 
 
Remission = CDAI < 150 at week 1033 
Concomitant immunomodulator use 
Placebo (25%) 
Natalizumab (40%) 
No concomitant immunomodulator 
use 
Placebo (33%) 
Natalizumab (35%) 
(P < 0.05) 
Corticosteroid-free remission (CDAI < 
150) at week 1246 
 
Prior AZA/MP use 
AZA/MP + placebo (34%) 
AZA/MP + infliximab (64%) 
No prior AZA/MP use 
AZA/MP + placebo (41%) 
AZA/MP + infliximab (83%) 
 (P = 0.10) 
 
Corticosteroid-free remission (CDAI < 
150) at week 5246 
 
Prior AZA/MP use  
AZA/MP + placebo (12%) 
AZA/MP + infliximab (27%) 
No prior AZA/MP use 
AZA/MP + placebo (32%) 
AZA/MP + infliximab (52%) 
 (P = 0.82) 
Reduction of ≥ 50% in number of 
draining fistulas44 
Concomitant thiopurine use 
Placebo (44%) 
Infliximab (59%; OR = 1.8; P = 0.46) 
No concomitant thiopurine use 
Placebo (18%) 
Infliximab (65%; OR = 8.3; P = 0.001) 
 
 
TNF-alpha inhibitor use Remission = CDAI < 150 at week 1033 
Prior treatment with TNF-alpha 
inhibitor 
Placebo (22%) 
Natalizumab (33%) 
No prior treatment with TNF-alpha 
inhibitor 
Placebo (35%) 
Natalizumab (39%) 
(P > 0.05) 
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 Subgroup Remission Steroid-free remission Other outcomes 
ASA use  Corticosteroid-free remission (CDAI < 
150) at week 2645 
Baseline 5-ASA use 
Infliximab + azathioprine (58%; OR = 
2.5; P = 0.002)  
Infliximab (49%; OR = 1.9; P = 0.04) 
Azathioprine (35%) 
No baseline 5-ASA use 
Infliximab + azathioprine (57%; OR = 
4.6; P < 0.001)  
Infliximab (39%; OR = 2.4; P = 0.03) 
Azathioprine (23%) 
 
Antibiotic use   Reduction of ≥ 50% in number of 
draining fistulas44 
Concomitant antibiotic use 
Placebo (27%) 
Infliximab (65%; OR = 4.9; P = 0.06) 
No concomitant antibiotic use 
Placebo (25%) 
Infliximab (61%; OR = 4.7; P = 0.01) 
Disease location Remission = CDAI < 175 at month 1553 
Disease location-ileum 
Placebo (17%) 
Azathioprine (50%; OR = 5.0; P > 0.05) 
Disease location- colon 
Placebo (0%) 
Azathioprine (20%; OR = 3.7; P > 0.05) 
Disease location- ileum/colon 
Placebo (5%) 
Azathioprine (45%; OR = 14.7; P < 0.05) 
 Reduction of ≥ 50% in number of 
draining fistulas44 
Disease location-ileum 
Placebo (0%) 
Infliximab (73%) 
Disease location-colon 
Placebo (33%) 
Infliximab (53%; OR = 2.3; P = 0.35) 
Disease location-ileum/colon Placebo 
(26%) 
Infliximab (65%%; OR = 5.1; P = 0.01) 
 
2-point drop in HBI after week 6240 
Disease location-ileum Placebo (38%) 
Mesalamine (33%) 
Disease location- colon 
Placebo (33%) 
Mesalamine (67%) 
Disease location- ileum/colon 
Placebo (0%) 
Mesalamine (40%) 
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 Subgroup Remission Steroid-free remission Other outcomes 
Other disease 
characteristics 
 
 
Corticosteroid-free remission (CDAI < 
150) at week 2645 
Duration of CD < 3 years 
Infliximab + azathioprine (51%; OR = 
2.9; P < 0.001)  
Infliximab (42%; OR = 2.1; P = 0.02) 
Azathioprine (26%; ref) 
Duration of CD ≥ 3 years 
Infliximab + azathioprine (64%; OR = 
3.4; P < 0.001)  
Infliximab (47%; OR = 1.7; P = 0.11) 
Azathioprine (35%; ref) 
 
Corticosteroid-free remission (CDAI < 
150) at week 2645 
Previous CD-related surgery 
Infliximab + azathioprine (48%; OR = 
2.2; P = 0.07)  
Infliximab (45%; OR = 1.8; P = 0.16) 
Azathioprine (30%; ref) 
No previous CD-related surgery 
Infliximab + azathioprine (60%; OR = 
3.6; P < 0.001)  
Infliximab (44%; OR = 1.8; P = 0.03) 
Azathioprine (30%) 
 
Corticosteroid-free remission (CDAI < 
150) at week 2645 
Baseline mucosal lesions 
Infliximab + azathioprine (61%; P < 
0.001 comp to AZA, P=0.12 comp to 
IFX)  
Infliximab (51%; P = 0.002 comp to AZA) 
Azathioprine (30%) 
No baseline mucosal lesions 
Infliximab + azathioprine (40%; P = 0.93 
comp to AZA, P=0.69 comp to IFX)  
Infliximab (33%; P = 0.37 comp to AZA) 
Azathioprine (41%) 
Unable to determine if baseline mucosal 
lesions 
Infliximab + azathioprine (57%; P = 
0.003)  
Infliximab (38%; P = 0.14) 
Azathioprine (21%) 
Reduction of ≥ 50% in number of 
draining fistulas44 
 
One enterocutaneous fistula 
Placebo (8%) 
Infliximab (52%; OR = 12.9; P = 0.02) 
>1 enterocutaneous fistula Placebo 
(39%) 
Infliximab (71%; OR = 3.8; P = 0.03) 
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 Results in BOLD CAPS reported a p-value for the interaction term. 
Sub-populations reported without all strata are not reported with percentages. 
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 Table 2. Comparative effectiveness of pharmacologic therapies to induce remission in sub-populations of patients with Crohn’s disease 
Subgroup Remission Other outcomes 
Baseline CRP Remission = CDAI < 150 at week 2682 
Baseline CRP <1 mg/dL 
Placebo (18%) 
Adalimumab 40mg every other week (39%) 
Adalimumab 40mg weekly (38%) 
Baseline CRP ≥1 mg/dL  
Placebo (17%) 
Adalimumab 40mg every other week (41%) 
Adalimumab 40mg weekly (56%) 
 
Remission= CDAI < 150 at week 5682 
Baseline CRP <1 mg/dL 
Placebo (13%) 
Adalimumab 40mg every other week (36%) 
Adalimumab 40mg weekly (33%) 
Baseline CRP ≥1 mg/dL  
Placebo (11%) 
Adalimumab 40mg every other week (37%) 
Adalimumab 40mg weekly (51%) 
 
Remission = CDAI < 150 at week 2684 
Baseline CRP < 10 mg/L 
Placebo (31%) 
Certolizumab pegol (54%; P < 0.001) 
Baseline CRP >10 mg/L  
Placebo (26%) 
Certolizumab pegol (42%; P = 0.01) 
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 Subgroup Remission Other outcomes 
Immunomodulator use Remission = CDAI < 150 at week 2682 
Baseline immunomodulator (AZA, MP, MTX)  use 
Placebo (16%) 
Adalimumab 40mg every other week (39%) 
Adalimumab 40mg weekly (44%) 
No baseline immunomodulator (AZA, MP, MTX)use 
Placebo (21%) 
Adalimumab 40mg every other week (42%) 
Adalimumab 40mg weekly (56%) 
 
Remission= CDAI < 150 at week 5682 
Baseline immunomodulator (AZA, MP, MTX)  use 
Placebo (12%) 
Adalimumab 40mg every other week (37%) 
Adalimumab 40mg weekly (39%) 
No baseline immunomodulator (AZA, MP, MTX)use 
Placebo (13%) 
Adalimumab 40mg every other week (33%) 
Adalimumab 40mg weekly (50%) 
 
Remission= CDAI <150 at week 5683 
Concomitant immunomodulator use  
Placebo (33%) 
Adalimumab 40mg every other week (100%) 
Adalimumab 40mg weekly (83%) 
No concomitant immunomodulator use 
Placebo (47%) 
Adalimumab 40mg every other week (73%) 
Adalimumab 40mg weekly (85%) 
 
Remission = avoidance of relapse (75-point increase in 
CDAI, CDAI > 150, or disease activity requiring 
intervention) after 1 year101 
Prior azathioprine dose ≤1.60 kg/mg/day 
Placebo (100%) 
Azathioprine (75%) 
Prior azathioprine dose >1.60 kg/mg/day 
Placebo (33%) 
Azathioprine (89%; P = 0.017) 
No draining fistulas at week 26241 
Baseline immunomodulator (AZA, MP, MTX) use 
Placebo (8%)  
Adalimumab (26%; P = 0.09)  
No baseline immunomodulator (AZA, MP, MTX) use 
Placebo (19%)  
Adalimumab (33%; P = 0.37)  
 
No draining fistulas at week 56241 
Baseline immunomodulator (AZA, MP, MTX) use 
Placebo (8%)  
Adalimumab (29%; P = 0.05) 
No baseline immunomodulator (AZA, MP, MTX) use 
Placebo (19%)  
Adalimumab (36%; P = 0.24)  
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 Subgroup Remission Other outcomes 
TNF-alpha inhibitor use Remission = CDAI < 150 at week 2682 
TNF-alpha inhibitor experienced at baseline  
Placebo (16%) 
Adalimumab 40mg every other week (32%) 
Adalimumab 40mg weekly (42%) 
TNF-alpha inhibitor naive at baseline  
Placebo (18%) 
Adalimumab 40mg every other week (47%) 
Adalimumab 40mg weekly (50%) 
 
Remission= CDAI < 150 at week 5682 
TNF-alpha inhibitor experienced at baseline  
Placebo (10%) 
Adalimumab 40mg every other week (31%) 
Adalimumab 40mg weekly (34%) 
TNF-alpha inhibitor naive at baseline  
Placebo (14%) 
Adalimumab 40mg every other week (42%) 
Adalimumab 40mg weekly (48%) 
 
Remission=CDAI < 150 at week 26242 
Infliximab naïve 
Placebo (33%) 
Certolizumab pegol (53%; P < 0.001) 
Infliximab experienced 
Placebo (14%) 
Certolizumab pegol (33%; P = 0.008) 
Serious infection242 
Infliximab naïve 
Placebo (1%) 
Certolizumab pegol (2%) 
Infliximab experienced 
Placebo (0%) 
Certolizumab pegol (4%) 
Antibiotic use  
 
 
 
No draining fistulas at week 26241 
Baseline antibiotic use 
Placebo (11%)  
Adalimumab (27%; P = 0.26)  
No baseline antibiotic use 
Placebo (14%)  
Adalimumab (32%; P = 0.16)  
 
No draining fistulas at week 56241 
Baseline antibiotic use 
Placebo (11%)  
Adalimumab (27%; P = 0.26)  
No baseline antibiotic use 
Placebo (14%) 
Adalimumab (36%; P = 0.06) 
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 Subgroup Remission Other outcomes 
Disease location  Relapse =  CDAI >150 and 100-point increase in CDAI at 
month 12123 
Disease location-ileum 
Placebo (57%) 
5-ASA (26%; P < 0.05) 
Disease location-colon 
Placebo (55%) 
5-ASA (40%; P > 0.05) 
Disease location- ileum/colon Placebo (50%) 
5-ASA (52%; P > 0.05) 
 
Relapse = CDAI > 150 after one year126 
Disease location-ileum 
Placebo (27%) 
Mesalamine (27%; P > 0.05) 
Disease location-colon 
Placebo (43%) 
Mesalamine (55%; P > 0.05) 
Disease location- ileum/colon  
Placebo (50%) 
Mesalamine (11%; P < 0.05) 
Other disease characteristics  Relapse = CDAI >150 and 100-point increase in CDAI at 
month 12123 
Baseline inflammation (CRP, ESR) 
Placebo (83%) 
5-ASA (62%; P > 0.05) 
No baseline inflammation (CRP, ESR)  
Placebo (45%) 
5-ASA (22%; P > 0.05) 
 
Relapse = CDAI >150 and 100-point increase in CDAI at 
month 12123 
Previous resection 
Placebo (58%) 
5-ASA (9%; P < 0.05) 
No previous resection 
Placebo (54%) 
5-ASA (41%; P > 0.05) 
Results in BOLD CAPS reported a p-value for the interaction term. 
Sub-populations reported without all strata are not reported with percentages. 
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